{"PMC7125716": [["Poor IAQ may lead to a loss in productive work time in commercial environments, expensive mechanical systems maintenance, and even litigation [2].", [["a loss", "PROBLEM", 21, 27], ["expensive mechanical systems maintenance", "TREATMENT", 80, 120]]], ["Gasses (carbon dioxide, volatile organic compounds, carbon monoxide, and radon) and airborne particulates (mold, atmospheric particulate matter, and microbial contaminants) are generally known to negatively affect IAQ.", [["carbon dioxide", "CHEMICAL", 8, 22], ["carbon monoxide", "CHEMICAL", 52, 67], ["radon", "CHEMICAL", 73, 78], ["carbon dioxide", "CHEMICAL", 8, 22], ["carbon monoxide", "CHEMICAL", 52, 67], ["carbon dioxide", "SIMPLE_CHEMICAL", 8, 22], ["volatile organic compounds", "SIMPLE_CHEMICAL", 24, 50], ["carbon monoxide", "SIMPLE_CHEMICAL", 52, 67], ["radon", "SIMPLE_CHEMICAL", 73, 78], ["IAQ", "PROTEIN", 214, 217], ["Gasses", "TEST", 0, 6], ["carbon dioxide", "TREATMENT", 8, 22], ["volatile organic compounds", "TREATMENT", 24, 50], ["carbon monoxide", "TREATMENT", 52, 67], ["airborne particulates (mold, atmospheric particulate matter", "PROBLEM", 84, 143]]], ["Control of these contaminants is critical in healthcare environments, clean rooms, and confined spaces.IntroductionFor instance, incidence of burn wound infections remains a high-risk proposition even today when the burn area covers a substantial portion of the patient's body.", [["wound", "ANATOMY", 147, 152], ["body", "ANATOMY", 272, 276], ["burn", "DISEASE", 142, 146], ["infections", "DISEASE", 153, 163], ["burn", "DISEASE", 216, 220], ["wound", "PATHOLOGICAL_FORMATION", 147, 152], ["patient", "ORGANISM", 262, 269], ["body", "ORGANISM_SUBDIVISION", 272, 276], ["patient", "SPECIES", 262, 269], ["burn wound infections", "PROBLEM", 142, 163], ["the burn area", "PROBLEM", 212, 225], ["contaminants", "OBSERVATION", 17, 29], ["burn", "OBSERVATION_MODIFIER", 142, 146], ["wound", "OBSERVATION_MODIFIER", 147, 152], ["infections", "OBSERVATION", 153, 163], ["burn", "OBSERVATION", 216, 220], ["substantial", "OBSERVATION_MODIFIER", 235, 246], ["portion", "OBSERVATION_MODIFIER", 247, 254], ["body", "ANATOMY", 272, 276]]], ["Controlling airborne contamination is of major importance in these cases.", [["airborne contamination", "OBSERVATION", 12, 34]]], ["The susceptibility of patients is partially due to infections (from the large amount of exposed area) and the unique environmental conditions (the required elevated temperatures and humidity in the patient room) that such rooms operate under.", [["infections", "DISEASE", 51, 61], ["patients", "ORGANISM", 22, 30], ["patient", "ORGANISM", 198, 205], ["patients", "SPECIES", 22, 30], ["patient", "SPECIES", 198, 205], ["infections", "PROBLEM", 51, 61], ["the unique environmental conditions", "PROBLEM", 106, 141], ["elevated temperatures", "PROBLEM", 156, 177], ["infections", "OBSERVATION", 51, 61], ["large", "OBSERVATION_MODIFIER", 72, 77], ["amount", "OBSERVATION_MODIFIER", 78, 84], ["environmental conditions", "OBSERVATION", 117, 141]]], ["Furthermore, the biological quality of air in hospital environments is of particular concern as patients may serve as a source of pathogenic microorganism to staff and hospital visitors in addition to other admitted patients.", [["patients", "ORGANISM", 96, 104], ["patients", "ORGANISM", 216, 224], ["patients", "SPECIES", 96, 104], ["patients", "SPECIES", 216, 224], ["pathogenic microorganism", "PROBLEM", 130, 154], ["air", "OBSERVATION", 39, 42]]], ["A classic example of this problem is the tuberculosis outbreak in 2000 [25].IntroductionOutside of healthcare facilities, confined spaces are also susceptible to the transmission of infectious diseases.", [["tuberculosis", "DISEASE", 41, 53], ["infectious diseases", "DISEASE", 182, 201], ["the tuberculosis outbreak", "PROBLEM", 37, 62], ["infectious diseases", "PROBLEM", 182, 201], ["tuberculosis", "OBSERVATION", 41, 53], ["infectious", "OBSERVATION", 182, 192]]], ["Public transportation (especially aircraft and underground subway systems), schools classrooms, and close office quarters provide an environment where a single infected individual can potentially infect a large number of people.", [["people", "ORGANISM", 221, 227], ["people", "SPECIES", 221, 227], ["large", "OBSERVATION_MODIFIER", 205, 210]]], ["Examples include the spread of influenza [26] and severe acute respiratory syndrome (SARS) [30] that have been reported in aircraft travel.", [["influenza", "DISEASE", 31, 40], ["acute respiratory syndrome", "DISEASE", 57, 83], ["SARS", "DISEASE", 85, 89], ["influenza", "PROBLEM", 31, 40], ["severe acute respiratory syndrome", "PROBLEM", 50, 83], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["Other examples include the gas attack on the Tokyo subway system in 1995 [31], and the measles outbreak in office spaces in 1985 [7].", [["measles", "DISEASE", 87, 94], ["the gas attack", "PROBLEM", 23, 37], ["gas attack", "OBSERVATION", 27, 37]]], ["In US schools, students miss approximately 38 million school days each year due to the influenza virus [8].IntroductionMotivated by these issues, it is clear that methods for prediction and control of these contaminants in indoor environments are needed.", [["influenza", "DISEASE", 87, 96], ["influenza virus", "ORGANISM", 87, 102], ["influenza virus", "SPECIES", 87, 102], ["the influenza virus", "PROBLEM", 83, 102]]], ["In this context, Computational Fluid Dynamics (CFD) simulations have been used extensively for determining airflow in indoor environments.", [["Computational Fluid Dynamics (CFD) simulations", "TREATMENT", 17, 63]]], ["The earliest reference to CFD being used for this purpose was the study of the velocity characteristics of ventilated rooms by P.V. Nielsen et al., in 1978 [27].", [["the study", "TEST", 62, 71]]], ["Since then the popularity of running CFD simulations for predicting air flow in indoor spaces has increased rapidly.", [["running CFD simulations", "TEST", 29, 52], ["predicting air flow in indoor spaces", "PROBLEM", 57, 93], ["air flow", "OBSERVATION", 68, 76], ["indoor spaces", "OBSERVATION", 80, 93], ["increased", "OBSERVATION_MODIFIER", 98, 107], ["rapidly", "OBSERVATION_MODIFIER", 108, 115]]], ["ASHRAE has taken efforts to standardize CFD simulation procedures, i.e. to setup, simulate, and perform both verification and validation [1].", [["ASHRAE", "PROTEIN", 0, 6], ["CFD simulation procedures", "TREATMENT", 40, 65]]], ["CFD simulations have also been integrated into building simulation programs like EnergyPlus [37] and ESP-r [16] for establishing boundary conditions of buoyancy based fluid flow.", [["fluid", "ANATOMY", 167, 172], ["ESP", "TEST", 101, 104], ["buoyancy based fluid flow", "TEST", 152, 177], ["fluid flow", "OBSERVATION", 167, 177]]], ["CFD flow fields have also been used for developing methods for scalar-transport in indoor environments.", [["CFD flow fields", "TEST", 0, 15]]], ["Validation for multi-zone CFD simulations with contaminant transport has been performed by building researchers [35], [40].", [["multi-zone CFD simulations", "TREATMENT", 15, 41]]], ["Other validations of scalar contaminant transport has been performed for ventilation efficiency [3], personal ventilation [22], occupant exposure [23] and dispersion [21] of toxic contaminants, and dispersion of contaminants in hospital wards [15].", [["ventilation efficiency", "TREATMENT", 73, 95], ["personal ventilation", "TREATMENT", 101, 121], ["toxic contaminants", "PROBLEM", 174, 192]]], ["The application of contaminant dispersion in the indoor environment applied to emergency situations was investigated by L. Wang et al. [41].", [["contaminant dispersion", "TREATMENT", 19, 41], ["contaminant dispersion", "OBSERVATION", 19, 41]]], ["A few examples include identification of sources using an inverse CFD approach [44], removal of contaminants using different ventilation strategies [17], and contaminant transport in an airliner by moving bodies [32].IntroductionIn the previous discussed work, contaminant transport simulations by solving the scalar transport equations have been shown to produce accurate results, but many limitations exist to utilizing these methods for real-time prediction and control of indoor environments.", [["an inverse CFD approach", "TREATMENT", 55, 78], ["removal of contaminants", "TREATMENT", 85, 108], ["different ventilation strategies", "TREATMENT", 115, 147], ["these methods", "TEST", 422, 435]]], ["Solving the scalar transport equations involves loading a potentially large CFD data and mesh into a computer's memory, and then solving a partial differential equation (PDE) for the transient contaminant transport.", [["Solving the scalar transport equations", "TREATMENT", 0, 38]]], ["Buildings with a complex geometry could require specialized hardware simply to load the CFD data and mesh into memory.", [["specialized hardware", "TREATMENT", 48, 68], ["hardware", "OBSERVATION", 60, 68], ["mesh", "OBSERVATION", 101, 105]]], ["The computational time and memory requirements are too much for wireless sensors designed for a long battery life to manage for real-time decisions.IntroductionThere have been some promising advances that enable simulating fluid behavior in real time.", [["fluid", "ANATOMY", 223, 228], ["wireless sensors", "TREATMENT", 64, 80], ["a long battery life", "TREATMENT", 94, 113]]], ["These include Fast fluid dynamics, lattice Boltzmann methods, and Markov methods.", [["Fast fluid dynamics", "TEST", 14, 33], ["lattice Boltzmann methods", "TREATMENT", 35, 60], ["Markov methods", "TREATMENT", 66, 80], ["Fast", "OBSERVATION_MODIFIER", 14, 18], ["fluid dynamics", "OBSERVATION", 19, 33]]], ["Fast fluid dynamics (FFD) [36] uses a set of low order schemes and a semi-lagrangian approach for advection to reduce computing cost.", [["Fast fluid dynamics (FFD)", "TEST", 0, 25], ["a semi-lagrangian approach", "TREATMENT", 67, 93], ["fluid", "OBSERVATION", 5, 10]]], ["Comparisons of FFD and CFD along with implementation of FFD on graphical hardware with promising results have been recently accomplished by Zuo et al. [45], [46].", [["FFD", "PROTEIN", 56, 59], ["FFD", "TEST", 15, 18], ["CFD", "TEST", 23, 26], ["graphical hardware", "TREATMENT", 63, 81], ["hardware", "OBSERVATION", 73, 81]]], ["The lattice Boltzmann method uses kinetic theory to incorporate physics of micro/mesoscopic processes on the behavior macroscopic modules [9].", [["The lattice Boltzmann method", "TREATMENT", 0, 28], ["micro/mesoscopic processes", "TREATMENT", 75, 101]]], ["Lattice Boltzmann methods have been popular due to their ability for parallelization and implementation on graphical processing units (GPU)s [4], [42].", [["Lattice Boltzmann methods", "TREATMENT", 0, 25]]], ["The third alternative is Markov matrices methods that are the focus of the current work.IntroductionMarkov matrices provide an efficient and elegant approach to modeling the contaminant transport problem.", [["Markov matrices methods", "TREATMENT", 25, 48], ["IntroductionMarkov matrices", "TREATMENT", 88, 115], ["an efficient and elegant approach", "TREATMENT", 124, 157]]], ["This was explored in the recent seminal work by Chen and co-workers for CFD data [10], [11] and Nicas for a multi-zone model [20].", [["CFD data", "TEST", 72, 80], ["a multi-zone model", "TREATMENT", 106, 124]]], ["These methodologies use either Lagrangian particle tracking or a contaminant flux to calculate entries of the Markov matrix.", [["matrix", "CELLULAR_COMPONENT", 117, 123], ["Lagrangian particle tracking", "TREATMENT", 31, 59], ["Markov matrix", "OBSERVATION", 110, 123]]], ["The Markov matrix is used to propagate concentrations of contaminants through time.", [["The Markov matrix", "TREATMENT", 0, 17], ["Markov matrix", "OBSERVATION", 4, 17]]], ["The simulation results using the Markov method compared well with experiments and CFD simulations [10], [11].", [["the Markov method", "TREATMENT", 29, 46], ["CFD simulations", "TEST", 82, 97]]], ["The Markov method is extremely fast compared to Eulerian transport, as only a single matrix-vector multiplication is needed to perform the transient contaminant transport.", [["Eulerian", "SIMPLE_CHEMICAL", 48, 56], ["matrix", "CELLULAR_COMPONENT", 85, 91], ["a single matrix-vector multiplication", "TREATMENT", 76, 113]]], ["Due to the speed of this method, real-time inference of the contaminant field can be performed.", [["this method", "TEST", 20, 31]]], ["Furthermore, by utilizing sparse matrix storage this method drastically reduces the memory requirements needed to perform the analysis.IntroductionAnalyzing the transport of contaminants using Markov matrices has some additional benefits over other fast simulation techniques.", [["matrix", "CELLULAR_COMPONENT", 33, 39], ["sparse matrix storage", "TREATMENT", 26, 47], ["the analysis", "TEST", 122, 134], ["Markov matrices", "TREATMENT", 193, 208]]], ["Not only can Markov matrices be used for forward propagation of contaminants, but they can also be used for inferring the positions of the contaminants at previous times.", [["forward propagation of contaminants", "PROBLEM", 41, 76]]], ["The Markov matrix can be used to develop systematic optimization-based procedure for the optimal locations of actuators and sensors for the sensing and control of contaminants [39], [34].", [["The Markov matrix", "TREATMENT", 0, 17], ["systematic optimization", "TREATMENT", 41, 64], ["based procedure", "TREATMENT", 65, 80], ["actuators and sensors", "TREATMENT", 110, 131]]], ["Furthermore, the linear property of a Markov matrix can also be used to develop a systematic procedure using linear system theory for the optimal control and estimation of contaminant [38], [33].", [["a Markov matrix", "TREATMENT", 36, 51], ["a systematic procedure", "TREATMENT", 80, 102], ["linear system theory", "TREATMENT", 109, 129], ["linear", "OBSERVATION_MODIFIER", 17, 23]]], ["Besides control and estimation applications, the spectral properties of the Markov matrix provides information about the long-term concentration profiles of contaminants in the space and the amount of time contaminants stay at a given position.", [["estimation applications", "TREATMENT", 20, 43], ["long-term concentration", "OBSERVATION_MODIFIER", 121, 144]]], ["Thus, utilization of the Markov matrix for flow field analysis and contaminant transport can be used to get more insight than the standard scalar transport methodology.", [["flow field analysis", "TEST", 43, 62]]], ["An approach dual to the Markov approach using finite dimension approximation of Koopman operator is proposed by M. Georgescu et al. [14] for reducing order modeling in building system.IntroductionWhile the Markov method is very promising, some aspects of the procedure to calculate the Markov matrix are still unclear.", [["matrix", "CELLULAR_COMPONENT", 293, 299], ["the Markov approach", "TREATMENT", 20, 39], ["finite dimension approximation of Koopman operator", "TREATMENT", 46, 96], ["the procedure", "TREATMENT", 255, 268], ["the Markov matrix", "TREATMENT", 282, 299], ["Markov matrix", "OBSERVATION", 286, 299]]], ["The Markov matrix is based on a time step that allows scalar density evolution in a flow field, Fig. 1.", [["Markov matrix", "OBSERVATION", 4, 17], ["scalar density", "OBSERVATION", 54, 68]]], ["Other open parameters are the size of the Markov states, h in Fig. 1, and the number of streamlines needed to construct an accurate Markov matrix.", [["Other open parameters", "TEST", 0, 21], ["size", "OBSERVATION_MODIFIER", 30, 34], ["Markov states", "OBSERVATION", 42, 55], ["Markov matrix", "OBSERVATION", 132, 145]]], ["Establishing guidelines for determining these parameters can help bring the utility of Markov matrices closer to practice.", [["Markov matrices", "TREATMENT", 87, 102]]], ["A standard methodology will provide engineers and researchers an enabling framework for real-time prediction of transient contaminant transport in indoor environments.IntroductionIn this paper, we develop a rigorous framework for estimating the parameters involved in the construction of the Markov matrix from CFD data.", [["CFD data", "TEST", 311, 319]]], ["We present a data driven approach to determine the size of the Markov states.", [["size", "OBSERVATION_MODIFIER", 51, 55]]], ["We then give simple formulas that provide bounds for the time step associated with the Markov matrix, and the ideal time step based on the flow field and Markov state discretization.", [["simple formulas", "TREATMENT", 13, 28], ["the Markov matrix", "TREATMENT", 83, 100], ["the flow field", "TEST", 135, 149]]], ["A set theory approach is utilized to calculate the entries of the Markov matrix that satisfies the contaminant flux from one state to another.", [["A set theory approach", "TREATMENT", 0, 21], ["the Markov matrix", "TREATMENT", 62, 79], ["Markov matrix", "OBSERVATION", 66, 79], ["contaminant flux", "OBSERVATION", 99, 115]]], ["We also provide a method for determining the number of particle traces used in the set theory approach to calculate accurate Markov matrices.", [["a method", "TREATMENT", 16, 24]]], ["Finally we present a flow chart that clearly describes the inputs, the calculation procedure of the Markov matrix, and steps for performing contaminant transport.", [["the calculation procedure", "TREATMENT", 67, 92], ["the Markov matrix", "TREATMENT", 96, 113]]], ["The results of this paper better define the methodology for using Markov matrices for real-time prediction of transient scalar transport.", [["Markov matrices", "TREATMENT", 66, 81], ["transient scalar transport", "TREATMENT", 110, 136]]], ["This methodology opens the door for real-time control, sensing of contaminants, and source identification effecting air quality of indoor environments.Rayleigh\u2013B\u00e9nard convective instability problem ::: Example flow fieldsThe Rayleigh\u2013B\u00e9rnard convective instability problem consists of an enclosed cavity, Fig. 2.", [["cavity", "ORGANISM_SUBDIVISION", 297, 303], ["real-time control", "TREATMENT", 36, 53], ["B\u00e9nard convective instability problem", "PROBLEM", 160, 197], ["Example flow fields", "TEST", 202, 221], ["The Rayleigh\u2013B\u00e9rnard convective instability problem", "PROBLEM", 221, 272], ["convective instability", "OBSERVATION", 167, 189], ["flow fields", "OBSERVATION", 210, 221], ["Rayleigh", "OBSERVATION_MODIFIER", 225, 233], ["convective instability", "OBSERVATION", 242, 264], ["enclosed", "OBSERVATION_MODIFIER", 288, 296], ["cavity", "OBSERVATION", 297, 303], ["Fig", "OBSERVATION_MODIFIER", 305, 308]]], ["The bottom boundary is heated, the top boundary is cooled, and the two side boundaries are perfectly insulated.", [["bottom", "OBSERVATION_MODIFIER", 4, 10], ["boundary", "OBSERVATION_MODIFIER", 11, 19], ["heated", "OBSERVATION", 23, 29], ["top", "OBSERVATION_MODIFIER", 35, 38], ["boundary", "OBSERVATION_MODIFIER", 39, 47], ["cooled", "OBSERVATION", 51, 57]]], ["The boundaries cause the fluid near the top boundary to fall and the fluid near the bottom boundary to rise.", [["fluid", "ANATOMY", 25, 30], ["the fluid", "PROBLEM", 21, 30], ["the fluid", "PROBLEM", 65, 74], ["fluid", "OBSERVATION", 25, 30], ["fall", "OBSERVATION", 56, 60], ["fluid", "OBSERVATION", 69, 74], ["bottom", "ANATOMY_MODIFIER", 84, 90], ["rise", "OBSERVATION_MODIFIER", 103, 107]]], ["The resulting steady flow field is two counter rotating convective cells, Fig. 2.Rayleigh\u2013B\u00e9nard convective instability problem ::: Example flow fieldsThe flow field was simulated using a CFD simulation with a domain discretization of 100 uniform cells in the x-direction, and uniform 50cells in the y-direction.", [["cells", "ANATOMY", 67, 72], ["cells", "ANATOMY", 247, 252], ["cells", "CELL", 67, 72], ["cells", "CELL", 247, 252], ["rotating convective cells", "CELL_LINE", 47, 72], ["B\u00e9nard convective instability problem", "PROBLEM", 90, 127], ["Example flow fields", "TEST", 132, 151], ["a CFD simulation", "TEST", 186, 202], ["a domain discretization", "TREATMENT", 208, 231], ["steady", "OBSERVATION_MODIFIER", 14, 20], ["flow", "OBSERVATION", 21, 25], ["convective cells", "OBSERVATION", 56, 72], ["convective instability", "OBSERVATION", 97, 119], ["flow fields", "OBSERVATION", 140, 151], ["flow", "OBSERVATION_MODIFIER", 155, 159]]], ["Governing equations solved on the domain were the laminar incompressible form of the Navier\u2013Stokes and energy equations.", [["laminar incompressible", "OBSERVATION", 50, 72], ["energy equations", "OBSERVATION", 103, 119]]], ["Buoyancy was introduced using the Boussinesq approximation for density.", [["the Boussinesq approximation", "TREATMENT", 30, 58], ["density", "OBSERVATION", 63, 70]]], ["The Rayleigh number, Ra, for this flow field is 4840.", [["this flow field", "TEST", 29, 44], ["Rayleigh", "OBSERVATION_MODIFIER", 4, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["Ra", "ANATOMY", 21, 23]]], ["Although not shown here, validation of the fluid flow model was performed for the Nusselt number on the boundaries for a cavity with an aspect ratio 1 length to 1 height.", [["fluid", "ANATOMY", 43, 48], ["the fluid flow model", "TEST", 39, 59], ["an aspect ratio", "TEST", 133, 148], ["cavity", "OBSERVATION", 121, 127]]], ["The Nusselt number for laminar flow (103 \u2264 Ra \u2264 105) agreed with the empirical correlation developed by G. Barakos et al. [5].IEA annex 20-2D isothermal benchmark ::: Example flow fieldsThe IEA-annex-20 problem is a ventilated cavity with the inlet on the top section of the left wall and an outlet on the lower right wall.", [["left wall", "ANATOMY", 275, 284], ["lower right wall", "ANATOMY", 306, 322], ["cavity", "ORGAN", 227, 233], ["left wall", "MULTI-TISSUE_STRUCTURE", 275, 284], ["right wall", "MULTI-TISSUE_STRUCTURE", 312, 322], ["laminar flow", "TEST", 23, 35], ["Example flow fields", "TEST", 167, 186], ["a ventilated cavity", "PROBLEM", 214, 233], ["laminar flow", "OBSERVATION", 23, 35], ["flow fields", "OBSERVATION", 175, 186], ["IEA", "ANATOMY", 190, 193], ["20 problem", "OBSERVATION_MODIFIER", 200, 210], ["ventilated cavity", "OBSERVATION", 216, 233], ["inlet", "ANATOMY_MODIFIER", 243, 248], ["left", "ANATOMY_MODIFIER", 275, 279], ["wall", "ANATOMY_MODIFIER", 280, 284], ["outlet", "OBSERVATION", 292, 298], ["lower", "ANATOMY_MODIFIER", 306, 311], ["right", "ANATOMY_MODIFIER", 312, 317], ["wall", "ANATOMY_MODIFIER", 318, 322]]], ["The dimensions of the inlet and outlet relative to the height are linlet/H = 0.056 and loutlet/H = 0.16 respectively.", [["the height", "TEST", 51, 61], ["linlet", "TEST", 66, 72], ["loutlet", "TEST", 87, 94], ["dimensions", "OBSERVATION_MODIFIER", 4, 14], ["inlet", "ANATOMY_MODIFIER", 22, 27], ["outlet", "ANATOMY_MODIFIER", 32, 38], ["height", "OBSERVATION_MODIFIER", 55, 61]]], ["The air at the inlet stays along the ceiling until the air reaches the far right wall.", [["right wall", "ANATOMY", 75, 85], ["right wall", "MULTI-TISSUE_STRUCTURE", 75, 85], ["The air at the inlet stays", "PROBLEM", 0, 26], ["air", "OBSERVATION", 4, 7], ["inlet", "ANATOMY_MODIFIER", 15, 20], ["air", "OBSERVATION", 55, 58], ["far", "ANATOMY_MODIFIER", 71, 74], ["right", "ANATOMY_MODIFIER", 75, 80], ["wall", "ANATOMY_MODIFIER", 81, 85]]], ["The air in the ventilated space creates one large recirculation zone.IEA annex 20-2D isothermal benchmark ::: Example flow fieldsThe flow field was also simulated using a CFD simulation.", [["The air in the ventilated space", "PROBLEM", 0, 31], ["Example flow fields", "TEST", 110, 129], ["a CFD simulation", "TEST", 169, 185], ["air", "OBSERVATION", 4, 7], ["ventilated space", "OBSERVATION", 15, 31], ["one", "OBSERVATION_MODIFIER", 40, 43], ["large", "OBSERVATION_MODIFIER", 44, 49], ["recirculation", "OBSERVATION_MODIFIER", 50, 63], ["zone", "OBSERVATION_MODIFIER", 64, 68], ["flow fields", "OBSERVATION", 118, 129], ["flow", "OBSERVATION_MODIFIER", 133, 137]]], ["The domain was discretized into 112 non-uniform cells in the x-direction, and 40 non-uniform cells in the y-direction, Fig. 3.", [["cells", "ANATOMY", 48, 53], ["x-direction", "ANATOMY", 61, 72], ["cells", "ANATOMY", 93, 98], ["cells", "CELL", 48, 53], ["cells", "CELL", 93, 98], ["the x-direction", "TEST", 57, 72], ["non-uniform cells", "OBSERVATION", 36, 53]]], ["The turbulence model chosen was the two-equation RNG k-\u03b5 model.", [["The turbulence model", "TREATMENT", 0, 20], ["the two-equation RNG k-\u03b5 model", "TREATMENT", 32, 62], ["turbulence", "OBSERVATION", 4, 14]]], ["The Reynolds number is 5000 based on the inlet dimension for the characteristic length.", [["Reynolds", "OBSERVATION_MODIFIER", 4, 12], ["number", "OBSERVATION_MODIFIER", 13, 19], ["length", "OBSERVATION_MODIFIER", 80, 86]]], ["Solutions of the flow field were compared according to the quantities specified by the benchmark (U-velocity at x/H = 1 and 2, and y/H = linlet/2 and H\u2212linlet/2).", [["the flow field", "TEST", 13, 27], ["U-velocity at x/H", "TEST", 98, 115], ["y/H", "TEST", 131, 134], ["linlet", "TEST", 137, 143]]], ["Although not shown here, data produced by the simulations agreed well with the published values [19].Discussion of the example flow fields ::: Example flow fieldsThe flow fields used are based on benchmark CFD problems with a lot of supporting literature.", [["Example flow fields", "TEST", 143, 162], ["The flow fields", "TREATMENT", 162, 177], ["benchmark CFD problems", "PROBLEM", 196, 218], ["flow fields", "OBSERVATION", 151, 162], ["flow fields", "OBSERVATION", 166, 177]]], ["The flow fields are steady state flow fields calculated on structured (uniform for case 1, non-uniform for case 2) CFD meshes.", [["The flow fields", "TEST", 0, 15], ["CFD meshes", "TREATMENT", 115, 125], ["flow", "OBSERVATION_MODIFIER", 4, 8], ["fields", "OBSERVATION_MODIFIER", 9, 15], ["steady", "OBSERVATION_MODIFIER", 20, 26]]], ["Although the flow fields are steady state, the methodology developed in this paper is trivially extended to transient flow fields.", [["transient flow fields", "PROBLEM", 108, 129], ["flow", "OBSERVATION", 13, 17], ["transient", "OBSERVATION_MODIFIER", 108, 117], ["flow fields", "OBSERVATION", 118, 129]]], ["In a transient flow field, the same process is used to construct a Markov matrix corresponding to each snapshot of the transient flow field.", [["transient", "OBSERVATION_MODIFIER", 5, 14], ["flow", "OBSERVATION", 15, 19], ["transient", "OBSERVATION_MODIFIER", 119, 128], ["flow field", "OBSERVATION", 129, 139]]], ["We emphasize that the methodology is very general and can be used on both structured and unstructured CFD meshes for arbitrarily complicated geometries.Mathematics of Markov matrices and scalar transport ::: MethodsIn order to predict the motion of contaminants in indoor environments, the movement of a particle or a discrete volume of the contaminant is tracked through time, Fig. 1.", [["arbitrarily complicated geometries", "PROBLEM", 117, 151], ["Methods", "TREATMENT", 208, 215], ["a particle", "PROBLEM", 302, 312], ["a discrete volume of the contaminant", "PROBLEM", 316, 352], ["discrete", "OBSERVATION_MODIFIER", 318, 326], ["volume", "OBSERVATION_MODIFIER", 327, 333], ["contaminant", "OBSERVATION", 341, 352]]], ["Given the current position of a particle in an airflow field, the particle will move according to the air velocity at its current position.", [["a particle in an airflow field", "TREATMENT", 30, 60], ["the air velocity", "TEST", 98, 114], ["airflow", "OBSERVATION", 47, 54], ["air velocity", "OBSERVATION", 102, 114]]], ["The underlying airflow field governs the motion of a contaminant at each time instant.Mathematics of Markov matrices and scalar transport ::: MethodsAny indoor environment can be discretized into a set of cells {\u03c91, \u2026, \u03c9n}, Fig. 4.", [["cells", "ANATOMY", 205, 210], ["cells", "CELL", 205, 210], ["The underlying airflow field", "PROBLEM", 0, 28], ["Methods", "TREATMENT", 142, 149], ["\u2026", "TEST", 216, 217], ["airflow field", "OBSERVATION", 15, 28]]], ["We also refer to these cells as states.", [["cells", "ANATOMY", 23, 28], ["cells", "CELL", 23, 28]]], ["If only one particle is placed at the center of the state the particle represents the entire volume of the state (state 3, 6, and 7 in Fig. 4).", [["one particle", "OBSERVATION_MODIFIER", 8, 20], ["particle", "OBSERVATION_MODIFIER", 62, 70], ["entire", "OBSERVATION_MODIFIER", 86, 92], ["volume", "OBSERVATION_MODIFIER", 93, 99]]], ["Since there is only one particle per cell, the transition is binary.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41], ["one", "OBSERVATION_MODIFIER", 20, 23], ["particle", "OBSERVATION_MODIFIER", 24, 32], ["per cell", "OBSERVATION", 33, 41]]], ["The result of these transitions are expressed in a transition matrix, Pij, Equation (1), where Pij denotes the probability of a particle placed in state i to transition to state j.", [["a transition matrix", "TREATMENT", 49, 68]]], ["In this example the entries of the transition matrix would be P (3, 6) = 1, P (6, 6) = 1, and P (7, 9) = 1 for initial states 3, 6, and 7 respectively.Mathematics of Markov matrices and scalar transport ::: MethodsIf a set of particles are uniformly placed in a state, each particle represents a fraction of the volume of the state, see state in 1 in Fig. 4.", [["matrix", "CELLULAR_COMPONENT", 46, 52], ["P", "TEST", 62, 63], ["P", "TEST", 76, 77], ["P", "TEST", 94, 95], ["Methods", "TREATMENT", 207, 214], ["transition matrix", "OBSERVATION", 35, 52]]], ["If multiple particles are used then a fraction of those particles after some time \u0394t may end up in different cells, see state 1 in Fig. 4.", [["cells", "ANATOMY", 109, 114], ["\u0394t", "GENE_OR_GENE_PRODUCT", 82, 84], ["cells", "CELL", 109, 114], ["\u0394t", "PROTEIN", 82, 84], ["multiple particles", "PROBLEM", 3, 21], ["a fraction of those particles", "TREATMENT", 36, 65], ["multiple", "OBSERVATION_MODIFIER", 3, 11], ["particles", "OBSERVATION", 12, 21]]], ["Since the transitions for a given state are probabilistic, the matrix in Equation (1) also has the following properties.", [["matrix", "CELLULAR_COMPONENT", 63, 69]]], ["All entries of the matrix, P, are positive (Equation (2)) and the row sum of the matrix is equal to one (Equation (3)), i.e. row stochastic.", [["matrix", "CELLULAR_COMPONENT", 19, 25], ["matrix", "CELLULAR_COMPONENT", 81, 87], ["positive", "OBSERVATION", 34, 42], ["matrix", "ANATOMY_MODIFIER", 81, 87], ["equal", "OBSERVATION_MODIFIER", 91, 96]]], ["A matrix with these properties is called a Markov matrix.", [["matrix", "ANATOMY", 2, 8], ["matrix", "CELLULAR_COMPONENT", 2, 8]]], ["The entries of the Markov matrix are often fairly sparse or limited to a relatively small bandwidth.", [["matrix", "CELLULAR_COMPONENT", 26, 32], ["Markov matrix", "OBSERVATION", 19, 32], ["relatively", "OBSERVATION_MODIFIER", 73, 83], ["small", "OBSERVATION_MODIFIER", 84, 89], ["bandwidth", "OBSERVATION_MODIFIER", 90, 99]]], ["In order to minimize the memory requirements for the Markov matrix, a sparse matrix format is used.", [["matrix", "CELLULAR_COMPONENT", 77, 83], ["the Markov matrix", "TREATMENT", 49, 66]]], ["In sparse matrix format only the nonzero entries are stored, thus minimizing the memory used to store the Markov matrix.(1)P=[P11P12\u22efP1nP21P22\u22efP2n\u22eePn1\u22eePn2\u22ee\u22ee\u22efPnn](2)Pij\u22650foralli,j(3)\u2211j=1n(Pij)=1foralli", [["(1)P=[P11P12\u22efP1nP21P22\u22efP2n\u22eePn1\u22eePn2\u22ee\u22ee\u22efPnn](2)Pij\u22650foralli", "CHEMICAL", 120, 176], ["matrix", "CELLULAR_COMPONENT", 113, 119], ["(1)P=[P11P12\u22efP1nP21P22\u22efP2n\u22eePn1\u22eePn2\u22ee\u22ee\u22efPnn](2)Pij\u22650foralli", "SIMPLE_CHEMICAL", 120, 176], ["j(3)\u2211j=1n(Pij)=1foralli", "SIMPLE_CHEMICAL", 177, 200], ["P11P12", "TEST", 126, 132], ["P1", "TEST", 133, 135], ["P2n\u22ee", "TEST", 143, 147], ["Pn1\u22eePn2\u22ee\u22ee", "TEST", 147, 156], ["Pnn", "TEST", 157, 160], ["Pij\u22650foralli", "TEST", 164, 176], ["\u2211j", "TEST", 181, 183], ["Pij", "TEST", 187, 190], ["sparse", "OBSERVATION_MODIFIER", 3, 9], ["matrix", "OBSERVATION_MODIFIER", 10, 16]]]], "PMC7127144": [["IntroductionSynthesis of C-nucleoside and carbocyclic nucleoside analogs has been inspired by their interesting biological activities as well as chemical and enzymatic stability.", [["C-nucleoside", "CHEMICAL", 25, 37], ["carbocyclic nucleoside", "CHEMICAL", 42, 64], ["C-nucleoside", "CHEMICAL", 25, 37], ["carbocyclic nucleoside", "CHEMICAL", 42, 64], ["C-nucleoside", "SIMPLE_CHEMICAL", 25, 37], ["carbocyclic nucleoside analogs", "SIMPLE_CHEMICAL", 42, 72], ["IntroductionSynthesis", "TREATMENT", 0, 21], ["C-nucleoside", "TREATMENT", 25, 37], ["carbocyclic nucleoside analogs", "TREATMENT", 42, 72], ["enzymatic stability", "OBSERVATION", 158, 177]]], ["C-Nucleosides are a unique class of compounds in which the heterocycle is connected to the sugar moiety by a C\u2013C bond instead of a C\u2013N bond of the natural nucleosides.", [["C-Nucleosides", "CHEMICAL", 0, 13], ["C\u2013C", "CHEMICAL", 109, 112], ["C-Nucleosides", "CHEMICAL", 0, 13], ["sugar", "CHEMICAL", 91, 96], ["C\u2013C", "CHEMICAL", 109, 112], ["C", "CHEMICAL", 131, 132], ["nucleosides", "CHEMICAL", 155, 166], ["C-Nucleosides", "SIMPLE_CHEMICAL", 0, 13], ["sugar moiety", "SIMPLE_CHEMICAL", 91, 103], ["C\u2013C", "SIMPLE_CHEMICAL", 109, 112], ["C\u2013N", "SIMPLE_CHEMICAL", 131, 134], ["natural nucleosides", "SIMPLE_CHEMICAL", 147, 166], ["Nucleosides", "TREATMENT", 2, 13], ["a C\u2013C bond", "TREATMENT", 107, 117], ["a C\u2013N bond of the natural nucleosides", "TREATMENT", 129, 166], ["natural nucleosides", "OBSERVATION", 147, 166]]], ["As a result, they are resistant to the chemical and enzymatic hydrolytic cleavage of the glycosidic bond.", [["enzymatic hydrolytic cleavage", "TREATMENT", 52, 81], ["hydrolytic cleavage", "OBSERVATION", 62, 81], ["glycosidic bond", "OBSERVATION", 89, 104]]], ["C-Nucleosides have received considerable attention due not only to their chemical stability, but also for their interesting biological activities of naturally occurring compounds such as showdomycin, formycins, oxazinomycin, pyrazomycin, etc.1 Also several biologically active synthetic C-nucleosides such as 9-deazaadenosine,2 pseudoisocytidine,3 and thiazofurin4 have been reported to possess both antitumor and antiviral activities.", [["antitumor", "ANATOMY", 400, 409], ["C-Nucleosides", "CHEMICAL", 0, 13], ["showdomycin", "CHEMICAL", 187, 198], ["formycins", "CHEMICAL", 200, 209], ["oxazinomycin", "CHEMICAL", 211, 223], ["pyrazomycin", "CHEMICAL", 225, 236], ["etc.1", "CHEMICAL", 238, 243], ["C-nucleosides", "CHEMICAL", 287, 300], ["9-deazaadenosine,2 pseudoisocytidine,3 and thiazofurin4", "CHEMICAL", 309, 364], ["C-Nucleosides", "CHEMICAL", 0, 13], ["showdomycin", "CHEMICAL", 187, 198], ["formycins", "CHEMICAL", 200, 209], ["oxazinomycin", "CHEMICAL", 211, 223], ["pyrazomycin", "CHEMICAL", 225, 236], ["etc.1", "CHEMICAL", 238, 243], ["C-nucleosides", "CHEMICAL", 287, 300], ["9-deazaadenosine", "CHEMICAL", 309, 325], ["pseudoisocytidine", "CHEMICAL", 328, 345], ["thiazofurin4", "CHEMICAL", 352, 364], ["C-Nucleosides", "GENE_OR_GENE_PRODUCT", 0, 13], ["showdomycin", "SIMPLE_CHEMICAL", 187, 198], ["formycins", "SIMPLE_CHEMICAL", 200, 209], ["oxazinomycin", "SIMPLE_CHEMICAL", 211, 223], ["pyrazomycin", "SIMPLE_CHEMICAL", 225, 236], ["etc.1", "SIMPLE_CHEMICAL", 238, 243], ["C-nucleosides", "SIMPLE_CHEMICAL", 287, 300], ["9-deazaadenosine", "SIMPLE_CHEMICAL", 309, 325], ["2 pseudoisocytidine,3", "SIMPLE_CHEMICAL", 326, 347], ["thiazofurin4", "SIMPLE_CHEMICAL", 352, 364], ["antitumor", "CANCER", 400, 409], ["Nucleosides", "TREATMENT", 2, 13], ["showdomycin", "TREATMENT", 187, 198], ["formycins", "TREATMENT", 200, 209], ["oxazinomycin", "TREATMENT", 211, 223], ["pyrazomycin", "TREATMENT", 225, 236], ["etc.1", "TREATMENT", 238, 243], ["synthetic C-nucleosides", "TREATMENT", 277, 300], ["deazaadenosine", "TREATMENT", 311, 325], ["2 pseudoisocytidine", "TREATMENT", 326, 345], ["thiazofurin4", "TREATMENT", 352, 364], ["antiviral activities", "TREATMENT", 414, 434]]], ["Carbocyclic nucleosides are another class of metabolically stable nucleosides, in which a methylene group replaces the oxygen in the furan ring of the natural nucleosides.5 The natural carbocyclic nucleosides such as neplanocin6 and aristeromycin7 were isolated from microorganisms and were found to possess various biological activities including antiviral and antitumor activities.", [["antitumor", "ANATOMY", 362, 371], ["Carbocyclic nucleosides", "CHEMICAL", 0, 23], ["nucleosides", "CHEMICAL", 66, 77], ["methylene", "CHEMICAL", 90, 99], ["oxygen", "CHEMICAL", 119, 125], ["furan", "CHEMICAL", 133, 138], ["carbocyclic nucleosides", "CHEMICAL", 185, 208], ["neplanocin6", "CHEMICAL", 217, 228], ["aristeromycin7", "CHEMICAL", 233, 247], ["Carbocyclic nucleosides", "CHEMICAL", 0, 23], ["nucleosides", "CHEMICAL", 66, 77], ["methylene", "CHEMICAL", 90, 99], ["oxygen", "CHEMICAL", 119, 125], ["furan", "CHEMICAL", 133, 138], ["nucleosides", "CHEMICAL", 159, 170], ["carbocyclic nucleosides", "CHEMICAL", 185, 208], ["neplanocin6", "CHEMICAL", 217, 228], ["aristeromycin7", "CHEMICAL", 233, 247], ["Carbocyclic nucleosides", "SIMPLE_CHEMICAL", 0, 23], ["nucleosides", "SIMPLE_CHEMICAL", 66, 77], ["methylene", "SIMPLE_CHEMICAL", 90, 99], ["oxygen", "SIMPLE_CHEMICAL", 119, 125], ["furan", "SIMPLE_CHEMICAL", 133, 138], ["natural nucleosides", "SIMPLE_CHEMICAL", 151, 170], ["natural carbocyclic nucleosides", "SIMPLE_CHEMICAL", 177, 208], ["neplanocin6", "SIMPLE_CHEMICAL", 217, 228], ["aristeromycin7", "SIMPLE_CHEMICAL", 233, 247], ["antitumor", "CANCER", 362, 371], ["Carbocyclic nucleosides", "TREATMENT", 0, 23], ["metabolically stable nucleosides", "TREATMENT", 45, 77], ["a methylene group", "TREATMENT", 88, 105], ["the oxygen", "TREATMENT", 115, 125], ["the natural nucleosides", "TREATMENT", 147, 170], ["The natural carbocyclic nucleosides", "TREATMENT", 173, 208], ["neplanocin6", "TREATMENT", 217, 228], ["aristeromycin7", "TREATMENT", 233, 247], ["microorganisms", "PROBLEM", 267, 281], ["antiviral and antitumor activities", "TREATMENT", 348, 382], ["stable", "OBSERVATION_MODIFIER", 59, 65], ["furan ring", "OBSERVATION", 133, 143], ["natural nucleosides", "OBSERVATION", 151, 170], ["carbocyclic nucleosides", "OBSERVATION", 185, 208]]], ["The synthetic carbocyclic nucleosides, abacavir,8 entecavir,9 and lobucavir,10 have shown promising antiviral activities.", [["carbocyclic nucleosides", "CHEMICAL", 14, 37], ["abacavir", "CHEMICAL", 39, 47], ["entecavir,9", "CHEMICAL", 50, 61], ["lobucavir", "CHEMICAL", 66, 75], ["carbocyclic nucleosides", "CHEMICAL", 14, 37], ["abacavir", "CHEMICAL", 39, 47], ["entecavir,9", "CHEMICAL", 50, 61], ["lobucavir", "CHEMICAL", 66, 75], ["carbocyclic nucleosides", "SIMPLE_CHEMICAL", 14, 37], ["abacavir", "SIMPLE_CHEMICAL", 39, 47], ["8 entecavir,9", "SIMPLE_CHEMICAL", 48, 61], ["lobucavir", "SIMPLE_CHEMICAL", 66, 75], ["The synthetic carbocyclic nucleosides", "TREATMENT", 0, 37], ["abacavir", "TREATMENT", 39, 47], ["entecavir,9", "TREATMENT", 50, 61], ["lobucavir", "TREATMENT", 66, 75], ["antiviral activities", "OBSERVATION", 100, 120]]], ["Recently, abacavir and entecavir were approved by the FDA as an anti-HIV agent and anti-hepatitis B virus agent, respectively.IntroductionOn the basis of these chemical and biological properties of C-nucleosides and carbocyclic nucleosides, it was of interest to synthesize hybrid nucleosides, carbocyclic C-nucleosides.", [["abacavir", "CHEMICAL", 10, 18], ["entecavir", "CHEMICAL", 23, 32], ["anti-hepatitis B", "CHEMICAL", 83, 99], ["C-nucleosides", "CHEMICAL", 198, 211], ["carbocyclic nucleosides", "CHEMICAL", 216, 239], ["carbocyclic C-nucleosides", "CHEMICAL", 294, 319], ["abacavir", "CHEMICAL", 10, 18], ["entecavir", "CHEMICAL", 23, 32], ["C-nucleosides", "CHEMICAL", 198, 211], ["carbocyclic nucleosides", "CHEMICAL", 216, 239], ["nucleosides", "CHEMICAL", 281, 292], ["carbocyclic C-nucleosides", "CHEMICAL", 294, 319], ["abacavir", "SIMPLE_CHEMICAL", 10, 18], ["entecavir", "SIMPLE_CHEMICAL", 23, 32], ["anti-hepatitis B virus", "ORGANISM", 83, 105], ["C-nucleosides", "SIMPLE_CHEMICAL", 198, 211], ["carbocyclic nucleosides", "SIMPLE_CHEMICAL", 216, 239], ["hybrid nucleosides", "SIMPLE_CHEMICAL", 274, 292], ["carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 294, 319], ["anti-hepatitis B virus", "SPECIES", 83, 105], ["anti-hepatitis B virus", "SPECIES", 83, 105], ["abacavir", "TREATMENT", 10, 18], ["entecavir", "TREATMENT", 23, 32], ["an anti-HIV agent", "TREATMENT", 61, 78], ["anti-hepatitis B virus agent", "TREATMENT", 83, 111], ["C-nucleosides", "TREATMENT", 198, 211], ["carbocyclic nucleosides", "TREATMENT", 216, 239], ["synthesize hybrid nucleosides", "TREATMENT", 263, 292], ["carbocyclic C-nucleosides", "TREATMENT", 294, 319]]], ["Although some carbocyclic nucleosides and C-nucleosides are naturally occurring, so far no natural carbocyclic C-nucleosides have been identified.", [["carbocyclic nucleosides", "CHEMICAL", 14, 37], ["C-nucleosides", "CHEMICAL", 42, 55], ["C-nucleosides", "CHEMICAL", 111, 124], ["nucleosides", "CHEMICAL", 26, 37], ["C-nucleosides", "CHEMICAL", 42, 55], ["carbocyclic C-nucleosides", "CHEMICAL", 99, 124], ["carbocyclic nucleosides", "SIMPLE_CHEMICAL", 14, 37], ["C-nucleosides", "SIMPLE_CHEMICAL", 42, 55], ["carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 99, 124], ["some carbocyclic nucleosides", "TREATMENT", 9, 37], ["C-nucleosides", "TREATMENT", 42, 55], ["natural carbocyclic C-nucleosides", "TREATMENT", 91, 124], ["carbocyclic nucleosides", "OBSERVATION", 14, 37]]], ["The history of the synthesis of carbocyclic C-nucleosides dates back to 1960s.11 Despite the long history of both carbocyclic and C-nucleosides, only a few carbocyclic C-nucleosides have been synthesized,12 probably due to the synthetic difficulties of these nucleosides.", [["carbocyclic C-nucleosides", "CHEMICAL", 32, 57], ["carbocyclic and C-nucleosides", "CHEMICAL", 114, 143], ["carbocyclic C-nucleosides", "CHEMICAL", 156, 181], ["carbocyclic C-nucleosides", "CHEMICAL", 32, 57], ["carbocyclic and C-nucleosides", "CHEMICAL", 114, 143], ["carbocyclic C-nucleosides", "CHEMICAL", 156, 181], ["nucleosides", "CHEMICAL", 259, 270], ["carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 32, 57], ["carbocyclic", "SIMPLE_CHEMICAL", 114, 125], ["C-nucleosides", "SIMPLE_CHEMICAL", 130, 143], ["carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 156, 181], ["the synthesis of carbocyclic C-nucleosides", "TREATMENT", 15, 57], ["both carbocyclic", "TREATMENT", 109, 125], ["C-nucleosides", "TREATMENT", 130, 143], ["a few carbocyclic C-nucleosides", "TREATMENT", 150, 181], ["the synthetic difficulties of these nucleosides", "PROBLEM", 223, 270]]], ["As part of our ongoing program toward synthesis of novel nucleosides, we were exploring the synthesis of cyclopentenyl carbocyclic nucleosides with unnatural bases.13 Therefore, it was of great interest to synthesize optically active carbocyclic C-nucleosides, possessing a cyclopentenyl moiety as analogs of neplanocin.", [["cyclopentenyl carbocyclic nucleosides", "CHEMICAL", 105, 142], ["carbocyclic C-nucleosides", "CHEMICAL", 234, 259], ["cyclopentenyl", "CHEMICAL", 274, 287], ["neplanocin", "CHEMICAL", 309, 319], ["nucleosides", "CHEMICAL", 57, 68], ["cyclopentenyl carbocyclic nucleosides", "CHEMICAL", 105, 142], ["carbocyclic C-nucleosides", "CHEMICAL", 234, 259], ["cyclopentenyl", "CHEMICAL", 274, 287], ["neplanocin", "CHEMICAL", 309, 319], ["cyclopentenyl carbocyclic nucleosides", "SIMPLE_CHEMICAL", 105, 142], ["carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 234, 259], ["cyclopentenyl moiety", "SIMPLE_CHEMICAL", 274, 294], ["neplanocin", "SIMPLE_CHEMICAL", 309, 319], ["synthesis of novel nucleosides", "TREATMENT", 38, 68], ["the synthesis of cyclopentenyl carbocyclic nucleosides", "TREATMENT", 88, 142], ["unnatural bases", "TREATMENT", 148, 163], ["carbocyclic C-nucleosides", "TREATMENT", 234, 259], ["a cyclopentenyl moiety", "TREATMENT", 272, 294], ["neplanocin", "TREATMENT", 309, 319], ["bases", "ANATOMY_MODIFIER", 158, 163]]], ["Herein, we report the enantiomeric synthesis of purine and pyrimidine cyclopentenyl C-nucleosides 1\u20134 (Fig. 1) from the key intermediate, 2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-ol (5), and their antiviral activities.Synthesis ::: Results and discussionFor the synthesis of target purine and pyrimidine carbocyclic C-nucleosides, we utilized the key intermediate 5 as a chiral starting material, which was prepared from d-ribose in eight steps using recently reported procedure from our group.13a In order to synthesize 9-deazaneplanocin A (1) (Scheme 1), the key intermediate 5 was converted to mesylate 6, followed by SN2 reaction with ethylcyanoacetate in the presence of sodium hydride to give compound 7 in 52% yield plus disubstituted product 8 in 10% yield.", [["purine", "CHEMICAL", 48, 54], ["pyrimidine", "CHEMICAL", 59, 69], ["cyclopentenyl C-nucleosides 1\u20134", "CHEMICAL", 70, 101], ["2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-ol", "CHEMICAL", 138, 202], ["purine", "CHEMICAL", 303, 309], ["pyrimidine", "CHEMICAL", 314, 324], ["C-nucleosides", "CHEMICAL", 337, 350], ["d-ribose", "CHEMICAL", 442, 450], ["9-deazaneplanocin A", "CHEMICAL", 542, 561], ["mesylate", "CHEMICAL", 618, 626], ["ethylcyanoacetate", "CHEMICAL", 660, 677], ["sodium hydride", "CHEMICAL", 697, 711], ["purine", "CHEMICAL", 48, 54], ["pyrimidine cyclopentenyl C-nucleosides", "CHEMICAL", 59, 97], ["2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-ol", "CHEMICAL", 138, 202], ["purine", "CHEMICAL", 303, 309], ["pyrimidine", "CHEMICAL", 314, 324], ["C-nucleosides", "CHEMICAL", 337, 350], ["d-ribose", "CHEMICAL", 442, 450], ["9-deazaneplanocin A", "CHEMICAL", 542, 561], ["mesylate", "CHEMICAL", 618, 626], ["ethylcyanoacetate", "CHEMICAL", 660, 677], ["sodium hydride", "CHEMICAL", 697, 711], ["purine", "SIMPLE_CHEMICAL", 48, 54], ["pyrimidine cyclopentenyl C-nucleosides 1\u20134", "SIMPLE_CHEMICAL", 59, 101], ["2,3-(isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-ol (5)", "SIMPLE_CHEMICAL", 138, 206], ["purine", "SIMPLE_CHEMICAL", 303, 309], ["pyrimidine carbocyclic C-nucleosides", "SIMPLE_CHEMICAL", 314, 350], ["d-ribose", "SIMPLE_CHEMICAL", 442, 450], ["9-deazaneplanocin A (1)", "SIMPLE_CHEMICAL", 542, 565], ["Scheme 1)", "SIMPLE_CHEMICAL", 567, 576], ["mesylate 6", "SIMPLE_CHEMICAL", 618, 628], ["ethylcyanoacetate", "SIMPLE_CHEMICAL", 660, 677], ["sodium hydride", "SIMPLE_CHEMICAL", 697, 711], ["the enantiomeric synthesis of purine", "TREATMENT", 18, 54], ["pyrimidine cyclopentenyl C-nucleosides", "TREATMENT", 59, 97], ["(isopropylidenedioxy)", "TREATMENT", 142, 163], ["trityloxymethyl)", "TREATMENT", 167, 183], ["cyclopenten", "TREATMENT", 186, 197], ["target purine", "TREATMENT", 296, 309], ["pyrimidine carbocyclic C-nucleosides", "TREATMENT", 314, 350], ["a chiral starting material", "TREATMENT", 390, 416], ["procedure", "TREATMENT", 490, 499], ["mesylate", "TREATMENT", 618, 626], ["ethylcyanoacetate", "TREATMENT", 660, 677], ["sodium hydride", "TREATMENT", 697, 711], ["disubstituted product", "TREATMENT", 749, 770]]], ["The optimal temperature was found to be 55 \u00b0C for this reaction, since at 70 \u00b0C the starting material decomposed.", [["The optimal temperature", "TEST", 0, 23], ["this reaction", "PROBLEM", 50, 63]]], ["The assignment of \u03b2-configuration of 7 was performed by proton NOE experiments.13a Selective reduction of ester group of 7 with DIBAL-H, followed by condensation with aminoacetonitrile bisulfate in the presence of sodium acetate, gave the pyrrole precursor 9.12a Protection of the amino nitrogen of 9 as a carbamate with ethylchloroformate followed by cyclization catalyzed by 1,8-diazabicyclo[5.4.0]-undec-7-ene (DBU) and subsequent deprotection of carbamate with sodium carbonate led to the substituted pyrrole 10.", [["ester", "CHEMICAL", 106, 111], ["DIBAL-H", "CHEMICAL", 128, 135], ["aminoacetonitrile bisulfate", "CHEMICAL", 167, 194], ["sodium acetate", "CHEMICAL", 214, 228], ["pyrrole", "CHEMICAL", 239, 246], ["amino nitrogen", "CHEMICAL", 281, 295], ["carbamate", "CHEMICAL", 306, 315], ["ethylchloroformate", "CHEMICAL", 321, 339], ["1,8-diazabicyclo[5.4.0]-undec-7-ene", "CHEMICAL", 377, 412], ["DBU", "CHEMICAL", 414, 417], ["carbamate", "CHEMICAL", 450, 459], ["sodium carbonate", "CHEMICAL", 465, 481], ["pyrrole", "CHEMICAL", 505, 512], ["ester", "CHEMICAL", 106, 111], ["DIBAL-H", "CHEMICAL", 128, 135], ["aminoacetonitrile bisulfate", "CHEMICAL", 167, 194], ["sodium acetate", "CHEMICAL", 214, 228], ["pyrrole", "CHEMICAL", 239, 246], ["amino nitrogen", "CHEMICAL", 281, 295], ["carbamate", "CHEMICAL", 306, 315], ["ethylchloroformate", "CHEMICAL", 321, 339], ["1,8-diazabicyclo[5.4.0]-undec-7-ene", "CHEMICAL", 377, 412], ["DBU", "CHEMICAL", 414, 417], ["carbamate", "CHEMICAL", 450, 459], ["sodium carbonate", "CHEMICAL", 465, 481], ["pyrrole", "CHEMICAL", 505, 512], ["ester", "SIMPLE_CHEMICAL", 106, 111], ["DIBAL-H", "SIMPLE_CHEMICAL", 128, 135], ["aminoacetonitrile bisulfate", "SIMPLE_CHEMICAL", 167, 194], ["sodium acetate", "SIMPLE_CHEMICAL", 214, 228], ["carbamate", "SIMPLE_CHEMICAL", 306, 315], ["ethylchloroformate", "SIMPLE_CHEMICAL", 321, 339], ["1,8-diazabicyclo[5.4.0]-undec-7-ene", "SIMPLE_CHEMICAL", 377, 412], ["DBU", "SIMPLE_CHEMICAL", 414, 417], ["carbamate", "SIMPLE_CHEMICAL", 450, 459], ["sodium carbonate", "SIMPLE_CHEMICAL", 465, 481], ["pyrrole 10", "SIMPLE_CHEMICAL", 505, 515], ["a Selective reduction of ester group", "TREATMENT", 81, 117], ["aminoacetonitrile bisulfate", "TREATMENT", 167, 194], ["sodium acetate", "TREATMENT", 214, 228], ["the pyrrole precursor", "TREATMENT", 235, 256], ["the amino nitrogen", "TREATMENT", 277, 295], ["a carbamate", "TREATMENT", 304, 315], ["ethylchloroformate", "TREATMENT", 321, 339], ["cyclization catalyzed", "TREATMENT", 352, 373], ["undec", "TREATMENT", 401, 406], ["subsequent deprotection of carbamate", "TREATMENT", 423, 459], ["sodium carbonate", "TREATMENT", 465, 481], ["the substituted pyrrole", "TREATMENT", 489, 512]]], ["Condensation of 10 with formamidine acetate in ethanol yielded the protected 9-deazaneplanocin 11 in 61%, which was deprotected with methanolic hydrochloric acid to afford the target compound, 9-deazaneplanocin A (1).Synthesis ::: Results and discussionTo synthesize the carbocyclic 9-deazaguanosine (2) (Scheme 1), substituted ethylcyanoacetate 7 was treated with DIBAL-H followed by condensation with ethylglycinate hydrochloride in the presence of sodium acetate to provide 12.", [["formamidine acetate", "CHEMICAL", 24, 43], ["ethanol", "CHEMICAL", 47, 54], ["9-deazaneplanocin 11", "CHEMICAL", 77, 97], ["hydrochloric acid", "CHEMICAL", 144, 161], ["9-deazaneplanocin A", "CHEMICAL", 193, 212], ["carbocyclic", "CHEMICAL", 271, 282], ["9-deazaguanosine", "CHEMICAL", 283, 299], ["ethylcyanoacetate", "CHEMICAL", 328, 345], ["DIBAL-H", "CHEMICAL", 365, 372], ["ethylglycinate hydrochloride", "CHEMICAL", 403, 431], ["sodium acetate", "CHEMICAL", 451, 465], ["formamidine acetate", "CHEMICAL", 24, 43], ["ethanol", "CHEMICAL", 47, 54], ["9-deazaneplanocin", "CHEMICAL", 77, 94], ["hydrochloric acid", "CHEMICAL", 144, 161], ["9-deazaneplanocin A", "CHEMICAL", 193, 212], ["9-deazaguanosine", "CHEMICAL", 283, 299], ["ethylcyanoacetate", "CHEMICAL", 328, 345], ["DIBAL-H", "CHEMICAL", 365, 372], ["ethylglycinate hydrochloride", "CHEMICAL", 403, 431], ["sodium acetate", "CHEMICAL", 451, 465], ["formamidine acetate", "SIMPLE_CHEMICAL", 24, 43], ["ethanol", "SIMPLE_CHEMICAL", 47, 54], ["9-deazaneplanocin 11", "SIMPLE_CHEMICAL", 77, 97], ["methanolic hydrochloric acid", "SIMPLE_CHEMICAL", 133, 161], ["9-deazaneplanocin A", "SIMPLE_CHEMICAL", 193, 212], ["carbocyclic 9-deazaguanosine (2) (Scheme 1)", "SIMPLE_CHEMICAL", 271, 314], ["substituted ethylcyanoacetate 7", "SIMPLE_CHEMICAL", 316, 347], ["DIBAL-H", "SIMPLE_CHEMICAL", 365, 372], ["ethylglycinate hydrochloride", "SIMPLE_CHEMICAL", 403, 431], ["sodium acetate", "SIMPLE_CHEMICAL", 451, 465], ["formamidine acetate", "TREATMENT", 24, 43], ["ethanol", "TREATMENT", 47, 54], ["deazaneplanocin", "TREATMENT", 79, 94], ["methanolic hydrochloric acid", "TREATMENT", 133, 161], ["the carbocyclic", "TREATMENT", 267, 282], ["deazaguanosine (2) (Scheme", "TREATMENT", 285, 311], ["substituted ethylcyanoacetate", "TREATMENT", 316, 345], ["DIBAL-H", "TREATMENT", 365, 372], ["ethylglycinate hydrochloride", "TREATMENT", 403, 431], ["sodium acetate", "TREATMENT", 451, 465]]], ["N-Protection of 12 with ethyl chloroformate, followed by ring closure with DBU and subsequent deprotection of carbamate, provided 13.", [["ethyl chloroformate", "CHEMICAL", 24, 43], ["DBU", "CHEMICAL", 75, 78], ["carbamate", "CHEMICAL", 110, 119], ["ethyl chloroformate", "CHEMICAL", 24, 43], ["DBU", "CHEMICAL", 75, 78], ["carbamate", "CHEMICAL", 110, 119], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 24, 43], ["DBU", "SIMPLE_CHEMICAL", 75, 78], ["carbamate", "SIMPLE_CHEMICAL", 110, 119], ["Protection", "TREATMENT", 2, 12], ["ethyl chloroformate", "TREATMENT", 24, 43], ["ring closure", "TREATMENT", 57, 69], ["DBU", "TREATMENT", 75, 78], ["subsequent deprotection of carbamate", "TREATMENT", 83, 119]]], ["Treatment of 13 with N-benzoylisothiocyanate and methyl iodide, followed by treatment with methanolic ammonia in a steel bomb at 95 \u00b0C, gave the protected carbocyclic 9-deazaguanosine (14) in 64% yield.", [["N-benzoylisothiocyanate", "CHEMICAL", 21, 44], ["methyl iodide", "CHEMICAL", 49, 62], ["ammonia", "CHEMICAL", 102, 109], ["carbocyclic", "CHEMICAL", 155, 166], ["9-deazaguanosine", "CHEMICAL", 167, 183], ["N-benzoylisothiocyanate", "CHEMICAL", 21, 44], ["methyl iodide", "CHEMICAL", 49, 62], ["ammonia", "CHEMICAL", 102, 109], ["9-deazaguanosine", "CHEMICAL", 167, 183], ["N-benzoylisothiocyanate", "SIMPLE_CHEMICAL", 21, 44], ["methyl iodide", "SIMPLE_CHEMICAL", 49, 62], ["methanolic ammonia", "SIMPLE_CHEMICAL", 91, 109], ["carbocyclic 9-deazaguanosine", "SIMPLE_CHEMICAL", 155, 183], ["N", "TREATMENT", 21, 22], ["benzoylisothiocyanate", "TREATMENT", 23, 44], ["methyl iodide", "TREATMENT", 49, 62], ["methanolic ammonia", "TREATMENT", 91, 109], ["the protected carbocyclic", "TREATMENT", 141, 166], ["deazaguanosine", "TREATMENT", 169, 183]]], ["Deprotection of 14 with methanolic hydrochloric acid gave the target compound 2.Synthesis ::: Results and discussionThe carbocyclic isocytosine (3) was prepared in four steps from the intermediate 6 (Scheme 2).", [["hydrochloric acid", "CHEMICAL", 35, 52], ["carbocyclic isocytosine", "CHEMICAL", 120, 143], ["hydrochloric acid", "CHEMICAL", 35, 52], ["carbocyclic isocytosine", "CHEMICAL", 120, 143], ["methanolic hydrochloric acid", "SIMPLE_CHEMICAL", 24, 52], ["carbocyclic isocytosine (3)", "SIMPLE_CHEMICAL", 120, 147], ["Deprotection", "TREATMENT", 0, 12], ["methanolic hydrochloric acid", "TREATMENT", 24, 52], ["The carbocyclic isocytosine", "TREATMENT", 116, 143]]], ["The SN2 reaction on 6 with diethylmalonate in the presence of sodium hydride gave 15 in 72% yield.", [["diethylmalonate", "CHEMICAL", 27, 42], ["sodium hydride", "CHEMICAL", 62, 76], ["diethylmalonate", "CHEMICAL", 27, 42], ["sodium hydride", "CHEMICAL", 62, 76], ["diethylmalonate", "SIMPLE_CHEMICAL", 27, 42], ["sodium hydride", "SIMPLE_CHEMICAL", 62, 76], ["The SN2 reaction", "PROBLEM", 0, 16], ["diethylmalonate", "TREATMENT", 27, 42], ["sodium hydride", "TREATMENT", 62, 76]]], ["Mono-decarbethoxylation of 15 in the presence of lithium chloride in DMSO gave 1614 in 86% yield, which was then treated with lithium diisopropylamide and ethyl formate in THF, followed by condensation with guanidine carbonate in the presence of sodium ethoxide in ethanol yielded 17 in 64%.", [["Mono-decarbethoxylation", "CHEMICAL", 0, 23], ["lithium chloride", "CHEMICAL", 49, 65], ["DMSO", "CHEMICAL", 69, 73], ["lithium diisopropylamide", "CHEMICAL", 126, 150], ["ethyl formate", "CHEMICAL", 155, 168], ["THF", "CHEMICAL", 172, 175], ["guanidine carbonate", "CHEMICAL", 207, 226], ["sodium ethoxide", "CHEMICAL", 246, 261], ["ethanol", "CHEMICAL", 265, 272], ["lithium chloride", "CHEMICAL", 49, 65], ["DMSO", "CHEMICAL", 69, 73], ["lithium diisopropylamide", "CHEMICAL", 126, 150], ["ethyl formate", "CHEMICAL", 155, 168], ["THF", "CHEMICAL", 172, 175], ["guanidine carbonate", "CHEMICAL", 207, 226], ["sodium ethoxide", "CHEMICAL", 246, 261], ["ethanol", "CHEMICAL", 265, 272], ["lithium chloride", "SIMPLE_CHEMICAL", 49, 65], ["DMSO", "SIMPLE_CHEMICAL", 69, 73], ["lithium diisopropylamide", "SIMPLE_CHEMICAL", 126, 150], ["ethyl formate", "SIMPLE_CHEMICAL", 155, 168], ["THF", "SIMPLE_CHEMICAL", 172, 175], ["guanidine carbonate", "SIMPLE_CHEMICAL", 207, 226], ["sodium ethoxide", "SIMPLE_CHEMICAL", 246, 261], ["ethanol", "SIMPLE_CHEMICAL", 265, 272], ["Mono-decarbethoxylation", "TEST", 0, 23], ["lithium chloride in DMSO", "TREATMENT", 49, 73], ["lithium diisopropylamide", "TREATMENT", 126, 150], ["ethyl formate", "TREATMENT", 155, 168], ["guanidine carbonate", "TREATMENT", 207, 226], ["sodium ethoxide in ethanol", "TREATMENT", 246, 272]]], ["Deprotection of 17 with methanolic hydrochloric acid gave the HCl salt of target compound 3.Synthesis ::: Results and discussionPreparation of the carbocyclic pseudouridine analog 4 was accomplished from 16 in three steps (Scheme 2).", [["hydrochloric acid", "CHEMICAL", 35, 52], ["HCl salt", "CHEMICAL", 62, 70], ["pseudouridine", "CHEMICAL", 159, 172], ["hydrochloric acid", "CHEMICAL", 35, 52], ["HCl", "CHEMICAL", 62, 65], ["carbocyclic pseudouridine", "CHEMICAL", 147, 172], ["methanolic hydrochloric acid", "SIMPLE_CHEMICAL", 24, 52], ["HCl salt", "SIMPLE_CHEMICAL", 62, 70], ["carbocyclic pseudouridine", "SIMPLE_CHEMICAL", 147, 172], ["Deprotection", "TREATMENT", 0, 12], ["methanolic hydrochloric acid", "TREATMENT", 24, 52], ["the HCl salt", "TREATMENT", 58, 70], ["the carbocyclic pseudouridine analog", "TREATMENT", 143, 179]]], ["Compound 16 was treated with lithium diisopropylamide and ethylformate, followed by methyl iodide in DMF, to give the, compound 1815 in 64% yield, which was condensed with urea in the presence of potassium tert-butoxide to afford 19.", [["lithium diisopropylamide", "CHEMICAL", 29, 53], ["ethylformate", "CHEMICAL", 58, 70], ["methyl iodide", "CHEMICAL", 84, 97], ["DMF", "CHEMICAL", 101, 104], ["compound 1815", "CHEMICAL", 119, 132], ["urea", "CHEMICAL", 172, 176], ["potassium tert-butoxide", "CHEMICAL", 196, 219], ["lithium diisopropylamide", "CHEMICAL", 29, 53], ["ethylformate", "CHEMICAL", 58, 70], ["methyl iodide", "CHEMICAL", 84, 97], ["DMF", "CHEMICAL", 101, 104], ["urea", "CHEMICAL", 172, 176], ["potassium tert-butoxide", "CHEMICAL", 196, 219], ["lithium diisopropylamide", "SIMPLE_CHEMICAL", 29, 53], ["ethylformate", "SIMPLE_CHEMICAL", 58, 70], ["methyl iodide", "SIMPLE_CHEMICAL", 84, 97], ["DMF", "SIMPLE_CHEMICAL", 101, 104], ["urea", "SIMPLE_CHEMICAL", 172, 176], ["potassium tert-butoxide", "SIMPLE_CHEMICAL", 196, 219], ["lithium diisopropylamide", "TREATMENT", 29, 53], ["ethylformate", "TREATMENT", 58, 70], ["methyl iodide in DMF", "TREATMENT", 84, 104], ["potassium tert-butoxide", "TREATMENT", 196, 219]]], ["Deprotection of 19 with methanolic hydrochloric acid gave the target compound 4 in 72% yield.", [["hydrochloric acid", "CHEMICAL", 35, 52], ["hydrochloric acid", "CHEMICAL", 35, 52], ["methanolic hydrochloric acid", "SIMPLE_CHEMICAL", 24, 52], ["Deprotection", "TREATMENT", 0, 12], ["methanolic hydrochloric acid", "TREATMENT", 24, 52]]], ["All the compound structures were assigned based on NMR, UV, mass spectroscopy, and elemental analysis.Biological results and conclusions ::: Results and discussionThe synthesized carbocyclic C-nucleosides 1\u20134 were tested for anti-HIV activity as well as cytotoxicity using AZT as the positive control, and the results are summarized in Table 1.", [["carbocyclic C-nucleosides 1\u20134", "CHEMICAL", 179, 208], ["AZT", "CHEMICAL", 273, 276], ["carbocyclic C-nucleosides", "CHEMICAL", 179, 204], ["AZT", "CHEMICAL", 273, 276], ["carbocyclic C-nucleosides 1\u20134", "SIMPLE_CHEMICAL", 179, 208], ["anti-HIV", "CANCER", 225, 233], ["AZT", "SIMPLE_CHEMICAL", 273, 276], ["NMR", "TEST", 51, 54], ["mass spectroscopy", "TEST", 60, 77], ["elemental analysis", "TEST", 83, 101], ["The synthesized carbocyclic C-nucleosides", "TREATMENT", 163, 204], ["anti-HIV activity", "TREATMENT", 225, 242], ["cytotoxicity", "TREATMENT", 254, 266], ["AZT", "TREATMENT", 273, 276], ["the positive control", "TREATMENT", 280, 300]]], ["Anti-HIV activity was determined in human peripheral blood mononuclear (PBM) cells infected with HIV-1 (strain LAI).", [["peripheral blood mononuclear (PBM) cells", "ANATOMY", 42, 82], ["human", "ORGANISM", 36, 41], ["peripheral blood mononuclear (PBM) cells", "CELL", 42, 82], ["HIV-1", "ORGANISM", 97, 102], ["human peripheral blood mononuclear (PBM) cells", "CELL_TYPE", 36, 82], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 97, 102], ["HIV", "SPECIES", 5, 8], ["human", "SPECIES", 36, 41], ["HIV-1", "SPECIES", 97, 102], ["HIV", "PROBLEM", 97, 100], ["HIV activity", "OBSERVATION", 5, 17]]], ["Among the synthesized nucleosides, only 9-deazaneplanocin A (1) showed moderate anti-HIV-1 activity (EC50 2.0 \u03bcM) and the other compounds did not display any anti-HIV activity.", [["nucleosides", "CHEMICAL", 22, 33], ["9-deazaneplanocin A", "CHEMICAL", 40, 59], ["nucleosides", "CHEMICAL", 22, 33], ["9-deazaneplanocin A", "CHEMICAL", 40, 59], ["nucleosides", "SIMPLE_CHEMICAL", 22, 33], ["9-deazaneplanocin A", "SIMPLE_CHEMICAL", 40, 59], ["anti-HIV-1", "GENE_OR_GENE_PRODUCT", 80, 90], ["anti-HIV", "CANCER", 158, 166], ["the synthesized nucleosides", "TREATMENT", 6, 33], ["moderate anti-HIV", "PROBLEM", 71, 88], ["EC50", "TEST", 101, 105], ["moderate", "OBSERVATION_MODIFIER", 71, 79], ["anti-HIV", "OBSERVATION", 80, 88], ["anti-HIV activity", "OBSERVATION", 158, 175]]], ["Compounds 1\u20134 were also evaluated against a wide variety of viruses, including vaccinia, cowpox, severe acute respiratory syndrome (SARS), Punta Toro virus, West Nile virus, yellow fever, herpes simplex virus 1 and 2, varicella zoster virus, Tacaribe, Venezulean equine encephalitis, Dengue, and hepatitis C. Compounds 2 (EC50 2.5 \u03bcM) and 4 (EC50 65 \u03bcM) showed moderate activity against Punta Toro virus (strain Adames, LLC-MK2 cell line) without any cytotoxicity.", [["LLC-MK2 cell line", "ANATOMY", 420, 437], ["vaccinia, cowpox", "DISEASE", 79, 95], ["acute respiratory syndrome", "DISEASE", 104, 130], ["SARS", "DISEASE", 132, 136], ["yellow fever", "DISEASE", 174, 186], ["herpes simplex virus", "DISEASE", 188, 208], ["varicella zoster", "DISEASE", 218, 234], ["Tacaribe", "CHEMICAL", 242, 250], ["Venezulean equine encephalitis", "DISEASE", 252, 282], ["Dengue", "DISEASE", 284, 290], ["hepatitis", "DISEASE", 296, 305], ["1\u20134", "SIMPLE_CHEMICAL", 10, 13], ["vaccinia", "ORGANISM", 79, 87], ["cowpox", "ORGANISM", 89, 95], ["Punta Toro virus", "ORGANISM", 139, 155], ["West Nile virus", "ORGANISM", 157, 172], ["yellow fever", "ORGANISM", 174, 186], ["herpes simplex virus 1", "ORGANISM", 188, 210], ["2", "ORGANISM", 215, 216], ["varicella zoster virus", "ORGANISM", 218, 240], ["Tacaribe", "ORGANISM", 242, 250], ["Venezulean equine encephalitis", "ORGANISM", 252, 282], ["Dengue", "ORGANISM", 284, 290], ["Punta Toro virus", "ORGANISM", 387, 403], ["LLC-MK2 cell line", "CELL", 420, 437], ["LLC-MK2 cell line", "CELL_LINE", 420, 437], ["Punta Toro virus", "SPECIES", 139, 155], ["West Nile virus", "SPECIES", 157, 172], ["yellow fever", "SPECIES", 174, 186], ["herpes simplex virus 1", "SPECIES", 188, 210], ["varicella zoster virus", "SPECIES", 218, 240], ["Venezulean equine encephalitis", "SPECIES", 252, 282], ["Punta Toro virus", "SPECIES", 387, 403], ["severe acute respiratory syndrome (SARS)", "SPECIES", 97, 137], ["Punta Toro virus", "SPECIES", 139, 155], ["West Nile virus", "SPECIES", 157, 172], ["yellow fever, herpes simplex virus 1", "SPECIES", 174, 210], ["varicella zoster virus", "SPECIES", 218, 240], ["Venezulean equine encephalitis", "SPECIES", 252, 282], ["Punta Toro virus", "SPECIES", 387, 403], ["a wide variety of viruses", "PROBLEM", 42, 67], ["vaccinia", "PROBLEM", 79, 87], ["cowpox", "PROBLEM", 89, 95], ["severe acute respiratory syndrome", "PROBLEM", 97, 130], ["SARS", "PROBLEM", 132, 136], ["Punta Toro virus", "PROBLEM", 139, 155], ["West Nile virus", "PROBLEM", 157, 172], ["yellow fever", "PROBLEM", 174, 186], ["herpes simplex virus", "PROBLEM", 188, 208], ["varicella zoster virus", "PROBLEM", 218, 240], ["Tacaribe", "TREATMENT", 242, 250], ["Venezulean equine encephalitis", "PROBLEM", 252, 282], ["Dengue", "PROBLEM", 284, 290], ["hepatitis C.", "PROBLEM", 296, 308], ["EC50", "TEST", 322, 326], ["EC50", "TEST", 342, 346], ["moderate activity against Punta Toro virus", "PROBLEM", 361, 403], ["MK2 cell line", "TREATMENT", 424, 437], ["any cytotoxicity", "PROBLEM", 447, 463], ["viruses", "OBSERVATION", 60, 67], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory syndrome", "OBSERVATION", 110, 130], ["varicella", "ANATOMY", 218, 227], ["zoster virus", "OBSERVATION", 228, 240], ["equine encephalitis", "OBSERVATION", 263, 282], ["hepatitis", "ANATOMY", 296, 305], ["moderate", "OBSERVATION_MODIFIER", 361, 369], ["LLC", "ANATOMY", 420, 423], ["MK2 cell line", "OBSERVATION", 424, 437]]], ["Compound 3 was slightly active against West Nile virus (New York isolate) (EC50 11 \u03bcM) and compound 4 (EC50 49 \u03bcM) showed marginal activity against SARSCoV (Table 2).", [["compound 4", "CHEMICAL", 91, 101], ["West Nile virus", "ORGANISM", 39, 54], ["West Nile virus", "SPECIES", 39, 54], ["West Nile virus", "SPECIES", 39, 54], ["slightly active", "PROBLEM", 15, 30], ["EC50", "TEST", 75, 79], ["EC50", "TEST", 103, 107], ["marginal activity", "OBSERVATION", 122, 139]]], ["None of other compounds showed any antiviral activity against all other tested viruses.Biological results and conclusions ::: Results and discussionIn summary, enantioselective synthesis of purine and pyrimidine cyclopentenyl C-nucleosides 1\u20134 was achieved from the common key intermediate 5, which was prepared from commercially available d-ribose.", [["purine", "CHEMICAL", 190, 196], ["pyrimidine", "CHEMICAL", 201, 211], ["cyclopentenyl C-nucleosides 1\u20134", "CHEMICAL", 212, 243], ["d-ribose", "CHEMICAL", 340, 348], ["purine", "CHEMICAL", 190, 196], ["pyrimidine cyclopentenyl C-nucleosides", "CHEMICAL", 201, 239], ["d-ribose", "CHEMICAL", 340, 348], ["purine", "SIMPLE_CHEMICAL", 190, 196], ["pyrimidine cyclopentenyl C-nucleosides 1\u20134", "SIMPLE_CHEMICAL", 201, 243], ["d-ribose", "SIMPLE_CHEMICAL", 340, 348], ["enantioselective synthesis of purine", "TREATMENT", 160, 196], ["pyrimidine cyclopentenyl C-nucleosides", "TREATMENT", 201, 239], ["d-ribose", "TREATMENT", 340, 348], ["antiviral activity", "OBSERVATION", 35, 53], ["viruses", "OBSERVATION", 79, 86]]], ["Synthesized compounds were tested as potential antiviral agents.", [["Synthesized compounds", "TREATMENT", 0, 21], ["antiviral agents", "TREATMENT", 47, 63]]], ["However, only 9-deazaneplanocin A (1) exhibited moderate anti-HIV activity.(1S,2R,3R)-[2,3-(Isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-methane sulfonate (6) ::: Materials and methods ::: ExperimentalTo a solution of 5 (12 g, 28.0 mmol) in anhydrous CH2Cl2 (100 mL), Et3N (11.64 mL, 84.0 mmol) was added under N2 atmosphere at 0 \u00b0C. After 5 min, methanesulfonyl chloride (3.24 mL, 42.0 mmol) was slowly added to the reaction mixture at 0 \u00b0C and then stirred for 1 h at room temperature.", [["9-deazaneplanocin A", "CHEMICAL", 14, 33], ["1S,2R,3R)-[2,3-(Isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-methane sulfonate", "CHEMICAL", 76, 170], ["anhydrous CH2Cl2", "CHEMICAL", 257, 273], ["Et3N", "CHEMICAL", 284, 288], ["methanesulfonyl chloride", "CHEMICAL", 363, 387], ["9-deazaneplanocin A", "CHEMICAL", 14, 33], ["(1S,2R,3R)-[2,3-(Isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-methane sulfonate", "CHEMICAL", 75, 170], ["anhydrous CH2Cl2", "CHEMICAL", 257, 273], ["Et3N", "CHEMICAL", 284, 288], ["N2", "CHEMICAL", 327, 329], ["methanesulfonyl chloride", "CHEMICAL", 363, 387], ["9-deazaneplanocin A", "SIMPLE_CHEMICAL", 14, 33], ["anti-HIV", "CANCER", 57, 65], ["1S,2R,3R)-[2,3-(Isopropylidenedioxy)-4-(trityloxymethyl)-4-cyclopenten-1-yl]-methane sulfonate", "SIMPLE_CHEMICAL", 76, 170], ["anhydrous CH2Cl2", "SIMPLE_CHEMICAL", 257, 273], ["Et3N", "SIMPLE_CHEMICAL", 284, 288], ["methanesulfonyl chloride", "SIMPLE_CHEMICAL", 363, 387], ["moderate anti-HIV activity", "PROBLEM", 48, 74], ["(Isopropylidenedioxy)", "TREATMENT", 91, 112], ["trityloxymethyl)", "TREATMENT", 116, 132], ["methane sulfonate", "TREATMENT", 153, 170], ["anhydrous CH2Cl2", "TREATMENT", 257, 273], ["Et3N", "TREATMENT", 284, 288], ["methanesulfonyl chloride", "TREATMENT", 363, 387], ["the reaction mixture", "TREATMENT", 429, 449], ["moderate", "OBSERVATION_MODIFIER", 48, 56], ["anti-HIV activity", "OBSERVATION", 57, 74]]], ["To the reaction mixture, Et3N (20 mL) was added until the solution became basic and then solvent was removed under reduced pressure.", [["Et3N", "CHEMICAL", 25, 29], ["Et3N", "CHEMICAL", 25, 29], ["Et3N", "SIMPLE_CHEMICAL", 25, 29], ["the reaction mixture", "TREATMENT", 3, 23], ["Et3N", "TREATMENT", 25, 29], ["reduced", "OBSERVATION_MODIFIER", 115, 122], ["pressure", "OBSERVATION_MODIFIER", 123, 131]]], ["The residue was purified by silica gel chromatography (hexane\u2013EtOAc = 8:2\u20137:3) to give compound 6 (13.2 g, 93%) as a white solid.", [["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc = 8:2\u20137:3", "CHEMICAL", 55, 77], ["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc", "CHEMICAL", 55, 67], ["silica", "SIMPLE_CHEMICAL", 28, 34], ["hexane\u2013", "SIMPLE_CHEMICAL", 55, 62], ["The residue", "PROBLEM", 0, 11], ["silica gel chromatography", "TEST", 28, 53], ["hexane\u2013EtOAc", "TREATMENT", 55, 67]]], ["Mp 92 \u00b0C; [\u03b1]D25-10.72 (c 1.0, CHCl3); 1H NMR (CDCl3, 500 MHz) \u03b4 7.45\u20137.42 (m, 6H, Tr-H), 7.32\u20137.22 (m, 9H, Tr-H), 6.02 (d, 1H, J= 2 Hz, H-6), 5.43 (m, 1H, H-1), 4.86 (m, 2H, H-2, 3), 3.96 (d, 1H, J= 15.2 Hz, H-5a), 3.69 (d, 1H, J= 15.2 Hz, H-5b), 3.15 (s, 3H, \u2013CH3), 1.37 (s, 3H, \u2013CH3), 1.35 (s, 3H, CH3); 13C NMR (CDCl3, 125 MHz) \u03b4 147.8, 143.7, 128.5, 127.9, 127.2, 124.0, 113.5, 86.4, 80.8, 77.2, 61.0, 39.0, 27.5, 27.1; HRMS-ESI (m/z): (M+H)+ calcd for C29H30O6S, 507.1842; found, 507.1843.(2R/S,1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (7) and (1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (8) ::: Materials and methods ::: ExperimentalTo a solution of NaH (1.87 g, 78.2 mmol) in THF (200 mL) was added ethylcyanoacetate (8.33 mL, 78.2 mmol) in THF (100 mL) under nitrogen atmosphere at 0 \u00b0C. After 1 h, 6 (13.2 g, 26.0 mmol) in THF (0.8 L) was added to the reaction mixture.", [["1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 501, 608], ["1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 618, 728], ["NaH", "CHEMICAL", 792, 795], ["THF", "CHEMICAL", 819, 822], ["ethylcyanoacetate", "CHEMICAL", 842, 859], ["THF", "CHEMICAL", 884, 887], ["THF", "CHEMICAL", 968, 971], ["CHCl3", "CHEMICAL", 31, 36], ["1H", "CHEMICAL", 39, 41], ["CDCl3", "CHEMICAL", 47, 52], ["H", "CHEMICAL", 86, 87], ["H", "CHEMICAL", 111, 112], ["1H", "CHEMICAL", 124, 126], ["1H", "CHEMICAL", 152, 154], ["1H", "CHEMICAL", 193, 195], ["1H", "CHEMICAL", 225, 227], ["3H", "CHEMICAL", 257, 259], ["3H", "CHEMICAL", 277, 279], ["3H", "CHEMICAL", 297, 299], ["CH3", "CHEMICAL", 301, 304], ["13C", "CHEMICAL", 307, 310], ["CDCl3", "CHEMICAL", 316, 321], ["C29H30O6S", "CHEMICAL", 458, 467], ["1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 501, 608], ["(1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 617, 728], ["NaH", "CHEMICAL", 792, 795], ["THF", "CHEMICAL", 819, 822], ["ethylcyanoacetate", "CHEMICAL", 842, 859], ["THF", "CHEMICAL", 884, 887], ["nitrogen", "CHEMICAL", 903, 911], ["THF", "CHEMICAL", 968, 971], ["H-2, 3)", "SIMPLE_CHEMICAL", 175, 182], ["13C", "SIMPLE_CHEMICAL", 307, 310], ["1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (7)", "SIMPLE_CHEMICAL", 501, 612], ["(1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "SIMPLE_CHEMICAL", 617, 728], ["NaH", "SIMPLE_CHEMICAL", 792, 795], ["THF", "SIMPLE_CHEMICAL", 819, 822], ["ethylcyanoacetate", "SIMPLE_CHEMICAL", 842, 859], ["THF", "SIMPLE_CHEMICAL", 884, 887], ["THF", "SIMPLE_CHEMICAL", 968, 971], ["Mp", "TEST", 0, 2], ["D25", "TEST", 13, 16], ["CHCl3", "TEST", 31, 36], ["NMR", "TEST", 42, 45], ["CDCl3", "TEST", 47, 52], ["MHz", "TEST", 58, 61], ["Tr", "TEST", 83, 85], ["Tr", "TEST", 108, 110], ["J", "TEST", 128, 129], ["Hz", "TEST", 133, 135], ["H", "TEST", 137, 138], ["H", "TEST", 156, 157], ["H", "TEST", 175, 176], ["J", "TEST", 197, 198], ["Hz", "TEST", 205, 207], ["H", "TEST", 209, 210], ["d", "TEST", 222, 223], ["1H", "TEST", 225, 227], ["J", "TEST", 229, 230], ["Hz", "TEST", 237, 239], ["H", "TEST", 241, 242], ["b)", "TEST", 244, 246], ["s", "TEST", 254, 255], ["3H", "TEST", 257, 259], ["\u2013CH3", "TEST", 261, 265], ["s", "TEST", 274, 275], ["3H", "TEST", 277, 279], ["\u2013CH3", "TEST", 281, 285], ["3H", "TEST", 297, 299], ["CH3", "TEST", 301, 304], ["NMR", "TEST", 311, 314], ["CDCl3", "TEST", 316, 321], ["MHz", "TEST", 327, 330], ["\u03b4", "TEST", 332, 333], ["HRMS", "TEST", 425, 429], ["ESI", "TEST", 430, 433], ["M+H", "TEST", 442, 445], ["calcd", "TEST", 448, 453], ["C29H30O6S", "TEST", 458, 467], ["S", "TEST", 503, 504], ["S", "TEST", 507, 508], ["Ethyl", "TEST", 514, 519], ["isopropylidenedioxy", "TEST", 530, 549], ["trityloxymethyl", "TEST", 555, 570], ["cyanoacetate", "TEST", 596, 608], ["ethyl", "TREATMENT", 631, 636], ["(isopropylidenedioxy)", "TREATMENT", 649, 670], ["ethylcyanoacetate", "TREATMENT", 842, 859], ["nitrogen atmosphere", "TREATMENT", 903, 922], ["THF", "TREATMENT", 968, 971], ["the reaction mixture", "TREATMENT", 993, 1013]]], ["The mixture was stirred at 50 \u00b0C for 40 h and then cooled to room temperature, H2O (100 mL) was added and extracted with ethyl acetate (2\u00d7 300 mL).", [["H2O", "CHEMICAL", 79, 82], ["ethyl acetate", "CHEMICAL", 121, 134], ["H2O", "CHEMICAL", 79, 82], ["ethyl acetate", "CHEMICAL", 121, 134], ["ethyl acetate", "SIMPLE_CHEMICAL", 121, 134], ["H2O", "TREATMENT", 79, 82], ["ethyl acetate", "TREATMENT", 121, 134]]], ["The combined organic layers were dried over MgSO4, concentrated, and then purified on silica gel column chromatography (hexane\u2013EtOAc = 9:1\u20138:2) to give compound 7 (7.09 g, 52%) and compound 8 (2.43 g, 10%) as white solids.", [["MgSO4", "CHEMICAL", 44, 49], ["silica gel", "CHEMICAL", 86, 96], ["hexane\u2013EtOAc", "CHEMICAL", 120, 132], ["MgSO4", "CHEMICAL", 44, 49], ["silica gel", "CHEMICAL", 86, 96], ["hexane\u2013EtOAc", "CHEMICAL", 120, 132], ["MgSO4", "SIMPLE_CHEMICAL", 44, 49], ["silica", "SIMPLE_CHEMICAL", 86, 92], ["The combined organic layers", "TREATMENT", 0, 27], ["MgSO4", "TREATMENT", 44, 49], ["silica gel column chromatography", "TREATMENT", 86, 118], ["hexane\u2013EtOAc", "TREATMENT", 120, 132], ["organic", "OBSERVATION_MODIFIER", 13, 20], ["layers", "OBSERVATION_MODIFIER", 21, 27]]], ["Compound 7: mp 50 \u00b0C; [\u03b1]D26-14.45 (c 0.5, CHCl3); 1H NMR (CDCl3, 500 MHz) \u03b4 7.45\u20137.43 (m, 6H, Tr-H), 7.31\u20137.22 (m, 9H, Tr-H), 5.87 (d, 1H, J= 11 Hz, H-6\u2032), 5.08 (d, 1H, J= 5.5 Hz, H-3\u2032), 4.68 (d, 0.55H, J= 6.0 Hz, H-2\u2032), 4.62 (d, 0.45H, J= 6.0 Hz, H-2\u2032), 4.31 (m, 2H, \u2013OCH2\u2013), 3.84 (d, 1H, J= 15 Hz, H-5\u2032a), 3.70 (m, 2H, H-5\u2032b, \u2013CHCN), 3.48 (br d, 1H, J= 2.5 Hz, H-1\u2032), 1.35\u20131.31 (m, 9H, \u2013CH3, \u2013C(CH3)2); 13C NMR (CDCl3, 125 MHz) \u03b4 165.0, 164.8, 147.27, 147.25, 143.9, 128.6, 128.5, 127.9, 123.4, 123.2, 115.2, 115.1, 111.4, 111.3, 87.1, 84.4, 84.3, 81.9, 81.4, 63.19, 63.14, 61.4, 51.8, 51.5, 41.2, 40.8, 27.4, 26.0, 25.9, 14.0; HRMS-ESI (m/z): (M+Na)+ calcd for C33H33NO5, 546.2256; found, 546.2248.(2R/S,1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (7) and (1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (8) ::: Materials and methods ::: ExperimentalCompound 8: mp 87 \u00b0C; [\u03b1]D26-18.13 (c 1, CHCl3); 1H NMR (CDCl3, 500 MHz) \u03b4 7.45\u20137.43 (m, 12H, Tr-H), 7.32\u20137.21 (m, 18H, Tr-H), 6.22 (s, 1H, H-6\u2032) 5.78 (s, 1H, H-6\u2033), 5.10 (d, 1H, J= 5.5 Hz, H-3\u2032), 5.01 (d, 1H, J= 6.0 Hz, H-3\u2033), 4.91 (d, 1H, J= 6.0 Hz, H-2\u2032), 4.63 (d, 1H, J= 6.0 Hz, H-2\u2033), 4.33 (m, 2H, \u2013OCH2\u2013), 3.88 (d, 1H, J= 15.5 Hz, H-5\u2032a), 3.82 (d, 1H, J= 14.5 Hz, H-5\u2033a), 3.74 (d, 1H, J= 15 Hz, H-5\u2032b), 3.72 (d, 1H, J= 15 Hz, H-5\u2033b) 3.64 (br s, 1H, H-1\u2032), 3.51 (s, 1H, H-1\u2033) 1.38, 1.35 (2\u00d7 s, 2\u00d7 3H, \u2013C(CH3)2), 130, 1.22 (2\u00d7 s, 2\u00d7 3H, \u2013C(CH3)2).", [["Na", "CHEMICAL", 650, 652], ["2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 712, 815], ["1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 825, 935], ["CHCl3", "CHEMICAL", 43, 48], ["1H", "CHEMICAL", 51, 53], ["CDCl3", "CHEMICAL", 59, 64], ["H", "CHEMICAL", 98, 99], ["H", "CHEMICAL", 123, 124], ["1H", "CHEMICAL", 136, 138], ["1H", "CHEMICAL", 166, 168], ["2H", "CHEMICAL", 265, 267], ["1H", "CHEMICAL", 287, 289], ["H-5\u2032a", "CHEMICAL", 301, 306], ["2H", "CHEMICAL", 318, 320], ["\u2013CHCN", "CHEMICAL", 329, 334], ["1H", "CHEMICAL", 349, 351], ["m, 9H, \u2013CH3, \u2013C(CH3)2", "CHEMICAL", 382, 403], ["13C", "CHEMICAL", 406, 409], ["CDCl3", "CHEMICAL", 415, 420], ["Na", "CHEMICAL", 650, 652], ["C33H33NO5, 546.2256", "CHEMICAL", 665, 684], ["1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 708, 815], ["(1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "CHEMICAL", 824, 935], ["CHCl3", "CHEMICAL", 1023, 1028], ["1H", "CHEMICAL", 1031, 1033], ["CDCl3", "CHEMICAL", 1039, 1044], ["(m, 12H, Tr-H", "CHEMICAL", 1067, 1080], ["(m, 18H, Tr-H", "CHEMICAL", 1093, 1106], ["(s, 1H, H-6\u2032)", "CHEMICAL", 1114, 1127], ["(s, 1H, H-6\u2033)", "CHEMICAL", 1133, 1146], ["1H", "CHEMICAL", 1157, 1159], ["1H", "CHEMICAL", 1188, 1190], ["1H", "CHEMICAL", 1219, 1221], ["1H", "CHEMICAL", 1250, 1252], ["(m, 2H, \u2013OCH2\u2013)", "CHEMICAL", 1277, 1292], ["1H", "CHEMICAL", 1303, 1305], ["H-5\u2032a", "CHEMICAL", 1319, 1324], ["1H", "CHEMICAL", 1336, 1338], ["H-5\u2033a", "CHEMICAL", 1352, 1357], ["1H", "CHEMICAL", 1369, 1371], ["1H", "CHEMICAL", 1400, 1402], ["1H", "CHEMICAL", 1433, 1435], ["1H", "CHEMICAL", 1453, 1455], ["2\u00d7 3H, \u2013C(CH3)2", "CHEMICAL", 1481, 1496], ["3H", "CHEMICAL", 1519, 1521], ["\u2013C(CH3)2", "CHEMICAL", 1523, 1531], ["[\u03b1]D26", "SIMPLE_CHEMICAL", 22, 28], ["H-5\u2032a", "SIMPLE_CHEMICAL", 301, 306], ["H-5\u2032b", "SIMPLE_CHEMICAL", 322, 327], ["\u2013C(CH3)2", "SIMPLE_CHEMICAL", 395, 403], ["13C", "SIMPLE_CHEMICAL", 406, 409], ["M+Na)", "SIMPLE_CHEMICAL", 648, 653], ["1\u2032S,2\u2032S,3\u2032R)-Ethyl-2-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate (7)", "SIMPLE_CHEMICAL", 708, 819], ["(1\u2032S,2\u2032S,3\u2032R)-ethyl-2-bis[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-2-cyanoacetate", "SIMPLE_CHEMICAL", 824, 935], ["H-6\u2032", "SIMPLE_CHEMICAL", 1122, 1126], ["H-6\u2033", "SIMPLE_CHEMICAL", 1141, 1145], ["H-3\u2032", "SIMPLE_CHEMICAL", 1172, 1176], ["H-3\u2033", "SIMPLE_CHEMICAL", 1203, 1207], ["H-2\u2033", "SIMPLE_CHEMICAL", 1265, 1269], ["H-5\u2032a", "SIMPLE_CHEMICAL", 1319, 1324], ["H-5\u2033a", "SIMPLE_CHEMICAL", 1352, 1357], ["H-5\u2033b", "SIMPLE_CHEMICAL", 1414, 1419], ["H-1\u2032", "SIMPLE_CHEMICAL", 1437, 1441], ["1H, H-1\u2033", "SIMPLE_CHEMICAL", 1453, 1461], ["\u2013C(CH3)2)", "SIMPLE_CHEMICAL", 1488, 1497], ["\u2013C(CH3)2", "SIMPLE_CHEMICAL", 1523, 1531], ["mp", "TEST", 12, 14], ["D26", "TEST", 25, 28], ["c", "TEST", 36, 37], ["CHCl3", "TEST", 43, 48], ["NMR", "TEST", 54, 57], ["CDCl3", "TEST", 59, 64], ["MHz", "TEST", 70, 73], ["Tr", "TEST", 95, 97], ["Tr", "TEST", 120, 122], ["J", "TEST", 140, 141], ["Hz", "TEST", 146, 148], ["H", "TEST", 150, 151], ["d", "TEST", 163, 164], ["1H", "TEST", 166, 168], ["J", "TEST", 170, 171], ["Hz", "TEST", 177, 179], ["H", "TEST", 181, 182], ["\u2032", "TEST", 184, 185], ["d", "TEST", 194, 195], ["J", "TEST", 204, 205], ["Hz", "TEST", 211, 213], ["H", "TEST", 215, 216], ["\u2032", "TEST", 218, 219], ["d", "TEST", 228, 229], ["J", "TEST", 238, 239], ["Hz", "TEST", 245, 247], ["H", "TEST", 249, 250], ["\u2032", "TEST", 252, 253], ["m", "TEST", 262, 263], ["2H", "TEST", 265, 267], ["\u2013OCH2\u2013", "TEST", 269, 275], ["d", "TEST", 284, 285], ["1H", "TEST", 287, 289], ["J", "TEST", 291, 292], ["Hz", "TEST", 297, 299], ["H", "TEST", 301, 302], ["m", "TEST", 315, 316], ["2H", "TEST", 318, 320], ["H", "TEST", 322, 323], ["\u2013CHCN", "TEST", 329, 334], ["d", "TEST", 346, 347], ["1H", "TEST", 349, 351], ["J", "TEST", 353, 354], ["Hz", "TEST", 360, 362], ["H", "TEST", 364, 365], ["\u2032", "TEST", 367, 368], ["\u2013", "TEST", 375, 376], ["m", "TEST", 382, 383], ["9H", "TEST", 385, 387], ["\u2013CH3", "TEST", 389, 393], ["\u2013C", "TEST", 395, 397], ["CH3", "TEST", 398, 401], ["13C NMR", "TEST", 406, 413], ["CDCl3", "TEST", 415, 420], ["MHz", "TEST", 426, 429], ["\u03b4", "TEST", 431, 432], ["HRMS", "TEST", 631, 635], ["ESI", "TEST", 636, 639], ["Na", "TEST", 650, 652], ["calcd", "TEST", 655, 660], ["C33H33NO5", "TEST", 665, 674], ["S", "TEST", 714, 715], ["Ethyl", "TEST", 721, 726], ["isopropylidenedioxy", "TEST", 737, 756], ["cyanoacetate", "TREATMENT", 803, 815], ["ethyl", "TREATMENT", 838, 843], ["(isopropylidenedioxy)", "TREATMENT", 856, 877], ["CHCl3", "TEST", 1023, 1028], ["NMR", "TEST", 1034, 1037], ["CDCl3", "TEST", 1039, 1044], ["MHz", "TEST", 1050, 1053], ["m", "TEST", 1068, 1069], ["Tr", "TEST", 1076, 1078], ["\u2013", "TEST", 1087, 1088], ["m", "TEST", 1094, 1095], ["Tr", "TEST", 1102, 1104], ["s", "TEST", 1115, 1116], ["1H", "TEST", 1118, 1120], ["H", "TEST", 1122, 1123], ["s", "TEST", 1134, 1135], ["1H", "TEST", 1137, 1139], ["H", "TEST", 1141, 1142], ["\u2033", "TEST", 1144, 1145], ["d", "TEST", 1154, 1155], ["1H", "TEST", 1157, 1159], ["J", "TEST", 1161, 1162], ["Hz", "TEST", 1168, 1170], ["H", "TEST", 1172, 1173], ["\u2032", "TEST", 1175, 1176], ["d", "TEST", 1185, 1186], ["1H", "TEST", 1188, 1190], ["J", "TEST", 1192, 1193], ["Hz", "TEST", 1199, 1201], ["H", "TEST", 1203, 1204], ["\u2033", "TEST", 1206, 1207], ["d", "TEST", 1216, 1217], ["1H", "TEST", 1219, 1221], ["J", "TEST", 1223, 1224], ["Hz", "TEST", 1230, 1232], ["H", "TEST", 1234, 1235], ["\u2032", "TEST", 1237, 1238], ["d", "TEST", 1247, 1248], ["1H", "TEST", 1250, 1252], ["J", "TEST", 1254, 1255], ["Hz", "TEST", 1261, 1263], ["H", "TEST", 1265, 1266], ["\u2033", "TEST", 1268, 1269], ["m", "TEST", 1278, 1279], ["2H", "TEST", 1281, 1283], ["\u2013OCH2\u2013", "TEST", 1285, 1291], ["d", "TEST", 1300, 1301], ["1H", "TEST", 1303, 1305], ["J", "TEST", 1307, 1308], ["Hz", "TEST", 1315, 1317], ["H", "TEST", 1319, 1320], ["5\u2032a", "TEST", 1321, 1324], ["d", "TEST", 1333, 1334], ["1H", "TEST", 1336, 1338], ["J", "TEST", 1340, 1341], ["Hz", "TEST", 1348, 1350], ["H", "TEST", 1352, 1353], ["5\u2033a", "TEST", 1354, 1357], ["d", "TEST", 1366, 1367], ["1H", "TEST", 1369, 1371], ["J", "TEST", 1373, 1374], ["Hz", "TEST", 1379, 1381], ["H", "TEST", 1383, 1384], ["\u2032b", "TEST", 1386, 1388], ["d", "TEST", 1397, 1398], ["1H", "TEST", 1400, 1402], ["J", "TEST", 1404, 1405], ["Hz", "TEST", 1410, 1412], ["H", "TEST", 1414, 1415], ["5\u2033b", "TEST", 1416, 1419], ["br s", "TEST", 1427, 1431], ["1H", "TEST", 1433, 1435], ["H", "TEST", 1437, 1438], ["\u2032", "TEST", 1440, 1441], ["s", "TEST", 1450, 1451], ["1H", "TEST", 1453, 1455], ["H", "TEST", 1457, 1458], ["1\u2033", "TEST", 1459, 1461], ["s", "TEST", 1478, 1479], ["3H", "TEST", 1484, 1486], ["\u2013C", "TEST", 1488, 1490], ["CH3", "TEST", 1491, 1494], ["s", "TEST", 1513, 1514], ["3H", "TEST", 1519, 1521], ["\u2013C", "TEST", 1523, 1525]]], ["1.31 (t, 3H, J= 6.5 Hz, \u2013CH3); 13C NMR (CDCl3, 125 MHz) \u03b4 167.3, 148.0, 147.4, 143.9, 143.8, 128.6, 128.5, 127.9, 127.1, 122.7, 121.7, 117.1, 111.4, 111.1, 87.1, 84.1, 83.9, 81.4, 81.1, 63.3, 61.5, 57.2, 56.4, 55.5, 27.1, 27.3, 26.1, 25.7, 14.2; HRMS-ESI (m/z): (M+H)+ calcd for C61H59NO8, 933.4319; found, 933.4317.(1\u2032S,2\u2032S,3\u2032R)-3-Amino-2-cyano-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole (10) ::: Materials and methods ::: ExperimentalTo a solution of 7 (3.50 g, 6.68 mmol) in anhydrous ether (60 mL), DIBAL-H (1 M in hexane, 13.36 mL, 13.36 mmol) was added at \u221278 \u00b0C over 10 min.", [["1\u2032S,2\u2032S,3\u2032R)-3-Amino-2-cyano-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole", "CHEMICAL", 317, 430], ["anhydrous ether", "CHEMICAL", 520, 535], ["DIBAL-H", "CHEMICAL", 545, 552], ["13C", "CHEMICAL", 31, 34], ["CDCl3", "CHEMICAL", 40, 45], ["(1\u2032S,2\u2032S,3\u2032R)-3-Amino-2-cyano-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole", "CHEMICAL", 316, 430], ["anhydrous ether", "CHEMICAL", 520, 535], ["DIBAL-H", "CHEMICAL", 545, 552], ["hexane", "CHEMICAL", 561, 567], ["1\u2032S,2\u2032S,3\u2032R)-3-Amino-2-cyano-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole (10) ::", "SIMPLE_CHEMICAL", 317, 438], ["anhydrous ether", "SIMPLE_CHEMICAL", 520, 535], ["DIBAL-H", "SIMPLE_CHEMICAL", 545, 552], ["hexane", "SIMPLE_CHEMICAL", 561, 567], ["t", "TEST", 6, 7], ["J", "TEST", 13, 14], ["Hz", "TEST", 20, 22], ["\u2013CH3", "TEST", 24, 28], ["NMR", "TEST", 35, 38], ["CDCl3", "TEST", 40, 45], ["MHz", "TEST", 51, 54], ["HRMS", "TEST", 246, 250], ["ESI", "TEST", 251, 254], ["C61H59NO8", "TEST", 279, 288], ["S", "TEST", 323, 324], ["Amino", "TEST", 332, 337], ["2-cyano", "TEST", 338, 345], ["isopropylidenedioxy", "TEST", 356, 375], ["trityloxymethyl", "TEST", 381, 396], ["DIBAL-H (1 M in hexane", "TREATMENT", 545, 567]]], ["The mixture was stirred at \u221278 \u00b0C for 30 min and quenched with MeOH (90 mL) at \u221278 \u00b0C. The mixture was stirred for 30 min and concentrated under reduced pressure.", [["MeOH", "CHEMICAL", 63, 67], ["MeOH", "CHEMICAL", 63, 67], ["MeOH", "SIMPLE_CHEMICAL", 63, 67], ["reduced", "OBSERVATION_MODIFIER", 145, 152], ["pressure", "OBSERVATION_MODIFIER", 153, 161]]], ["The resultant solid cake was suspended in EtOAc\u2013MeOH (30:2) and then stirred for 2 h and filtered.", [["solid cake", "ANATOMY", 14, 24], ["EtOAc\u2013MeOH", "CHEMICAL", 42, 52], ["EtOAc\u2013MeOH", "CHEMICAL", 42, 52], ["EtOAc\u2013MeOH", "SIMPLE_CHEMICAL", 42, 52], ["The resultant solid cake", "TREATMENT", 0, 24], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["solid cake", "OBSERVATION", 14, 24]]], ["After removal of the filtrate under reduced pressure, the residue was dissolved in MeOH (70 mL).", [["MeOH", "CHEMICAL", 83, 87], ["MeOH", "SIMPLE_CHEMICAL", 83, 87], ["removal", "TREATMENT", 6, 13], ["the filtrate", "TREATMENT", 17, 29], ["reduced pressure", "TREATMENT", 36, 52], ["the residue", "PROBLEM", 54, 65], ["filtrate", "OBSERVATION", 21, 29], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["pressure", "OBSERVATION_MODIFIER", 44, 52]]], ["Aminoacetonitrile bisulfate (2.57 g, 16.71 mmol), NaOAc\u00b73H2O (2.18 g, 16.04 mmol) were added and the mixture was stirred at rt for 24 h.", [["Aminoacetonitrile bisulfate", "CHEMICAL", 0, 27], ["NaOAc\u00b73H2O", "CHEMICAL", 50, 60], ["Aminoacetonitrile bisulfate", "CHEMICAL", 0, 27], ["NaOAc\u00b73H2O", "CHEMICAL", 50, 60], ["Aminoacetonitrile bisulfate", "SIMPLE_CHEMICAL", 0, 27], ["NaOAc\u00b73H2O", "SIMPLE_CHEMICAL", 50, 60], ["Aminoacetonitrile bisulfate", "TREATMENT", 0, 27], ["NaOAc", "TREATMENT", 50, 55]]], ["The solvent was evaporated and the residue was co-evaporated with MeOH (3\u00d7 60 mL).", [["MeOH", "CHEMICAL", 66, 70], ["MeOH", "CHEMICAL", 66, 70], ["MeOH", "SIMPLE_CHEMICAL", 66, 70], ["The solvent", "TREATMENT", 0, 11], ["the residue", "PROBLEM", 31, 42]]], ["The obtained residue was suspended in EtOAc (100 mL) and stirred for 30 min.", [["EtOAc", "CHEMICAL", 38, 43], ["EtOAc", "SIMPLE_CHEMICAL", 38, 43]]], ["After filtration and concentration, the residue was purified using silica gel column chromatography (hexane\u2013EtOAc = 8:2\u20137:3) to give compound 9 (1.54 g, 45%) as a white solid.", [["silica gel", "CHEMICAL", 67, 77], ["hexane\u2013EtOAc = 8:2\u20137:3", "CHEMICAL", 101, 123], ["compound 9", "CHEMICAL", 133, 143], ["silica gel", "CHEMICAL", 67, 77], ["hexane\u2013EtOAc", "CHEMICAL", 101, 113], ["silica", "SIMPLE_CHEMICAL", 67, 73], ["filtration", "TREATMENT", 6, 16], ["concentration", "TREATMENT", 21, 34], ["the residue", "PROBLEM", 36, 47], ["silica gel column chromatography", "TREATMENT", 67, 99], ["hexane\u2013EtOAc", "TREATMENT", 101, 113]]], ["To a solution of 9 (1.54 g, 2.97 mmol) in anhydrous CH2Cl2 (75 mL), DBU (8.89 mL, 59.5 mmol) and ethyl chloroformate (2.26 g, 20.8 mmol) were added at 0 \u00b0C and the mixture was heated to reflux for 12 h.", [["anhydrous CH2Cl2", "CHEMICAL", 42, 58], ["DBU", "CHEMICAL", 68, 71], ["ethyl chloroformate", "CHEMICAL", 97, 116], ["reflux", "DISEASE", 186, 192], ["anhydrous CH2Cl2", "CHEMICAL", 42, 58], ["DBU", "CHEMICAL", 68, 71], ["ethyl chloroformate", "CHEMICAL", 97, 116], ["anhydrous CH2Cl2", "SIMPLE_CHEMICAL", 42, 58], ["DBU", "SIMPLE_CHEMICAL", 68, 71], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 97, 116], ["anhydrous CH2Cl2", "TREATMENT", 42, 58], ["DBU", "TREATMENT", 68, 71], ["ethyl chloroformate", "TREATMENT", 97, 116], ["the mixture", "TREATMENT", 160, 171], ["reflux", "OBSERVATION", 186, 192]]], ["After removal of the solvent, the residue was dissolved in MeOH (30 mL) and water (1 mL), and then treated with K2CO3 (55 mg, 0.42 mmol).", [["MeOH", "CHEMICAL", 59, 63], ["K2CO3", "CHEMICAL", 112, 117], ["MeOH", "CHEMICAL", 59, 63], ["K2CO3", "CHEMICAL", 112, 117], ["MeOH", "SIMPLE_CHEMICAL", 59, 63], ["K2CO3", "SIMPLE_CHEMICAL", 112, 117], ["removal of the solvent", "TREATMENT", 6, 28], ["the residue", "PROBLEM", 30, 41], ["K2CO3", "TREATMENT", 112, 117]]], ["The new mixture was stirred for 1 h at rt and solvent was removed under reduced pressure.", [["The new mixture", "TREATMENT", 0, 15], ["new", "OBSERVATION_MODIFIER", 4, 7], ["mixture", "OBSERVATION_MODIFIER", 8, 15], ["reduced", "OBSERVATION_MODIFIER", 72, 79], ["pressure", "OBSERVATION_MODIFIER", 80, 88]]], ["The residue was purified by silica gel column chromatography (hexane\u2013EtOAc = 8:2) to give 10 (730 mg, 21% from 7) as a white solid.", [["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc", "CHEMICAL", 62, 74], ["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc", "CHEMICAL", 62, 74], ["silica", "SIMPLE_CHEMICAL", 28, 34], ["The residue", "PROBLEM", 0, 11], ["silica gel column chromatography", "TREATMENT", 28, 60], ["hexane\u2013EtOAc", "TREATMENT", 62, 74]]], ["Mp 92 \u00b0C; [\u03b1]D25-18.37 (c 0.5, CHCl3); UV (MeOH) \u03bbmax, nm: 249; 1H NMR (CDCl3, 500 MHz) \u03b4 7.87 (s, 1H, NH), 7.46 (m, 6H, Tr-H), 7.27 (m, 9H, Tr-H), 6.42 (s, 1H, H-5), 5.97 (s, 1H, H-6\u2032), 5.09 (d, 1H, J= 5.5 Hz, 1H, H-3\u2032), 4.49 (d, 1H, J= 5.5 Hz, H-2\u2032), 3.90 (d, 1H, J= 14 Hz, H-5\u2032a), 3.79 (s, 1H, H-1\u2032), 3.73 (d, 1H, J= 14 Hz, H-5\u2032b), 3.71 (br s, 2H, NH2), 1.40 (s, 3H, CH3), 1.31 (s, 3H, CH3); 13C NMR (CDCl3, 125 MHz) \u03b4 150.0, 143.9, 143.2, 141.6, 128.6, 127.8, 127.18, 127.12, 120.9, 114.6, 113.7, 111.2, 87.1, 85.0, 84.7, 61.4, 47.0, 27.5, 26.0; HRMS-ESI (m/z): (M+Na)+ calcd for C33H31N3O3, 540.2262; found, 540.2286.(1\u2032S,2\u2032S,3\u2032R)-4-Amino-7-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-5H-pyrrolo[3,2-d]pyrimidine (11) ::: Materials and methods ::: ExperimentalA solution of 10 (350 mg, 0.67 mmol) and formamidine acetate (352 mg, 3.38 mmol) in EtOH (20 mL) was heated under reflux for 8 h.", [["Na", "CHEMICAL", 569, 571], ["2\u2032S,3\u2032R)-4-Amino-7-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-5H-pyrrolo[3,2-d]pyrimidine", "CHEMICAL", 627, 745], ["formamidine acetate", "CHEMICAL", 834, 853], ["EtOH", "CHEMICAL", 877, 881], ["reflux", "DISEASE", 907, 913], ["[\u03b1]D25-18.37", "CHEMICAL", 10, 22], ["CHCl3", "CHEMICAL", 31, 36], ["MeOH", "CHEMICAL", 43, 47], ["1H", "CHEMICAL", 64, 66], ["CDCl3", "CHEMICAL", 72, 77], ["1H", "CHEMICAL", 99, 101], ["NH", "CHEMICAL", 103, 105], ["(m, 6H, Tr-H", "CHEMICAL", 113, 125], ["(m, 9H, Tr-H", "CHEMICAL", 133, 145], ["1H", "CHEMICAL", 157, 159], ["1H", "CHEMICAL", 176, 178], ["H", "CHEMICAL", 180, 181], ["1H", "CHEMICAL", 196, 198], ["1H", "CHEMICAL", 211, 213], ["1H", "CHEMICAL", 231, 233], ["1H", "CHEMICAL", 262, 264], ["H-5\u2032a", "CHEMICAL", 276, 281], ["1H", "CHEMICAL", 293, 295], ["1H", "CHEMICAL", 313, 315], ["2H", "CHEMICAL", 347, 349], ["NH2", "CHEMICAL", 351, 354], ["3H", "CHEMICAL", 366, 368], ["CH3", "CHEMICAL", 370, 373], ["3H", "CHEMICAL", 385, 387], ["CH3", "CHEMICAL", 389, 392], ["13C", "CHEMICAL", 395, 398], ["CDCl3", "CHEMICAL", 404, 409], ["Na", "CHEMICAL", 569, 571], ["C33H31N3O3", "CHEMICAL", 584, 594], ["2\u2032S,3\u2032R)-4-Amino-7-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-5H-pyrrolo[3,2-d]pyrimidine", "CHEMICAL", 627, 745], ["formamidine acetate", "CHEMICAL", 834, 853], ["EtOH", "CHEMICAL", 877, 881], ["H-6\u2032", "SIMPLE_CHEMICAL", 180, 184], ["H-3\u2032", "SIMPLE_CHEMICAL", 215, 219], ["H-5\u2032a", "SIMPLE_CHEMICAL", 276, 281], ["H-1\u2032", "SIMPLE_CHEMICAL", 297, 301], ["M+Na)", "SIMPLE_CHEMICAL", 567, 572], ["2\u2032S,3\u2032R)-4-Amino-7-[2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl]-5H-pyrrolo[3,2-d]pyrimidine", "SIMPLE_CHEMICAL", 627, 745], ["formamidine acetate", "SIMPLE_CHEMICAL", 834, 853], ["EtOH", "SIMPLE_CHEMICAL", 877, 881], ["Mp", "TEST", 0, 2], ["D25", "TEST", 13, 16], ["CHCl3", "TEST", 31, 36], ["UV", "TEST", 39, 41], ["nm", "TEST", 55, 57], ["NMR", "TEST", 67, 70], ["CDCl3", "TEST", 72, 77], ["MHz", "TEST", 83, 86], ["s", "TEST", 96, 97], ["NH", "TEST", 103, 105], ["Tr", "TEST", 121, 123], ["Tr", "TEST", 141, 143], ["H", "TEST", 161, 162], ["H", "TEST", 180, 181], ["d", "TEST", 193, 194], ["J", "TEST", 200, 201], ["Hz", "TEST", 207, 209], ["1H", "TEST", 211, 213], ["H", "TEST", 215, 216], ["d", "TEST", 228, 229], ["1H", "TEST", 231, 233], ["J", "TEST", 235, 236], ["Hz", "TEST", 242, 244], ["H", "TEST", 246, 247], ["\u2032", "TEST", 249, 250], ["d", "TEST", 259, 260], ["1H", "TEST", 262, 264], ["J", "TEST", 266, 267], ["Hz", "TEST", 272, 274], ["H", "TEST", 276, 277], ["s", "TEST", 290, 291], ["1H", "TEST", 293, 295], ["H", "TEST", 297, 298], ["\u2032", "TEST", 300, 301], ["d", "TEST", 310, 311], ["1H", "TEST", 313, 315], ["J", "TEST", 317, 318], ["Hz", "TEST", 323, 325], ["H", "TEST", 327, 328], ["\u2032b", "TEST", 330, 332], ["br s", "TEST", 341, 345], ["2H", "TEST", 347, 349], ["NH2", "TEST", 351, 354], ["s", "TEST", 363, 364], ["3H", "TEST", 366, 368], ["CH3", "TEST", 370, 373], ["s", "TEST", 382, 383], ["3H", "TEST", 385, 387], ["CH3", "TEST", 389, 392], ["NMR", "TEST", 399, 402], ["CDCl3", "TEST", 404, 409], ["MHz", "TEST", 415, 418], ["\u03b4", "TEST", 420, 421], ["HRMS", "TEST", 550, 554], ["ESI", "TEST", 555, 558], ["Na", "TEST", 569, 571], ["calcd", "TEST", 574, 579], ["C33H31N3O3", "TEST", 584, 594], ["S", "TEST", 625, 626], ["S", "TEST", 629, 630], ["Amino", "TEST", 638, 643], ["isopropylidenedioxy", "TEST", 654, 673], ["pyrrolo[3,2-d]pyrimidine", "TREATMENT", 721, 745], ["ExperimentalA solution", "TREATMENT", 781, 803], ["formamidine acetate", "TREATMENT", 834, 853], ["reflux", "OBSERVATION", 907, 913]]], ["The solvent was removed by reduced pressure and the residue was purified by silica gel column chromatography (CH2Cl2\u2013MeOH = 98:2) to give 11 (224 mg, 61%) as a white solid.", [["silica gel", "CHEMICAL", 76, 86], ["CH2Cl2\u2013MeOH", "CHEMICAL", 110, 121], ["silica gel", "CHEMICAL", 76, 86], ["CH2Cl2", "CHEMICAL", 110, 116], ["MeOH", "CHEMICAL", 117, 121], ["silica", "SIMPLE_CHEMICAL", 76, 82], ["The solvent", "TREATMENT", 0, 11], ["the residue", "PROBLEM", 48, 59], ["silica gel column chromatography", "TEST", 76, 108], ["pressure", "OBSERVATION_MODIFIER", 35, 43]]], ["Mp 132 \u00b0C; [\u03b1]D25-16.12 (c 0.40, MeOH); UV (MeOH) \u03bbmax, nm: 274; 1H NMR (DMSO-d6, 500 MHz) \u03b4 10.82 (s, 1H, NH), 8.11 (s, 1H, H-2), 7.46\u20137.25 (m, 16H, Tr-H, H-6), 6.75 (s, 2H, \u2013NH2), 5.98 (s, 1H, H-6\u2032), 5.22 (d, 1H, J= 5.5 Hz, H-3\u2032), 4.65 (d, 1H, J= 6 Hz, H-2\u2032), 4.16 (s, 1H, H-1\u2032), 3.70 (d, 1H, J= 13.5 Hz, H-5\u2032a), 3.60 (d, 1H, J= 14 Hz, H-5\u2032b), 1.31 (s, 3H, \u2013CH3), 1.24 (s, 3H, \u2013CH3); 13C NMR (DMSO-d6, 125 MHz) \u03b4 150.6, 150.3, 145.0, 144.1, 141.2, 128.7, 128.5, 128.4, 127.6, 125.6, 115.5, 114.1, 110.4, 86.8, 85.0, 84.7, 61.4, 46.1, 27.9, 26.3; HRMS-ESI (m/z): (M+H)+ calcd for C34H32N4O3, 545.2553; found, 545.2558; Anal.", [["[\u03b1]D25-16.12", "CHEMICAL", 11, 23], ["MeOH", "CHEMICAL", 33, 37], ["MeOH", "CHEMICAL", 44, 48], ["1H", "CHEMICAL", 65, 67], ["DMSO", "CHEMICAL", 73, 77], ["1H", "CHEMICAL", 103, 105], ["NH", "CHEMICAL", 107, 109], ["1H", "CHEMICAL", 121, 123], ["m, 16H, Tr-H, H-6", "CHEMICAL", 142, 159], ["2H", "CHEMICAL", 171, 173], ["NH2", "CHEMICAL", 176, 179], ["1H", "CHEMICAL", 191, 193], ["1H", "CHEMICAL", 211, 213], ["1H", "CHEMICAL", 242, 244], ["1H", "CHEMICAL", 271, 273], ["1H", "CHEMICAL", 291, 293], ["H-5\u2032a", "CHEMICAL", 307, 312], ["1H", "CHEMICAL", 324, 326], ["3H", "CHEMICAL", 355, 357], ["3H", "CHEMICAL", 375, 377], ["13C", "CHEMICAL", 386, 389], ["DMSO", "CHEMICAL", 395, 399], ["C34H32N4O3", "CHEMICAL", 581, 591], ["\u2013NH2)", "SIMPLE_CHEMICAL", 175, 180], ["H-6\u2032", "SIMPLE_CHEMICAL", 195, 199], ["Mp", "TEST", 0, 2], ["\u00b0C", "TEST", 7, 9], ["\u03b1]", "TEST", 12, 14], ["D25", "TEST", 14, 17], ["MeOH", "TEST", 33, 37], ["UV", "TEST", 40, 42], ["MeOH", "TEST", 44, 48], ["\u03bbmax", "TEST", 50, 54], ["nm", "TEST", 56, 58], ["NMR", "TEST", 68, 71], ["DMSO", "TEST", 73, 77], ["d6", "TEST", 78, 80], ["MHz", "TEST", 86, 89], ["s", "TEST", 100, 101], ["1H", "TEST", 103, 105], ["NH", "TEST", 107, 109], ["s", "TEST", 118, 119], ["1H", "TEST", 121, 123], ["H", "TEST", 125, 126], ["m", "TEST", 142, 143], ["Tr", "TEST", 150, 152], ["H", "TEST", 156, 157], ["s", "TEST", 168, 169], ["2H", "TEST", 171, 173], ["NH2", "TEST", 176, 179], ["s", "TEST", 188, 189], ["1H", "TEST", 191, 193], ["H", "TEST", 195, 196], ["\u2032", "TEST", 198, 199], ["d", "TEST", 208, 209], ["1H", "TEST", 211, 213], ["J", "TEST", 215, 216], ["Hz", "TEST", 222, 224], ["H", "TEST", 226, 227], ["\u2032", "TEST", 229, 230], ["d", "TEST", 239, 240], ["1H", "TEST", 242, 244], ["J", "TEST", 246, 247], ["Hz", "TEST", 251, 253], ["H", "TEST", 255, 256], ["\u2032", "TEST", 258, 259], ["s", "TEST", 268, 269], ["1H", "TEST", 271, 273], ["H", "TEST", 275, 276], ["\u2032", "TEST", 278, 279], ["d", "TEST", 288, 289], ["1H", "TEST", 291, 293], ["J", "TEST", 295, 296], ["Hz", "TEST", 303, 305], ["H", "TEST", 307, 308], ["5\u2032a", "TEST", 309, 312], ["d", "TEST", 321, 322], ["1H", "TEST", 324, 326], ["J", "TEST", 328, 329], ["Hz", "TEST", 334, 336], ["H", "TEST", 338, 339], ["\u2032b", "TEST", 341, 343], ["s", "TEST", 352, 353], ["3H", "TEST", 355, 357], ["\u2013CH3", "TEST", 359, 363], ["s", "TEST", 372, 373], ["3H", "TEST", 375, 377], ["\u2013CH3", "TEST", 379, 383], ["NMR", "TEST", 390, 393], ["DMSO", "TEST", 395, 399], ["d6", "TEST", 400, 402], ["MHz", "TEST", 408, 411], ["\u03b4", "TEST", 413, 414], ["HRMS", "TEST", 548, 552], ["ESI", "TEST", 553, 556], ["M+H", "TEST", 565, 568], ["calcd", "TEST", 571, 576], ["C34H32N4O3", "TEST", 581, 591], ["Anal", "ANATOMY", 620, 624]]], ["Calcd for C34H32N4O3: C, 74.98; H, 5.92; N, 10.29; found: C, 74.96; H, 5.88; N, 10.01.(1\u2032S,2\u2032S,3\u2032R)-4-Amino-7-(2\u2032,3\u2032-dihydroxy-4\u2032-hydroxymethyl-4\u2032-cyclopenten-1\u2032-yl)-5H-pyrrolo[3,2-d]pyrimidine (9-deazaneplanocin) (1) ::: Materials and methods ::: ExperimentalA solution of 11 (200 mg, 0.36 mmol) in 12% methanolic HCl (10 mL) was stirred at rt for 2 h.", [["C34H32N4O3", "CHEMICAL", 10, 20], ["1\u2032S,2\u2032S,3\u2032R)-4-Amino-7-(2\u2032,3\u2032-dihydroxy-4\u2032-hydroxymethyl-4\u2032-cyclopenten-1\u2032-yl)-5H-pyrrolo[3,2-d]pyrimidine", "CHEMICAL", 87, 193], ["9-deazaneplanocin", "CHEMICAL", 195, 212], ["methanolic HCl", "CHEMICAL", 304, 318], ["C34H32N4O3", "CHEMICAL", 10, 20], ["C", "CHEMICAL", 22, 23], ["H", "CHEMICAL", 32, 33], ["N", "CHEMICAL", 41, 42], ["C", "CHEMICAL", 58, 59], ["H", "CHEMICAL", 68, 69], ["N", "CHEMICAL", 77, 78], ["(1\u2032S,2\u2032S,3\u2032R)-4-Amino-7-(2\u2032,3\u2032-dihydroxy-4\u2032-hydroxymethyl-4\u2032-cyclopenten-1\u2032-yl)-5H-pyrrolo[3,2-d]pyrimidine", "CHEMICAL", 86, 193], ["9-deazaneplanocin", "CHEMICAL", 195, 212], ["HCl", "CHEMICAL", 315, 318], ["C34H32N4O3: C", "SIMPLE_CHEMICAL", 10, 23], ["C", "SIMPLE_CHEMICAL", 58, 59], ["1\u2032S,2\u2032S,3\u2032R)-4-Amino-7-(2\u2032,3\u2032-dihydroxy-4\u2032-hydroxymethyl-4\u2032-cyclopenten-1\u2032-yl)-5H-pyrrolo[3,2-d]pyrimidine", "SIMPLE_CHEMICAL", 87, 193], ["9-deazaneplanocin", "SIMPLE_CHEMICAL", 195, 212], ["HCl", "SIMPLE_CHEMICAL", 315, 318], ["C", "TEST", 22, 23], ["H", "TEST", 32, 33], ["N", "TEST", 41, 42], ["C", "TEST", 58, 59], ["H", "TEST", 68, 69], ["N", "TEST", 77, 78], ["S", "TEST", 93, 94], ["Amino", "TEST", 102, 107], ["dihydroxy", "TEST", 117, 126], ["pyrrolo", "TREATMENT", 169, 176], ["pyrimidine", "TREATMENT", 183, 193], ["ExperimentalA solution", "TREATMENT", 248, 270], ["12% methanolic HCl", "TREATMENT", 300, 318]]], ["The solvent was evaporated under reduced pressure and the residue was co-evaporated with MeOH (3\u00d7 30 mL).", [["MeOH", "CHEMICAL", 89, 93], ["MeOH", "CHEMICAL", 89, 93], ["MeOH", "SIMPLE_CHEMICAL", 89, 93], ["The solvent", "TREATMENT", 0, 11], ["the residue", "PROBLEM", 54, 65], ["reduced", "OBSERVATION_MODIFIER", 33, 40], ["pressure", "OBSERVATION_MODIFIER", 41, 49]]], ["The product was dissolved in MeOH (15 mL), neutralized with solid NaHCO3, stirred for 2 h, filtered, and concentrated to dryness under reduced pressure.", [["MeOH", "CHEMICAL", 29, 33], ["NaHCO3", "CHEMICAL", 66, 72], ["MeOH", "CHEMICAL", 29, 33], ["NaHCO3", "CHEMICAL", 66, 72], ["MeOH", "SIMPLE_CHEMICAL", 29, 33], ["NaHCO3", "SIMPLE_CHEMICAL", 66, 72], ["solid NaHCO3", "TREATMENT", 60, 72], ["dissolved", "OBSERVATION_MODIFIER", 16, 25], ["reduced pressure", "OBSERVATION", 135, 151]]], ["The residue was purified by column chromatography (amine functionalized silica gel) (CH2Cl2\u2013MeOH = 5:1) to give 1 (60 mg, 63%) as a white solid.", [["amine", "CHEMICAL", 51, 56], ["silica gel", "CHEMICAL", 72, 82], ["CH2Cl2\u2013MeOH", "CHEMICAL", 85, 96], ["amine", "CHEMICAL", 51, 56], ["silica gel", "CHEMICAL", 72, 82], ["CH2Cl2", "CHEMICAL", 85, 91], ["MeOH", "CHEMICAL", 92, 96], ["amine", "SIMPLE_CHEMICAL", 51, 56], ["The residue", "PROBLEM", 0, 11], ["column chromatography", "TEST", 28, 49], ["amine functionalized silica gel", "TREATMENT", 51, 82], ["CH2Cl2\u2013MeOH", "TREATMENT", 85, 96]]], ["Mp 202 \u00b0C; [\u03b1]D26-129.56 (c 0.30, MeOH); UV (H2O) \u03bbmax, nm: 276 (18,530, pH 2), 275 (11,760, pH 7), 274 (11,720, pH 11); 1H NMR (DMSO-d6, 500 MHz) \u03b4 10.76 (s, 1H, NH), 8.11 (s, 1H, H-2), 7.33 (d, 1H, J= 2.0 Hz, H-6), 6.73 (s, 2H, NH2), 5.83 (d, 1H, J= 2 Hz, H-6\u2032), 5.41 (br s, 1H, OH), 4.75 (t, 1H, J= 5.5 Hz, OH), 4.53 (d, 1H, J= 6.5 Hz, OH), 4.37 (t, 1H, J= 5.5 Hz, H-3\u2032), 4.08 (m, 3H, H-2\u2032,5\u2032a,b), 3.92 (d, 1H, J= 2.5 Hz, H-1\u2032); 13C NMR (DMSO-d6, 125 MHz) \u03b4 150.6, 149.9, 145.3, 144.9, 129.1, 125.6, 116.1, 114.1, 78.3, 73.6, 58.9, 46.0; HRMS-ESI (m/z): (M+Na)+ calcd for C12H14N4O3, 263.1148; found, 263.1170; Anal.", [["H2O", "CHEMICAL", 45, 48], ["Na", "CHEMICAL", 560, 562], ["MeOH", "CHEMICAL", 34, 38], ["H2O", "CHEMICAL", 45, 48], ["1H", "CHEMICAL", 121, 123], ["DMSO", "CHEMICAL", 129, 133], ["1H", "CHEMICAL", 159, 161], ["NH", "CHEMICAL", 163, 165], ["1H", "CHEMICAL", 177, 179], ["1H", "CHEMICAL", 196, 198], ["2H", "CHEMICAL", 226, 228], ["NH2", "CHEMICAL", 230, 233], ["1H", "CHEMICAL", 245, 247], ["1H", "CHEMICAL", 277, 279], ["OH", "CHEMICAL", 281, 283], ["1H", "CHEMICAL", 295, 297], ["OH", "CHEMICAL", 310, 312], ["1H", "CHEMICAL", 324, 326], ["OH", "CHEMICAL", 339, 341], ["1H", "CHEMICAL", 353, 355], ["3H", "CHEMICAL", 384, 386], ["1H", "CHEMICAL", 410, 412], ["H", "CHEMICAL", 425, 426], ["13C", "CHEMICAL", 432, 435], ["DMSO", "CHEMICAL", 441, 445], ["Na", "CHEMICAL", 560, 562], ["C12H14N4O3", "CHEMICAL", 575, 585], ["H-6\u2032", "SIMPLE_CHEMICAL", 258, 262], ["H-2\u2032,5\u2032a,b)", "SIMPLE_CHEMICAL", 388, 399], ["13C", "SIMPLE_CHEMICAL", 432, 435], ["Mp", "TEST", 0, 2], ["MeOH", "TEST", 34, 38], ["pH", "TEST", 73, 75], ["pH", "TEST", 93, 95], ["pH", "TEST", 113, 115], ["NMR", "TEST", 124, 127], ["DMSO", "TEST", 129, 133], ["MHz", "TEST", 142, 145], ["s", "TEST", 174, 175], ["1H", "TEST", 177, 179], ["H", "TEST", 181, 182], ["d", "TEST", 193, 194], ["1H", "TEST", 196, 198], ["J", "TEST", 200, 201], ["Hz", "TEST", 207, 209], ["H", "TEST", 211, 212], ["s", "TEST", 223, 224], ["NH2", "TEST", 230, 233], ["d", "TEST", 242, 243], ["1H", "TEST", 245, 247], ["J", "TEST", 249, 250], ["Hz", "TEST", 254, 256], ["H", "TEST", 258, 259], ["\u2032", "TEST", 261, 262], ["br s", "TEST", 271, 275], ["1H", "TEST", 277, 279], ["OH", "TEST", 281, 283], ["t", "TEST", 292, 293], ["1H", "TEST", 295, 297], ["J", "TEST", 299, 300], ["Hz", "TEST", 306, 308], ["OH", "TEST", 310, 312], ["d", "TEST", 321, 322], ["1H", "TEST", 324, 326], ["J", "TEST", 328, 329], ["Hz", "TEST", 335, 337], ["OH", "TEST", 339, 341], ["t", "TEST", 350, 351], ["1H", "TEST", 353, 355], ["J", "TEST", 357, 358], ["Hz", "TEST", 364, 366], ["H", "TEST", 368, 369], ["\u2032", "TEST", 371, 372], ["m", "TEST", 381, 382], ["3H", "TEST", 384, 386], ["H", "TEST", 388, 389], ["\u2032", "TEST", 391, 392], ["b", "TEST", 397, 398], ["d", "TEST", 407, 408], ["1H", "TEST", 410, 412], ["J", "TEST", 414, 415], ["Hz", "TEST", 421, 423], ["H", "TEST", 425, 426], ["NMR", "TEST", 436, 439], ["DMSO", "TEST", 441, 445], ["d6", "TEST", 446, 448], ["MHz", "TEST", 454, 457], ["\u03b4", "TEST", 459, 460], ["HRMS", "TEST", 541, 545], ["ESI", "TEST", 546, 549], ["Na", "TEST", 560, 562], ["calcd", "TEST", 565, 570], ["C12H14N4O3", "TEST", 575, 585], ["Anal", "ANATOMY", 614, 618]]], ["Calcd for C12H14N4O3\u00b70.8H2O: C, 52.03; H, 5.69; N, 20.02; found: C, 52.03; H, 5.69; N, 19.98.(1\u2032S,2\u2032S,3\u2032R)-[3-Amino-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole]-2-carboxylic acid ethyl ester (13) ::: Materials and methods ::: ExperimentalTo a solution of 7 (5.2 g, 9.93 mmol) in anhydrous ether (80 mL), DIBAL-H (1 M in hexane, 19.8 mL) was added at \u221278 \u00b0C over 10 min.", [["C12H14N4O3", "CHEMICAL", 10, 20], ["1\u2032S,2\u2032S,3\u2032R)-[3-Amino-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole]-2-carboxylic acid ethyl ester", "CHEMICAL", 94, 231], ["anhydrous ether", "CHEMICAL", 320, 335], ["DIBAL-H", "CHEMICAL", 345, 352], ["C12H14N4O3", "CHEMICAL", 10, 20], ["0.8H2O", "CHEMICAL", 21, 27], ["C", "CHEMICAL", 29, 30], ["H", "CHEMICAL", 39, 40], ["N", "CHEMICAL", 48, 49], ["C", "CHEMICAL", 65, 66], ["H", "CHEMICAL", 75, 76], ["N", "CHEMICAL", 84, 85], ["(1\u2032S,2\u2032S,3\u2032R)-[3-Amino-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole]-2-carboxylic acid ethyl ester", "CHEMICAL", 93, 231], ["anhydrous ether", "CHEMICAL", 320, 335], ["DIBAL-H", "CHEMICAL", 345, 352], ["hexane", "CHEMICAL", 361, 367], ["C", "SIMPLE_CHEMICAL", 29, 30], ["C", "SIMPLE_CHEMICAL", 65, 66], ["1\u2032S,2\u2032S,3\u2032R)-[3-Amino-4-(2\u2032,3\u2032-(isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-1H-pyrrole]-2-carboxylic acid ethyl ester", "SIMPLE_CHEMICAL", 94, 231], ["anhydrous ether", "SIMPLE_CHEMICAL", 320, 335], ["DIBAL-H", "SIMPLE_CHEMICAL", 345, 352], ["hexane", "SIMPLE_CHEMICAL", 361, 367], ["Calcd", "TEST", 0, 5], ["C12H14N4O3", "TEST", 10, 20], ["C", "TEST", 29, 30], ["H", "TEST", 39, 40], ["N", "TEST", 48, 49], ["C", "TEST", 65, 66], ["H", "TEST", 75, 76], ["N", "TEST", 84, 85], ["S", "TEST", 100, 101], ["Amino", "TEST", 110, 115], ["isopropylidenedioxy", "TEST", 126, 145], ["trityloxymethyl", "TEST", 151, 166], ["DIBAL-H (1 M in hexane", "TREATMENT", 345, 367]]], ["The mixture was stirred at \u221278 \u00b0C for 30 min and quenched with MeOH (90 mL) at \u221278 \u00b0C. The mixture was stirred for 30 min and concentrated under reduced pressure.", [["MeOH", "CHEMICAL", 63, 67], ["MeOH", "CHEMICAL", 63, 67], ["MeOH", "SIMPLE_CHEMICAL", 63, 67], ["reduced", "OBSERVATION_MODIFIER", 145, 152], ["pressure", "OBSERVATION_MODIFIER", 153, 161]]], ["The resultant solid cake was suspended in EtOAc\u2013MeOH (30:2) and then stirred for 1 h and filtered.", [["solid cake", "ANATOMY", 14, 24], ["EtOAc\u2013MeOH", "CHEMICAL", 42, 52], ["EtOAc\u2013MeOH", "CHEMICAL", 42, 52], ["EtOAc\u2013MeOH", "SIMPLE_CHEMICAL", 42, 52], ["The resultant solid cake", "TREATMENT", 0, 24], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["solid cake", "OBSERVATION", 14, 24]]], ["After removal of the filtrate under reduced pressure, the residue was dissolved in MeOH (70 mL).", [["MeOH", "CHEMICAL", 83, 87], ["MeOH", "SIMPLE_CHEMICAL", 83, 87], ["removal", "TREATMENT", 6, 13], ["the filtrate", "TREATMENT", 17, 29], ["reduced pressure", "TREATMENT", 36, 52], ["the residue", "PROBLEM", 54, 65], ["filtrate", "OBSERVATION", 21, 29], ["reduced", "OBSERVATION_MODIFIER", 36, 43], ["pressure", "OBSERVATION_MODIFIER", 44, 52]]], ["Ethylglycinate hydrochloride (3.32 g, 23.8 mmol) and NaOAc\u00b73H2O (3.37 g, 24.8 mmol) were added and the mixture was stirred at rt for 24 h.", [["Ethylglycinate hydrochloride", "CHEMICAL", 0, 28], ["NaOAc\u00b73H2O", "CHEMICAL", 53, 63], ["Ethylglycinate hydrochloride", "CHEMICAL", 0, 28], ["NaOAc\u00b73H2O", "CHEMICAL", 53, 63], ["Ethylglycinate hydrochloride", "SIMPLE_CHEMICAL", 0, 28], ["NaOAc\u00b73H2O", "SIMPLE_CHEMICAL", 53, 63], ["Ethylglycinate hydrochloride", "TREATMENT", 0, 28], ["NaOAc", "TREATMENT", 53, 58]]], ["The solvent was evaporated and the residue was co-evaporated with MeOH (3\u00d7 60 mL).", [["MeOH", "CHEMICAL", 66, 70], ["MeOH", "CHEMICAL", 66, 70], ["MeOH", "SIMPLE_CHEMICAL", 66, 70], ["The solvent", "TREATMENT", 0, 11], ["the residue", "PROBLEM", 31, 42]]], ["The obtained residue was suspended in EtOAc (100 mL) and stirred for 30 min.", [["EtOAc", "CHEMICAL", 38, 43], ["EtOAc", "SIMPLE_CHEMICAL", 38, 43]]], ["After filtration and concentration under vacuum, the residue was purified using silica gel column chromatography (hexane\u2013EtOAc = 8:2\u20137:3) to give compound 12 (2.12 g, 38%) as a white solid.", [["silica gel", "CHEMICAL", 80, 90], ["hexane\u2013EtOAc = 8:2\u20137:3", "CHEMICAL", 114, 136], ["silica gel", "CHEMICAL", 80, 90], ["silica", "SIMPLE_CHEMICAL", 80, 86], ["hexane\u2013EtOAc", "SIMPLE_CHEMICAL", 114, 126], ["filtration", "TREATMENT", 6, 16], ["concentration under vacuum", "TREATMENT", 21, 47], ["the residue", "PROBLEM", 49, 60], ["silica gel column chromatography", "TREATMENT", 80, 112], ["hexane\u2013EtOAc", "TREATMENT", 114, 126]]], ["To a solution of 12 (2.12 g, 3.75 mmol) in dry CH2Cl2 (75 mL) were added DBU (11.23 mL, 75.14 mmol) and ethyl chloroformate (2.50 mL, 26.30 mmol) at 0 \u00b0C and then the mixture was heated to reflux for 6 h.", [["dry CH2Cl2", "CHEMICAL", 43, 53], ["DBU", "CHEMICAL", 73, 76], ["ethyl chloroformate", "CHEMICAL", 104, 123], ["reflux", "DISEASE", 189, 195], ["CH2Cl2", "CHEMICAL", 47, 53], ["DBU", "CHEMICAL", 73, 76], ["ethyl chloroformate", "CHEMICAL", 104, 123], ["DBU", "SIMPLE_CHEMICAL", 73, 76], ["ethyl chloroformate", "SIMPLE_CHEMICAL", 104, 123], ["ethyl chloroformate", "TREATMENT", 104, 123], ["reflux", "OBSERVATION", 189, 195]]], ["After removal of the solvent, the residue was dissolved in MeOH (30 mL) and water (1 mL), and then treated with K2CO3 (50 mg).", [["MeOH", "CHEMICAL", 59, 63], ["K2CO3", "CHEMICAL", 112, 117], ["MeOH", "CHEMICAL", 59, 63], ["K2CO3", "CHEMICAL", 112, 117], ["MeOH", "SIMPLE_CHEMICAL", 59, 63], ["K2CO3", "SIMPLE_CHEMICAL", 112, 117], ["removal of the solvent", "TREATMENT", 6, 28], ["the residue", "PROBLEM", 30, 41], ["K2CO3", "TREATMENT", 112, 117]]], ["This mixture was stirred for 1 h at rt and solvent was removed under reduced pressure.", [["reduced", "OBSERVATION_MODIFIER", 69, 76], ["pressure", "OBSERVATION_MODIFIER", 77, 85]]], ["The residue was purified by silica gel column chromatography (hexane\u2013EtOAc = 4:1) to give 13 (0.986 g, 18% from 7) as a white solid.", [["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc", "CHEMICAL", 62, 74], ["silica gel", "CHEMICAL", 28, 38], ["hexane\u2013EtOAc", "CHEMICAL", 62, 74], ["silica", "SIMPLE_CHEMICAL", 28, 34], ["The residue", "PROBLEM", 0, 11], ["silica gel column chromatography", "TREATMENT", 28, 60], ["hexane\u2013EtOAc", "TREATMENT", 62, 74]]], ["Mp 86 \u00b0C; [\u03b1]D25-16.94 (c 0.50, CHCl3); 1H NMR (CDCl3, 500 MHz) \u03b4 7.49\u20137.46 (m, 6H, Tr-H), 7.32\u20137.22 (m, 9H, Tr-H), 6.45 (br s, 1H, H-5), 6.0 (s, 1H, H-6\u2032), 5.10 (d, 1H, J= 5.5 Hz, H-3\u2032), 4.53 (d, 1H, J= 6.5 Hz, H-2\u2032), 4.31 (q, 2H, \u2013CH2), 3.90 (d, 1H, J= 14 Hz, H-5\u2032a), 3.81 (s, 1H, H-1\u2032), 3.73 (d, 1H, J= 14 Hz, H-5\u2032b), 1.41 (s, 3H, \u2013CH3), 1.35 (t, 3H, J= 7 Hz, \u2013CH3), 1.31 (s, 3H, \u2013CH3); 13C NMR (CDCl3, 125 MHz) \u03b4 162.1, 144.0, 142.7, 128.6, 127.8, 127.5, 127.0, 120.2, 113.2, 111.0, 87.05, 85.2, 84.8, 61.4, 47.0, 27.6, 26.0, 14.7; HRMS-ESI (m/z): (M+Na)+ calcd for C35H36N2O5, 587.2521; found, 587.2438.(1\u2032S,2\u2032S,3\u2032R)-9-(2\u2032,3\u2032-(Isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-9-deazaguanosine (14) ::: Materials and methods ::: Experimental", [["Na", "CHEMICAL", 555, 557], ["3\u2032R)-9-(2\u2032,3\u2032-(Isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-9-deazaguanosine", "CHEMICAL", 617, 712], ["CHCl3", "CHEMICAL", 32, 37], ["1H", "CHEMICAL", 40, 42], ["CDCl3", "CHEMICAL", 48, 53], ["H", "CHEMICAL", 87, 88], ["H", "CHEMICAL", 112, 113], ["1H", "CHEMICAL", 128, 130], ["1H", "CHEMICAL", 146, 148], ["1H", "CHEMICAL", 166, 168], ["1H", "CHEMICAL", 197, 199], ["2H", "CHEMICAL", 228, 230], ["1H", "CHEMICAL", 248, 250], ["H-5\u2032a", "CHEMICAL", 262, 267], ["1H", "CHEMICAL", 279, 281], ["1H", "CHEMICAL", 299, 301], ["3H", "CHEMICAL", 330, 332], ["3H", "CHEMICAL", 379, 381], ["13C", "CHEMICAL", 390, 393], ["CDCl3", "CHEMICAL", 399, 404], ["Na", "CHEMICAL", 555, 557], ["C35H36N2O5", "CHEMICAL", 570, 580], ["(1\u2032S,2\u2032S,3\u2032R)-9-(2\u2032,3\u2032-(Isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-9-deazaguanosine", "CHEMICAL", 608, 712], ["H-6\u2032", "SIMPLE_CHEMICAL", 150, 154], ["H-5\u2032a", "SIMPLE_CHEMICAL", 262, 267], ["H-1\u2032", "SIMPLE_CHEMICAL", 283, 287], ["M+Na)", "SIMPLE_CHEMICAL", 553, 558], ["2\u2032S,3\u2032R)-9-(2\u2032,3\u2032-(Isopropylidenedioxy)-4\u2032-(trityloxymethyl)-4\u2032-cyclopenten-1\u2032-yl)-9-deazaguanosine", "SIMPLE_CHEMICAL", 613, 712], ["Mp", "TEST", 0, 2], ["D25", "TEST", 13, 16], ["CHCl3", "TEST", 32, 37], ["NMR", "TEST", 43, 46], ["CDCl3", "TEST", 48, 53], ["MHz", "TEST", 59, 62], ["m", "TEST", 77, 78], ["6H", "TEST", 80, 82], ["Tr", "TEST", 84, 86], ["m", "TEST", 102, 103], ["Tr", "TEST", 109, 111], ["s", "TEST", 125, 126], ["1H", "TEST", 128, 130], ["H", "TEST", 132, 133], ["s", "TEST", 143, 144], ["1H", "TEST", 146, 148], ["H", "TEST", 150, 151], ["d", "TEST", 163, 164], ["1H", "TEST", 166, 168], ["J", "TEST", 170, 171], ["Hz", "TEST", 177, 179], ["H", "TEST", 181, 182], ["d", "TEST", 194, 195], ["1H", "TEST", 197, 199], ["J", "TEST", 201, 202], ["Hz", "TEST", 208, 210], ["H", "TEST", 212, 213], ["\u2032", "TEST", 215, 216], ["\u2013CH2", "TEST", 232, 236], ["d", "TEST", 245, 246], ["1H", "TEST", 248, 250], ["J", "TEST", 252, 253], ["Hz", "TEST", 258, 260], ["H", "TEST", 262, 263], ["5\u2032a", "TEST", 264, 267], ["s", "TEST", 276, 277], ["1H", "TEST", 279, 281], ["H", "TEST", 283, 284], ["\u2032", "TEST", 286, 287], ["d", "TEST", 296, 297], ["1H", "TEST", 299, 301], ["J", "TEST", 303, 304], ["Hz", "TEST", 309, 311], ["H", "TEST", 313, 314], ["\u2032b", "TEST", 316, 318], ["s", "TEST", 327, 328], ["3H", "TEST", 330, 332], ["\u2013CH3", "TEST", 334, 338], ["t", "TEST", 347, 348], ["3H", "TEST", 350, 352], ["J", "TEST", 354, 355], ["Hz", "TEST", 359, 361], ["\u2013CH3", "TEST", 363, 367], ["s", "TEST", 376, 377], ["3H", "TEST", 379, 381], ["\u2013CH3", "TEST", 383, 387], ["NMR", "TEST", 394, 397], ["CDCl3", "TEST", 399, 404], ["MHz", "TEST", 410, 413], ["\u03b4", "TEST", 415, 416], ["HRMS", "TEST", 536, 540], ["ESI", "TEST", 541, 544], ["Na", "TEST", 555, 557], ["calcd", "TEST", 560, 565], ["C35H36N2O5", "TEST", 570, 580], ["S", "TEST", 611, 612], ["S", "TEST", 615, 616], ["Isopropylidenedioxy", "TEST", 632, 651]]]], "PMC3293432": [["Approaches To Detect Clinical Emerging IssuesMost surveillance programs deal with a restricted set of known diseases that fail to address the challenges of looking for the unknown.", [["known diseases", "PROBLEM", 102, 116], ["diseases", "OBSERVATION", 108, 116]]], ["However, in the United States, many new human infectious diseases have been recognized by examining illnesses without identified cause (7).", [["infectious diseases", "DISEASE", 46, 65], ["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["many new human infectious diseases", "PROBLEM", 31, 65], ["new", "OBSERVATION_MODIFIER", 36, 39], ["human", "OBSERVATION_MODIFIER", 40, 45], ["infectious", "OBSERVATION", 46, 56]]], ["Furthermore, in Great Britain, the unusual neurologic clinical signs in cattle forewarned of a new disease, BSE (8).", [["neurologic", "ANATOMY", 43, 53], ["BSE", "DISEASE", 108, 111], ["cattle", "SPECIES", 72, 78], ["cattle", "SPECIES", 72, 78], ["the unusual neurologic clinical signs", "PROBLEM", 31, 68], ["a new disease", "PROBLEM", 93, 106], ["new", "OBSERVATION_MODIFIER", 95, 98], ["disease", "OBSERVATION", 99, 106]]], ["Developing the ability to detect atypical syndromes in a timely fashion is critical to reducing the impact of disease emergence.Approaches To Detect Clinical Emerging IssuesPrograms targeted to detect atypical animal diseases follow 2 approaches.", [["atypical syndromes", "PROBLEM", 33, 51], ["disease emergence", "PROBLEM", 110, 127], ["Emerging IssuesPrograms", "TEST", 158, 181], ["atypical animal diseases", "PROBLEM", 201, 225], ["atypical", "OBSERVATION_MODIFIER", 33, 41], ["syndromes", "OBSERVATION", 42, 51], ["disease", "OBSERVATION", 110, 117]]], ["The first approach, syndromic surveillance, monitors disease trends by grouping clinical diseases into syndromes on the basis of clinical features rather than specific diagnoses (9).", [["syndromic surveillance", "TEST", 20, 42], ["grouping clinical diseases into syndromes", "PROBLEM", 71, 112]]], ["Even though syndromic surveillance systems seek to minimize the amount of data collected from each case, their main drawback is the heavy reporting load and requirement for disciplined reporting of recognized case data.Approaches To Detect Clinical Emerging IssuesThe second approach focuses on detecting individual atypical cases.", [["syndromic surveillance systems", "PROBLEM", 12, 42]]], ["Based on how previous emerging diseases have been detected (Table 1), atypical cases can arise from a new disease that shows clinical signs the clinician cannot link to a known disease.", [["previous emerging diseases", "PROBLEM", 13, 39], ["atypical cases", "PROBLEM", 70, 84], ["a new disease", "PROBLEM", 100, 113], ["a known disease", "PROBLEM", 169, 184], ["diseases", "OBSERVATION", 31, 39], ["new", "OBSERVATION_MODIFIER", 102, 105], ["disease", "OBSERVATION", 106, 113], ["disease", "OBSERVATION", 177, 184]]], ["Alternatively, they arise from a known disease expressed atypically through unusual clinical signs, atypical region or species, or increased severity.", [["a known disease", "PROBLEM", 31, 46], ["unusual clinical signs", "PROBLEM", 76, 98], ["atypical region or species", "PROBLEM", 100, 126], ["increased severity", "PROBLEM", 131, 149], ["disease", "OBSERVATION", 39, 46], ["atypical", "OBSERVATION_MODIFIER", 100, 108], ["species", "OBSERVATION_MODIFIER", 119, 126], ["increased", "OBSERVATION_MODIFIER", 131, 140], ["severity", "OBSERVATION_MODIFIER", 141, 149]]], ["An atypical case can also result from the detection of a rare or inadequately documented sporadic disease.", [["a rare or inadequately documented sporadic disease", "PROBLEM", 55, 105], ["sporadic", "OBSERVATION_MODIFIER", 89, 97], ["disease", "OBSERVATION", 98, 105]]], ["Detection focused on atypical cases requires a lighter reporting load than syndromic surveillance, but the practitioner response is likely to be variable and require regular prompting.Data Capture and Strategies ::: Information Systems To Analyze Clinical Data from Farm AnimalsAll 3 systems work from the premise that practicing veterinarians hold key animal health information, which could improve means for early detection of emerging disease if aggregated efficiently through advanced information technology.", [["syndromic surveillance", "TEST", 75, 97], ["emerging disease", "PROBLEM", 429, 445]]], ["While all systems capture basic epidemiologic data, they each represent a different approach to emerging disease surveillance.Data Capture and Strategies ::: Information Systems To Analyze Clinical Data from Farm AnimalsVetPAD has a syndromic surveillance approach.", [["emerging disease surveillance", "TEST", 96, 125], ["disease", "OBSERVATION", 105, 112]]], ["Based on the categorizations, cases can be flexibly aggregated for syndromic surveillance.", [["syndromic surveillance", "TEST", 67, 89]]], ["The strategy to minimize the surveillance reporting impact is to provide a tool capturing the ordinary business data veterinarians must manage anyway (medical records, inventory, and accounts).", [["the surveillance", "TEST", 25, 41]]], ["Surveillance data are a subset of these other data.Data Capture and Strategies ::: Information Systems To Analyze Clinical Data from Farm AnimalsThe RSVP-A system employs an aggregation-based syndromic surveillance but focuses on a restricted set of syndromes (nonneonatal diarrhea, neurologic dysfunction or recumbency, abortion or birth defect, unexpected death, erosive or ulcerative lesions, and unexplained feed refusal or weight loss).", [["neurologic", "ANATOMY", 283, 293], ["ulcerative lesions", "ANATOMY", 376, 394], ["diarrhea", "DISEASE", 273, 281], ["neurologic dysfunction", "DISEASE", 283, 305], ["abortion", "DISEASE", 321, 329], ["birth defect", "DISEASE", 333, 345], ["death", "DISEASE", 358, 363], ["weight loss", "DISEASE", 428, 439], ["ulcerative lesions", "PATHOLOGICAL_FORMATION", 376, 394], ["Surveillance data", "TEST", 0, 17], ["these other data", "TEST", 34, 50], ["The RSVP", "TEST", 145, 153], ["an aggregation-based syndromic surveillance", "PROBLEM", 171, 214], ["syndromes", "PROBLEM", 250, 259], ["nonneonatal diarrhea", "PROBLEM", 261, 281], ["neurologic dysfunction", "PROBLEM", 283, 305], ["recumbency", "PROBLEM", 309, 319], ["abortion", "PROBLEM", 321, 329], ["birth defect", "PROBLEM", 333, 345], ["unexpected death", "PROBLEM", 347, 363], ["erosive or ulcerative lesions", "PROBLEM", 365, 394], ["unexplained feed refusal", "PROBLEM", 400, 424], ["weight loss)", "PROBLEM", 428, 440], ["erosive", "OBSERVATION_MODIFIER", 365, 372], ["ulcerative", "OBSERVATION_MODIFIER", 376, 386], ["lesions", "OBSERVATION", 387, 394]]], ["These syndromes are defined to cover clinical signs of emerging disease other than the common production problems on which most livestock enterprises are focused.", [["These syndromes", "PROBLEM", 0, 15], ["emerging disease", "PROBLEM", 55, 71], ["the common production problems", "PROBLEM", 83, 113]]], ["Practitioners determine the specific syndrome each case best fits and record demographic data about the diseased animals.", [["the specific syndrome", "PROBLEM", 24, 45], ["demographic data", "TEST", 77, 93]]], ["The RSVP-A system also requests additional clinical observations potentially useful to further characterize incident patterns.", [["The RSVP", "TEST", 0, 8]]], ["The strategy to minimize the reporting impact is to focus on less common clinical syndromes and to make data capture for each case require <1 minute.Data Capture and Strategies ::: Information Systems To Analyze Clinical Data from Farm Animals\"\u00e9mergences\" has a different approach as it targets atypical cases and specific diseases, which correspond to known diseases hypothesized to be emerging.", [["atypical cases", "PROBLEM", 295, 309], ["specific diseases", "PROBLEM", 314, 331], ["known diseases", "PROBLEM", 353, 367], ["diseases", "OBSERVATION", 359, 367]]], ["Moreover, atypical cases can be categorized by the system administrator according to clinical description similarities to facilitate exploration of their potential links.", [["exploration", "TEST", 133, 144]]], ["The system has generic features, making it available for any country, any disease, and any domestic species.", [["any disease", "PROBLEM", 70, 81], ["any domestic species", "PROBLEM", 87, 107]]], ["Description of atypical cases for \"\u00e9mergences\" is a less frequent and more open process than the syndromic surveillance methods.Data Capture and Strategies ::: Information Systems To Analyze Clinical Data from Farm AnimalsIn all these systems, routine data recording is simplified by the use of pick-up lists.", [["\"\u00e9mergences", "PROBLEM", 34, 45], ["a less frequent and more open process", "PROBLEM", 50, 87], ["routine data recording", "TEST", 244, 266]]], ["VetPAD and RSVP-A use mobile telephones or personal data assistants for data capture. \"\u00e9mergences\" primarily uses the Internet.Output and Statistics ::: Information Systems To Analyze Clinical Data from Farm AnimalsA successful surveillance system must be able to keep veterinarians engaged and continuing to submit data after the novelty of the new system wears off.", [["VetPAD", "TEST", 0, 6]]], ["To trigger interactions and learning from participants' experiences, practitioners participating in \"\u00e9mergences\" have access to all case descriptions.", [["participants", "SPECIES", 42, 54]]], ["In addition, illness and death rates are available in real time either at the clientele level (\"\u00e9mergences\") or at a custom-made level (\"\u00e9mergences,\" RSVP-A).", [["illness", "DISEASE", 13, 20], ["death", "DISEASE", 25, 30], ["illness and death rates", "PROBLEM", 13, 36]]], ["In VetPAD, customized reports are available to involved parties.Output and Statistics ::: Information Systems To Analyze Clinical Data from Farm AnimalsOne output of these surveillance systems is an indication of unusual events that require additional investigation.", [["unusual events", "PROBLEM", 213, 227], ["additional investigation", "TEST", 241, 265], ["output", "OBSERVATION_MODIFIER", 156, 162]]], ["This investigation might include communication with other veterinarians to find additional cases, targeted epidemiologic studies, research projects, or control programs.Output and Statistics ::: Information Systems To Analyze Clinical Data from Farm AnimalsOther outputs are data upon which analyses can be conducted.", [["This investigation", "TEST", 0, 18], ["targeted epidemiologic studies", "TEST", 98, 128], ["research projects", "TREATMENT", 130, 147]]], ["Procedures based on contextual analysis must be developed to analyze pick-up list data as well as free text (26).", [["contextual analysis", "TEST", 20, 39]]], ["Each system must also address the challenge of detecting increased incidence of a rare event.", [["a rare event", "PROBLEM", 80, 92]]], ["The first is the emergence from a \"zero case\" situation (e.g., BSE occurred probably as erratic cases before its amplification [27]).", [["BSE", "DISEASE", 63, 66]]], ["Incidence threshold analysis needed for this situation requires methods such as the evaluation of record process (28).", [["Incidence threshold analysis", "TEST", 0, 28], ["the evaluation", "TEST", 80, 94]]], ["The second situation is the emergence of clusters of highly pathogenic variants of an endemic disease.", [["an endemic disease", "PROBLEM", 83, 101], ["highly", "OBSERVATION_MODIFIER", 53, 59], ["pathogenic variants", "OBSERVATION", 60, 79], ["endemic", "OBSERVATION_MODIFIER", 86, 93], ["disease", "OBSERVATION", 94, 101]]], ["Spatial-temporal analysis can provide helpful insights concerning baseline patterns of clinical syndromes and aberrations from them, which can trigger further investigation.Limitations ::: Limitations and Evaluation of Systems Based on Clinical ObservationAtypical case detection is limited by practitioners' experience, knowledge, vigilance, and willingness to report findings (30).", [["Spatial-temporal analysis", "TEST", 0, 25], ["clinical syndromes", "PROBLEM", 87, 105], ["aberrations from them", "PROBLEM", 110, 131], ["further investigation", "TEST", 151, 172], ["Evaluation of Systems", "TEST", 205, 226]]], ["Multiple, similar reports of atypical cases improve confidence that a new disease is emerging.", [["atypical cases", "PROBLEM", 29, 43], ["a new disease", "PROBLEM", 68, 81], ["atypical", "OBSERVATION_MODIFIER", 29, 37], ["new", "OBSERVATION_MODIFIER", 70, 73], ["disease", "OBSERVATION", 74, 81]]], ["Making case data available through surveillance systems, such as the 3 we have indicated, will also foster basic common knowledge and shared practical experience among veterinarians.", [["surveillance systems", "TEST", 35, 55]]], ["Because surveillance for the unknown requires a mindset different from surveillance of the known, notification quality and vigilance should be enhanced by specific training courses (31).Limitations ::: Limitations and Evaluation of Systems Based on Clinical ObservationA substantial limitation of syndromic surveillance is the need to establish baseline levels for defined syndromes.", [["surveillance", "TEST", 8, 20], ["Evaluation of Systems", "TEST", 218, 239], ["syndromic surveillance", "TEST", 297, 319], ["defined syndromes", "PROBLEM", 365, 382]]], ["This step requires time and resources; however, without them, we cannot know when the incidence of a syndrome has significantly increased.", [["a syndrome", "PROBLEM", 99, 109], ["syndrome", "OBSERVATION", 101, 109], ["significantly", "OBSERVATION_MODIFIER", 114, 127], ["increased", "OBSERVATION_MODIFIER", 128, 137]]], ["VetPAD and RSVP-A are developing such baselines.Limitations ::: Limitations and Evaluation of Systems Based on Clinical ObservationEconomic consideration leaves few alternatives to clinical detection of farm animal diseases.", [["animal diseases", "DISEASE", 208, 223], ["VetPAD", "TEST", 0, 6], ["Evaluation of Systems", "TEST", 80, 101], ["Clinical Observation", "TEST", 111, 131], ["clinical detection", "TEST", 181, 199], ["farm animal diseases", "PROBLEM", 203, 223], ["RSVP", "OBSERVATION", 11, 15], ["animal diseases", "OBSERVATION", 208, 223]]], ["Laboratory analyses are infrequently performed and generally more basic compared to human medicine (32).", [["human", "ORGANISM", 84, 89], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["Laboratory analyses", "TEST", 0, 19]]], ["However, slaughterhouses and other assembly points do provide surveillance opportunities.Limitations ::: Limitations and Evaluation of Systems Based on Clinical ObservationFinally, a clinical reporting tool alone is only the first step to determine if the cases share an etiologic pathway.", [["Evaluation of Systems", "TEST", 121, 142], ["Clinical Observation", "TEST", 152, 172]]], ["Review by expert clinicians, necropsy findings, immunologic screenings, and focused epidemiologic studies play key roles in such determination (33).", [["immunologic screenings", "TEST", 48, 70], ["epidemiologic studies", "TEST", 84, 105]]], ["Similarities between distinct submitted atypical cases provide additional evidence.", [["distinct", "OBSERVATION_MODIFIER", 21, 29]]], ["For example, BSE was identified as a novel syndrome through epidemiologic, clinical, and pathologic findings (8).Evaluation ::: Limitations and Evaluation of Systems Based on Clinical ObservationTo determine whether to extend an information system, several points must be reviewed.", [["BSE", "SPECIES", 13, 16], ["a novel syndrome", "PROBLEM", 35, 51], ["Evaluation", "TEST", 113, 123], ["Evaluation of Systems", "TEST", 144, 165]]], ["First, the activity and number of participating veterinarians can be evaluated by quantifying indicators such as number of entries submitted, number of atypical cases entered, and participants' levels of accessing posted results.", [["participants", "SPECIES", 180, 192], ["activity", "OBSERVATION_MODIFIER", 11, 19]]], ["Moreover, all systems include reference diseases or symptoms for which descriptive statistics are available, which can serve to check quality recording (e.g., babesiosis in the \"\u00e9mergences\" pilot study).", [["babesiosis", "DISEASE", 159, 169], ["reference diseases", "PROBLEM", 30, 48], ["symptoms", "PROBLEM", 52, 60], ["babesiosis", "PROBLEM", 159, 169], ["pilot study", "TEST", 190, 201]]], ["In addition, the likelihood of detecting an emerging event is high.", [["high", "OBSERVATION_MODIFIER", 62, 66]]], ["Many rare diseases are not defined in cattle, so a dedicated information system should detect >1 unexpected event over the test period.", [["cattle", "ORGANISM", 38, 44], ["cattle", "SPECIES", 38, 44], ["cattle", "SPECIES", 38, 44], ["Many rare diseases", "PROBLEM", 0, 18], ["a dedicated information system", "TEST", 49, 79], ["rare", "OBSERVATION_MODIFIER", 5, 9], ["diseases", "OBSERVATION", 10, 18]]], ["For example, the initial \"\u00e9mergences\" pilot found 3 sets of clinical signs not linked to a known disease (persistent, ultimately fatal paraplegia, without general clinical signs [Figure]; weight loss, depilation at the extremities leading to death; and congenital cataract neither linked to bovine virus diarrhea nor familial history) and 1 rare known syndrome (facial eczema).", [["extremities", "ANATOMY", 219, 230], ["facial", "ANATOMY", 362, 368], ["paraplegia", "DISEASE", 135, 145], ["weight loss", "DISEASE", 188, 199], ["depilation", "DISEASE", 201, 211], ["death", "DISEASE", 242, 247], ["congenital cataract", "DISEASE", 253, 272], ["diarrhea", "DISEASE", 304, 312], ["facial eczema", "DISEASE", 362, 375], ["extremities", "ORGANISM_SUBDIVISION", 219, 230], ["bovine", "ORGANISM", 291, 297], ["bovine", "SPECIES", 291, 297], ["clinical signs", "TEST", 60, 74], ["a known disease", "PROBLEM", 89, 104], ["ultimately fatal paraplegia", "PROBLEM", 118, 145], ["general clinical signs", "PROBLEM", 155, 177], ["Figure]", "PROBLEM", 179, 186], ["weight loss", "PROBLEM", 188, 199], ["depilation at the extremities", "PROBLEM", 201, 230], ["death", "PROBLEM", 242, 247], ["congenital cataract", "PROBLEM", 253, 272], ["bovine virus diarrhea", "PROBLEM", 291, 312], ["1 rare known syndrome", "PROBLEM", 339, 360], ["facial eczema", "PROBLEM", 362, 375], ["disease", "OBSERVATION", 97, 104], ["persistent", "OBSERVATION_MODIFIER", 106, 116], ["fatal", "OBSERVATION_MODIFIER", 129, 134], ["paraplegia", "OBSERVATION", 135, 145], ["extremities", "ANATOMY", 219, 230], ["cataract", "OBSERVATION", 264, 272], ["syndrome", "OBSERVATION", 352, 360], ["facial", "ANATOMY", 362, 368], ["eczema", "OBSERVATION", 369, 375]]], ["Finally, the decision to extend a detection system will depend largely on the interest veterinarians hold and on the inclusion of new diseases as a national surveillance objective (6,34).Other Systems To Capture Clinical DataWe have presented examples of clinical data capture from cattle herds at the veterinary level, in which sufficient individual health data are available.", [["cattle", "SPECIES", 282, 288], ["a detection system", "TEST", 32, 50], ["new diseases", "PROBLEM", 130, 142], ["a national surveillance objective", "TEST", 146, 179], ["clinical data", "TEST", 255, 268], ["new", "OBSERVATION_MODIFIER", 130, 133], ["diseases", "OBSERVATION", 134, 142]]], ["For species concerned by herd health approaches (sheep, poultry), initiatives have been taken for information systems through online questionnaires answered by farmers (35).", [["sheep", "ORGANISM_SUBDIVISION", 49, 54], ["sheep", "SPECIES", 49, 54], ["sheep", "SPECIES", 49, 54]]], ["In 1 such system, New Zealand producers must complete questionnaires targeted on diseases that occurred in the previous 12 months and have clinical signs similar to exotic diseases.", [["exotic diseases", "DISEASE", 165, 180], ["New Zealand producers", "TREATMENT", 18, 39], ["diseases", "PROBLEM", 81, 89], ["clinical signs", "PROBLEM", 139, 153], ["exotic diseases", "PROBLEM", 165, 180], ["New", "OBSERVATION_MODIFIER", 18, 21], ["exotic diseases", "OBSERVATION", 165, 180]]], ["The ultimate research goal is to develop a disease sentinel Web module to integrate with veterinary practice Web sites.", [["a disease sentinel Web module", "PROBLEM", 41, 70]]], ["The main problem is the disparity in response quality between farmers.Other Systems To Capture Clinical DataThe reality of an emergence can be tested by survey of a set of representative herds.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["problem", "OBSERVATION", 9, 16], ["disparity", "OBSERVATION_MODIFIER", 24, 33], ["response quality", "OBSERVATION", 37, 53]]], ["In the United States, the National Animal Health Monitoring System is not designed to collect information regarding emerging diseases per se; however, questions about a previously identified emerging disease have been inserted into surveys.", [["emerging diseases", "PROBLEM", 116, 133], ["a previously identified emerging disease", "PROBLEM", 167, 207]]], ["In addition, the National Animal Health Monitoring System has provided baseline data on emerging disease analysis and assessment.", [["emerging disease analysis", "TEST", 88, 113], ["assessment", "TEST", 118, 128]]], ["In France, the Central Service for Survey and Statistical Studies, which runs economic surveys among a representative national sample of herds, has added specific questions regarding animal health issues (36).Other Systems To Capture Clinical DataIn addition to farm animals, pets, zoo animals, and wildlife must be considered as sources of transmission and reservoirs for emerging diseases.", [["Statistical Studies", "TEST", 46, 65], ["emerging diseases", "PROBLEM", 373, 390]]], ["For pets and zoo animals, tools similar to the ones proposed can be adapted because these animals are regularly seen by veterinarians.", [["animals", "ORGANISM", 90, 97], ["pets", "PROBLEM", 4, 8]]], ["Wildlife can be a source of new farm animal or human diseases and is affected by many farm animal diseases (Table 1).", [["human diseases", "DISEASE", 47, 61], ["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human diseases", "PROBLEM", 47, 61]]], ["Thus, all observations of health problems in wildlife can potentially contribute relevant information for human or domestic animal populations (37).", [["human", "ORGANISM", 106, 111], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111]]], ["However, the ability to closely monitor clinical signs is lacking.", [["clinical signs", "TEST", 40, 54]]], ["Death rate is the most feasible way to monitor wildlife health and has indeed been the detection trigger of many emerging diseases (38).", [["Death", "DISEASE", 0, 5], ["Death rate", "TEST", 0, 10], ["many emerging diseases", "PROBLEM", 108, 130]]], ["Testing sampled healthy animals for a set of diseases is another strategy, but few disease surveillance programs not targeted at specific diseases are in place (e.g., \"marine mammal strandings\" project in United Kingdom [39]).", [["diseases", "PROBLEM", 45, 53], ["few disease surveillance programs", "PROBLEM", 79, 112], ["diseases", "OBSERVATION", 45, 53]]], ["Alternatives such as monitoring risk factors for emergence (e.g., encroachment of habitats), as well as minimizing contact between domestic and wild species by good, on-farm biosecurity, could reduce the likelihood of new domestic animal or human diseases emerging from wildlife reservoirs.", [["human", "ORGANISM", 241, 246], ["human", "SPECIES", 241, 246], ["human", "SPECIES", 241, 246], ["Alternatives", "TREATMENT", 0, 12], ["human diseases", "PROBLEM", 241, 255], ["new", "OBSERVATION_MODIFIER", 218, 221]]], ["In all cases, approaches must seek to increase collaboration among wildlife and domestic animals health workers to break down traditional boundaries between fields.Conclusion and Interest for Human HealthMuch effort is being put into developing new tools to detect emerging diseases through veterinary practitioners.", [["Human", "ORGANISM", 192, 197], ["Human", "SPECIES", 192, 197], ["Human", "SPECIES", 192, 197], ["Human HealthMuch effort", "TREATMENT", 192, 215]]], ["If successful, this effort will also define the \"normal\" clinical baseline for syndromes and rare diseases, allowing statistical confirmation that an atypical syndrome is emerging.", [["syndromes", "PROBLEM", 79, 88], ["rare diseases", "PROBLEM", 93, 106], ["statistical confirmation", "TEST", 117, 141], ["an atypical syndrome", "PROBLEM", 147, 167], ["atypical", "OBSERVATION_MODIFIER", 150, 158], ["syndrome", "OBSERVATION", 159, 167]]], ["In addition to building new information technologies, early disease identification with timely responses requires synergy across a group of partners, including those who traditionally interact in animal health management as well as in public health (40) and across geopolitical boundaries.", [["early disease identification", "PROBLEM", 54, 82], ["animal health management", "TREATMENT", 196, 220]]], ["Although human and animal worlds remain fairly separated, initiatives are narrowing this separation.", [["human", "ORGANISM", 9, 14], ["human", "SPECIES", 9, 14], ["human", "SPECIES", 9, 14], ["narrowing this separation", "PROBLEM", 74, 99], ["narrowing", "OBSERVATION", 74, 83]]], ["For instance, integration of emerging animal disease surveillance systems with those in the human arena is proposed in the UK's \"RADAR\" veterinary surveillance information management system (41).", [["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["emerging animal disease surveillance systems", "PROBLEM", 29, 73]]], ["Finally, the most relevant challenge is to promote joint human-animal projects concerning potentially common emerging diseases, such as the avian-porcine-human influenza complex.", [["avian-porcine-human influenza complex", "DISEASE", 140, 177], ["human", "ORGANISM", 57, 62], ["avian-", "ORGANISM", 140, 146], ["porcine-", "ORGANISM", 146, 154], ["human", "ORGANISM", 154, 159], ["human", "SPECIES", 57, 62], ["porcine", "SPECIES", 146, 153], ["human", "SPECIES", 154, 159], ["influenza", "SPECIES", 160, 169], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 154, 159], ["common emerging diseases", "PROBLEM", 102, 126], ["the avian-porcine-human influenza complex", "TREATMENT", 136, 177], ["joint", "ANATOMY", 51, 56]]], ["Effective combination of such emerging disease surveillance systems would result in earlier identification of potential issues, providing opportunity for quicker response.", [["such emerging disease surveillance systems", "PROBLEM", 25, 67]]]], "00ec586d591bfbe2f07a1322fe6501addac51798": [["The relation of pneumococcal carriage and diseasePneumococcal disease is preceeded by colonisation of the nasopharynx of uninfected adults and children.", [["diseasePneumococcal", "ANATOMY", 42, 61], ["nasopharynx", "ANATOMY", 106, 117], ["pneumococcal carriage", "DISEASE", 16, 37], ["diseasePneumococcal disease", "DISEASE", 42, 69], ["pneumococcal", "ORGANISM", 16, 28], ["nasopharynx", "ORGAN", 106, 117], ["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["pneumococcal", "SPECIES", 16, 28], ["pneumococcal carriage", "PROBLEM", 16, 37], ["diseasePneumococcal disease", "PROBLEM", 42, 69], ["pneumococcal", "OBSERVATION_MODIFIER", 16, 28], ["carriage", "OBSERVATION", 29, 37], ["diseasePneumococcal disease", "OBSERVATION", 42, 69], ["colonisation", "OBSERVATION_MODIFIER", 86, 98], ["nasopharynx", "ANATOMY", 106, 117]]], ["\"Asymptomatic\" colonisation may be followed by carriage which remains asymptomatic or may (rarely) progress to disease.", [["Asymptomatic\" colonisation", "PROBLEM", 1, 27], ["asymptomatic", "PROBLEM", 70, 82], ["disease", "PROBLEM", 111, 118]]], ["Most episodes of carriage result in improved immunity to future infection without the development of disease.", [["infection", "DISEASE", 64, 73], ["carriage", "PROBLEM", 17, 25], ["future infection", "PROBLEM", 57, 73], ["disease", "PROBLEM", 101, 108], ["infection", "OBSERVATION", 64, 73], ["disease", "OBSERVATION", 101, 108]]], ["As such, the mechanisms by which carriage is established, the immunity that results from carriage and the mechanisms that determine when carriage ends are all of critical importance in the design of mucosal vaccines against pneumococcal disease.Immune responses to carriageAlthough there are many studies measuring natural pneumococcal carriage rates and serotypes in humans, there are very limited data on the immune response to pneumococcal carriage in humans because the timing of any natural carriage episode is difficult to determine.", [["mucosal", "ANATOMY", 199, 206], ["pneumococcal disease", "DISEASE", 224, 244], ["pneumococcal carriage", "DISEASE", 430, 451], ["mucosal", "ORGANISM_SUBDIVISION", 199, 206], ["pneumococcal", "ORGANISM", 323, 335], ["humans", "ORGANISM", 368, 374], ["pneumococcal", "ORGANISM", 430, 442], ["humans", "ORGANISM", 455, 461], ["humans", "SPECIES", 368, 374], ["humans", "SPECIES", 455, 461], ["pneumococcal", "SPECIES", 224, 236], ["pneumococcal", "SPECIES", 323, 335], ["humans", "SPECIES", 368, 374], ["pneumococcal", "SPECIES", 430, 442], ["humans", "SPECIES", 455, 461], ["carriage", "PROBLEM", 89, 97], ["mucosal vaccines", "TREATMENT", 199, 215], ["pneumococcal disease", "PROBLEM", 224, 244], ["many studies", "TEST", 292, 304], ["natural pneumococcal carriage rates", "PROBLEM", 315, 350], ["serotypes", "PROBLEM", 355, 364], ["pneumococcal carriage in humans", "PROBLEM", 430, 461], ["any natural carriage episode", "PROBLEM", 484, 512], ["pneumococcal", "OBSERVATION_MODIFIER", 323, 335], ["carriage rates", "OBSERVATION", 336, 350]]], ["Experimental human pneumococcal carriage has been safely established in two previous studies.", [["human", "ORGANISM", 13, 18], ["human", "SPECIES", 13, 18], ["human", "SPECIES", 13, 18], ["pneumococcal", "SPECIES", 19, 31], ["Experimental human pneumococcal carriage", "PROBLEM", 0, 40], ["pneumococcal carriage", "OBSERVATION", 19, 40]]], ["[6, 7] From these studies, it is known that a variable proportion of those subjects inoculated with pneumococci become colonised.", [["these studies", "TEST", 12, 25], ["pneumococci", "PROBLEM", 100, 111]]], ["The rate of colonisation following nasal inoculation in these studies was reported as <50%, with a duration of carriage between 21 and 122 days.", [["nasal", "ANATOMY", 35, 40], ["nasal", "ORGANISM_SUBDIVISION", 35, 40], ["colonisation", "PROBLEM", 12, 24], ["nasal inoculation", "TREATMENT", 35, 52], ["these studies", "TEST", 56, 69], ["carriage", "PROBLEM", 111, 119], ["colonisation", "OBSERVATION_MODIFIER", 12, 24], ["nasal", "ANATOMY", 35, 40], ["inoculation", "OBSERVATION", 41, 52]]], ["The immune response in nasal washings and serum showed an association between humoral responses (to protein and polysaccharide antigens) and carriage.", [["nasal washings", "ANATOMY", 23, 37], ["serum", "ANATOMY", 42, 47], ["nasal washings", "ORGANISM_SUBSTANCE", 23, 37], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["polysaccharide antigens", "GENE_OR_GENE_PRODUCT", 112, 135], ["polysaccharide antigens", "PROTEIN", 112, 135], ["The immune response", "TEST", 0, 19], ["nasal washings", "TEST", 23, 37], ["serum", "TEST", 42, 47], ["protein and polysaccharide antigens", "TREATMENT", 100, 135], ["nasal", "ANATOMY", 23, 28]]], ["The humoral and cellular responses in the lung that result in response to nasopharyngeal pneumococcal carriage have not been described.Pneumococcal antigens and humoral responseMurine studies have identified a number of pneumococcal proteins on the cell surface that induce antibodies in the host including pneumococcal surface protein A (PspA), pneumococcal surface adhesion A (PsaA) and choline binding protein A (CbpA, also called PspC).", [["cellular", "ANATOMY", 16, 24], ["lung", "ANATOMY", 42, 46], ["cell surface", "ANATOMY", 249, 261], ["choline", "CHEMICAL", 389, 396], ["choline", "CHEMICAL", 389, 396], ["cellular", "CELL", 16, 24], ["lung", "ORGAN", 42, 46], ["cell surface", "CELLULAR_COMPONENT", 249, 261], ["pneumococcal surface protein A", "GENE_OR_GENE_PRODUCT", 307, 337], ["PspA", "GENE_OR_GENE_PRODUCT", 339, 343], ["pneumococcal surface adhesion A", "GENE_OR_GENE_PRODUCT", 346, 377], ["PsaA", "GENE_OR_GENE_PRODUCT", 379, 383], ["choline binding protein A", "GENE_OR_GENE_PRODUCT", 389, 414], ["CbpA", "GENE_OR_GENE_PRODUCT", 416, 420], ["PspC", "GENE_OR_GENE_PRODUCT", 434, 438], ["Pneumococcal antigens", "PROTEIN", 135, 156], ["pneumococcal proteins", "PROTEIN", 220, 241], ["antibodies", "PROTEIN", 274, 284], ["pneumococcal surface protein A", "PROTEIN", 307, 337], ["PspA", "PROTEIN", 339, 343], ["pneumococcal surface adhesion A", "PROTEIN", 346, 377], ["PsaA", "PROTEIN", 379, 383], ["choline binding protein A", "PROTEIN", 389, 414], ["CbpA", "PROTEIN", 416, 420], ["PspC", "PROTEIN", 434, 438], ["pneumococcal", "SPECIES", 89, 101], ["pneumococcal", "SPECIES", 220, 232], ["pneumococcal", "SPECIES", 307, 319], ["pneumococcal", "SPECIES", 346, 358], ["nasopharyngeal pneumococcal carriage", "TREATMENT", 74, 110], ["Pneumococcal antigens", "TEST", 135, 156], ["humoral responseMurine studies", "TEST", 161, 191], ["pneumococcal proteins", "PROBLEM", 220, 241], ["the cell surface", "TREATMENT", 245, 261], ["antibodies", "TEST", 274, 284], ["pneumococcal surface protein", "TEST", 307, 335], ["PspA", "TEST", 339, 343], ["pneumococcal surface adhesion", "TEST", 346, 375], ["humoral", "ANATOMY", 4, 11], ["cellular responses", "OBSERVATION", 16, 34], ["lung", "ANATOMY", 42, 46], ["nasopharyngeal", "ANATOMY", 74, 88], ["pneumococcal carriage", "OBSERVATION", 89, 110], ["pneumococcal proteins", "OBSERVATION", 220, 241], ["pneumococcal", "OBSERVATION_MODIFIER", 346, 358], ["surface adhesion", "OBSERVATION", 359, 375]]], ["These proteins are common to the cell surface of all pneumococci.", [["cell surface", "ANATOMY", 33, 45], ["cell surface", "CELLULAR_COMPONENT", 33, 45], ["pneumococci", "CELL", 53, 64], ["all pneumococci", "PROBLEM", 49, 64], ["all", "OBSERVATION_MODIFIER", 49, 52], ["pneumococci", "OBSERVATION", 53, 64]]], ["In addition, pneumolysin (Ply) is a cytoplasmic protein also expressed by all pneumococci.", [["cytoplasmic", "ANATOMY", 36, 47], ["pneumolysin", "GENE_OR_GENE_PRODUCT", 13, 24], ["Ply", "GENE_OR_GENE_PRODUCT", 26, 29], ["cytoplasmic", "ORGANISM_SUBSTANCE", 36, 47], ["pneumolysin", "PROTEIN", 13, 24], ["Ply", "PROTEIN", 26, 29], ["cytoplasmic protein", "PROTEIN", 36, 55], ["pneumolysin", "PROBLEM", 13, 24], ["a cytoplasmic protein", "PROBLEM", 34, 55], ["all pneumococci", "PROBLEM", 74, 89], ["pneumolysin", "OBSERVATION", 13, 24], ["pneumococci", "OBSERVATION", 78, 89]]], ["These surface and cytoplasmic proteins are both highly immunogenic and humoral responses confer protection against both invasive disease and carriage in mice [8] [9] [10] [11] [12] .", [["surface", "ANATOMY", 6, 13], ["cytoplasmic", "ANATOMY", 18, 29], ["invasive disease", "DISEASE", 120, 136], ["surface", "CELLULAR_COMPONENT", 6, 13], ["cytoplasmic", "ORGANISM_SUBSTANCE", 18, 29], ["mice", "ORGANISM", 153, 157], ["surface and cytoplasmic proteins", "PROTEIN", 6, 38], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 153, 157], ["cytoplasmic proteins", "TEST", 18, 38], ["both invasive disease", "PROBLEM", 115, 136], ["cytoplasmic proteins", "OBSERVATION", 18, 38], ["invasive", "OBSERVATION_MODIFIER", 120, 128]]], ["Pre-existing antibody to cell wall polysaccharide has been demonstrated to be predictive of resistance to colonisation [6, 7] .", [["cell wall", "ANATOMY", 25, 34], ["antibody to cell wall polysaccharide", "GENE_OR_GENE_PRODUCT", 13, 49], ["Pre-existing antibody to cell wall polysaccharide", "PROBLEM", 0, 49], ["antibody", "OBSERVATION", 13, 21], ["cell", "OBSERVATION", 25, 29], ["wall", "ANATOMY_MODIFIER", 30, 34]]], ["Susceptibility to carriage does not appear to correlate with pre-existing levels of immunoglobulin G (IgG) to the specific capsular polysaccharide.", [["immunoglobulin G", "GENE_OR_GENE_PRODUCT", 84, 100], ["IgG", "GENE_OR_GENE_PRODUCT", 102, 105], ["capsular polysaccharide", "GENE_OR_GENE_PRODUCT", 123, 146], ["immunoglobulin G", "PROTEIN", 84, 100], ["IgG", "PROTEIN", 102, 105], ["immunoglobulin G (IgG)", "TREATMENT", 84, 106]]], ["A rise in specific antibodies to protein (CbpA and PspA) during human carriage has also been demonstrated [6, 7] .Mucosal cellular responses to pneumococciIt has been demonstrated that mice lacking effective T-cell function have an increased duration of pneumococcal colonisation following inoculation, suggesting that further examination of the cellular immune response to colonisation may provide useful information [13] .", [["Mucosal", "ANATOMY", 114, 121], ["cellular", "ANATOMY", 122, 130], ["T-cell", "ANATOMY", 208, 214], ["cellular", "ANATOMY", 346, 354], ["pneumococciIt", "CHEMICAL", 144, 157], ["pneumococciIt", "CHEMICAL", 144, 157], ["CbpA", "GENE_OR_GENE_PRODUCT", 42, 46], ["PspA", "GENE_OR_GENE_PRODUCT", 51, 55], ["human", "ORGANISM", 64, 69], ["Mucosal cellular", "CELL", 114, 130], ["mice", "ORGANISM", 185, 189], ["T-cell", "CELL", 208, 214], ["cellular", "CELL", 346, 354], ["antibodies to protein", "PROTEIN", 19, 40], ["CbpA", "PROTEIN", 42, 46], ["PspA", "PROTEIN", 51, 55], ["human", "SPECIES", 64, 69], ["mice", "SPECIES", 185, 189], ["human", "SPECIES", 64, 69], ["mice", "SPECIES", 185, 189], ["pneumococcal", "SPECIES", 254, 266], ["A rise", "PROBLEM", 0, 6], ["specific antibodies", "TEST", 10, 29], ["protein", "TEST", 33, 40], ["CbpA", "TEST", 42, 46], ["PspA", "TEST", 51, 55], ["pneumococcal colonisation", "PROBLEM", 254, 279], ["inoculation", "PROBLEM", 290, 301], ["further examination", "TEST", 319, 338], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["cellular responses", "OBSERVATION", 122, 140], ["increased", "OBSERVATION_MODIFIER", 232, 241], ["pneumococcal", "OBSERVATION_MODIFIER", 254, 266], ["colonisation", "OBSERVATION", 267, 279]]], ["Mucosal T lymphocytes are critical in the regulation of mucosal defence.", [["Mucosal T lymphocytes", "ANATOMY", 0, 21], ["mucosal", "ANATOMY", 56, 63], ["Mucosal T lymphocytes", "CELL", 0, 21], ["mucosal", "ANATOMICAL_SYSTEM", 56, 63], ["Mucosal T lymphocytes", "CELL_TYPE", 0, 21], ["Mucosal T lymphocytes", "PROBLEM", 0, 21], ["T lymphocytes", "OBSERVATION", 8, 21], ["mucosal defence", "OBSERVATION", 56, 71]]], ["Recent data have emphasized the importance of both humoral responses and Th17 subsets of CD4 lymphocytes in mucosal defence in murine model [14, 15] .", [["CD4 lymphocytes", "ANATOMY", 89, 104], ["mucosal", "ANATOMY", 108, 115], ["Th17", "CELL", 73, 77], ["CD4 lymphocytes", "CELL", 89, 104], ["mucosal", "ANATOMICAL_SYSTEM", 108, 115], ["murine", "ORGANISM", 127, 133], ["Th17 subsets", "CELL_TYPE", 73, 85], ["CD4 lymphocytes", "CELL_TYPE", 89, 104], ["murine", "SPECIES", 127, 133], ["CD4 lymphocytes", "TEST", 89, 104], ["CD4 lymphocytes", "OBSERVATION", 89, 104]]], ["Our group has recently demonstated the upregulation of Th17 lymphocytes in human lung following EHPC.", [["Th17 lymphocytes", "ANATOMY", 55, 71], ["lung", "ANATOMY", 81, 85], ["Th17 lymphocytes", "CELL", 55, 71], ["human", "ORGANISM", 75, 80], ["lung", "ORGAN", 81, 85], ["Th17 lymphocytes", "CELL_TYPE", 55, 71], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["Th17 lymphocytes in human lung", "PROBLEM", 55, 85], ["EHPC", "TREATMENT", 96, 100], ["Th17 lymphocytes", "OBSERVATION", 55, 71], ["human", "ANATOMY_MODIFIER", 75, 80], ["lung", "ANATOMY", 81, 85]]], ["Up-regulation of Th17 antigen-specific cells is consistent with enhanced protection against pneumonia; this could be tested in future by observing the association between Th17 response and vaccine protection against a pneumococcal challenge.Important current questionsThis study will address important current questions including dose dependency to establish pneumococcal carriage in human subjects, the immune response in the lower airway to nasal carriage and innate, humoral and cellular responses in both mucosal and systemic compartments.", [["cells", "ANATOMY", 39, 44], ["lower airway", "ANATOMY", 427, 439], ["nasal", "ANATOMY", 443, 448], ["cellular", "ANATOMY", 482, 490], ["mucosal", "ANATOMY", 509, 516], ["systemic compartments", "ANATOMY", 521, 542], ["pneumonia", "DISEASE", 92, 101], ["Th17 antigen", "GENE_OR_GENE_PRODUCT", 17, 29], ["cells", "CELL", 39, 44], ["pneumococcal", "ORGANISM", 359, 371], ["human", "ORGANISM", 384, 389], ["lower airway", "ORGANISM_SUBDIVISION", 427, 439], ["nasal", "ORGANISM_SUBDIVISION", 443, 448], ["cellular", "CELL", 482, 490], ["mucosal", "MULTI-TISSUE_STRUCTURE", 509, 516], ["Th17 antigen", "PROTEIN", 17, 29], ["human", "SPECIES", 384, 389], ["pneumococcal", "SPECIES", 218, 230], ["pneumococcal", "SPECIES", 359, 371], ["human", "SPECIES", 384, 389], ["Up-regulation of Th17 antigen", "TEST", 0, 29], ["pneumonia", "PROBLEM", 92, 101], ["Th17 response", "TREATMENT", 171, 184], ["vaccine protection", "TREATMENT", 189, 207], ["a pneumococcal challenge", "TREATMENT", 216, 240], ["This study", "TEST", 268, 278], ["dose dependency", "PROBLEM", 330, 345], ["pneumococcal carriage in human subjects", "PROBLEM", 359, 398], ["the immune response", "TEST", 400, 419], ["Th17", "OBSERVATION", 17, 21], ["consistent with", "UNCERTAINTY", 48, 63], ["pneumonia", "OBSERVATION", 92, 101], ["immune response", "OBSERVATION", 404, 419], ["lower", "ANATOMY_MODIFIER", 427, 432], ["airway", "ANATOMY", 433, 439], ["nasal carriage", "ANATOMY", 443, 457], ["cellular responses", "OBSERVATION", 482, 500], ["both", "ANATOMY_MODIFIER", 504, 508], ["mucosal", "ANATOMY", 509, 516], ["systemic compartments", "ANATOMY", 521, 542]]], ["We have previously demonstrated these responses to polysaccharide and conjugate vaccines [16] [17] [18] .", [["polysaccharide", "SIMPLE_CHEMICAL", 51, 65], ["[16] [17] [18]", "SIMPLE_CHEMICAL", 89, 103], ["polysaccharide and conjugate vaccines", "TREATMENT", 51, 88]]], ["Examination of individuals pre and post pneumococcal carriage, and comparison between the immune response of colonised against un-colonised subjects will provide new information on the innate, cellular and humoral immune responses to pneumococcal colonisation.", [["cellular", "ANATOMY", 193, 201], ["individuals", "ORGANISM", 15, 26], ["pneumococcal", "ORGANISM", 40, 52], ["cellular", "CELL", 193, 201], ["pneumococcal", "ORGANISM", 234, 246], ["pneumococcal", "SPECIES", 40, 52], ["pneumococcal", "SPECIES", 234, 246], ["Examination", "TEST", 0, 11], ["individuals pre and post pneumococcal carriage", "PROBLEM", 15, 61], ["pneumococcal colonisation", "PROBLEM", 234, 259], ["pneumococcal colonisation", "OBSERVATION", 234, 259]]], ["In future this model will be used in testing the effect of new candidate vaccines.", [["new candidate vaccines", "TREATMENT", 59, 81]]], ["A major roadblock identified in the process of developing new protein vaccines has been a means of down-selecting from among the candidate antigen combinations proposed as vaccines -the EHPC model offers a means of doing just this by testing the effectiveness of candidate vaccines in blocking subsequent EHPC.Study design overviewWe will carry out (a) dose-ranging study using 10 experimental carriage volunteers at each of 6 test doses and construct a dose-response curve, (b) prospectively test the reproducibility and confidence interval associated with 50-80% carriage using Lot Quality Assurance Sampling (LQAS), (c) vaccine effect testing.Study design overviewDose-ranging study -Healthy volunteer adults will be screened to exclude subjects at risk of disease or subjects in contact with others at risk.", [["EHPC", "DISEASE", 305, 309], ["EHPC", "CANCER", 305, 309], ["volunteers", "ORGANISM", 403, 413], ["adults", "ORGANISM", 705, 711], ["A major roadblock", "TREATMENT", 0, 17], ["new protein vaccines", "TREATMENT", 58, 78], ["vaccines", "TREATMENT", 172, 180], ["vaccines", "TREATMENT", 273, 281], ["ranging study", "TEST", 358, 371], ["response curve", "TEST", 459, 473], ["Sampling (LQAS), (c) vaccine effect testing", "TEST", 602, 645], ["disease", "PROBLEM", 760, 767], ["major", "OBSERVATION_MODIFIER", 2, 7], ["roadblock", "OBSERVATION", 8, 17], ["new", "OBSERVATION_MODIFIER", 58, 61], ["protein vaccines", "OBSERVATION", 62, 78], ["disease", "OBSERVATION", 760, 767]]], ["Recruited volunteers will be screened for native pneumococcal carriage by nasal wash.", [["nasal", "ANATOMY", 74, 79], ["pneumococcal carriage", "DISEASE", 49, 70], ["volunteers", "ORGANISM", 10, 20], ["pneumococcal", "ORGANISM", 49, 61], ["nasal", "ORGANISM_SUBDIVISION", 74, 79], ["pneumococcal", "SPECIES", 49, 61], ["native pneumococcal carriage", "TREATMENT", 42, 70], ["nasal", "ANATOMY", 74, 79], ["wash", "OBSERVATION", 80, 84]]], ["Natural carriage volunteers will be excluded from inoculation but continue with the rest of the study as per experimental carriage volunteers.", [["volunteers", "ORGANISM", 17, 27], ["volunteers", "ORGANISM", 131, 141], ["the study", "TEST", 92, 101]]], ["Up to 40 natural carriage volunteers will be recruited.", [["volunteers", "ORGANISM", 26, 36]]], ["Each group of 10 experimental carriage subjects will be inoculated with 0.1ml pneumococci to each nostril.", [["nostril", "ANATOMY", 98, 105], ["subjects", "ORGANISM", 39, 47], ["nostril", "ORGANISM_SUBDIVISION", 98, 105], ["pneumococci", "TREATMENT", 78, 89], ["nostril", "ANATOMY", 98, 105]]], ["The inoculated doses will be increased in each cohort of ten subjects from the initial cohort (1x10 4 cfu/nostril), to 2x10 4 , 4x10 4 , 8x10 4 , 1.6x10 5 , 3.2x10 5 cfu/nostril.", [["nostril", "ORGAN", 170, 177], ["The inoculated doses", "TREATMENT", 0, 20], ["nostril", "ANATOMY", 170, 177]]], ["We plan to recruit up to 20 participants to receive an inoculation of 0.9% saline solution to provide a control arm.", [["saline", "SIMPLE_CHEMICAL", 75, 81], ["participants", "SPECIES", 28, 40], ["an inoculation of 0.9% saline solution", "TREATMENT", 52, 90], ["a control arm", "TREATMENT", 102, 115], ["arm", "ANATOMY", 112, 115]]], ["We will use the data to construct a graph of the carriage rate achieved with each inoculum dose.", [["the carriage rate", "TEST", 45, 62], ["each inoculum dose", "TREATMENT", 77, 95]]], ["The full dose ranging study will be done with serotype 6B and the repeated with serotype 23Fboth of these types have been used in our pilot studies.Study design overviewThe primary endpoint in each subject will be the detection of pneumococci by classical culture methods in nasal wash at 48hrs and/or 7-10 days following inoculation.", [["nasal", "ANATOMY", 275, 280], ["pneumococci", "DISEASE", 231, 242], ["pneumococci", "ORGANISM", 231, 242], ["nasal", "ORGANISM_SUBDIVISION", 275, 280], ["The full dose ranging study", "TEST", 0, 27], ["serotype 6B", "TREATMENT", 46, 57], ["serotype", "TREATMENT", 80, 88], ["our pilot studies", "TEST", 130, 147], ["pneumococci", "PROBLEM", 231, 242], ["classical culture methods", "TEST", 246, 271], ["nasal wash", "TREATMENT", 275, 285], ["inoculation", "PROBLEM", 322, 333], ["nasal", "ANATOMY", 275, 280]]], ["The dose-response curve will then be used to tailor future vaccine assessment studies to purpose.", [["tailor future vaccine assessment studies", "TEST", 45, 85]]], ["Predicted 80% carriage will allow the EHPC model to have high sensitivity for vaccine efficacy with small study numbers.", [["the EHPC model", "TREATMENT", 34, 48], ["high sensitivity", "PROBLEM", 57, 73], ["vaccine efficacy", "TREATMENT", 78, 94], ["small study numbers", "TEST", 100, 119]]], ["The dose-response curve will also allow prediction of a 50% endpoint that will allow the combined testing for benefit and harm in future vaccine studies, but at the cost of larger study numbers.Study design overviewThe secondary endpoints are immunological assays to determine defence against infection.", [["infection", "DISEASE", 293, 302], ["the combined testing", "TEST", 85, 105], ["future vaccine studies", "TEST", 130, 152], ["The secondary endpoints", "PROBLEM", 215, 238], ["immunological assays", "TEST", 243, 263], ["infection", "PROBLEM", 293, 302], ["infection", "OBSERVATION", 293, 302]]], ["We will collect samples in order to apply these assays to nasal wash, saliva, bronchoalveolar lavage, urine, throat swabs and blood before and after experimental challenge.", [["samples", "ANATOMY", 16, 23], ["nasal", "ANATOMY", 58, 63], ["saliva", "ANATOMY", 70, 76], ["bronchoalveolar lavage", "ANATOMY", 78, 100], ["urine", "ANATOMY", 102, 107], ["throat swabs", "ANATOMY", 109, 121], ["blood", "ANATOMY", 126, 131], ["saliva", "ORGANISM_SUBSTANCE", 70, 76], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 78, 100], ["urine", "ORGANISM_SUBSTANCE", 102, 107], ["throat swabs", "ORGANISM_SUBSTANCE", 109, 121], ["blood", "ORGANISM_SUBSTANCE", 126, 131], ["these assays", "TEST", 42, 54], ["nasal wash", "TREATMENT", 58, 68], ["saliva", "TREATMENT", 70, 76], ["bronchoalveolar lavage", "TEST", 78, 100], ["urine, throat swabs", "TEST", 102, 121], ["experimental challenge", "TREATMENT", 149, 171], ["throat", "ANATOMY", 109, 115]]], ["This will provide data on the density of colonisation as well as upper and lower airway innate, humoral and cellular defence.", [["airway", "ANATOMY", 81, 87], ["cellular", "ANATOMY", 108, 116], ["upper", "ORGANISM_SUBDIVISION", 65, 70], ["airway", "MULTI-TISSUE_STRUCTURE", 81, 87], ["cellular", "CELL", 108, 116], ["colonisation", "PROBLEM", 41, 53], ["upper and lower airway innate", "PROBLEM", 65, 94], ["colonisation", "OBSERVATION", 41, 53], ["upper", "ANATOMY_MODIFIER", 65, 70], ["lower", "ANATOMY_MODIFIER", 75, 80], ["airway", "ANATOMY", 81, 87], ["humoral", "ANATOMY", 96, 103], ["cellular defence", "OBSERVATION", 108, 124]]], ["For example, it may be that subjects with pre-existing high levels of anti-capsular IgG or innate factors are resistant to EHPC and a future highly reproducible model may have to exclude these subjects at screening.Study design overviewReproducibility study -We will recruit 30 experimental carriage volunteers for each of the 2 serotypes.", [["EHPC", "CHEMICAL", 123, 127], ["IgG", "GENE_OR_GENE_PRODUCT", 84, 87], ["volunteers", "ORGANISM", 300, 310], ["anti-capsular IgG", "PROTEIN", 70, 87], ["innate factors", "PROTEIN", 91, 105], ["pre-existing high levels of anti-capsular IgG", "PROBLEM", 42, 87], ["innate factors", "PROBLEM", 91, 105], ["EHPC", "TREATMENT", 123, 127], ["screening", "TEST", 205, 214], ["Reproducibility study", "TEST", 236, 257], ["the 2 serotypes", "PROBLEM", 323, 338], ["may be", "UNCERTAINTY", 16, 22]]], ["A target carriage rate will be chosen from the dose ranging study and using the dose and protocol refined in that study, simple reproducibility will be assessed by obtaining a confidence interval for the mean carriage.", [["A target carriage rate", "TREATMENT", 0, 22], ["the dose ranging study", "TEST", 43, 65], ["that study", "TEST", 109, 119], ["the mean carriage", "PROBLEM", 200, 217]]], ["LQAS allows each sample to be defined as acceptable or unacceptable within a range of values and the hypothesis that the ratio of acceptable:unacceptable is the same can be tested in the most parsimonious manner, together with an estimate of the predictive value of this estimate.", [["LQAS", "PROTEIN", 0, 4]]], ["LQAS combines modelling with hypothesis testing and is directly applicable to the vaccine down-selection planned later.Study design overviewWe will re-challenge volunteers successfully colonized in the reproducibility study with either the homologous or heterologous serotype using the same protocol (re-challenge protocol) to determine within serotype and across-serotype protection.", [["volunteers", "ORGANISM", 161, 171], ["LQAS", "DNA", 0, 4], ["hypothesis testing", "TEST", 29, 47], ["the vaccine", "TREATMENT", 78, 89], ["the reproducibility study", "TEST", 198, 223], ["heterologous serotype", "TREATMENT", 254, 275], ["across-serotype protection", "TREATMENT", 357, 383]]], ["This is optional to the volunteer.Study design overviewWe will inoculate natural carriers that were recruited during the study with the 6B strain to determine within serotype and across-serotype protection accounting for the previous natural serotype.", [["the study", "TEST", 117, 126], ["the 6B strain", "TREATMENT", 132, 145], ["across-serotype protection", "TREATMENT", 179, 205], ["the previous natural serotype", "PROBLEM", 221, 250]]], ["This will be performed according to the re-challenge protocol however this will include those volunteers that were previously removed from the study due to natural carriage.", [["volunteers", "ORGANISM", 94, 104], ["the re-challenge protocol", "TREATMENT", 36, 61], ["the study", "TEST", 139, 148], ["natural carriage", "PROBLEM", 156, 172]]], ["The 2-6month interval will be counted from the termination of study in those that were previously removed from the study due to natural carriage or from completion of study in all other natural carriers.", [["study", "TEST", 62, 67], ["the study", "TEST", 111, 120], ["natural carriage", "PROBLEM", 128, 144], ["completion of study", "TEST", 153, 172]]], ["This is optional to the volunteer.AimsThe study aims to investigate the innate, acquired humoral and cellular immune response to induced pneumococcal nasal carriage in a safe and controlled manner.", [["cellular", "ANATOMY", 101, 109], ["nasal", "ANATOMY", 150, 155], ["cellular", "CELL", 101, 109], ["nasal", "ORGAN", 150, 155], ["pneumococcal", "SPECIES", 137, 149], ["The study", "TEST", 38, 47], ["pneumococcal nasal carriage", "PROBLEM", 137, 164], ["cellular immune", "OBSERVATION", 101, 116], ["pneumococcal", "OBSERVATION_MODIFIER", 137, 149], ["nasal", "ANATOMY", 150, 155], ["carriage", "OBSERVATION", 156, 164]]], ["We will carry out a dose-ranging study with type 6B and 23F pneumococci in order to find the optimal dose for 50-80% carriage with each serotype (n=10 experimental carriage subjects per dose range).", [["type 6B", "PROBLEM", 44, 51], ["23F pneumococci", "PROBLEM", 56, 71]]], ["We will re-challenge carriers with pneumococci to determine the protective effect of experimental human pneumococcal carriage (EHPC) itself as a surrogate for vaccine induced immunity.", [["human", "ORGANISM", 98, 103], ["pneumococcal", "ORGANISM", 104, 116], ["human", "SPECIES", 98, 103], ["human", "SPECIES", 98, 103], ["pneumococcal", "SPECIES", 104, 116], ["pneumococci", "TREATMENT", 35, 46], ["experimental human pneumococcal carriage (EHPC)", "TREATMENT", 85, 132], ["vaccine induced immunity", "TREATMENT", 159, 183]]], ["We will describe the mechanisms underlying EHPC +/-protection from carriage.AimsThree major applications of this study are (a) as an immunological probe of mucosal immunity in the upper and lower airway, (b) as a mucosal vaccine model and (c) as a potential surrogate of protection for testing novel protein vaccines (with the eventual goal of a needle-free inhaled vaccine against S. pneumoniae).Subjects and timelinesWe will inoculate healthy non-smoking adult volunteers with a well-characterised penicillin-sensitive pneumococcus (23F or 6B) and observe the volunteers for the development of pneumococcal carriage.", [["mucosal", "ANATOMY", 156, 163], ["upper", "ANATOMY", 180, 185], ["lower airway", "ANATOMY", 190, 202], ["mucosal", "ANATOMY", 213, 220], ["penicillin", "CHEMICAL", 500, 510], ["pneumococcus", "DISEASE", 521, 533], ["pneumococcal carriage", "DISEASE", 596, 617], ["penicillin", "CHEMICAL", 500, 510], ["EHPC", "GENE_OR_GENE_PRODUCT", 43, 47], ["mucosal", "MULTI-TISSUE_STRUCTURE", 156, 163], ["upper", "ORGANISM_SUBDIVISION", 180, 185], ["lower airway", "ORGANISM_SUBDIVISION", 190, 202], ["S. pneumoniae", "ORGANISM", 382, 395], ["volunteers", "ORGANISM", 463, 473], ["penicillin", "SIMPLE_CHEMICAL", 500, 510], ["pneumococcus", "ORGANISM", 521, 533], ["volunteers", "ORGANISM", 562, 572], ["pneumococcal", "ORGANISM", 596, 608], ["S. pneumoniae", "SPECIES", 382, 395], ["S. pneumoniae", "SPECIES", 382, 395], ["pneumococcal", "SPECIES", 596, 608], ["EHPC", "TEST", 43, 47], ["carriage", "PROBLEM", 67, 75], ["this study", "TEST", 108, 118], ["an immunological probe", "TEST", 130, 152], ["a mucosal vaccine model", "TREATMENT", 211, 234], ["testing novel protein vaccines", "TREATMENT", 286, 316], ["a needle-free inhaled vaccine", "TREATMENT", 344, 373], ["S. pneumoniae", "PROBLEM", 382, 395], ["penicillin", "TREATMENT", 500, 510], ["sensitive pneumococcus", "PROBLEM", 511, 533], ["pneumococcal carriage", "PROBLEM", 596, 617], ["mucosal immunity", "OBSERVATION", 156, 172], ["upper", "ANATOMY_MODIFIER", 180, 185], ["lower airway", "ANATOMY", 190, 202], ["pneumococcal", "OBSERVATION_MODIFIER", 596, 608], ["carriage", "OBSERVATION", 609, 617]]], ["Colonisation may be expected to occur in 50-80% of the group while the remainder will clear the inoculum in a few hours.Subjects and timelinesOutline timetable of dose-ranging study for volunteers:Subjects and timelinesWeek 0Subjects and timelinesInitial appointment to discuss potential study involvementSubjects and timelinesWeek 1 Appointment for consent, initial nasal wash, urine, throat swab, saliva and blood (serum) collection Week 2 If no natural carriage found from initial nasal wash -0.1ml of either 23F or 6B is inoculated into each nostril.", [["nasal", "ANATOMY", 367, 372], ["urine", "ANATOMY", 379, 384], ["throat swab", "ANATOMY", 386, 397], ["saliva", "ANATOMY", 399, 405], ["blood", "ANATOMY", 410, 415], ["serum", "ANATOMY", 417, 422], ["nasal", "ANATOMY", 484, 489], ["nostril", "ANATOMY", 546, 553], ["Colonisation", "DISEASE", 0, 12], ["23F or 6B", "CHEMICAL", 512, 521], ["volunteers", "ORGANISM", 186, 196], ["urine", "ORGANISM_SUBSTANCE", 379, 384], ["throat swab", "ORGANISM_SUBSTANCE", 386, 397], ["saliva", "ORGANISM_SUBSTANCE", 399, 405], ["blood", "ORGANISM_SUBSTANCE", 410, 415], ["serum", "ORGANISM_SUBSTANCE", 417, 422], ["nostril", "ORGANISM_SUBDIVISION", 546, 553], ["initial nasal wash, urine, throat swab", "TEST", 359, 397], ["saliva and blood (serum) collection", "TEST", 399, 434], ["natural carriage", "PROBLEM", 448, 464], ["initial nasal wash", "TREATMENT", 476, 494], ["inoculum", "OBSERVATION", 96, 104], ["nasal", "ANATOMY", 484, 489]]], ["Daily contact with researcher for 7/7 by phone ensues Week 2 Nasal wash (48hrs post inoculation), throat swab and urine sampleSubjects and timelinesWeek 3 Nasal wash (7 days post inoculation)Subjects and timelinesWeek 4 Nasal wash, saliva, blood and urine collection.", [["throat swab", "ANATOMY", 98, 109], ["urine", "ANATOMY", 114, 119], ["Nasal", "ANATOMY", 155, 160], ["Nasal", "ANATOMY", 220, 225], ["blood", "ANATOMY", 240, 245], ["urine", "ANATOMY", 250, 255], ["urine", "ORGANISM_SUBSTANCE", 114, 119], ["saliva", "ORGANISM_SUBSTANCE", 232, 238], ["blood", "ORGANISM_SUBSTANCE", 240, 245], ["urine", "ORGANISM_SUBSTANCE", 250, 255], ["Nasal wash", "TREATMENT", 61, 71], ["throat swab", "TEST", 98, 109], ["urine sampleSubjects", "TEST", 114, 134], ["Nasal wash", "TREATMENT", 155, 165], ["saliva, blood and urine collection", "TEST", 232, 266], ["Nasal", "ANATOMY", 61, 66], ["throat", "ANATOMY", 98, 104], ["Nasal", "ANATOMY", 155, 160], ["Nasal", "ANATOMY", 220, 225]]], ["Amoxicillin 500mg tds for 3 days in all volunteers with carriage.Subjects and timelinesWeek [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Blood sampleSubjects and timelinesOutline timetable of reproducibility study for volunteers:Subjects and timelinesWeek 0 Initial appointment to discuss potential study involvementSubjects and timelinesWeek 1 Appointment for consent, initial nasal wash, saliva, blood, throat swab and urine collection Week 2 If no natural carriage found from initial nasal wash -0.1ml of either 23F or 6B is inoculated into each nostril.", [["nasal", "ANATOMY", 388, 393], ["saliva", "ANATOMY", 400, 406], ["blood", "ANATOMY", 408, 413], ["throat swab", "ANATOMY", 415, 426], ["urine", "ANATOMY", 431, 436], ["nasal", "ANATOMY", 497, 502], ["nostril", "ANATOMY", 559, 566], ["Amoxicillin", "CHEMICAL", 0, 11], ["23F or 6B", "CHEMICAL", 525, 534], ["Amoxicillin", "CHEMICAL", 0, 11], ["Amoxicillin", "SIMPLE_CHEMICAL", 0, 11], ["volunteers", "ORGANISM", 40, 50], ["Week [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Blood sampleSubjects", "SIMPLE_CHEMICAL", 87, 167], ["volunteers", "ORGANISM", 228, 238], ["saliva", "ORGANISM_SUBSTANCE", 400, 406], ["blood", "ORGANISM_SUBSTANCE", 408, 413], ["throat swab", "ORGANISM_SUBSTANCE", 415, 426], ["urine", "ORGANISM_SUBSTANCE", 431, 436], ["nostril", "ORGANISM_SUBDIVISION", 559, 566], ["Amoxicillin", "TREATMENT", 0, 11], ["Blood sampleSubjects", "TEST", 147, 167], ["reproducibility study", "TEST", 202, 223], ["initial nasal wash", "TREATMENT", 380, 398], ["saliva", "TREATMENT", 400, 406], ["blood, throat swab and urine collection", "TEST", 408, 447], ["natural carriage", "PROBLEM", 461, 477], ["initial nasal wash", "TREATMENT", 489, 507], ["nasal", "ANATOMY", 497, 502]]], ["Daily contact with researcher for 7/7 by phone ensuesSubjects and timelinesWeek 2Subjects and timelinesNasal wash (48hrs post inoculation), throat swab and urineSubjects and timelinesWeek 3 Nasal wash, blood and urine (7 days post inoculation)Subjects and timelinesWeek 4 Nasal wash, blood and urineSubjects and timelinesWeek 5 Nasal wash, blood and urineSubjects and timelinesWeek 6 Nasal wash, blood and urine.", [["throat swab", "ANATOMY", 140, 151], ["Nasal", "ANATOMY", 190, 195], ["blood", "ANATOMY", 202, 207], ["urine", "ANATOMY", 212, 217], ["Nasal", "ANATOMY", 272, 277], ["blood", "ANATOMY", 284, 289], ["Nasal", "ANATOMY", 328, 333], ["blood", "ANATOMY", 340, 345], ["Nasal", "ANATOMY", 384, 389], ["blood", "ANATOMY", 396, 401], ["urine", "ANATOMY", 406, 411], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["urine", "ORGANISM_SUBSTANCE", 212, 217], ["blood", "ORGANISM_SUBSTANCE", 284, 289], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["blood", "ORGANISM_SUBSTANCE", 396, 401], ["urine", "ORGANISM_SUBSTANCE", 406, 411], ["Nasal wash", "TREATMENT", 103, 113], ["throat swab", "TEST", 140, 151], ["blood and urine", "TEST", 202, 217], ["Nasal wash, blood and urine", "TEST", 384, 411], ["Nasal", "ANATOMY", 103, 108], ["wash", "OBSERVATION", 109, 113], ["throat", "ANATOMY", 140, 146], ["Nasal", "ANATOMY", 190, 195], ["Nasal", "ANATOMY", 272, 277], ["wash", "OBSERVATION", 278, 282], ["Nasal", "ANATOMY", 328, 333], ["wash", "OBSERVATION", 334, 338], ["Nasal", "ANATOMY", 384, 389], ["wash", "OBSERVATION", 390, 394]]], ["Amoxicillin 500mg for 3 days in all volunteers with carriage Week 7-9Subjects and timelinesNasal wash, saliva, blood and urine collection.", [["blood", "ANATOMY", 111, 116], ["urine", "ANATOMY", 121, 126], ["Amoxicillin", "CHEMICAL", 0, 11], ["Amoxicillin", "CHEMICAL", 0, 11], ["Amoxicillin", "SIMPLE_CHEMICAL", 0, 11], ["volunteers", "ORGANISM", 36, 46], ["saliva", "ORGANISM_SUBSTANCE", 103, 109], ["blood", "ORGANISM_SUBSTANCE", 111, 116], ["urine", "ORGANISM_SUBSTANCE", 121, 126], ["Amoxicillin", "TREATMENT", 0, 11], ["Nasal wash", "TREATMENT", 91, 101], ["blood and urine collection", "TEST", 111, 137]]], ["Bronchoscopy for BAL collection (when consent obtained as per separate consent form attached)Subjects and timelinesWeek 10-20 Blood sampleSubjects and timelinesOutline time-table for re-challenge study; after a 2-6 mth time interval of completing the study volunteers are re-challenged with a timeline as follows (this is optional for the volunteer):Subjects and timelinesWeek 0 Initial appointment to discuss potential study involvementSubjects and timelinesWeek 1 Appointment for consent, initial nasal washand blood collectionSubjects and timelinesWeek 2 If no natural carriage found from initial nasal wash -0.1ml of either 23F or 6B is inoculated into each nostril.", [["BAL", "ANATOMY", 17, 20], ["Blood", "ANATOMY", 126, 131], ["nasal", "ANATOMY", 499, 504], ["blood", "ANATOMY", 513, 518], ["nasal", "ANATOMY", 600, 605], ["nostril", "ANATOMY", 662, 669], ["23F or 6B", "CHEMICAL", 628, 637], ["volunteers", "ORGANISM", 257, 267], ["blood", "ORGANISM_SUBSTANCE", 513, 518], ["nostril", "ORGANISM_SUBDIVISION", 662, 669], ["Bronchoscopy", "TEST", 0, 12], ["BAL collection", "TEST", 17, 31], ["Blood sampleSubjects", "TEST", 126, 146], ["re-challenge study", "TEST", 183, 201], ["the study", "TEST", 247, 256], ["initial nasal washand blood collectionSubjects", "TREATMENT", 491, 537], ["natural carriage", "PROBLEM", 564, 580], ["initial nasal wash", "TREATMENT", 592, 610], ["nasal", "ANATOMY", 499, 504], ["nasal", "ANATOMY", 600, 605]]], ["Daily contact with researcher for 7/7 by phone ensuesSubjects and timelinesWeek 2Subjects and timelinesNasal wash(48hrs post inoculation)Subjects and timelinesWeek 3 Nasal wash (7 days post inoculation)Subjects and timelinesWeek 4 Final sample collection (nasal wash and blood).Subjects and timelinesAmoxicillin 500mg for 3 days in all volunteers with carriage at any time point.Subjects and timelinesEnriched sample set collection for secondary endpoints: a) In a sub-set of subjects, consent may be obtained to collect venous blood on days 2, 3, 4, 5 and 10 in addition to the samples planned on days 0, 7, 14, 21 and weekly to week 7 as detailed above.", [["Nasal", "ANATOMY", 166, 171], ["sample", "ANATOMY", 237, 243], ["nasal", "ANATOMY", 256, 261], ["blood", "ANATOMY", 271, 276], ["venous blood", "ANATOMY", 521, 533], ["samples", "ANATOMY", 579, 586], ["Amoxicillin", "CHEMICAL", 300, 311], ["Amoxicillin", "CHEMICAL", 300, 311], ["nasal", "ORGANISM_SUBDIVISION", 256, 261], ["blood", "ORGANISM_SUBSTANCE", 271, 276], ["Amoxicillin", "SIMPLE_CHEMICAL", 300, 311], ["volunteers", "ORGANISM", 336, 346], ["venous blood", "ORGANISM_SUBSTANCE", 521, 533], ["Nasal wash", "TREATMENT", 103, 113], ["Nasal wash", "TREATMENT", 166, 176], ["Final sample collection", "TEST", 231, 254], ["nasal wash and blood)", "TREATMENT", 256, 277], ["Amoxicillin", "TREATMENT", 300, 311], ["venous blood", "TEST", 521, 533], ["Nasal", "ANATOMY", 103, 108], ["wash", "OBSERVATION", 109, 113], ["Nasal", "ANATOMY", 166, 171], ["nasal", "ANATOMY", 256, 261], ["venous", "ANATOMY", 521, 527]]], ["Subjects in the reproducibility study will all be invited to take part in this limb of the study; a small number of subjects in the dose-ranging study will be invited if carriage is likely to occur (higher inoculum doses).Subjects and timelinesIn subjects willing to undergo bronchoscopy, this will be carried out after the termination of carriage/full protocol using a separate consent form to the simple EHPC consent.", [["limb", "ANATOMY", 79, 83], ["limb", "ORGANISM_SUBDIVISION", 79, 83], ["the reproducibility study", "TEST", 12, 37], ["the study", "TEST", 87, 96], ["bronchoscopy", "TREATMENT", 275, 287], ["small", "OBSERVATION_MODIFIER", 100, 105]]], ["Subjects in the reproducibility study will all be invited to take part in this limb of the study; subjects in the dose-ranging study will only be invited if carriage occurs.Recruitment and selectionAdvertisements will be placed on physical notice boards in public areas and on the intranet of Liverpool University and RLBUHT, as well as in the local press inviting healthy volunteers to participate.", [["limb", "ANATOMY", 79, 83], ["limb", "ORGANISM_SUBDIVISION", 79, 83], ["volunteers", "ORGANISM", 373, 383], ["the reproducibility study", "TEST", 12, 37], ["the study", "TEST", 87, 96]]], ["Interested persons are asked to contact the research team for further information and an initial appointment will be made should they wish to consider participating.Inclusion criteria:Adults aged 18-60 yrs -ages chosen to minimise the risk of pneumococcal infection Unable to give fully informed consentScreening and preliminary assessmentClinical examination -the initial clinic visit will include a focused clinical history and targeted clinical examination involving auscultation of the lung fields and heart sounds.", [["lung", "ANATOMY", 490, 494], ["heart", "ANATOMY", 506, 511], ["pneumococcal infection", "DISEASE", 243, 265], ["persons", "ORGANISM", 11, 18], ["Adults", "ORGANISM", 184, 190], ["pneumococcal", "ORGANISM", 243, 255], ["lung", "ORGAN", 490, 494], ["heart", "ORGAN", 506, 511], ["persons", "SPECIES", 11, 18], ["Adults", "SPECIES", 184, 190], ["pneumococcal", "SPECIES", 243, 255], ["pneumococcal infection", "PROBLEM", 243, 265], ["preliminary assessment", "TEST", 317, 339], ["Clinical examination", "TEST", 339, 359], ["targeted clinical examination", "TEST", 430, 459], ["auscultation of the lung fields", "TEST", 470, 501], ["heart sounds", "TEST", 506, 518], ["pneumococcal", "OBSERVATION_MODIFIER", 243, 255], ["infection", "OBSERVATION", 256, 265], ["lung", "ANATOMY", 490, 494], ["fields", "ANATOMY_MODIFIER", 495, 501], ["heart", "ANATOMY", 506, 511], ["sounds", "OBSERVATION", 512, 518]]], ["Should a previously unrecognised abnormality be identified this will be explained to the individual, who will be informed, they will be excluded from enrolling in the study and appropriate follow up and investigation will be arranged through the General Practitioner.Screening and preliminary assessmentSaliva samples -will be collected as per timetabled protocol above including the first clinic visit.", [["Saliva samples", "ANATOMY", 303, 317], ["Saliva samples", "ORGANISM_SUBSTANCE", 303, 317], ["a previously unrecognised abnormality", "PROBLEM", 7, 44], ["the study", "TEST", 163, 172], ["Screening", "TEST", 267, 276], ["preliminary assessment", "TEST", 281, 303], ["Saliva samples", "TEST", 303, 317]]], ["Samples will be collected using salivates retained for 2 minutes between the gum and buccal mucosa as per the manufacturer\"s instructions.Screening and preliminary assessmentNasal lavage -will be performed using a modified Naclerio method [1] .", [["Samples", "ANATOMY", 0, 7], ["buccal mucosa", "ANATOMY", 85, 98], ["Nasal lavage", "ANATOMY", 174, 186], ["gum", "ORGANISM_SUBDIVISION", 77, 80], ["buccal mucosa", "MULTI-TISSUE_STRUCTURE", 85, 98], ["Samples", "TEST", 0, 7], ["salivates", "TREATMENT", 32, 41], ["Screening", "TEST", 138, 147], ["preliminary assessment", "TEST", 152, 174], ["Nasal lavage", "TREATMENT", 174, 186], ["a modified Naclerio method", "TREATMENT", 212, 238], ["buccal mucosa", "ANATOMY", 85, 98], ["lavage", "OBSERVATION", 180, 186]]], ["This is a well used and validated technique to collect nasal cytology specimens with which we now have 2 years experience.", [["nasal cytology specimens", "ANATOMY", 55, 79], ["nasal cytology specimens", "CANCER", 55, 79], ["nasal cytology specimens", "TEST", 55, 79]]], ["Briefly, 10ml of saline is instilled and held for a few seconds in the nares before being expelled in to a petri dish.", [["nares", "ANATOMY", 71, 76], ["saline", "SIMPLE_CHEMICAL", 17, 23], ["nares", "ORGANISM_SUBDIVISION", 71, 76], ["saline", "TREATMENT", 17, 23], ["nares", "ANATOMY", 71, 76], ["petri dish", "OBSERVATION", 107, 117]]], ["In the event of nasal wash loss (defined as cough/sneeze/swallow) the procedure may then be repeated to obtain an adequate specimen.", [["nasal", "ANATOMY", 16, 21], ["specimen", "ANATOMY", 123, 131], ["nasal wash loss", "DISEASE", 16, 31], ["cough", "DISEASE", 44, 49], ["nasal", "ORGANISM_SUBDIVISION", 16, 21], ["nasal wash loss", "PROBLEM", 16, 31], ["cough/sneeze/swallow", "TREATMENT", 44, 64], ["the procedure", "TREATMENT", 66, 79], ["nasal", "ANATOMY", 16, 21], ["wash loss", "OBSERVATION", 22, 31]]], ["Should this initial wash demonstrate that a potential volunteer is already colonised with pneumococci, they will follow the study but without inoculation.Screening and preliminary assessmentBloodvenous blood will be taken by an appropriately trained team member.", [["Bloodvenous blood", "ANATOMY", 190, 207], ["blood", "ORGANISM_SUBSTANCE", 202, 207], ["pneumococci", "PROBLEM", 90, 101], ["the study", "TEST", 120, 129], ["inoculation", "PROBLEM", 142, 153], ["Screening", "TEST", 154, 163], ["preliminary assessment", "TEST", 168, 190], ["pneumococci", "OBSERVATION", 90, 101]]], ["In the standard visits, up to 40ml of blood will be collected for extraction of serum and whole blood, an EDTA sample will be taken on the screening visit to determine normal range of white cell count.", [["blood", "ANATOMY", 38, 43], ["serum", "ANATOMY", 80, 85], ["whole blood", "ANATOMY", 90, 101], ["white cell", "ANATOMY", 184, 194], ["EDTA", "CHEMICAL", 106, 110], ["blood", "ORGANISM_SUBSTANCE", 38, 43], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["blood", "ORGANISM_SUBSTANCE", 96, 101], ["white cell", "CELL", 184, 194], ["extraction of serum and whole blood", "TEST", 66, 101], ["an EDTA sample", "TEST", 103, 117], ["white cell count", "TEST", 184, 200]]], ["In the enriched sample sets, 2 Paxgene tubes (each 5ml) will be collected on the additional days but the 40ml draw will only occur on the standard days.", [["sample", "ANATOMY", 16, 22], ["2 Paxgene tubes", "TREATMENT", 29, 44]]], ["Volunteers will therefore give 40ml per week normally, or 80ml in week 1 and 50 ml in week 2 in the enriched sampling.Screening and preliminary assessmentA viral throat swab will be obtained to assess viral load and viral co-infections in individuals who are colonised and not colonised following inoculation.", [["throat swab", "ANATOMY", 162, 173], ["viral co-infections", "DISEASE", 216, 235], ["Volunteers", "ORGANISM", 0, 10], ["Screening", "TEST", 118, 127], ["preliminary assessment", "TEST", 132, 154], ["A viral throat swab", "TEST", 154, 173], ["viral load", "PROBLEM", 201, 211], ["viral co-infections", "PROBLEM", 216, 235], ["viral co-infections", "OBSERVATION", 216, 235]]], ["Samples will be taken pre and 48 hours post pneumococcal inoculum to investigate the relationship between upper respiratory tract viral infections and susceptibility and density of pneumococcal colonisation.", [["Samples", "ANATOMY", 0, 7], ["respiratory tract viral infections", "DISEASE", 112, 146], ["upper", "ORGANISM_SUBDIVISION", 106, 111], ["respiratory tract", "ORGANISM_SUBDIVISION", 112, 129], ["pneumococcal", "ORGANISM", 181, 193], ["pneumococcal", "SPECIES", 44, 56], ["pneumococcal", "SPECIES", 181, 193], ["Samples", "TEST", 0, 7], ["pneumococcal inoculum", "TREATMENT", 44, 65], ["upper respiratory tract viral infections", "PROBLEM", 106, 146], ["pneumococcal colonisation", "PROBLEM", 181, 206], ["upper", "ANATOMY_MODIFIER", 106, 111], ["respiratory tract", "ANATOMY", 112, 129], ["viral infections", "OBSERVATION", 130, 146], ["density", "OBSERVATION_MODIFIER", 170, 177], ["pneumococcal colonisation", "OBSERVATION", 181, 206]]], ["In brief, the individuals tongue will be depressed using a tongue depressor exposing the palatopharyngeal arch.", [["tongue", "ANATOMY", 26, 32], ["tongue", "ANATOMY", 59, 65], ["palatopharyngeal arch", "ANATOMY", 89, 110], ["depressed", "DISEASE", 41, 50], ["individuals", "ORGANISM", 14, 25], ["tongue", "ORGAN", 26, 32], ["tongue", "ORGANISM_SUBDIVISION", 59, 65], ["palatopharyngeal arch", "MULTI-TISSUE_STRUCTURE", 89, 110], ["depressed", "PROBLEM", 41, 50], ["a tongue depressor", "TREATMENT", 57, 75], ["tongue", "ANATOMY", 26, 32], ["tongue", "ANATOMY", 59, 65], ["palatopharyngeal arch", "ANATOMY", 89, 110]]], ["A sample will be obtained by making 5 small circular motions of the right palatopharyngeal in contact with the mucosa whilst avoiding the patients tongue.", [["sample", "ANATOMY", 2, 8], ["right palatopharyngeal", "ANATOMY", 68, 90], ["mucosa", "ANATOMY", 111, 117], ["tongue", "ANATOMY", 147, 153], ["mucosa", "MULTI-TISSUE_STRUCTURE", 111, 117], ["patients", "ORGANISM", 138, 146], ["tongue", "ORGAN", 147, 153], ["patients", "SPECIES", 138, 146], ["A sample", "TEST", 0, 8], ["the patients tongue", "PROBLEM", 134, 153], ["circular motions", "OBSERVATION", 44, 60], ["right", "ANATOMY_MODIFIER", 68, 73], ["palatopharyngeal", "ANATOMY", 74, 90], ["mucosa", "ANATOMY", 111, 117], ["tongue", "ANATOMY", 147, 153]]], ["The swab will be returned to the respective container and viral multiplex PCR will be used to evaluate the presence of Flu A, Flu B, RSV, hMPV, Paraflus 1-4, adenovirus, rhinovirus, and coronaviruses OC43, 229E, NL63, and HKU1.Preparation of bacterial stockPreparation of bacteria for carriage studies -mid-log broth culture of pneumococcus (type 23F or 6B) will be frozen at -80\u00b0C in aliquots of glycerol-enriched media.", [["swab", "ANATOMY", 4, 8], ["pneumococcus", "DISEASE", 328, 340], ["glycerol", "CHEMICAL", 397, 405], ["glycerol", "CHEMICAL", 397, 405], ["Flu A", "GENE_OR_GENE_PRODUCT", 119, 124], ["Flu B", "ORGANISM", 126, 131], ["RSV", "ORGANISM", 133, 136], ["hMPV", "ORGANISM", 138, 142], ["Paraflus 1-4", "ORGANISM", 144, 156], ["adenovirus", "ORGANISM", 158, 168], ["rhinovirus", "ORGANISM", 170, 180], ["coronaviruses", "ORGANISM", 186, 199], ["OC43", "GENE_OR_GENE_PRODUCT", 200, 204], ["229E", "GENE_OR_GENE_PRODUCT", 206, 210], ["NL63", "GENE_OR_GENE_PRODUCT", 212, 216], ["HKU1", "GENE_OR_GENE_PRODUCT", 222, 226], ["pneumococcus", "ORGANISM", 328, 340], ["glycerol", "SIMPLE_CHEMICAL", 397, 405], ["HKU1", "PROTEIN", 222, 226], ["Flu A", "SPECIES", 119, 124], ["RSV", "SPECIES", 133, 136], ["hMPV", "SPECIES", 138, 142], ["The swab", "TEST", 0, 8], ["viral multiplex PCR", "TEST", 58, 77], ["Flu A", "PROBLEM", 119, 124], ["Flu B", "TEST", 126, 131], ["RSV", "PROBLEM", 133, 136], ["hMPV", "PROBLEM", 138, 142], ["Paraflus", "TEST", 144, 152], ["adenovirus", "PROBLEM", 158, 168], ["rhinovirus", "PROBLEM", 170, 180], ["coronaviruses OC43", "TEST", 186, 204], ["NL63", "TEST", 212, 216], ["HKU1", "TEST", 222, 226], ["bacterial stockPreparation of bacteria", "PROBLEM", 242, 280], ["carriage studies", "TEST", 285, 301], ["log broth culture", "TEST", 307, 324], ["pneumococcus", "PROBLEM", 328, 340], ["glycerol-enriched media", "TREATMENT", 397, 420], ["Flu", "OBSERVATION", 119, 122], ["RSV", "ANATOMY", 133, 136], ["hMPV", "ANATOMY", 138, 142], ["bacterial stockPreparation", "OBSERVATION", 242, 268]]], ["Frozen aliquots will be thawed and checked for cfu/ml, E-test penicillin susceptibility and purity.", [["penicillin", "CHEMICAL", 62, 72], ["penicillin", "CHEMICAL", 62, 72], ["penicillin", "SIMPLE_CHEMICAL", 62, 72], ["Frozen aliquots", "TEST", 0, 15], ["cfu/ml", "TEST", 47, 53], ["E-test penicillin susceptibility", "TEST", 55, 87]]], ["These checks will first be carried out in our laboratory and then identification and characterisation will be confirmed in a reference laboratory.", [["These checks", "TEST", 0, 12]]], ["On experimental days, aliquots will be thawed, washed twice, and re-suspended at an appropriate density for each inoculation dose.Preparation of bacterial stockInoculation -using a P200 micropipette 0.1ml broth containing the desired dose (ranging from 1x10 4 to 3.2x10 5 cfu/nostril) of type 23F or 6B pneumococcus will be instilled.", [["nostril", "ORGANISM_SUBDIVISION", 276, 283], ["aliquots", "TREATMENT", 22, 30], ["bacterial stockInoculation", "TREATMENT", 145, 171], ["a P200 micropipette", "TREATMENT", 179, 198], ["type 23F", "TREATMENT", 288, 296], ["6B pneumococcus", "TREATMENT", 300, 315], ["bacterial stockInoculation", "OBSERVATION", 145, 171]]], ["Patient will be seated in a semirecumbent position.", [["Patient", "ORGANISM", 0, 7], ["Patient", "SPECIES", 0, 7]]], ["After inoculation, patient will remain in this position for up to 15mins.", [["patient", "ORGANISM", 19, 26], ["patient", "SPECIES", 19, 26], ["inoculation", "TREATMENT", 6, 17]]], ["Patient will be given post-inoculation advice sheet (including emergency contact details), thermometer, amoxicillin and a daily symptom log to be completed by the participant.Preparation of bacterial stockDetermination of colonisation -colonisation will be defined by the result of nasal washes taken at 48hrs and 7 days post inoculation.", [["nasal", "ANATOMY", 282, 287], ["amoxicillin", "CHEMICAL", 104, 115], ["amoxicillin", "CHEMICAL", 104, 115], ["amoxicillin", "SIMPLE_CHEMICAL", 104, 115], ["nasal", "ORGANISM_SUBDIVISION", 282, 287], ["Patient", "SPECIES", 0, 7], ["participant", "SPECIES", 163, 174], ["thermometer", "TREATMENT", 91, 102], ["amoxicillin", "TREATMENT", 104, 115], ["bacterial stockDetermination", "TREATMENT", 190, 218], ["colonisation", "PROBLEM", 222, 234], ["colonisation", "PROBLEM", 236, 248], ["nasal washes", "TREATMENT", 282, 294], ["inoculation", "PROBLEM", 326, 337], ["bacterial stockDetermination", "OBSERVATION", 190, 218], ["colonisation", "OBSERVATION", 222, 234], ["colonisation", "OBSERVATION", 236, 248], ["nasal", "ANATOMY", 282, 287], ["washes", "OBSERVATION", 288, 294]]], ["Nasal washes will be plated on to culture media and incubated overnight at 37\u00b0C in 5% CO2.", [["Nasal", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 86, 89], ["CO2", "CHEMICAL", 86, 89], ["CO2", "SIMPLE_CHEMICAL", 86, 89], ["Nasal washes", "TREATMENT", 0, 12], ["culture media", "TEST", 34, 47], ["washes", "OBSERVATION", 6, 12]]], ["Colonies will be confirmed as S. pneumoniae using classical techniques including (i) typical draughtsman-like colony morphology (ii) the presence of \u03b1-haemolysis (iii) optochin sensitivity (iv)solubility in bile salts and (v) Gram-positive diplococci.", [["colony", "ANATOMY", 110, 116], ["bile", "ANATOMY", 207, 211], ["bile salts", "CHEMICAL", 207, 217], ["bile salts", "CHEMICAL", 207, 217], ["S. pneumoniae", "ORGANISM", 30, 43], ["bile salts", "SIMPLE_CHEMICAL", 207, 217], ["S. pneumoniae", "SPECIES", 30, 43], ["S. pneumoniae", "SPECIES", 30, 43], ["S. pneumoniae", "PROBLEM", 30, 43], ["\u03b1-haemolysis (iii) optochin sensitivity (iv)solubility in bile salts and (v) Gram-positive diplococci", "PROBLEM", 149, 250], ["pneumoniae", "OBSERVATION", 33, 43], ["bile", "ANATOMY", 207, 211]]], ["Typing by Quellung reaction will be done using a typing kit with specific sera to confirm inoculated pneumococcal types.", [["sera", "ANATOMY", 74, 78], ["sera", "ORGANISM_SUBSTANCE", 74, 78], ["pneumococcal", "SPECIES", 101, 113], ["a typing kit", "TEST", 47, 59], ["specific sera", "TEST", 65, 78], ["inoculated pneumococcal types", "PROBLEM", 90, 119]]], ["Isolates will be frozen at -80\u00baC for storage and reference laboratory confirmation.", [["Isolates", "TEST", 0, 8], ["reference laboratory confirmation", "TEST", 49, 82]]], ["Results from the cultured nasal wash will also be confirmed using PCR based methods of bacterial detection.Monitoring of colonisation -monitoring of colonisation will be done by weekly nasal washes (reproducibility study).", [["nasal", "ANATOMY", 26, 31], ["nasal", "ANATOMY", 185, 190], ["nasal", "ORGAN", 26, 31], ["nasal", "ORGANISM_SUBDIVISION", 185, 190], ["the cultured nasal wash", "TREATMENT", 13, 36], ["PCR", "TEST", 66, 69], ["bacterial detection", "PROBLEM", 87, 106], ["colonisation", "PROBLEM", 121, 133], ["colonisation", "PROBLEM", 149, 161], ["reproducibility study", "TEST", 199, 220], ["colonisation", "OBSERVATION", 121, 133]]], ["Home monitoring will include a symptom check-list with a clear flow chart of the necessary intervention should any symptoms develop (see patient information sheet).", [["patient", "ORGANISM", 137, 144], ["patient", "SPECIES", 137, 144], ["Home monitoring", "TEST", 0, 15], ["a symptom check", "TEST", 29, 44], ["the necessary intervention", "TREATMENT", 77, 103], ["any symptoms", "PROBLEM", 111, 123]]], ["A three day course of amoxicillin will be issued on enrolment.", [["amoxicillin", "CHEMICAL", 22, 33], ["amoxicillin", "CHEMICAL", 22, 33], ["amoxicillin", "SIMPLE_CHEMICAL", 22, 33], ["amoxicillin", "TREATMENT", 22, 33]]], ["Participants will be required to make text message contact with a specified member of the research team before 1400hrs every day until study completion.", [["Participants", "SPECIES", 0, 12]]], ["During the post inoculation period volunteers will have access to a 24/7 on-call telephone service until after the end of the study.Termination of carriageAll study participants who are still carrying pneumococcus at the end of the study, will take amoxicillin 500mg tds for 3 days orally at the end of the study.Response measurementsThe study primary outcomes are carriage at 48 hours and/or 7days in inoculated volunteers.", [["pneumococcus", "DISEASE", 201, 213], ["amoxicillin", "CHEMICAL", 249, 260], ["amoxicillin", "CHEMICAL", 249, 260], ["volunteers", "ORGANISM", 35, 45], ["participants", "ORGANISM", 165, 177], ["amoxicillin", "SIMPLE_CHEMICAL", 249, 260], ["volunteers", "ORGANISM", 413, 423], ["participants", "SPECIES", 165, 177], ["the study", "TEST", 122, 131], ["pneumococcus", "PROBLEM", 201, 213], ["the study", "TEST", 228, 237], ["amoxicillin", "TREATMENT", 249, 260], ["the study", "TEST", 303, 312], ["Response measurements", "TEST", 313, 334], ["The study", "TEST", 334, 343], ["carriage", "OBSERVATION", 147, 155], ["pneumococcus", "OBSERVATION", 201, 213]]], ["This will be determined by culture of the 48 hour +/-7 day nasal wash sample.Response measurementsSecondary endpoints are immunological parameters and further bacterial carriage characterisation.", [["nasal", "ANATOMY", 59, 64], ["culture", "TEST", 27, 34], ["Response measurements", "TEST", 77, 98], ["Secondary endpoints", "PROBLEM", 98, 117], ["immunological parameters", "TEST", 122, 146], ["further bacterial carriage characterisation", "PROBLEM", 151, 194]]], ["In particular, innate, humoral and cellular responses to pneumococcal proteins and polysaccharide measured in serum, saliva, nasal wash.Innate ResponsesSoluble factors -serum, saliva, nasal wash supernatant and BAL supernatant will be assayed for antimicrobial peptides such as SLPI, lysozyme, lactoferrin, LL-37 and beta defensins as well as neutrophil recruiting chemokines such as CXCL-1, 2 (and their receptors) and CXCL-8, IL-8, SLPI.Innate ResponsesCellular responses -nasal washings, saliva and BAL will be examined by Giemsa stained cytospin for recruitment of neutrophils.", [["cellular", "ANATOMY", 35, 43], ["serum", "ANATOMY", 110, 115], ["saliva", "ANATOMY", 117, 123], ["nasal", "ANATOMY", 125, 130], ["serum", "ANATOMY", 169, 174], ["saliva", "ANATOMY", 176, 182], ["nasal", "ANATOMY", 184, 189], ["supernatant", "ANATOMY", 195, 206], ["BAL supernatant", "ANATOMY", 211, 226], ["neutrophil", "ANATOMY", 343, 353], ["Cellular", "ANATOMY", 455, 463], ["nasal", "ANATOMY", 475, 480], ["saliva", "ANATOMY", 491, 497], ["BAL", "ANATOMY", 502, 505], ["neutrophils", "ANATOMY", 569, 580], ["cellular", "CELL", 35, 43], ["serum", "ORGANISM_SUBSTANCE", 110, 115], ["saliva", "ORGANISM_SUBSTANCE", 117, 123], ["nasal", "ORGANISM_SUBDIVISION", 125, 130], ["serum", "ORGANISM_SUBSTANCE", 169, 174], ["saliva", "ORGANISM_SUBSTANCE", 176, 182], ["nasal", "ORGANISM_SUBSTANCE", 184, 189], ["BAL supernatant", "ORGANISM_SUBSTANCE", 211, 226], ["SLPI", "GENE_OR_GENE_PRODUCT", 278, 282], ["lysozyme", "GENE_OR_GENE_PRODUCT", 284, 292], ["lactoferrin", "GENE_OR_GENE_PRODUCT", 294, 305], ["LL-37", "GENE_OR_GENE_PRODUCT", 307, 312], ["beta defensins", "GENE_OR_GENE_PRODUCT", 317, 331], ["neutrophil", "CELL", 343, 353], ["CXCL-1", "GENE_OR_GENE_PRODUCT", 384, 390], ["2", "GENE_OR_GENE_PRODUCT", 392, 393], ["CXCL-8", "GENE_OR_GENE_PRODUCT", 420, 426], ["IL-8", "GENE_OR_GENE_PRODUCT", 428, 432], ["SLPI", "GENE_OR_GENE_PRODUCT", 434, 438], ["saliva", "ORGANISM_SUBSTANCE", 491, 497], ["BAL", "ORGANISM_SUBSTANCE", 502, 505], ["Giemsa", "SIMPLE_CHEMICAL", 526, 532], ["neutrophils", "CELL", 569, 580], ["pneumococcal proteins", "PROTEIN", 57, 78], ["Innate ResponsesSoluble factors", "PROTEIN", 136, 167], ["SLPI", "PROTEIN", 278, 282], ["lysozyme", "PROTEIN", 284, 292], ["lactoferrin", "PROTEIN", 294, 305], ["LL-37 and beta defensins", "PROTEIN", 307, 331], ["neutrophil", "CELL_TYPE", 343, 353], ["chemokines", "PROTEIN", 365, 375], ["CXCL-1, 2", "PROTEIN", 384, 393], ["CXCL-8", "PROTEIN", 420, 426], ["IL-8", "PROTEIN", 428, 432], ["SLPI", "PROTEIN", 434, 438], ["neutrophils", "CELL_TYPE", 569, 580], ["pneumococcal", "SPECIES", 57, 69], ["pneumococcal proteins", "TEST", 57, 78], ["polysaccharide", "TEST", 83, 97], ["serum", "TEST", 110, 115], ["saliva", "TREATMENT", 117, 123], ["nasal wash", "TREATMENT", 125, 135], ["Innate ResponsesSoluble factors", "TEST", 136, 167], ["serum", "TEST", 169, 174], ["saliva", "TEST", 176, 182], ["nasal wash supernatant", "TREATMENT", 184, 206], ["BAL supernatant", "TREATMENT", 211, 226], ["antimicrobial peptides", "TREATMENT", 247, 269], ["SLPI, lysozyme", "TREATMENT", 278, 292], ["lactoferrin", "TREATMENT", 294, 305], ["beta defensins", "TREATMENT", 317, 331], ["neutrophil recruiting chemokines", "TREATMENT", 343, 375], ["CXCL", "TEST", 384, 388], ["CXCL", "TEST", 420, 424], ["SLPI", "TREATMENT", 434, 438], ["Cellular responses", "TEST", 455, 473], ["nasal washings", "TEST", 475, 489], ["BAL", "TREATMENT", 502, 505], ["neutrophils", "TEST", 569, 580], ["nasal", "ANATOMY", 125, 130], ["wash", "OBSERVATION", 131, 135], ["nasal", "ANATOMY", 184, 189], ["beta defensins", "OBSERVATION_MODIFIER", 317, 331], ["Cellular responses", "OBSERVATION", 455, 473], ["nasal", "ANATOMY", 475, 480]]], ["In addition, the number of macrophages and the apoptotic fraction of these macrophages will be determined if possible.", [["macrophages", "ANATOMY", 27, 38], ["macrophages", "ANATOMY", 75, 86], ["macrophages", "CELL", 27, 38], ["macrophages", "CELL", 75, 86], ["macrophages", "CELL_TYPE", 27, 38], ["macrophages", "CELL_TYPE", 75, 86], ["macrophages", "OBSERVATION", 27, 38], ["apoptotic fraction", "OBSERVATION", 47, 65], ["macrophages", "OBSERVATION", 75, 86]]], ["NB the cellular fraction of nasal wash is highly variable and many samples may have inadequate cellular material for analysis.", [["NB", "ANATOMY", 0, 2], ["cellular", "ANATOMY", 7, 15], ["nasal", "ANATOMY", 28, 33], ["samples", "ANATOMY", 67, 74], ["cellular", "ANATOMY", 95, 103], ["NB", "CANCER", 0, 2], ["cellular", "CELL", 7, 15], ["nasal", "ORGAN", 28, 33], ["samples", "CANCER", 67, 74], ["cellular material", "TISSUE", 95, 112], ["nasal wash", "PROBLEM", 28, 38], ["inadequate cellular material", "PROBLEM", 84, 112], ["analysis", "TEST", 117, 125], ["cellular", "OBSERVATION_MODIFIER", 7, 15], ["fraction", "OBSERVATION_MODIFIER", 16, 24], ["nasal", "ANATOMY", 28, 33], ["wash", "OBSERVATION", 34, 38]]], ["It may be possible to use transcriptomic techniques to examine cellular RNA if whole cell analyses are not possible.Humoral ResponsesHumoral immunoglobulin specific levelsincluding anti-capsule and anti-protein (PspA, PsaA, PspC, Ply) IgG and IgA will be examined by ELISA as well as opsonophagocytic activity (OPA).", [["cellular", "ANATOMY", 63, 71], ["whole cell", "ANATOMY", 79, 89], ["cellular", "CELL", 63, 71], ["cell", "CELL", 85, 89], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 141, 155], ["anti-protein", "GENE_OR_GENE_PRODUCT", 198, 210], ["PspA", "GENE_OR_GENE_PRODUCT", 212, 216], ["PsaA", "GENE_OR_GENE_PRODUCT", 218, 222], ["PspC", "GENE_OR_GENE_PRODUCT", 224, 228], ["Ply) IgG", "GENE_OR_GENE_PRODUCT", 230, 238], ["IgA", "GENE_OR_GENE_PRODUCT", 243, 246], ["cellular RNA", "RNA", 63, 75], ["Humoral ResponsesHumoral immunoglobulin specific levelsincluding anti-capsule", "PROTEIN", 116, 193], ["anti-protein", "PROTEIN", 198, 210], ["PspA", "PROTEIN", 212, 216], ["PsaA", "PROTEIN", 218, 222], ["PspC", "PROTEIN", 224, 228], ["Ply", "PROTEIN", 230, 233], ["IgG", "PROTEIN", 235, 238], ["IgA", "PROTEIN", 243, 246], ["transcriptomic techniques", "TREATMENT", 26, 51], ["cellular RNA", "PROBLEM", 63, 75], ["whole cell analyses", "TEST", 79, 98], ["Humoral ResponsesHumoral immunoglobulin", "TEST", 116, 155], ["anti-capsule", "TEST", 181, 193], ["anti-protein", "TEST", 198, 210], ["PspA", "TEST", 212, 216], ["PsaA", "TEST", 218, 222], ["PspC", "TEST", 224, 228], ["IgG", "TEST", 235, 238], ["IgA", "TEST", 243, 246], ["ELISA", "TEST", 267, 272], ["may be possible", "UNCERTAINTY", 3, 18], ["not possible", "UNCERTAINTY", 103, 115]]], ["Some immunoglobulin responses may alter adhesion, or be anti-inflammatory.", [["immunoglobulin", "GENE_OR_GENE_PRODUCT", 5, 19], ["immunoglobulin", "PROTEIN", 5, 19], ["Some immunoglobulin responses", "PROBLEM", 0, 29], ["anti-inflammatory", "OBSERVATION_MODIFIER", 56, 73]]], ["We will collaborate with CDC Atlanta to optimise Ig response measurement using Luminex (hence parsimonious use of sample) and then develop both adhesion and avidity assays to determine immunoglobulin function.Cellular ResponsesDifferential cell counts will be performed by cytospin on all nasal washes and BAL samples, before and after pneumococcal carriage to confirm the absence of inflammation.", [["sample", "ANATOMY", 114, 120], ["Cellular", "ANATOMY", 209, 217], ["cell", "ANATOMY", 240, 244], ["nasal", "ANATOMY", 289, 294], ["BAL samples", "ANATOMY", 306, 317], ["inflammation", "DISEASE", 384, 396], ["Ig", "GENE_OR_GENE_PRODUCT", 49, 51], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 185, 199], ["Cellular", "CELL", 209, 217], ["Differential cell", "CELL", 227, 244], ["BAL samples", "ORGANISM_SUBSTANCE", 306, 317], ["Ig", "PROTEIN", 49, 51], ["immunoglobulin", "PROTEIN", 185, 199], ["pneumococcal", "SPECIES", 336, 348], ["Luminex", "TREATMENT", 79, 86], ["avidity assays", "TEST", 157, 171], ["immunoglobulin function", "TEST", 185, 208], ["Cellular Responses", "TEST", 209, 227], ["Differential cell counts", "TEST", 227, 251], ["cytospin", "TEST", 273, 281], ["all nasal washes", "TREATMENT", 285, 301], ["BAL samples", "TEST", 306, 317], ["pneumococcal carriage", "PROBLEM", 336, 357], ["inflammation", "PROBLEM", 384, 396], ["Differential cell counts", "OBSERVATION", 227, 251], ["inflammation", "OBSERVATION", 384, 396]]], ["Antigen specific CD4 T cell responses are critical in defence against pneumococcal carriage [2] in animal models.", [["CD4 T cell", "ANATOMY", 17, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 17, 20], ["CD4", "PROTEIN", 17, 20], ["pneumococcal", "SPECIES", 70, 82], ["Antigen", "TEST", 0, 7], ["pneumococcal carriage", "PROBLEM", 70, 91]]], ["We will determine these responses in nasal wash if possible (above) and BAL samples using multi-parameter flow cytometry [4] .", [["nasal", "ANATOMY", 37, 42], ["BAL samples", "ANATOMY", 72, 83], ["nasal", "ORGANISM_SUBDIVISION", 37, 42], ["nasal wash", "TREATMENT", 37, 47], ["BAL samples", "TEST", 72, 83], ["multi-parameter flow cytometry", "TEST", 90, 120]]], ["In particular, we will determine the CD4 Th1/Th2 ratio and gate on memory CD4 T cells to examine the percentage of antigen specific cells against cell free supernatant from the pneumococcus culture broth.", [["memory CD4 T cells", "ANATOMY", 67, 85], ["cells", "ANATOMY", 132, 137], ["cell", "ANATOMY", 146, 150], ["supernatant", "ANATOMY", 156, 167], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD4 T cells", "CELL", 74, 85], ["cells", "CELL", 132, 137], ["cell", "CELL", 146, 150], ["CD4", "PROTEIN", 37, 40], ["memory CD4 T cells", "CELL_TYPE", 67, 85], ["antigen specific cells", "CELL_TYPE", 115, 137], ["the CD4 Th1", "TEST", 33, 44], ["antigen specific cells", "PROBLEM", 115, 137], ["cell free supernatant", "PROBLEM", 146, 167], ["the pneumococcus culture broth", "TEST", 173, 203]]], ["A proliferation index (CFSE staining), activation (CD154 signal) and cytokine profile (IFN gamma, IL-4, TNF and IL-2) of the specific cells can be determined to interrogate the functional \"quality\" of the responsive cells including regulatory T cell responses.", [["cells", "ANATOMY", 134, 139], ["cells", "ANATOMY", 216, 221], ["T cell", "ANATOMY", 243, 249], ["CFSE", "CHEMICAL", 23, 27], ["CFSE", "SIMPLE_CHEMICAL", 23, 27], ["CD154", "GENE_OR_GENE_PRODUCT", 51, 56], ["IFN gamma", "GENE_OR_GENE_PRODUCT", 87, 96], ["IL-4", "GENE_OR_GENE_PRODUCT", 98, 102], ["TNF", "GENE_OR_GENE_PRODUCT", 104, 107], ["IL-2", "GENE_OR_GENE_PRODUCT", 112, 116], ["cells", "CELL", 134, 139], ["cells", "CELL", 216, 221], ["T cell", "CELL", 243, 249], ["CD154", "PROTEIN", 51, 56], ["cytokine", "PROTEIN", 69, 77], ["IFN gamma, IL-4", "PROTEIN", 87, 102], ["TNF", "PROTEIN", 104, 107], ["responsive cells", "CELL_TYPE", 205, 221], ["A proliferation index", "TEST", 0, 21], ["CFSE staining", "TEST", 23, 36], ["activation (CD154 signal", "TEST", 39, 63], ["cytokine profile", "TEST", 69, 85], ["IFN gamma", "TEST", 87, 96], ["IL", "TEST", 98, 100], ["TNF", "TEST", 104, 107], ["IL", "TEST", 112, 114], ["the specific cells", "PROBLEM", 121, 139], ["proliferation index", "OBSERVATION", 2, 21], ["responsive cells", "OBSERVATION", 205, 221]]], ["We will compare volunteers\" baseline and post-carriage observations to determine response to carriage.", [["volunteers", "ORGANISM", 16, 26], ["post-carriage observations", "TEST", 41, 67]]], ["We will then compare volunteers with carriage to non-carriage subjects, to determine the type of T cell response that is associated with eradication of carriage.", [["T cell", "ANATOMY", 97, 103], ["volunteers", "ORGANISM", 21, 31], ["T cell", "CELL", 97, 103], ["T cell response", "PROBLEM", 97, 112], ["eradication of carriage", "PROBLEM", 137, 160]]], ["Cellular defence (T cell proliferation by CFSE, intracellular cytokine staining following antigen stimulation) will be measured in peripheral blood (and BAL if available).Bacterial carriage and microbiota evaluationMolecular techniques will be employed to determine the carriage density (primers including lytA) of pneumococcus and other nasopharyngeal and lower airway microbiota.", [["Cellular", "ANATOMY", 0, 8], ["T cell", "ANATOMY", 18, 24], ["intracellular", "ANATOMY", 48, 61], ["peripheral blood", "ANATOMY", 131, 147], ["BAL", "ANATOMY", 153, 156], ["nasopharyngeal", "ANATOMY", 338, 352], ["lower airway microbiota", "ANATOMY", 357, 380], ["CFSE", "CHEMICAL", 42, 46], ["Cellular", "CELL", 0, 8], ["T cell", "CELL", 18, 24], ["CFSE", "SIMPLE_CHEMICAL", 42, 46], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 48, 61], ["peripheral blood", "ORGANISM_SUBSTANCE", 131, 147], ["BAL", "ORGANISM_SUBSTANCE", 153, 156], ["lytA", "GENE_OR_GENE_PRODUCT", 306, 310], ["nasopharyngeal", "CANCER", 338, 352], ["lower airway microbiota", "PATHOLOGICAL_FORMATION", 357, 380], ["intracellular cytokine", "PROTEIN", 48, 70], ["Cellular defence", "PROBLEM", 0, 16], ["T cell proliferation", "PROBLEM", 18, 38], ["CFSE", "TEST", 42, 46], ["intracellular cytokine staining", "TEST", 48, 79], ["antigen stimulation", "TREATMENT", 90, 109], ["peripheral blood", "TEST", 131, 147], ["Bacterial carriage", "PROBLEM", 171, 189], ["microbiota evaluation", "TEST", 194, 215], ["Molecular techniques", "TREATMENT", 215, 235], ["the carriage density", "PROBLEM", 266, 286], ["lytA", "TEST", 306, 310], ["pneumococcus", "PROBLEM", 315, 327], ["other nasopharyngeal and lower airway microbiota", "PROBLEM", 332, 380], ["cell proliferation", "OBSERVATION", 20, 38], ["pneumococcus", "OBSERVATION", 315, 327], ["nasopharyngeal", "ANATOMY", 338, 352], ["lower", "ANATOMY_MODIFIER", 357, 362], ["airway microbiota", "ANATOMY", 363, 380]]], ["Modern techniques include 16SrDNA typing, deep sequencing with 454 technology and transcriptomic profiling (in collaboration with Liverpool University, Imperial College, WT Sanger Institute, U Penn or Univ Nijmegen).", [["Modern techniques", "TREATMENT", 0, 17], ["16SrDNA typing", "TEST", 26, 40]]], ["None of these methods are clinically validated and so we will use conventional techniques to determine the primary endpoint.", [["conventional techniques", "TREATMENT", 66, 89]]], ["We will also characterise the dynamics of co-colonisation, particularly of S.pneumoniae with staphylococci and Haemophilus spp (in collaboration with Emory University).Safety notes Experimental Human Pneumococcal ChallengePneumococcus is responsible for infections including otitis media (OM), sinusitis, pneumonia, bacteraemia and meningitis.", [["staphylococci", "DISEASE", 93, 106], ["Haemophilus spp", "DISEASE", 111, 126], ["ChallengePneumococcus", "CHEMICAL", 213, 234], ["infections", "DISEASE", 254, 264], ["otitis media", "DISEASE", 275, 287], ["OM", "DISEASE", 289, 291], ["sinusitis", "DISEASE", 294, 303], ["pneumonia", "DISEASE", 305, 314], ["bacteraemia", "DISEASE", 316, 327], ["meningitis", "DISEASE", 332, 342], ["Haemophilus spp", "ORGANISM", 111, 126], ["Human", "ORGANISM", 194, 199], ["Human", "SPECIES", 194, 199], ["Human Pneumococcal ChallengePneumococcus", "SPECIES", 194, 234], ["co-colonisation", "PROBLEM", 42, 57], ["S.pneumoniae", "PROBLEM", 75, 87], ["staphylococci", "PROBLEM", 93, 106], ["Haemophilus spp", "PROBLEM", 111, 126], ["Experimental Human Pneumococcal ChallengePneumococcus", "TREATMENT", 181, 234], ["infections", "PROBLEM", 254, 264], ["otitis media", "PROBLEM", 275, 287], ["sinusitis", "PROBLEM", 294, 303], ["pneumonia", "PROBLEM", 305, 314], ["bacteraemia", "PROBLEM", 316, 327], ["meningitis", "PROBLEM", 332, 342], ["staphylococci", "OBSERVATION", 93, 106], ["responsible for", "UNCERTAINTY", 238, 253], ["infections", "OBSERVATION", 254, 264], ["otitis", "OBSERVATION", 275, 281], ["sinusitis", "OBSERVATION", 294, 303], ["pneumonia", "OBSERVATION", 305, 314], ["bacteraemia", "OBSERVATION", 316, 327], ["meningitis", "OBSERVATION", 332, 342]]], ["The milder forms of infection (OM, sinusitis) are many times more common than the serious invasive forms of disease.", [["infection", "DISEASE", 20, 29], ["OM", "DISEASE", 31, 33], ["sinusitis", "DISEASE", 35, 44], ["infection", "PROBLEM", 20, 29], ["sinusitis", "PROBLEM", 35, 44], ["disease", "PROBLEM", 108, 115], ["milder", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 20, 29], ["sinusitis", "OBSERVATION", 35, 44], ["serious", "OBSERVATION_MODIFIER", 82, 89], ["invasive", "OBSERVATION", 90, 98], ["disease", "OBSERVATION", 108, 115]]], ["While the risk to individuals of developing any infection is very low (10% adults experience colonisation at any time, and the incidence of invasive disease is 20/100 000 patient years), the study is designed to ensure any risk is minimal by appropriate - The DMSC will receive a weekly update on all recruitment (by email) and will meet by telephone conference in the event of any adverse events.", [["infection", "DISEASE", 48, 57], ["patient", "ORGANISM", 171, 178], ["patient", "SPECIES", 171, 178], ["any infection", "PROBLEM", 44, 57], ["very low", "PROBLEM", 61, 69], ["invasive disease", "PROBLEM", 140, 156], ["the study", "TEST", 187, 196], ["any adverse events", "PROBLEM", 378, 396], ["infection", "OBSERVATION", 48, 57]]], ["A face to face meeting will be arranged after the dose-ranging studies to make recommendations.Bronchoscopy and BALWe have experience of over 1000 of these procedures and have published an audit of volunteer experience in the Journal of Medical Ethics.", [["Bronchoscopy", "TREATMENT", 95, 107], ["these procedures", "TREATMENT", 150, 166]]], ["We have a full risk assessment that can be provided as separate documents but in summary we have had a low complication rate (mild symptoms in less than 25% subjects) and no serious adverse events.Analysis planThe primary endpoint of carriage will be plotted as a rate against dose and a dose-carriage plot used to predict 50% and 80% carriage (if reached).", [["a full risk assessment", "TEST", 8, 30], ["a low complication rate (mild symptoms", "PROBLEM", 101, 139], ["serious adverse events", "PROBLEM", 174, 196], ["carriage plot", "PROBLEM", 293, 306], ["mild", "OBSERVATION_MODIFIER", 126, 130], ["no", "UNCERTAINTY", 171, 173], ["serious", "OBSERVATION_MODIFIER", 174, 181]]], ["Using a target carriage rate, LQAS methods will be used to test the confidence limits of the protocol in a reproducibility study.Analysis planImmunological parameters will all be compared against pre-exposure values where possible in paired analyses using parametric or non-parametric tests as appropriate.", [["a target carriage rate", "TREATMENT", 6, 28], ["LQAS methods", "TREATMENT", 30, 42], ["the protocol", "TEST", 89, 101], ["a reproducibility study", "TEST", 105, 128], ["Analysis planImmunological parameters", "TEST", 129, 166], ["pre-exposure values", "TEST", 196, 215], ["parametric or non-parametric tests", "TEST", 256, 290]]], ["In the case of BAL data, we will only have one sample and therefore and will test hypotheses against test values and by non-paired comparison between groups (e.g. carriers/non-carriers).", [["BAL data", "TEST", 15, 23], ["test values", "TEST", 101, 112]]], ["For example, in current studies we know that the percentage of antigen-specific T cells does not exceed 1 in normal subjects in the absence of carriage.Analysis planHypotheses regarding bacterial co-colonisation will be tested using molecular techniques.", [["T cells", "ANATOMY", 80, 87], ["antigen", "GENE_OR_GENE_PRODUCT", 63, 70], ["T cells", "CELL", 80, 87], ["T cells", "CELL_TYPE", 80, 87], ["current studies", "TEST", 16, 31], ["antigen", "TEST", 63, 70], ["Analysis planHypotheses", "TEST", 152, 175], ["bacterial co-colonisation", "PROBLEM", 186, 211], ["molecular techniques", "TREATMENT", 233, 253], ["bacterial co-colonisation", "OBSERVATION", 186, 211]]], ["These methods are inherently semi-quantitative and so evaluation will be by comparison of proportions in samples at different time points and between subject groups.", [["samples", "ANATOMY", 105, 112], ["evaluation", "TEST", 54, 64]]], ["We will be advised by Dr Brian Faragher and Professor Joe Valadez in the complex analyses planned in this study.Future plan and implications of the workSuccess in this project will result in: a) A robust EHPC protocol that can be used in novel vaccine evaluation. b) New information regarding mucosal responses and bacterial colonisation with direct application to mucosal vaccine development.", [["mucosal", "ANATOMY", 293, 300], ["mucosal", "ANATOMY", 365, 372], ["mucosal", "MULTI-TISSUE_STRUCTURE", 293, 300], ["mucosal", "ORGANISM_SUBDIVISION", 365, 372], ["this study", "TEST", 101, 111], ["A robust EHPC protocol", "TREATMENT", 195, 217], ["novel vaccine evaluation", "TEST", 238, 262], ["mucosal responses", "PROBLEM", 293, 310], ["bacterial colonisation", "PROBLEM", 315, 337], ["direct application", "TREATMENT", 343, 361], ["mucosal vaccine development", "TREATMENT", 365, 392], ["mucosal", "ANATOMY", 293, 300], ["bacterial colonisation", "OBSERVATION", 315, 337]]], ["Future work will be planned to build on both of these anticipated outcomes by engaging with vaccine manufacturing companies and mucosal adjuvant programmes.", [["mucosal", "ANATOMY", 128, 135], ["mucosal", "ORGANISM_SUBDIVISION", 128, 135], ["vaccine manufacturing companies", "TREATMENT", 92, 123], ["mucosal adjuvant programmes", "TREATMENT", 128, 155], ["mucosal", "ANATOMY", 128, 135]]]], "28a98145eda693bae14b52abfc3d37ced6c5fd90": [["T he emergence of Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 represents the second severe CoV to strike the human population since the beginning of the 21st century (1) .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 18, 62], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 18, 62], ["MERS-CoV", "ORGANISM", 64, 72], ["CoV", "ORGANISM", 111, 114], ["human", "ORGANISM", 129, 134], ["human", "SPECIES", 129, 134], ["Middle East respiratory syndrome coronavirus", "SPECIES", 18, 62], ["MERS-CoV", "SPECIES", 64, 72], ["human", "SPECIES", 129, 134], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 18, 62], ["the second severe CoV", "PROBLEM", 93, 114], ["the human population", "PROBLEM", 125, 145], ["Middle", "ANATOMY_MODIFIER", 18, 24], ["respiratory syndrome", "OBSERVATION", 30, 50]]], ["Similar to its predecessor, severe acute respiratory syndrome CoV (SARS-CoV), MERS-CoV is characterized by severe lung infection and high mortality rates (2) .", [["lung", "ANATOMY", 114, 118], ["acute respiratory syndrome CoV", "DISEASE", 35, 65], ["SARS-CoV)", "DISEASE", 67, 76], ["lung infection", "DISEASE", 114, 128], ["SARS-CoV", "ORGANISM", 67, 75], ["MERS-CoV", "ORGANISM", 78, 86], ["lung", "ORGAN", 114, 118], ["severe acute respiratory syndrome CoV", "SPECIES", 28, 65], ["SARS-CoV", "SPECIES", 67, 75], ["MERS-CoV", "SPECIES", 78, 86], ["severe acute respiratory syndrome CoV (SARS-CoV)", "PROBLEM", 28, 76], ["MERS", "PROBLEM", 78, 82], ["CoV", "PROBLEM", 83, 86], ["severe lung infection", "PROBLEM", 107, 128], ["high mortality rates", "PROBLEM", 133, 153], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory syndrome", "OBSERVATION", 41, 61], ["severe", "OBSERVATION_MODIFIER", 107, 113], ["lung", "ANATOMY", 114, 118], ["infection", "OBSERVATION", 119, 128], ["high", "OBSERVATION_MODIFIER", 133, 137]]], ["Associated with elderly patients and nosocomial spread, MERS-CoV is likely harbored in camel populations with periodic reintroductions into humans, followed by periodic nosocomial outbreaks in hospital settings (3) .", [["nosocomial outbreaks", "DISEASE", 169, 189], ["patients", "ORGANISM", 24, 32], ["MERS-CoV", "ORGANISM", 56, 64], ["camel", "ORGANISM", 87, 92], ["humans", "ORGANISM", 140, 146], ["patients", "SPECIES", 24, 32], ["humans", "SPECIES", 140, 146], ["MERS-CoV", "SPECIES", 56, 64], ["camel", "SPECIES", 87, 92], ["humans", "SPECIES", 140, 146], ["elderly patients and nosocomial spread", "PROBLEM", 16, 54], ["likely", "UNCERTAINTY", 68, 74]]], ["Importantly, with the continued rate of globalization, MERS-CoV remains an ongoing threat for future outbreaks both in and outside the Middle East, as evidenced by the large outbreak in South Korea (4) .", [["MERS-CoV", "ORGANISM", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["Middle", "ANATOMY_MODIFIER", 135, 141], ["large", "OBSERVATION_MODIFIER", 168, 173], ["outbreak", "OBSERVATION_MODIFIER", 174, 182]]], ["Together, these factors highlight the importance of examining CoV pathogenesis and developing conserved therapeutic targets for the treatment of current and future emergent strains.", [["CoV", "ORGANISM", 62, 65], ["examining CoV pathogenesis", "PROBLEM", 52, 78], ["the treatment", "TREATMENT", 128, 141], ["future emergent strains", "TREATMENT", 157, 180]]]], "de2180f7d4c952901f9a99facc9cac1264be9434": [["WHAT?\u2022 The most common causes of a cloudy eye are diseases that cause edema or scarring of the cornea, and uveitis, which causes cloudiness in the aqueous humor and/or vitreous as a result of protein and cells leaking through inflamed uveal blood vessels.", [["eye", "ANATOMY", 42, 45], ["edema", "ANATOMY", 70, 75], ["cornea", "ANATOMY", 95, 101], ["aqueous humor", "ANATOMY", 147, 160], ["vitreous", "ANATOMY", 168, 176], ["cells", "ANATOMY", 204, 209], ["uveal blood vessels", "ANATOMY", 235, 254], ["edema", "DISEASE", 70, 75], ["scarring of the cornea", "DISEASE", 79, 101], ["uveitis", "DISEASE", 107, 114], ["eye", "ORGAN", 42, 45], ["edema", "PATHOLOGICAL_FORMATION", 70, 75], ["cornea", "ORGAN", 95, 101], ["aqueous humor", "ORGANISM_SUBSTANCE", 147, 160], ["vitreous", "ORGANISM_SUBSTANCE", 168, 176], ["cells", "CELL", 204, 209], ["uveal blood vessels", "MULTI-TISSUE_STRUCTURE", 235, 254], ["a cloudy eye are diseases", "PROBLEM", 33, 58], ["edema", "PROBLEM", 70, 75], ["scarring of the cornea", "PROBLEM", 79, 101], ["uveitis", "PROBLEM", 107, 114], ["cloudiness", "PROBLEM", 129, 139], ["the aqueous humor", "PROBLEM", 143, 160], ["vitreous", "PROBLEM", 168, 176], ["protein and cells", "PROBLEM", 192, 209], ["inflamed uveal blood vessels", "PROBLEM", 226, 254], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["cloudy", "OBSERVATION", 35, 41], ["eye", "ANATOMY", 42, 45], ["diseases", "OBSERVATION", 50, 58], ["edema", "OBSERVATION", 70, 75], ["scarring", "OBSERVATION", 79, 87], ["cornea", "ANATOMY", 95, 101], ["uveitis", "OBSERVATION", 107, 114], ["aqueous humor", "OBSERVATION", 147, 160], ["inflamed", "OBSERVATION_MODIFIER", 226, 234], ["uveal", "OBSERVATION", 235, 240], ["vessels", "ANATOMY", 247, 254]]], ["Hereditary cataract (opacity of the lens) is rare in cats, but cataracts may develop secondary to uveitis.", [["lens", "ANATOMY", 36, 40], ["Hereditary cataract", "DISEASE", 0, 19], ["opacity of the lens", "DISEASE", 21, 40], ["cataracts", "DISEASE", 63, 72], ["uveitis", "DISEASE", 98, 105], ["cats", "ORGANISM", 53, 57], ["cats", "SPECIES", 53, 57], ["Hereditary cataract (opacity of the lens", "PROBLEM", 0, 40], ["rare in cats", "PROBLEM", 45, 57], ["cataracts", "PROBLEM", 63, 72], ["uveitis", "PROBLEM", 98, 105], ["cataract", "OBSERVATION", 11, 19], ["opacity", "OBSERVATION", 21, 28], ["lens", "ANATOMY", 36, 40], ["rare", "OBSERVATION_MODIFIER", 45, 49], ["cataracts", "OBSERVATION", 63, 72], ["uveitis", "OBSERVATION", 98, 105]]], ["Nuclear sclerosis is a common cause of lens cloudiness in old cats.QUICK REFERENCE SUMMARYDiseases causing a cloudy eye WHERE?CORNEA DEGENERATIVE\u2022 Corneal sequestrum (feline keratitis nigrum)** (p 1260)CORNEA DEGENERATIVEPresents with an axial (central) area of staining (light brown to black) in the cornea, and is usually unilateral.", [["Nuclear", "ANATOMY", 0, 7], ["lens", "ANATOMY", 39, 43], ["eye", "ANATOMY", 116, 119], ["cornea", "ANATOMY", 301, 307], ["Nuclear sclerosis", "DISEASE", 0, 17], ["lens cloudiness", "DISEASE", 39, 54], ["keratitis", "DISEASE", 174, 183], ["lens", "TISSUE", 39, 43], ["cats", "ORGANISM", 62, 66], ["eye", "ORGAN", 116, 119], ["feline", "ORGANISM", 167, 173], ["cornea", "ORGAN", 301, 307], ["cats", "SPECIES", 62, 66], ["feline", "SPECIES", 167, 173], ["Nuclear sclerosis", "PROBLEM", 0, 17], ["lens cloudiness in old cats", "PROBLEM", 39, 66], ["a cloudy eye", "PROBLEM", 107, 119], ["CORNEA DEGENERATIVE", "PROBLEM", 126, 145], ["Corneal sequestrum (feline keratitis nigrum", "PROBLEM", 147, 190], ["CORNEA DEGENERATIVEPresents", "PROBLEM", 202, 229], ["an axial (central) area of staining", "PROBLEM", 235, 270], ["light brown to black) in the cornea", "PROBLEM", 272, 307], ["sclerosis", "OBSERVATION", 8, 17], ["lens cloudiness", "OBSERVATION", 39, 54], ["cloudy eye", "OBSERVATION", 109, 119], ["DEGENERATIVE", "OBSERVATION", 133, 145], ["Corneal", "ANATOMY", 147, 154], ["CORNEA", "ANATOMY", 202, 208], ["staining", "OBSERVATION", 262, 270], ["cornea", "ANATOMY", 301, 307], ["unilateral", "OBSERVATION", 324, 334]]], ["Most common in brachycephalic breeds such as Persians and Himalayans.", [["brachycephalic breeds", "OBSERVATION", 15, 36]]], ["Approximately 80% are associated with herpetic keratitis.", [["herpetic keratitis", "DISEASE", 38, 56], ["herpetic keratitis", "PROBLEM", 38, 56], ["associated with", "UNCERTAINTY", 22, 37], ["herpetic keratitis", "OBSERVATION", 38, 56]]], ["In the early stages there is no ulceration, but chronic lesions may have ulcerated borders surrounded by an inflammatory zone with intense vascularization.ANOMALY \u2022 Corneal (stromal) dystrophy of Manx cats (p 1264)A rare condition in young Manx cats that starts with axial stromal edema and progresses to a diffuse corneal edema with a thickened stroma full of bullae (fluid-filled vesicles).", [["lesions", "ANATOMY", 56, 63], ["Corneal", "ANATOMY", 165, 172], ["stromal", "ANATOMY", 174, 181], ["axial stromal edema", "ANATOMY", 267, 286], ["corneal", "ANATOMY", 315, 322], ["stroma", "ANATOMY", 346, 352], ["bullae", "ANATOMY", 361, 367], ["fluid", "ANATOMY", 369, 374], ["vesicles", "ANATOMY", 382, 390], ["Corneal (stromal) dystrophy", "DISEASE", 165, 192], ["stromal edema", "DISEASE", 273, 286], ["corneal edema", "DISEASE", 315, 328], ["lesions", "PATHOLOGICAL_FORMATION", 56, 63], ["Corneal", "TISSUE", 165, 172], ["stromal", "TISSUE", 174, 181], ["Manx cats", "ORGANISM", 240, 249], ["corneal edema", "PATHOLOGICAL_FORMATION", 315, 328], ["stroma", "TISSUE", 346, 352], ["bullae", "PATHOLOGICAL_FORMATION", 361, 367], ["vesicles", "CELLULAR_COMPONENT", 382, 390], ["cats", "SPECIES", 201, 205], ["cats", "SPECIES", 245, 249], ["Manx cats", "SPECIES", 240, 249], ["ulceration", "PROBLEM", 32, 42], ["chronic lesions", "PROBLEM", 48, 63], ["ulcerated borders", "PROBLEM", 73, 90], ["an inflammatory zone", "PROBLEM", 105, 125], ["intense vascularization", "PROBLEM", 131, 154], ["Corneal (stromal) dystrophy of Manx cats", "PROBLEM", 165, 205], ["A rare condition", "PROBLEM", 214, 230], ["axial stromal edema", "PROBLEM", 267, 286], ["a diffuse corneal edema", "PROBLEM", 305, 328], ["a thickened stroma", "PROBLEM", 334, 352], ["bullae (fluid-filled vesicles", "PROBLEM", 361, 390], ["early stages", "OBSERVATION_MODIFIER", 7, 19], ["no", "UNCERTAINTY", 29, 31], ["ulceration", "OBSERVATION", 32, 42], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["lesions", "OBSERVATION", 56, 63], ["ulcerated", "OBSERVATION_MODIFIER", 73, 82], ["inflammatory", "OBSERVATION_MODIFIER", 108, 120], ["intense", "OBSERVATION_MODIFIER", 131, 138], ["vascularization", "OBSERVATION", 139, 154], ["Corneal", "ANATOMY", 165, 172], ["edema", "OBSERVATION", 281, 286], ["diffuse", "OBSERVATION_MODIFIER", 307, 314], ["corneal", "ANATOMY", 315, 322], ["edema", "OBSERVATION", 323, 328], ["thickened", "OBSERVATION_MODIFIER", 336, 345], ["stroma", "OBSERVATION_MODIFIER", 346, 352], ["full", "OBSERVATION_MODIFIER", 353, 357], ["bullae", "OBSERVATION", 361, 367], ["fluid", "OBSERVATION", 369, 374], ["filled vesicles", "OBSERVATION", 375, 390]]], ["It is a blinding corneal disease with no treatment possible.INFLAMMATION/INFECTIOUS\u2022 Feline herpesvirus-1 keratitis*** (p 1259)INFLAMMATION/INFECTIOUSCats may have a history of FHV-1 infection as kittens.", [["corneal", "ANATOMY", 17, 24], ["corneal disease", "DISEASE", 17, 32], ["Feline herpesvirus-1 keratitis", "DISEASE", 85, 115], ["infection", "DISEASE", 183, 192], ["corneal", "TISSUE", 17, 24], ["Feline herpesvirus-1", "ORGANISM", 85, 105], ["FHV-1", "GENE_OR_GENE_PRODUCT", 177, 182], ["kittens", "ORGANISM", 196, 203], ["Feline herpesvirus-1", "SPECIES", 85, 105], ["Feline herpesvirus-1", "SPECIES", 85, 105], ["FHV-1", "SPECIES", 177, 182], ["a blinding corneal disease", "PROBLEM", 6, 32], ["treatment", "TREATMENT", 41, 50], ["INFLAMMATION", "PROBLEM", 60, 72], ["keratitis", "PROBLEM", 106, 115], ["INFLAMMATION/INFECTIOUSCats", "PROBLEM", 127, 154], ["FHV", "PROBLEM", 177, 180], ["1 infection", "PROBLEM", 181, 192], ["blinding corneal disease", "OBSERVATION", 8, 32], ["no", "UNCERTAINTY", 38, 40], ["INFECTIOUS", "OBSERVATION_MODIFIER", 73, 83], ["keratitis", "OBSERVATION", 106, 115], ["FHV", "OBSERVATION", 177, 180], ["infection", "OBSERVATION", 183, 192]]], ["Often appears as a unilateral disease in older cats.", [["cats", "ORGANISM", 47, 51], ["cats", "SPECIES", 47, 51], ["a unilateral disease in older cats", "PROBLEM", 17, 51], ["unilateral", "OBSERVATION_MODIFIER", 19, 29], ["disease", "OBSERVATION", 30, 37]]], ["The epithelium may show dendritic lesions (finger-like projections of thickened epithelium that stain with rose bengal stain) in early cases.", [["epithelium", "ANATOMY", 4, 14], ["dendritic lesions", "ANATOMY", 24, 41], ["finger", "ANATOMY", 43, 49], ["thickened epithelium", "ANATOMY", 70, 90], ["epithelium", "TISSUE", 4, 14], ["dendritic lesions", "PATHOLOGICAL_FORMATION", 24, 41], ["thickened epithelium", "TISSUE", 70, 90], ["dendritic lesions", "PROBLEM", 24, 41], ["thickened epithelium", "PROBLEM", 70, 90], ["rose bengal stain", "TEST", 107, 124], ["epithelium", "ANATOMY", 4, 14], ["may show", "UNCERTAINTY", 15, 23], ["dendritic", "OBSERVATION_MODIFIER", 24, 33], ["lesions", "OBSERVATION", 34, 41]]], ["Chronic cases show irregular (geographic) ulceration to the level of the superficial stroma.", [["superficial stroma", "ANATOMY", 73, 91], ["ulceration", "PATHOLOGICAL_FORMATION", 42, 52], ["superficial stroma", "TISSUE", 73, 91], ["Chronic cases", "PROBLEM", 0, 13], ["irregular (geographic) ulceration", "PROBLEM", 19, 52], ["irregular", "OBSERVATION_MODIFIER", 19, 28], ["geographic", "OBSERVATION_MODIFIER", 30, 40], ["ulceration", "OBSERVATION", 42, 52], ["superficial", "ANATOMY_MODIFIER", 73, 84], ["stroma", "OBSERVATION", 85, 91]]], ["Scarring and vascularization of the cornea follows after repeated inflammatory episodes.INFLAMMATION/INFECTIOUS\u2022 Mycobacterial keratitis (\"Florida spots\") (p 1264)INFLAMMATION/INFECTIOUSFocal grayish opacities seen in the stroma caused by a mycobacterium.", [["cornea", "ANATOMY", 36, 42], ["stroma", "ANATOMY", 222, 228], ["Scarring", "DISEASE", 0, 8], ["Mycobacterial keratitis", "DISEASE", 113, 136], ["opacities", "DISEASE", 200, 209], ["mycobacterium", "DISEASE", 241, 254], ["cornea", "ORGAN", 36, 42], ["stroma", "TISSUE", 222, 228], ["Scarring", "PROBLEM", 0, 8], ["vascularization of the cornea", "PROBLEM", 13, 42], ["repeated inflammatory episodes", "PROBLEM", 57, 87], ["INFLAMMATION", "PROBLEM", 88, 100], ["Mycobacterial keratitis", "PROBLEM", 113, 136], ["INFLAMMATION/INFECTIOUSFocal grayish opacities", "PROBLEM", 163, 209], ["the stroma", "PROBLEM", 218, 228], ["a mycobacterium", "PROBLEM", 239, 254], ["vascularization", "OBSERVATION", 13, 28], ["cornea", "ANATOMY", 36, 42], ["inflammatory", "OBSERVATION_MODIFIER", 66, 78], ["INFECTIOUS", "OBSERVATION_MODIFIER", 101, 111], ["Mycobacterial keratitis", "OBSERVATION", 113, 136], ["grayish opacities", "OBSERVATION", 192, 209], ["stroma", "ANATOMY", 222, 228], ["mycobacterium", "OBSERVATION", 241, 254]]], ["Only seen in the southeast USA.INFLAMMATORY/NON-INFECTIOUS \u2022 Ulcerative keratitis* (p 1262)A very painful, cloudy eye with serous discharge, blepharospasm and photophobia.", [["eye", "ANATOMY", 114, 117], ["serous", "ANATOMY", 123, 129], ["Ulcerative keratitis", "DISEASE", 61, 81], ["blepharospasm", "DISEASE", 141, 154], ["photophobia", "DISEASE", 159, 170], ["eye", "ORGAN", 114, 117], ["serous", "ORGANISM_SUBSTANCE", 123, 129], ["Ulcerative keratitis", "PROBLEM", 61, 81], ["A very painful", "PROBLEM", 91, 105], ["cloudy eye", "PROBLEM", 107, 117], ["serous discharge", "PROBLEM", 123, 139], ["blepharospasm", "PROBLEM", 141, 154], ["photophobia", "PROBLEM", 159, 170], ["NON-", "OBSERVATION_MODIFIER", 44, 48], ["INFECTIOUS", "OBSERVATION_MODIFIER", 48, 58], ["Ulcerative", "OBSERVATION_MODIFIER", 61, 71], ["keratitis", "OBSERVATION", 72, 81], ["very", "OBSERVATION_MODIFIER", 93, 97], ["painful", "OBSERVATION_MODIFIER", 98, 105], ["cloudy", "OBSERVATION_MODIFIER", 107, 113], ["eye", "ANATOMY", 114, 117], ["serous discharge", "OBSERVATION", 123, 139], ["blepharospasm", "OBSERVATION", 141, 154], ["photophobia", "OBSERVATION", 159, 170]]], ["Usually occurs secondary to corneal trauma.", [["corneal", "ANATOMY", 28, 35], ["corneal trauma", "DISEASE", 28, 42], ["corneal", "TISSUE", 28, 35], ["corneal trauma", "PROBLEM", 28, 42], ["corneal", "ANATOMY", 28, 35], ["trauma", "OBSERVATION", 36, 42]]], ["Superficial ulcers have loss of epithelium, which is seen as an erosion of the surface, and stains green with fluorescein dye.", [["Superficial ulcers", "ANATOMY", 0, 18], ["epithelium", "ANATOMY", 32, 42], ["surface", "ANATOMY", 79, 86], ["ulcers", "DISEASE", 12, 18], ["fluorescein dye", "CHEMICAL", 110, 125], ["fluorescein", "CHEMICAL", 110, 121], ["Superficial ulcers", "PATHOLOGICAL_FORMATION", 0, 18], ["epithelium", "TISSUE", 32, 42], ["surface", "CELLULAR_COMPONENT", 79, 86], ["fluorescein dye", "SIMPLE_CHEMICAL", 110, 125], ["Superficial ulcers", "PROBLEM", 0, 18], ["loss of epithelium", "PROBLEM", 24, 42], ["an erosion of the surface", "PROBLEM", 61, 86], ["fluorescein dye", "PROBLEM", 110, 125], ["ulcers", "OBSERVATION", 12, 18], ["loss", "OBSERVATION_MODIFIER", 24, 28], ["epithelium", "OBSERVATION_MODIFIER", 32, 42], ["erosion", "OBSERVATION", 64, 71], ["surface", "OBSERVATION_MODIFIER", 79, 86], ["fluorescein dye", "OBSERVATION", 110, 125]]], ["Deeper ulcers have a hollow caused by loss of stroma.Immune-mediated:\u2022 Eosinophilic keratitis* (p 1261)Immune-mediated:Seen as a cloudy, red cornea, sometimes with a muco-purulent discharge.", [["ulcers", "ANATOMY", 7, 13], ["stroma", "ANATOMY", 46, 52], ["red cornea", "ANATOMY", 137, 147], ["ulcers", "DISEASE", 7, 13], ["loss of stroma", "DISEASE", 38, 52], ["keratitis", "DISEASE", 84, 93], ["ulcers", "PATHOLOGICAL_FORMATION", 7, 13], ["stroma", "TISSUE", 46, 52], ["cornea", "ORGAN", 141, 147], ["Deeper ulcers", "PROBLEM", 0, 13], ["loss of stroma", "PROBLEM", 38, 52], ["Eosinophilic keratitis", "PROBLEM", 71, 93], ["a cloudy, red cornea", "PROBLEM", 127, 147], ["a muco-purulent discharge", "PROBLEM", 164, 189], ["ulcers", "OBSERVATION", 7, 13], ["hollow", "OBSERVATION_MODIFIER", 21, 27], ["loss", "OBSERVATION", 38, 42], ["stroma", "OBSERVATION", 46, 52], ["Eosinophilic keratitis", "OBSERVATION", 71, 93], ["cloudy", "OBSERVATION", 129, 135], ["red cornea", "ANATOMY", 137, 147]]], ["A proliferative white to pinkish plaque develops on the cornea, with superficial and in chronic cases, deep vascularization.", [["pinkish plaque", "ANATOMY", 25, 39], ["cornea", "ANATOMY", 56, 62], ["pinkish plaque", "PATHOLOGICAL_FORMATION", 25, 39], ["cornea", "ORGAN", 56, 62], ["A proliferative white to pinkish plaque", "PROBLEM", 0, 39], ["superficial and in chronic cases", "PROBLEM", 69, 101], ["deep vascularization", "PROBLEM", 103, 123], ["proliferative", "OBSERVATION_MODIFIER", 2, 15], ["white", "OBSERVATION_MODIFIER", 16, 21], ["pinkish", "OBSERVATION_MODIFIER", 25, 32], ["plaque", "OBSERVATION", 33, 39], ["cornea", "ANATOMY", 56, 62], ["superficial", "OBSERVATION_MODIFIER", 69, 80], ["chronic", "OBSERVATION_MODIFIER", 88, 95], ["cases", "OBSERVATION", 96, 101], ["deep vascularization", "OBSERVATION", 103, 123]]], ["Usually a history of poor response to antibiotic therapy.", [["poor response", "PROBLEM", 21, 34], ["antibiotic therapy", "TREATMENT", 38, 56]]], ["Eosinophils demonstrated on cytology from corneal scrapings are diagnostic.Trauma:\u2022 Cornea scarring from injury* (p 1263)Trauma:Opaque areas on cornea, which vary in size and intensity.", [["Eosinophils", "ANATOMY", 0, 11], ["corneal scrapings", "ANATOMY", 42, 59], ["cornea", "ANATOMY", 144, 150], ["Trauma", "DISEASE", 75, 81], ["Trauma", "DISEASE", 121, 127], ["Eosinophils", "CELL", 0, 11], ["corneal scrapings", "TISSUE", 42, 59], ["cornea", "ORGAN", 144, 150], ["Eosinophils", "CELL_TYPE", 0, 11], ["Eosinophils", "TEST", 0, 11], ["cytology", "TEST", 28, 36], ["corneal scrapings", "TEST", 42, 59], ["Trauma", "PROBLEM", 75, 81], ["Cornea scarring", "PROBLEM", 84, 99], ["injury", "PROBLEM", 105, 111], ["Trauma", "PROBLEM", 121, 127], ["Opaque areas on cornea", "PROBLEM", 128, 150], ["corneal", "ANATOMY", 42, 49], ["scrapings", "OBSERVATION", 50, 59], ["Cornea", "ANATOMY", 84, 90], ["scarring", "OBSERVATION", 91, 99], ["injury", "OBSERVATION", 105, 111], ["Opaque", "OBSERVATION_MODIFIER", 128, 134], ["areas", "OBSERVATION", 135, 140], ["cornea", "ANATOMY", 144, 150], ["size", "OBSERVATION_MODIFIER", 166, 170], ["intensity", "OBSERVATION_MODIFIER", 175, 184]]], ["There is no pain or discharge associated with these opacities, and usually there is a history of previous severe ocular inflammation or trauma.WHERE?ANTERIOR CHAMBERMETABOLIC\u2022 Lipemic aqueous (p 1270)METABOLICThe anterior chamber looks milky, but intra-ocular architecture can be visualized.", [["ocular", "ANATOMY", 113, 119], ["anterior chamber", "ANATOMY", 213, 229], ["milky", "ANATOMY", 236, 241], ["intra-ocular", "ANATOMY", 247, 259], ["pain", "DISEASE", 12, 16], ["opacities", "DISEASE", 52, 61], ["ocular inflammation", "DISEASE", 113, 132], ["trauma", "DISEASE", 136, 142], ["intra-ocular architecture", "MULTI-TISSUE_STRUCTURE", 247, 272], ["pain", "PROBLEM", 12, 16], ["discharge", "PROBLEM", 20, 29], ["these opacities", "PROBLEM", 46, 61], ["previous severe ocular inflammation", "PROBLEM", 97, 132], ["trauma", "PROBLEM", 136, 142], ["no", "UNCERTAINTY", 9, 11], ["pain", "OBSERVATION", 12, 16], ["opacities", "OBSERVATION", 52, 61], ["severe", "OBSERVATION_MODIFIER", 106, 112], ["ocular", "ANATOMY", 113, 119], ["inflammation", "OBSERVATION", 120, 132], ["trauma", "OBSERVATION", 136, 142], ["Lipemic", "OBSERVATION_MODIFIER", 176, 183], ["anterior", "ANATOMY_MODIFIER", 213, 221], ["chamber", "ANATOMY_MODIFIER", 222, 229], ["milky", "OBSERVATION", 236, 241], ["intra-ocular architecture", "OBSERVATION", 247, 272]]], ["Signs may be unilateral or bilateral, and may have a sudden onset.", [["may be", "UNCERTAINTY", 6, 12], ["unilateral", "OBSERVATION", 13, 23], ["bilateral", "ANATOMY_MODIFIER", 27, 36]]], ["Occurs secondary to anterior uveitis in cats on a high-fat diet, or is associated with hyperlipidemia.", [["uveitis", "DISEASE", 29, 36], ["hyperlipidemia", "DISEASE", 87, 101], ["cats", "ORGANISM", 40, 44], ["fat", "TISSUE", 55, 58], ["cats", "SPECIES", 40, 44], ["anterior uveitis in cats", "PROBLEM", 20, 44], ["a high-fat diet", "TREATMENT", 48, 63], ["hyperlipidemia", "PROBLEM", 87, 101], ["anterior", "OBSERVATION_MODIFIER", 20, 28], ["uveitis", "OBSERVATION", 29, 36], ["associated with", "UNCERTAINTY", 71, 86], ["hyperlipidemia", "OBSERVATION", 87, 101]]], ["Idiopathic in Burmese cats.NEOPLASTIC \u2022 Ocular neoplasia* (p 1267)Most cases present as anterior uveitis with corneal edema and a cloudy aqueous, and have some form of swelling seen in the iris, which may cause distortion of the pupil (dyscoria).", [["Ocular", "ANATOMY", 40, 46], ["corneal", "ANATOMY", 110, 117], ["iris", "ANATOMY", 189, 193], ["pupil", "ANATOMY", 229, 234], ["Ocular neoplasia*", "DISEASE", 40, 57], ["uveitis", "DISEASE", 97, 104], ["corneal edema", "DISEASE", 110, 123], ["swelling", "DISEASE", 168, 176], ["distortion of the pupil", "DISEASE", 211, 234], ["cats", "ORGANISM", 22, 26], ["corneal edema", "PATHOLOGICAL_FORMATION", 110, 123], ["aqueous", "ORGANISM_SUBSTANCE", 137, 144], ["iris", "ORGAN", 189, 193], ["pupil", "ORGANISM_SUBDIVISION", 229, 234], ["dyscoria", "CANCER", 236, 244], ["cats", "SPECIES", 22, 26], ["Idiopathic in Burmese cats", "PROBLEM", 0, 26], ["NEOPLASTIC \u2022 Ocular neoplasia*", "PROBLEM", 27, 57], ["anterior uveitis", "PROBLEM", 88, 104], ["corneal edema", "PROBLEM", 110, 123], ["a cloudy aqueous", "PROBLEM", 128, 144], ["swelling", "PROBLEM", 168, 176], ["distortion of the pupil (dyscoria)", "PROBLEM", 211, 245], ["Burmese cats", "OBSERVATION", 14, 26], ["Ocular", "ANATOMY", 40, 46], ["anterior", "ANATOMY_MODIFIER", 88, 96], ["uveitis", "OBSERVATION", 97, 104], ["corneal", "ANATOMY", 110, 117], ["edema", "OBSERVATION", 118, 123], ["cloudy", "OBSERVATION_MODIFIER", 130, 136], ["aqueous", "OBSERVATION_MODIFIER", 137, 144], ["swelling", "OBSERVATION", 168, 176], ["iris", "ANATOMY", 189, 193], ["may cause", "UNCERTAINTY", 201, 210], ["pupil", "OBSERVATION", 229, 234]]], ["The retina may be distorted and have a color change.", [["retina", "ANATOMY", 4, 10], ["retina", "MULTI-TISSUE_STRUCTURE", 4, 10], ["a color change", "PROBLEM", 37, 51], ["retina", "ANATOMY", 4, 10], ["may be", "UNCERTAINTY", 11, 17], ["distorted", "OBSERVATION", 18, 27], ["color change", "OBSERVATION", 39, 51]]], ["Lymphosarcoma is the most common tumor and often presents as bilateral iris swelling with a \"creamy\" color change, and anterior chamber hypopyon and/or hemorrhage in a young cat, with or without other signs suggesting multicentric neoplasia.", [["tumor", "ANATOMY", 33, 38], ["iris", "ANATOMY", 71, 75], ["anterior chamber hypopyon", "ANATOMY", 119, 144], ["multicentric neoplasia", "ANATOMY", 218, 240], ["Lymphosarcoma", "DISEASE", 0, 13], ["tumor", "DISEASE", 33, 38], ["iris swelling", "DISEASE", 71, 84], ["hemorrhage", "DISEASE", 152, 162], ["neoplasia", "DISEASE", 231, 240], ["tumor", "CANCER", 33, 38], ["cat", "ORGANISM", 174, 177], ["multicentric neoplasia", "CANCER", 218, 240], ["Lymphosarcoma", "PROBLEM", 0, 13], ["the most common tumor", "PROBLEM", 17, 38], ["bilateral iris swelling", "PROBLEM", 61, 84], ["a \"creamy\" color change", "PROBLEM", 90, 113], ["anterior chamber hypopyon", "PROBLEM", 119, 144], ["hemorrhage", "PROBLEM", 152, 162], ["multicentric neoplasia", "PROBLEM", 218, 240], ["most common", "OBSERVATION_MODIFIER", 21, 32], ["tumor", "OBSERVATION", 33, 38], ["bilateral", "ANATOMY_MODIFIER", 61, 70], ["iris", "ANATOMY", 71, 75], ["swelling", "OBSERVATION", 76, 84], ["change", "OBSERVATION_MODIFIER", 107, 113], ["anterior", "ANATOMY_MODIFIER", 119, 127], ["chamber hypopyon", "OBSERVATION", 128, 144], ["hemorrhage", "OBSERVATION", 152, 162], ["suggesting", "UNCERTAINTY", 207, 217], ["multicentric", "OBSERVATION_MODIFIER", 218, 230], ["neoplasia", "OBSERVATION", 231, 240]]], ["The pupil may be distorted (dyscoria).INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)FeLV may present as a cloudy aqueous associated with white cells and fibrin in the eye caused by a uveitis.", [["pupil", "ANATOMY", 4, 9], ["white cells", "ANATOMY", 148, 159], ["eye", "ANATOMY", 178, 181], ["Feline leukemia", "DISEASE", 64, 79], ["uveitis", "DISEASE", 194, 201], ["pupil", "MULTI-TISSUE_STRUCTURE", 4, 9], ["Feline leukemia virus", "ORGANISM", 64, 85], ["FeLV", "ORGANISM", 95, 99], ["white cells", "CELL", 148, 159], ["fibrin", "GENE_OR_GENE_PRODUCT", 164, 170], ["eye", "ORGAN", 178, 181], ["white cells", "CELL_TYPE", 148, 159], ["fibrin", "PROTEIN", 164, 170], ["Feline leukemia virus* (p 1266)", "SPECIES", 64, 95], ["distorted (dyscoria)", "PROBLEM", 17, 37], ["INFLAMMATION", "PROBLEM", 38, 50], ["Feline leukemia virus", "PROBLEM", 64, 85], ["FeLV", "PROBLEM", 95, 99], ["a cloudy aqueous", "PROBLEM", 115, 131], ["white cells", "PROBLEM", 148, 159], ["fibrin in the eye", "PROBLEM", 164, 181], ["a uveitis", "PROBLEM", 192, 201], ["pupil", "OBSERVATION", 4, 9], ["may be", "UNCERTAINTY", 10, 16], ["distorted", "OBSERVATION", 17, 26], ["dyscoria", "OBSERVATION", 28, 36], ["INFECTIOUS", "OBSERVATION_MODIFIER", 51, 61], ["Feline leukemia", "OBSERVATION", 64, 79], ["white cells", "OBSERVATION", 148, 159], ["fibrin", "OBSERVATION", 164, 170], ["eye", "ANATOMY", 178, 181], ["uveitis", "OBSERVATION", 194, 201]]], ["Changes to iris appearance and abnormal pupil size and shape occur.", [["iris", "ANATOMY", 11, 15], ["pupil", "ANATOMY", 40, 45], ["iris", "TISSUE", 11, 15], ["pupil", "MULTI-TISSUE_STRUCTURE", 40, 45], ["Changes to iris appearance", "PROBLEM", 0, 26], ["abnormal pupil size", "PROBLEM", 31, 50], ["iris", "ANATOMY", 11, 15], ["abnormal", "OBSERVATION_MODIFIER", 31, 39], ["pupil", "OBSERVATION_MODIFIER", 40, 45], ["size", "OBSERVATION_MODIFIER", 46, 50], ["shape", "OBSERVATION_MODIFIER", 55, 60]]], ["It may or may not be associated with lymphosarcoma.INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)\u2022 Feline infectious peritonitis (p 1266)INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)Ocular form usually occurs in cats 6-12 months old.", [["lymphosarcoma", "ANATOMY", 37, 50], ["lymphosarcoma", "DISEASE", 37, 50], ["Feline leukemia virus", "DISEASE", 77, 98], ["Feline infectious peritonitis", "DISEASE", 110, 139], ["Feline leukemia virus", "DISEASE", 174, 195], ["lymphosarcoma", "CANCER", 37, 50], ["Feline leukemia virus", "ORGANISM", 77, 98], ["Feline", "ORGANISM", 110, 116], ["Feline leukemia virus", "ORGANISM", 174, 195], ["cats", "ORGANISM", 235, 239], ["cats", "SPECIES", 235, 239], ["Feline leukemia virus* (p 1266)", "SPECIES", 77, 108], ["Feline leukemia virus* (p 1266)", "SPECIES", 174, 205], ["lymphosarcoma", "PROBLEM", 37, 50], ["INFLAMMATION", "PROBLEM", 51, 63], ["Feline leukemia virus", "PROBLEM", 77, 98], ["Feline infectious peritonitis", "PROBLEM", 110, 139], ["INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus", "PROBLEM", 148, 195], ["may not be associated with", "UNCERTAINTY", 10, 36], ["lymphosarcoma", "OBSERVATION", 37, 50], ["INFECTIOUS", "OBSERVATION", 64, 74], ["Feline leukemia", "OBSERVATION", 77, 92], ["infectious", "OBSERVATION_MODIFIER", 117, 127], ["peritonitis", "OBSERVATION", 128, 139], ["INFECTIOUS", "OBSERVATION_MODIFIER", 161, 171], ["Feline leukemia", "OBSERVATION", 174, 189], ["Ocular", "ANATOMY", 205, 211]]], ["Ocular signs may be unilateral or bilateral.", [["Ocular", "ANATOMY", 0, 6], ["Ocular", "ORGAN", 0, 6], ["Ocular signs", "TEST", 0, 12], ["signs", "OBSERVATION", 7, 12], ["may be", "UNCERTAINTY", 13, 19], ["unilateral", "OBSERVATION", 20, 30], ["bilateral", "ANATOMY_MODIFIER", 34, 43]]], ["Typically there is fibrinous anterior uveitis and hypopyon, and initially no systemic signs.", [["uveitis", "DISEASE", 38, 45], ["hypopyon", "DISEASE", 50, 58], ["fibrinous anterior uveitis", "PROBLEM", 19, 45], ["hypopyon", "PROBLEM", 50, 58], ["systemic signs", "PROBLEM", 77, 91], ["fibrinous", "OBSERVATION_MODIFIER", 19, 28], ["anterior", "OBSERVATION_MODIFIER", 29, 37], ["uveitis", "OBSERVATION", 38, 45], ["hypopyon", "OBSERVATION", 50, 58], ["no", "UNCERTAINTY", 74, 76], ["systemic", "OBSERVATION_MODIFIER", 77, 85], ["signs", "OBSERVATION", 86, 91]]], ["Advanced cases show serous retinal detachment and may have neurological signs.INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)\u2022 Toxoplasma gondii (toxoplasmosis)** (p 1265) Most common sign is a cloudy anterior chamber from anterior uveitis and hypopyon.", [["serous retinal", "ANATOMY", 20, 34], ["neurological", "ANATOMY", 59, 71], ["retinal detachment", "DISEASE", 27, 45], ["Feline leukemia virus", "DISEASE", 104, 125], ["Toxoplasma gondii", "DISEASE", 137, 154], ["toxoplasmosis", "DISEASE", 156, 169], ["uveitis", "DISEASE", 242, 249], ["hypopyon", "DISEASE", 254, 262], ["retinal", "MULTI-TISSUE_STRUCTURE", 27, 34], ["Feline leukemia virus", "ORGANISM", 104, 125], ["Toxoplasma gondii", "ORGANISM", 137, 154], ["Toxoplasma gondii", "SPECIES", 137, 154], ["Feline leukemia virus* (p 1266)", "SPECIES", 104, 135], ["Toxoplasma gondii", "SPECIES", 137, 154], ["serous retinal detachment", "PROBLEM", 20, 45], ["neurological signs", "PROBLEM", 59, 77], ["INFLAMMATION", "PROBLEM", 78, 90], ["Feline leukemia virus", "PROBLEM", 104, 125], ["Toxoplasma gondii (toxoplasmosis)", "PROBLEM", 137, 170], ["a cloudy anterior chamber", "PROBLEM", 202, 227], ["anterior uveitis", "PROBLEM", 233, 249], ["hypopyon", "PROBLEM", 254, 262], ["serous retinal detachment", "OBSERVATION", 20, 45], ["INFECTIOUS", "OBSERVATION", 91, 101], ["Feline leukemia", "OBSERVATION", 104, 119], ["cloudy", "OBSERVATION_MODIFIER", 204, 210], ["anterior chamber", "OBSERVATION", 211, 227], ["anterior", "ANATOMY_MODIFIER", 233, 241], ["uveitis", "OBSERVATION", 242, 249], ["hypopyon", "OBSERVATION", 254, 262]]], ["Older cats may develop small translucent nodules in the iris from lymphocytic-plasmocytic uveitis.", [["nodules", "ANATOMY", 41, 48], ["iris", "ANATOMY", 56, 60], ["uveitis", "DISEASE", 90, 97], ["cats", "ORGANISM", 6, 10], ["translucent nodules", "PATHOLOGICAL_FORMATION", 29, 48], ["iris", "TISSUE", 56, 60], ["cats", "SPECIES", 6, 10], ["small translucent nodules in the iris", "PROBLEM", 23, 60], ["lymphocytic-plasmocytic uveitis", "PROBLEM", 66, 97], ["small", "OBSERVATION_MODIFIER", 23, 28], ["translucent", "OBSERVATION_MODIFIER", 29, 40], ["nodules", "OBSERVATION", 41, 48], ["iris", "ANATOMY", 56, 60], ["lymphocytic", "OBSERVATION_MODIFIER", 66, 77], ["plasmocytic uveitis", "OBSERVATION", 78, 97]]], ["Advanced cases may develop serous retinal detachment.", [["serous retinal", "ANATOMY", 27, 41], ["retinal detachment", "DISEASE", 34, 52], ["serous retinal", "MULTI-TISSUE_STRUCTURE", 27, 41], ["serous retinal detachment", "PROBLEM", 27, 52], ["serous retinal detachment", "OBSERVATION", 27, 52]]], ["Occasionally systemic signs are present including fever, weight loss, and respiratory, neurological and hepatic signs.INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)\u2022 Cryptococcus neoformans (cryptococcosis) (p 1268)INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)Usually presents as anterior uveitis with a cloudy aqueous secondary to leakage of white cells and protein.", [["respiratory", "ANATOMY", 74, 85], ["neurological", "ANATOMY", 87, 99], ["hepatic", "ANATOMY", 104, 111], ["white cells", "ANATOMY", 366, 377], ["fever", "DISEASE", 50, 55], ["weight loss", "DISEASE", 57, 68], ["respiratory, neurological and hepatic signs", "DISEASE", 74, 117], ["Feline leukemia virus", "DISEASE", 144, 165], ["Cryptococcus neoformans", "DISEASE", 177, 200], ["cryptococcosis", "DISEASE", 202, 216], ["Feline leukemia virus", "DISEASE", 252, 273], ["uveitis", "DISEASE", 312, 319], ["hepatic", "ORGAN", 104, 111], ["Feline leukemia virus", "ORGANISM", 144, 165], ["Cryptococcus neoformans", "ORGANISM", 177, 200], ["Feline leukemia virus", "ORGANISM", 252, 273], ["cells", "CELL", 372, 377], ["white cells", "CELL_TYPE", 366, 377], ["Cryptococcus neoformans", "SPECIES", 177, 200], ["Feline leukemia virus* (p 1266)", "SPECIES", 144, 175], ["Cryptococcus neoformans", "SPECIES", 177, 200], ["Feline leukemia virus* (p 1266)", "SPECIES", 252, 283], ["Occasionally systemic signs", "PROBLEM", 0, 27], ["fever", "PROBLEM", 50, 55], ["weight loss", "PROBLEM", 57, 68], ["respiratory, neurological and hepatic signs", "PROBLEM", 74, 117], ["INFLAMMATION", "PROBLEM", 118, 130], ["Feline leukemia virus", "PROBLEM", 144, 165], ["Cryptococcus neoformans (cryptococcosis)", "PROBLEM", 177, 217], ["INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus", "PROBLEM", 226, 273], ["anterior uveitis", "PROBLEM", 303, 319], ["a cloudy aqueous", "PROBLEM", 325, 341], ["leakage of white cells and protein", "PROBLEM", 355, 389], ["systemic", "OBSERVATION_MODIFIER", 13, 21], ["signs", "OBSERVATION", 22, 27], ["fever", "OBSERVATION", 50, 55], ["respiratory", "ANATOMY", 74, 85], ["hepatic", "ANATOMY", 104, 111], ["signs", "OBSERVATION", 112, 117], ["INFECTIOUS", "OBSERVATION", 131, 141], ["Feline leukemia", "OBSERVATION", 144, 159], ["neoformans", "OBSERVATION", 190, 200], ["cryptococcosis", "OBSERVATION", 202, 216], ["INFECTIOUS", "OBSERVATION_MODIFIER", 239, 249], ["Feline leukemia", "OBSERVATION", 252, 267], ["anterior", "ANATOMY_MODIFIER", 303, 311], ["uveitis", "OBSERVATION", 312, 319], ["cloudy", "OBSERVATION_MODIFIER", 327, 333], ["leakage", "OBSERVATION", 355, 362], ["white cells", "OBSERVATION", 366, 377]]], ["Examination of the retina shows focal granulomas with a cloudy vitreous.", [["retina", "ANATOMY", 19, 25], ["focal granulomas", "ANATOMY", 32, 48], ["vitreous", "ANATOMY", 63, 71], ["granulomas", "DISEASE", 38, 48], ["retina", "MULTI-TISSUE_STRUCTURE", 19, 25], ["focal granulomas", "PATHOLOGICAL_FORMATION", 32, 48], ["vitreous", "ORGANISM_SUBSTANCE", 63, 71], ["Examination of the retina", "TEST", 0, 25], ["focal granulomas", "PROBLEM", 32, 48], ["a cloudy vitreous", "PROBLEM", 54, 71], ["retina", "ANATOMY", 19, 25], ["focal", "OBSERVATION_MODIFIER", 32, 37], ["granulomas", "OBSERVATION", 38, 48], ["cloudy vitreous", "OBSERVATION", 56, 71]]], ["Blindness occurs in advanced cases.INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus* (p 1266)Typically there is a cloudy aqueous secondary to white cells and protein leaking into eye from anterior uveitis.", [["white cells", "ANATOMY", 141, 152], ["eye", "ANATOMY", 178, 181], ["Blindness", "DISEASE", 0, 9], ["Feline leukemia virus", "DISEASE", 61, 82], ["uveitis", "DISEASE", 196, 203], ["Feline leukemia virus", "ORGANISM", 61, 82], ["white cells", "CELL", 141, 152], ["eye", "ORGAN", 178, 181], ["white cells", "CELL_TYPE", 141, 152], ["Feline leukemia virus* (p 1266)", "SPECIES", 61, 92], ["Blindness", "PROBLEM", 0, 9], ["INFLAMMATION/INFECTIOUS \u2022 Feline leukemia virus", "PROBLEM", 35, 82], ["a cloudy aqueous", "PROBLEM", 111, 127], ["white cells", "PROBLEM", 141, 152], ["protein leaking into eye", "PROBLEM", 157, 181], ["anterior uveitis", "PROBLEM", 187, 203], ["INFECTIOUS", "OBSERVATION_MODIFIER", 48, 58], ["Feline leukemia virus", "OBSERVATION", 61, 82], ["cloudy", "OBSERVATION_MODIFIER", 113, 119], ["white cells", "OBSERVATION", 141, 152], ["protein leaking", "OBSERVATION", 157, 172], ["eye", "ANATOMY", 178, 181], ["anterior", "ANATOMY_MODIFIER", 187, 195], ["uveitis", "OBSERVATION", 196, 203]]], ["Pre-iridal fibrovascular membranes are seen in chronic cases.", [["fibrovascular membranes", "ANATOMY", 11, 34], ["fibrovascular membranes", "TISSUE", 11, 34], ["Pre-iridal fibrovascular membranes", "PROBLEM", 0, 34], ["fibrovascular membranes", "OBSERVATION", 11, 34], ["chronic", "OBSERVATION_MODIFIER", 47, 54], ["cases", "OBSERVATION", 55, 60]]], ["Hemorrhage is associated with the PFIMs.", [["Hemorrhage", "DISEASE", 0, 10], ["Hemorrhage", "PROBLEM", 0, 10], ["the PFIMs", "PROBLEM", 30, 39]]], ["Retinal hemorrhage is seen occasionally in areas of granuloma formation and appears as focal cloudy swelling in the retina.LENS DEGENERATIVE\u2022 Nuclear sclerosis and senile cataract** (p 1271)LENS DEGENERATIVEIn nuclear sclerosis, the central part of the lens (nucleus) becomes slightly cloudy but the cat is still visual.", [["Retinal", "ANATOMY", 0, 7], ["granuloma", "ANATOMY", 52, 61], ["retina", "ANATOMY", 116, 122], ["lens", "ANATOMY", 253, 257], ["nucleus", "ANATOMY", 259, 266], ["Retinal hemorrhage", "DISEASE", 0, 18], ["granuloma", "DISEASE", 52, 61], ["Nuclear sclerosis", "DISEASE", 142, 159], ["cataract", "DISEASE", 171, 179], ["nuclear sclerosis", "DISEASE", 210, 227], ["Retinal", "MULTI-TISSUE_STRUCTURE", 0, 7], ["granuloma", "PATHOLOGICAL_FORMATION", 52, 61], ["retina", "MULTI-TISSUE_STRUCTURE", 116, 122], ["lens", "TISSUE", 253, 257], ["nucleus", "CELLULAR_COMPONENT", 259, 266], ["cat", "ORGANISM", 300, 303], ["Retinal hemorrhage", "PROBLEM", 0, 18], ["granuloma formation", "PROBLEM", 52, 71], ["focal cloudy swelling in the retina", "PROBLEM", 87, 122], ["LENS DEGENERATIVE", "PROBLEM", 123, 140], ["Nuclear sclerosis", "PROBLEM", 142, 159], ["senile cataract", "PROBLEM", 164, 179], ["LENS DEGENERATIVEIn nuclear sclerosis", "PROBLEM", 190, 227], ["slightly cloudy", "PROBLEM", 276, 291], ["hemorrhage", "OBSERVATION", 8, 18], ["areas", "OBSERVATION_MODIFIER", 43, 48], ["granuloma", "OBSERVATION", 52, 61], ["focal", "OBSERVATION_MODIFIER", 87, 92], ["cloudy", "OBSERVATION_MODIFIER", 93, 99], ["swelling", "OBSERVATION", 100, 108], ["retina", "ANATOMY", 116, 122], ["DEGENERATIVE", "OBSERVATION_MODIFIER", 128, 140], ["Nuclear", "OBSERVATION_MODIFIER", 142, 149], ["sclerosis", "OBSERVATION", 150, 159], ["senile cataract", "OBSERVATION", 164, 179], ["nuclear", "OBSERVATION_MODIFIER", 210, 217], ["sclerosis", "OBSERVATION", 218, 227], ["central", "ANATOMY_MODIFIER", 233, 240], ["lens", "ANATOMY", 253, 257], ["nucleus", "ANATOMY_MODIFIER", 259, 266], ["slightly", "OBSERVATION_MODIFIER", 276, 284], ["cloudy", "OBSERVATION", 285, 291]]], ["Sclerosis is a normal aging process that starts from 8 years and becomes progressively cloudier with age.", [["Sclerosis", "DISEASE", 0, 9], ["Sclerosis", "PROBLEM", 0, 9], ["normal aging", "OBSERVATION_MODIFIER", 15, 27]]], ["Senile cataract is seen in much older cats from 12-20 years of age.", [["cataract", "DISEASE", 7, 15], ["cats", "ORGANISM", 38, 42], ["cats", "SPECIES", 38, 42], ["Senile cataract", "PROBLEM", 0, 15], ["cataract", "OBSERVATION", 7, 15]]], ["Nuclear continued cells finally break down so the nucleus becomes very cloudy and vision deteriorates.", [["Nuclear", "ANATOMY", 0, 7], ["cells", "ANATOMY", 18, 23], ["nucleus", "ANATOMY", 50, 57], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["cells", "CELL", 18, 23], ["nucleus", "CELLULAR_COMPONENT", 50, 57], ["Nuclear continued cells", "PROBLEM", 0, 23], ["very cloudy", "PROBLEM", 66, 77], ["vision", "PROBLEM", 82, 88], ["nucleus", "ANATOMY", 50, 57], ["very", "OBSERVATION_MODIFIER", 66, 70], ["cloudy", "OBSERVATION", 71, 77]]], ["The lens cortex may also start to degenerate resulting in cortical changes in addition to nuclear changes.METABOLIC\u2022 Diabetic cataract (p 1273)METABOLICRare finding in aged diabetic cats.", [["lens cortex", "ANATOMY", 4, 15], ["cortical", "ANATOMY", 58, 66], ["nuclear", "ANATOMY", 90, 97], ["Diabetic cataract", "DISEASE", 117, 134], ["diabetic", "DISEASE", 173, 181], ["lens cortex", "CANCER", 4, 15], ["cortical", "MULTI-TISSUE_STRUCTURE", 58, 66], ["nuclear", "CELLULAR_COMPONENT", 90, 97], ["cats", "ORGANISM", 182, 186], ["cortical changes", "PROBLEM", 58, 74], ["nuclear changes", "PROBLEM", 90, 105], ["Diabetic cataract", "PROBLEM", 117, 134], ["lens", "ANATOMY", 4, 8], ["cortex", "ANATOMY_MODIFIER", 9, 15], ["may also start to", "UNCERTAINTY", 16, 33], ["cortical changes", "OBSERVATION", 58, 74], ["nuclear changes", "OBSERVATION", 90, 105], ["Diabetic cataract", "OBSERVATION", 117, 134]]], ["Lens is cloudy with an immature to mature cataract and impaired vision.INFLAMMATION/INFECTIOUS\u2022 Cataract secondary to infectious uveitis** (p 1271)INFLAMMATION/INFECTIOUSThe lens becomes very cloudy because of a cortical cataract developing from poor nutrition and toxic states within the eye.", [["lens", "ANATOMY", 174, 178], ["cortical", "ANATOMY", 212, 220], ["eye", "ANATOMY", 289, 292], ["cataract", "DISEASE", 42, 50], ["impaired vision", "DISEASE", 55, 70], ["Cataract", "DISEASE", 96, 104], ["uveitis", "DISEASE", 129, 136], ["cataract", "DISEASE", 221, 229], ["Lens", "TISSUE", 0, 4], ["eye", "ORGAN", 289, 292], ["an immature to mature cataract", "PROBLEM", 20, 50], ["impaired vision", "PROBLEM", 55, 70], ["INFLAMMATION", "PROBLEM", 71, 83], ["Cataract", "PROBLEM", 96, 104], ["infectious uveitis", "PROBLEM", 118, 136], ["INFLAMMATION", "PROBLEM", 147, 159], ["very cloudy", "PROBLEM", 187, 198], ["a cortical cataract", "PROBLEM", 210, 229], ["poor nutrition and toxic states within the eye", "PROBLEM", 246, 292], ["cloudy", "OBSERVATION", 8, 14], ["immature", "OBSERVATION_MODIFIER", 23, 31], ["mature", "OBSERVATION_MODIFIER", 35, 41], ["cataract", "OBSERVATION", 42, 50], ["impaired vision", "OBSERVATION", 55, 70], ["INFECTIOUS", "OBSERVATION_MODIFIER", 84, 94], ["Cataract", "OBSERVATION", 96, 104], ["infectious", "OBSERVATION_MODIFIER", 118, 128], ["uveitis", "OBSERVATION", 129, 136], ["INFLAMMATION", "OBSERVATION", 147, 159], ["INFECTIOUS", "OBSERVATION", 160, 170], ["lens", "ANATOMY", 174, 178], ["very", "OBSERVATION_MODIFIER", 187, 191], ["cloudy", "OBSERVATION", 192, 198], ["cortical", "OBSERVATION_MODIFIER", 212, 220], ["cataract", "OBSERVATION", 221, 229], ["poor nutrition", "OBSERVATION", 246, 260], ["toxic", "OBSERVATION_MODIFIER", 265, 270], ["eye", "ANATOMY", 289, 292]]], ["Signs of uveitis are present such as a cloudy eye due to aqueous flare and fibrovascular membranes on the iris (PFIMs).INFLAMMATION/NON-INFECTIOUS\u2022 Cataract secondary to non-infectious uveitis (p 1273)INFLAMMATION/NON-INFECTIOUSNuclear cataract in a young healthy cat with no evidence of ocular inflammation.", [["eye", "ANATOMY", 46, 49], ["fibrovascular membranes", "ANATOMY", 75, 98], ["iris", "ANATOMY", 106, 110], ["PFIMs", "ANATOMY", 112, 117], ["ocular", "ANATOMY", 288, 294], ["uveitis", "DISEASE", 9, 16], ["Cataract", "DISEASE", 148, 156], ["non-infectious uveitis", "DISEASE", 170, 192], ["cataract", "DISEASE", 236, 244], ["ocular inflammation", "DISEASE", 288, 307], ["eye", "ORGAN", 46, 49], ["fibrovascular membranes", "TISSUE", 75, 98], ["iris", "TISSUE", 106, 110], ["cat", "ORGANISM", 264, 267], ["ocular", "ORGAN", 288, 294], ["uveitis", "PROBLEM", 9, 16], ["a cloudy eye", "PROBLEM", 37, 49], ["aqueous flare", "PROBLEM", 57, 70], ["fibrovascular membranes", "PROBLEM", 75, 98], ["INFLAMMATION", "PROBLEM", 119, 131], ["Cataract", "PROBLEM", 148, 156], ["non-infectious uveitis", "PROBLEM", 170, 192], ["INFLAMMATION", "PROBLEM", 201, 213], ["NON-INFECTIOUSNuclear cataract", "PROBLEM", 214, 244], ["ocular inflammation", "PROBLEM", 288, 307], ["uveitis", "OBSERVATION", 9, 16], ["cloudy", "OBSERVATION_MODIFIER", 39, 45], ["eye", "ANATOMY", 46, 49], ["aqueous flare", "OBSERVATION", 57, 70], ["fibrovascular membranes", "OBSERVATION", 75, 98], ["iris", "ANATOMY", 106, 110], ["NON-", "OBSERVATION_MODIFIER", 132, 136], ["INFECTIOUS", "OBSERVATION_MODIFIER", 136, 146], ["Cataract", "OBSERVATION", 148, 156], ["non-infectious", "OBSERVATION_MODIFIER", 170, 184], ["uveitis", "OBSERVATION", 185, 192], ["NON-INFECTIOUSNuclear cataract", "OBSERVATION", 214, 244], ["no evidence of", "UNCERTAINTY", 273, 287], ["ocular", "ANATOMY", 288, 294], ["inflammation", "OBSERVATION", 295, 307]]], ["Rare.Trauma:\u2022 Cataract secondary to lens trauma* (p 1272)Trauma:Penetrating injuries that rupture the lens capsule will disrupt normal lens physiology and cause cataract development.", [["lens", "ANATOMY", 36, 40], ["lens capsule", "ANATOMY", 102, 114], ["lens", "ANATOMY", 135, 139], ["Trauma", "DISEASE", 5, 11], ["Cataract", "DISEASE", 14, 22], ["trauma", "DISEASE", 41, 47], ["Trauma", "DISEASE", 57, 63], ["Penetrating injuries", "DISEASE", 64, 84], ["cataract", "DISEASE", 161, 169], ["lens", "MULTI-TISSUE_STRUCTURE", 135, 139], ["Trauma", "PROBLEM", 5, 11], ["Cataract", "PROBLEM", 14, 22], ["lens trauma", "PROBLEM", 36, 47], ["Trauma", "PROBLEM", 57, 63], ["Penetrating injuries", "PROBLEM", 64, 84], ["rupture the lens capsule", "PROBLEM", 90, 114], ["cataract development", "PROBLEM", 161, 181], ["Cataract", "OBSERVATION", 14, 22], ["lens trauma", "OBSERVATION", 36, 47], ["rupture", "OBSERVATION", 90, 97], ["lens capsule", "OBSERVATION", 102, 114], ["normal lens physiology", "OBSERVATION", 128, 150], ["cataract", "OBSERVATION", 161, 169]]], ["This causes an acute uveitis from the released lens proteins within the eye (lens-induced uveitis).", [["lens", "ANATOMY", 47, 51], ["eye", "ANATOMY", 72, 75], ["lens", "ANATOMY", 77, 81], ["uveitis", "DISEASE", 21, 28], ["uveitis", "DISEASE", 90, 97], ["eye", "ORGAN", 72, 75], ["lens", "TISSUE", 77, 81], ["lens proteins", "PROTEIN", 47, 60], ["an acute uveitis", "PROBLEM", 12, 28], ["the released lens proteins", "PROBLEM", 34, 60], ["uveitis", "PROBLEM", 90, 97], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["uveitis", "OBSERVATION", 21, 28], ["released lens proteins", "OBSERVATION", 38, 60], ["eye", "ANATOMY", 72, 75], ["lens", "ANATOMY", 77, 81], ["uveitis", "OBSERVATION", 90, 97]]], ["Blunt trauma to the eye may also rupture the lens.", [["eye", "ANATOMY", 20, 23], ["lens", "ANATOMY", 45, 49], ["trauma", "DISEASE", 6, 12], ["eye", "ORGAN", 20, 23], ["lens", "TISSUE", 45, 49], ["Blunt trauma to the eye", "PROBLEM", 0, 23], ["rupture the lens", "PROBLEM", 33, 49], ["trauma", "OBSERVATION", 6, 12], ["eye", "ANATOMY", 20, 23], ["rupture", "OBSERVATION", 33, 40], ["lens", "ANATOMY", 45, 49]]], ["A tentative diagnosis is based on a history or signs of eye trauma and the presence of a mature or immature cataract.INFLAMMATION/INFECTIOUS\u2022 Feline immune deficiency virus* (p 1275)INFLAMMATION/INFECTIOUSFIV infection causes pars planitis which is a \"Snowbank\" inflammation of the pars plana and thought to be almost pathognomonic for FIV infection.", [["eye", "ANATOMY", 56, 59], ["pars planitis", "ANATOMY", 226, 239], ["pars", "ANATOMY", 282, 286], ["eye trauma", "DISEASE", 56, 66], ["cataract", "DISEASE", 108, 116], ["Feline immune deficiency", "DISEASE", 142, 166], ["infection", "DISEASE", 209, 218], ["pars planitis", "DISEASE", 226, 239], ["inflammation of the pars plana", "DISEASE", 262, 292], ["FIV infection", "DISEASE", 336, 349], ["eye", "ORGAN", 56, 59], ["Feline immune deficiency virus", "ORGANISM", 142, 172], ["pars planitis", "CANCER", 226, 239], ["pars", "TISSUE", 282, 286], ["FIV", "ORGANISM", 336, 339], ["FIV", "SPECIES", 336, 339], ["eye trauma", "PROBLEM", 56, 66], ["immature cataract", "PROBLEM", 99, 116], ["INFLAMMATION", "PROBLEM", 117, 129], ["Feline immune deficiency virus", "PROBLEM", 142, 172], ["INFLAMMATION/INFECTIOUSFIV infection", "PROBLEM", 182, 218], ["pars planitis", "PROBLEM", 226, 239], ["a \"Snowbank\" inflammation of the pars plana", "PROBLEM", 249, 292], ["FIV infection", "PROBLEM", 336, 349], ["eye", "ANATOMY", 56, 59], ["trauma", "OBSERVATION", 60, 66], ["mature", "OBSERVATION_MODIFIER", 89, 95], ["immature", "OBSERVATION_MODIFIER", 99, 107], ["cataract", "OBSERVATION", 108, 116], ["INFECTIOUS", "OBSERVATION_MODIFIER", 130, 140], ["Feline immune deficiency", "OBSERVATION", 142, 166], ["infection", "OBSERVATION", 209, 218], ["pars planitis", "OBSERVATION", 226, 239], ["thought to be", "UNCERTAINTY", 297, 310], ["infection", "OBSERVATION", 340, 349]]], ["It results in a cloudy vitreous.MECHANISM?The eye is an organ with various media that normally maintain clarity for transmission of light by very specialized means.MECHANISM?\u2022 The corneal stoma maintains optical clarity by the highly organized structure of the collagen fibrils, lack of blood vessels and lack of pigment. \u2022 The lens fibers (cells) are also laid down in a very orderly fashion and contain soluble lens proteins known as crystallins. \u2022 The aqueous humor is a clear fluid secreted by the ciliary body to maintain the anterior chamber. \u2022 The vitreous is a complex, transparent living tissue made mainly from complex carbohydrates.MECHANISM?Cloudiness of the eye results from changes in structure and composition of the cornea, aqueous (anterior chamber), lens or vitreous (posterior chamber).Cloudy corneaFor details on the structure and function of the cornea see \"The Cat With Abnormalities Confined to the Cornea\" (page 1236).Cloudy corneaThe cornea becomes cloudy from edema when the surface develops an ulcer (ulcerative keratitis).", [["vitreous", "ANATOMY", 23, 31], ["eye", "ANATOMY", 46, 49], ["organ", "ANATOMY", 56, 61], ["corneal stoma", "ANATOMY", 180, 193], ["collagen fibrils", "ANATOMY", 261, 277], ["blood vessels", "ANATOMY", 287, 300], ["lens fibers", "ANATOMY", 328, 339], ["cells", "ANATOMY", 341, 346], ["aqueous humor", "ANATOMY", 455, 468], ["fluid", "ANATOMY", 480, 485], ["ciliary body", "ANATOMY", 502, 514], ["anterior chamber", "ANATOMY", 531, 547], ["vitreous", "ANATOMY", 555, 563], ["tissue", "ANATOMY", 597, 603], ["eye", "ANATOMY", 671, 674], ["cornea", "ANATOMY", 732, 738], ["aqueous", "ANATOMY", 740, 747], ["anterior chamber", "ANATOMY", 749, 765], ["lens", "ANATOMY", 768, 772], ["vitreous", "ANATOMY", 776, 784], ["cornea", "ANATOMY", 812, 818], ["cornea", "ANATOMY", 867, 873], ["cornea", "ANATOMY", 949, 955], ["cornea", "ANATOMY", 959, 965], ["edema", "ANATOMY", 986, 991], ["surface", "ANATOMY", 1001, 1008], ["ulcer", "ANATOMY", 1021, 1026], ["edema", "DISEASE", 986, 991], ["ulcer", "DISEASE", 1021, 1026], ["ulcerative keratitis", "DISEASE", 1028, 1048], ["carbohydrates", "CHEMICAL", 629, 642], ["vitreous", "ORGANISM_SUBSTANCE", 23, 31], ["eye", "ORGAN", 46, 49], ["organ", "ORGAN", 56, 61], ["corneal stoma", "PATHOLOGICAL_FORMATION", 180, 193], ["collagen", "GENE_OR_GENE_PRODUCT", 261, 269], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 287, 300], ["pigment", "TISSUE", 313, 320], ["lens fibers", "CELL", 328, 339], ["cells", "CELL", 341, 346], ["aqueous humor", "ORGANISM_SUBSTANCE", 455, 468], ["fluid", "ORGANISM_SUBSTANCE", 480, 485], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 502, 514], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 531, 547], ["vitreous", "MULTI-TISSUE_STRUCTURE", 555, 563], ["tissue", "TISSUE", 597, 603], ["eye", "ORGAN", 671, 674], ["cornea", "TISSUE", 732, 738], ["aqueous", "TISSUE", 740, 747], ["lens", "TISSUE", 768, 772], ["vitreous", "MULTI-TISSUE_STRUCTURE", 776, 784], ["cornea", "ORGAN", 867, 873], ["cornea", "TISSUE", 959, 965], ["edema", "PATHOLOGICAL_FORMATION", 986, 991], ["surface", "CELLULAR_COMPONENT", 1001, 1008], ["ulcer", "PATHOLOGICAL_FORMATION", 1021, 1026], ["collagen fibrils", "PROTEIN", 261, 277], ["lens proteins", "PROTEIN", 413, 426], ["crystallins", "PROTEIN", 436, 447], ["a cloudy vitreous", "PROBLEM", 14, 31], ["various media", "TREATMENT", 67, 80], ["The corneal stoma", "TREATMENT", 176, 193], ["the collagen fibrils", "PROBLEM", 257, 277], ["lack of blood vessels", "PROBLEM", 279, 300], ["lack of pigment", "PROBLEM", 305, 320], ["soluble lens proteins", "TREATMENT", 405, 426], ["changes in structure and composition of the cornea", "PROBLEM", 688, 738], ["lens or vitreous (posterior chamber", "TREATMENT", 768, 803], ["Cloudy cornea", "PROBLEM", 805, 818], ["Cloudy cornea", "PROBLEM", 942, 955], ["cloudy", "PROBLEM", 974, 980], ["edema", "PROBLEM", 986, 991], ["an ulcer (ulcerative keratitis", "PROBLEM", 1018, 1048], ["cloudy vitreous", "OBSERVATION", 16, 31], ["eye", "ANATOMY", 46, 49], ["organ", "ANATOMY", 56, 61], ["corneal", "ANATOMY", 180, 187], ["stoma", "OBSERVATION", 188, 193], ["optical clarity", "OBSERVATION", 204, 219], ["highly", "OBSERVATION_MODIFIER", 227, 233], ["organized", "OBSERVATION", 234, 243], ["collagen fibrils", "OBSERVATION", 261, 277], ["blood vessels", "ANATOMY", 287, 300], ["pigment", "OBSERVATION_MODIFIER", 313, 320], ["lens", "ANATOMY", 328, 332], ["fibers", "ANATOMY_MODIFIER", 333, 339], ["soluble lens", "OBSERVATION", 405, 417], ["aqueous humor", "OBSERVATION", 455, 468], ["clear", "OBSERVATION_MODIFIER", 474, 479], ["fluid", "OBSERVATION", 480, 485], ["ciliary body", "ANATOMY_MODIFIER", 502, 514], ["anterior", "ANATOMY_MODIFIER", 531, 539], ["chamber", "ANATOMY_MODIFIER", 540, 547], ["vitreous", "OBSERVATION", 555, 563], ["complex", "OBSERVATION_MODIFIER", 569, 576], ["transparent", "OBSERVATION_MODIFIER", 578, 589], ["living tissue", "OBSERVATION", 590, 603], ["eye", "ANATOMY", 671, 674], ["composition", "OBSERVATION_MODIFIER", 713, 724], ["cornea", "ANATOMY", 732, 738], ["aqueous", "OBSERVATION_MODIFIER", 740, 747], ["anterior", "ANATOMY_MODIFIER", 749, 757], ["chamber", "ANATOMY_MODIFIER", 758, 765], ["lens", "ANATOMY", 768, 772], ["vitreous", "OBSERVATION_MODIFIER", 776, 784], ["posterior", "ANATOMY_MODIFIER", 786, 795], ["chamber", "ANATOMY_MODIFIER", 796, 803], ["cornea", "ANATOMY", 812, 818], ["cornea", "ANATOMY", 867, 873], ["Cornea", "ANATOMY", 922, 928], ["cornea", "ANATOMY", 949, 955], ["cornea", "ANATOMY", 959, 965], ["cloudy", "OBSERVATION_MODIFIER", 974, 980], ["edema", "OBSERVATION", 986, 991], ["ulcer", "OBSERVATION", 1021, 1026], ["ulcerative", "OBSERVATION_MODIFIER", 1028, 1038], ["keratitis", "OBSERVATION", 1039, 1048]]], ["Loss of epithelial cells allows the stroma to absorb fluid.", [["epithelial cells", "ANATOMY", 8, 24], ["stroma", "ANATOMY", 36, 42], ["fluid", "ANATOMY", 53, 58], ["epithelial cells", "CELL", 8, 24], ["stroma", "TISSUE", 36, 42], ["fluid", "ORGANISM_SUBSTANCE", 53, 58], ["epithelial cells", "CELL_TYPE", 8, 24], ["Loss of epithelial cells", "PROBLEM", 0, 24], ["epithelial cells", "OBSERVATION", 8, 24], ["absorb", "OBSERVATION_MODIFIER", 46, 52], ["fluid", "OBSERVATION", 53, 58]]], ["This causes the intercellular matrix to swell, which in turn, disrupts the normal pattern of the keratocytes and the cornea becomes cloudy.Cloudy corneaCorneal edema is also seen in cases of glaucoma and uveitis where the endothelial pump mechanism is disturbed, so that aqueous enters the stroma from the anterior chamber.Cloudy corneaInflammatory conditions in the cornea cause cloudiness by disrupting the normal cellular matrix, either with cellular infiltrates or by changing the normal cellular structure, such as scar tissue formation.Cloudy anterior chamberThe anterior chamber is a fluid-filled compartment bounded by the cornea anteriorly and the lens and ciliary body posteriorly.Cloudy anterior chamberThe fluid is called aqueous humor and is produced by a process of ultrafiltration and active secretion in the ciliary body.", [["intercellular matrix", "ANATOMY", 16, 36], ["keratocytes", "ANATOMY", 97, 108], ["cornea", "ANATOMY", 117, 123], ["glaucoma", "ANATOMY", 191, 199], ["endothelial", "ANATOMY", 222, 233], ["stroma", "ANATOMY", 290, 296], ["anterior chamber", "ANATOMY", 306, 322], ["cornea", "ANATOMY", 367, 373], ["cellular matrix", "ANATOMY", 416, 431], ["cellular", "ANATOMY", 445, 453], ["cellular", "ANATOMY", 492, 500], ["scar tissue", "ANATOMY", 520, 531], ["anterior chamber", "ANATOMY", 569, 585], ["fluid", "ANATOMY", 591, 596], ["cornea", "ANATOMY", 631, 637], ["lens", "ANATOMY", 657, 661], ["ciliary body", "ANATOMY", 666, 678], ["fluid", "ANATOMY", 718, 723], ["aqueous humor", "ANATOMY", 734, 747], ["ciliary body", "ANATOMY", 824, 836], ["edema", "DISEASE", 160, 165], ["glaucoma", "DISEASE", 191, 199], ["uveitis", "DISEASE", 204, 211], ["intercellular matrix", "CELLULAR_COMPONENT", 16, 36], ["keratocytes", "CELL", 97, 108], ["cornea", "ORGAN", 117, 123], ["endothelial", "CELL", 222, 233], ["aqueous", "ORGANISM_SUBSTANCE", 271, 278], ["stroma", "TISSUE", 290, 296], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 306, 322], ["cornea", "ORGAN", 367, 373], ["cellular matrix", "CELLULAR_COMPONENT", 416, 431], ["cellular", "CELL", 445, 453], ["cellular", "CELL", 492, 500], ["scar tissue", "TISSUE", 520, 531], ["cornea anteriorly", "TISSUE", 631, 648], ["lens", "TISSUE", 657, 661], ["ciliary body", "TISSUE", 666, 678], ["fluid", "ORGANISM_SUBSTANCE", 718, 723], ["aqueous humor", "ORGANISM_SUBSTANCE", 734, 747], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 824, 836], ["keratocytes", "CELL_TYPE", 97, 108], ["cloudy", "PROBLEM", 132, 138], ["Cloudy corneaCorneal edema", "PROBLEM", 139, 165], ["glaucoma", "PROBLEM", 191, 199], ["uveitis", "PROBLEM", 204, 211], ["the endothelial pump mechanism", "TREATMENT", 218, 248], ["Cloudy corneaInflammatory conditions in the cornea", "PROBLEM", 323, 373], ["cloudiness", "PROBLEM", 380, 390], ["cellular infiltrates", "PROBLEM", 445, 465], ["scar tissue formation", "PROBLEM", 520, 541], ["Cloudy anterior chamber", "PROBLEM", 542, 565], ["a fluid-filled compartment", "PROBLEM", 589, 615], ["Cloudy anterior chamber", "PROBLEM", 691, 714], ["aqueous humor", "PROBLEM", 734, 747], ["ultrafiltration", "TREATMENT", 780, 795], ["active secretion in the ciliary body", "PROBLEM", 800, 836], ["intercellular", "OBSERVATION_MODIFIER", 16, 29], ["matrix", "OBSERVATION_MODIFIER", 30, 36], ["swell", "OBSERVATION", 40, 45], ["normal", "OBSERVATION", 75, 81], ["pattern", "OBSERVATION_MODIFIER", 82, 89], ["keratocytes", "OBSERVATION", 97, 108], ["cornea", "ANATOMY", 117, 123], ["cloudy", "OBSERVATION", 132, 138], ["corneaCorneal", "OBSERVATION_MODIFIER", 146, 159], ["edema", "OBSERVATION", 160, 165], ["glaucoma", "OBSERVATION", 191, 199], ["uveitis", "OBSERVATION", 204, 211], ["endothelial pump", "OBSERVATION", 222, 238], ["disturbed", "OBSERVATION_MODIFIER", 252, 261], ["stroma", "OBSERVATION", 290, 296], ["anterior", "ANATOMY_MODIFIER", 306, 314], ["chamber", "ANATOMY_MODIFIER", 315, 322], ["corneaInflammatory conditions", "OBSERVATION", 330, 359], ["cornea", "ANATOMY", 367, 373], ["normal cellular matrix", "OBSERVATION", 409, 431], ["cellular", "OBSERVATION_MODIFIER", 445, 453], ["infiltrates", "OBSERVATION", 454, 465], ["normal cellular structure", "OBSERVATION", 485, 510], ["scar tissue", "OBSERVATION", 520, 531], ["anterior", "ANATOMY_MODIFIER", 549, 557], ["chamber", "ANATOMY_MODIFIER", 558, 565], ["anterior", "ANATOMY_MODIFIER", 569, 577], ["chamber", "ANATOMY_MODIFIER", 578, 585], ["fluid", "OBSERVATION", 591, 596], ["filled compartment", "OBSERVATION", 597, 615], ["cornea", "ANATOMY", 631, 637], ["anteriorly", "ANATOMY_MODIFIER", 638, 648], ["lens", "ANATOMY_MODIFIER", 657, 661], ["ciliary", "ANATOMY_MODIFIER", 666, 673], ["body", "ANATOMY_MODIFIER", 674, 678], ["posteriorly", "ANATOMY_MODIFIER", 679, 690], ["anterior", "ANATOMY_MODIFIER", 698, 706], ["chamber", "ANATOMY_MODIFIER", 707, 714], ["fluid", "OBSERVATION", 718, 723], ["aqueous humor", "OBSERVATION", 734, 747], ["ultrafiltration", "OBSERVATION", 780, 795], ["active", "OBSERVATION_MODIFIER", 800, 806], ["secretion", "OBSERVATION", 807, 816], ["ciliary body", "ANATOMY", 824, 836]]], ["Aqueous exits the anterior chamber through the trabecular meshwork in the iridocorneal angle to reach the vascular system via the scleral vessels.", [["anterior chamber", "ANATOMY", 18, 34], ["trabecular meshwork", "ANATOMY", 47, 66], ["iridocorneal", "ANATOMY", 74, 86], ["vascular system", "ANATOMY", 106, 121], ["scleral vessels", "ANATOMY", 130, 145], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 18, 34], ["trabecular meshwork", "TISSUE", 47, 66], ["vascular system", "MULTI-TISSUE_STRUCTURE", 106, 121], ["scleral vessels", "MULTI-TISSUE_STRUCTURE", 130, 145], ["anterior", "ANATOMY_MODIFIER", 18, 26], ["chamber", "ANATOMY_MODIFIER", 27, 34], ["trabecular meshwork", "OBSERVATION", 47, 66], ["iridocorneal angle", "ANATOMY", 74, 92], ["vascular system", "ANATOMY", 106, 121], ["scleral vessels", "ANATOMY", 130, 145]]], ["The dynamics of aqueous humor production and drainage is very complex, but simply, it keeps the eye inflated at a predetermined pressure known as the intra-ocular pressure (IOP).", [["aqueous humor", "ANATOMY", 16, 29], ["eye", "ANATOMY", 96, 99], ["intra-ocular", "ANATOMY", 150, 162], ["aqueous humor", "ORGANISM_SUBSTANCE", 16, 29], ["eye", "ORGAN", 96, 99], ["intra-ocular", "ORGANISM_SUBDIVISION", 150, 162], ["aqueous humor production", "TREATMENT", 16, 40], ["drainage", "TREATMENT", 45, 53], ["the intra-ocular pressure", "TEST", 146, 171], ["aqueous humor", "OBSERVATION", 16, 29], ["drainage", "OBSERVATION", 45, 53], ["eye", "ANATOMY", 96, 99], ["inflated", "OBSERVATION", 100, 108], ["intra-ocular pressure", "OBSERVATION", 150, 171]]], ["Interference of aqueous drainage causes glaucoma.", [["glaucoma", "ANATOMY", 40, 48], ["glaucoma", "DISEASE", 40, 48], ["aqueous drainage", "TREATMENT", 16, 32], ["glaucoma", "PROBLEM", 40, 48], ["aqueous", "OBSERVATION_MODIFIER", 16, 23], ["drainage", "OBSERVATION", 24, 32], ["glaucoma", "OBSERVATION", 40, 48]]], ["The increased intraocular pressure disturbs the corneal physiology resulting in corneal edema and a cloudy eye.", [["intraocular", "ANATOMY", 14, 25], ["corneal", "ANATOMY", 48, 55], ["corneal edema", "ANATOMY", 80, 93], ["eye", "ANATOMY", 107, 110], ["corneal edema", "DISEASE", 80, 93], ["intraocular", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 25], ["corneal", "TISSUE", 48, 55], ["corneal edema", "PATHOLOGICAL_FORMATION", 80, 93], ["eye", "ORGAN", 107, 110], ["The increased intraocular pressure", "TEST", 0, 34], ["corneal edema", "PROBLEM", 80, 93], ["a cloudy eye", "PROBLEM", 98, 110], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["intraocular pressure", "OBSERVATION", 14, 34], ["corneal physiology", "OBSERVATION", 48, 66], ["corneal", "ANATOMY", 80, 87], ["edema", "OBSERVATION", 88, 93], ["cloudy", "OBSERVATION", 100, 106], ["eye", "ANATOMY", 107, 110]]], ["See \"The Cat with Abnormal Globe Position or Size\" (page 1312).Cloudy anterior chamberAqueous is a clear fluid that also supplies nutrients to the inner structures of the eye.", [["fluid", "ANATOMY", 105, 110], ["inner structures", "ANATOMY", 147, 163], ["eye", "ANATOMY", 171, 174], ["inner structures", "TISSUE", 147, 163], ["eye", "ORGAN", 171, 174], ["a clear fluid", "PROBLEM", 97, 110], ["Size", "OBSERVATION_MODIFIER", 45, 49], ["anterior", "OBSERVATION_MODIFIER", 70, 78], ["chamberAqueous", "OBSERVATION", 79, 93], ["clear", "OBSERVATION_MODIFIER", 99, 104], ["fluid", "OBSERVATION", 105, 110], ["inner", "ANATOMY_MODIFIER", 147, 152], ["structures", "ANATOMY_MODIFIER", 153, 163], ["eye", "ANATOMY", 171, 174]]], ["When the anterior uveal tract (ciliary body and iris) becomes inflamed this is called anterior uveitis.", [["anterior uveal tract", "ANATOMY", 9, 29], ["ciliary body", "ANATOMY", 31, 43], ["iris", "ANATOMY", 48, 52], ["uveitis", "DISEASE", 95, 102], ["anterior uveal tract", "MULTI-TISSUE_STRUCTURE", 9, 29], ["ciliary body", "TISSUE", 31, 43], ["iris", "TISSUE", 48, 52], ["inflamed", "PROBLEM", 62, 70], ["anterior uveitis", "PROBLEM", 86, 102], ["anterior", "ANATOMY_MODIFIER", 9, 17], ["uveal tract", "ANATOMY", 18, 29], ["ciliary body", "ANATOMY", 31, 43], ["iris", "ANATOMY", 48, 52], ["inflamed", "OBSERVATION", 62, 70], ["anterior", "ANATOMY_MODIFIER", 86, 94], ["uveitis", "OBSERVATION", 95, 102]]], ["Inflammation of the vascularrich uveal tract causes the blood vessels to leak protein and white blood cells into the aqueous causing \"aqueous flare\".", [["vascularrich uveal tract", "ANATOMY", 20, 44], ["blood vessels", "ANATOMY", 56, 69], ["white blood cells", "ANATOMY", 90, 107], ["aqueous", "ANATOMY", 117, 124], ["Inflammation", "DISEASE", 0, 12], ["uveal tract", "ORGAN", 33, 44], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 56, 69], ["blood cells", "CELL", 96, 107], ["aqueous", "ORGANISM_SUBSTANCE", 117, 124], ["aqueous", "ORGANISM_SUBSTANCE", 134, 141], ["white blood cells", "CELL_TYPE", 90, 107], ["Inflammation of the vascularrich uveal tract", "PROBLEM", 0, 44], ["the blood vessels to leak protein", "PROBLEM", 52, 85], ["white blood cells", "TEST", 90, 107], ["aqueous flare\"", "PROBLEM", 134, 148], ["vascularrich uveal tract", "ANATOMY", 20, 44], ["blood vessels", "ANATOMY", 56, 69], ["aqueous", "OBSERVATION_MODIFIER", 134, 141], ["flare", "OBSERVATION", 142, 147]]], ["Accumulations of protein and white blood cells may form opaque clots known as \"hypopyon\".", [["white blood cells", "ANATOMY", 29, 46], ["clots", "ANATOMY", 63, 68], ["white blood cells", "CELL", 29, 46], ["clots", "ORGANISM_SUBSTANCE", 63, 68], ["white blood cells", "CELL_TYPE", 29, 46], ["Accumulations of protein", "PROBLEM", 0, 24], ["white blood cells", "TEST", 29, 46], ["opaque clots", "PROBLEM", 56, 68], ["hypopyon\"", "PROBLEM", 79, 88], ["protein", "OBSERVATION", 17, 24], ["white blood cells", "OBSERVATION", 29, 46], ["opaque", "OBSERVATION_MODIFIER", 56, 62], ["clots", "OBSERVATION", 63, 68], ["hypopyon", "OBSERVATION", 79, 87]]], ["This causes a cloudy anterior chamber.", [["a cloudy anterior chamber", "PROBLEM", 12, 37], ["cloudy", "OBSERVATION_MODIFIER", 14, 20], ["anterior", "OBSERVATION_MODIFIER", 21, 29], ["chamber", "OBSERVATION_MODIFIER", 30, 37]]], ["See \"The Cat With Abnormal Iris Appearance\" (page 1294).Cloudy anterior chamberAt the same time, anterior uveitis disturbs the endothelial pump mechanism, allowing aqueous to enter the stroma.", [["endothelial", "ANATOMY", 127, 138], ["stroma", "ANATOMY", 185, 191], ["uveitis", "DISEASE", 106, 113], ["endothelial", "CELL", 127, 138], ["stroma", "TISSUE", 185, 191], ["anterior uveitis", "PROBLEM", 97, 113], ["the endothelial pump", "TREATMENT", 123, 143], ["anterior", "ANATOMY_MODIFIER", 63, 71], ["anterior", "ANATOMY_MODIFIER", 97, 105], ["uveitis", "OBSERVATION", 106, 113], ["endothelial pump", "OBSERVATION", 127, 143], ["stroma", "OBSERVATION", 185, 191]]], ["This causes edema of the cornea seen as a cloudy eye.Cloudy lensA cloudy lens is seen when the lens develops a cataract.Cloudy lensA cataract is defined as an opacity of the lens.", [["edema", "ANATOMY", 12, 17], ["cornea", "ANATOMY", 25, 31], ["eye", "ANATOMY", 49, 52], ["lens", "ANATOMY", 95, 99], ["lens", "ANATOMY", 174, 178], ["edema of the cornea", "DISEASE", 12, 31], ["cataract", "DISEASE", 111, 119], ["cataract", "DISEASE", 133, 141], ["edema", "PATHOLOGICAL_FORMATION", 12, 17], ["cornea", "ORGAN", 25, 31], ["eye", "ORGAN", 49, 52], ["lens", "TISSUE", 174, 178], ["edema of the cornea", "PROBLEM", 12, 31], ["a cloudy eye", "PROBLEM", 40, 52], ["Cloudy lensA cloudy lens", "PROBLEM", 53, 77], ["a cataract", "PROBLEM", 109, 119], ["Cloudy lensA cataract", "PROBLEM", 120, 141], ["an opacity of the lens", "PROBLEM", 156, 178], ["edema", "OBSERVATION", 12, 17], ["cornea", "ANATOMY", 25, 31], ["cloudy", "OBSERVATION", 42, 48], ["eye", "ANATOMY", 49, 52], ["lensA", "OBSERVATION_MODIFIER", 60, 65], ["cloudy lens", "OBSERVATION", 66, 77], ["lens", "ANATOMY", 95, 99], ["cataract", "OBSERVATION", 111, 119], ["lensA cataract", "OBSERVATION", 127, 141], ["opacity", "OBSERVATION", 159, 166], ["lens", "ANATOMY", 174, 178]]], ["Lens fibers become opaque when they are no longer viable.", [["Lens fibers", "ANATOMY", 0, 11], ["Lens fibers", "CELL", 0, 11], ["opaque", "OBSERVATION", 19, 25], ["no longer", "UNCERTAINTY", 40, 49]]], ["A cataract is classified according to the position in the lens, and according to whether it is immature or mature.Cloudy lensThe lens consists of an anterior and posterior capsule on the outer surface of the cortex.", [["lens", "ANATOMY", 58, 62], ["lens", "ANATOMY", 129, 133], ["anterior", "ANATOMY", 149, 157], ["posterior capsule", "ANATOMY", 162, 179], ["outer surface", "ANATOMY", 187, 200], ["cortex", "ANATOMY", 208, 214], ["cataract", "DISEASE", 2, 10], ["lens", "TISSUE", 58, 62], ["anterior", "MULTI-TISSUE_STRUCTURE", 149, 157], ["posterior capsule", "CANCER", 162, 179], ["outer surface", "CELLULAR_COMPONENT", 187, 200], ["cortex", "CANCER", 208, 214], ["A cataract", "PROBLEM", 0, 10], ["Cloudy lens", "PROBLEM", 114, 125], ["cataract", "OBSERVATION", 2, 10], ["lens", "ANATOMY", 58, 62], ["immature", "OBSERVATION", 95, 103], ["lens", "ANATOMY", 121, 125], ["lens", "ANATOMY_MODIFIER", 129, 133], ["anterior", "ANATOMY_MODIFIER", 149, 157], ["posterior", "ANATOMY_MODIFIER", 162, 171], ["capsule", "ANATOMY_MODIFIER", 172, 179], ["outer", "ANATOMY_MODIFIER", 187, 192], ["surface", "ANATOMY_MODIFIER", 193, 200], ["cortex", "ANATOMY_MODIFIER", 208, 214]]], ["The central part of the lens is known as the nucleus.", [["lens", "ANATOMY", 24, 28], ["nucleus", "ANATOMY", 45, 52], ["central part", "MULTI-TISSUE_STRUCTURE", 4, 16], ["lens", "TISSUE", 24, 28], ["nucleus", "CELLULAR_COMPONENT", 45, 52], ["central", "ANATOMY_MODIFIER", 4, 11], ["lens", "ANATOMY", 24, 28], ["nucleus", "ANATOMY_MODIFIER", 45, 52]]], ["The lens is suspended by fibers known as zonules, which extend from the equator (outer circumference) of the lens to the ciliary processes.", [["lens", "ANATOMY", 4, 8], ["fibers", "ANATOMY", 25, 31], ["zonules", "ANATOMY", 41, 48], ["lens", "ANATOMY", 109, 113], ["ciliary", "ANATOMY", 121, 128], ["fibers", "CELLULAR_COMPONENT", 25, 31], ["zonules", "GENE_OR_GENE_PRODUCT", 41, 48], ["ciliary processes", "MULTI-TISSUE_STRUCTURE", 121, 138], ["lens", "ANATOMY", 4, 8], ["equator", "OBSERVATION_MODIFIER", 72, 79], ["lens", "ANATOMY", 109, 113], ["ciliary", "ANATOMY_MODIFIER", 121, 128]]], ["Lens cells are known as lens fibers and are continually produced from the lens epithelium, which is most active at the equator.Cloudy lensThe lens has no blood supply, and therefore relies on the nutrients in the aqueous humor and the vitreous for its nutritional requirements.", [["Lens cells", "ANATOMY", 0, 10], ["lens fibers", "ANATOMY", 24, 35], ["lens epithelium", "ANATOMY", 74, 89], ["lens", "ANATOMY", 142, 146], ["blood", "ANATOMY", 154, 159], ["aqueous humor", "ANATOMY", 213, 226], ["vitreous", "ANATOMY", 235, 243], ["Lens cells", "CELL", 0, 10], ["lens fibers", "CELL", 24, 35], ["lens epithelium", "TISSUE", 74, 89], ["lens", "TISSUE", 142, 146], ["blood", "ORGANISM_SUBSTANCE", 154, 159], ["aqueous humor", "ORGANISM_SUBSTANCE", 213, 226], ["vitreous", "ORGANISM_SUBSTANCE", 235, 243], ["Lens cells", "CELL_TYPE", 0, 10], ["Lens cells", "PROBLEM", 0, 10], ["Cloudy lens", "PROBLEM", 127, 138], ["the aqueous humor", "TREATMENT", 209, 226], ["the vitreous", "TREATMENT", 231, 243], ["cells", "OBSERVATION", 5, 10], ["lens fibers", "OBSERVATION", 24, 35], ["lens epithelium", "OBSERVATION", 74, 89], ["most", "OBSERVATION_MODIFIER", 100, 104], ["active", "OBSERVATION_MODIFIER", 105, 111], ["equator", "OBSERVATION_MODIFIER", 119, 126], ["lens", "ANATOMY", 134, 138], ["lens", "ANATOMY", 142, 146], ["no", "UNCERTAINTY", 151, 153], ["blood supply", "OBSERVATION", 154, 166], ["vitreous", "OBSERVATION", 235, 243]]], ["Disturbance to the nutrition of the lens will result in death of lens fibers and development of a cataract.Cloudy lensGenetic cataract is rare in the cat.Cloudy lensMost cataracts in cats are secondary to disease processes within the eye such as uveitis or neoplasia.Cloudy lensLens fibers in the nucleus become slightly opaque with age.", [["lens", "ANATOMY", 36, 40], ["lens fibers", "ANATOMY", 65, 76], ["eye", "ANATOMY", 234, 237], ["neoplasia", "ANATOMY", 257, 266], ["Cloudy lensLens fibers", "ANATOMY", 267, 289], ["nucleus", "ANATOMY", 297, 304], ["death", "DISEASE", 56, 61], ["cataract", "DISEASE", 98, 106], ["cataract", "DISEASE", 126, 134], ["cataracts", "DISEASE", 170, 179], ["uveitis", "DISEASE", 246, 253], ["neoplasia", "DISEASE", 257, 266], ["lens fibers", "TISSUE", 65, 76], ["cat", "ORGANISM", 150, 153], ["cats", "ORGANISM", 183, 187], ["eye", "ORGAN", 234, 237], ["neoplasia", "CANCER", 257, 266], ["nucleus", "CELLULAR_COMPONENT", 297, 304], ["cat", "SPECIES", 150, 153], ["cats", "SPECIES", 183, 187], ["death of lens fibers", "PROBLEM", 56, 76], ["a cataract", "PROBLEM", 96, 106], ["Cloudy lensGenetic cataract", "PROBLEM", 107, 134], ["Cloudy lensMost cataracts in cats", "PROBLEM", 154, 187], ["disease processes within the eye", "PROBLEM", 205, 237], ["uveitis", "PROBLEM", 246, 253], ["neoplasia", "PROBLEM", 257, 266], ["slightly opaque", "PROBLEM", 312, 327], ["lens", "ANATOMY", 36, 40], ["lens fibers", "OBSERVATION", 65, 76], ["cataract", "OBSERVATION", 98, 106], ["lensGenetic", "OBSERVATION_MODIFIER", 114, 125], ["cataract", "OBSERVATION", 126, 134], ["rare", "OBSERVATION_MODIFIER", 138, 142], ["lens", "OBSERVATION_MODIFIER", 161, 165], ["Most", "OBSERVATION_MODIFIER", 165, 169], ["cataracts", "OBSERVATION", 170, 179], ["disease", "OBSERVATION", 205, 212], ["eye", "ANATOMY", 234, 237], ["uveitis", "OBSERVATION", 246, 253], ["neoplasia", "OBSERVATION", 257, 266], ["lensLens fibers", "OBSERVATION", 274, 289], ["nucleus", "ANATOMY_MODIFIER", 297, 304], ["slightly", "OBSERVATION_MODIFIER", 312, 320], ["opaque", "OBSERVATION", 321, 327]]], ["This is known as nuclear sclerosis and may be seen from about 8 years of age.", [["nuclear", "ANATOMY", 17, 24], ["nuclear sclerosis", "DISEASE", 17, 34], ["nuclear", "CELLULAR_COMPONENT", 17, 24], ["nuclear sclerosis", "PROBLEM", 17, 34], ["nuclear", "OBSERVATION_MODIFIER", 17, 24], ["sclerosis", "OBSERVATION", 25, 34], ["may be seen", "UNCERTAINTY", 39, 50]]], ["This is not a true cataract as the fibers are viable and the eye is usually visual.", [["fibers", "ANATOMY", 35, 41], ["eye", "ANATOMY", 61, 64], ["cataract", "DISEASE", 19, 27], ["fibers", "CELLULAR_COMPONENT", 35, 41], ["eye", "ORGAN", 61, 64], ["a true cataract", "PROBLEM", 12, 27], ["true", "OBSERVATION_MODIFIER", 14, 18], ["cataract", "OBSERVATION", 19, 27], ["eye", "ANATOMY", 61, 64]]], ["With age, the nuclear fibers may die, so nuclear sclerosis may develop into a nuclear cataract.Cloudy vitreousThe vitreous is a living tissue (mainly mucopolysaccharide; also called glycosaminoglycans) that fills the space between the retina, ciliary body and lens.Cloudy vitreousInflammation or hypertension of the inner retinal blood vessels will allow protein and white/red blood cells to leak into the vitreous causing \"vitreous flare\".", [["nuclear fibers", "ANATOMY", 14, 28], ["nuclear", "ANATOMY", 41, 48], ["nuclear", "ANATOMY", 78, 85], ["vitreous", "ANATOMY", 102, 110], ["vitreous", "ANATOMY", 114, 122], ["tissue", "ANATOMY", 135, 141], ["retina", "ANATOMY", 235, 241], ["ciliary body", "ANATOMY", 243, 255], ["lens", "ANATOMY", 260, 264], ["vitreous", "ANATOMY", 272, 280], ["inner retinal blood vessels", "ANATOMY", 316, 343], ["red blood cells", "ANATOMY", 373, 388], ["vitreous", "ANATOMY", 406, 414], ["vitreous", "ANATOMY", 424, 432], ["nuclear sclerosis", "DISEASE", 41, 58], ["cataract", "DISEASE", 86, 94], ["Inflammation", "DISEASE", 280, 292], ["hypertension", "DISEASE", 296, 308], ["nuclear fibers", "CELLULAR_COMPONENT", 14, 28], ["nuclear", "CELLULAR_COMPONENT", 41, 48], ["nuclear", "CELLULAR_COMPONENT", 78, 85], ["vitreous", "MULTI-TISSUE_STRUCTURE", 114, 122], ["tissue", "TISSUE", 135, 141], ["mucopolysaccharide", "SIMPLE_CHEMICAL", 150, 168], ["glycosaminoglycans", "GENE_OR_GENE_PRODUCT", 182, 200], ["retina", "MULTI-TISSUE_STRUCTURE", 235, 241], ["ciliary body", "TISSUE", 243, 255], ["lens", "TISSUE", 260, 264], ["vitreous", "MULTI-TISSUE_STRUCTURE", 272, 280], ["inner retinal blood vessels", "MULTI-TISSUE_STRUCTURE", 316, 343], ["red blood cells", "CELL", 373, 388], ["vitreous", "ORGANISM_SUBSTANCE", 406, 414], ["vitreous", "ORGANISM_SUBSTANCE", 424, 432], ["white/red blood cells", "CELL_TYPE", 367, 388], ["nuclear sclerosis", "PROBLEM", 41, 58], ["a nuclear cataract", "PROBLEM", 76, 94], ["Cloudy vitreous", "PROBLEM", 95, 110], ["Cloudy vitreousInflammation", "PROBLEM", 265, 292], ["hypertension of the inner retinal blood vessels", "PROBLEM", 296, 343], ["protein", "TEST", 355, 362], ["white/red blood cells", "PROBLEM", 367, 388], ["leak into the vitreous", "PROBLEM", 392, 414], ["vitreous flare\"", "PROBLEM", 424, 439], ["sclerosis", "OBSERVATION", 49, 58], ["nuclear", "OBSERVATION_MODIFIER", 78, 85], ["cataract", "OBSERVATION", 86, 94], ["vitreous", "OBSERVATION", 102, 110], ["vitreous", "OBSERVATION", 114, 122], ["living tissue", "OBSERVATION_MODIFIER", 128, 141], ["space", "ANATOMY_MODIFIER", 217, 222], ["retina", "ANATOMY", 235, 241], ["ciliary body", "ANATOMY", 243, 255], ["lens", "ANATOMY", 260, 264], ["vitreousInflammation", "OBSERVATION", 272, 292], ["hypertension", "OBSERVATION", 296, 308], ["inner", "ANATOMY_MODIFIER", 316, 321], ["retinal", "ANATOMY_MODIFIER", 322, 329], ["blood vessels", "ANATOMY", 330, 343], ["vitreous flare", "OBSERVATION", 424, 438]]], ["This may present as a cloudy eye behind the pupil.Cloudy vitreousInflammation of the choroid (posterior uvea) leads to leakage of protein and blood cells into the outer retinal space leading to a serous retinal detachment.", [["eye", "ANATOMY", 29, 32], ["pupil", "ANATOMY", 44, 49], ["vitreous", "ANATOMY", 57, 65], ["choroid", "ANATOMY", 85, 92], ["posterior uvea", "ANATOMY", 94, 108], ["blood cells", "ANATOMY", 142, 153], ["outer retinal space", "ANATOMY", 163, 182], ["serous retinal", "ANATOMY", 196, 210], ["retinal detachment", "DISEASE", 203, 221], ["eye", "ORGAN", 29, 32], ["pupil", "ORGANISM_SUBDIVISION", 44, 49], ["choroid", "MULTI-TISSUE_STRUCTURE", 85, 92], ["posterior uvea", "MULTI-TISSUE_STRUCTURE", 94, 108], ["blood cells", "CELL", 142, 153], ["outer retinal", "MULTI-TISSUE_STRUCTURE", 163, 176], ["retinal", "MULTI-TISSUE_STRUCTURE", 203, 210], ["blood cells", "CELL_TYPE", 142, 153], ["Cloudy vitreousInflammation of the choroid (posterior uvea", "PROBLEM", 50, 108], ["leakage of protein and blood cells into the outer retinal space", "PROBLEM", 119, 182], ["a serous retinal detachment", "PROBLEM", 194, 221], ["cloudy", "OBSERVATION", 22, 28], ["pupil", "ANATOMY", 44, 49], ["vitreousInflammation", "OBSERVATION", 57, 77], ["choroid", "ANATOMY", 85, 92], ["posterior", "ANATOMY_MODIFIER", 94, 103], ["uvea", "ANATOMY", 104, 108], ["leakage", "OBSERVATION_MODIFIER", 119, 126], ["blood cells", "OBSERVATION", 142, 153], ["outer", "ANATOMY_MODIFIER", 163, 168], ["retinal", "ANATOMY", 169, 176], ["space", "ANATOMY_MODIFIER", 177, 182], ["serous retinal detachment", "OBSERVATION", 196, 221]]], ["Retinal detachment can present as a cloudy eye behind the pupil.Cloudy vitreousVitreous degeneration is rare in the cat.WHERE?Disease affecting the cornea, anterior chamber, lens or vitreous may result in a cloudy eye.WHERE?Decide which of the media have become cloudy and go to that part of the text for greater detail.WHAT?Cloudiness of cornea, anterior chamber, lens or vitreous may be caused by:WHAT?\u2022 Infiltrates of inflammatory cells or infusion of tissue fluid (edema), which produces swelling of the corneal stroma, will result in a cloudy cornea. \u2022 Alteration of the cellular matrix in the cornea and lens causes a change in the refractive index, because of changed chemical properties of these structures.", [["Retinal", "ANATOMY", 0, 7], ["eye", "ANATOMY", 43, 46], ["pupil", "ANATOMY", 58, 63], ["vitreous", "ANATOMY", 71, 79], ["Vitreous", "ANATOMY", 79, 87], ["cornea", "ANATOMY", 148, 154], ["anterior chamber", "ANATOMY", 156, 172], ["lens", "ANATOMY", 174, 178], ["vitreous", "ANATOMY", 182, 190], ["eye", "ANATOMY", 214, 217], ["cornea", "ANATOMY", 339, 345], ["anterior chamber", "ANATOMY", 347, 363], ["lens", "ANATOMY", 365, 369], ["vitreous", "ANATOMY", 373, 381], ["inflammatory cells", "ANATOMY", 421, 439], ["tissue fluid", "ANATOMY", 455, 467], ["edema", "ANATOMY", 469, 474], ["corneal stroma", "ANATOMY", 508, 522], ["cornea", "ANATOMY", 548, 554], ["cellular matrix", "ANATOMY", 576, 591], ["cornea", "ANATOMY", 599, 605], ["lens", "ANATOMY", 610, 614], ["Retinal detachment", "DISEASE", 0, 18], ["Vitreous degeneration", "DISEASE", 79, 100], ["edema", "DISEASE", 469, 474], ["Retinal", "MULTI-TISSUE_STRUCTURE", 0, 7], ["eye", "ORGAN", 43, 46], ["pupil", "ORGAN", 58, 63], ["Vitreous", "TISSUE", 79, 87], ["cat", "ORGANISM", 116, 119], ["cornea", "TISSUE", 148, 154], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 156, 172], ["lens", "MULTI-TISSUE_STRUCTURE", 174, 178], ["vitreous", "MULTI-TISSUE_STRUCTURE", 182, 190], ["eye", "ORGAN", 214, 217], ["cornea", "TISSUE", 339, 345], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 347, 363], ["lens", "MULTI-TISSUE_STRUCTURE", 365, 369], ["vitreous", "MULTI-TISSUE_STRUCTURE", 373, 381], ["inflammatory cells", "CELL", 421, 439], ["tissue", "TISSUE", 455, 461], ["fluid", "ORGANISM_SUBSTANCE", 462, 467], ["edema", "PATHOLOGICAL_FORMATION", 469, 474], ["corneal stroma", "TISSUE", 508, 522], ["cornea", "TISSUE", 548, 554], ["cellular matrix", "CELLULAR_COMPONENT", 576, 591], ["cornea", "TISSUE", 599, 605], ["inflammatory cells", "CELL_TYPE", 421, 439], ["cat", "SPECIES", 116, 119], ["Retinal detachment", "PROBLEM", 0, 18], ["Cloudy vitreous", "PROBLEM", 64, 79], ["Vitreous degeneration", "PROBLEM", 79, 100], ["Disease affecting the cornea", "PROBLEM", 126, 154], ["a cloudy eye", "PROBLEM", 205, 217], ["cloudy", "PROBLEM", 262, 268], ["Cloudiness of cornea", "PROBLEM", 325, 345], ["Infiltrates of inflammatory cells", "PROBLEM", 406, 439], ["tissue fluid", "PROBLEM", 455, 467], ["edema", "PROBLEM", 469, 474], ["swelling of the corneal stroma", "PROBLEM", 492, 522], ["a cloudy cornea", "PROBLEM", 539, 554], ["a change in the refractive index", "PROBLEM", 622, 654], ["detachment", "OBSERVATION", 8, 18], ["pupil", "ANATOMY", 58, 63], ["vitreous", "OBSERVATION", 71, 79], ["degeneration", "OBSERVATION", 88, 100], ["rare", "OBSERVATION_MODIFIER", 104, 108], ["cornea", "ANATOMY", 148, 154], ["anterior", "ANATOMY_MODIFIER", 156, 164], ["chamber", "ANATOMY_MODIFIER", 165, 172], ["lens", "ANATOMY", 174, 178], ["vitreous", "OBSERVATION", 182, 190], ["cloudy", "OBSERVATION", 207, 213], ["cloudy", "OBSERVATION", 262, 268], ["cornea", "ANATOMY", 339, 345], ["anterior", "ANATOMY_MODIFIER", 347, 355], ["chamber", "ANATOMY_MODIFIER", 356, 363], ["lens", "ANATOMY", 365, 369], ["vitreous", "OBSERVATION", 373, 381], ["inflammatory cells", "OBSERVATION", 421, 439], ["infusion of tissue", "OBSERVATION_MODIFIER", 443, 461], ["fluid", "OBSERVATION", 462, 467], ["edema", "OBSERVATION", 469, 474], ["swelling", "OBSERVATION", 492, 500], ["corneal stroma", "ANATOMY", 508, 522], ["cloudy cornea", "OBSERVATION", 541, 554], ["Alteration", "OBSERVATION", 558, 568], ["cellular matrix", "OBSERVATION", 576, 591], ["cornea", "ANATOMY", 599, 605], ["lens", "ANATOMY", 610, 614], ["change", "OBSERVATION_MODIFIER", 624, 630], ["refractive index", "OBSERVATION", 638, 654]]], ["For example, the change in the structure of the crystallins in the lens results in cataract formation. \u2022 Accumulation of protein and cells in the aqueous humor causes a cloudy aqueous called hypopyon. \u2022 On rare occasions lipid may be seen in the aqueous (aqueous lipid) forming a very cloudy eye. \u2022 Leakage of cells and protein into the vitreous from inflammation of the ciliary body and/or choroid causes a cloudy vitreous.WHAT?The most common causes of corneal cloudiness are from inflammation associated with herpesvirus keratitis or eosinophilic keratitis, or from trauma resulting in edema, cellular infiltrates, ulcerative keratitis, and/or scarring or corneal sequestrum.WHAT?The most common causes of anterior chamber cloudiness are inflammation from infectious agents such as Toxoplamsa gondii, Cryptococcus, other systemic fungi, feline infectious peritonitis virus, feline leukemia virus or from neoplasia.WHAT?The most common causes of lens cloudiness are from nuclear sclerosis or cataract secondary to infectious uveitis or trauma.WHAT?The most common cause of posterior chamber cloudiness is from systemic hypertension.Clinical signsHerpesvirus is one of the most common causes of acute and chronic corneal disease in older cats.Clinical signsAcute primary infection with herpesvirus may result in the following signs:Clinical signs\u2022 Conjunctival hyperemia and serous ocular discharge that becomes purulent by days 5-7 of infection. \u2022 Mild to moderate chemosis and blepharospasm. \u2022 Non-specific upper respiratory signs such as sneezing and serous nasal discharge. \u2022 Fine-branching (microdendritic) corneal lesions may be seen, especially if the cornea is stained with rose bengal.", [["lens", "ANATOMY", 67, 71], ["cells", "ANATOMY", 133, 138], ["aqueous humor", "ANATOMY", 146, 159], ["eye", "ANATOMY", 292, 295], ["cells", "ANATOMY", 310, 315], ["vitreous", "ANATOMY", 337, 345], ["ciliary body", "ANATOMY", 371, 383], ["choroid", "ANATOMY", 391, 398], ["vitreous", "ANATOMY", 415, 423], ["corneal", "ANATOMY", 455, 462], ["edema", "ANATOMY", 589, 594], ["cellular", "ANATOMY", 596, 604], ["ulcerative", "ANATOMY", 618, 628], ["corneal", "ANATOMY", 659, 666], ["anterior chamber", "ANATOMY", 709, 725], ["neoplasia", "ANATOMY", 907, 916], ["lens", "ANATOMY", 948, 952], ["nuclear", "ANATOMY", 973, 980], ["corneal", "ANATOMY", 1214, 1221], ["Conjunctival", "ANATOMY", 1349, 1361], ["serous ocular", "ANATOMY", 1376, 1389], ["respiratory", "ANATOMY", 1516, 1527], ["serous nasal", "ANATOMY", 1555, 1567], ["corneal lesions", "ANATOMY", 1613, 1628], ["cornea", "ANATOMY", 1660, 1666], ["cataract", "DISEASE", 83, 91], ["inflammation", "DISEASE", 351, 363], ["inflammation", "DISEASE", 483, 495], ["herpesvirus keratitis", "DISEASE", 512, 533], ["keratitis", "DISEASE", 550, 559], ["trauma", "DISEASE", 569, 575], ["edema", "DISEASE", 589, 594], ["ulcerative keratitis", "DISEASE", 618, 638], ["scarring", "DISEASE", 647, 655], ["inflammation", "DISEASE", 741, 753], ["Toxoplamsa gondii", "DISEASE", 785, 802], ["feline infectious peritonitis", "DISEASE", 840, 869], ["feline leukemia virus", "DISEASE", 877, 898], ["neoplasia", "DISEASE", 907, 916], ["nuclear sclerosis", "DISEASE", 973, 990], ["cataract", "DISEASE", 994, 1002], ["uveitis", "DISEASE", 1027, 1034], ["trauma", "DISEASE", 1038, 1044], ["cloudiness", "DISEASE", 1093, 1103], ["hypertension", "DISEASE", 1121, 1133], ["corneal disease", "DISEASE", 1214, 1229], ["primary infection", "DISEASE", 1264, 1281], ["herpesvirus", "DISEASE", 1287, 1298], ["hyperemia", "DISEASE", 1362, 1371], ["purulent", "DISEASE", 1413, 1421], ["infection", "DISEASE", 1437, 1446], ["chemosis", "DISEASE", 1467, 1475], ["blepharospasm", "DISEASE", 1480, 1493], ["sneezing", "DISEASE", 1542, 1550], ["cataract", "PATHOLOGICAL_FORMATION", 83, 91], ["cells", "CELL", 133, 138], ["aqueous humor", "ORGANISM_SUBSTANCE", 146, 159], ["aqueous", "ORGANISM_SUBSTANCE", 246, 253], ["aqueous lipid", "ORGANISM_SUBSTANCE", 255, 268], ["eye", "ORGAN", 292, 295], ["cells", "CELL", 310, 315], ["vitreous", "TISSUE", 337, 345], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 371, 383], ["choroid", "ORGAN", 391, 398], ["vitreous", "ORGANISM_SUBSTANCE", 415, 423], ["corneal", "TISSUE", 455, 462], ["herpesvirus", "ORGANISM", 512, 523], ["edema", "PATHOLOGICAL_FORMATION", 589, 594], ["cellular", "CELL", 596, 604], ["Toxoplamsa gondii", "ORGANISM", 785, 802], ["feline infectious peritonitis virus", "ORGANISM", 840, 875], ["feline leukemia virus", "ORGANISM", 877, 898], ["neoplasia", "CANCER", 907, 916], ["lens", "TISSUE", 948, 952], ["Herpesvirus", "ORGANISM", 1148, 1159], ["corneal", "ORGAN", 1214, 1221], ["cats", "ORGANISM", 1239, 1243], ["herpesvirus", "ORGANISM", 1287, 1298], ["Conjunctival", "TISSUE", 1349, 1361], ["ocular", "ORGAN", 1383, 1389], ["nasal", "ORGANISM_SUBDIVISION", 1562, 1567], ["corneal lesions", "PATHOLOGICAL_FORMATION", 1613, 1628], ["cornea", "ORGAN", 1660, 1666], ["bengal", "SIMPLE_CHEMICAL", 1688, 1694], ["crystallins", "PROTEIN", 48, 59], ["Toxoplamsa gondii", "SPECIES", 785, 802], ["feline infectious peritonitis virus", "SPECIES", 840, 875], ["feline leukemia virus", "SPECIES", 877, 898], ["cats", "SPECIES", 1239, 1243], ["Toxoplamsa gondii", "SPECIES", 785, 802], ["feline infectious peritonitis virus", "SPECIES", 840, 875], ["feline leukemia virus", "SPECIES", 877, 898], ["the change", "PROBLEM", 13, 23], ["cataract formation", "PROBLEM", 83, 101], ["Accumulation of protein and cells", "PROBLEM", 105, 138], ["hypopyon", "PROBLEM", 191, 199], ["a very cloudy eye", "PROBLEM", 278, 295], ["Leakage of cells", "PROBLEM", 299, 315], ["inflammation of the ciliary body", "PROBLEM", 351, 383], ["a cloudy vitreous", "PROBLEM", 406, 423], ["corneal cloudiness", "PROBLEM", 455, 473], ["inflammation", "PROBLEM", 483, 495], ["herpesvirus keratitis", "PROBLEM", 512, 533], ["eosinophilic keratitis", "PROBLEM", 537, 559], ["trauma", "PROBLEM", 569, 575], ["edema", "PROBLEM", 589, 594], ["cellular infiltrates", "PROBLEM", 596, 616], ["ulcerative keratitis", "PROBLEM", 618, 638], ["scarring", "PROBLEM", 647, 655], ["corneal sequestrum", "PROBLEM", 659, 677], ["anterior chamber cloudiness", "PROBLEM", 709, 736], ["inflammation", "PROBLEM", 741, 753], ["infectious agents", "TREATMENT", 759, 776], ["Toxoplamsa gondii", "PROBLEM", 785, 802], ["Cryptococcus", "PROBLEM", 804, 816], ["other systemic fungi", "PROBLEM", 818, 838], ["feline infectious peritonitis virus", "PROBLEM", 840, 875], ["feline leukemia virus", "PROBLEM", 877, 898], ["neoplasia", "PROBLEM", 907, 916], ["lens cloudiness", "PROBLEM", 948, 963], ["nuclear sclerosis", "PROBLEM", 973, 990], ["cataract", "PROBLEM", 994, 1002], ["infectious uveitis", "PROBLEM", 1016, 1034], ["trauma", "PROBLEM", 1038, 1044], ["posterior chamber cloudiness", "PROBLEM", 1075, 1103], ["systemic hypertension", "PROBLEM", 1112, 1133], ["Clinical signsHerpesvirus", "PROBLEM", 1134, 1159], ["acute and chronic corneal disease in older cats", "PROBLEM", 1196, 1243], ["Clinical signs", "PROBLEM", 1244, 1258], ["Acute primary infection", "PROBLEM", 1258, 1281], ["herpesvirus", "PROBLEM", 1287, 1298], ["Clinical signs", "TEST", 1333, 1347], ["Conjunctival hyperemia", "PROBLEM", 1349, 1371], ["serous ocular discharge", "PROBLEM", 1376, 1399], ["purulent", "PROBLEM", 1413, 1421], ["infection", "PROBLEM", 1437, 1446], ["Mild to moderate chemosis", "PROBLEM", 1450, 1475], ["blepharospasm", "PROBLEM", 1480, 1493], ["Non-specific upper respiratory signs", "PROBLEM", 1497, 1533], ["sneezing", "PROBLEM", 1542, 1550], ["serous nasal discharge", "PROBLEM", 1555, 1577], ["Fine-branching (microdendritic) corneal lesions", "PROBLEM", 1581, 1628], ["rose bengal", "PROBLEM", 1683, 1694], ["change", "OBSERVATION_MODIFIER", 17, 23], ["crystallins", "OBSERVATION", 48, 59], ["lens", "ANATOMY", 67, 71], ["cataract", "OBSERVATION", 83, 91], ["Accumulation of protein and cells", "OBSERVATION", 105, 138], ["aqueous humor", "OBSERVATION", 146, 159], ["cloudy", "OBSERVATION_MODIFIER", 169, 175], ["aqueous", "OBSERVATION_MODIFIER", 176, 183], ["hypopyon", "OBSERVATION", 191, 199], ["may be seen", "UNCERTAINTY", 227, 238], ["very", "OBSERVATION_MODIFIER", 280, 284], ["cloudy", "OBSERVATION", 285, 291], ["eye", "ANATOMY", 292, 295], ["cells", "OBSERVATION", 310, 315], ["vitreous", "OBSERVATION_MODIFIER", 337, 345], ["inflammation", "OBSERVATION", 351, 363], ["ciliary body", "ANATOMY_MODIFIER", 371, 383], ["choroid", "ANATOMY", 391, 398], ["cloudy vitreous", "OBSERVATION", 408, 423], ["most common", "OBSERVATION_MODIFIER", 433, 444], ["corneal cloudiness", "OBSERVATION", 455, 473], ["inflammation", "OBSERVATION", 483, 495], ["herpesvirus keratitis", "OBSERVATION", 512, 533], ["eosinophilic keratitis", "OBSERVATION", 537, 559], ["edema", "OBSERVATION", 589, 594], ["cellular", "OBSERVATION_MODIFIER", 596, 604], ["infiltrates", "OBSERVATION", 605, 616], ["ulcerative", "OBSERVATION_MODIFIER", 618, 628], ["keratitis", "OBSERVATION", 629, 638], ["scarring", "OBSERVATION", 647, 655], ["corneal sequestrum", "OBSERVATION", 659, 677], ["anterior", "ANATOMY_MODIFIER", 709, 717], ["chamber cloudiness", "OBSERVATION", 718, 736], ["inflammation", "OBSERVATION", 741, 753], ["infectious", "OBSERVATION", 759, 769], ["infectious", "OBSERVATION_MODIFIER", 847, 857], ["peritonitis", "OBSERVATION", 858, 869], ["feline leukemia virus", "OBSERVATION", 877, 898], ["neoplasia", "OBSERVATION", 907, 916], ["most common", "OBSERVATION_MODIFIER", 926, 937], ["lens cloudiness", "OBSERVATION", 948, 963], ["nuclear", "OBSERVATION_MODIFIER", 973, 980], ["sclerosis", "OBSERVATION", 981, 990], ["cataract", "OBSERVATION", 994, 1002], ["infectious", "OBSERVATION_MODIFIER", 1016, 1026], ["uveitis", "OBSERVATION", 1027, 1034], ["trauma", "OBSERVATION", 1038, 1044], ["most common", "OBSERVATION_MODIFIER", 1054, 1065], ["posterior", "ANATOMY_MODIFIER", 1075, 1084], ["chamber cloudiness", "OBSERVATION", 1085, 1103], ["systemic", "OBSERVATION_MODIFIER", 1112, 1120], ["hypertension", "OBSERVATION", 1121, 1133], ["Herpesvirus", "OBSERVATION", 1148, 1159], ["one of the most common", "OBSERVATION_MODIFIER", 1163, 1185], ["acute", "OBSERVATION_MODIFIER", 1196, 1201], ["chronic", "OBSERVATION_MODIFIER", 1206, 1213], ["corneal disease", "OBSERVATION", 1214, 1229], ["Acute", "OBSERVATION_MODIFIER", 1258, 1263], ["primary", "OBSERVATION_MODIFIER", 1264, 1271], ["infection", "OBSERVATION", 1272, 1281], ["hyperemia", "OBSERVATION", 1362, 1371], ["serous", "OBSERVATION_MODIFIER", 1376, 1382], ["ocular discharge", "OBSERVATION", 1383, 1399], ["purulent", "OBSERVATION_MODIFIER", 1413, 1421], ["infection", "OBSERVATION", 1437, 1446], ["moderate", "OBSERVATION_MODIFIER", 1458, 1466], ["chemosis", "OBSERVATION", 1467, 1475], ["blepharospasm", "OBSERVATION", 1480, 1493], ["upper", "ANATOMY_MODIFIER", 1510, 1515], ["respiratory", "ANATOMY", 1516, 1527], ["signs", "OBSERVATION", 1528, 1533], ["sneezing", "OBSERVATION", 1542, 1550], ["serous", "OBSERVATION_MODIFIER", 1555, 1561], ["nasal", "ANATOMY", 1562, 1567], ["Fine", "OBSERVATION_MODIFIER", 1581, 1585], ["branching", "OBSERVATION_MODIFIER", 1586, 1595], ["corneal", "ANATOMY", 1613, 1620], ["lesions", "OBSERVATION", 1621, 1628], ["may be seen", "UNCERTAINTY", 1629, 1640], ["cornea", "ANATOMY", 1660, 1666]]], ["They result from the direct cytopathic effect of the virus, and are finger-like projections of epithelium.Clinical signsSymblepharon formation with adhesion of conjunctiva to conjunctiva and conjunctiva to cornea may follow severe inflammation especially in young kittens.Recrudescent infections may show any of the following signs:\u2022 Dendritic ulcers.Recrudescent infections may show any of the following signs:\u2022 Corneal sequestrum.Recrudescent infections may show any of the following signs:\u2022 Superficial indolent epithelial ulcers.Recrudescent infections may show any of the following signs:\u2022 Serous ocular discharge.Recrudescent infections may show any of the following signs:\u2022 Stromal edema and scarring.FHV-1 keratitis is primarily a disease of older cats.Frequently unilateral but may be bilateral.FHV-1 keratitis is primarily a disease of older cats.A large shallow ulcer with an irregular shape that appears to look like a continent or land mass (geographic ulcer) may be evident, and is often associated with superficial vascularization.", [["epithelium", "ANATOMY", 95, 105], ["conjunctiva", "ANATOMY", 160, 171], ["conjunctiva", "ANATOMY", 175, 186], ["conjunctiva", "ANATOMY", 191, 202], ["cornea", "ANATOMY", 206, 212], ["Dendritic ulcers", "ANATOMY", 334, 350], ["Corneal", "ANATOMY", 413, 420], ["Superficial indolent epithelial ulcers", "ANATOMY", 494, 532], ["Serous ocular", "ANATOMY", 595, 608], ["Stromal edema", "ANATOMY", 681, 694], ["ulcer", "ANATOMY", 873, 878], ["ulcer", "ANATOMY", 966, 971], ["inflammation", "DISEASE", 231, 243], ["infections", "DISEASE", 285, 295], ["Dendritic ulcers", "DISEASE", 334, 350], ["infections", "DISEASE", 364, 374], ["infections", "DISEASE", 445, 455], ["ulcers", "DISEASE", 526, 532], ["infections", "DISEASE", 546, 556], ["infections", "DISEASE", 632, 642], ["Stromal edema", "DISEASE", 681, 694], ["scarring", "DISEASE", 699, 707], ["keratitis", "DISEASE", 714, 723], ["keratitis", "DISEASE", 810, 819], ["ulcer", "DISEASE", 873, 878], ["ulcer", "DISEASE", 966, 971], ["epithelium", "TISSUE", 95, 105], ["conjunctiva", "ORGAN", 160, 171], ["conjunctiva", "MULTI-TISSUE_STRUCTURE", 175, 186], ["conjunctiva", "ORGAN", 191, 202], ["cornea", "ORGAN", 206, 212], ["kittens", "ORGANISM", 264, 271], ["Dendritic ulcers", "PATHOLOGICAL_FORMATION", 334, 350], ["epithelial ulcers", "PATHOLOGICAL_FORMATION", 515, 532], ["Stromal", "TISSUE", 681, 688], ["cats", "ORGANISM", 756, 760], ["cats", "ORGANISM", 852, 856], ["ulcer", "PATHOLOGICAL_FORMATION", 873, 878], ["ulcer", "PATHOLOGICAL_FORMATION", 966, 971], ["cats", "SPECIES", 756, 760], ["cats", "SPECIES", 852, 856], ["FHV-1", "SPECIES", 708, 713], ["FHV-1", "SPECIES", 804, 809], ["the direct cytopathic effect of the virus", "PROBLEM", 17, 58], ["Clinical signsSymblepharon formation", "PROBLEM", 106, 142], ["adhesion of conjunctiva", "PROBLEM", 148, 171], ["severe inflammation", "PROBLEM", 224, 243], ["Recrudescent infections", "PROBLEM", 272, 295], ["Dendritic ulcers", "PROBLEM", 334, 350], ["Recrudescent infections", "PROBLEM", 351, 374], ["Corneal sequestrum", "TEST", 413, 431], ["Recrudescent infections", "PROBLEM", 432, 455], ["Superficial indolent epithelial ulcers", "PROBLEM", 494, 532], ["Recrudescent infections", "PROBLEM", 533, 556], ["Serous ocular discharge", "PROBLEM", 595, 618], ["Recrudescent infections", "PROBLEM", 619, 642], ["Stromal edema", "PROBLEM", 681, 694], ["scarring", "PROBLEM", 699, 707], ["FHV", "PROBLEM", 708, 711], ["keratitis", "PROBLEM", 714, 723], ["a disease of older cats", "PROBLEM", 737, 760], ["FHV", "PROBLEM", 804, 807], ["keratitis", "PROBLEM", 810, 819], ["a disease of older cats", "PROBLEM", 833, 856], ["A large shallow ulcer", "PROBLEM", 857, 878], ["an irregular shape", "PROBLEM", 884, 902], ["a continent or land mass (geographic ulcer", "PROBLEM", 929, 971], ["superficial vascularization", "PROBLEM", 1018, 1045], ["virus", "OBSERVATION", 53, 58], ["epithelium", "ANATOMY_MODIFIER", 95, 105], ["Symblepharon formation", "OBSERVATION", 120, 142], ["conjunctiva", "ANATOMY", 160, 171], ["conjunctiva", "ANATOMY", 175, 186], ["conjunctiva", "ANATOMY", 191, 202], ["cornea", "ANATOMY", 206, 212], ["severe", "OBSERVATION_MODIFIER", 224, 230], ["inflammation", "OBSERVATION", 231, 243], ["ulcers", "OBSERVATION", 344, 350], ["sequestrum", "OBSERVATION", 421, 431], ["indolent", "OBSERVATION_MODIFIER", 506, 514], ["epithelial ulcers", "OBSERVATION", 515, 532], ["ocular", "ANATOMY", 602, 608], ["discharge", "OBSERVATION", 609, 618], ["edema", "OBSERVATION", 689, 694], ["scarring", "OBSERVATION", 699, 707], ["keratitis", "OBSERVATION", 714, 723], ["may be", "UNCERTAINTY", 787, 793], ["bilateral", "ANATOMY_MODIFIER", 794, 803], ["keratitis", "OBSERVATION", 810, 819], ["large", "OBSERVATION_MODIFIER", 859, 864], ["shallow", "OBSERVATION_MODIFIER", 865, 872], ["ulcer", "OBSERVATION", 873, 878], ["irregular", "OBSERVATION_MODIFIER", 887, 896], ["shape", "OBSERVATION_MODIFIER", 897, 902], ["appears to look", "UNCERTAINTY", 908, 923], ["continent", "OBSERVATION_MODIFIER", 931, 940], ["land", "OBSERVATION_MODIFIER", 944, 948], ["mass", "OBSERVATION", 949, 953], ["geographic", "OBSERVATION_MODIFIER", 955, 965], ["ulcer", "OBSERVATION", 966, 971], ["may be evident", "UNCERTAINTY", 973, 987], ["often associated with", "UNCERTAINTY", 996, 1017], ["superficial", "ANATOMY_MODIFIER", 1018, 1029], ["vascularization", "OBSERVATION", 1030, 1045]]], ["It is the result of an immune response to viral antigen.", [["viral antigen", "PROTEIN", 42, 55], ["viral antigen", "PROBLEM", 42, 55]]], ["There may be edema and in chronic cases scarring with calcific degeneration (calcium deposition in the anterior stroma).FHV-1 keratitis is primarily a disease of older cats.Typically there is a history of acute episodes followed by quiescent periods, but close examination will reveal a slightly cloudy, scarred cornea.DiagnosisA tentative diagnosis is usually based on the clinical signs.DiagnosisA definitive diagnosis requires specific techniques, which are available from some la oratories.", [["edema", "ANATOMY", 13, 18], ["anterior stroma", "ANATOMY", 103, 118], ["cornea", "ANATOMY", 312, 318], ["edema", "DISEASE", 13, 18], ["calcium", "CHEMICAL", 77, 84], ["keratitis", "DISEASE", 126, 135], ["calcium", "CHEMICAL", 77, 84], ["edema", "PATHOLOGICAL_FORMATION", 13, 18], ["calcium", "SIMPLE_CHEMICAL", 77, 84], ["anterior stroma", "TISSUE", 103, 118], ["cats", "ORGANISM", 168, 172], ["cornea", "TISSUE", 312, 318], ["cats", "SPECIES", 168, 172], ["FHV-1", "SPECIES", 120, 125], ["edema", "PROBLEM", 13, 18], ["chronic cases scarring", "PROBLEM", 26, 48], ["calcific degeneration", "PROBLEM", 54, 75], ["calcium deposition in the anterior stroma", "PROBLEM", 77, 118], ["FHV", "PROBLEM", 120, 123], ["keratitis", "PROBLEM", 126, 135], ["a disease of older cats", "PROBLEM", 149, 172], ["acute episodes", "PROBLEM", 205, 219], ["close examination", "TEST", 255, 272], ["a slightly cloudy, scarred cornea", "PROBLEM", 285, 318], ["the clinical signs", "TEST", 370, 388], ["specific techniques", "TEST", 430, 449], ["may be", "UNCERTAINTY", 6, 12], ["edema", "OBSERVATION", 13, 18], ["chronic", "OBSERVATION_MODIFIER", 26, 33], ["cases", "OBSERVATION_MODIFIER", 34, 39], ["scarring", "OBSERVATION", 40, 48], ["calcific", "OBSERVATION_MODIFIER", 54, 62], ["degeneration", "OBSERVATION", 63, 75], ["calcium deposition", "OBSERVATION", 77, 95], ["anterior", "ANATOMY_MODIFIER", 103, 111], ["stroma", "ANATOMY", 112, 118], ["keratitis", "OBSERVATION", 126, 135], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["episodes", "OBSERVATION", 211, 219], ["slightly", "OBSERVATION_MODIFIER", 287, 295], ["cloudy", "OBSERVATION", 296, 302], ["scarred", "OBSERVATION", 304, 311], ["cornea", "ANATOMY", 312, 318]]], ["PCR is the most useful of these.Diagnosis\u2022 Cytological examination of corneal/conjunctival smears stained with immunoperoxidase may demonstrate intranuclear inclusions in epithelial cells in some acute primary infections, but is not very reliable. \u2022 Immunofluorescence using direct or indirect fluorescent antibody techniques on corneal/conjunctival smears or tissue sections may demonstrate the virus, but has poor sensitivity. \u2022 Virus isolation is the gold standard for detection, but is not often used because of logistical difficulties in getting rapid results.", [["corneal", "ANATOMY", 70, 77], ["conjunctival smears", "ANATOMY", 78, 97], ["epithelial cells", "ANATOMY", 171, 187], ["corneal", "ANATOMY", 329, 336], ["conjunctival smears", "ANATOMY", 337, 356], ["tissue sections", "ANATOMY", 360, 375], ["acute primary infections", "DISEASE", 196, 220], ["corneal", "TISSUE", 70, 77], ["immunoperoxidase", "GENE_OR_GENE_PRODUCT", 111, 127], ["epithelial cells", "CELL", 171, 187], ["corneal", "TISSUE", 329, 336], ["conjunctival smears", "MULTI-TISSUE_STRUCTURE", 337, 356], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 360, 375], ["Virus", "ORGANISM", 431, 436], ["epithelial cells", "CELL_TYPE", 171, 187], ["PCR", "TEST", 0, 3], ["Cytological examination", "TEST", 43, 66], ["corneal/conjunctival smears", "TEST", 70, 97], ["immunoperoxidase", "TEST", 111, 127], ["intranuclear inclusions", "PROBLEM", 144, 167], ["epithelial cells", "PROBLEM", 171, 187], ["some acute primary infections", "PROBLEM", 191, 220], ["Immunofluorescence", "TEST", 250, 268], ["direct or indirect fluorescent antibody techniques", "TEST", 275, 325], ["corneal/conjunctival smears", "TEST", 329, 356], ["tissue sections", "TEST", 360, 375], ["the virus", "PROBLEM", 392, 401], ["poor sensitivity", "PROBLEM", 411, 427], ["Virus isolation", "TREATMENT", 431, 446], ["logistical difficulties", "PROBLEM", 516, 539], ["most useful", "OBSERVATION_MODIFIER", 11, 22], ["corneal", "ANATOMY", 70, 77], ["conjunctival", "ANATOMY", 78, 90], ["intranuclear inclusions", "OBSERVATION", 144, 167], ["epithelial cells", "OBSERVATION", 171, 187], ["some", "OBSERVATION_MODIFIER", 191, 195], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["primary", "OBSERVATION_MODIFIER", 202, 209], ["infections", "OBSERVATION", 210, 220], ["corneal", "ANATOMY", 329, 336], ["conjunctival", "ANATOMY", 337, 349], ["virus", "OBSERVATION", 396, 401]]], ["It depends on demonstration of cytopathic effects of the virus in cell culture. \u2022 Serological techniques are not very useful because antibody titers tend to be of low magnitude after primary infection sometimes reaching only 1:64 at 60 days after infection.", [["cell culture", "ANATOMY", 66, 78], ["primary infection", "DISEASE", 183, 200], ["infection", "DISEASE", 247, 256], ["cell culture", "CELL", 66, 78], ["cytopathic effects", "PROBLEM", 31, 49], ["the virus in cell culture", "PROBLEM", 53, 78], ["Serological techniques", "TEST", 82, 104], ["antibody titers", "TEST", 133, 148], ["low magnitude", "PROBLEM", 163, 176], ["primary infection", "PROBLEM", 183, 200], ["infection", "PROBLEM", 247, 256], ["cytopathic", "OBSERVATION_MODIFIER", 31, 41], ["low magnitude", "OBSERVATION_MODIFIER", 163, 176], ["infection", "OBSERVATION", 191, 200], ["infection", "OBSERVATION", 247, 256]]], ["High titers are rarely seen after recrudescent infection. \u2022 Polymerase chain reaction (PCR) testing depends on DNA amplification of an amino acid sequence of the thymidine kinase gene, and is perhaps the most sensitive test available.", [["infection", "DISEASE", 47, 56], ["amino acid", "CHEMICAL", 135, 145], ["thymidine", "CHEMICAL", 162, 171], ["amino acid", "CHEMICAL", 135, 145], ["thymidine", "CHEMICAL", 162, 171], ["DNA", "CELLULAR_COMPONENT", 111, 114], ["amino acid", "AMINO_ACID", 135, 145], ["thymidine kinase", "GENE_OR_GENE_PRODUCT", 162, 178], ["thymidine kinase gene", "DNA", 162, 183], ["High titers", "PROBLEM", 0, 11], ["recrudescent infection", "PROBLEM", 34, 56], ["Polymerase chain reaction", "PROBLEM", 60, 85], ["PCR) testing", "TEST", 87, 99], ["DNA amplification", "TEST", 111, 128], ["an amino acid sequence", "TEST", 132, 154], ["titers", "OBSERVATION", 5, 11], ["recrudescent", "OBSERVATION_MODIFIER", 34, 46], ["infection", "OBSERVATION", 47, 56]]], ["Theoretically the test could pick up one strand of viral DNA.", [["DNA", "CELLULAR_COMPONENT", 57, 60], ["viral DNA", "DNA", 51, 60], ["the test", "TEST", 14, 22], ["viral DNA", "PROBLEM", 51, 60], ["viral DNA", "OBSERVATION", 51, 60]]], ["High sensitivity in nested PCR tests may reduce specificity by the detection of non-viral DNA contaminants.Classical signs\u2022 Area of pigmented cornea varying from a very light coffee-colored stain to an intense thick black plaque. \u2022 +/-Blepharospasm and photophobia.Clinical signsThe classic presentation is an area of pigmented cornea.", [["pigmented cornea", "ANATOMY", 132, 148], ["plaque", "ANATOMY", 222, 228], ["pigmented cornea", "ANATOMY", 318, 334], ["Blepharospasm", "DISEASE", 235, 248], ["photophobia", "DISEASE", 253, 264], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["pigmented cornea", "TISSUE", 132, 148], ["plaque", "PATHOLOGICAL_FORMATION", 222, 228], ["pigmented cornea", "TISSUE", 318, 334], ["High sensitivity", "PROBLEM", 0, 16], ["nested PCR tests", "TEST", 20, 36], ["non-viral DNA contaminants", "PROBLEM", 80, 106], ["Classical signs", "TEST", 107, 122], ["pigmented cornea", "PROBLEM", 132, 148], ["an intense thick black plaque", "PROBLEM", 199, 228], ["Blepharospasm", "PROBLEM", 235, 248], ["photophobia", "PROBLEM", 253, 264], ["Clinical signs", "TEST", 265, 279], ["pigmented cornea", "PROBLEM", 318, 334], ["Area", "OBSERVATION_MODIFIER", 124, 128], ["pigmented cornea", "OBSERVATION", 132, 148], ["varying", "OBSERVATION_MODIFIER", 149, 156], ["very", "OBSERVATION_MODIFIER", 164, 168], ["intense", "OBSERVATION_MODIFIER", 202, 209], ["thick", "OBSERVATION_MODIFIER", 210, 215], ["black", "OBSERVATION_MODIFIER", 216, 221], ["plaque", "OBSERVATION", 222, 228], ["Blepharospasm", "OBSERVATION", 235, 248], ["photophobia", "OBSERVATION", 253, 264], ["area", "OBSERVATION_MODIFIER", 310, 314], ["pigmented cornea", "OBSERVATION", 318, 334]]], ["The degree of pigmentation varies from a very light coffee-colored stain to an intense thick black plaque.Clinical signsApproximately 80% are associated with herpetic keratitis.", [["plaque", "ANATOMY", 99, 105], ["herpetic keratitis", "DISEASE", 158, 176], ["plaque", "PATHOLOGICAL_FORMATION", 99, 105], ["pigmentation", "PROBLEM", 14, 26], ["an intense thick black plaque", "PROBLEM", 76, 105], ["Clinical signsApproximately", "TEST", 106, 133], ["herpetic keratitis", "PROBLEM", 158, 176], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["pigmentation", "OBSERVATION", 14, 26], ["varies", "OBSERVATION_MODIFIER", 27, 33], ["very", "OBSERVATION_MODIFIER", 41, 45], ["intense", "OBSERVATION_MODIFIER", 79, 86], ["thick", "OBSERVATION_MODIFIER", 87, 92], ["black", "OBSERVATION_MODIFIER", 93, 98], ["plaque", "OBSERVATION", 99, 105], ["associated with", "UNCERTAINTY", 142, 157], ["herpetic keratitis", "OBSERVATION", 158, 176]]], ["There may be a history of previous infection with FHV-1 as a kitten, or later in life, with herpetic keratitis.", [["infection", "DISEASE", 35, 44], ["herpetic keratitis", "DISEASE", 92, 110], ["FHV-1", "GENE_OR_GENE_PRODUCT", 50, 55], ["FHV-1", "SPECIES", 50, 55], ["previous infection", "PROBLEM", 26, 44], ["herpetic keratitis", "PROBLEM", 92, 110], ["infection", "OBSERVATION", 35, 44], ["herpetic keratitis", "OBSERVATION", 92, 110]]], ["However, cases may develop after corneal ulceration or from medial entropion.Clinical signsThe disease is initially seen unilaterally, but eventually both eyes may become involved.Clinical signsInitially the cat may not show any signs of discomfort, but as the lesion progresses blepharospasm and photophobia develop.Clinical signsEarly, light-staining lesions have an intact epithelium and do not stain with fluorescein.", [["corneal", "ANATOMY", 33, 40], ["eyes", "ANATOMY", 155, 159], ["lesion", "ANATOMY", 261, 267], ["lesions", "ANATOMY", 353, 360], ["epithelium", "ANATOMY", 376, 386], ["entropion", "DISEASE", 67, 76], ["blepharospasm", "DISEASE", 279, 292], ["photophobia", "DISEASE", 297, 308], ["fluorescein", "CHEMICAL", 409, 420], ["fluorescein", "CHEMICAL", 409, 420], ["corneal", "TISSUE", 33, 40], ["eyes", "ORGAN", 155, 159], ["cat", "ORGANISM", 208, 211], ["lesions", "PATHOLOGICAL_FORMATION", 353, 360], ["epithelium", "TISSUE", 376, 386], ["fluorescein", "SIMPLE_CHEMICAL", 409, 420], ["corneal ulceration", "PROBLEM", 33, 51], ["medial entropion", "PROBLEM", 60, 76], ["Clinical signs", "TEST", 77, 91], ["The disease", "PROBLEM", 91, 102], ["discomfort", "PROBLEM", 238, 248], ["the lesion", "PROBLEM", 257, 267], ["blepharospasm", "PROBLEM", 279, 292], ["photophobia", "PROBLEM", 297, 308], ["Clinical signsEarly", "TEST", 317, 336], ["light-staining lesions", "PROBLEM", 338, 360], ["fluorescein", "PROBLEM", 409, 420], ["corneal", "ANATOMY", 33, 40], ["ulceration", "OBSERVATION", 41, 51], ["medial", "OBSERVATION_MODIFIER", 60, 66], ["entropion", "OBSERVATION", 67, 76], ["disease", "OBSERVATION", 95, 102], ["discomfort", "OBSERVATION", 238, 248], ["lesion", "OBSERVATION", 261, 267], ["blepharospasm", "OBSERVATION", 279, 292], ["light-staining", "OBSERVATION_MODIFIER", 338, 352], ["lesions", "OBSERVATION", 353, 360], ["intact epithelium", "OBSERVATION_MODIFIER", 369, 386]]], ["Lesions that have developed a dense plaque may have a fine ring of ulceration surrounding the lesion, which may stain positive with fluorescein.Clinical signsIn mild cases, the surrounding cornea will not show signs of edema or vascularization, but as the degree of degeneration progresses, corneal edema with marked deep stromal vascularization may be prominent.Clinical signsEyes that have a faint stain usually do not have any ocular discharge.", [["plaque", "ANATOMY", 36, 42], ["lesion", "ANATOMY", 94, 100], ["cornea", "ANATOMY", 189, 195], ["edema", "ANATOMY", 219, 224], ["corneal", "ANATOMY", 291, 298], ["stromal", "ANATOMY", 322, 329], ["ocular", "ANATOMY", 430, 436], ["plaque", "DISEASE", 36, 42], ["fluorescein", "CHEMICAL", 132, 143], ["edema", "DISEASE", 219, 224], ["edema", "DISEASE", 299, 304], ["fluorescein", "CHEMICAL", 132, 143], ["plaque", "PATHOLOGICAL_FORMATION", 36, 42], ["ulceration", "PATHOLOGICAL_FORMATION", 67, 77], ["lesion", "CANCER", 94, 100], ["fluorescein", "SIMPLE_CHEMICAL", 132, 143], ["cornea", "ORGAN", 189, 195], ["edema", "PATHOLOGICAL_FORMATION", 219, 224], ["corneal edema", "PATHOLOGICAL_FORMATION", 291, 304], ["stromal", "TISSUE", 322, 329], ["Lesions", "PROBLEM", 0, 7], ["a dense plaque", "PROBLEM", 28, 42], ["ulceration", "PROBLEM", 67, 77], ["the lesion", "PROBLEM", 90, 100], ["fluorescein", "PROBLEM", 132, 143], ["Clinical signs", "TEST", 144, 158], ["edema", "PROBLEM", 219, 224], ["vascularization", "PROBLEM", 228, 243], ["degeneration", "PROBLEM", 266, 278], ["corneal edema", "PROBLEM", 291, 304], ["marked deep stromal vascularization", "PROBLEM", 310, 345], ["a faint stain", "PROBLEM", 392, 405], ["any ocular discharge", "PROBLEM", 426, 446], ["dense", "OBSERVATION_MODIFIER", 30, 35], ["plaque", "OBSERVATION", 36, 42], ["fine", "OBSERVATION_MODIFIER", 54, 58], ["ring", "OBSERVATION_MODIFIER", 59, 63], ["ulceration", "OBSERVATION", 67, 77], ["lesion", "OBSERVATION", 94, 100], ["may stain", "UNCERTAINTY", 108, 117], ["mild", "OBSERVATION_MODIFIER", 161, 165], ["cases", "OBSERVATION", 166, 171], ["cornea", "ANATOMY", 189, 195], ["edema", "OBSERVATION", 219, 224], ["vascularization", "OBSERVATION", 228, 243], ["degeneration", "OBSERVATION", 266, 278], ["corneal", "ANATOMY", 291, 298], ["edema", "OBSERVATION", 299, 304], ["marked", "OBSERVATION_MODIFIER", 310, 316], ["deep", "ANATOMY_MODIFIER", 317, 321], ["stromal vascularization", "OBSERVATION", 322, 345], ["may be", "UNCERTAINTY", 346, 352], ["prominent", "OBSERVATION_MODIFIER", 353, 362]]], ["Eyes that have a dark plaque with surrounding ulceration and intense corneal vascularization often have a mucopurulent ocular discharge.Clinical signsThe condition is seen in any breed of cat, but it occurs predominantly in brachycephalic breeds such as Persians and Himalayans.", [["plaque", "ANATOMY", 22, 28], ["corneal", "ANATOMY", 69, 76], ["ocular", "ANATOMY", 119, 125], ["plaque", "DISEASE", 22, 28], ["ulceration", "PATHOLOGICAL_FORMATION", 46, 56], ["corneal", "TISSUE", 69, 76], ["ocular", "ORGAN", 119, 125], ["cat", "ORGANISM", 188, 191], ["a dark plaque", "PROBLEM", 15, 28], ["surrounding ulceration", "PROBLEM", 34, 56], ["intense corneal vascularization", "PROBLEM", 61, 92], ["a mucopurulent ocular discharge", "PROBLEM", 104, 135], ["Clinical signs", "TEST", 136, 150], ["dark", "OBSERVATION_MODIFIER", 17, 21], ["plaque", "OBSERVATION", 22, 28], ["surrounding", "OBSERVATION_MODIFIER", 34, 45], ["ulceration", "OBSERVATION", 46, 56], ["intense", "OBSERVATION_MODIFIER", 61, 68], ["corneal vascularization", "OBSERVATION", 69, 92], ["mucopurulent", "OBSERVATION_MODIFIER", 106, 118], ["predominantly", "OBSERVATION_MODIFIER", 207, 220], ["brachycephalic breeds", "OBSERVATION", 224, 245]]], ["There is no sex or age predilection.DiagnosisA tentative diagnosis is based on the signalment and clinical signs.", [["age predilection", "PROBLEM", 19, 35], ["the signalment", "TEST", 79, 93], ["clinical signs", "TEST", 98, 112], ["no", "UNCERTAINTY", 9, 11]]], ["Typically there is a mild brown-staining cornea to a dense black plaque with keratitis.DiagnosisA definitive diagnosis is based on histopathological examination of resected cornea.", [["cornea", "ANATOMY", 41, 47], ["plaque", "ANATOMY", 65, 71], ["cornea", "ANATOMY", 173, 179], ["black plaque", "DISEASE", 59, 71], ["keratitis", "DISEASE", 77, 86], ["cornea", "TISSUE", 41, 47], ["plaque", "PATHOLOGICAL_FORMATION", 65, 71], ["cornea", "ORGAN", 173, 179], ["a mild brown-staining cornea", "PROBLEM", 19, 47], ["a dense black plaque", "PROBLEM", 51, 71], ["keratitis", "PROBLEM", 77, 86], ["histopathological examination", "TEST", 131, 160], ["resected cornea", "PROBLEM", 164, 179], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["brown", "OBSERVATION_MODIFIER", 26, 31], ["staining cornea", "OBSERVATION", 32, 47], ["dense", "OBSERVATION_MODIFIER", 53, 58], ["black", "OBSERVATION_MODIFIER", 59, 64], ["plaque", "OBSERVATION", 65, 71], ["keratitis", "OBSERVATION", 77, 86], ["resected", "OBSERVATION", 164, 172], ["cornea", "ANATOMY", 173, 179]]], ["There is a typical pattern of degenerated stroma surrounded by a ring of inflammatory cells.DiagnosisPCR tests on resected cornea may confirm the presence of FHV-1 infection.Classical signs\u2022 Irregular white to pinkish plaque on the cornea. \u2022 Corneal edema and vascularization. \u2022 +/-Similar conjunctival lesion. \u2022 Unilateral or bilateral.Classical signs\u2022 Poor response to a variety of antibacterial agents.Classical signsSee the main reference on page 1245 (The Cat With Abnormalities Confined to the Cornea).Clinical signsSigns begin unilaterally, but may become bilateral.Clinical signsSeen as a cloudy, red cornea.", [["stroma", "ANATOMY", 42, 48], ["ring", "ANATOMY", 65, 69], ["inflammatory cells", "ANATOMY", 73, 91], ["cornea", "ANATOMY", 123, 129], ["pinkish plaque", "ANATOMY", 210, 224], ["cornea", "ANATOMY", 232, 238], ["Corneal", "ANATOMY", 242, 249], ["conjunctival lesion", "ANATOMY", 290, 309], ["red cornea", "ANATOMY", 605, 615], ["infection", "DISEASE", 164, 173], ["edema", "DISEASE", 250, 255], ["stroma", "TISSUE", 42, 48], ["cells", "CELL", 86, 91], ["cornea", "ORGAN", 123, 129], ["FHV-1", "GENE_OR_GENE_PRODUCT", 158, 163], ["pinkish plaque", "PATHOLOGICAL_FORMATION", 210, 224], ["cornea", "ORGAN", 232, 238], ["Corneal", "TISSUE", 242, 249], ["conjunctival lesion", "PATHOLOGICAL_FORMATION", 290, 309], ["cornea", "TISSUE", 609, 615], ["inflammatory cells", "CELL_TYPE", 73, 91], ["FHV-1", "SPECIES", 158, 163], ["degenerated stroma", "PROBLEM", 30, 48], ["inflammatory cells", "PROBLEM", 73, 91], ["DiagnosisPCR tests", "TEST", 92, 110], ["resected cornea", "PROBLEM", 114, 129], ["FHV", "PROBLEM", 158, 161], ["1 infection", "PROBLEM", 162, 173], ["Classical signs", "TEST", 174, 189], ["Irregular white to pinkish plaque on the cornea", "PROBLEM", 191, 238], ["Corneal edema", "PROBLEM", 242, 255], ["vascularization", "PROBLEM", 260, 275], ["+/-Similar conjunctival lesion", "PROBLEM", 279, 309], ["Classical signs", "TEST", 337, 352], ["antibacterial agents", "TREATMENT", 384, 404], ["Classical signs", "TEST", 405, 420], ["a cloudy, red cornea", "PROBLEM", 595, 615], ["typical", "OBSERVATION_MODIFIER", 11, 18], ["pattern", "OBSERVATION_MODIFIER", 19, 26], ["degenerated stroma", "OBSERVATION", 30, 48], ["ring", "OBSERVATION_MODIFIER", 65, 69], ["inflammatory cells", "OBSERVATION", 73, 91], ["FHV", "OBSERVATION", 158, 161], ["infection", "OBSERVATION", 164, 173], ["Irregular", "OBSERVATION_MODIFIER", 191, 200], ["white", "OBSERVATION_MODIFIER", 201, 206], ["pinkish", "OBSERVATION_MODIFIER", 210, 217], ["plaque", "OBSERVATION", 218, 224], ["cornea", "ANATOMY", 232, 238], ["Corneal", "ANATOMY", 242, 249], ["edema", "OBSERVATION", 250, 255], ["vascularization", "OBSERVATION", 260, 275], ["conjunctival", "ANATOMY", 290, 302], ["lesion", "OBSERVATION", 303, 309], ["Unilateral", "ANATOMY_MODIFIER", 313, 323], ["bilateral", "ANATOMY_MODIFIER", 327, 336], ["Cornea", "ANATOMY", 500, 506], ["bilateral", "ANATOMY_MODIFIER", 563, 572], ["cloudy", "OBSERVATION", 597, 603], ["cornea", "ANATOMY", 609, 615]]], ["This is a proliferative lesion producing whitish to pink, plaque-like tissue that may be covered by a thick white discharge.Clinical signsThe corneal epithelium is usually intact, but may show patchy staining with fluorescein.", [["lesion", "ANATOMY", 24, 30], ["plaque", "ANATOMY", 58, 64], ["tissue", "ANATOMY", 70, 76], ["corneal epithelium", "ANATOMY", 142, 160], ["plaque", "DISEASE", 58, 64], ["fluorescein", "CHEMICAL", 214, 225], ["fluorescein", "CHEMICAL", 214, 225], ["plaque-like tissue", "TISSUE", 58, 76], ["corneal epithelium", "TISSUE", 142, 160], ["fluorescein", "SIMPLE_CHEMICAL", 214, 225], ["a proliferative lesion", "PROBLEM", 8, 30], ["whitish to pink, plaque-like tissue", "PROBLEM", 41, 76], ["a thick white discharge", "PROBLEM", 100, 123], ["Clinical signs", "TEST", 124, 138], ["patchy staining with fluorescein", "PROBLEM", 193, 225], ["proliferative", "OBSERVATION_MODIFIER", 10, 23], ["lesion", "OBSERVATION", 24, 30], ["whitish", "OBSERVATION_MODIFIER", 41, 48], ["pink", "OBSERVATION_MODIFIER", 52, 56], ["plaque", "OBSERVATION", 58, 64], ["like tissue", "OBSERVATION_MODIFIER", 65, 76], ["may be", "UNCERTAINTY", 82, 88], ["corneal", "ANATOMY", 142, 149], ["epithelium", "ANATOMY_MODIFIER", 150, 160], ["intact", "OBSERVATION", 172, 178], ["patchy", "OBSERVATION_MODIFIER", 193, 199], ["staining", "OBSERVATION", 200, 208]]], ["There is usually an intense neovascularization (superficial and deep) in chronic cases.", [["superficial", "ANATOMY", 48, 59], ["neovascularization", "DISEASE", 28, 46], ["an intense neovascularization (superficial and deep) in chronic cases", "PROBLEM", 17, 86], ["intense", "OBSERVATION_MODIFIER", 20, 27], ["neovascularization", "OBSERVATION", 28, 46], ["superficial", "OBSERVATION_MODIFIER", 48, 59], ["deep", "ANATOMY_MODIFIER", 64, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["cases", "OBSERVATION", 81, 86]]], ["There are varying degrees of edema, usually involving the entire cornea.Clinical signsThe conjunctiva is usually involved secondary to the cornea, and may present with a similar white, proliferative plaque and mucopurulent ocular discharge.Clinical signsThe third eyelid may also show proliferative lesions.Clinical signsThere is often a history of a poor response to a variety of antibacterial agents.DiagnosisA tentative diagnosis is based on the history of an edematous, vascularized cornea that will not respond to antibiotic therapy.DiagnosisClean the eye with saline or eye wash and take a scraping of the lesion using a scalpel blade, spatula or cytology brush.", [["edema", "ANATOMY", 29, 34], ["cornea", "ANATOMY", 65, 71], ["conjunctiva", "ANATOMY", 90, 101], ["cornea", "ANATOMY", 139, 145], ["plaque", "ANATOMY", 199, 205], ["ocular", "ANATOMY", 223, 229], ["eyelid", "ANATOMY", 264, 270], ["proliferative lesions", "ANATOMY", 285, 306], ["cornea", "ANATOMY", 487, 493], ["eye", "ANATOMY", 557, 560], ["eye", "ANATOMY", 576, 579], ["lesion", "ANATOMY", 612, 618], ["brush", "ANATOMY", 662, 667], ["edema", "DISEASE", 29, 34], ["plaque", "DISEASE", 199, 205], ["edema", "PATHOLOGICAL_FORMATION", 29, 34], ["cornea", "ORGAN", 65, 71], ["conjunctiva", "ORGAN", 90, 101], ["cornea", "ORGAN", 139, 145], ["ocular", "ORGAN", 223, 229], ["eyelid", "ORGAN", 264, 270], ["proliferative lesions", "CANCER", 285, 306], ["cornea", "ORGAN", 487, 493], ["eye", "ORGAN", 557, 560], ["saline", "SIMPLE_CHEMICAL", 566, 572], ["eye", "ORGAN", 576, 579], ["edema", "PROBLEM", 29, 34], ["Clinical signs", "TEST", 72, 86], ["a similar white, proliferative plaque", "PROBLEM", 168, 205], ["mucopurulent ocular discharge", "PROBLEM", 210, 239], ["Clinical signs", "TEST", 240, 254], ["proliferative lesions", "PROBLEM", 285, 306], ["Clinical signs", "TEST", 307, 321], ["antibacterial agents", "TREATMENT", 381, 401], ["an edematous, vascularized cornea", "PROBLEM", 460, 493], ["antibiotic therapy", "TREATMENT", 519, 537], ["saline", "TREATMENT", 566, 572], ["eye wash", "TREATMENT", 576, 584], ["a scraping", "TREATMENT", 594, 604], ["the lesion", "PROBLEM", 608, 618], ["a scalpel blade", "TREATMENT", 625, 640], ["cytology brush", "TEST", 653, 667], ["varying", "OBSERVATION_MODIFIER", 10, 17], ["degrees", "OBSERVATION_MODIFIER", 18, 25], ["edema", "OBSERVATION", 29, 34], ["entire", "ANATOMY_MODIFIER", 58, 64], ["cornea", "ANATOMY", 65, 71], ["conjunctiva", "ANATOMY", 90, 101], ["cornea", "ANATOMY", 139, 145], ["similar", "OBSERVATION_MODIFIER", 170, 177], ["white", "OBSERVATION_MODIFIER", 178, 183], ["proliferative", "OBSERVATION_MODIFIER", 185, 198], ["plaque", "OBSERVATION", 199, 205], ["mucopurulent", "OBSERVATION_MODIFIER", 210, 222], ["ocular discharge", "OBSERVATION", 223, 239], ["third eyelid", "ANATOMY", 258, 270], ["may also show", "UNCERTAINTY", 271, 284], ["proliferative", "OBSERVATION_MODIFIER", 285, 298], ["lesions", "OBSERVATION", 299, 306], ["edematous", "OBSERVATION", 463, 472], ["vascularized cornea", "OBSERVATION", 474, 493], ["eye", "ANATOMY", 557, 560], ["eye", "ANATOMY", 576, 579], ["lesion", "OBSERVATION", 612, 618], ["scalpel", "ANATOMY", 627, 634]]], ["Gently spread the tissue onto a glass microscope slide and stain with a Wright or Romanofski stain.", [["tissue", "ANATOMY", 18, 24], ["tissue", "TISSUE", 18, 24], ["a glass microscope slide", "TEST", 30, 54], ["a Wright or Romanofski stain", "TEST", 70, 98]]], ["The presence of eosinophils is diagnostic.", [["eosinophils", "ANATOMY", 16, 27], ["eosinophils", "CELL", 16, 27], ["eosinophils", "CELL_TYPE", 16, 27], ["eosinophils", "PROBLEM", 16, 27], ["eosinophils", "OBSERVATION", 16, 27]]], ["If conjunctival lesions are present, preferably take a sample from the conjunctiva.DiagnosisSmall conjunctival biopsies can be submitted in formalin for histopatholgy.", [["conjunctival lesions", "ANATOMY", 3, 23], ["sample", "ANATOMY", 55, 61], ["conjunctiva", "ANATOMY", 71, 82], ["conjunctival biopsies", "ANATOMY", 98, 119], ["formalin", "CHEMICAL", 140, 148], ["conjunctival lesions", "PATHOLOGICAL_FORMATION", 3, 23], ["conjunctiva", "ORGAN", 71, 82], ["conjunctival biopsies", "TISSUE", 98, 119], ["conjunctival lesions", "PROBLEM", 3, 23], ["Small conjunctival biopsies", "TEST", 92, 119], ["histopatholgy", "PROBLEM", 153, 166], ["conjunctival", "ANATOMY", 3, 15], ["lesions", "OBSERVATION", 16, 23], ["conjunctiva", "ANATOMY", 71, 82], ["Small", "OBSERVATION_MODIFIER", 92, 97], ["conjunctival biopsies", "OBSERVATION", 98, 119]]], ["The presence of eosinophils is diagnostic.DiagnosisHematology may reveal a peripheral eosinophilia.TreatmentThe condition will rapidly respond to systemic corticosteroids dosed at 1 mg/kg daily.TreatmentIf the tips of the ears show alopecia, pruritis and crusting, the condition may be caused by biting insects.", [["eosinophils", "ANATOMY", 16, 27], ["ears", "ANATOMY", 222, 226], ["peripheral eosinophilia", "DISEASE", 75, 98], ["alopecia", "DISEASE", 232, 240], ["pruritis", "DISEASE", 242, 250], ["crusting", "DISEASE", 255, 263], ["eosinophils", "CELL", 16, 27], ["ears", "ORGAN", 222, 226], ["eosinophils", "CELL_TYPE", 16, 27], ["eosinophils", "PROBLEM", 16, 27], ["a peripheral eosinophilia", "PROBLEM", 73, 98], ["Treatment", "TREATMENT", 99, 108], ["systemic corticosteroids", "TREATMENT", 146, 170], ["Treatment", "TREATMENT", 194, 203], ["alopecia", "PROBLEM", 232, 240], ["pruritis", "PROBLEM", 242, 250], ["crusting", "PROBLEM", 255, 263], ["the condition", "PROBLEM", 265, 278], ["biting insects", "PROBLEM", 296, 310], ["eosinophils", "OBSERVATION", 16, 27], ["peripheral", "ANATOMY_MODIFIER", 75, 85], ["eosinophilia", "OBSERVATION", 86, 98], ["ears", "ANATOMY", 222, 226], ["alopecia", "OBSERVATION", 232, 240], ["pruritis", "OBSERVATION", 242, 250]]], ["In such cases the cats must be housed in conditions that are insect free.Clinical signsThere may be evidence of the underlying cause.", [["cats", "ORGANISM", 18, 22], ["cats", "SPECIES", 18, 22], ["Clinical signs", "TEST", 73, 87], ["the underlying cause", "PROBLEM", 112, 132], ["may be evidence of", "UNCERTAINTY", 93, 111]]], ["Most ulcers that are not associated with a specific corneal disease are caused by corneal trauma.", [["ulcers", "ANATOMY", 5, 11], ["corneal", "ANATOMY", 52, 59], ["corneal", "ANATOMY", 82, 89], ["ulcers", "DISEASE", 5, 11], ["corneal disease", "DISEASE", 52, 67], ["corneal trauma", "DISEASE", 82, 96], ["ulcers", "PATHOLOGICAL_FORMATION", 5, 11], ["corneal", "TISSUE", 52, 59], ["corneal", "TISSUE", 82, 89], ["Most ulcers", "PROBLEM", 0, 11], ["a specific corneal disease", "PROBLEM", 41, 67], ["corneal trauma", "PROBLEM", 82, 96], ["ulcers", "OBSERVATION", 5, 11], ["not associated with", "UNCERTAINTY", 21, 40], ["corneal", "ANATOMY", 52, 59], ["disease", "OBSERVATION", 60, 67], ["corneal trauma", "OBSERVATION", 82, 96]]], ["Foreign bodies such as grass seeds and thorns, or blunt trauma from motor vehicle accidents are the most common causes of corneal trauma.", [["bodies", "ANATOMY", 8, 14], ["seeds", "ANATOMY", 29, 34], ["thorns", "ANATOMY", 39, 45], ["corneal", "ANATOMY", 122, 129], ["blunt trauma", "DISEASE", 50, 62], ["motor vehicle accidents", "DISEASE", 68, 91], ["corneal trauma", "DISEASE", 122, 136], ["thorns", "ORGANISM_SUBDIVISION", 39, 45], ["corneal", "TISSUE", 122, 129], ["Foreign bodies", "PROBLEM", 0, 14], ["grass seeds and thorns", "PROBLEM", 23, 45], ["blunt trauma", "PROBLEM", 50, 62], ["corneal trauma", "PROBLEM", 122, 136], ["grass seeds", "OBSERVATION", 23, 34], ["blunt", "OBSERVATION_MODIFIER", 50, 55], ["most common", "OBSERVATION_MODIFIER", 100, 111], ["corneal", "ANATOMY", 122, 129], ["trauma", "OBSERVATION", 130, 136]]], ["Trauma may cause a superficial ulcer, a deep ulcer or penetrating wound.Clinical signsEyes with ulceration are invariably very painful.", [["superficial ulcer", "ANATOMY", 19, 36], ["ulcer", "ANATOMY", 45, 50], ["wound", "ANATOMY", 66, 71], ["Trauma", "DISEASE", 0, 6], ["ulcer", "DISEASE", 31, 36], ["ulcer", "DISEASE", 45, 50], ["ulceration", "DISEASE", 96, 106], ["superficial ulcer", "PATHOLOGICAL_FORMATION", 19, 36], ["ulcer", "PATHOLOGICAL_FORMATION", 45, 50], ["wound", "PATHOLOGICAL_FORMATION", 66, 71], ["Trauma", "PROBLEM", 0, 6], ["a superficial ulcer", "PROBLEM", 17, 36], ["a deep ulcer", "PROBLEM", 38, 50], ["penetrating wound", "PROBLEM", 54, 71], ["ulceration", "PROBLEM", 96, 106], ["very painful", "PROBLEM", 122, 134], ["may cause", "UNCERTAINTY", 7, 16], ["superficial", "OBSERVATION_MODIFIER", 19, 30], ["ulcer", "OBSERVATION", 31, 36], ["deep", "OBSERVATION_MODIFIER", 40, 44], ["ulcer", "OBSERVATION", 45, 50], ["penetrating", "OBSERVATION_MODIFIER", 54, 65], ["wound", "OBSERVATION", 66, 71], ["ulceration", "OBSERVATION", 96, 106]]], ["Cats show serous ocular discharge, blepharospasm, photophobia and ocular guarding in severe injuries.Clinical signsUlcers stain positive with fluorescein dye.", [["serous ocular", "ANATOMY", 10, 23], ["ocular", "ANATOMY", 66, 72], ["serous ocular discharge", "DISEASE", 10, 33], ["blepharospasm", "DISEASE", 35, 48], ["photophobia", "DISEASE", 50, 61], ["ocular guarding", "DISEASE", 66, 81], ["injuries", "DISEASE", 92, 100], ["fluorescein dye", "CHEMICAL", 142, 157], ["fluorescein", "CHEMICAL", 142, 153], ["fluorescein dye", "SIMPLE_CHEMICAL", 142, 157], ["serous ocular discharge", "PROBLEM", 10, 33], ["blepharospasm", "PROBLEM", 35, 48], ["photophobia", "PROBLEM", 50, 61], ["ocular guarding", "PROBLEM", 66, 81], ["severe injuries", "PROBLEM", 85, 100], ["Clinical signsUlcers stain", "TEST", 101, 127], ["fluorescein dye", "TREATMENT", 142, 157], ["serous", "OBSERVATION_MODIFIER", 10, 16], ["ocular discharge", "OBSERVATION", 17, 33], ["blepharospasm", "OBSERVATION", 35, 48], ["ocular", "ANATOMY", 66, 72], ["guarding", "OBSERVATION", 73, 81], ["severe", "OBSERVATION_MODIFIER", 85, 91], ["injuries", "OBSERVATION", 92, 100]]], ["A very deep ulcer that has formed a Descemetocele may not show any staining because Descemet's membrane will not stain with fluorescein.Clinical signsExamination of the cornea with magnification will show a deficit in the corneal surface because of loss of epithelium and stroma.Clinical signsCorneal edema will be present in cases that have loss of epithelium, because fluid will be absorbed by the stromal matrix.", [["deep ulcer", "ANATOMY", 7, 17], ["Descemet's membrane", "ANATOMY", 84, 103], ["cornea", "ANATOMY", 169, 175], ["corneal surface", "ANATOMY", 222, 237], ["epithelium", "ANATOMY", 257, 267], ["stroma", "ANATOMY", 272, 278], ["Corneal edema", "ANATOMY", 293, 306], ["epithelium", "ANATOMY", 350, 360], ["fluid", "ANATOMY", 370, 375], ["stromal matrix", "ANATOMY", 400, 414], ["ulcer", "DISEASE", 12, 17], ["fluorescein", "CHEMICAL", 124, 135], ["Corneal edema", "DISEASE", 293, 306], ["fluorescein", "CHEMICAL", 124, 135], ["ulcer", "PATHOLOGICAL_FORMATION", 12, 17], ["membrane", "CELLULAR_COMPONENT", 95, 103], ["fluorescein", "SIMPLE_CHEMICAL", 124, 135], ["cornea", "ORGAN", 169, 175], ["corneal surface", "TISSUE", 222, 237], ["epithelium", "TISSUE", 257, 267], ["stroma", "TISSUE", 272, 278], ["epithelium", "TISSUE", 350, 360], ["fluid", "ORGANISM_SUBSTANCE", 370, 375], ["stromal matrix", "CELLULAR_COMPONENT", 400, 414], ["A very deep ulcer", "PROBLEM", 0, 17], ["any staining", "PROBLEM", 63, 75], ["Descemet's membrane", "TREATMENT", 84, 103], ["fluorescein", "PROBLEM", 124, 135], ["Clinical signs", "TEST", 136, 150], ["Examination of the cornea with magnification", "TEST", 150, 194], ["a deficit in the corneal surface", "PROBLEM", 205, 237], ["loss of epithelium and stroma", "PROBLEM", 249, 278], ["Corneal edema", "PROBLEM", 293, 306], ["loss of epithelium", "PROBLEM", 342, 360], ["fluid", "PROBLEM", 370, 375], ["very", "OBSERVATION_MODIFIER", 2, 6], ["deep", "OBSERVATION_MODIFIER", 7, 11], ["ulcer", "OBSERVATION", 12, 17], ["may not show", "UNCERTAINTY", 50, 62], ["cornea", "ANATOMY", 169, 175], ["deficit", "OBSERVATION", 207, 214], ["corneal", "ANATOMY", 222, 229], ["loss", "OBSERVATION", 249, 253], ["epithelium", "ANATOMY_MODIFIER", 257, 267], ["Corneal", "ANATOMY", 293, 300], ["edema", "OBSERVATION", 301, 306], ["stromal matrix", "OBSERVATION", 400, 414]]], ["This will show as a cloudy cornea.", [["cornea", "ANATOMY", 27, 33], ["cornea", "TISSUE", 27, 33], ["a cloudy cornea", "PROBLEM", 18, 33], ["cloudy cornea", "OBSERVATION", 20, 33]]], ["Edema may be focal around the ulcer, or diffuse when large ulcers are present.Clinical signsPenetrating injuries are common after cat fights.", [["Edema", "ANATOMY", 0, 5], ["ulcer", "ANATOMY", 30, 35], ["ulcers", "ANATOMY", 59, 65], ["Edema", "DISEASE", 0, 5], ["ulcer", "DISEASE", 30, 35], ["ulcers", "DISEASE", 59, 65], ["Penetrating injuries", "DISEASE", 92, 112], ["ulcer", "PATHOLOGICAL_FORMATION", 30, 35], ["ulcers", "PATHOLOGICAL_FORMATION", 59, 65], ["cat", "ORGANISM", 130, 133], ["Edema", "PROBLEM", 0, 5], ["the ulcer", "PROBLEM", 26, 35], ["diffuse when large ulcers", "PROBLEM", 40, 65], ["Clinical signsPenetrating injuries", "PROBLEM", 78, 112], ["may be", "UNCERTAINTY", 6, 12], ["focal", "OBSERVATION_MODIFIER", 13, 18], ["ulcer", "OBSERVATION", 30, 35], ["diffuse", "OBSERVATION_MODIFIER", 40, 47], ["large", "OBSERVATION_MODIFIER", 53, 58], ["ulcers", "OBSERVATION", 59, 65], ["Penetrating", "OBSERVATION_MODIFIER", 92, 103], ["injuries", "OBSERVATION", 104, 112]]], ["They present with a perforation of the cornea surrounded by a dense area of edema and swelling.", [["cornea", "ANATOMY", 39, 45], ["area", "ANATOMY", 68, 72], ["edema", "ANATOMY", 76, 81], ["perforation of the cornea", "DISEASE", 20, 45], ["edema", "DISEASE", 76, 81], ["swelling", "DISEASE", 86, 94], ["cornea", "TISSUE", 39, 45], ["edema", "PATHOLOGICAL_FORMATION", 76, 81], ["a perforation of the cornea", "PROBLEM", 18, 45], ["a dense area of edema", "PROBLEM", 60, 81], ["swelling", "PROBLEM", 86, 94], ["perforation", "OBSERVATION", 20, 31], ["cornea", "ANATOMY", 39, 45], ["dense", "OBSERVATION_MODIFIER", 62, 67], ["area", "OBSERVATION_MODIFIER", 68, 72], ["edema", "OBSERVATION", 76, 81], ["swelling", "OBSERVATION", 86, 94]]], ["A fibrin plug may be present in the corneal wound.", [["corneal wound", "ANATOMY", 36, 49], ["fibrin", "GENE_OR_GENE_PRODUCT", 2, 8], ["corneal wound", "PATHOLOGICAL_FORMATION", 36, 49], ["A fibrin plug", "PROBLEM", 0, 13], ["the corneal wound", "PROBLEM", 32, 49], ["fibrin plug", "OBSERVATION", 2, 13], ["may be present", "UNCERTAINTY", 14, 28], ["corneal", "ANATOMY", 36, 43], ["wound", "OBSERVATION", 44, 49]]], ["If the iris has prolapsed into the wound, the center of the perforation will be dark brown or black in color.", [["iris", "ANATOMY", 7, 11], ["wound", "ANATOMY", 35, 40], ["perforation", "DISEASE", 60, 71], ["iris", "ORGAN", 7, 11], ["wound", "PATHOLOGICAL_FORMATION", 35, 40], ["the iris", "PROBLEM", 3, 11], ["prolapsed into the wound", "PROBLEM", 16, 40], ["the perforation", "PROBLEM", 56, 71], ["dark brown or black in color", "PROBLEM", 80, 108], ["iris", "ANATOMY", 7, 11], ["prolapsed", "OBSERVATION", 16, 25], ["wound", "OBSERVATION", 35, 40], ["perforation", "OBSERVATION", 60, 71], ["black", "OBSERVATION_MODIFIER", 94, 99]]], ["The anterior chamber may be collapsed and contain blood (hyphema) and fibrin.Clinical signsPerforating injuries that are not sealed by fibrin and/or iris, will leak aqueous so the cat will have a very wet eye and face.DiagnosisThere may be a history of trauma or a cat fight.", [["anterior chamber", "ANATOMY", 4, 20], ["blood", "ANATOMY", 50, 55], ["iris", "ANATOMY", 149, 153], ["eye", "ANATOMY", 205, 208], ["hyphema", "DISEASE", 57, 64], ["Perforating injuries", "DISEASE", 91, 111], ["trauma", "DISEASE", 253, 259], ["blood", "ORGANISM_SUBSTANCE", 50, 55], ["fibrin", "GENE_OR_GENE_PRODUCT", 70, 76], ["fibrin", "GENE_OR_GENE_PRODUCT", 135, 141], ["iris", "TISSUE", 149, 153], ["cat", "ORGANISM", 180, 183], ["eye", "ORGAN", 205, 208], ["cat", "ORGANISM", 265, 268], ["fibrin", "PROTEIN", 70, 76], ["fibrin", "PROTEIN", 135, 141], ["blood (hyphema)", "PROBLEM", 50, 65], ["fibrin", "PROBLEM", 70, 76], ["Clinical signsPerforating injuries", "PROBLEM", 77, 111], ["fibrin and/or iris", "PROBLEM", 135, 153], ["leak aqueous", "PROBLEM", 160, 172], ["a very wet eye and face", "PROBLEM", 194, 217], ["trauma", "PROBLEM", 253, 259], ["anterior", "ANATOMY_MODIFIER", 4, 12], ["chamber", "ANATOMY_MODIFIER", 13, 20], ["may be", "UNCERTAINTY", 21, 27], ["collapsed", "OBSERVATION", 28, 37], ["blood", "OBSERVATION_MODIFIER", 50, 55], ["hyphema", "OBSERVATION", 57, 64], ["fibrin", "OBSERVATION_MODIFIER", 70, 76], ["Perforating", "OBSERVATION_MODIFIER", 91, 102], ["injuries", "OBSERVATION", 103, 111], ["fibrin", "OBSERVATION", 135, 141], ["iris", "ANATOMY", 149, 153], ["face", "ANATOMY", 213, 217], ["may be", "UNCERTAINTY", 233, 239]]], ["The diagnosis of ulcerative keratitis is based on clinical signs of a painful eye showing a stromal deficit.DiagnosisThe ulcer will stain with fluorescein except in the case of a Descemetocele.", [["eye", "ANATOMY", 78, 81], ["stromal", "ANATOMY", 92, 99], ["ulcer", "ANATOMY", 121, 126], ["ulcerative keratitis", "DISEASE", 17, 37], ["stromal deficit", "DISEASE", 92, 107], ["ulcer", "DISEASE", 121, 126], ["fluorescein", "CHEMICAL", 143, 154], ["Descemetocele", "DISEASE", 179, 192], ["fluorescein", "CHEMICAL", 143, 154], ["eye", "ORGAN", 78, 81], ["stromal", "TISSUE", 92, 99], ["ulcer", "PATHOLOGICAL_FORMATION", 121, 126], ["fluorescein", "SIMPLE_CHEMICAL", 143, 154], ["ulcerative keratitis", "PROBLEM", 17, 37], ["a painful eye", "PROBLEM", 68, 81], ["a stromal deficit", "PROBLEM", 90, 107], ["The ulcer", "PROBLEM", 117, 126], ["fluorescein", "TREATMENT", 143, 154], ["a Descemetocele", "PROBLEM", 177, 192], ["ulcerative", "OBSERVATION_MODIFIER", 17, 27], ["keratitis", "OBSERVATION", 28, 37], ["stromal deficit", "OBSERVATION", 92, 107], ["ulcer", "OBSERVATION", 121, 126], ["Descemetocele", "OBSERVATION", 179, 192]]], ["If the center of the ulcer is dark, and the area bulges, there may be a Descemetocele.", [["ulcer", "ANATOMY", 21, 26], ["ulcer", "DISEASE", 21, 26], ["ulcer", "PATHOLOGICAL_FORMATION", 21, 26], ["the ulcer", "PROBLEM", 17, 26], ["dark", "PROBLEM", 30, 34], ["the area bulges", "PROBLEM", 40, 55], ["a Descemetocele", "PROBLEM", 70, 85], ["center", "OBSERVATION_MODIFIER", 7, 13], ["ulcer", "OBSERVATION", 21, 26], ["dark", "OBSERVATION_MODIFIER", 30, 34], ["area", "OBSERVATION_MODIFIER", 44, 48], ["bulges", "OBSERVATION", 49, 55], ["may be", "UNCERTAINTY", 63, 69], ["Descemetocele", "OBSERVATION", 72, 85]]], ["Descemet's membrane is very elastic in cats and can bulge forward quite noticeably.DiagnosisPerforating injuries are very painful and show changes in the anterior chamber such as hyphema and protein leakage with fibrin.TreatmentAs a general rule, eliminate the cause of the ulcer and provide protection for the cornea using lubrication, appropriate antibiotics where necessary and surgical techniques to close and protect the eye.TreatmentSuperficial epithelial erosions heal rapidly with minimal treatment.", [["Descemet's membrane", "ANATOMY", 0, 19], ["anterior chamber", "ANATOMY", 154, 170], ["ulcer", "ANATOMY", 274, 279], ["cornea", "ANATOMY", 311, 317], ["eye", "ANATOMY", 426, 429], ["epithelial", "ANATOMY", 451, 461], ["injuries", "DISEASE", 104, 112], ["hyphema", "DISEASE", 179, 186], ["ulcer", "DISEASE", 274, 279], ["Descemet's membrane", "CELLULAR_COMPONENT", 0, 19], ["cats", "ORGANISM", 39, 43], ["fibrin", "GENE_OR_GENE_PRODUCT", 212, 218], ["ulcer", "PATHOLOGICAL_FORMATION", 274, 279], ["cornea", "TISSUE", 311, 317], ["eye", "ORGAN", 426, 429], ["epithelial", "TISSUE", 451, 461], ["fibrin", "PROTEIN", 212, 218], ["cats", "SPECIES", 39, 43], ["Descemet's membrane", "TREATMENT", 0, 19], ["DiagnosisPerforating injuries", "PROBLEM", 83, 112], ["very painful", "PROBLEM", 117, 129], ["changes in the anterior chamber", "PROBLEM", 139, 170], ["hyphema", "PROBLEM", 179, 186], ["protein leakage", "PROBLEM", 191, 206], ["fibrin", "PROBLEM", 212, 218], ["Treatment", "TREATMENT", 219, 228], ["the ulcer", "PROBLEM", 270, 279], ["the cornea using lubrication", "TREATMENT", 307, 335], ["appropriate antibiotics", "TREATMENT", 337, 360], ["surgical techniques", "TREATMENT", 381, 400], ["TreatmentSuperficial epithelial erosions heal", "PROBLEM", 430, 475], ["minimal treatment", "TREATMENT", 489, 506], ["very", "OBSERVATION_MODIFIER", 23, 27], ["elastic", "OBSERVATION", 28, 35], ["injuries", "OBSERVATION", 104, 112], ["anterior", "ANATOMY_MODIFIER", 154, 162], ["chamber", "ANATOMY_MODIFIER", 163, 170], ["hyphema", "OBSERVATION", 179, 186], ["protein leakage", "OBSERVATION", 191, 206], ["fibrin", "OBSERVATION", 212, 218], ["ulcer", "OBSERVATION", 274, 279], ["cornea", "ANATOMY", 311, 317], ["eye", "ANATOMY", 426, 429], ["epithelial", "ANATOMY_MODIFIER", 451, 461], ["erosions", "OBSERVATION", 462, 470], ["heal", "OBSERVATION_MODIFIER", 471, 475], ["rapidly", "OBSERVATION_MODIFIER", 476, 483], ["minimal", "OBSERVATION_MODIFIER", 489, 496], ["treatment", "OBSERVATION", 497, 506]]], ["The use of antibiotics is not encouraged as they are rarely infected.", [["antibiotics", "TREATMENT", 11, 22], ["infected", "OBSERVATION", 60, 68]]], ["Support with artificial tear solutions will make the eye more comfortable.TreatmentCorneas with deep ulcers that have stromal loss need to be protected with surgical techniques such as third eyelid flaps or temporary tarsorrhaphies (see references for texts that show details of these surgical techniques).Treatment\u2022 Antibiotics are often used topically to prevent secondary infection.", [["eye", "ANATOMY", 53, 56], ["deep ulcers", "ANATOMY", 96, 107], ["stromal", "ANATOMY", 118, 125], ["eyelid", "ANATOMY", 191, 197], ["ulcers", "DISEASE", 101, 107], ["stromal loss", "DISEASE", 118, 130], ["tarsorrhaphies", "DISEASE", 217, 231], ["infection", "DISEASE", 375, 384], ["eye", "ORGAN", 53, 56], ["ulcers", "PATHOLOGICAL_FORMATION", 101, 107], ["artificial tear solutions", "TREATMENT", 13, 38], ["deep ulcers", "PROBLEM", 96, 107], ["stromal loss", "PROBLEM", 118, 130], ["surgical techniques", "TREATMENT", 157, 176], ["third eyelid flaps", "TREATMENT", 185, 203], ["temporary tarsorrhaphies", "TREATMENT", 207, 231], ["these surgical techniques", "TREATMENT", 279, 304], ["Treatment", "TREATMENT", 306, 315], ["Antibiotics", "TREATMENT", 317, 328], ["secondary infection", "PROBLEM", 365, 384], ["eye", "ANATOMY", 53, 56], ["deep", "ANATOMY_MODIFIER", 96, 100], ["ulcers", "OBSERVATION", 101, 107], ["stromal loss", "OBSERVATION", 118, 130], ["secondary", "OBSERVATION_MODIFIER", 365, 374], ["infection", "OBSERVATION", 375, 384]]], ["If the ulcer is infected, then appropriate antibiotics should be used after culture of a swab taken from the edge of the ulcer. \u2022 Artificial tear solutions will lubricate the eye and make the cat feel more comfortable. \u2022 Atropine ophthalmic drops (most commonly 1%) are used to dilate the pupil and to prevent ciliary muscle spasm.", [["ulcer", "ANATOMY", 7, 12], ["swab", "ANATOMY", 89, 93], ["ulcer", "ANATOMY", 121, 126], ["eye", "ANATOMY", 175, 178], ["pupil", "ANATOMY", 289, 294], ["ciliary muscle", "ANATOMY", 310, 324], ["ulcer", "DISEASE", 7, 12], ["ulcer", "DISEASE", 121, 126], ["Atropine", "CHEMICAL", 221, 229], ["muscle spasm", "DISEASE", 318, 330], ["Atropine", "CHEMICAL", 221, 229], ["ulcer", "PATHOLOGICAL_FORMATION", 7, 12], ["ulcer", "PATHOLOGICAL_FORMATION", 121, 126], ["eye", "ORGAN", 175, 178], ["cat", "ORGANISM", 192, 195], ["Atropine", "SIMPLE_CHEMICAL", 221, 229], ["pupil", "MULTI-TISSUE_STRUCTURE", 289, 294], ["ciliary muscle", "MULTI-TISSUE_STRUCTURE", 310, 324], ["the ulcer", "PROBLEM", 3, 12], ["infected", "PROBLEM", 16, 24], ["appropriate antibiotics", "TREATMENT", 31, 54], ["culture", "TEST", 76, 83], ["a swab", "TEST", 87, 93], ["the ulcer", "PROBLEM", 117, 126], ["Artificial tear solutions", "TREATMENT", 130, 155], ["Atropine ophthalmic drops", "TREATMENT", 221, 246], ["ciliary muscle spasm", "PROBLEM", 310, 330], ["ulcer", "OBSERVATION", 7, 12], ["infected", "OBSERVATION", 16, 24], ["ulcer", "OBSERVATION", 121, 126], ["Artificial tear", "OBSERVATION", 130, 145], ["eye", "ANATOMY", 175, 178], ["pupil", "ANATOMY", 289, 294], ["ciliary muscle", "ANATOMY", 310, 324], ["spasm", "OBSERVATION", 325, 330]]], ["They should be used two to three times daily until the pupil is dilated, and daily thereafter (NOTE: atropine drops are very bitter and often make cats salivate profusely).", [["pupil", "ANATOMY", 55, 60], ["atropine", "CHEMICAL", 101, 109], ["atropine", "CHEMICAL", 101, 109], ["pupil", "ORGAN", 55, 60], ["atropine", "SIMPLE_CHEMICAL", 101, 109], ["cats", "SPECIES", 147, 151], ["dilated", "PROBLEM", 64, 71], ["atropine drops", "TREATMENT", 101, 115], ["dilated", "OBSERVATION", 64, 71]]], ["For this reason 1% atropine ointment is often used, as the drug does not run down the tear duct as fast.TreatmentWhere a Pseudomonas infection is suspected or confirmed by laboratory analysis, the cat must be treated vigorously with aminoglycoside (commonly gentomycin or tobramycin in gentomycin-resistant cases) or fluoroquinalone (some generations such as flucloxacillin are effective) antibiotics topically every 15 minutes to 1 hour until the infection is controlled.", [["tear duct", "ANATOMY", 86, 95], ["atropine", "CHEMICAL", 19, 27], ["Pseudomonas infection", "DISEASE", 121, 142], ["aminoglycoside", "CHEMICAL", 233, 247], ["gentomycin", "CHEMICAL", 258, 268], ["tobramycin", "CHEMICAL", 272, 282], ["gentomycin", "CHEMICAL", 286, 296], ["fluoroquinalone", "CHEMICAL", 317, 332], ["flucloxacillin", "CHEMICAL", 359, 373], ["infection", "DISEASE", 448, 457], ["atropine", "CHEMICAL", 19, 27], ["aminoglycoside", "CHEMICAL", 233, 247], ["gentomycin", "CHEMICAL", 258, 268], ["tobramycin", "CHEMICAL", 272, 282], ["gentomycin", "CHEMICAL", 286, 296], ["fluoroquinalone", "CHEMICAL", 317, 332], ["flucloxacillin", "CHEMICAL", 359, 373], ["atropine", "SIMPLE_CHEMICAL", 19, 27], ["tear duct", "MULTI-TISSUE_STRUCTURE", 86, 95], ["cat", "ORGANISM", 197, 200], ["aminoglycoside", "SIMPLE_CHEMICAL", 233, 247], ["gentomycin", "SIMPLE_CHEMICAL", 258, 268], ["tobramycin", "SIMPLE_CHEMICAL", 272, 282], ["gentomycin", "SIMPLE_CHEMICAL", 286, 296], ["fluoroquinalone", "SIMPLE_CHEMICAL", 317, 332], ["flucloxacillin", "SIMPLE_CHEMICAL", 359, 373], ["atropine ointment", "TREATMENT", 19, 36], ["a Pseudomonas infection", "PROBLEM", 119, 142], ["laboratory analysis", "TEST", 172, 191], ["aminoglycoside", "TREATMENT", 233, 247], ["gentomycin", "TREATMENT", 258, 268], ["tobramycin", "TREATMENT", 272, 282], ["gentomycin", "TREATMENT", 286, 296], ["resistant cases)", "TREATMENT", 297, 313], ["fluoroquinalone", "TREATMENT", 317, 332], ["flucloxacillin", "TREATMENT", 359, 373], ["antibiotics", "TREATMENT", 389, 400], ["the infection", "PROBLEM", 444, 457], ["tear", "OBSERVATION", 86, 90], ["duct", "ANATOMY", 91, 95], ["Pseudomonas", "OBSERVATION_MODIFIER", 121, 132], ["infection", "OBSERVATION", 133, 142], ["infection", "OBSERVATION", 448, 457]]], ["They may also be used systemically but particular care should be used with aminoglycosides in cats as they are ototoxic and nephrotoxic.", [["aminoglycosides", "CHEMICAL", 75, 90], ["ototoxic", "DISEASE", 111, 119], ["nephrotoxic", "DISEASE", 124, 135], ["aminoglycosides", "CHEMICAL", 75, 90], ["aminoglycosides", "SIMPLE_CHEMICAL", 75, 90], ["cats", "ORGANISM", 94, 98], ["cats", "SPECIES", 94, 98], ["aminoglycosides", "TREATMENT", 75, 90], ["ototoxic", "PROBLEM", 111, 119], ["nephrotoxic", "PROBLEM", 124, 135]]], ["Toxicity may occur from frequent topical use, so monitor cases carefully.TreatmentNEVER use topical corticosteroids when a corneal ulcer is present, as this will predispose to keratomalacia (melting ulcer).TreatmentIf there is a penetrating corneal lesion, examine the eye carefully for signs of iris prolapse and lens rupture.", [["corneal ulcer", "ANATOMY", 123, 136], ["corneal lesion", "ANATOMY", 241, 255], ["eye", "ANATOMY", 269, 272], ["iris", "ANATOMY", 296, 300], ["lens", "ANATOMY", 314, 318], ["Toxicity", "DISEASE", 0, 8], ["corneal ulcer", "DISEASE", 123, 136], ["keratomalacia", "DISEASE", 176, 189], ["ulcer", "DISEASE", 199, 204], ["corneal lesion", "DISEASE", 241, 255], ["iris prolapse", "DISEASE", 296, 309], ["lens rupture", "DISEASE", 314, 326], ["corneal ulcer", "PATHOLOGICAL_FORMATION", 123, 136], ["ulcer", "PATHOLOGICAL_FORMATION", 199, 204], ["corneal lesion", "PATHOLOGICAL_FORMATION", 241, 255], ["eye", "ORGAN", 269, 272], ["iris", "TISSUE", 296, 300], ["lens", "TISSUE", 314, 318], ["Toxicity", "PROBLEM", 0, 8], ["TreatmentNEVER", "TREATMENT", 73, 87], ["topical corticosteroids", "TREATMENT", 92, 115], ["a corneal ulcer", "PROBLEM", 121, 136], ["keratomalacia (melting ulcer", "PROBLEM", 176, 204], ["Treatment", "TREATMENT", 206, 215], ["a penetrating corneal lesion", "PROBLEM", 227, 255], ["iris prolapse", "PROBLEM", 296, 309], ["lens rupture", "PROBLEM", 314, 326], ["corneal", "ANATOMY", 123, 130], ["ulcer", "OBSERVATION", 131, 136], ["melting", "OBSERVATION_MODIFIER", 191, 198], ["ulcer", "OBSERVATION", 199, 204], ["penetrating", "OBSERVATION_MODIFIER", 229, 240], ["corneal", "ANATOMY", 241, 248], ["lesion", "OBSERVATION", 249, 255], ["eye", "ANATOMY", 269, 272], ["iris prolapse", "OBSERVATION", 296, 309], ["lens rupture", "OBSERVATION", 314, 326]]], ["These cases need to be referred to a veterinary ophthalmologist whenever possible.Treatment\u2022 If there is a corneal tear that is well sealed with a fibrin plug, protect the cornea with a third eyelid flap or temporary tarsorrhaphy.", [["corneal", "ANATOMY", 107, 114], ["cornea", "ANATOMY", 172, 178], ["eyelid", "ANATOMY", 192, 198], ["corneal tear", "DISEASE", 107, 119], ["tarsorrhaphy", "DISEASE", 217, 229], ["fibrin", "GENE_OR_GENE_PRODUCT", 147, 153], ["cornea", "ORGAN", 172, 178], ["eyelid", "ORGAN", 192, 198], ["Treatment", "TREATMENT", 82, 91], ["a corneal tear", "PROBLEM", 105, 119], ["a fibrin plug", "PROBLEM", 145, 158], ["the cornea", "PROBLEM", 168, 178], ["a third eyelid flap", "TREATMENT", 184, 203], ["temporary tarsorrhaphy", "TREATMENT", 207, 229], ["corneal", "ANATOMY", 107, 114], ["tear", "OBSERVATION", 115, 119], ["fibrin plug", "OBSERVATION", 147, 158], ["cornea", "ANATOMY", 172, 178], ["eyelid", "ANATOMY", 192, 198], ["flap", "OBSERVATION", 199, 203], ["temporary tarsorrhaphy", "OBSERVATION", 207, 229]]], ["Dilate the pupil with atropine and use a topical broad-spectrum antibiotic drop.", [["pupil", "ANATOMY", 11, 16], ["atropine", "CHEMICAL", 22, 30], ["atropine", "CHEMICAL", 22, 30], ["pupil", "ORGAN", 11, 16], ["atropine", "SIMPLE_CHEMICAL", 22, 30], ["atropine", "TREATMENT", 22, 30], ["a topical broad-spectrum antibiotic drop", "TREATMENT", 39, 79], ["pupil", "ANATOMY", 11, 16], ["antibiotic drop", "OBSERVATION", 64, 79]]], ["NEVER use an ointment when there has been a penetrating corneal injury, because ointment bases that enter the anterior chamber will cause an intense and chronic foreign body uveitis.TreatmentAnimals with acute eye injuries should be given systemic NSAIDs to minimize the effects of an intra-ocular prostaglandin reaction.", [["corneal", "ANATOMY", 56, 63], ["anterior chamber", "ANATOMY", 110, 126], ["body", "ANATOMY", 169, 173], ["eye", "ANATOMY", 210, 213], ["intra-ocular", "ANATOMY", 285, 297], ["corneal injury", "DISEASE", 56, 70], ["uveitis", "DISEASE", 174, 181], ["acute eye injuries", "DISEASE", 204, 222], ["prostaglandin", "CHEMICAL", 298, 311], ["prostaglandin", "CHEMICAL", 298, 311], ["corneal", "TISSUE", 56, 63], ["eye", "ORGAN", 210, 213], ["NSAIDs", "SIMPLE_CHEMICAL", 248, 254], ["prostaglandin", "SIMPLE_CHEMICAL", 298, 311], ["an ointment", "TREATMENT", 10, 21], ["a penetrating corneal injury", "PROBLEM", 42, 70], ["ointment bases", "TREATMENT", 80, 94], ["an intense and chronic foreign body uveitis", "PROBLEM", 138, 181], ["acute eye injuries", "PROBLEM", 204, 222], ["systemic NSAIDs", "TREATMENT", 239, 254], ["an intra-ocular prostaglandin reaction", "TREATMENT", 282, 320], ["penetrating", "OBSERVATION_MODIFIER", 44, 55], ["corneal", "ANATOMY", 56, 63], ["injury", "OBSERVATION", 64, 70], ["anterior", "ANATOMY_MODIFIER", 110, 118], ["intense", "OBSERVATION_MODIFIER", 141, 148], ["chronic", "OBSERVATION_MODIFIER", 153, 160], ["foreign body uveitis", "OBSERVATION", 161, 181], ["acute", "OBSERVATION_MODIFIER", 204, 209], ["eye", "ANATOMY", 210, 213], ["injuries", "OBSERVATION", 214, 222], ["intra-ocular prostaglandin", "OBSERVATION", 285, 311]]], ["The eye should also be protected from infection with systemic broadspectrum antibiotics.TreatmentWhen there is an iris prolapse, microsurgery is required to suture the cornea.", [["eye", "ANATOMY", 4, 7], ["iris", "ANATOMY", 114, 118], ["cornea", "ANATOMY", 168, 174], ["infection", "DISEASE", 38, 47], ["iris prolapse", "DISEASE", 114, 127], ["eye", "ORGAN", 4, 7], ["cornea", "TISSUE", 168, 174], ["infection", "PROBLEM", 38, 47], ["systemic broadspectrum antibiotics", "TREATMENT", 53, 87], ["an iris prolapse", "PROBLEM", 111, 127], ["microsurgery", "TREATMENT", 129, 141], ["eye", "ANATOMY", 4, 7], ["infection", "OBSERVATION", 38, 47], ["iris prolapse", "OBSERVATION", 114, 127], ["cornea", "ANATOMY", 168, 174]]], ["The iris needs to be gently teased back into the anterior chamber, and the chamber flushed to remove blood and fibrin.", [["iris", "ANATOMY", 4, 8], ["anterior chamber", "ANATOMY", 49, 65], ["blood", "ANATOMY", 101, 106], ["iris", "ORGAN", 4, 8], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 49, 65], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["fibrin", "GENE_OR_GENE_PRODUCT", 111, 117], ["fibrin", "PROTEIN", 111, 117], ["the chamber", "TREATMENT", 71, 82], ["fibrin", "PROBLEM", 111, 117], ["iris", "ANATOMY", 4, 8], ["anterior", "ANATOMY_MODIFIER", 49, 57], ["chamber", "ANATOMY_MODIFIER", 58, 65], ["fibrin", "OBSERVATION", 111, 117]]], ["Viscoelastic solutions are then used to space the anterior chamber, and the corneal deficit is sutured with interrupted 8/0 to 10/0 nylon or absorbable suture material.", [["anterior chamber", "ANATOMY", 50, 66], ["corneal", "ANATOMY", 76, 83], ["corneal", "TISSUE", 76, 83], ["Viscoelastic solutions", "TREATMENT", 0, 22], ["the corneal deficit", "PROBLEM", 72, 91], ["absorbable suture material", "TREATMENT", 141, 167], ["anterior", "ANATOMY_MODIFIER", 50, 58], ["chamber", "ANATOMY_MODIFIER", 59, 66], ["corneal", "ANATOMY", 76, 83], ["deficit", "OBSERVATION", 84, 91], ["sutured", "OBSERVATION", 95, 102], ["absorbable suture", "OBSERVATION", 141, 158]]], ["This is very specialized surgery that requires specialist training, magnification and specialized instrumentation.", [["specialized surgery", "TREATMENT", 13, 32], ["specialist training", "TREATMENT", 47, 66], ["magnification", "TREATMENT", 68, 81], ["specialized instrumentation", "TREATMENT", 86, 113], ["very", "OBSERVATION_MODIFIER", 8, 12], ["specialized", "OBSERVATION_MODIFIER", 13, 24], ["surgery", "OBSERVATION", 25, 32]]], ["The pupil is then dilated with atropine, infection prevented with broad-spectrum topical and systemic antibiotics and NSAIDs given to minimize inflammation.Classical signs\u2022 Range from faint cloudiness of the superficial stroma to dense opacity. \u2022 Variable position, size, shape and density of scar. \u2022 History of previous severe inflammation or trauma.PathogenesisScarring may be secondary to disease processes or trauma.PathogenesisScars form secondary to stromal damage.", [["pupil", "ANATOMY", 4, 9], ["superficial stroma", "ANATOMY", 208, 226], ["scar", "ANATOMY", 293, 297], ["stromal", "ANATOMY", 456, 463], ["atropine", "CHEMICAL", 31, 39], ["infection", "DISEASE", 41, 50], ["NSAIDs", "CHEMICAL", 118, 124], ["inflammation", "DISEASE", 143, 155], ["opacity", "DISEASE", 236, 243], ["inflammation", "DISEASE", 328, 340], ["trauma", "DISEASE", 344, 350], ["PathogenesisScarring", "DISEASE", 351, 371], ["trauma", "DISEASE", 413, 419], ["stromal damage", "DISEASE", 456, 470], ["atropine", "CHEMICAL", 31, 39], ["pupil", "MULTI-TISSUE_STRUCTURE", 4, 9], ["atropine", "SIMPLE_CHEMICAL", 31, 39], ["NSAIDs", "SIMPLE_CHEMICAL", 118, 124], ["superficial stroma", "TISSUE", 208, 226], ["scar", "PATHOLOGICAL_FORMATION", 293, 297], ["stromal", "TISSUE", 456, 463], ["dilated", "PROBLEM", 18, 25], ["atropine", "TREATMENT", 31, 39], ["infection", "PROBLEM", 41, 50], ["broad-spectrum topical", "TREATMENT", 66, 88], ["systemic antibiotics", "TREATMENT", 93, 113], ["NSAIDs", "TREATMENT", 118, 124], ["inflammation", "PROBLEM", 143, 155], ["Classical signs", "TEST", 156, 171], ["faint cloudiness of the superficial stroma", "PROBLEM", 184, 226], ["dense opacity", "PROBLEM", 230, 243], ["Variable position, size, shape and density of scar", "PROBLEM", 247, 297], ["previous severe inflammation", "PROBLEM", 312, 340], ["trauma", "PROBLEM", 344, 350], ["PathogenesisScarring", "PROBLEM", 351, 371], ["disease processes", "PROBLEM", 392, 409], ["trauma", "PROBLEM", 413, 419], ["PathogenesisScars", "PROBLEM", 420, 437], ["stromal damage", "PROBLEM", 456, 470], ["pupil", "OBSERVATION", 4, 9], ["dilated", "OBSERVATION", 18, 25], ["infection", "OBSERVATION", 41, 50], ["inflammation", "OBSERVATION", 143, 155], ["faint", "OBSERVATION_MODIFIER", 184, 189], ["cloudiness", "OBSERVATION", 190, 200], ["superficial", "ANATOMY_MODIFIER", 208, 219], ["stroma", "ANATOMY", 220, 226], ["dense", "OBSERVATION_MODIFIER", 230, 235], ["opacity", "OBSERVATION", 236, 243], ["position", "OBSERVATION_MODIFIER", 256, 264], ["size", "OBSERVATION_MODIFIER", 266, 270], ["shape", "OBSERVATION_MODIFIER", 272, 277], ["density", "OBSERVATION_MODIFIER", 282, 289], ["scar", "OBSERVATION", 293, 297], ["severe", "OBSERVATION_MODIFIER", 321, 327], ["inflammation", "OBSERVATION", 328, 340], ["trauma", "OBSERVATION", 344, 350], ["may be", "UNCERTAINTY", 372, 378], ["disease", "OBSERVATION", 392, 399], ["trauma", "OBSERVATION", 413, 419], ["stromal damage", "OBSERVATION", 456, 470]]], ["When stroma is infected or lost from ulceration, keratocytes metaplase into fibrocytes.Clinical signsScars present as cloudy areas on the cornea.", [["stroma", "ANATOMY", 5, 11], ["keratocytes", "ANATOMY", 49, 60], ["fibrocytes", "ANATOMY", 76, 86], ["cornea", "ANATOMY", 138, 144], ["stroma", "TISSUE", 5, 11], ["keratocytes", "CELL", 49, 60], ["fibrocytes", "CELL", 76, 86], ["cornea", "TISSUE", 138, 144], ["keratocytes", "CELL_TYPE", 49, 60], ["fibrocytes", "CELL_TYPE", 76, 86], ["infected", "PROBLEM", 15, 23], ["ulceration", "PROBLEM", 37, 47], ["keratocytes metaplase into fibrocytes", "PROBLEM", 49, 86], ["Clinical signsScars", "PROBLEM", 87, 106], ["cloudy areas on the cornea", "PROBLEM", 118, 144], ["infected", "OBSERVATION", 15, 23], ["ulceration", "OBSERVATION", 37, 47], ["fibrocytes", "OBSERVATION", 76, 86], ["cloudy", "OBSERVATION_MODIFIER", 118, 124], ["areas", "OBSERVATION_MODIFIER", 125, 130], ["cornea", "ANATOMY", 138, 144]]], ["Superficial scarring of the cornea is seen as a faint cloudiness of the superficial stroma.", [["cornea", "ANATOMY", 28, 34], ["superficial stroma", "ANATOMY", 72, 90], ["cornea", "ORGAN", 28, 34], ["superficial stroma", "TISSUE", 72, 90], ["Superficial scarring of the cornea", "PROBLEM", 0, 34], ["a faint cloudiness of the superficial stroma", "PROBLEM", 46, 90], ["scarring", "OBSERVATION", 12, 20], ["cornea", "ANATOMY", 28, 34], ["faint", "OBSERVATION_MODIFIER", 48, 53], ["cloudiness", "OBSERVATION", 54, 64], ["superficial", "ANATOMY_MODIFIER", 72, 83], ["stroma", "OBSERVATION", 84, 90]]], ["Dense opacity is seen with deep scars that involve the deep layers of the cornea.Clinical signsScars vary considerably in position, size, shape and density depending on the depth and area of corneal stroma that has been damaged.Clinical signsUsually there is no inflammation in the affected eye.Clinical signsVision is always affected by corneal scarring.DiagnosisA diagnosis is based on clinical findings and history.DiagnosisTypically the cornea has cloudy areas of varying density, there is no positive staining with fluorescein, and the eye has no sign of inflammation, pain or discharge.DiagnosisUsually, there is a history of previous severe inflammation or trauma, with healing of the cornea.MYCOBACTERIAL KERATITIS (FLORIDA SPOTS)Classical signsMYCOBACTERIAL KERATITIS (FLORIDA SPOTS)\u2022 An asymptomatic keratitis recognized in the southeastern USA. \u2022 The cornea has focal gray-white opacities in the anterior stroma, varying in diameter from 1-8 mm in size. \u2022 The lesions usually affect both eyes.MYCOBACTERIAL KERATITIS (FLORIDA SPOTS)See the main reference on page 1251 (The Cat With Abnormalities Confined to the Cornea).Clinical signsOne, or more commonly, both corneas have focal white to gray opacities in the anterior stroma.Clinical signsThe condition is asymptomatic, as cats show no signs of ocular pain or irritation, and there is no associated inflammation in the cornea.Clinical signsThe condition has only been described in the USA.DiagnosisA tentative diagnosis is based on clinical signsmultiple focal opacities in the anterior stroma of the cornea, not associated with irritation or inflammation.DiagnosisRhinosporidium was initially diagnosed from histological samples.", [["deep layers", "ANATOMY", 55, 66], ["cornea", "ANATOMY", 74, 80], ["corneal stroma", "ANATOMY", 191, 205], ["eye", "ANATOMY", 291, 294], ["corneal", "ANATOMY", 338, 345], ["cornea", "ANATOMY", 441, 447], ["eye", "ANATOMY", 541, 544], ["cornea", "ANATOMY", 692, 698], ["cornea", "ANATOMY", 862, 868], ["anterior stroma", "ANATOMY", 907, 922], ["lesions", "ANATOMY", 971, 978], ["eyes", "ANATOMY", 999, 1003], ["corneas", "ANATOMY", 1173, 1180], ["anterior stroma", "ANATOMY", 1223, 1238], ["ocular", "ANATOMY", 1309, 1315], ["cornea", "ANATOMY", 1383, 1389], ["anterior stroma", "ANATOMY", 1542, 1557], ["cornea", "ANATOMY", 1565, 1571], ["samples", "ANATOMY", 1686, 1693], ["inflammation", "DISEASE", 262, 274], ["corneal scarring", "DISEASE", 338, 354], ["fluorescein", "CHEMICAL", 520, 531], ["inflammation", "DISEASE", 560, 572], ["pain", "DISEASE", 574, 578], ["inflammation", "DISEASE", 648, 660], ["trauma", "DISEASE", 664, 670], ["keratitis", "DISEASE", 810, 819], ["ocular pain", "DISEASE", 1309, 1320], ["irritation", "DISEASE", 1324, 1334], ["inflammation", "DISEASE", 1363, 1375], ["irritation", "DISEASE", 1593, 1603], ["inflammation", "DISEASE", 1607, 1619], ["fluorescein", "CHEMICAL", 520, 531], ["scars", "PATHOLOGICAL_FORMATION", 32, 37], ["cornea", "TISSUE", 74, 80], ["corneal stroma", "TISSUE", 191, 205], ["eye", "ORGAN", 291, 294], ["corneal", "TISSUE", 338, 345], ["cornea", "ORGAN", 441, 447], ["fluorescein", "SIMPLE_CHEMICAL", 520, 531], ["eye", "ORGAN", 541, 544], ["cornea", "ORGAN", 692, 698], ["cornea", "ORGAN", 862, 868], ["anterior stroma", "TISSUE", 907, 922], ["lesions", "CANCER", 971, 978], ["eyes", "ORGAN", 999, 1003], ["corneas", "ORGAN", 1173, 1180], ["anterior stroma", "TISSUE", 1223, 1238], ["cats", "ORGANISM", 1287, 1291], ["ocular", "ORGAN", 1309, 1315], ["cornea", "ORGAN", 1383, 1389], ["anterior stroma", "TISSUE", 1542, 1557], ["cornea", "ORGAN", 1565, 1571], ["histological samples", "CANCER", 1673, 1693], ["Dense opacity", "PROBLEM", 0, 13], ["deep scars", "PROBLEM", 27, 37], ["Clinical signsScars vary", "PROBLEM", 81, 105], ["corneal stroma", "PROBLEM", 191, 205], ["inflammation in the affected eye", "PROBLEM", 262, 294], ["corneal scarring", "PROBLEM", 338, 354], ["cloudy areas of varying density", "PROBLEM", 452, 483], ["positive staining", "PROBLEM", 497, 514], ["fluorescein", "TEST", 520, 531], ["inflammation", "PROBLEM", 560, 572], ["pain", "PROBLEM", 574, 578], ["previous severe inflammation", "PROBLEM", 632, 660], ["trauma", "PROBLEM", 664, 670], ["healing of the cornea", "PROBLEM", 677, 698], ["MYCOBACTERIAL KERATITIS", "PROBLEM", 699, 722], ["Classical signsMYCOBACTERIAL KERATITIS", "PROBLEM", 738, 776], ["An asymptomatic keratitis", "PROBLEM", 794, 819], ["focal gray-white opacities in the anterior stroma", "PROBLEM", 873, 922], ["The lesions", "PROBLEM", 967, 978], ["MYCOBACTERIAL KERATITIS", "PROBLEM", 1004, 1027], ["focal white to gray opacities in the anterior stroma", "PROBLEM", 1186, 1238], ["Clinical signs", "TEST", 1239, 1253], ["asymptomatic", "PROBLEM", 1270, 1282], ["ocular pain", "PROBLEM", 1309, 1320], ["irritation", "PROBLEM", 1324, 1334], ["associated inflammation in the cornea", "PROBLEM", 1352, 1389], ["Clinical signs", "TEST", 1390, 1404], ["clinical signsmultiple focal opacities in the anterior stroma of the cornea", "PROBLEM", 1496, 1571], ["irritation", "PROBLEM", 1593, 1603], ["inflammation", "PROBLEM", 1607, 1619], ["DiagnosisRhinosporidium", "TEST", 1620, 1643], ["histological samples", "TEST", 1673, 1693], ["opacity", "OBSERVATION", 6, 13], ["deep", "ANATOMY_MODIFIER", 27, 31], ["scars", "OBSERVATION", 32, 37], ["deep", "ANATOMY_MODIFIER", 55, 59], ["layers", "ANATOMY_MODIFIER", 60, 66], ["cornea", "ANATOMY", 74, 80], ["vary", "OBSERVATION_MODIFIER", 101, 105], ["considerably", "OBSERVATION_MODIFIER", 106, 118], ["position", "OBSERVATION_MODIFIER", 122, 130], ["size", "OBSERVATION_MODIFIER", 132, 136], ["shape", "OBSERVATION_MODIFIER", 138, 143], ["density", "OBSERVATION", 148, 155], ["depth", "OBSERVATION_MODIFIER", 173, 178], ["area", "OBSERVATION_MODIFIER", 183, 187], ["corneal stroma", "OBSERVATION", 191, 205], ["damaged", "OBSERVATION_MODIFIER", 220, 227], ["no", "UNCERTAINTY", 259, 261], ["inflammation", "OBSERVATION", 262, 274], ["affected", "ANATOMY_MODIFIER", 282, 290], ["eye", "ANATOMY", 291, 294], ["corneal", "ANATOMY", 338, 345], ["scarring", "OBSERVATION", 346, 354], ["cornea", "ANATOMY", 441, 447], ["cloudy", "OBSERVATION_MODIFIER", 452, 458], ["areas", "OBSERVATION_MODIFIER", 459, 464], ["varying", "OBSERVATION_MODIFIER", 468, 475], ["density", "OBSERVATION", 476, 483], ["no", "UNCERTAINTY", 494, 496], ["positive", "OBSERVATION_MODIFIER", 497, 505], ["staining", "OBSERVATION", 506, 514], ["eye", "ANATOMY", 541, 544], ["no sign of", "UNCERTAINTY", 549, 559], ["inflammation", "OBSERVATION", 560, 572], ["severe", "OBSERVATION_MODIFIER", 641, 647], ["inflammation", "OBSERVATION", 648, 660], ["trauma", "OBSERVATION", 664, 670], ["healing", "OBSERVATION_MODIFIER", 677, 684], ["cornea", "ANATOMY", 692, 698], ["KERATITIS", "OBSERVATION", 713, 722], ["signsMYCOBACTERIAL KERATITIS", "OBSERVATION", 748, 776], ["asymptomatic", "OBSERVATION_MODIFIER", 797, 809], ["keratitis", "OBSERVATION", 810, 819], ["cornea", "ANATOMY", 862, 868], ["focal", "OBSERVATION_MODIFIER", 873, 878], ["gray", "OBSERVATION_MODIFIER", 879, 883], ["white opacities", "OBSERVATION", 884, 899], ["anterior", "ANATOMY_MODIFIER", 907, 915], ["stroma", "ANATOMY_MODIFIER", 916, 922], ["varying", "OBSERVATION_MODIFIER", 924, 931], ["diameter", "OBSERVATION_MODIFIER", 935, 943], ["1-8 mm", "OBSERVATION_MODIFIER", 949, 955], ["size", "OBSERVATION_MODIFIER", 959, 963], ["lesions", "OBSERVATION", 971, 978], ["both", "ANATOMY_MODIFIER", 994, 998], ["eyes", "ANATOMY", 999, 1003], ["KERATITIS", "OBSERVATION", 1018, 1027], ["Cornea", "ANATOMY", 1123, 1129], ["corneas", "ANATOMY", 1173, 1180], ["focal", "OBSERVATION_MODIFIER", 1186, 1191], ["white to gray", "OBSERVATION_MODIFIER", 1192, 1205], ["opacities", "OBSERVATION", 1206, 1215], ["anterior", "ANATOMY_MODIFIER", 1223, 1231], ["stroma", "ANATOMY", 1232, 1238], ["asymptomatic", "OBSERVATION", 1270, 1282], ["no signs of", "UNCERTAINTY", 1297, 1308], ["ocular", "ANATOMY", 1309, 1315], ["pain", "OBSERVATION", 1316, 1320], ["irritation", "OBSERVATION", 1324, 1334], ["no associated", "UNCERTAINTY", 1349, 1362], ["inflammation", "OBSERVATION", 1363, 1375], ["cornea", "ANATOMY", 1383, 1389], ["focal", "OBSERVATION_MODIFIER", 1519, 1524], ["opacities", "OBSERVATION", 1525, 1534], ["anterior", "ANATOMY_MODIFIER", 1542, 1550], ["stroma", "ANATOMY_MODIFIER", 1551, 1557], ["cornea", "ANATOMY", 1565, 1571], ["not associated with", "UNCERTAINTY", 1573, 1592], ["irritation", "OBSERVATION", 1593, 1603], ["inflammation", "OBSERVATION", 1607, 1619]]], ["However, ultrastructural examination of affected cornea showed vacuoles with amorphous material and rod-like organisms characteristic of mycobacteria that stain positively with Ziehl-Neelsen carbolfuchsin stain.Clinical signsRare disease of young Manx cats.", [["cornea", "ANATOMY", 49, 55], ["vacuoles", "ANATOMY", 63, 71], ["Ziehl-Neelsen carbolfuchsin", "CHEMICAL", 177, 204], ["Rare disease", "DISEASE", 225, 237], ["cornea", "ORGAN", 49, 55], ["vacuoles", "CELLULAR_COMPONENT", 63, 71], ["Ziehl-Neelsen carbolfuchsin", "GENE_OR_GENE_PRODUCT", 177, 204], ["Manx cats", "ORGANISM", 247, 256], ["cats", "SPECIES", 252, 256], ["ultrastructural examination of affected cornea", "TEST", 9, 55], ["vacuoles", "PROBLEM", 63, 71], ["amorphous material", "PROBLEM", 77, 95], ["rod-like organisms", "PROBLEM", 100, 118], ["mycobacteria", "PROBLEM", 137, 149], ["Ziehl", "TEST", 177, 182], ["cornea", "ANATOMY", 49, 55], ["amorphous material", "OBSERVATION", 77, 95], ["mycobacteria", "OBSERVATION", 137, 149], ["Rare", "OBSERVATION_MODIFIER", 225, 229], ["disease", "OBSERVATION", 230, 237]]], ["Cats present with an axial (central) stromal edema which progresses to diffuse corneal edema and a thickened corneal stroma filled with bullae (fluid-filled vesicles).Clinical signsAffected cats become blind.DiagnosisA tentative diagnosis is based on the presentation of a young Manx cat with corneal edema.DiagnosisA definitive diagnosis is based on histopathology.Diagnosis\u2022 Histology demonstrates progressive disintegration of stromal collagen fibers, which are replaced with fluid-filled vesicles.", [["stromal edema", "ANATOMY", 37, 50], ["corneal", "ANATOMY", 79, 86], ["corneal stroma", "ANATOMY", 109, 123], ["bullae", "ANATOMY", 136, 142], ["fluid", "ANATOMY", 144, 149], ["vesicles", "ANATOMY", 157, 165], ["corneal", "ANATOMY", 293, 300], ["stromal collagen fibers", "ANATOMY", 430, 453], ["fluid", "ANATOMY", 479, 484], ["vesicles", "ANATOMY", 492, 500], ["edema", "DISEASE", 45, 50], ["corneal edema", "DISEASE", 79, 92], ["corneal edema", "DISEASE", 293, 306], ["stromal edema", "PATHOLOGICAL_FORMATION", 37, 50], ["corneal edema", "PATHOLOGICAL_FORMATION", 79, 92], ["corneal stroma", "TISSUE", 109, 123], ["bullae", "PATHOLOGICAL_FORMATION", 136, 142], ["vesicles", "CELLULAR_COMPONENT", 157, 165], ["cats", "ORGANISM", 190, 194], ["cat", "ORGANISM", 284, 287], ["corneal edema", "PATHOLOGICAL_FORMATION", 293, 306], ["collagen", "GENE_OR_GENE_PRODUCT", 438, 446], ["fibers", "CELLULAR_COMPONENT", 447, 453], ["vesicles", "CELLULAR_COMPONENT", 492, 500], ["cats", "SPECIES", 190, 194], ["cat", "SPECIES", 284, 287], ["Manx cat", "SPECIES", 279, 287], ["an axial (central) stromal edema", "PROBLEM", 18, 50], ["diffuse corneal edema", "PROBLEM", 71, 92], ["a thickened corneal stroma", "PROBLEM", 97, 123], ["bullae (fluid-filled vesicles", "PROBLEM", 136, 165], ["blind", "PROBLEM", 202, 207], ["corneal edema", "PROBLEM", 293, 306], ["histopathology", "TEST", 351, 365], ["Histology", "TEST", 377, 386], ["progressive disintegration of stromal collagen fibers", "PROBLEM", 400, 453], ["fluid-filled vesicles", "PROBLEM", 479, 500], ["stromal", "ANATOMY", 37, 44], ["edema", "OBSERVATION", 45, 50], ["diffuse", "OBSERVATION_MODIFIER", 71, 78], ["corneal", "ANATOMY", 79, 86], ["edema", "OBSERVATION", 87, 92], ["thickened", "OBSERVATION_MODIFIER", 99, 108], ["corneal stroma", "ANATOMY", 109, 123], ["bullae", "OBSERVATION", 136, 142], ["fluid", "OBSERVATION_MODIFIER", 144, 149], ["filled vesicles", "OBSERVATION", 150, 165], ["corneal", "ANATOMY", 293, 300], ["edema", "OBSERVATION", 301, 306], ["progressive", "OBSERVATION_MODIFIER", 400, 411], ["disintegration", "OBSERVATION_MODIFIER", 412, 426], ["stromal collagen fibers", "OBSERVATION", 430, 453], ["fluid", "OBSERVATION", 479, 484], ["filled vesicles", "OBSERVATION", 485, 500]]], ["Eventually the epithelium separates from its basement membrane and ulceration occurs.Classical signs\u2022 Cloudy anterior chamber from anterior uveitis is the most common sign. \u2022 +/-Gray to tan-colored nodules on the iris surface (lymphocytic-plasmacytic uveitis). \u2022 Cloudy vitreous (chorioretinitis and optic neuritis). \u2022 Rarely, systemic signs may be seen concurrently with ocular signs. \u2022 These include fever, weight loss, +/muscular pain, +/signs of respiratory or neurological disease.Clinical signsSystemic signs are rare but may include: \u2022 Fever, weight loss and muscle pain.Clinical signs\u2022 Respiratory signs associated with pneumonia.Clinical signs\u2022 Signs of multifocal neurologic disease.Clinical signs\u2022 Liver disease.Clinical signsOcular signs are more common, and may include one or all of the following signs: \u2022 Anterior uveitis is the most common sign and is seen as a cloudy anterior chamber.", [["epithelium", "ANATOMY", 15, 25], ["basement membrane", "ANATOMY", 45, 62], ["anterior chamber", "ANATOMY", 109, 125], ["nodules", "ANATOMY", 198, 205], ["iris surface", "ANATOMY", 213, 225], ["lymphocytic", "ANATOMY", 227, 238], ["vitreous", "ANATOMY", 270, 278], ["ocular", "ANATOMY", 372, 378], ["muscular", "ANATOMY", 424, 432], ["respiratory", "ANATOMY", 450, 461], ["neurological", "ANATOMY", 465, 477], ["muscle", "ANATOMY", 566, 572], ["Respiratory", "ANATOMY", 594, 605], ["neurologic", "ANATOMY", 674, 684], ["Liver", "ANATOMY", 709, 714], ["uveitis", "DISEASE", 140, 147], ["uveitis", "DISEASE", 251, 258], ["chorioretinitis", "DISEASE", 280, 295], ["optic neuritis", "DISEASE", 300, 314], ["ocular signs", "DISEASE", 372, 384], ["fever", "DISEASE", 402, 407], ["weight loss", "DISEASE", 409, 420], ["muscular pain", "DISEASE", 424, 437], ["respiratory or neurological disease", "DISEASE", 450, 485], ["Fever", "DISEASE", 543, 548], ["weight loss", "DISEASE", 550, 561], ["muscle pain", "DISEASE", 566, 577], ["Respiratory signs", "DISEASE", 594, 611], ["pneumonia", "DISEASE", 628, 637], ["neurologic disease", "DISEASE", 674, 692], ["Liver disease", "DISEASE", 709, 722], ["Anterior uveitis", "DISEASE", 820, 836], ["epithelium", "TISSUE", 15, 25], ["basement membrane", "CELLULAR_COMPONENT", 45, 62], ["ulceration", "PATHOLOGICAL_FORMATION", 67, 77], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 109, 125], ["iris surface", "MULTI-TISSUE_STRUCTURE", 213, 225], ["lymphocytic-plasmacytic uveitis", "CANCER", 227, 258], ["vitreous", "MULTI-TISSUE_STRUCTURE", 270, 278], ["ocular", "ORGAN", 372, 378], ["muscle", "ORGAN", 566, 572], ["Liver", "ORGAN", 709, 714], ["ulceration", "PROBLEM", 67, 77], ["Classical signs", "TEST", 85, 100], ["Cloudy anterior chamber", "PROBLEM", 102, 125], ["anterior uveitis", "PROBLEM", 131, 147], ["tan-colored nodules", "PROBLEM", 186, 205], ["lymphocytic-plasmacytic uveitis", "PROBLEM", 227, 258], ["Cloudy vitreous (chorioretinitis and optic neuritis", "PROBLEM", 263, 314], ["systemic signs", "TEST", 327, 341], ["ocular signs", "PROBLEM", 372, 384], ["fever", "PROBLEM", 402, 407], ["weight loss", "PROBLEM", 409, 420], ["muscular pain", "PROBLEM", 424, 437], ["respiratory or neurological disease", "PROBLEM", 450, 485], ["Clinical signsSystemic signs", "TEST", 486, 514], ["Fever", "PROBLEM", 543, 548], ["weight loss", "PROBLEM", 550, 561], ["muscle pain", "PROBLEM", 566, 577], ["Clinical signs", "TEST", 578, 592], ["Respiratory signs", "PROBLEM", 594, 611], ["pneumonia", "PROBLEM", 628, 637], ["Clinical signs", "TEST", 638, 652], ["multifocal neurologic disease", "PROBLEM", 663, 692], ["Liver disease", "PROBLEM", 709, 722], ["Clinical signsOcular signs", "TEST", 723, 749], ["Anterior uveitis", "PROBLEM", 820, 836], ["a cloudy anterior chamber", "PROBLEM", 876, 901], ["epithelium", "ANATOMY_MODIFIER", 15, 25], ["basement membrane", "OBSERVATION_MODIFIER", 45, 62], ["ulceration", "OBSERVATION", 67, 77], ["anterior", "OBSERVATION_MODIFIER", 109, 117], ["chamber", "OBSERVATION_MODIFIER", 118, 125], ["anterior", "OBSERVATION_MODIFIER", 131, 139], ["uveitis", "OBSERVATION", 140, 147], ["most common", "OBSERVATION_MODIFIER", 155, 166], ["tan-colored", "OBSERVATION_MODIFIER", 186, 197], ["nodules", "OBSERVATION", 198, 205], ["iris", "ANATOMY", 213, 217], ["surface", "ANATOMY_MODIFIER", 218, 225], ["lymphocytic", "OBSERVATION_MODIFIER", 227, 238], ["plasmacytic uveitis", "OBSERVATION", 239, 258], ["vitreous", "OBSERVATION", 270, 278], ["chorioretinitis", "OBSERVATION", 280, 295], ["optic neuritis", "OBSERVATION", 300, 314], ["may be seen", "UNCERTAINTY", 342, 353], ["fever", "OBSERVATION", 402, 407], ["muscular", "ANATOMY", 424, 432], ["pain", "OBSERVATION", 433, 437], ["respiratory", "ANATOMY", 450, 461], ["neurological disease", "OBSERVATION", 465, 485], ["muscle", "ANATOMY", 566, 572], ["pain", "OBSERVATION", 573, 577], ["Respiratory signs", "OBSERVATION", 594, 611], ["pneumonia", "OBSERVATION", 628, 637], ["multifocal", "OBSERVATION_MODIFIER", 663, 673], ["neurologic disease", "OBSERVATION", 674, 692], ["Liver", "ANATOMY", 709, 714], ["disease", "OBSERVATION", 715, 722], ["more common", "OBSERVATION_MODIFIER", 754, 765], ["Anterior", "ANATOMY_MODIFIER", 820, 828], ["uveitis", "OBSERVATION", 829, 836], ["most common", "OBSERVATION_MODIFIER", 844, 855], ["cloudy", "OBSERVATION_MODIFIER", 878, 884], ["anterior chamber", "OBSERVATION", 885, 901]]], ["This is caused by leakage of protein and white blood cells from inflamed iris and ciliary body blood vessels into the aqueous humor.", [["white blood cells", "ANATOMY", 41, 58], ["iris", "ANATOMY", 73, 77], ["ciliary body blood vessels", "ANATOMY", 82, 108], ["aqueous humor", "ANATOMY", 118, 131], ["white blood cells", "CELL", 41, 58], ["inflamed iris", "TISSUE", 64, 77], ["ciliary body blood vessels", "MULTI-TISSUE_STRUCTURE", 82, 108], ["aqueous humor", "ORGANISM_SUBSTANCE", 118, 131], ["white blood cells", "CELL_TYPE", 41, 58], ["leakage of protein", "PROBLEM", 18, 36], ["white blood cells", "TEST", 41, 58], ["inflamed iris", "PROBLEM", 64, 77], ["ciliary body blood vessels into the aqueous humor", "PROBLEM", 82, 131], ["leakage", "OBSERVATION", 18, 25], ["white blood cells", "OBSERVATION", 41, 58], ["inflamed iris", "OBSERVATION", 64, 77], ["ciliary", "ANATOMY_MODIFIER", 82, 89], ["body", "ANATOMY_MODIFIER", 90, 94], ["vessels", "ANATOMY", 101, 108], ["aqueous humor", "OBSERVATION", 118, 131]]], ["It is also known as hypopyon. \u2022 In severe cases of uveitis, the cornea may be cloudy due to edema caused by aqueous leakage through a compromised endothelium. \u2022 Keratic precipitates may be seen on the surface of the endothelium.", [["cornea", "ANATOMY", 64, 70], ["edema", "ANATOMY", 92, 97], ["endothelium", "ANATOMY", 146, 157], ["surface", "ANATOMY", 201, 208], ["endothelium", "ANATOMY", 216, 227], ["uveitis", "DISEASE", 51, 58], ["edema", "DISEASE", 92, 97], ["cornea", "ORGAN", 64, 70], ["edema", "PATHOLOGICAL_FORMATION", 92, 97], ["aqueous", "ORGANISM_SUBSTANCE", 108, 115], ["endothelium", "TISSUE", 146, 157], ["surface", "CELLULAR_COMPONENT", 201, 208], ["endothelium", "TISSUE", 216, 227], ["hypopyon", "PROBLEM", 20, 28], ["uveitis", "PROBLEM", 51, 58], ["cloudy", "PROBLEM", 78, 84], ["edema", "PROBLEM", 92, 97], ["aqueous leakage", "PROBLEM", 108, 123], ["a compromised endothelium", "PROBLEM", 132, 157], ["Keratic precipitates", "PROBLEM", 161, 181], ["hypopyon", "OBSERVATION", 20, 28], ["severe", "OBSERVATION_MODIFIER", 35, 41], ["uveitis", "OBSERVATION", 51, 58], ["cornea", "ANATOMY", 64, 70], ["edema", "OBSERVATION", 92, 97], ["aqueous leakage", "OBSERVATION", 108, 123], ["compromised endothelium", "OBSERVATION", 134, 157], ["may be seen", "UNCERTAINTY", 182, 193], ["surface", "ANATOMY_MODIFIER", 201, 208], ["endothelium", "ANATOMY", 216, 227]]], ["These are the so-called \"mutton fat\" deposits that consist of white cells and protein attached to the endothelium.", [["fat", "ANATOMY", 32, 35], ["white cells", "ANATOMY", 62, 73], ["endothelium", "ANATOMY", 102, 113], ["fat", "TISSUE", 32, 35], ["white cells", "CELL", 62, 73], ["endothelium", "TISSUE", 102, 113], ["white cells", "CELL_TYPE", 62, 73], ["the so-called \"mutton fat\" deposits", "PROBLEM", 10, 45], ["white cells", "PROBLEM", 62, 73], ["white cells", "OBSERVATION", 62, 73], ["endothelium", "ANATOMY", 102, 113]]], ["They are more common in the inferior cornea. \u2022 Cloudy vitreous caused by chorioretinitis; white cells and protein leak into the vitreous through inflamed retinal and choroidal blood vessels. \u2022 Lymphocytic plasmocytic uveitis is seen as pale nodules on the iris surface. \u2022 Secondary cataract formation is common in chronic cases, and will be seen as a cloudy eye within the pupil space. \u2022 Glaucoma is a sequel to chronic uveitis. \u2022 Signs may be unilateral or bilateral.DiagnosisA tentative diagnosis may be based on the clinical signs.DiagnosisA definitive diagnosis requires supportive laboratory data which may include: \u2022 Serology.Diagnosis-Demonstration of a rise in IgM titers indicates a recent active infection. -Comparison of levels of aqueous humor T. gondii antibody levels with serum levels (Goldman-Witmer coefficient or C-value) has been advocated, with higher aqueous levels suggesting the anterior uveitis was caused by T. gondii.", [["inferior cornea", "ANATOMY", 28, 43], ["vitreous", "ANATOMY", 54, 62], ["white cells", "ANATOMY", 90, 101], ["vitreous", "ANATOMY", 128, 136], ["retinal", "ANATOMY", 154, 161], ["choroidal blood vessels", "ANATOMY", 166, 189], ["pale nodules", "ANATOMY", 236, 248], ["iris surface", "ANATOMY", 256, 268], ["eye", "ANATOMY", 358, 361], ["pupil space", "ANATOMY", 373, 384], ["serum", "ANATOMY", 787, 792], ["chorioretinitis", "DISEASE", 73, 88], ["uveitis", "DISEASE", 217, 224], ["cataract", "DISEASE", 282, 290], ["Glaucoma", "DISEASE", 388, 396], ["uveitis", "DISEASE", 420, 427], ["infection", "DISEASE", 706, 715], ["uveitis", "DISEASE", 911, 918], ["inferior cornea", "MULTI-TISSUE_STRUCTURE", 28, 43], ["vitreous", "ORGANISM_SUBSTANCE", 54, 62], ["white cells", "CELL", 90, 101], ["vitreous", "TISSUE", 128, 136], ["retinal", "MULTI-TISSUE_STRUCTURE", 154, 161], ["choroidal blood vessels", "MULTI-TISSUE_STRUCTURE", 166, 189], ["pale nodules", "PATHOLOGICAL_FORMATION", 236, 248], ["iris surface", "TISSUE", 256, 268], ["eye", "ORGAN", 358, 361], ["pupil space", "MULTI-TISSUE_STRUCTURE", 373, 384], ["IgM", "GENE_OR_GENE_PRODUCT", 669, 672], ["aqueous humor", "ORGANISM_SUBSTANCE", 742, 755], ["T. gondii", "ORGANISM", 756, 765], ["serum", "ORGANISM_SUBSTANCE", 787, 792], ["aqueous", "ORGANISM_SUBSTANCE", 872, 879], ["T. gondii", "ORGANISM", 933, 942], ["white cells", "CELL_TYPE", 90, 101], ["IgM", "PROTEIN", 669, 672], ["T. gondii", "SPECIES", 756, 765], ["T. gondii", "SPECIES", 933, 942], ["T. gondii", "SPECIES", 756, 765], ["T. gondii", "SPECIES", 933, 942], ["Cloudy vitreous", "PROBLEM", 47, 62], ["chorioretinitis", "PROBLEM", 73, 88], ["white cells", "PROBLEM", 90, 101], ["protein leak into the vitreous through inflamed retinal and choroidal blood vessels", "PROBLEM", 106, 189], ["Lymphocytic plasmocytic uveitis", "PROBLEM", 193, 224], ["pale nodules on the iris surface", "PROBLEM", 236, 268], ["Secondary cataract formation", "PROBLEM", 272, 300], ["a cloudy eye within the pupil space", "PROBLEM", 349, 384], ["Glaucoma", "PROBLEM", 388, 396], ["chronic uveitis", "PROBLEM", 412, 427], ["the clinical signs", "TEST", 515, 533], ["supportive laboratory data", "TEST", 575, 601], ["Serology", "TEST", 623, 631], ["a rise in IgM titers", "PROBLEM", 659, 679], ["a recent active infection", "PROBLEM", 690, 715], ["levels", "TEST", 732, 738], ["aqueous humor T. gondii antibody levels", "TEST", 742, 781], ["serum levels", "TEST", 787, 799], ["Goldman", "TEST", 801, 808], ["the anterior uveitis", "PROBLEM", 898, 918], ["T. gondii", "PROBLEM", 933, 942], ["more", "OBSERVATION_MODIFIER", 9, 13], ["common", "OBSERVATION_MODIFIER", 14, 20], ["inferior", "ANATOMY_MODIFIER", 28, 36], ["cornea", "ANATOMY", 37, 43], ["vitreous", "OBSERVATION", 54, 62], ["chorioretinitis", "OBSERVATION", 73, 88], ["white cells", "OBSERVATION", 90, 101], ["protein leak", "OBSERVATION", 106, 118], ["vitreous", "ANATOMY_MODIFIER", 128, 136], ["inflamed", "ANATOMY_MODIFIER", 145, 153], ["retinal", "ANATOMY", 154, 161], ["choroidal", "ANATOMY_MODIFIER", 166, 175], ["blood vessels", "ANATOMY", 176, 189], ["Lymphocytic plasmocytic uveitis", "OBSERVATION", 193, 224], ["pale", "OBSERVATION_MODIFIER", 236, 240], ["nodules", "OBSERVATION", 241, 248], ["iris", "ANATOMY", 256, 260], ["surface", "ANATOMY_MODIFIER", 261, 268], ["cataract", "OBSERVATION", 282, 290], ["chronic", "OBSERVATION_MODIFIER", 314, 321], ["cases", "OBSERVATION", 322, 327], ["cloudy", "OBSERVATION", 351, 357], ["pupil", "ANATOMY", 373, 378], ["Glaucoma", "OBSERVATION", 388, 396], ["chronic", "OBSERVATION_MODIFIER", 412, 419], ["uveitis", "OBSERVATION", 420, 427], ["may be", "UNCERTAINTY", 437, 443], ["unilateral", "OBSERVATION", 444, 454], ["bilateral", "ANATOMY_MODIFIER", 458, 467], ["rise", "OBSERVATION_MODIFIER", 661, 665], ["IgM titers", "OBSERVATION", 669, 679], ["active", "OBSERVATION_MODIFIER", 699, 705], ["infection", "OBSERVATION", 706, 715], ["anterior", "ANATOMY_MODIFIER", 902, 910], ["uveitis", "OBSERVATION", 911, 918]]], ["The use of C-values is still controversial. \u2022 Polymerase chain reaction (PCR) testing for parasite DNA in tissue or fluid samples.Clinical signsThe ocular form of the disease is usually seen in young cats from 6 months to 1 year of age.Ocular signs may be unilateral or bilateral.The main presenting sign is uveitis.", [["tissue", "ANATOMY", 106, 112], ["fluid samples", "ANATOMY", 116, 129], ["ocular", "ANATOMY", 148, 154], ["Ocular", "ANATOMY", 236, 242], ["ocular form of the disease", "DISEASE", 148, 174], ["uveitis", "DISEASE", 308, 315], ["C", "SIMPLE_CHEMICAL", 11, 12], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["tissue", "TISSUE", 106, 112], ["fluid samples", "ORGANISM_SUBSTANCE", 116, 129], ["cats", "ORGANISM", 200, 204], ["Ocular", "ORGAN", 236, 242], ["parasite DNA", "DNA", 90, 102], ["cats", "SPECIES", 200, 204], ["C-values", "TEST", 11, 19], ["Polymerase chain reaction", "PROBLEM", 46, 71], ["PCR) testing", "TEST", 73, 85], ["parasite DNA in tissue", "PROBLEM", 90, 112], ["fluid samples", "TEST", 116, 129], ["Clinical signs", "TEST", 130, 144], ["the disease", "PROBLEM", 163, 174], ["Ocular signs", "TEST", 236, 248], ["uveitis", "PROBLEM", 308, 315], ["fluid", "OBSERVATION", 116, 121], ["ocular", "ANATOMY", 148, 154], ["disease", "OBSERVATION", 167, 174], ["signs", "OBSERVATION", 243, 248], ["may be", "UNCERTAINTY", 249, 255], ["unilateral", "OBSERVATION", 256, 266], ["bilateral", "ANATOMY_MODIFIER", 270, 279], ["main", "OBSERVATION_MODIFIER", 284, 288], ["sign", "OBSERVATION", 300, 304], ["uveitis", "OBSERVATION", 308, 315]]], ["Large fibrin clots mixed with exudated white and red blood cells form a hypopyon.", [["fibrin clots", "ANATOMY", 6, 18], ["red blood cells", "ANATOMY", 49, 64], ["fibrin", "GENE_OR_GENE_PRODUCT", 6, 12], ["clots", "ORGANISM_SUBSTANCE", 13, 18], ["red blood cells", "CELL", 49, 64], ["red blood cells", "CELL_TYPE", 49, 64], ["Large fibrin clots", "PROBLEM", 0, 18], ["exudated white and red blood cells", "PROBLEM", 30, 64], ["a hypopyon", "PROBLEM", 70, 80], ["fibrin clots", "OBSERVATION", 6, 18], ["mixed", "OBSERVATION_MODIFIER", 19, 24], ["red blood cells", "OBSERVATION", 49, 64], ["hypopyon", "OBSERVATION", 72, 80]]], ["Keratic precipitates are common and appear as large pinkish, brown spots on the inferior endothelial surface of the cornea (\"mutton fat deposits\").Ocular signs may be unilateral or bilateral.The vitreous may be hazy due to a similar exudation of cells from the ciliary body.Ocular signs may be unilateral or bilateral.The retina may show a focal or total exudative retinal detachment.", [["inferior endothelial surface", "ANATOMY", 80, 108], ["cornea", "ANATOMY", 116, 122], ["fat deposits", "ANATOMY", 132, 144], ["Ocular", "ANATOMY", 147, 153], ["vitreous", "ANATOMY", 195, 203], ["cells", "ANATOMY", 246, 251], ["ciliary body", "ANATOMY", 261, 273], ["Ocular", "ANATOMY", 274, 280], ["retina", "ANATOMY", 322, 328], ["retinal", "ANATOMY", 365, 372], ["retinal detachment", "DISEASE", 365, 383], ["inferior endothelial surface", "TISSUE", 80, 108], ["cornea", "TISSUE", 116, 122], ["fat", "TISSUE", 132, 135], ["Ocular", "ORGAN", 147, 153], ["vitreous", "MULTI-TISSUE_STRUCTURE", 195, 203], ["cells", "CELL", 246, 251], ["ciliary body", "MULTI-TISSUE_STRUCTURE", 261, 273], ["Ocular", "ORGAN", 274, 280], ["retina", "MULTI-TISSUE_STRUCTURE", 322, 328], ["retinal", "MULTI-TISSUE_STRUCTURE", 365, 372], ["large pinkish, brown spots", "PROBLEM", 46, 72], ["Ocular signs", "TEST", 147, 159], ["hazy", "PROBLEM", 211, 215], ["a similar exudation of cells from the ciliary body", "PROBLEM", 223, 273], ["Ocular signs", "TEST", 274, 286], ["a focal or total exudative retinal detachment", "PROBLEM", 338, 383], ["large", "OBSERVATION_MODIFIER", 46, 51], ["pinkish", "OBSERVATION", 52, 59], ["brown spots", "OBSERVATION", 61, 72], ["inferior", "ANATOMY_MODIFIER", 80, 88], ["endothelial", "ANATOMY_MODIFIER", 89, 100], ["surface", "ANATOMY_MODIFIER", 101, 108], ["cornea", "ANATOMY", 116, 122], ["signs", "OBSERVATION", 154, 159], ["may be", "UNCERTAINTY", 160, 166], ["unilateral", "OBSERVATION", 167, 177], ["bilateral", "ANATOMY_MODIFIER", 181, 190], ["vitreous", "OBSERVATION", 195, 203], ["may be", "UNCERTAINTY", 204, 210], ["hazy", "OBSERVATION", 211, 215], ["similar", "OBSERVATION_MODIFIER", 225, 232], ["exudation", "OBSERVATION", 233, 242], ["ciliary body", "ANATOMY_MODIFIER", 261, 273], ["signs", "OBSERVATION", 281, 286], ["may be", "UNCERTAINTY", 287, 293], ["unilateral", "OBSERVATION", 294, 304], ["bilateral", "ANATOMY_MODIFIER", 308, 317], ["retina", "ANATOMY", 322, 328], ["focal", "OBSERVATION_MODIFIER", 340, 345], ["total", "OBSERVATION_MODIFIER", 349, 354], ["exudative", "OBSERVATION_MODIFIER", 355, 364], ["retinal detachment", "OBSERVATION", 365, 383]]], ["It is common to see an inflammatory exudate sheathing the major retinal blood vessels, which form a cloudy sheath around the vessels.Ocular signs may be unilateral or bilateral.Blindness may be seen with abnormal pupil reflexes (miotic in early stages with uveitis, followed by dilation in blind cases) and abnormal pupil size (anisocoria).Ocular signs may be unilateral or bilateral.Cats with ocular signs frequently develop neurological signs, and die or are euthanized as a result of meningioencephalitis and its associated signs, which include behavioral changes, cranial nerve abnormalities, seizures and head tremor (seizures most common).Ocular signs may be unilateral or bilateral.Cats with ocular signs of FIP rarely show systemic signs of illness such as fever, inappetence and weight loss at the initial presentation.", [["retinal blood vessels", "ANATOMY", 64, 85], ["cloudy sheath", "ANATOMY", 100, 113], ["vessels", "ANATOMY", 125, 132], ["Ocular", "ANATOMY", 133, 139], ["pupil", "ANATOMY", 213, 218], ["pupil", "ANATOMY", 316, 321], ["Ocular", "ANATOMY", 340, 346], ["ocular", "ANATOMY", 394, 400], ["neurological", "ANATOMY", 426, 438], ["cranial nerve", "ANATOMY", 568, 581], ["head", "ANATOMY", 610, 614], ["Ocular", "ANATOMY", 645, 651], ["ocular", "ANATOMY", 699, 705], ["Blindness", "DISEASE", 177, 186], ["abnormal pupil reflexes", "DISEASE", 204, 227], ["uveitis", "DISEASE", 257, 264], ["ocular signs", "DISEASE", 394, 406], ["neurological signs", "DISEASE", 426, 444], ["meningioencephalitis", "DISEASE", 487, 507], ["cranial nerve abnormalities", "DISEASE", 568, 595], ["seizures", "DISEASE", 597, 605], ["tremor", "DISEASE", 615, 621], ["seizures", "DISEASE", 623, 631], ["FIP", "DISEASE", 715, 718], ["illness", "DISEASE", 749, 756], ["fever", "DISEASE", 765, 770], ["inappetence", "DISEASE", 772, 783], ["weight loss", "DISEASE", 788, 799], ["retinal blood vessels", "MULTI-TISSUE_STRUCTURE", 64, 85], ["vessels", "MULTI-TISSUE_STRUCTURE", 125, 132], ["Ocular", "ORGAN", 133, 139], ["pupil", "ORGANISM_SUBDIVISION", 213, 218], ["pupil", "ORGAN", 316, 321], ["Ocular", "ORGAN", 340, 346], ["meningioencephalitis", "CANCER", 487, 507], ["cranial nerve", "MULTI-TISSUE_STRUCTURE", 568, 581], ["head", "ORGANISM_SUBDIVISION", 610, 614], ["Ocular", "ORGAN", 645, 651], ["an inflammatory exudate", "PROBLEM", 20, 43], ["a cloudy sheath", "TREATMENT", 98, 113], ["Ocular signs", "TEST", 133, 145], ["Blindness", "PROBLEM", 177, 186], ["abnormal pupil reflexes", "PROBLEM", 204, 227], ["miotic in early stages", "PROBLEM", 229, 251], ["uveitis", "PROBLEM", 257, 264], ["dilation in blind cases", "TEST", 278, 301], ["abnormal pupil size", "PROBLEM", 307, 326], ["anisocoria", "PROBLEM", 328, 338], ["Ocular signs", "TEST", 340, 352], ["ocular signs", "PROBLEM", 394, 406], ["neurological signs", "PROBLEM", 426, 444], ["meningioencephalitis", "PROBLEM", 487, 507], ["its associated signs", "PROBLEM", 512, 532], ["behavioral changes", "PROBLEM", 548, 566], ["cranial nerve abnormalities", "PROBLEM", 568, 595], ["seizures", "PROBLEM", 597, 605], ["head tremor", "PROBLEM", 610, 621], ["seizures", "PROBLEM", 623, 631], ["Ocular signs", "TEST", 645, 657], ["ocular signs of FIP", "PROBLEM", 699, 718], ["illness", "PROBLEM", 749, 756], ["fever", "PROBLEM", 765, 770], ["inappetence", "PROBLEM", 772, 783], ["weight loss", "PROBLEM", 788, 799], ["inflammatory", "OBSERVATION_MODIFIER", 23, 35], ["exudate", "OBSERVATION", 36, 43], ["major", "ANATOMY_MODIFIER", 58, 63], ["retinal", "ANATOMY_MODIFIER", 64, 71], ["blood vessels", "ANATOMY", 72, 85], ["cloudy sheath", "OBSERVATION", 100, 113], ["vessels", "ANATOMY", 125, 132], ["signs", "OBSERVATION", 140, 145], ["may be", "UNCERTAINTY", 146, 152], ["unilateral", "OBSERVATION", 153, 163], ["bilateral", "ANATOMY_MODIFIER", 167, 176], ["pupil reflexes", "OBSERVATION", 213, 227], ["miotic", "OBSERVATION_MODIFIER", 229, 235], ["uveitis", "OBSERVATION", 257, 264], ["abnormal", "OBSERVATION_MODIFIER", 307, 315], ["pupil", "OBSERVATION_MODIFIER", 316, 321], ["size", "OBSERVATION_MODIFIER", 322, 326], ["anisocoria", "OBSERVATION", 328, 338], ["signs", "OBSERVATION", 347, 352], ["may be", "UNCERTAINTY", 353, 359], ["unilateral", "OBSERVATION", 360, 370], ["bilateral", "ANATOMY_MODIFIER", 374, 383], ["cranial nerve", "ANATOMY", 568, 581], ["head", "ANATOMY", 610, 614], ["tremor", "OBSERVATION", 615, 621], ["signs", "OBSERVATION", 652, 657], ["may be", "UNCERTAINTY", 658, 664], ["unilateral", "OBSERVATION", 665, 675], ["bilateral", "ANATOMY_MODIFIER", 679, 688], ["ocular", "ANATOMY", 699, 705], ["FIP", "OBSERVATION", 715, 718], ["systemic", "OBSERVATION_MODIFIER", 731, 739], ["illness", "OBSERVATION", 749, 756], ["fever", "OBSERVATION", 765, 770]]], ["As the disease becomes chronic, weight loss and neurological signs develop.DiagnosisThere is no definitive diagnosis for FIP.DiagnosisA tentative diagnosis is initially based on clinical signs; a young cat with uveitis showing hypopyon and keratic precipitates.DiagnosisSerology is usually regarded as being of dubious benefit in the diagnosis, as the FIP organism cross-reacts with enteric forms of coronavirus.DiagnosisDiagnosis can only be confirmed on characteristic histopathology of affected tissues on biopsy or necropsy examination.", [["neurological", "ANATOMY", 48, 60], ["tissues", "ANATOMY", 498, 505], ["weight loss", "DISEASE", 32, 43], ["neurological signs", "DISEASE", 48, 66], ["FIP", "DISEASE", 121, 124], ["uveitis", "DISEASE", 211, 218], ["coronavirus", "DISEASE", 400, 411], ["cat", "ORGANISM", 202, 205], ["hypopyon", "CANCER", 227, 235], ["coronavirus", "ORGANISM", 400, 411], ["tissues", "TISSUE", 498, 505], ["the disease", "PROBLEM", 3, 14], ["chronic", "PROBLEM", 23, 30], ["weight loss", "PROBLEM", 32, 43], ["neurological signs", "PROBLEM", 48, 66], ["FIP", "PROBLEM", 121, 124], ["clinical signs", "TEST", 178, 192], ["uveitis", "PROBLEM", 211, 218], ["hypopyon", "PROBLEM", 227, 235], ["keratic precipitates", "PROBLEM", 240, 260], ["the FIP organism cross", "TEST", 348, 370], ["coronavirus", "PROBLEM", 400, 411], ["affected tissues", "PROBLEM", 489, 505], ["biopsy", "TEST", 509, 515], ["necropsy examination", "TEST", 519, 539], ["disease", "OBSERVATION", 7, 14], ["chronic", "OBSERVATION_MODIFIER", 23, 30], ["no definitive", "UNCERTAINTY", 93, 106], ["FIP", "OBSERVATION", 121, 124], ["uveitis", "OBSERVATION", 211, 218], ["hypopyon", "OBSERVATION", 227, 235], ["coronavirus", "OBSERVATION", 400, 411]]], ["The typical change is described as a pyogranulomatous vasculitis.", [["vasculitis", "DISEASE", 54, 64], ["The typical change", "PROBLEM", 0, 18], ["a pyogranulomatous vasculitis", "PROBLEM", 35, 64], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["change", "OBSERVATION", 12, 18], ["pyogranulomatous", "OBSERVATION_MODIFIER", 37, 53], ["vasculitis", "OBSERVATION", 54, 64]]], ["Necrosis and a fibrinoid response are seen in some cases.", [["fibrinoid", "ANATOMY", 15, 24], ["Necrosis", "DISEASE", 0, 8], ["Necrosis", "PROBLEM", 0, 8], ["a fibrinoid response", "PROBLEM", 13, 33], ["fibrinoid", "OBSERVATION", 15, 24]]], ["The ocular cellular response includes neutrophils, lymphocytes, plasma cells, macrophages and large, spindle-shaped histiocytes.DiagnosisCats often have a large increase in plasma total protein, globulin and IgG concentration, because of the chronic nature of the inflammatory disease process.", [["ocular cellular", "ANATOMY", 4, 19], ["neutrophils", "ANATOMY", 38, 49], ["lymphocytes", "ANATOMY", 51, 62], ["plasma cells", "ANATOMY", 64, 76], ["macrophages", "ANATOMY", 78, 89], ["spindle", "ANATOMY", 101, 108], ["histiocytes", "ANATOMY", 116, 127], ["plasma", "ANATOMY", 173, 179], ["ocular cellular", "CELL", 4, 19], ["neutrophils", "CELL", 38, 49], ["lymphocytes", "CELL", 51, 62], ["plasma cells", "CELL", 64, 76], ["macrophages", "CELL", 78, 89], ["histiocytes", "CELL", 116, 127], ["plasma", "ORGANISM_SUBSTANCE", 173, 179], ["globulin", "GENE_OR_GENE_PRODUCT", 195, 203], ["IgG", "GENE_OR_GENE_PRODUCT", 208, 211], ["neutrophils", "CELL_TYPE", 38, 49], ["lymphocytes", "CELL_TYPE", 51, 62], ["plasma cells", "CELL_TYPE", 64, 76], ["macrophages", "CELL_TYPE", 78, 89], ["large, spindle-shaped histiocytes", "CELL_TYPE", 94, 127], ["plasma total protein", "PROTEIN", 173, 193], ["globulin", "PROTEIN", 195, 203], ["IgG", "PROTEIN", 208, 211], ["The ocular cellular response", "TEST", 0, 28], ["neutrophils", "TEST", 38, 49], ["lymphocytes", "TEST", 51, 62], ["plasma cells", "TEST", 64, 76], ["macrophages", "TEST", 78, 89], ["large, spindle-shaped histiocytes", "PROBLEM", 94, 127], ["a large increase in plasma total protein", "PROBLEM", 153, 193], ["globulin", "TEST", 195, 203], ["IgG concentration", "TEST", 208, 225], ["the inflammatory disease process", "PROBLEM", 260, 292], ["ocular", "ANATOMY", 4, 10], ["cellular response", "OBSERVATION", 11, 28], ["lymphocytes", "ANATOMY", 51, 62], ["plasma cells", "OBSERVATION", 64, 76], ["macrophages", "ANATOMY", 78, 89], ["large", "OBSERVATION_MODIFIER", 94, 99], ["spindle", "OBSERVATION_MODIFIER", 101, 108], ["-shaped", "OBSERVATION_MODIFIER", 108, 115], ["histiocytes", "OBSERVATION", 116, 127], ["large", "OBSERVATION_MODIFIER", 155, 160], ["increase", "OBSERVATION_MODIFIER", 161, 169], ["chronic", "OBSERVATION_MODIFIER", 242, 249], ["inflammatory", "OBSERVATION_MODIFIER", 264, 276], ["disease", "OBSERVATION", 277, 284]]], ["The polyclonal increase in gammaglobulins is caused by virus antigen and cell destruction from the intense inflammation associated with the infection.Classical signs\u2022 Discrete iris or ciliary body masses (FeLVassociated lymphosarcoma). \u2022 Anterior uveitis. \u2022 Intermittent asymmetric changes in pupil size, shape or response. \u2022 Other FeLV-associated signs, e.g. anemia.Classical signs\u2022 Retinal detachment.Classical signsSee the main reference on page 1300 (The Cat With Abnormal Iris Appearance).Clinical signsFeLV may cause ocular lymphosarcoma, which appears as discrete iris or ciliary body masses, usually bilateral, which may cause gross distortion of the iris structure.Clinical signsFeLV more commonly presents as a uveitis, with changes to iris appearance, and abnormal pupil size and shape.", [["cell", "ANATOMY", 73, 77], ["iris", "ANATOMY", 176, 180], ["ciliary body masses", "ANATOMY", 184, 203], ["lymphosarcoma", "ANATOMY", 220, 233], ["pupil", "ANATOMY", 293, 298], ["Retinal", "ANATOMY", 384, 391], ["ocular lymphosarcoma", "ANATOMY", 523, 543], ["iris", "ANATOMY", 571, 575], ["ciliary body masses", "ANATOMY", 579, 598], ["iris", "ANATOMY", 659, 663], ["iris", "ANATOMY", 746, 750], ["pupil", "ANATOMY", 776, 781], ["inflammation", "DISEASE", 107, 119], ["infection", "DISEASE", 140, 149], ["FeLVassociated lymphosarcoma", "DISEASE", 205, 233], ["Anterior uveitis", "DISEASE", 238, 254], ["anemia", "DISEASE", 360, 366], ["Retinal detachment", "DISEASE", 384, 402], ["ocular lymphosarcoma", "DISEASE", 523, 543], ["uveitis", "DISEASE", 721, 728], ["gammaglobulins", "GENE_OR_GENE_PRODUCT", 27, 41], ["cell", "CELL", 73, 77], ["iris", "TISSUE", 176, 180], ["ciliary body masses", "CANCER", 184, 203], ["FeLVassociated lymphosarcoma", "CANCER", 205, 233], ["pupil", "MULTI-TISSUE_STRUCTURE", 293, 298], ["FeLV", "ORGANISM", 332, 336], ["Retinal", "MULTI-TISSUE_STRUCTURE", 384, 391], ["ocular lymphosarcoma", "CANCER", 523, 543], ["iris", "TISSUE", 571, 575], ["ciliary body masses", "CANCER", 579, 598], ["iris", "TISSUE", 659, 663], ["iris", "TISSUE", 746, 750], ["pupil", "ORGAN", 776, 781], ["gammaglobulins", "PROTEIN", 27, 41], ["The polyclonal increase in gammaglobulins", "PROBLEM", 0, 41], ["virus antigen", "PROBLEM", 55, 68], ["cell destruction", "PROBLEM", 73, 89], ["the intense inflammation", "PROBLEM", 95, 119], ["the infection", "PROBLEM", 136, 149], ["Classical signs", "TEST", 150, 165], ["Discrete iris", "PROBLEM", 167, 180], ["ciliary body masses", "PROBLEM", 184, 203], ["FeLVassociated lymphosarcoma", "PROBLEM", 205, 233], ["Anterior uveitis", "PROBLEM", 238, 254], ["Intermittent asymmetric changes in pupil size", "PROBLEM", 258, 303], ["Other FeLV", "TEST", 326, 336], ["e.g. anemia", "PROBLEM", 355, 366], ["Classical signs", "TEST", 367, 382], ["Retinal detachment", "PROBLEM", 384, 402], ["Classical signs", "TEST", 403, 418], ["ocular lymphosarcoma", "PROBLEM", 523, 543], ["discrete iris", "PROBLEM", 562, 575], ["ciliary body masses", "PROBLEM", 579, 598], ["gross distortion of the iris structure", "PROBLEM", 635, 673], ["a uveitis", "PROBLEM", 719, 728], ["changes to iris appearance", "PROBLEM", 735, 761], ["abnormal pupil size and shape", "PROBLEM", 767, 796], ["polyclonal", "OBSERVATION_MODIFIER", 4, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["caused by", "UNCERTAINTY", 45, 54], ["virus", "OBSERVATION", 55, 60], ["cell destruction", "OBSERVATION", 73, 89], ["intense", "OBSERVATION_MODIFIER", 99, 106], ["inflammation", "OBSERVATION", 107, 119], ["infection", "OBSERVATION", 140, 149], ["Discrete", "OBSERVATION_MODIFIER", 167, 175], ["iris", "OBSERVATION", 176, 180], ["ciliary", "ANATOMY_MODIFIER", 184, 191], ["body", "ANATOMY", 192, 196], ["masses", "OBSERVATION", 197, 203], ["FeLVassociated lymphosarcoma", "OBSERVATION", 205, 233], ["Anterior", "ANATOMY_MODIFIER", 238, 246], ["uveitis", "OBSERVATION", 247, 254], ["Intermittent", "OBSERVATION_MODIFIER", 258, 270], ["asymmetric", "OBSERVATION_MODIFIER", 271, 281], ["changes", "OBSERVATION", 282, 289], ["pupil", "OBSERVATION_MODIFIER", 293, 298], ["size", "OBSERVATION_MODIFIER", 299, 303], ["shape", "OBSERVATION_MODIFIER", 305, 310], ["response", "OBSERVATION_MODIFIER", 314, 322], ["FeLV", "OBSERVATION", 332, 336], ["anemia", "OBSERVATION", 360, 366], ["Retinal", "ANATOMY", 384, 391], ["detachment", "OBSERVATION", 392, 402], ["Iris", "ANATOMY", 477, 481], ["may cause", "UNCERTAINTY", 513, 522], ["ocular lymphosarcoma", "OBSERVATION", 523, 543], ["discrete", "OBSERVATION_MODIFIER", 562, 570], ["iris", "OBSERVATION", 571, 575], ["ciliary", "OBSERVATION_MODIFIER", 579, 586], ["body", "OBSERVATION_MODIFIER", 587, 591], ["masses", "OBSERVATION", 592, 598], ["bilateral", "ANATOMY_MODIFIER", 608, 617], ["may cause", "UNCERTAINTY", 625, 634], ["gross", "OBSERVATION_MODIFIER", 635, 640], ["distortion", "OBSERVATION", 641, 651], ["iris structure", "OBSERVATION", 659, 673], ["uveitis", "OBSERVATION", 721, 728], ["abnormal", "OBSERVATION_MODIFIER", 767, 775], ["pupil", "OBSERVATION_MODIFIER", 776, 781], ["size", "OBSERVATION_MODIFIER", 782, 786], ["shape", "OBSERVATION_MODIFIER", 791, 796]]], ["The anterior chamber may contain fibrin and/or blood.", [["anterior chamber", "ANATOMY", 4, 20], ["fibrin", "ANATOMY", 33, 39], ["blood", "ANATOMY", 47, 52], ["fibrin", "GENE_OR_GENE_PRODUCT", 33, 39], ["blood", "ORGANISM_SUBSTANCE", 47, 52], ["fibrin", "PROTEIN", 33, 39], ["fibrin and/or blood", "PROBLEM", 33, 52], ["anterior", "ANATOMY_MODIFIER", 4, 12], ["chamber", "ANATOMY_MODIFIER", 13, 20], ["fibrin", "OBSERVATION", 33, 39]]], ["Anterior uveitis may occur in the absence of discernible intra-ocular neoplasia.Clinical signsSome cats develop spastic pupil syndrome, which presents as otherwise unexplainable intermittent asymmetric changes in pupil size, shape or response.", [["intra-ocular neoplasia", "ANATOMY", 57, 79], ["pupil", "ANATOMY", 213, 218], ["Anterior uveitis", "DISEASE", 0, 16], ["intra-ocular neoplasia", "DISEASE", 57, 79], ["spastic pupil syndrome", "DISEASE", 112, 134], ["intra-ocular neoplasia", "CANCER", 57, 79], ["cats", "ORGANISM", 99, 103], ["pupil", "MULTI-TISSUE_STRUCTURE", 213, 218], ["cats", "SPECIES", 99, 103], ["Anterior uveitis", "PROBLEM", 0, 16], ["discernible intra-ocular neoplasia", "PROBLEM", 45, 79], ["Clinical signs", "TEST", 80, 94], ["spastic pupil syndrome", "PROBLEM", 112, 134], ["intermittent asymmetric changes in pupil size", "PROBLEM", 178, 223], ["uveitis", "OBSERVATION", 9, 16], ["discernible", "OBSERVATION_MODIFIER", 45, 56], ["intra-ocular neoplasia", "OBSERVATION", 57, 79], ["spastic", "OBSERVATION_MODIFIER", 112, 119], ["pupil syndrome", "OBSERVATION", 120, 134], ["asymmetric", "OBSERVATION_MODIFIER", 191, 201], ["changes", "OBSERVATION", 202, 209], ["pupil", "OBSERVATION_MODIFIER", 213, 218], ["size", "OBSERVATION_MODIFIER", 219, 223], ["shape", "OBSERVATION_MODIFIER", 225, 230]]], ["For more detail see page 1300 (The Cat With Abnormal Iris Appearance).Clinical signsIt is possible to see retinal detachment when the neoplastic process involves the choroid.Clinical signsThere may be other signs of FeLV-associated disease, e.g. anemia or multicentric lymphosarcoma.DiagnosisDiagnosis is based on the clinical signs observed in the eye, in association with other signs suggestive of FeLV, e.g. multicentric lymphoma, FeLV-associated anemia.DiagnosisDiagnosis is confirmed on clinical pathology, for example on cytology of lymph nodes or aqueous centesis samples, or occasionally on hematology.DiagnosisA positive serological test using an antigen-based test for FeLV is supportive evidence of the disease.", [["retinal", "ANATOMY", 106, 113], ["neoplastic", "ANATOMY", 134, 144], ["choroid", "ANATOMY", 166, 173], ["multicentric lymphosarcoma", "ANATOMY", 256, 282], ["eye", "ANATOMY", 349, 352], ["multicentric lymphoma", "ANATOMY", 411, 432], ["lymph nodes", "ANATOMY", 539, 550], ["aqueous centesis samples", "ANATOMY", 554, 578], ["retinal detachment", "DISEASE", 106, 124], ["FeLV-associated disease", "DISEASE", 216, 239], ["anemia", "DISEASE", 246, 252], ["lymphosarcoma", "DISEASE", 269, 282], ["DiagnosisDiagnosis", "DISEASE", 283, 301], ["FeLV", "DISEASE", 400, 404], ["multicentric lymphoma", "DISEASE", 411, 432], ["FeLV", "DISEASE", 434, 438], ["anemia", "DISEASE", 450, 456], ["DiagnosisDiagnosis", "DISEASE", 457, 475], ["FeLV", "DISEASE", 679, 683], ["retinal", "MULTI-TISSUE_STRUCTURE", 106, 113], ["choroid", "MULTI-TISSUE_STRUCTURE", 166, 173], ["FeLV", "ORGANISM", 216, 220], ["lymphosarcoma", "CANCER", 269, 282], ["eye", "ORGAN", 349, 352], ["FeLV", "ORGANISM", 400, 404], ["lymphoma", "CANCER", 424, 432], ["FeLV", "ORGANISM", 434, 438], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 539, 550], ["aqueous centesis samples", "CANCER", 554, 578], ["FeLV", "ORGANISM", 679, 683], ["FeLV", "SPECIES", 679, 683], ["Clinical signs", "TEST", 70, 84], ["retinal detachment", "PROBLEM", 106, 124], ["the neoplastic process", "PROBLEM", 130, 152], ["Clinical signs", "TEST", 174, 188], ["FeLV-associated disease", "PROBLEM", 216, 239], ["anemia", "PROBLEM", 246, 252], ["multicentric lymphosarcoma", "PROBLEM", 256, 282], ["the clinical signs", "TEST", 314, 332], ["FeLV", "PROBLEM", 400, 404], ["multicentric lymphoma", "PROBLEM", 411, 432], ["FeLV", "PROBLEM", 434, 438], ["associated anemia", "PROBLEM", 439, 456], ["clinical pathology", "TEST", 492, 510], ["cytology", "TEST", 527, 535], ["lymph nodes", "PROBLEM", 539, 550], ["aqueous centesis samples", "TEST", 554, 578], ["serological test", "TEST", 630, 646], ["an antigen", "TEST", 653, 663], ["FeLV", "PROBLEM", 679, 683], ["the disease", "PROBLEM", 710, 721], ["Iris", "ANATOMY", 53, 57], ["retinal", "ANATOMY", 106, 113], ["detachment", "OBSERVATION", 114, 124], ["neoplastic", "OBSERVATION", 134, 144], ["choroid", "ANATOMY", 166, 173], ["may be", "UNCERTAINTY", 194, 200], ["FeLV", "OBSERVATION", 216, 220], ["disease", "OBSERVATION", 232, 239], ["anemia", "OBSERVATION", 246, 252], ["multicentric lymphosarcoma", "OBSERVATION", 256, 282], ["eye", "ANATOMY", 349, 352], ["suggestive of", "UNCERTAINTY", 386, 399], ["FeLV", "OBSERVATION", 400, 404], ["multicentric lymphoma", "OBSERVATION", 411, 432], ["anemia", "OBSERVATION", 450, 456], ["lymph nodes", "OBSERVATION", 539, 550], ["disease", "OBSERVATION", 714, 721]]], ["For more detail see page 543 (The Anemic Cat).Clinical signsMost cases present as anterior uveitis with corneal edema and a cloudy aqueous, and have some form of swelling seen in the iris, which may cause distortion of the pupil (dyscoria).Clinical signsVarious tumors occur in the eye.", [["corneal", "ANATOMY", 104, 111], ["iris", "ANATOMY", 183, 187], ["pupil", "ANATOMY", 223, 228], ["signsVarious tumors", "ANATOMY", 249, 268], ["eye", "ANATOMY", 282, 285], ["uveitis", "DISEASE", 91, 98], ["corneal edema", "DISEASE", 104, 117], ["swelling", "DISEASE", 162, 170], ["distortion of the pupil", "DISEASE", 205, 228], ["tumors", "DISEASE", 262, 268], ["corneal edema", "PATHOLOGICAL_FORMATION", 104, 117], ["aqueous", "ORGANISM_SUBSTANCE", 131, 138], ["iris", "ORGAN", 183, 187], ["pupil", "ORGANISM_SUBDIVISION", 223, 228], ["dyscoria", "CANCER", 230, 238], ["signsVarious tumors", "CANCER", 249, 268], ["eye", "ORGAN", 282, 285], ["Clinical signs", "TEST", 46, 60], ["anterior uveitis", "PROBLEM", 82, 98], ["corneal edema", "PROBLEM", 104, 117], ["a cloudy aqueous", "PROBLEM", 122, 138], ["swelling", "PROBLEM", 162, 170], ["distortion of the pupil (dyscoria)", "PROBLEM", 205, 239], ["Clinical signsVarious tumors", "PROBLEM", 240, 268], ["anterior", "ANATOMY_MODIFIER", 82, 90], ["uveitis", "OBSERVATION", 91, 98], ["corneal", "ANATOMY", 104, 111], ["edema", "OBSERVATION", 112, 117], ["cloudy", "OBSERVATION_MODIFIER", 124, 130], ["aqueous", "OBSERVATION_MODIFIER", 131, 138], ["swelling", "OBSERVATION", 162, 170], ["iris", "ANATOMY", 183, 187], ["may cause", "UNCERTAINTY", 195, 204], ["pupil", "OBSERVATION", 223, 228], ["tumors", "OBSERVATION", 262, 268], ["eye", "ANATOMY", 282, 285]]], ["They may arise from the iris such as melanoma, lymphosarcoma, sarcoma and ciliary body tumors or arise from the retina including lymphosarcoma and adenocarcinoma from lung, uterus and undetermined origin.Clinical signsLymphosarcoma is the most common ocular neoplasm, and may be FeLV-associated, although more commonly does not appear to be associated with FeLV.Clinical signsLymphosarcoma often presents as bilateral iris swelling, and anterior chamber hypopyon and/or hemorrhage in a young cat, with or without other signs suggesting multicentric neoplasia.Clinical signsSigns of lymphosarcoma typically include: \u2022 The anterior chamber is cloudy from white blood cells and proteins that have leaked from diseased iris blood vessels. \u2022 The iris may have red cells on the surface mixed with protein and white blood cells caused by disruption of the endothelial cells on the blood vessel walls.", [["iris", "ANATOMY", 24, 28], ["melanoma", "ANATOMY", 37, 45], ["lymphosarcoma", "ANATOMY", 47, 60], ["sarcoma", "ANATOMY", 62, 69], ["ciliary body tumors", "ANATOMY", 74, 93], ["retina", "ANATOMY", 112, 118], ["lymphosarcoma", "ANATOMY", 129, 142], ["adenocarcinoma", "ANATOMY", 147, 161], ["lung", "ANATOMY", 167, 171], ["uterus", "ANATOMY", 173, 179], ["ocular neoplasm", "ANATOMY", 251, 266], ["iris", "ANATOMY", 418, 422], ["anterior chamber hypopyon", "ANATOMY", 437, 462], ["multicentric neoplasia", "ANATOMY", 536, 558], ["lymphosarcoma", "ANATOMY", 582, 595], ["anterior chamber", "ANATOMY", 621, 637], ["white blood cells", "ANATOMY", 653, 670], ["iris blood vessels", "ANATOMY", 715, 733], ["iris", "ANATOMY", 741, 745], ["red cells", "ANATOMY", 755, 764], ["surface", "ANATOMY", 772, 779], ["white blood cells", "ANATOMY", 803, 820], ["endothelial cells", "ANATOMY", 849, 866], ["blood vessel walls", "ANATOMY", 874, 892], ["melanoma", "DISEASE", 37, 45], ["lymphosarcoma", "DISEASE", 47, 60], ["sarcoma", "DISEASE", 62, 69], ["ciliary body tumors", "DISEASE", 74, 93], ["lymphosarcoma", "DISEASE", 129, 142], ["adenocarcinoma", "DISEASE", 147, 161], ["signsLymphosarcoma", "DISEASE", 213, 231], ["ocular neoplasm", "DISEASE", 251, 266], ["FeLV", "DISEASE", 357, 361], ["signsLymphosarcoma", "DISEASE", 371, 389], ["iris swelling", "DISEASE", 418, 431], ["hemorrhage", "DISEASE", 470, 480], ["neoplasia", "DISEASE", 549, 558], ["lymphosarcoma", "DISEASE", 582, 595], ["iris", "TISSUE", 24, 28], ["melanoma", "CANCER", 37, 45], ["lymphosarcoma", "CANCER", 47, 60], ["sarcoma", "CANCER", 62, 69], ["ciliary body tumors", "CANCER", 74, 93], ["retina", "MULTI-TISSUE_STRUCTURE", 112, 118], ["lymphosarcoma", "CANCER", 129, 142], ["adenocarcinoma", "CANCER", 147, 161], ["lung", "ORGAN", 167, 171], ["uterus", "ORGAN", 173, 179], ["ocular neoplasm", "CANCER", 251, 266], ["FeLV", "ORGANISM", 279, 283], ["FeLV", "ORGANISM", 357, 361], ["cat", "ORGANISM", 492, 495], ["multicentric neoplasia", "CANCER", 536, 558], ["lymphosarcoma", "CANCER", 582, 595], ["white blood cells", "CELL", 653, 670], ["iris blood vessels", "MULTI-TISSUE_STRUCTURE", 715, 733], ["iris", "ORGAN", 741, 745], ["red cells", "CELL", 755, 764], ["surface", "CELLULAR_COMPONENT", 772, 779], ["white blood cells", "CELL", 803, 820], ["endothelial cells", "CELL", 849, 866], ["blood vessel walls", "MULTI-TISSUE_STRUCTURE", 874, 892], ["white blood cells", "CELL_TYPE", 653, 670], ["red cells", "CELL_TYPE", 755, 764], ["white blood cells", "CELL_TYPE", 803, 820], ["endothelial cells", "CELL_TYPE", 849, 866], ["melanoma", "PROBLEM", 37, 45], ["lymphosarcoma", "PROBLEM", 47, 60], ["sarcoma", "PROBLEM", 62, 69], ["ciliary body tumors", "PROBLEM", 74, 93], ["lymphosarcoma", "PROBLEM", 129, 142], ["adenocarcinoma from lung, uterus", "PROBLEM", 147, 179], ["Clinical signsLymphosarcoma", "PROBLEM", 204, 231], ["ocular neoplasm", "PROBLEM", 251, 266], ["FeLV", "PROBLEM", 279, 283], ["FeLV", "PROBLEM", 357, 361], ["Clinical signsLymphosarcoma", "PROBLEM", 362, 389], ["bilateral iris swelling", "PROBLEM", 408, 431], ["anterior chamber hypopyon", "PROBLEM", 437, 462], ["hemorrhage", "PROBLEM", 470, 480], ["multicentric neoplasia", "PROBLEM", 536, 558], ["lymphosarcoma", "PROBLEM", 582, 595], ["white blood cells", "TEST", 653, 670], ["red cells", "PROBLEM", 755, 764], ["the surface", "TEST", 768, 779], ["protein", "TEST", 791, 798], ["white blood cells", "TEST", 803, 820], ["disruption of the endothelial cells", "PROBLEM", 831, 866], ["iris", "ANATOMY", 24, 28], ["melanoma", "OBSERVATION", 37, 45], ["lymphosarcoma", "OBSERVATION", 47, 60], ["sarcoma", "OBSERVATION", 62, 69], ["ciliary", "ANATOMY_MODIFIER", 74, 81], ["body", "ANATOMY", 82, 86], ["tumors", "OBSERVATION", 87, 93], ["retina", "ANATOMY", 112, 118], ["lymphosarcoma", "OBSERVATION", 129, 142], ["adenocarcinoma", "OBSERVATION", 147, 161], ["lung", "ANATOMY", 167, 171], ["uterus", "ANATOMY", 173, 179], ["most common", "OBSERVATION_MODIFIER", 239, 250], ["ocular", "ANATOMY", 251, 257], ["neoplasm", "OBSERVATION", 258, 266], ["may be", "UNCERTAINTY", 272, 278], ["FeLV", "OBSERVATION", 279, 283], ["FeLV", "OBSERVATION", 357, 361], ["bilateral", "ANATOMY_MODIFIER", 408, 417], ["iris", "ANATOMY", 418, 422], ["swelling", "OBSERVATION", 423, 431], ["anterior", "ANATOMY_MODIFIER", 437, 445], ["chamber", "ANATOMY_MODIFIER", 446, 453], ["hypopyon", "OBSERVATION", 454, 462], ["hemorrhage", "OBSERVATION", 470, 480], ["suggesting", "UNCERTAINTY", 525, 535], ["multicentric", "OBSERVATION_MODIFIER", 536, 548], ["neoplasia", "OBSERVATION", 549, 558], ["lymphosarcoma", "OBSERVATION", 582, 595], ["anterior", "ANATOMY_MODIFIER", 621, 629], ["chamber", "ANATOMY_MODIFIER", 630, 637], ["cloudy", "OBSERVATION", 641, 647], ["white blood cells", "OBSERVATION", 653, 670], ["leaked", "OBSERVATION_MODIFIER", 694, 700], ["diseased iris", "OBSERVATION", 706, 719], ["blood vessels", "OBSERVATION", 720, 733], ["iris", "ANATOMY", 741, 745], ["red cells", "OBSERVATION", 755, 764], ["surface", "OBSERVATION_MODIFIER", 772, 779], ["white blood cells", "OBSERVATION", 803, 820], ["disruption", "OBSERVATION", 831, 841], ["endothelial cells", "OBSERVATION", 849, 866], ["blood vessel", "ANATOMY", 874, 886], ["walls", "ANATOMY_MODIFIER", 887, 892]]], ["Lymphosarcoma does not usually cause frank hemorrhage.", [["Lymphosarcoma", "DISEASE", 0, 13], ["hemorrhage", "DISEASE", 43, 53], ["Lymphosarcoma", "PROBLEM", 0, 13], ["frank hemorrhage", "PROBLEM", 37, 53], ["not usually cause", "UNCERTAINTY", 19, 36], ["frank", "OBSERVATION_MODIFIER", 37, 42], ["hemorrhage", "OBSERVATION", 43, 53]]], ["Varying degrees of hyphema are present. \u2022 The iris appears thickened with a pale fleshy color change, and may be tinged with blood. \u2022 The pupil is distorted (dyscoria) if the iris is grossly distorted with infiltrated cells. \u2022 Glaucoma is often an associated complication. \u2022 Corneal edema may be present. \u2022 Regional lymph nodes may be increased in size.Clinical signsDiffuse iris melanoma typically appears as an enlarging area over months to years of light tan to dark brown pigmentation on the iris surface.", [["iris", "ANATOMY", 46, 50], ["blood", "ANATOMY", 125, 130], ["pupil", "ANATOMY", 138, 143], ["iris", "ANATOMY", 175, 179], ["cells", "ANATOMY", 218, 223], ["Corneal edema", "ANATOMY", 275, 288], ["lymph nodes", "ANATOMY", 316, 327], ["iris melanoma", "ANATOMY", 375, 388], ["iris surface", "ANATOMY", 496, 508], ["hyphema", "DISEASE", 19, 26], ["Glaucoma", "DISEASE", 227, 235], ["Corneal edema", "DISEASE", 275, 288], ["iris melanoma", "DISEASE", 375, 388], ["iris", "TISSUE", 46, 50], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["pupil", "MULTI-TISSUE_STRUCTURE", 138, 143], ["iris", "ORGAN", 175, 179], ["cells", "CELL", 218, 223], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 316, 327], ["iris melanoma", "CANCER", 375, 388], ["iris surface", "MULTI-TISSUE_STRUCTURE", 496, 508], ["infiltrated cells", "CELL_TYPE", 206, 223], ["hyphema", "PROBLEM", 19, 26], ["thickened", "PROBLEM", 59, 68], ["a pale fleshy color change", "PROBLEM", 74, 100], ["tinged with blood", "PROBLEM", 113, 130], ["distorted (dyscoria", "PROBLEM", 147, 166], ["infiltrated cells", "PROBLEM", 206, 223], ["Glaucoma", "PROBLEM", 227, 235], ["an associated complication", "PROBLEM", 245, 271], ["Corneal edema", "PROBLEM", 275, 288], ["Regional lymph nodes", "PROBLEM", 307, 327], ["Clinical signsDiffuse iris melanoma", "PROBLEM", 353, 388], ["an enlarging area", "PROBLEM", 410, 427], ["light tan to dark brown pigmentation on the iris surface", "PROBLEM", 452, 508], ["degrees", "OBSERVATION_MODIFIER", 8, 15], ["hyphema", "OBSERVATION", 19, 26], ["iris", "ANATOMY", 46, 50], ["appears", "UNCERTAINTY", 51, 58], ["thickened", "OBSERVATION", 59, 68], ["pale", "OBSERVATION_MODIFIER", 76, 80], ["fleshy color", "OBSERVATION", 81, 93], ["change", "OBSERVATION_MODIFIER", 94, 100], ["may be", "UNCERTAINTY", 106, 112], ["tinged", "OBSERVATION", 113, 119], ["pupil", "OBSERVATION", 138, 143], ["distorted", "OBSERVATION_MODIFIER", 147, 156], ["dyscoria", "OBSERVATION", 158, 166], ["iris", "ANATOMY", 175, 179], ["grossly", "OBSERVATION_MODIFIER", 183, 190], ["distorted", "OBSERVATION", 191, 200], ["infiltrated cells", "OBSERVATION", 206, 223], ["Glaucoma", "OBSERVATION", 227, 235], ["complication", "OBSERVATION", 259, 271], ["edema", "OBSERVATION", 283, 288], ["may be", "UNCERTAINTY", 289, 295], ["lymph nodes", "OBSERVATION", 316, 327], ["may be", "UNCERTAINTY", 328, 334], ["increased", "OBSERVATION_MODIFIER", 335, 344], ["size", "OBSERVATION_MODIFIER", 348, 352], ["iris melanoma", "OBSERVATION", 375, 388], ["enlarging", "OBSERVATION_MODIFIER", 413, 422], ["area", "OBSERVATION_MODIFIER", 423, 427], ["light tan to dark", "OBSERVATION_MODIFIER", 452, 469], ["brown pigmentation", "OBSERVATION", 470, 488], ["iris", "ANATOMY", 496, 500], ["surface", "ANATOMY_MODIFIER", 501, 508]]], ["Usually the neoplasm does not form an obvious discrete mass, but the iris may become diffusely thickened.", [["neoplasm", "ANATOMY", 12, 20], ["mass", "ANATOMY", 55, 59], ["iris", "ANATOMY", 69, 73], ["neoplasm", "DISEASE", 12, 20], ["neoplasm", "CANCER", 12, 20], ["iris", "ORGAN", 69, 73], ["the neoplasm", "PROBLEM", 8, 20], ["an obvious discrete mass", "PROBLEM", 35, 59], ["diffusely thickened", "PROBLEM", 85, 104], ["neoplasm", "OBSERVATION", 12, 20], ["does not form", "UNCERTAINTY", 21, 34], ["obvious", "OBSERVATION_MODIFIER", 38, 45], ["discrete", "OBSERVATION_MODIFIER", 46, 54], ["mass", "OBSERVATION", 55, 59], ["iris", "ANATOMY", 69, 73], ["diffusely", "OBSERVATION_MODIFIER", 85, 94], ["thickened", "OBSERVATION", 95, 104]]], ["The disease is usually unilateral and typically occurs in older cats. \u2022 Presentation may more resemble uveal inflammation than neoplasia. \u2022 Sometimes the disease may present in an advanced state with secondary glaucoma. \u2022 Amelanotic diffuse iris melanomas have also been reported.", [["uveal", "ANATOMY", 103, 108], ["neoplasia", "ANATOMY", 127, 136], ["glaucoma", "ANATOMY", 210, 218], ["diffuse iris melanomas", "ANATOMY", 233, 255], ["uveal inflammation", "DISEASE", 103, 121], ["neoplasia", "DISEASE", 127, 136], ["glaucoma", "DISEASE", 210, 218], ["iris melanomas", "DISEASE", 241, 255], ["cats", "ORGANISM", 64, 68], ["uveal inflammation", "PATHOLOGICAL_FORMATION", 103, 121], ["neoplasia", "CANCER", 127, 136], ["diffuse iris melanomas", "CANCER", 233, 255], ["cats", "SPECIES", 64, 68], ["The disease", "PROBLEM", 0, 11], ["uveal inflammation", "PROBLEM", 103, 121], ["neoplasia", "PROBLEM", 127, 136], ["the disease", "PROBLEM", 150, 161], ["secondary glaucoma", "PROBLEM", 200, 218], ["Amelanotic diffuse iris melanomas", "PROBLEM", 222, 255], ["disease", "OBSERVATION", 4, 11], ["unilateral", "OBSERVATION_MODIFIER", 23, 33], ["may more resemble", "UNCERTAINTY", 85, 102], ["uveal inflammation", "OBSERVATION", 103, 121], ["neoplasia", "OBSERVATION", 127, 136], ["disease", "OBSERVATION", 154, 161], ["secondary glaucoma", "OBSERVATION", 200, 218], ["Amelanotic", "OBSERVATION_MODIFIER", 222, 232], ["diffuse", "OBSERVATION_MODIFIER", 233, 240], ["iris melanomas", "OBSERVATION", 241, 255]]], ["These are difficult to diagnose unless the effects of the tumor on angle obstruction and resultant glaucoma are observed.Clinical signsPost-traumatic sarcoma more commonly forms discrete masses within the eye.Clinical signsCiliary body adenoma is a rare slow-growing neoplasm, which appears as a whitish to cream mass behind the pupil margin.Clinical signsMetastatic neoplasia from an extra-ocular primary tumor appears as an intra-ocular neoplasm involving the iris, and is associated with a similar neoplasm remote from the eye, e.g. mammary or uterine adenocarcinoma.DiagnosisA tentative diagnosis is based initially on the appearance of the eye (uveitis, iris swelling and/or distortion of the retina) and consideration of the history.DiagnosisExamination of the buffy coat is useful for diagnosis of lymphosarcoma.", [["tumor", "ANATOMY", 58, 63], ["glaucoma", "ANATOMY", 99, 107], ["sarcoma", "ANATOMY", 150, 157], ["masses", "ANATOMY", 187, 193], ["eye", "ANATOMY", 205, 208], ["signsCiliary body adenoma", "ANATOMY", 218, 243], ["neoplasm", "ANATOMY", 267, 275], ["pupil margin", "ANATOMY", 329, 341], ["signsMetastatic neoplasia", "ANATOMY", 351, 376], ["extra-ocular primary tumor", "ANATOMY", 385, 411], ["intra-ocular neoplasm", "ANATOMY", 426, 447], ["iris", "ANATOMY", 462, 466], ["neoplasm", "ANATOMY", 501, 509], ["eye", "ANATOMY", 526, 529], ["mammary", "ANATOMY", 536, 543], ["uterine adenocarcinoma", "ANATOMY", 547, 569], ["eye", "ANATOMY", 645, 648], ["iris", "ANATOMY", 659, 663], ["retina", "ANATOMY", 698, 704], ["buffy coat", "ANATOMY", 767, 777], ["lymphosarcoma", "ANATOMY", 805, 818], ["tumor", "DISEASE", 58, 63], ["obstruction", "DISEASE", 73, 84], ["glaucoma", "DISEASE", 99, 107], ["traumatic sarcoma", "DISEASE", 140, 157], ["signsCiliary body adenoma", "DISEASE", 218, 243], ["neoplasm", "DISEASE", 267, 275], ["signsMetastatic neoplasia", "DISEASE", 351, 376], ["primary tumor", "DISEASE", 398, 411], ["intra-ocular neoplasm", "DISEASE", 426, 447], ["neoplasm", "DISEASE", 501, 509], ["uterine adenocarcinoma", "DISEASE", 547, 569], ["uveitis", "DISEASE", 650, 657], ["iris swelling", "DISEASE", 659, 672], ["lymphosarcoma", "DISEASE", 805, 818], ["tumor", "CANCER", 58, 63], ["sarcoma", "CANCER", 150, 157], ["masses", "CANCER", 187, 193], ["eye", "ORGAN", 205, 208], ["signsCiliary body adenoma", "CANCER", 218, 243], ["neoplasm", "CANCER", 267, 275], ["pupil margin", "MULTI-TISSUE_STRUCTURE", 329, 341], ["signsMetastatic neoplasia", "CANCER", 351, 376], ["extra-ocular primary tumor", "CANCER", 385, 411], ["intra-ocular neoplasm", "CANCER", 426, 447], ["iris", "ORGAN", 462, 466], ["neoplasm", "CANCER", 501, 509], ["eye", "ORGAN", 526, 529], ["mammary", "ORGAN", 536, 543], ["uterine adenocarcinoma", "CANCER", 547, 569], ["eye", "ORGAN", 645, 648], ["retina", "MULTI-TISSUE_STRUCTURE", 698, 704], ["lymphosarcoma", "CANCER", 805, 818], ["the tumor", "PROBLEM", 54, 63], ["angle obstruction", "PROBLEM", 67, 84], ["resultant glaucoma", "PROBLEM", 89, 107], ["Clinical signsPost-traumatic sarcoma", "PROBLEM", 121, 157], ["discrete masses within the eye", "PROBLEM", 178, 208], ["Clinical signsCiliary body adenoma", "PROBLEM", 209, 243], ["a rare slow-growing neoplasm", "PROBLEM", 247, 275], ["a whitish to cream mass", "PROBLEM", 294, 317], ["Clinical signsMetastatic neoplasia", "PROBLEM", 342, 376], ["an extra-ocular primary tumor", "PROBLEM", 382, 411], ["an intra-ocular neoplasm involving the iris", "PROBLEM", 423, 466], ["a similar neoplasm", "PROBLEM", 491, 509], ["uterine adenocarcinoma", "PROBLEM", 547, 569], ["uveitis", "PROBLEM", 650, 657], ["iris swelling", "PROBLEM", 659, 672], ["distortion of the retina", "PROBLEM", 680, 704], ["the buffy coat", "TEST", 763, 777], ["lymphosarcoma", "PROBLEM", 805, 818], ["tumor", "OBSERVATION", 58, 63], ["angle", "OBSERVATION_MODIFIER", 67, 72], ["obstruction", "OBSERVATION", 73, 84], ["resultant", "OBSERVATION_MODIFIER", 89, 98], ["glaucoma", "OBSERVATION", 99, 107], ["traumatic", "OBSERVATION_MODIFIER", 140, 149], ["sarcoma", "OBSERVATION", 150, 157], ["more commonly", "OBSERVATION_MODIFIER", 158, 171], ["discrete", "OBSERVATION_MODIFIER", 178, 186], ["masses", "OBSERVATION", 187, 193], ["eye", "ANATOMY", 205, 208], ["body adenoma", "OBSERVATION", 231, 243], ["rare", "OBSERVATION_MODIFIER", 249, 253], ["slow", "OBSERVATION_MODIFIER", 254, 258], ["growing", "OBSERVATION_MODIFIER", 259, 266], ["neoplasm", "OBSERVATION", 267, 275], ["whitish", "OBSERVATION_MODIFIER", 296, 303], ["mass", "OBSERVATION", 313, 317], ["pupil", "ANATOMY", 329, 334], ["margin", "OBSERVATION_MODIFIER", 335, 341], ["signsMetastatic", "OBSERVATION_MODIFIER", 351, 366], ["neoplasia", "OBSERVATION", 367, 376], ["extra-ocular", "OBSERVATION_MODIFIER", 385, 397], ["primary", "OBSERVATION_MODIFIER", 398, 405], ["tumor", "OBSERVATION", 406, 411], ["intra-ocular", "OBSERVATION_MODIFIER", 426, 438], ["neoplasm", "OBSERVATION", 439, 447], ["iris", "ANATOMY", 462, 466], ["similar", "OBSERVATION_MODIFIER", 493, 500], ["neoplasm", "OBSERVATION", 501, 509], ["eye", "ANATOMY", 526, 529], ["mammary", "ANATOMY", 536, 543], ["uterine", "ANATOMY", 547, 554], ["adenocarcinoma", "OBSERVATION", 555, 569], ["eye", "ANATOMY", 645, 648], ["uveitis", "OBSERVATION", 650, 657], ["iris", "ANATOMY", 659, 663], ["retina", "ANATOMY", 698, 704], ["buffy coat", "OBSERVATION", 767, 777], ["lymphosarcoma", "OBSERVATION", 805, 818]]], ["The presence of abnormal plump lymphocytes with large prominent nucleoli is highly suggestive.", [["plump lymphocytes", "ANATOMY", 25, 42], ["nucleoli", "ANATOMY", 64, 72], ["plump lymphocytes", "CELL", 25, 42], ["nucleoli", "CELLULAR_COMPONENT", 64, 72], ["abnormal plump lymphocytes", "CELL_TYPE", 16, 42], ["abnormal plump lymphocytes", "PROBLEM", 16, 42], ["large prominent nucleoli", "PROBLEM", 48, 72], ["abnormal", "OBSERVATION_MODIFIER", 16, 24], ["plump lymphocytes", "OBSERVATION", 25, 42], ["large", "OBSERVATION_MODIFIER", 48, 53], ["prominent", "OBSERVATION_MODIFIER", 54, 63], ["nucleoli", "OBSERVATION", 64, 72], ["highly suggestive", "UNCERTAINTY", 76, 93]]], ["Biopsy of regional lymph nodes is useful if there is lymphomegaly.DiagnosisDefinitive diagnosis may be obtained by fine-needle aspirate biopsies or anterior chamber centesis and cytology.DiagnosisSerology for FeLV may support the diagnosis of lymphosarcoma.DiagnosisChest and abdominal radiology and/or ultrasound may be indicated.Clinical signsCryptococcosis is the most common fungal infection affecting cats, and occurs throughout the world.Clinical signsThe initial ocular site for establishment of infection is usually the choroid, and the anterior uveal tract is often involved later in the course of the infection.Clinical signsCats may present with sudden blindness caused by multifocal granulomatous chorioretinitis with varying degrees of retinal detachment. \u2022 Vitreous flare (cloudy vitreous) is present, and makes the retina difficult to examine in cases with severe inflammation. \u2022 If the retina can be visualized, the granulomas appear as small swollen brownish discolored areas in the tapetal and non-tapetal retina.Clinical signsThere is usually anterior uveitis with corneal edema, anterior chamber flare (with or without hypopyon and keratic precipitates), swollen iris with varying degrees of posterior synechia causing a distorted pupil, and in chronic cases, new vascular growth on the anterior surface of the iris (pre-iridal fibrovascular membrane formation).Complications include secondary cataract and glaucoma.Some cats present with exophthalmos (eye bulging forward), where there has been an extension of the disease from the sinuses and nasal cavity into the orbital tissues.Complications include secondary cataract and glaucoma.In cases with nasal infection, there may be a mucopurulent discharge with sneezing.", [["lymph nodes", "ANATOMY", 19, 30], ["lymphosarcoma", "ANATOMY", 243, 256], ["abdominal", "ANATOMY", 276, 285], ["ocular site", "ANATOMY", 470, 481], ["choroid", "ANATOMY", 528, 535], ["anterior uveal tract", "ANATOMY", 545, 565], ["retinal", "ANATOMY", 749, 756], ["Vitreous", "ANATOMY", 771, 779], ["vitreous", "ANATOMY", 794, 802], ["retina", "ANATOMY", 830, 836], ["retina", "ANATOMY", 902, 908], ["granulomas", "ANATOMY", 932, 942], ["tapetal", "ANATOMY", 1000, 1007], ["non-tapetal retina", "ANATOMY", 1012, 1030], ["corneal", "ANATOMY", 1084, 1091], ["anterior chamber", "ANATOMY", 1099, 1115], ["hypopyon", "ANATOMY", 1139, 1147], ["iris", "ANATOMY", 1183, 1187], ["posterior synechia", "ANATOMY", 1212, 1230], ["pupil", "ANATOMY", 1251, 1256], ["vascular", "ANATOMY", 1284, 1292], ["anterior surface", "ANATOMY", 1307, 1323], ["iris", "ANATOMY", 1331, 1335], ["fibrovascular membrane", "ANATOMY", 1348, 1370], ["glaucoma", "ANATOMY", 1427, 1435], ["eye", "ANATOMY", 1473, 1476], ["sinuses", "ANATOMY", 1553, 1560], ["nasal cavity", "ANATOMY", 1565, 1577], ["orbital tissues", "ANATOMY", 1587, 1602], ["glaucoma", "ANATOMY", 1648, 1656], ["nasal", "ANATOMY", 1671, 1676], ["lymphomegaly", "DISEASE", 53, 65], ["lymphosarcoma", "DISEASE", 243, 256], ["signsCryptococcosis", "DISEASE", 340, 359], ["fungal infection", "DISEASE", 379, 395], ["infection", "DISEASE", 503, 512], ["infection", "DISEASE", 611, 620], ["sudden blindness", "DISEASE", 657, 673], ["chorioretinitis", "DISEASE", 709, 724], ["retinal detachment", "DISEASE", 749, 767], ["inflammation", "DISEASE", 879, 891], ["granulomas", "DISEASE", 932, 942], ["uveitis", "DISEASE", 1071, 1078], ["corneal edema", "DISEASE", 1084, 1097], ["synechia", "DISEASE", 1222, 1230], ["cataract", "DISEASE", 1414, 1422], ["glaucoma", "DISEASE", 1427, 1435], ["exophthalmos", "DISEASE", 1459, 1471], ["cataract", "DISEASE", 1635, 1643], ["glaucoma", "DISEASE", 1648, 1656], ["nasal infection", "DISEASE", 1671, 1686], ["sneezing", "DISEASE", 1731, 1739], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 19, 30], ["aspirate biopsies", "MULTI-TISSUE_STRUCTURE", 127, 144], ["FeLV", "ORGANISM", 209, 213], ["lymphosarcoma", "CANCER", 243, 256], ["abdominal", "ORGAN", 276, 285], ["cats", "ORGANISM", 406, 410], ["choroid", "MULTI-TISSUE_STRUCTURE", 528, 535], ["anterior uveal tract", "ORGAN", 545, 565], ["retinal", "MULTI-TISSUE_STRUCTURE", 749, 756], ["Vitreous", "TISSUE", 771, 779], ["vitreous", "ORGANISM_SUBSTANCE", 794, 802], ["retina", "MULTI-TISSUE_STRUCTURE", 830, 836], ["retina", "MULTI-TISSUE_STRUCTURE", 902, 908], ["granulomas", "PATHOLOGICAL_FORMATION", 932, 942], ["tapetal", "CANCER", 1000, 1007], ["non-tapetal retina", "TISSUE", 1012, 1030], ["corneal edema", "PATHOLOGICAL_FORMATION", 1084, 1097], ["pupil", "ORGAN", 1251, 1256], ["vascular", "MULTI-TISSUE_STRUCTURE", 1284, 1292], ["anterior surface", "MULTI-TISSUE_STRUCTURE", 1307, 1323], ["iris", "TISSUE", 1331, 1335], ["pre-iridal fibrovascular membrane", "TISSUE", 1337, 1370], ["cats", "ORGANISM", 1441, 1445], ["eye", "ORGAN", 1473, 1476], ["sinuses", "ORGAN", 1553, 1560], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 1565, 1577], ["orbital tissues", "TISSUE", 1587, 1602], ["nasal", "ORGAN", 1671, 1676], ["cats", "SPECIES", 406, 410], ["cats", "SPECIES", 1441, 1445], ["FeLV", "SPECIES", 209, 213], ["Biopsy of regional lymph nodes", "TEST", 0, 30], ["lymphomegaly", "PROBLEM", 53, 65], ["fine-needle aspirate biopsies", "TEST", 115, 144], ["anterior chamber centesis", "TEST", 148, 173], ["cytology", "TEST", 178, 186], ["FeLV", "PROBLEM", 209, 213], ["lymphosarcoma", "PROBLEM", 243, 256], ["DiagnosisChest and abdominal radiology and/or ultrasound", "TEST", 257, 313], ["Clinical signsCryptococcosis", "PROBLEM", 331, 359], ["fungal infection affecting cats", "PROBLEM", 379, 410], ["Clinical signs", "TEST", 444, 458], ["The initial ocular site", "PROBLEM", 458, 481], ["infection", "PROBLEM", 503, 512], ["the infection", "PROBLEM", 607, 620], ["sudden blindness", "PROBLEM", 657, 673], ["multifocal granulomatous chorioretinitis", "PROBLEM", 684, 724], ["retinal detachment", "PROBLEM", 749, 767], ["Vitreous flare (cloudy vitreous", "PROBLEM", 771, 802], ["severe inflammation", "PROBLEM", 872, 891], ["the granulomas", "PROBLEM", 928, 942], ["small swollen brownish discolored areas in the tapetal and non-tapetal retina", "PROBLEM", 953, 1030], ["Clinical signs", "TEST", 1031, 1045], ["usually anterior uveitis", "PROBLEM", 1054, 1078], ["corneal edema", "PROBLEM", 1084, 1097], ["anterior chamber flare", "PROBLEM", 1099, 1121], ["hypopyon and keratic precipitates", "PROBLEM", 1139, 1172], ["swollen iris", "PROBLEM", 1175, 1187], ["posterior synechia", "PROBLEM", 1212, 1230], ["a distorted pupil", "PROBLEM", 1239, 1256], ["chronic cases", "PROBLEM", 1265, 1278], ["new vascular growth", "PROBLEM", 1280, 1299], ["pre-iridal fibrovascular membrane formation", "PROBLEM", 1337, 1380], ["secondary cataract", "PROBLEM", 1404, 1422], ["glaucoma", "PROBLEM", 1427, 1435], ["exophthalmos (eye bulging forward", "PROBLEM", 1459, 1492], ["the disease from the sinuses and nasal cavity into the orbital tissues", "PROBLEM", 1532, 1602], ["secondary cataract", "PROBLEM", 1625, 1643], ["glaucoma", "PROBLEM", 1648, 1656], ["nasal infection", "PROBLEM", 1671, 1686], ["a mucopurulent discharge", "PROBLEM", 1701, 1725], ["sneezing", "PROBLEM", 1731, 1739], ["regional", "OBSERVATION_MODIFIER", 10, 18], ["lymph nodes", "OBSERVATION", 19, 30], ["lymphomegaly", "OBSERVATION", 53, 65], ["lymphosarcoma", "OBSERVATION", 243, 256], ["Chest", "ANATOMY", 266, 271], ["abdominal", "ANATOMY", 276, 285], ["most common", "OBSERVATION_MODIFIER", 367, 378], ["fungal", "OBSERVATION_MODIFIER", 379, 385], ["infection", "OBSERVATION", 386, 395], ["ocular", "ANATOMY", 470, 476], ["infection", "OBSERVATION", 503, 512], ["choroid", "ANATOMY", 528, 535], ["anterior", "ANATOMY_MODIFIER", 545, 553], ["uveal tract", "ANATOMY", 554, 565], ["infection", "OBSERVATION", 611, 620], ["blindness", "OBSERVATION", 664, 673], ["multifocal", "OBSERVATION_MODIFIER", 684, 694], ["granulomatous", "OBSERVATION_MODIFIER", 695, 708], ["chorioretinitis", "OBSERVATION", 709, 724], ["varying degrees", "OBSERVATION_MODIFIER", 730, 745], ["retinal", "ANATOMY", 749, 756], ["detachment", "OBSERVATION", 757, 767], ["flare", "OBSERVATION", 780, 785], ["cloudy vitreous", "OBSERVATION", 787, 802], ["retina", "ANATOMY", 830, 836], ["severe", "OBSERVATION_MODIFIER", 872, 878], ["inflammation", "OBSERVATION", 879, 891], ["retina", "ANATOMY", 902, 908], ["granulomas", "OBSERVATION", 932, 942], ["small", "OBSERVATION_MODIFIER", 953, 958], ["swollen", "OBSERVATION_MODIFIER", 959, 966], ["brownish", "OBSERVATION_MODIFIER", 967, 975], ["discolored", "OBSERVATION_MODIFIER", 976, 986], ["areas", "OBSERVATION", 987, 992], ["tapetal", "ANATOMY_MODIFIER", 1000, 1007], ["non-tapetal retina", "ANATOMY", 1012, 1030], ["anterior", "ANATOMY_MODIFIER", 1062, 1070], ["uveitis", "OBSERVATION", 1071, 1078], ["corneal", "ANATOMY", 1084, 1091], ["edema", "OBSERVATION", 1092, 1097], ["anterior", "ANATOMY_MODIFIER", 1099, 1107], ["chamber flare", "OBSERVATION", 1108, 1121], ["swollen iris", "OBSERVATION", 1175, 1187], ["varying degrees", "OBSERVATION_MODIFIER", 1193, 1208], ["posterior", "ANATOMY_MODIFIER", 1212, 1221], ["synechia", "OBSERVATION", 1222, 1230], ["distorted pupil", "OBSERVATION", 1241, 1256], ["chronic", "OBSERVATION_MODIFIER", 1265, 1272], ["cases", "OBSERVATION", 1273, 1278], ["new", "OBSERVATION_MODIFIER", 1280, 1283], ["vascular", "ANATOMY", 1284, 1292], ["growth", "OBSERVATION_MODIFIER", 1293, 1299], ["anterior", "ANATOMY_MODIFIER", 1307, 1315], ["surface", "ANATOMY_MODIFIER", 1316, 1323], ["iris", "ANATOMY", 1331, 1335], ["fibrovascular membrane formation", "OBSERVATION", 1348, 1380], ["secondary cataract", "OBSERVATION", 1404, 1422], ["glaucoma", "OBSERVATION", 1427, 1435], ["cats", "OBSERVATION", 1441, 1445], ["exophthalmos", "OBSERVATION", 1459, 1471], ["eye", "ANATOMY", 1473, 1476], ["bulging", "OBSERVATION", 1477, 1484], ["disease", "OBSERVATION", 1536, 1543], ["sinuses", "ANATOMY", 1553, 1560], ["nasal cavity", "ANATOMY", 1565, 1577], ["orbital tissues", "ANATOMY", 1587, 1602], ["secondary cataract", "OBSERVATION", 1625, 1643], ["glaucoma", "OBSERVATION", 1648, 1656], ["nasal", "ANATOMY", 1671, 1676], ["infection", "OBSERVATION", 1677, 1686], ["may be", "UNCERTAINTY", 1694, 1700], ["mucopurulent", "OBSERVATION_MODIFIER", 1703, 1715], ["sneezing", "OBSERVATION", 1731, 1739]]], ["Distortion and swelling over the bridge of nose, or a polyp-like mass projecting from the nasal cavity are present in 70% of cats with the respiratory form.Complications include secondary cataract and glaucoma.Chronic skin granulomas may be present.", [["nose", "ANATOMY", 43, 47], ["polyp-like mass", "ANATOMY", 54, 69], ["nasal cavity", "ANATOMY", 90, 102], ["respiratory", "ANATOMY", 139, 150], ["glaucoma", "ANATOMY", 201, 209], ["skin granulomas", "ANATOMY", 218, 233], ["swelling", "DISEASE", 15, 23], ["cataract", "DISEASE", 188, 196], ["glaucoma", "DISEASE", 201, 209], ["granulomas", "DISEASE", 223, 233], ["nose", "ORGAN", 43, 47], ["polyp", "PATHOLOGICAL_FORMATION", 54, 59], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 90, 102], ["cats", "ORGANISM", 125, 129], ["skin granulomas", "PATHOLOGICAL_FORMATION", 218, 233], ["Distortion and swelling over the bridge of nose", "PROBLEM", 0, 47], ["a polyp-like mass", "PROBLEM", 52, 69], ["secondary cataract", "PROBLEM", 178, 196], ["glaucoma", "PROBLEM", 201, 209], ["Chronic skin granulomas", "PROBLEM", 210, 233], ["swelling", "OBSERVATION", 15, 23], ["bridge", "ANATOMY_MODIFIER", 33, 39], ["nose", "ANATOMY", 43, 47], ["polyp", "OBSERVATION", 54, 59], ["mass", "OBSERVATION", 65, 69], ["nasal cavity", "ANATOMY", 90, 102], ["respiratory", "ANATOMY", 139, 150], ["secondary cataract", "OBSERVATION", 178, 196], ["glaucoma", "OBSERVATION", 201, 209], ["skin", "ANATOMY", 218, 222], ["granulomas", "OBSERVATION", 223, 233]]], ["Skin lesions consist of papules or nodules varying from 0.1-1 cm in diameter.", [["Skin lesions", "ANATOMY", 0, 12], ["papules", "ANATOMY", 24, 31], ["nodules", "ANATOMY", 35, 42], ["papules", "DISEASE", 24, 31], ["Skin lesions", "PATHOLOGICAL_FORMATION", 0, 12], ["papules", "PATHOLOGICAL_FORMATION", 24, 31], ["nodules", "CANCER", 35, 42], ["Skin lesions", "PROBLEM", 0, 12], ["papules", "PROBLEM", 24, 31], ["nodules", "PROBLEM", 35, 42], ["lesions", "OBSERVATION", 5, 12], ["papules", "OBSERVATION", 24, 31], ["nodules", "OBSERVATION", 35, 42], ["varying", "OBSERVATION_MODIFIER", 43, 50], ["0.1-1 cm", "OBSERVATION_MODIFIER", 56, 64], ["diameter", "OBSERVATION_MODIFIER", 68, 76]]], ["Lesions may ulcerate and exude serous fluid, or remain as intact nodules.Complications include secondary cataract and glaucoma.Cats with disseminated disease may show neurological signs.Complications include secondary cataract and glaucoma.Cats may present with chronic nasal or skin disease, and the ocular involvement is identified secondarily on physical examination.", [["serous fluid", "ANATOMY", 31, 43], ["nodules", "ANATOMY", 65, 72], ["glaucoma", "ANATOMY", 118, 126], ["neurological", "ANATOMY", 167, 179], ["glaucoma", "ANATOMY", 231, 239], ["nasal", "ANATOMY", 270, 275], ["skin", "ANATOMY", 279, 283], ["ocular", "ANATOMY", 301, 307], ["cataract", "DISEASE", 105, 113], ["glaucoma", "DISEASE", 118, 126], ["disseminated disease", "DISEASE", 137, 157], ["neurological signs", "DISEASE", 167, 185], ["cataract", "DISEASE", 218, 226], ["glaucoma", "DISEASE", 231, 239], ["chronic nasal or skin disease", "DISEASE", 262, 291], ["serous fluid", "ORGANISM_SUBSTANCE", 31, 43], ["nodules", "CANCER", 65, 72], ["nasal", "ORGANISM_SUBDIVISION", 270, 275], ["skin", "ORGAN", 279, 283], ["ocular", "ORGAN", 301, 307], ["Lesions", "PROBLEM", 0, 7], ["serous fluid", "PROBLEM", 31, 43], ["intact nodules", "PROBLEM", 58, 72], ["secondary cataract", "PROBLEM", 95, 113], ["glaucoma", "PROBLEM", 118, 126], ["disseminated disease", "PROBLEM", 137, 157], ["neurological signs", "PROBLEM", 167, 185], ["secondary cataract", "PROBLEM", 208, 226], ["glaucoma", "PROBLEM", 231, 239], ["chronic nasal or skin disease", "PROBLEM", 262, 291], ["the ocular involvement", "PROBLEM", 297, 319], ["physical examination", "TEST", 349, 369], ["serous", "OBSERVATION_MODIFIER", 31, 37], ["fluid", "OBSERVATION", 38, 43], ["intact", "OBSERVATION_MODIFIER", 58, 64], ["nodules", "OBSERVATION", 65, 72], ["secondary cataract", "OBSERVATION", 95, 113], ["glaucoma", "OBSERVATION", 118, 126], ["disseminated", "OBSERVATION_MODIFIER", 137, 149], ["disease", "OBSERVATION", 150, 157], ["secondary cataract", "OBSERVATION", 208, 226], ["glaucoma", "OBSERVATION", 231, 239], ["chronic", "OBSERVATION_MODIFIER", 262, 269], ["nasal", "ANATOMY", 270, 275], ["skin", "ANATOMY", 279, 283], ["disease", "OBSERVATION", 284, 291], ["ocular", "ANATOMY", 301, 307]]], ["Cats may also be presented primarily for the ocular signs, where the owner has seen the development of a cloudy eye and the cat has gone blind.DiagnosisA tentative diagnosis is based on typical clinical signs of nasal or skin disease and concurrent ocular signs.", [["ocular", "ANATOMY", 45, 51], ["eye", "ANATOMY", 112, 115], ["nasal", "ANATOMY", 212, 217], ["skin", "ANATOMY", 221, 225], ["ocular", "ANATOMY", 249, 255], ["ocular signs", "DISEASE", 45, 57], ["nasal or skin disease", "DISEASE", 212, 233], ["ocular signs", "DISEASE", 249, 261], ["eye", "ORGAN", 112, 115], ["cat", "ORGANISM", 124, 127], ["nasal", "ORGANISM_SUBDIVISION", 212, 217], ["skin", "ORGAN", 221, 225], ["ocular", "ORGAN", 249, 255], ["the ocular signs", "TEST", 41, 57], ["a cloudy eye", "PROBLEM", 103, 115], ["nasal or skin disease", "PROBLEM", 212, 233], ["concurrent ocular signs", "PROBLEM", 238, 261], ["cloudy", "OBSERVATION", 105, 111], ["eye", "ANATOMY", 112, 115], ["nasal", "ANATOMY", 212, 217], ["skin", "ANATOMY", 221, 225], ["disease", "OBSERVATION", 226, 233], ["ocular", "ANATOMY", 249, 255], ["signs", "OBSERVATION", 256, 261]]], ["The presence of small swollen brownish discolored areas in the retina suggests fungal disease.", [["retina", "ANATOMY", 63, 69], ["fungal disease", "DISEASE", 79, 93], ["retina", "MULTI-TISSUE_STRUCTURE", 63, 69], ["small swollen brownish discolored areas", "PROBLEM", 16, 55], ["fungal disease", "PROBLEM", 79, 93], ["small", "OBSERVATION_MODIFIER", 16, 21], ["swollen", "OBSERVATION_MODIFIER", 22, 29], ["brownish", "OBSERVATION_MODIFIER", 30, 38], ["discolored", "OBSERVATION_MODIFIER", 39, 49], ["areas", "OBSERVATION", 50, 55], ["retina", "ANATOMY", 63, 69], ["suggests", "UNCERTAINTY", 70, 78], ["fungal disease", "OBSERVATION", 79, 93]]], ["The frequency of occurrence of individual fungal diseases in the geographical area helps establish a tentative diagnosis.DiagnosisCytology can be very useful in the diagnosis of C. neoformans.", [["fungal diseases", "DISEASE", 42, 57], ["C. neoformans", "DISEASE", 178, 191], ["C. neoformans", "ORGANISM", 178, 191], ["C. neoformans", "SPECIES", 178, 191], ["C. neoformans", "SPECIES", 178, 191], ["individual fungal diseases", "PROBLEM", 31, 57], ["C. neoformans", "PROBLEM", 178, 191], ["individual", "OBSERVATION_MODIFIER", 31, 41], ["fungal diseases", "OBSERVATION", 42, 57], ["neoformans", "OBSERVATION", 181, 191]]], ["Demonstration of the organism can be made via anterior chamber centesis or by fine-needle biopsy (using a 25-gauge needle) taken from the subretinal space.", [["subretinal space", "ANATOMY", 138, 154], ["subretinal space", "MULTI-TISSUE_STRUCTURE", 138, 154], ["the organism", "PROBLEM", 17, 29], ["anterior chamber centesis", "TREATMENT", 46, 71], ["fine-needle biopsy", "TEST", 78, 96], ["a 25-gauge needle", "TREATMENT", 104, 121], ["subretinal space", "ANATOMY", 138, 154]]], ["The sample is best stained with new methylene blue, Indian ink or Diff-Quick.DiagnosisSerology to detect capsule antigen is sensitive using serum, CSF fluid or urine.DiagnosisHistopathology from tissue biopsies demonstrates the organism.DiagnosisRadiology of the nasal cavity, sinuses and chest may be useful in cases that do not demonstrate nasal or skin signs.DiagnosisOcular ultrasound can be used to detect retinal detachment when anterior chamber flare, cataract or vitreal flare prevents ophthalmoscopic examination of the fundus.", [["sample", "ANATOMY", 4, 10], ["capsule", "ANATOMY", 105, 112], ["serum", "ANATOMY", 140, 145], ["CSF fluid", "ANATOMY", 147, 156], ["urine", "ANATOMY", 160, 165], ["tissue biopsies", "ANATOMY", 195, 210], ["nasal cavity", "ANATOMY", 263, 275], ["sinuses", "ANATOMY", 277, 284], ["chest", "ANATOMY", 289, 294], ["nasal", "ANATOMY", 342, 347], ["skin", "ANATOMY", 351, 355], ["retinal", "ANATOMY", 411, 418], ["anterior chamber", "ANATOMY", 435, 451], ["vitreal", "ANATOMY", 471, 478], ["fundus", "ANATOMY", 529, 535], ["methylene blue", "CHEMICAL", 36, 50], ["retinal detachment", "DISEASE", 411, 429], ["cataract", "DISEASE", 459, 467], ["methylene blue", "CHEMICAL", 36, 50], ["methylene blue", "SIMPLE_CHEMICAL", 36, 50], ["capsule antigen", "GENE_OR_GENE_PRODUCT", 105, 120], ["serum", "ORGANISM_SUBSTANCE", 140, 145], ["CSF fluid", "ORGANISM_SUBSTANCE", 147, 156], ["urine", "ORGANISM_SUBSTANCE", 160, 165], ["tissue biopsies", "MULTI-TISSUE_STRUCTURE", 195, 210], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 263, 275], ["sinuses", "MULTI-TISSUE_STRUCTURE", 277, 284], ["chest", "ORGAN", 289, 294], ["nasal", "ORGANISM_SUBDIVISION", 342, 347], ["skin", "ORGAN", 351, 355], ["retinal", "MULTI-TISSUE_STRUCTURE", 411, 418], ["vitreal", "IMMATERIAL_ANATOMICAL_ENTITY", 471, 478], ["fundus", "MULTI-TISSUE_STRUCTURE", 529, 535], ["capsule antigen", "PROTEIN", 105, 120], ["The sample", "TEST", 0, 10], ["new methylene blue", "TREATMENT", 32, 50], ["Diff", "TEST", 66, 70], ["capsule antigen", "TEST", 105, 120], ["serum, CSF fluid or urine", "TEST", 140, 165], ["tissue biopsies", "TEST", 195, 210], ["the organism", "PROBLEM", 224, 236], ["DiagnosisRadiology of the nasal cavity, sinuses and chest", "TEST", 237, 294], ["nasal or skin signs", "PROBLEM", 342, 361], ["DiagnosisOcular ultrasound", "TEST", 362, 388], ["retinal detachment", "PROBLEM", 411, 429], ["anterior chamber flare", "PROBLEM", 435, 457], ["cataract", "PROBLEM", 459, 467], ["vitreal flare", "PROBLEM", 471, 484], ["ophthalmoscopic examination of the fundus", "TEST", 494, 535], ["new", "OBSERVATION_MODIFIER", 32, 35], ["methylene blue", "OBSERVATION", 36, 50], ["nasal cavity", "ANATOMY", 263, 275], ["sinuses", "ANATOMY", 277, 284], ["chest", "ANATOMY", 289, 294], ["nasal", "ANATOMY", 342, 347], ["skin", "ANATOMY", 351, 355], ["signs", "OBSERVATION", 356, 361], ["retinal", "ANATOMY", 411, 418], ["detachment", "OBSERVATION", 419, 429], ["anterior", "ANATOMY_MODIFIER", 435, 443], ["chamber", "ANATOMY", 444, 451], ["flare", "OBSERVATION", 452, 457], ["cataract", "OBSERVATION", 459, 467], ["vitreal", "ANATOMY", 471, 478], ["fundus", "ANATOMY", 529, 535]]], ["It is also used in cases of exophthalmos to examine, and do ultrasound-guided biopsies of the orbital tissue.OTHER SYSTEMIC FUNGAL INFECTIONS (BLASTOMYCES DERMATITIDIS, CANDIDA ALBICANS, COCCIDIOIDES IMMITIS, HISTOPLASMA CAPSULATUM)Classical signsOTHER SYSTEMIC FUNGAL INFECTIONS (BLASTOMYCES DERMATITIDIS, CANDIDA ALBICANS, COCCIDIOIDES IMMITIS, HISTOPLASMA CAPSULATUM)\u2022 Chorioretinitis progressing to anterior uveitis (cloudy eye) and endophthalmitis, in a geographical area where fungal infections occur.Clinical signsMost intra-ocular fungal infections cause similar ocular signs.Clinical signs\u2022 Choroidal granulomas are the most characteristic sign on fundoscopy, and appear as a raised area of tapetal hyporeflectivity, or small swollen brownish discolored areas in the retina. \u2022 A generalized chorioretinitis and secondary retinal detachments, with ballooning of the retina into the vitreous. \u2022 Optic neuritis may be present, seen as a red, swollen optic nerve that is hyperemic. \u2022 Anterior uveitis seen as cloudy, red eye with corneal edema, hypopyon and inflamed conjunctiva.Clinical signsAffected cats show varying degrees of blindness, depending on the severity of the ocular infection.Clinical signsSystemic signs can involve many other organs, especially the lungs, brain, nasal cavity, as well as the periorbital tissues, lymph nodes, bones, toenails and skin.DiagnosisA tentative diagnosis is based on the presenting signs of a cat with rapidly progressive, usually bilateral chorioretinitis, progressing to anterior uveitis, with signs of other systemic disease, and occurring in a geographic area where such fungal disease is known to occur.DiagnosisImaging techniques can be used to obtain more supportive evidence of a deep fungal infection:Diagnosis\u2022 Thoracic radiography to demonstrate pulmonary granulomas. \u2022 Nasal cavity radiography.", [["orbital tissue", "ANATOMY", 94, 108], ["eye", "ANATOMY", 428, 431], ["intra-ocular", "ANATOMY", 526, 538], ["ocular", "ANATOMY", 571, 577], ["Choroidal granulomas", "ANATOMY", 600, 620], ["tapetal", "ANATOMY", 700, 707], ["retina", "ANATOMY", 776, 782], ["retinal", "ANATOMY", 830, 837], ["retina", "ANATOMY", 874, 880], ["vitreous", "ANATOMY", 890, 898], ["optic nerve", "ANATOMY", 956, 967], ["red eye", "ANATOMY", 1022, 1029], ["corneal", "ANATOMY", 1035, 1042], ["hypopyon", "ANATOMY", 1050, 1058], ["conjunctiva", "ANATOMY", 1072, 1083], ["ocular", "ANATOMY", 1180, 1186], ["organs", "ANATOMY", 1249, 1255], ["lungs", "ANATOMY", 1272, 1277], ["brain", "ANATOMY", 1279, 1284], ["nasal cavity", "ANATOMY", 1286, 1298], ["periorbital tissues", "ANATOMY", 1315, 1334], ["lymph nodes", "ANATOMY", 1336, 1347], ["bones", "ANATOMY", 1349, 1354], ["toenails", "ANATOMY", 1356, 1364], ["skin", "ANATOMY", 1369, 1373], ["pulmonary granulomas", "ANATOMY", 1807, 1827], ["Nasal cavity", "ANATOMY", 1831, 1843], ["exophthalmos", "DISEASE", 28, 40], ["Chorioretinitis", "DISEASE", 372, 387], ["anterior uveitis", "DISEASE", 403, 419], ["endophthalmitis", "DISEASE", 437, 452], ["fungal infections", "DISEASE", 483, 500], ["intra-ocular fungal infections", "DISEASE", 526, 556], ["ocular signs", "DISEASE", 571, 583], ["Choroidal granulomas", "DISEASE", 600, 620], ["hyporeflectivity", "DISEASE", 708, 724], ["chorioretinitis", "DISEASE", 800, 815], ["retinal detachments", "DISEASE", 830, 849], ["Optic neuritis", "DISEASE", 902, 916], ["uveitis", "DISEASE", 998, 1005], ["corneal edema", "DISEASE", 1035, 1048], ["hypopyon", "DISEASE", 1050, 1058], ["blindness", "DISEASE", 1136, 1145], ["ocular infection", "DISEASE", 1180, 1196], ["chorioretinitis", "DISEASE", 1491, 1506], ["uveitis", "DISEASE", 1532, 1539], ["systemic disease", "DISEASE", 1561, 1577], ["fungal disease", "DISEASE", 1625, 1639], ["fungal infection", "DISEASE", 1743, 1759], ["pulmonary granulomas", "DISEASE", 1807, 1827], ["biopsies", "TISSUE", 78, 86], ["orbital tissue", "TISSUE", 94, 108], ["eye", "ORGAN", 428, 431], ["Choroidal granulomas", "PATHOLOGICAL_FORMATION", 600, 620], ["retina", "MULTI-TISSUE_STRUCTURE", 776, 782], ["retinal", "MULTI-TISSUE_STRUCTURE", 830, 837], ["retina", "MULTI-TISSUE_STRUCTURE", 874, 880], ["vitreous", "TISSUE", 890, 898], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 956, 967], ["eye", "ORGAN", 1026, 1029], ["corneal edema", "PATHOLOGICAL_FORMATION", 1035, 1048], ["conjunctiva", "ORGAN", 1072, 1083], ["cats", "ORGANISM", 1107, 1111], ["ocular", "ORGAN", 1180, 1186], ["organs", "ORGAN", 1249, 1255], ["lungs", "ORGAN", 1272, 1277], ["brain", "ORGAN", 1279, 1284], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 1286, 1298], ["periorbital tissues", "TISSUE", 1315, 1334], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 1336, 1347], ["bones", "TISSUE", 1349, 1354], ["toenails", "TISSUE", 1356, 1364], ["skin", "ORGAN", 1369, 1373], ["cat", "ORGANISM", 1443, 1446], ["pulmonary granulomas", "PATHOLOGICAL_FORMATION", 1807, 1827], ["Nasal cavity", "MULTI-TISSUE_STRUCTURE", 1831, 1843], ["cats", "SPECIES", 1107, 1111], ["exophthalmos", "PROBLEM", 28, 40], ["ultrasound", "TEST", 60, 70], ["biopsies", "TEST", 78, 86], ["OTHER SYSTEMIC FUNGAL INFECTIONS (BLASTOMYCES DERMATITIDIS", "PROBLEM", 109, 167], ["CANDIDA ALBICANS", "TEST", 169, 185], ["SYSTEMIC FUNGAL INFECTIONS (BLASTOMYCES DERMATITIDIS", "PROBLEM", 253, 305], ["CANDIDA ALBICANS", "PROBLEM", 307, 323], ["COCCIDIOIDES IMMITIS", "PROBLEM", 325, 345], ["HISTOPLASMA CAPSULATUM", "PROBLEM", 347, 369], ["Chorioretinitis", "PROBLEM", 372, 387], ["anterior uveitis", "PROBLEM", 403, 419], ["cloudy eye)", "PROBLEM", 421, 432], ["endophthalmitis", "PROBLEM", 437, 452], ["fungal infections", "PROBLEM", 483, 500], ["Clinical signs", "TEST", 507, 521], ["intra-ocular fungal infections", "PROBLEM", 526, 556], ["similar ocular signs", "PROBLEM", 563, 583], ["Clinical signs", "TEST", 584, 598], ["Choroidal granulomas", "PROBLEM", 600, 620], ["fundoscopy", "TEST", 657, 667], ["tapetal hyporeflectivity", "PROBLEM", 700, 724], ["small swollen brownish discolored areas in the retina", "PROBLEM", 729, 782], ["A generalized chorioretinitis", "PROBLEM", 786, 815], ["secondary retinal detachments", "PROBLEM", 820, 849], ["ballooning of the retina into the vitreous", "PROBLEM", 856, 898], ["Optic neuritis", "PROBLEM", 902, 916], ["a red, swollen optic nerve", "PROBLEM", 941, 967], ["hyperemic", "PROBLEM", 976, 985], ["Anterior uveitis", "PROBLEM", 989, 1005], ["cloudy", "PROBLEM", 1014, 1020], ["corneal edema", "PROBLEM", 1035, 1048], ["hypopyon", "PROBLEM", 1050, 1058], ["inflamed conjunctiva", "PROBLEM", 1063, 1083], ["Clinical signsAffected cats", "TEST", 1084, 1111], ["blindness", "PROBLEM", 1136, 1145], ["the ocular infection", "PROBLEM", 1176, 1196], ["Clinical signsSystemic signs", "PROBLEM", 1197, 1225], ["many other organs, especially the lungs, brain, nasal cavity", "PROBLEM", 1238, 1298], ["lymph nodes, bones, toenails and skin", "PROBLEM", 1336, 1373], ["a cat", "PROBLEM", 1441, 1446], ["usually bilateral chorioretinitis", "PROBLEM", 1473, 1506], ["anterior uveitis", "PROBLEM", 1523, 1539], ["other systemic disease", "PROBLEM", 1555, 1577], ["such fungal disease", "PROBLEM", 1620, 1639], ["DiagnosisImaging techniques", "TREATMENT", 1658, 1685], ["a deep fungal infection", "PROBLEM", 1736, 1759], ["Thoracic radiography", "TEST", 1771, 1791], ["pulmonary granulomas", "PROBLEM", 1807, 1827], ["Nasal cavity radiography", "TEST", 1831, 1855], ["orbital tissue", "ANATOMY", 94, 108], ["SYSTEMIC", "OBSERVATION_MODIFIER", 115, 123], ["FUNGAL INFECTIONS", "OBSERVATION", 124, 141], ["BLASTOMYCES DERMATITIDIS", "OBSERVATION", 143, 167], ["CANDIDA ALBICANS", "OBSERVATION", 169, 185], ["HISTOPLASMA CAPSULATUM", "OBSERVATION", 209, 231], ["SYSTEMIC", "OBSERVATION_MODIFIER", 253, 261], ["FUNGAL INFECTIONS", "OBSERVATION", 262, 279], ["BLASTOMYCES DERMATITIDIS", "OBSERVATION", 281, 305], ["HISTOPLASMA CAPSULATUM", "OBSERVATION", 347, 369], ["Chorioretinitis", "OBSERVATION", 372, 387], ["anterior", "ANATOMY_MODIFIER", 403, 411], ["uveitis", "OBSERVATION", 412, 419], ["cloudy", "OBSERVATION_MODIFIER", 421, 427], ["eye", "ANATOMY", 428, 431], ["endophthalmitis", "OBSERVATION", 437, 452], ["fungal", "OBSERVATION_MODIFIER", 483, 489], ["infections", "OBSERVATION", 490, 500], ["Most intra-ocular", "OBSERVATION_MODIFIER", 521, 538], ["fungal", "OBSERVATION_MODIFIER", 539, 545], ["infections", "OBSERVATION", 546, 556], ["ocular signs", "OBSERVATION", 571, 583], ["Choroidal", "ANATOMY", 600, 609], ["granulomas", "OBSERVATION", 610, 620], ["most characteristic", "OBSERVATION_MODIFIER", 629, 648], ["tapetal hyporeflectivity", "OBSERVATION", 700, 724], ["small", "OBSERVATION_MODIFIER", 729, 734], ["swollen", "OBSERVATION_MODIFIER", 735, 742], ["brownish", "OBSERVATION_MODIFIER", 743, 751], ["discolored", "OBSERVATION_MODIFIER", 752, 762], ["areas", "OBSERVATION", 763, 768], ["retina", "ANATOMY", 776, 782], ["generalized", "OBSERVATION_MODIFIER", 788, 799], ["chorioretinitis", "OBSERVATION", 800, 815], ["secondary retinal detachments", "OBSERVATION", 820, 849], ["ballooning", "OBSERVATION", 856, 866], ["retina", "ANATOMY", 874, 880], ["vitreous", "OBSERVATION_MODIFIER", 890, 898], ["neuritis", "OBSERVATION", 908, 916], ["may be", "UNCERTAINTY", 917, 923], ["red", "OBSERVATION", 943, 946], ["swollen", "OBSERVATION", 948, 955], ["optic nerve", "ANATOMY", 956, 967], ["hyperemic", "OBSERVATION_MODIFIER", 976, 985], ["Anterior", "ANATOMY_MODIFIER", 989, 997], ["uveitis", "OBSERVATION", 998, 1005], ["cloudy", "OBSERVATION_MODIFIER", 1014, 1020], ["eye", "ANATOMY", 1026, 1029], ["corneal", "ANATOMY", 1035, 1042], ["edema", "OBSERVATION", 1043, 1048], ["hypopyon", "OBSERVATION", 1050, 1058], ["inflamed conjunctiva", "OBSERVATION", 1063, 1083], ["varying degrees", "OBSERVATION_MODIFIER", 1117, 1132], ["blindness", "OBSERVATION", 1136, 1145], ["ocular", "ANATOMY", 1180, 1186], ["infection", "OBSERVATION", 1187, 1196], ["lungs", "ANATOMY", 1272, 1277], ["brain", "ANATOMY", 1279, 1284], ["nasal cavity", "ANATOMY", 1286, 1298], ["periorbital tissues", "ANATOMY", 1315, 1334], ["lymph nodes", "OBSERVATION", 1336, 1347], ["bones", "ANATOMY", 1349, 1354], ["toenails", "ANATOMY", 1356, 1364], ["skin", "ANATOMY", 1369, 1373], ["rapidly", "OBSERVATION_MODIFIER", 1452, 1459], ["progressive", "OBSERVATION_MODIFIER", 1460, 1471], ["bilateral", "ANATOMY_MODIFIER", 1481, 1490], ["chorioretinitis", "OBSERVATION", 1491, 1506], ["anterior", "ANATOMY_MODIFIER", 1523, 1531], ["uveitis", "OBSERVATION", 1532, 1539], ["systemic", "OBSERVATION_MODIFIER", 1561, 1569], ["disease", "OBSERVATION", 1570, 1577], ["geographic", "OBSERVATION_MODIFIER", 1598, 1608], ["fungal disease", "OBSERVATION", 1625, 1639], ["deep", "OBSERVATION_MODIFIER", 1738, 1742], ["fungal", "OBSERVATION_MODIFIER", 1743, 1749], ["infection", "OBSERVATION", 1750, 1759], ["Thoracic", "ANATOMY", 1771, 1779], ["pulmonary", "ANATOMY", 1807, 1816], ["granulomas", "OBSERVATION", 1817, 1827], ["cavity", "OBSERVATION", 1837, 1843]]], ["Serological tests can be performed, looking for elevated antibodies (blastomycosis, histoplasmosis, coccidiodomycosis).Classical signs\u2022 Eye may suddenly become very cloudy with a \"milky appearance\". \u2022 Unilateral or bilateral. \u2022 Idiopathic in Burmese cats associated with hyperlipidemia. \u2022 May occur in cats with uveitis that are on a high-fat diet.PathogenesisHigh concentrations of lipid can enter the anterior chamber from the uveal vessels if there is either:Pathogenesis\u2022 Breakdown of the blood-aqueous barrier in anterior uveitis. \u2022 Abnormally high concentrations of serum lipids, which can be secondary or primary hyperlipidemia.PathogenesisLipemic aqueous is idiopathic in Burmese cats associated with hyperlipidemia.Clinical signsTypically there is a diffusely and uniformly cloudy anterior chamber.", [["Eye", "ANATOMY", 136, 139], ["milky", "ANATOMY", 180, 185], ["anterior chamber", "ANATOMY", 403, 419], ["uveal vessels", "ANATOMY", 429, 442], ["blood", "ANATOMY", 493, 498], ["aqueous barrier", "ANATOMY", 499, 514], ["anterior uveitis", "ANATOMY", 518, 534], ["serum", "ANATOMY", 572, 577], ["blastomycosis", "DISEASE", 69, 82], ["histoplasmosis", "DISEASE", 84, 98], ["coccidiodomycosis", "DISEASE", 100, 117], ["hyperlipidemia", "DISEASE", 271, 285], ["uveitis", "DISEASE", 312, 319], ["uveitis", "DISEASE", 527, 534], ["hyperlipidemia", "DISEASE", 620, 634], ["hyperlipidemia", "DISEASE", 709, 723], ["cats", "ORGANISM", 250, 254], ["cats", "ORGANISM", 302, 306], ["fat", "TISSUE", 339, 342], ["lipid", "SIMPLE_CHEMICAL", 383, 388], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 403, 419], ["uveal vessels", "MULTI-TISSUE_STRUCTURE", 429, 442], ["blood", "ORGANISM_SUBSTANCE", 493, 498], ["aqueous barrier", "MULTI-TISSUE_STRUCTURE", 499, 514], ["serum", "ORGANISM_SUBSTANCE", 572, 577], ["lipids", "SIMPLE_CHEMICAL", 578, 584], ["aqueous", "ORGANISM_SUBSTANCE", 655, 662], ["cats", "ORGANISM", 688, 692], ["antibodies", "PROTEIN", 57, 67], ["cats", "SPECIES", 250, 254], ["cats", "SPECIES", 302, 306], ["cats", "SPECIES", 688, 692], ["Serological tests", "TEST", 0, 17], ["elevated antibodies", "PROBLEM", 48, 67], ["blastomycosis", "PROBLEM", 69, 82], ["histoplasmosis", "PROBLEM", 84, 98], ["coccidiodomycosis", "PROBLEM", 100, 117], ["Classical signs", "TEST", 119, 134], ["very cloudy", "PROBLEM", 160, 171], ["Idiopathic in Burmese cats", "PROBLEM", 228, 254], ["hyperlipidemia", "PROBLEM", 271, 285], ["uveitis", "PROBLEM", 312, 319], ["a high-fat diet", "TREATMENT", 332, 347], ["PathogenesisHigh concentrations of lipid", "PROBLEM", 348, 388], ["Pathogenesis", "PROBLEM", 462, 474], ["the blood", "PROBLEM", 489, 498], ["aqueous barrier", "TREATMENT", 499, 514], ["anterior uveitis", "PROBLEM", 518, 534], ["Abnormally high concentrations of serum lipids", "PROBLEM", 538, 584], ["primary hyperlipidemia", "PROBLEM", 612, 634], ["PathogenesisLipemic aqueous", "PROBLEM", 635, 662], ["idiopathic", "PROBLEM", 666, 676], ["hyperlipidemia", "PROBLEM", 709, 723], ["Clinical signs", "TEST", 724, 738], ["a diffusely and uniformly cloudy anterior chamber", "PROBLEM", 757, 806], ["blastomycosis", "OBSERVATION", 69, 82], ["histoplasmosis", "OBSERVATION", 84, 98], ["very", "OBSERVATION_MODIFIER", 160, 164], ["cloudy", "OBSERVATION", 165, 171], ["Unilateral", "ANATOMY_MODIFIER", 201, 211], ["bilateral", "ANATOMY_MODIFIER", 215, 224], ["Idiopathic", "OBSERVATION", 228, 238], ["hyperlipidemia", "OBSERVATION", 271, 285], ["uveitis", "OBSERVATION", 312, 319], ["anterior", "ANATOMY_MODIFIER", 403, 411], ["chamber", "ANATOMY_MODIFIER", 412, 419], ["uveal vessels", "ANATOMY", 429, 442], ["Breakdown", "OBSERVATION_MODIFIER", 476, 485], ["blood", "ANATOMY", 493, 498], ["aqueous", "OBSERVATION_MODIFIER", 499, 506], ["barrier", "OBSERVATION_MODIFIER", 507, 514], ["anterior", "ANATOMY_MODIFIER", 518, 526], ["uveitis", "OBSERVATION", 527, 534], ["high concentrations", "OBSERVATION_MODIFIER", 549, 568], ["serum lipids", "OBSERVATION_MODIFIER", 572, 584], ["primary", "OBSERVATION_MODIFIER", 612, 619], ["hyperlipidemia", "OBSERVATION", 620, 634], ["idiopathic", "OBSERVATION_MODIFIER", 666, 676], ["hyperlipidemia", "OBSERVATION", 709, 723], ["diffusely", "OBSERVATION_MODIFIER", 759, 768], ["uniformly", "OBSERVATION_MODIFIER", 773, 782], ["cloudy", "OBSERVATION_MODIFIER", 783, 789], ["anterior chamber", "OBSERVATION", 790, 806]]], ["The aqueous appears as if it is full of milk.Clinical signsUsually the iris, pupil and tapetal reflex can still be visualized.Clinical signsLipemic aqueous is often unilateral and may be sudden in onset.Clinical signsOccasionally it is associated with cats that have uveitis caused by systemic diseases such as toxoplasmosis, FIP, fungal infections, when they have hyperlipidemia caused by a high-fat content in the diet.DiagnosisA tentative diagnosis is based on clinical signs.DiagnosisA definitive diagnosis is based on biochemical analysis of aqueous centesis samples and demonstration of high serum lipid concentrations.", [["milk", "ANATOMY", 40, 44], ["iris", "ANATOMY", 71, 75], ["pupil", "ANATOMY", 77, 82], ["tapetal", "ANATOMY", 87, 94], ["aqueous centesis samples", "ANATOMY", 547, 571], ["serum", "ANATOMY", 598, 603], ["uveitis", "DISEASE", 267, 274], ["systemic diseases", "DISEASE", 285, 302], ["toxoplasmosis", "DISEASE", 311, 324], ["FIP", "DISEASE", 326, 329], ["fungal infections", "DISEASE", 331, 348], ["hyperlipidemia", "DISEASE", 365, 379], ["aqueous", "ORGANISM_SUBSTANCE", 4, 11], ["milk", "ORGANISM_SUBSTANCE", 40, 44], ["iris", "TISSUE", 71, 75], ["pupil", "MULTI-TISSUE_STRUCTURE", 77, 82], ["aqueous", "ORGANISM_SUBSTANCE", 148, 155], ["cats", "ORGANISM", 252, 256], ["fat", "TISSUE", 397, 400], ["aqueous centesis samples", "ORGANISM_SUBSTANCE", 547, 571], ["serum", "ORGANISM_SUBSTANCE", 598, 603], ["lipid", "SIMPLE_CHEMICAL", 604, 609], ["cats", "SPECIES", 252, 256], ["pupil and tapetal reflex", "TEST", 77, 101], ["Clinical signsLipemic aqueous", "PROBLEM", 126, 155], ["uveitis", "PROBLEM", 267, 274], ["systemic diseases", "PROBLEM", 285, 302], ["toxoplasmosis", "PROBLEM", 311, 324], ["FIP", "PROBLEM", 326, 329], ["fungal infections", "PROBLEM", 331, 348], ["hyperlipidemia", "PROBLEM", 365, 379], ["a high-fat content", "PROBLEM", 390, 408], ["clinical signs", "TEST", 464, 478], ["biochemical analysis", "TEST", 523, 543], ["aqueous centesis samples", "TEST", 547, 571], ["high serum lipid concentrations", "PROBLEM", 593, 624], ["aqueous", "OBSERVATION", 4, 11], ["iris", "ANATOMY", 71, 75], ["tapetal reflex", "OBSERVATION", 87, 101], ["aqueous", "OBSERVATION_MODIFIER", 148, 155], ["may be", "UNCERTAINTY", 180, 186], ["sudden", "OBSERVATION_MODIFIER", 187, 193], ["uveitis", "OBSERVATION", 267, 274], ["systemic", "OBSERVATION_MODIFIER", 285, 293], ["diseases", "OBSERVATION", 294, 302], ["toxoplasmosis", "OBSERVATION", 311, 324], ["fungal", "OBSERVATION_MODIFIER", 331, 337], ["infections", "OBSERVATION", 338, 348], ["hyperlipidemia", "OBSERVATION", 365, 379]]], ["Lipid electrophoretograms may be performed on the sample.DiagnosisDiagnosis of the underlying cause should be pursued, if lipemic acqueous is not in a predisposed breed such as the Burmese.", [["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["Lipid electrophoretograms", "TEST", 0, 25], ["the sample", "TEST", 46, 56], ["lipemic acqueous", "PROBLEM", 122, 138]]], ["If it is the result of a systemic disease combined with a high-fat diet, the underlying disease should be identified (see The Cat With Abnormal Iris Appearance, page 1294 and With Retinal Disease, page 1186).TreatmentReduce plasma lipid concentrations using a low-fat diet.TreatmentTreat other underlying medical problems, which are associated with hyperlipidemia such as diabetes mellitus, and systemic diseases causing uveitis (see The Cat With Abnormal Iris Appearance, page 1294).PathogenesisInflammation in the eye results in changes to the lens nutrition and accumulation of toxic products in the eye which results in death of cells.", [["plasma", "ANATOMY", 224, 230], ["eye", "ANATOMY", 516, 519], ["lens", "ANATOMY", 546, 550], ["eye", "ANATOMY", 603, 606], ["cells", "ANATOMY", 633, 638], ["systemic disease", "DISEASE", 25, 41], ["Retinal Disease", "DISEASE", 180, 195], ["hyperlipidemia", "DISEASE", 349, 363], ["diabetes mellitus", "DISEASE", 372, 389], ["systemic diseases", "DISEASE", 395, 412], ["uveitis", "DISEASE", 421, 428], ["PathogenesisInflammation", "DISEASE", 484, 508], ["death", "DISEASE", 624, 629], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["lipid", "SIMPLE_CHEMICAL", 231, 236], ["eye", "ORGAN", 516, 519], ["eye", "ORGAN", 603, 606], ["cells", "CELL", 633, 638], ["a systemic disease", "PROBLEM", 23, 41], ["a high-fat diet", "TREATMENT", 56, 71], ["the underlying disease", "PROBLEM", 73, 95], ["Retinal Disease", "PROBLEM", 180, 195], ["plasma lipid concentrations", "TREATMENT", 224, 251], ["a low-fat diet", "TREATMENT", 258, 272], ["Treatment", "TREATMENT", 273, 282], ["other underlying medical problems", "PROBLEM", 288, 321], ["hyperlipidemia", "PROBLEM", 349, 363], ["diabetes mellitus", "PROBLEM", 372, 389], ["systemic diseases", "PROBLEM", 395, 412], ["uveitis", "PROBLEM", 421, 428], ["PathogenesisInflammation in the eye", "PROBLEM", 484, 519], ["the lens nutrition", "TREATMENT", 542, 560], ["toxic products in the eye", "PROBLEM", 581, 606], ["death of cells", "PROBLEM", 624, 638], ["systemic", "OBSERVATION_MODIFIER", 25, 33], ["disease", "OBSERVATION", 34, 41], ["disease", "OBSERVATION", 88, 95], ["Retinal", "ANATOMY", 180, 187], ["Disease", "OBSERVATION", 188, 195], ["hyperlipidemia", "OBSERVATION", 349, 363], ["systemic", "OBSERVATION_MODIFIER", 395, 403], ["diseases", "OBSERVATION", 404, 412], ["uveitis", "OBSERVATION", 421, 428], ["Iris", "ANATOMY", 456, 460], ["eye", "ANATOMY", 516, 519], ["lens", "ANATOMY", 546, 550], ["toxic products", "OBSERVATION", 581, 595], ["eye", "ANATOMY", 603, 606]]], ["This will cause a cloudy lens (cataract).PathogenesisCataract is often associated with chronic uveitis caused by infectious agent such as toxoplasmosis or fungal disease.Clinical signsThe lens appears cloudy due to the formation of a cortical cataract.Clinical signsThe cataract may be unilateral or bilateral, but is more often unilateral.", [["lens", "ANATOMY", 188, 192], ["cortical", "ANATOMY", 234, 242], ["cataract", "DISEASE", 31, 39], ["PathogenesisCataract", "DISEASE", 41, 61], ["uveitis", "DISEASE", 95, 102], ["toxoplasmosis", "DISEASE", 138, 151], ["fungal disease", "DISEASE", 155, 169], ["cataract", "DISEASE", 243, 251], ["cataract", "DISEASE", 270, 278], ["cortical", "MULTI-TISSUE_STRUCTURE", 234, 242], ["a cloudy lens (cataract)", "PROBLEM", 16, 40], ["PathogenesisCataract", "PROBLEM", 41, 61], ["chronic uveitis", "PROBLEM", 87, 102], ["infectious agent", "TREATMENT", 113, 129], ["toxoplasmosis", "PROBLEM", 138, 151], ["fungal disease", "PROBLEM", 155, 169], ["Clinical signs", "TEST", 170, 184], ["cloudy", "PROBLEM", 201, 207], ["a cortical cataract", "PROBLEM", 232, 251], ["Clinical signs", "TEST", 252, 266], ["The cataract", "PROBLEM", 266, 278], ["cloudy lens", "OBSERVATION", 18, 29], ["cataract", "OBSERVATION", 31, 39], ["often associated with", "UNCERTAINTY", 65, 86], ["chronic", "OBSERVATION_MODIFIER", 87, 94], ["uveitis", "OBSERVATION", 95, 102], ["infectious", "OBSERVATION", 113, 123], ["toxoplasmosis", "OBSERVATION", 138, 151], ["fungal disease", "OBSERVATION", 155, 169], ["lens", "ANATOMY", 188, 192], ["cloudy", "OBSERVATION", 201, 207], ["cortical cataract", "OBSERVATION", 234, 251], ["cataract", "OBSERVATION", 270, 278], ["may be", "UNCERTAINTY", 279, 285], ["unilateral", "OBSERVATION", 286, 296], ["bilateral", "ANATOMY_MODIFIER", 300, 309]]], ["Vision is poor if bilateral.Clinical signsOther signs of uveitis will be present such as aqueous flare and fibrovascular membrane growth on the iris.", [["fibrovascular membrane", "ANATOMY", 107, 129], ["iris", "ANATOMY", 144, 148], ["uveitis", "DISEASE", 57, 64], ["fibrovascular membrane", "MULTI-TISSUE_STRUCTURE", 107, 129], ["iris", "TISSUE", 144, 148], ["uveitis", "PROBLEM", 57, 64], ["aqueous flare", "PROBLEM", 89, 102], ["fibrovascular membrane growth on the iris", "PROBLEM", 107, 148], ["poor", "OBSERVATION_MODIFIER", 10, 14], ["bilateral", "ANATOMY_MODIFIER", 18, 27], ["uveitis", "OBSERVATION", 57, 64], ["fibrovascular membrane", "OBSERVATION", 107, 129], ["growth", "OBSERVATION_MODIFIER", 130, 136], ["iris", "ANATOMY", 144, 148]]], ["The iris may have a darker color than the opposite eye, or have changes in contour due to adhesions of the iris to the anterior lens capsule (posterior synechia).Clinical signsThere may be changes in the cornea such as edema or scarring, with or without superficial vascularization.Clinical signsHypopyon or keratic precipitates may be evident.Clinical signsSome cats develop secondary glaucoma.DiagnosisA tentative diagnosis is based on the signs of a cloudy lens or cataract.Classical signs\u2022 Milky appearance of lens in cats older than 10 years of age. \u2022 Cats are usually visual and leading a normal lifestyle. \u2022 The fundus can be seen clearly with an ophthalmoscope.PathogenesisNuclear sclerosis is a normal aging process in the lens which starts in animals from about 8 years of age and is evident by 10 years.PathogenesisLens fibers are produced throughout life, but the lens does not increase in size.", [["iris", "ANATOMY", 4, 8], ["eye", "ANATOMY", 51, 54], ["iris", "ANATOMY", 107, 111], ["anterior lens capsule", "ANATOMY", 119, 140], ["posterior synechia", "ANATOMY", 142, 160], ["cornea", "ANATOMY", 204, 210], ["edema", "ANATOMY", 219, 224], ["glaucoma", "ANATOMY", 386, 394], ["lens", "ANATOMY", 460, 464], ["lens", "ANATOMY", 514, 518], ["fundus", "ANATOMY", 619, 625], ["lens", "ANATOMY", 732, 736], ["PathogenesisLens fibers", "ANATOMY", 814, 837], ["edema", "DISEASE", 219, 224], ["scarring", "DISEASE", 228, 236], ["glaucoma", "DISEASE", 386, 394], ["cataract", "DISEASE", 468, 476], ["PathogenesisNuclear sclerosis", "DISEASE", 669, 698], ["iris", "ORGAN", 4, 8], ["eye", "ORGAN", 51, 54], ["iris", "TISSUE", 107, 111], ["cornea", "TISSUE", 204, 210], ["edema", "PATHOLOGICAL_FORMATION", 219, 224], ["Hypopyon", "SIMPLE_CHEMICAL", 296, 304], ["cats", "ORGANISM", 363, 367], ["lens", "TISSUE", 514, 518], ["cats", "ORGANISM", 522, 526], ["fundus", "MULTI-TISSUE_STRUCTURE", 619, 625], ["lens", "TISSUE", 732, 736], ["PathogenesisLens fibers", "CELL", 814, 837], ["cats", "SPECIES", 363, 367], ["cats", "SPECIES", 522, 526], ["a darker color", "PROBLEM", 18, 32], ["changes in contour", "PROBLEM", 64, 82], ["adhesions of the iris", "PROBLEM", 90, 111], ["Clinical signs", "TEST", 162, 176], ["changes in the cornea", "PROBLEM", 189, 210], ["edema", "PROBLEM", 219, 224], ["scarring", "PROBLEM", 228, 236], ["superficial vascularization", "PROBLEM", 254, 281], ["Hypopyon", "PROBLEM", 296, 304], ["keratic precipitates", "PROBLEM", 308, 328], ["Clinical signs", "TEST", 344, 358], ["Some cats", "PROBLEM", 358, 367], ["glaucoma", "PROBLEM", 386, 394], ["a cloudy lens", "PROBLEM", 451, 464], ["cataract", "PROBLEM", 468, 476], ["Classical signs", "TEST", 477, 492], ["an ophthalmoscope", "TEST", 651, 668], ["PathogenesisNuclear sclerosis", "PROBLEM", 669, 698], ["PathogenesisLens fibers", "PROBLEM", 814, 837], ["iris", "ANATOMY", 4, 8], ["darker", "OBSERVATION_MODIFIER", 20, 26], ["color", "OBSERVATION", 27, 32], ["opposite", "ANATOMY_MODIFIER", 42, 50], ["eye", "ANATOMY", 51, 54], ["contour", "OBSERVATION_MODIFIER", 75, 82], ["adhesions", "OBSERVATION", 90, 99], ["iris", "ANATOMY", 107, 111], ["anterior", "ANATOMY_MODIFIER", 119, 127], ["lens", "ANATOMY", 128, 132], ["capsule", "ANATOMY_MODIFIER", 133, 140], ["posterior", "ANATOMY_MODIFIER", 142, 151], ["synechia", "OBSERVATION", 152, 160], ["may be", "UNCERTAINTY", 182, 188], ["cornea", "ANATOMY", 204, 210], ["edema", "OBSERVATION", 219, 224], ["scarring", "OBSERVATION", 228, 236], ["without", "UNCERTAINTY", 246, 253], ["superficial", "OBSERVATION_MODIFIER", 254, 265], ["vascularization", "OBSERVATION", 266, 281], ["Hypopyon", "OBSERVATION", 296, 304], ["may be evident", "UNCERTAINTY", 329, 343], ["secondary glaucoma", "OBSERVATION", 376, 394], ["cloudy lens", "OBSERVATION", 453, 464], ["cataract", "OBSERVATION", 468, 476], ["lens", "OBSERVATION_MODIFIER", 514, 518], ["normal", "OBSERVATION", 595, 601], ["fundus", "ANATOMY", 619, 625], ["sclerosis", "OBSERVATION", 689, 698], ["normal aging", "OBSERVATION", 704, 716], ["lens", "ANATOMY", 732, 736], ["lens", "ANATOMY", 876, 880], ["does not", "UNCERTAINTY", 881, 889], ["increase", "OBSERVATION_MODIFIER", 890, 898], ["size", "OBSERVATION_MODIFIER", 902, 906]]], ["Therefore, the fibers in the center become thinner and pack closer together causing a slight opacity, termed sclerosis.", [["fibers", "ANATOMY", 15, 21], ["opacity", "DISEASE", 93, 100], ["sclerosis", "DISEASE", 109, 118], ["fibers", "CELLULAR_COMPONENT", 15, 21], ["a slight opacity", "PROBLEM", 84, 100], ["termed sclerosis", "PROBLEM", 102, 118], ["thinner", "OBSERVATION_MODIFIER", 43, 50], ["slight", "OBSERVATION_MODIFIER", 86, 92], ["opacity", "OBSERVATION", 93, 100], ["sclerosis", "OBSERVATION", 109, 118]]], ["As the lens ages further some of these fibers may break-down and then a nuclear cataract develops.", [["lens", "ANATOMY", 7, 11], ["fibers", "ANATOMY", 39, 45], ["nuclear", "ANATOMY", 72, 79], ["cataract", "DISEASE", 80, 88], ["fibers", "CELLULAR_COMPONENT", 39, 45], ["nuclear", "CELLULAR_COMPONENT", 72, 79], ["a nuclear cataract", "PROBLEM", 70, 88], ["nuclear", "OBSERVATION_MODIFIER", 72, 79], ["cataract", "OBSERVATION", 80, 88]]], ["In very old cats, the nuclear cataract may become quite dense with secondary changes in the surrounding cortex leading to a mature cataract.Clinical signsThe center of the lens becomes slightly cloudy, but the cat will be able to see quite well until the changes are advanced and become a cataract.Clinical signsNuclear sclerosis is seen from 10 years of age and cataracts typically occur in cats 12-20 years of age.Clinical signsOn ophthalmoscopic examination, the fundus will be clearly visible until a true cataract forms.DiagnosisDiagnosis of nuclear sclerosis is based on clinical signs of a slightly cloudy lens in an older cat, with vision intact.", [["nuclear", "ANATOMY", 22, 29], ["cortex", "ANATOMY", 104, 110], ["lens", "ANATOMY", 172, 176], ["fundus", "ANATOMY", 466, 472], ["nuclear", "ANATOMY", 547, 554], ["cataract", "DISEASE", 30, 38], ["cataract", "DISEASE", 131, 139], ["cataract", "DISEASE", 289, 297], ["Nuclear sclerosis", "DISEASE", 312, 329], ["cataracts", "DISEASE", 363, 372], ["cataract", "DISEASE", 510, 518], ["nuclear sclerosis", "DISEASE", 547, 564], ["cats", "ORGANISM", 12, 16], ["nuclear", "CELLULAR_COMPONENT", 22, 29], ["cortex", "CANCER", 104, 110], ["lens", "TISSUE", 172, 176], ["cat", "ORGANISM", 210, 213], ["cats", "ORGANISM", 392, 396], ["fundus", "MULTI-TISSUE_STRUCTURE", 466, 472], ["nuclear", "CELLULAR_COMPONENT", 547, 554], ["cat", "ORGANISM", 630, 633], ["cats", "SPECIES", 12, 16], ["cats", "SPECIES", 392, 396], ["the nuclear cataract", "PROBLEM", 18, 38], ["secondary changes in the surrounding cortex", "PROBLEM", 67, 110], ["a mature cataract", "PROBLEM", 122, 139], ["Clinical signs", "TEST", 140, 154], ["slightly cloudy", "PROBLEM", 185, 200], ["a cataract", "PROBLEM", 287, 297], ["Clinical signsNuclear sclerosis", "PROBLEM", 298, 329], ["cataracts", "PROBLEM", 363, 372], ["Clinical signsOn ophthalmoscopic examination", "TEST", 416, 460], ["nuclear sclerosis", "PROBLEM", 547, 564], ["a slightly cloudy lens", "PROBLEM", 595, 617], ["cats", "OBSERVATION", 12, 16], ["cataract", "OBSERVATION", 30, 38], ["dense", "OBSERVATION", 56, 61], ["secondary changes", "OBSERVATION", 67, 84], ["surrounding cortex", "ANATOMY", 92, 110], ["mature", "OBSERVATION_MODIFIER", 124, 130], ["cataract", "OBSERVATION", 131, 139], ["center", "OBSERVATION_MODIFIER", 158, 164], ["lens", "ANATOMY", 172, 176], ["slightly", "OBSERVATION_MODIFIER", 185, 193], ["cloudy", "OBSERVATION", 194, 200], ["cataract", "OBSERVATION", 289, 297], ["Nuclear", "OBSERVATION_MODIFIER", 312, 319], ["sclerosis", "OBSERVATION", 320, 329], ["cataracts", "OBSERVATION", 363, 372], ["fundus", "ANATOMY", 466, 472], ["cataract", "OBSERVATION", 510, 518], ["nuclear", "OBSERVATION_MODIFIER", 547, 554], ["sclerosis", "OBSERVATION", 555, 564], ["slightly", "OBSERVATION_MODIFIER", 597, 605], ["cloudy lens", "OBSERVATION", 606, 617]]], ["The fundus can be clearly seen with an ophthalmoscope.DiagnosisDiagnosis of senile cataract is based on clinical signs of a cloudy lens in an older cat, with no history or signs of preceding ocular trauma or inflammation.TreatmentThere is no definitive treatment for this aging change.TreatmentIf a cataract develops and the cat is healthy, cataract surgery can be performed.", [["fundus", "ANATOMY", 4, 10], ["lens", "ANATOMY", 131, 135], ["ocular", "ANATOMY", 191, 197], ["cataract", "DISEASE", 83, 91], ["ocular trauma", "DISEASE", 191, 204], ["inflammation", "DISEASE", 208, 220], ["cataract", "DISEASE", 299, 307], ["cataract", "DISEASE", 341, 349], ["fundus", "MULTI-TISSUE_STRUCTURE", 4, 10], ["cat", "ORGANISM", 148, 151], ["ocular", "ORGAN", 191, 197], ["cat", "ORGANISM", 325, 328], ["an ophthalmoscope", "TEST", 36, 53], ["senile cataract", "PROBLEM", 76, 91], ["a cloudy lens", "PROBLEM", 122, 135], ["preceding ocular trauma", "PROBLEM", 181, 204], ["inflammation", "PROBLEM", 208, 220], ["Treatment", "TREATMENT", 221, 230], ["definitive treatment", "TREATMENT", 242, 262], ["this aging change", "PROBLEM", 267, 284], ["Treatment", "TREATMENT", 285, 294], ["a cataract", "PROBLEM", 297, 307], ["cataract surgery", "TREATMENT", 341, 357], ["fundus", "ANATOMY", 4, 10], ["senile cataract", "OBSERVATION", 76, 91], ["cloudy lens", "OBSERVATION", 124, 135], ["ocular", "ANATOMY", 191, 197], ["trauma", "OBSERVATION", 198, 204], ["inflammation", "OBSERVATION", 208, 220], ["no definitive", "UNCERTAINTY", 239, 252], ["cataract", "OBSERVATION", 299, 307]]], ["Because senile cataract occurs in aged cats, it is important to check renal function and blood pressure before proceeding with surgery.Classical signs\u2022 History of previous eye injury, frequently caused by a cat claw. \u2022 Cornea has scar from old wound. \u2022 \u00b1 Anterior or posterior synechia (iris adhesions to cornea or lens). \u2022 Lens may be partially or completely cloudy. \u2022 \u00b1 Chronic inflammation (uveitis) caused by lens protein outside the capsule.PathogenesisAny injury to the lens fibers will disrupt the normal lens metabolism, and cause death of lens fibers leading to cataract formation.PathogenesisThe most common cause of lens injury in cats is from cat fights when a cat claw penetrates the globe and tears the anterior lens capsule.", [["renal", "ANATOMY", 70, 75], ["blood", "ANATOMY", 89, 94], ["eye", "ANATOMY", 172, 175], ["Cornea", "ANATOMY", 219, 225], ["scar", "ANATOMY", 230, 234], ["wound", "ANATOMY", 244, 249], ["posterior synechia", "ANATOMY", 267, 285], ["iris adhesions", "ANATOMY", 287, 301], ["cornea", "ANATOMY", 305, 311], ["lens", "ANATOMY", 315, 319], ["capsule", "ANATOMY", 438, 445], ["lens fibers", "ANATOMY", 476, 487], ["lens", "ANATOMY", 512, 516], ["lens fibers", "ANATOMY", 548, 559], ["lens", "ANATOMY", 627, 631], ["globe", "ANATOMY", 697, 702], ["anterior lens capsule", "ANATOMY", 717, 738], ["senile cataract", "DISEASE", 8, 23], ["eye injury", "DISEASE", 172, 182], ["inflammation", "DISEASE", 380, 392], ["uveitis", "DISEASE", 394, 401], ["death", "DISEASE", 539, 544], ["cataract", "DISEASE", 571, 579], ["lens injury", "DISEASE", 627, 638], ["cats", "ORGANISM", 39, 43], ["renal", "ORGAN", 70, 75], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["eye", "ORGAN", 172, 175], ["cat", "ORGANISM", 207, 210], ["claw", "ORGANISM_SUBDIVISION", 211, 215], ["scar", "PATHOLOGICAL_FORMATION", 230, 234], ["wound", "PATHOLOGICAL_FORMATION", 244, 249], ["cornea", "TISSUE", 305, 311], ["lens", "TISSUE", 315, 319], ["Lens", "GENE_OR_GENE_PRODUCT", 324, 328], ["capsule", "CANCER", 438, 445], ["lens fibers", "TISSUE", 476, 487], ["lens", "TISSUE", 512, 516], ["lens fibers", "CELLULAR_COMPONENT", 548, 559], ["lens", "TISSUE", 627, 631], ["cats", "ORGANISM", 642, 646], ["cat", "ORGANISM", 655, 658], ["cat", "ORGANISM", 673, 676], ["claw", "ORGANISM_SUBDIVISION", 677, 681], ["globe", "ORGANISM_SUBDIVISION", 697, 702], ["lens protein", "PROTEIN", 413, 425], ["cats", "SPECIES", 39, 43], ["cats", "SPECIES", 642, 646], ["senile cataract", "PROBLEM", 8, 23], ["blood pressure", "TEST", 89, 103], ["surgery", "TREATMENT", 127, 134], ["Classical signs", "TEST", 135, 150], ["previous eye injury", "PROBLEM", 163, 182], ["scar", "PROBLEM", 230, 234], ["old wound", "PROBLEM", 240, 249], ["Anterior or posterior synechia (iris adhesions", "PROBLEM", 255, 301], ["completely cloudy", "PROBLEM", 349, 366], ["Chronic inflammation (uveitis", "PROBLEM", 372, 401], ["Any injury to the lens fibers", "PROBLEM", 458, 487], ["lens fibers", "PROBLEM", 548, 559], ["cataract formation", "PROBLEM", 571, 589], ["Pathogenesis", "PROBLEM", 590, 602], ["lens injury in cats", "PROBLEM", 627, 646], ["senile", "OBSERVATION_MODIFIER", 8, 14], ["cataract", "OBSERVATION", 15, 23], ["eye", "ANATOMY", 172, 175], ["injury", "OBSERVATION", 176, 182], ["Cornea", "ANATOMY", 219, 225], ["scar", "OBSERVATION", 230, 234], ["wound", "OBSERVATION", 244, 249], ["Anterior", "ANATOMY_MODIFIER", 255, 263], ["posterior", "ANATOMY_MODIFIER", 267, 276], ["synechia", "OBSERVATION", 277, 285], ["iris adhesions", "OBSERVATION", 287, 301], ["cornea", "ANATOMY", 305, 311], ["lens", "ANATOMY", 315, 319], ["completely", "OBSERVATION_MODIFIER", 349, 359], ["cloudy", "OBSERVATION", 360, 366], ["Chronic", "OBSERVATION_MODIFIER", 372, 379], ["inflammation", "OBSERVATION", 380, 392], ["uveitis", "OBSERVATION", 394, 401], ["lens protein", "OBSERVATION", 413, 425], ["capsule", "ANATOMY", 438, 445], ["injury", "OBSERVATION", 462, 468], ["lens", "ANATOMY", 476, 480], ["normal lens metabolism", "OBSERVATION", 505, 527], ["lens fibers", "OBSERVATION", 548, 559], ["cataract", "OBSERVATION", 571, 579], ["most common", "OBSERVATION_MODIFIER", 606, 617], ["lens injury", "OBSERVATION", 627, 638], ["globe", "ANATOMY", 697, 702], ["tears", "OBSERVATION", 707, 712], ["anterior", "ANATOMY_MODIFIER", 717, 725], ["lens", "ANATOMY", 726, 730], ["capsule", "ANATOMY_MODIFIER", 731, 738]]], ["This may be obvious when the tear is visible through the pupil, but some injuries occur under the iris root in the equator of the lens and are not possible to visualize.PathogenesisOther causes of injury are blunt trauma, which is frequently associated with motor vehicle accidents.", [["pupil", "ANATOMY", 57, 62], ["iris root", "ANATOMY", 98, 107], ["lens", "ANATOMY", 130, 134], ["injuries", "DISEASE", 73, 81], ["blunt trauma", "DISEASE", 208, 220], ["motor vehicle accidents", "DISEASE", 258, 281], ["pupil", "ORGAN", 57, 62], ["iris root", "MULTI-TISSUE_STRUCTURE", 98, 107], ["the tear", "PROBLEM", 25, 33], ["some injuries", "PROBLEM", 68, 81], ["injury", "PROBLEM", 197, 203], ["blunt trauma", "PROBLEM", 208, 220], ["may be obvious", "UNCERTAINTY", 5, 19], ["tear", "OBSERVATION", 29, 33], ["pupil", "ANATOMY", 57, 62], ["injuries", "OBSERVATION", 73, 81], ["iris root", "OBSERVATION", 98, 107], ["equator", "ANATOMY_MODIFIER", 115, 122], ["lens", "ANATOMY", 130, 134], ["not possible", "UNCERTAINTY", 143, 155], ["injury", "OBSERVATION", 197, 203], ["blunt", "OBSERVATION_MODIFIER", 208, 213], ["trauma", "OBSERVATION", 214, 220]]], ["With blunt trauma, the sudden compression of the eye followed by rapid decompression causes rupture of the lens capsule.PathogenesisOnce the nutrition of the lens fibers is disturbed, the cells will start to die and become opaque, resulting in typical cloudy lens and cataract formation.PathogenesisAn injured lens in a cat can lead to sarcoma formation due to metaplasia of the lens epithelial cells.", [["eye", "ANATOMY", 49, 52], ["lens capsule", "ANATOMY", 107, 119], ["lens fibers", "ANATOMY", 158, 169], ["cells", "ANATOMY", 188, 193], ["lens", "ANATOMY", 259, 263], ["lens", "ANATOMY", 310, 314], ["sarcoma", "ANATOMY", 336, 343], ["metaplasia", "ANATOMY", 361, 371], ["lens epithelial cells", "ANATOMY", 379, 400], ["blunt trauma", "DISEASE", 5, 17], ["sudden compression of the eye", "DISEASE", 23, 52], ["cataract", "DISEASE", 268, 276], ["sarcoma", "DISEASE", 336, 343], ["eye", "ORGAN", 49, 52], ["lens capsule", "CANCER", 107, 119], ["lens fibers", "MULTI-TISSUE_STRUCTURE", 158, 169], ["cells", "CELL", 188, 193], ["lens", "TISSUE", 259, 263], ["lens", "MULTI-TISSUE_STRUCTURE", 310, 314], ["cat", "ORGANISM", 320, 323], ["sarcoma", "CANCER", 336, 343], ["metaplasia", "CANCER", 361, 371], ["lens epithelial cells", "CELL", 379, 400], ["lens epithelial cells", "CELL_TYPE", 379, 400], ["blunt trauma", "PROBLEM", 5, 17], ["the sudden compression of the eye", "PROBLEM", 19, 52], ["rapid decompression", "TREATMENT", 65, 84], ["rupture of the lens capsule", "PROBLEM", 92, 119], ["typical cloudy lens", "PROBLEM", 244, 263], ["cataract formation", "PROBLEM", 268, 286], ["PathogenesisAn injured lens", "PROBLEM", 287, 314], ["sarcoma formation", "PROBLEM", 336, 353], ["metaplasia of the lens epithelial cells", "PROBLEM", 361, 400], ["blunt trauma", "OBSERVATION", 5, 17], ["sudden", "OBSERVATION_MODIFIER", 23, 29], ["compression", "OBSERVATION", 30, 41], ["eye", "ANATOMY", 49, 52], ["rapid", "OBSERVATION_MODIFIER", 65, 70], ["decompression", "OBSERVATION", 71, 84], ["rupture", "OBSERVATION", 92, 99], ["lens", "ANATOMY", 107, 111], ["capsule", "ANATOMY_MODIFIER", 112, 119], ["opaque", "OBSERVATION", 223, 229], ["typical", "OBSERVATION_MODIFIER", 244, 251], ["cloudy lens", "OBSERVATION", 252, 263], ["cataract formation", "OBSERVATION", 268, 286], ["injured lens", "OBSERVATION", 302, 314], ["sarcoma", "OBSERVATION", 336, 343], ["metaplasia", "OBSERVATION", 361, 371], ["lens epithelial cells", "OBSERVATION", 379, 400]]], ["See pages 1276 (Feline intra-ocular sarcoma).Clinical signsTypically, there is a history or signs of eye trauma, usually a cat-fight claw injury or blunt trauma.", [["intra-ocular sarcoma", "ANATOMY", 23, 43], ["eye", "ANATOMY", 101, 104], ["claw", "ANATOMY", 133, 137], ["Feline intra-ocular sarcoma", "DISEASE", 16, 43], ["eye trauma", "DISEASE", 101, 111], ["blunt trauma", "DISEASE", 148, 160], ["Feline", "ORGANISM", 16, 22], ["intra-ocular sarcoma", "CANCER", 23, 43], ["eye", "ORGAN", 101, 104], ["claw", "ORGANISM_SUBDIVISION", 133, 137], ["Feline intra-ocular sarcoma", "PROBLEM", 16, 43], ["eye trauma", "PROBLEM", 101, 111], ["claw injury", "PROBLEM", 133, 144], ["blunt trauma", "PROBLEM", 148, 160], ["intra-ocular sarcoma", "OBSERVATION", 23, 43], ["eye", "ANATOMY", 101, 104], ["trauma", "OBSERVATION", 105, 111], ["blunt trauma", "OBSERVATION", 148, 160]]], ["The cornea may have a scar from an old wound.Clinical signsLens may be partially or completely cloudy because of an immature or mature cataract.Clinical signsIn anterior capsule tears, lens material can be seen in the anterior chamber as a cloudy flocculent material.Clinical signsThere is intense inflammation associated with leakage of lens material, and it may be difficult to see through a very cloudy cornea.Clinical signsTears in the equatorial region of the lens may often be sealed by the ciliary body and iris root, and only develop a local cataract.", [["cornea", "ANATOMY", 4, 10], ["scar", "ANATOMY", 22, 26], ["wound", "ANATOMY", 39, 44], ["anterior capsule tears", "ANATOMY", 161, 183], ["lens", "ANATOMY", 185, 189], ["lens", "ANATOMY", 338, 342], ["cornea", "ANATOMY", 406, 412], ["lens", "ANATOMY", 465, 469], ["ciliary body", "ANATOMY", 497, 509], ["iris root", "ANATOMY", 514, 523], ["cataract", "DISEASE", 135, 143], ["inflammation", "DISEASE", 298, 310], ["cataract", "DISEASE", 550, 558], ["cornea", "ORGAN", 4, 10], ["scar", "PATHOLOGICAL_FORMATION", 22, 26], ["wound", "PATHOLOGICAL_FORMATION", 39, 44], ["anterior capsule tears", "TISSUE", 161, 183], ["lens material", "TISSUE", 185, 198], ["cornea", "TISSUE", 406, 412], ["lens", "TISSUE", 465, 469], ["ciliary body", "TISSUE", 497, 509], ["iris root", "TISSUE", 514, 523], ["a scar", "PROBLEM", 20, 26], ["an old wound", "PROBLEM", 32, 44], ["completely cloudy", "PROBLEM", 84, 101], ["an immature or mature cataract", "PROBLEM", 113, 143], ["Clinical signs", "TEST", 144, 158], ["anterior capsule tears", "PROBLEM", 161, 183], ["lens material", "PROBLEM", 185, 198], ["a cloudy flocculent material", "PROBLEM", 238, 266], ["Clinical signs", "TEST", 267, 281], ["intense inflammation", "PROBLEM", 290, 310], ["leakage of lens material", "PROBLEM", 327, 351], ["a very cloudy cornea", "PROBLEM", 392, 412], ["Clinical signs", "TEST", 413, 427], ["Tears", "PROBLEM", 427, 432], ["a local cataract", "PROBLEM", 542, 558], ["cornea", "ANATOMY", 4, 10], ["scar", "OBSERVATION", 22, 26], ["old", "OBSERVATION_MODIFIER", 35, 38], ["wound", "OBSERVATION", 39, 44], ["cloudy", "OBSERVATION", 95, 101], ["immature", "OBSERVATION_MODIFIER", 116, 124], ["mature", "OBSERVATION_MODIFIER", 128, 134], ["cataract", "OBSERVATION", 135, 143], ["anterior", "ANATOMY_MODIFIER", 161, 169], ["capsule tears", "OBSERVATION", 170, 183], ["lens material", "OBSERVATION", 185, 198], ["can be seen", "UNCERTAINTY", 199, 210], ["anterior", "ANATOMY_MODIFIER", 218, 226], ["chamber", "ANATOMY_MODIFIER", 227, 234], ["cloudy", "OBSERVATION_MODIFIER", 240, 246], ["flocculent material", "OBSERVATION", 247, 266], ["intense", "OBSERVATION_MODIFIER", 290, 297], ["inflammation", "OBSERVATION", 298, 310], ["leakage of lens material", "OBSERVATION", 327, 351], ["very", "OBSERVATION_MODIFIER", 394, 398], ["cloudy", "OBSERVATION", 399, 405], ["cornea", "ANATOMY", 406, 412], ["equatorial", "ANATOMY_MODIFIER", 440, 450], ["region", "ANATOMY_MODIFIER", 451, 457], ["lens", "ANATOMY", 465, 469], ["may often be", "UNCERTAINTY", 470, 482], ["sealed", "OBSERVATION", 483, 489], ["ciliary body", "ANATOMY", 497, 509], ["iris root", "ANATOMY", 514, 523], ["local", "OBSERVATION_MODIFIER", 544, 549], ["cataract", "OBSERVATION", 550, 558]]], ["Generally, an injury to the lens fibers will lead to a mature cataract.Clinical signsWhere the eye has hyphema (red eye), the lens will not be able to be seen ophthalmoscopically.Clinical signsOften the tear in the lens capsule has iris pigment adhered to it, visible as a black area.", [["lens fibers", "ANATOMY", 28, 39], ["eye", "ANATOMY", 95, 98], ["eye", "ANATOMY", 116, 119], ["lens", "ANATOMY", 126, 130], ["lens capsule", "ANATOMY", 215, 227], ["iris pigment", "ANATOMY", 232, 244], ["cataract", "DISEASE", 62, 70], ["hyphema", "DISEASE", 103, 110], ["eye", "ORGAN", 95, 98], ["eye", "ORGAN", 116, 119], ["lens capsule", "TISSUE", 215, 227], ["iris pigment", "TISSUE", 232, 244], ["an injury to the lens fibers", "PROBLEM", 11, 39], ["a mature cataract", "PROBLEM", 53, 70], ["Clinical signs", "TEST", 71, 85], ["hyphema", "PROBLEM", 103, 110], ["Clinical signsOften the tear", "PROBLEM", 179, 207], ["iris pigment", "PROBLEM", 232, 244], ["injury", "OBSERVATION", 14, 20], ["lens", "ANATOMY", 28, 32], ["mature", "OBSERVATION_MODIFIER", 55, 61], ["cataract", "OBSERVATION", 62, 70], ["eye", "ANATOMY", 95, 98], ["hyphema", "OBSERVATION", 103, 110], ["eye", "ANATOMY", 116, 119], ["lens", "ANATOMY", 126, 130], ["tear", "OBSERVATION", 203, 207], ["lens", "ANATOMY", 215, 219], ["capsule", "ANATOMY_MODIFIER", 220, 227], ["iris pigment", "OBSERVATION", 232, 244], ["adhered", "OBSERVATION_MODIFIER", 245, 252], ["black", "OBSERVATION_MODIFIER", 273, 278], ["area", "OBSERVATION_MODIFIER", 279, 283]]], ["Anterior or posterior synechia (iris adhesions to cornea or lens) may be evident.Clinical signsBe aware that cats with chronic inflammation after trauma often have a ruptured lens causing chronic lens-induced uveitis.DiagnosisA tentative diagnosis is based on a history or signs of eye trauma and the presence of a mature or immature cataract.DiagnosisIn acute cases, lens material is visible in the anterior chamber.DiagnosisIn chronic cases, chronic uveitis is evident after an eye injury.DiagnosisOcular ultrasound is a very useful tool for detecting lens rupture.", [["Anterior", "ANATOMY", 0, 8], ["posterior synechia", "ANATOMY", 12, 30], ["iris adhesions", "ANATOMY", 32, 46], ["cornea", "ANATOMY", 50, 56], ["lens", "ANATOMY", 60, 64], ["lens", "ANATOMY", 175, 179], ["lens", "ANATOMY", 196, 200], ["eye", "ANATOMY", 282, 285], ["lens material", "ANATOMY", 368, 381], ["anterior chamber", "ANATOMY", 400, 416], ["eye", "ANATOMY", 480, 483], ["lens", "ANATOMY", 554, 558], ["inflammation", "DISEASE", 127, 139], ["trauma", "DISEASE", 146, 152], ["uveitis", "DISEASE", 209, 216], ["eye trauma", "DISEASE", 282, 292], ["cataract", "DISEASE", 334, 342], ["uveitis", "DISEASE", 452, 459], ["eye injury", "DISEASE", 480, 490], ["lens rupture", "DISEASE", 554, 566], ["Anterior", "MULTI-TISSUE_STRUCTURE", 0, 8], ["cornea", "TISSUE", 50, 56], ["cats", "ORGANISM", 109, 113], ["eye", "ORGAN", 282, 285], ["lens material", "TISSUE", 368, 381], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 400, 416], ["eye", "ORGAN", 480, 483], ["lens", "TISSUE", 554, 558], ["cats", "SPECIES", 109, 113], ["Anterior or posterior synechia (iris adhesions to cornea", "PROBLEM", 0, 56], ["chronic inflammation", "PROBLEM", 119, 139], ["trauma", "PROBLEM", 146, 152], ["a ruptured lens", "PROBLEM", 164, 179], ["chronic lens-induced uveitis", "PROBLEM", 188, 216], ["eye trauma", "PROBLEM", 282, 292], ["immature cataract", "PROBLEM", 325, 342], ["acute cases", "PROBLEM", 355, 366], ["lens material", "PROBLEM", 368, 381], ["chronic cases", "PROBLEM", 429, 442], ["chronic uveitis", "PROBLEM", 444, 459], ["an eye injury", "PROBLEM", 477, 490], ["DiagnosisOcular ultrasound", "TEST", 491, 517], ["lens rupture", "PROBLEM", 554, 566], ["posterior", "ANATOMY_MODIFIER", 12, 21], ["synechia", "OBSERVATION", 22, 30], ["iris adhesions", "OBSERVATION", 32, 46], ["cornea", "ANATOMY", 50, 56], ["lens", "ANATOMY", 60, 64], ["may be evident", "UNCERTAINTY", 66, 80], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["inflammation", "OBSERVATION", 127, 139], ["ruptured", "OBSERVATION", 166, 174], ["chronic lens", "OBSERVATION", 188, 200], ["uveitis", "OBSERVATION", 209, 216], ["eye", "ANATOMY", 282, 285], ["trauma", "OBSERVATION", 286, 292], ["mature", "OBSERVATION_MODIFIER", 315, 321], ["immature", "OBSERVATION_MODIFIER", 325, 333], ["cataract", "OBSERVATION", 334, 342], ["acute", "OBSERVATION_MODIFIER", 355, 360], ["cases", "OBSERVATION", 361, 366], ["lens material", "OBSERVATION", 368, 381], ["visible", "OBSERVATION_MODIFIER", 385, 392], ["anterior", "ANATOMY_MODIFIER", 400, 408], ["chamber", "ANATOMY_MODIFIER", 409, 416], ["chronic", "OBSERVATION_MODIFIER", 429, 436], ["cases", "OBSERVATION", 437, 442], ["chronic", "OBSERVATION_MODIFIER", 444, 451], ["uveitis", "OBSERVATION", 452, 459], ["eye", "ANATOMY", 480, 483], ["injury", "OBSERVATION", 484, 490], ["lens", "ANATOMY", 554, 558], ["rupture", "OBSERVATION", 559, 566]]], ["Look for the normal position of the lens as seen by the anterior and posterior hyperechoic line defining the anterior and posterior lens capsule.", [["lens", "ANATOMY", 36, 40], ["anterior", "ANATOMY", 56, 64], ["posterior hyperechoic line", "ANATOMY", 69, 95], ["anterior", "ANATOMY", 109, 117], ["posterior lens capsule", "ANATOMY", 122, 144], ["lens", "TISSUE", 36, 40], ["anterior", "TISSUE", 56, 64], ["anterior", "MULTI-TISSUE_STRUCTURE", 109, 117], ["normal", "OBSERVATION", 13, 19], ["position", "OBSERVATION_MODIFIER", 20, 28], ["lens", "ANATOMY", 36, 40], ["anterior", "ANATOMY_MODIFIER", 56, 64], ["posterior", "ANATOMY_MODIFIER", 69, 78], ["hyperechoic line", "OBSERVATION", 79, 95], ["anterior", "ANATOMY_MODIFIER", 109, 117], ["posterior", "ANATOMY_MODIFIER", 122, 131], ["lens", "ANATOMY_MODIFIER", 132, 136], ["capsule", "ANATOMY_MODIFIER", 137, 144]]], ["In high-quality machines with a 10-MHz probe, the lens shape and position can be visualized quite easily.", [["lens", "ANATOMY", 50, 54], ["lens", "TISSUE", 50, 54], ["10-MHz probe", "DNA", 32, 44], ["a 10-MHz probe", "TREATMENT", 30, 44], ["high", "OBSERVATION_MODIFIER", 3, 7], ["lens", "OBSERVATION_MODIFIER", 50, 54], ["shape", "OBSERVATION_MODIFIER", 55, 60]]], ["Any change to the appearance or lack of hyperechoic lines is suspicious for lens rupture.TreatmentIf there is corneal edema and the anterior chamber is filled with blood and protein, treat the eye with broadspectrum antibiotics topically and systemically.", [["hyperechoic lines", "ANATOMY", 40, 57], ["lens", "ANATOMY", 76, 80], ["corneal", "ANATOMY", 110, 117], ["anterior chamber", "ANATOMY", 132, 148], ["blood", "ANATOMY", 164, 169], ["eye", "ANATOMY", 193, 196], ["lens rupture", "DISEASE", 76, 88], ["corneal edema", "DISEASE", 110, 123], ["lens", "TISSUE", 76, 80], ["corneal edema", "PATHOLOGICAL_FORMATION", 110, 123], ["blood", "ORGANISM_SUBSTANCE", 164, 169], ["eye", "ORGAN", 193, 196], ["Any change", "PROBLEM", 0, 10], ["hyperechoic lines", "PROBLEM", 40, 57], ["lens rupture", "PROBLEM", 76, 88], ["Treatment", "TREATMENT", 89, 98], ["corneal edema", "PROBLEM", 110, 123], ["blood and protein", "TEST", 164, 181], ["broadspectrum antibiotics", "TREATMENT", 202, 227], ["hyperechoic lines", "OBSERVATION", 40, 57], ["suspicious for", "UNCERTAINTY", 61, 75], ["lens rupture", "OBSERVATION", 76, 88], ["corneal", "ANATOMY", 110, 117], ["edema", "OBSERVATION", 118, 123], ["anterior", "ANATOMY_MODIFIER", 132, 140], ["chamber", "ANATOMY_MODIFIER", 141, 148], ["eye", "ANATOMY", 193, 196]]], ["Inflammation should be controlled initially with NSAIDs.", [["Inflammation", "DISEASE", 0, 12], ["NSAIDs", "SIMPLE_CHEMICAL", 49, 55], ["Inflammation", "PROBLEM", 0, 12], ["NSAIDs", "TREATMENT", 49, 55]]], ["If the lens is ruptured, corticosteroids systemically will be needed to control the lens-induced uveitis, which is an immune reaction in the eye against the exposed lens fibers.TreatmentIf the injury has recently occurred, and the cornea and anterior chamber allows visualization of the lens, a lentectomy should be performed immediately.", [["lens", "ANATOMY", 7, 11], ["lens", "ANATOMY", 84, 88], ["eye", "ANATOMY", 141, 144], ["lens fibers", "ANATOMY", 165, 176], ["cornea", "ANATOMY", 231, 237], ["anterior chamber", "ANATOMY", 242, 258], ["lens", "ANATOMY", 287, 291], ["uveitis", "DISEASE", 97, 104], ["corticosteroids", "CHEMICAL", 25, 40], ["lens", "TISSUE", 7, 11], ["corticosteroids", "SIMPLE_CHEMICAL", 25, 40], ["lens", "TISSUE", 84, 88], ["eye", "ORGAN", 141, 144], ["lens fibers", "TISSUE", 165, 176], ["cornea", "TISSUE", 231, 237], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 242, 258], ["lentectomy", "CANCER", 295, 305], ["ruptured", "PROBLEM", 15, 23], ["corticosteroids", "TREATMENT", 25, 40], ["uveitis", "PROBLEM", 97, 104], ["an immune reaction", "PROBLEM", 115, 133], ["Treatment", "TREATMENT", 177, 186], ["the injury", "PROBLEM", 189, 199], ["a lentectomy", "TREATMENT", 293, 305], ["lens", "ANATOMY", 7, 11], ["ruptured", "OBSERVATION", 15, 23], ["lens", "ANATOMY", 84, 88], ["uveitis", "OBSERVATION", 97, 104], ["immune reaction", "OBSERVATION", 118, 133], ["eye", "ANATOMY", 141, 144], ["lens fibers", "OBSERVATION", 165, 176], ["injury", "OBSERVATION", 193, 199], ["cornea", "ANATOMY", 231, 237], ["anterior", "ANATOMY_MODIFIER", 242, 250], ["chamber", "ANATOMY_MODIFIER", 251, 258], ["lens", "ANATOMY", 287, 291]]], ["This treatment is controversial because of the danger of sarcoma formation later in life.TreatmentCataract surgery can be performed later if a mature cataract develops.TreatmentCats with an injured lens have a high risk of developing ocular sarcoma, and enucleation should be considered.Classical signs\u2022 Nuclear cataract in a young healthy cat that with no evidence of ocular inflammation.PathogenesisIn contrast to dogs, genetic cataract is rare in cats, but has been reported.PathogenesisCongenital cataract is seen when the lens development is disrupted or altered in the early embryonic development of the eye.PathogenesisAs the nucleus is the first part of the lens to develop, this is the usual area of cataract development seen in young cats (nuclear cataract).", [["sarcoma", "ANATOMY", 57, 64], ["ocular sarcoma", "ANATOMY", 234, 248], ["ocular", "ANATOMY", 369, 375], ["lens", "ANATOMY", 527, 531], ["embryonic", "ANATOMY", 581, 590], ["eye", "ANATOMY", 610, 613], ["nucleus", "ANATOMY", 633, 640], ["lens", "ANATOMY", 666, 670], ["nuclear", "ANATOMY", 750, 757], ["sarcoma", "DISEASE", 57, 64], ["Cataract", "DISEASE", 98, 106], ["cataract", "DISEASE", 150, 158], ["ocular sarcoma", "DISEASE", 234, 248], ["Nuclear cataract", "DISEASE", 304, 320], ["ocular inflammation", "DISEASE", 369, 388], ["genetic cataract", "DISEASE", 422, 438], ["Congenital cataract", "DISEASE", 490, 509], ["cataract", "DISEASE", 709, 717], ["cataract", "DISEASE", 758, 766], ["sarcoma", "CANCER", 57, 64], ["ocular sarcoma", "CANCER", 234, 248], ["cat", "ORGANISM", 340, 343], ["ocular", "ORGAN", 369, 375], ["dogs", "ORGANISM", 416, 420], ["cats", "ORGANISM", 450, 454], ["lens", "TISSUE", 527, 531], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 581, 590], ["eye", "ORGAN", 610, 613], ["nucleus", "CELLULAR_COMPONENT", 633, 640], ["cats", "ORGANISM", 744, 748], ["dogs", "SPECIES", 416, 420], ["cats", "SPECIES", 450, 454], ["cats", "SPECIES", 744, 748], ["This treatment", "TREATMENT", 0, 14], ["sarcoma formation", "PROBLEM", 57, 74], ["Treatment", "TREATMENT", 89, 98], ["Cataract surgery", "TREATMENT", 98, 114], ["a mature cataract", "PROBLEM", 141, 158], ["an injured lens", "PROBLEM", 187, 202], ["developing ocular sarcoma", "PROBLEM", 223, 248], ["enucleation", "TREATMENT", 254, 265], ["Classical signs", "TEST", 287, 302], ["Nuclear cataract", "PROBLEM", 304, 320], ["ocular inflammation", "PROBLEM", 369, 388], ["genetic cataract", "PROBLEM", 422, 438], ["Congenital cataract", "PROBLEM", 490, 509], ["cataract development", "PROBLEM", 709, 729], ["sarcoma", "OBSERVATION", 57, 64], ["cataract", "OBSERVATION", 150, 158], ["injured lens", "OBSERVATION", 190, 202], ["high risk", "OBSERVATION_MODIFIER", 210, 219], ["ocular", "ANATOMY", 234, 240], ["sarcoma", "OBSERVATION", 241, 248], ["Nuclear", "OBSERVATION_MODIFIER", 304, 311], ["cataract", "OBSERVATION", 312, 320], ["no evidence of", "UNCERTAINTY", 354, 368], ["ocular", "ANATOMY", 369, 375], ["inflammation", "OBSERVATION", 376, 388], ["cataract", "OBSERVATION", 430, 438], ["rare", "OBSERVATION_MODIFIER", 442, 446], ["Congenital", "OBSERVATION_MODIFIER", 490, 500], ["cataract", "OBSERVATION", 501, 509], ["disrupted", "OBSERVATION", 547, 556], ["altered", "OBSERVATION_MODIFIER", 560, 567], ["early", "OBSERVATION_MODIFIER", 575, 580], ["embryonic", "OBSERVATION_MODIFIER", 581, 590], ["eye", "ANATOMY", 610, 613], ["nucleus", "ANATOMY_MODIFIER", 633, 640], ["lens", "OBSERVATION", 666, 670], ["cataract", "OBSERVATION", 709, 717], ["cataract", "OBSERVATION", 758, 766]]], ["As the cat ages, the lens cortex may become cataractous and the eye develops a mature cataract.Clinical signsCloudy lens in a young cat with no history of illness and no sign of inflammation in the eye.Clinical signsVision is reduced or absent if both eyes are affected.DiagnosisDiagnosis is based on the classical appearance of a cloudy lens in a young healthy cat, which has no evidence of ocular inflammation.TreatmentCataract surgery can be done by a trained ophthalmologist if the globe and retina is normal.Treatment\u2022 Ocular ultrasound should be done to determine whether the retina is detached.", [["lens cortex", "ANATOMY", 21, 32], ["eye", "ANATOMY", 64, 67], ["eye", "ANATOMY", 198, 201], ["eyes", "ANATOMY", 252, 256], ["cloudy lens", "ANATOMY", 331, 342], ["ocular", "ANATOMY", 392, 398], ["globe", "ANATOMY", 486, 491], ["retina", "ANATOMY", 496, 502], ["Ocular", "ANATOMY", 524, 530], ["retina", "ANATOMY", 582, 588], ["cataract", "DISEASE", 86, 94], ["illness", "DISEASE", 155, 162], ["inflammation", "DISEASE", 178, 190], ["DiagnosisDiagnosis", "DISEASE", 270, 288], ["ocular inflammation", "DISEASE", 392, 411], ["Cataract", "DISEASE", 421, 429], ["cat", "ORGANISM", 7, 10], ["lens cortex", "CANCER", 21, 32], ["cataractous", "TISSUE", 44, 55], ["eye", "ORGAN", 64, 67], ["cat", "ORGANISM", 132, 135], ["eye", "ORGAN", 198, 201], ["eyes", "ORGAN", 252, 256], ["cat", "ORGANISM", 362, 365], ["ocular", "ORGAN", 392, 398], ["globe", "MULTI-TISSUE_STRUCTURE", 486, 491], ["retina", "MULTI-TISSUE_STRUCTURE", 496, 502], ["Ocular", "ORGAN", 524, 530], ["retina", "MULTI-TISSUE_STRUCTURE", 582, 588], ["cat", "SPECIES", 132, 135], ["cataractous", "PROBLEM", 44, 55], ["a mature cataract", "PROBLEM", 77, 94], ["Clinical signs", "TEST", 95, 109], ["Cloudy lens", "PROBLEM", 109, 120], ["illness", "PROBLEM", 155, 162], ["inflammation in the eye", "PROBLEM", 178, 201], ["Clinical signsVision", "TEST", 202, 222], ["a cloudy lens", "PROBLEM", 329, 342], ["ocular inflammation", "PROBLEM", 392, 411], ["Treatment", "TREATMENT", 412, 421], ["Cataract surgery", "TREATMENT", 421, 437], ["Ocular ultrasound", "TEST", 524, 541], ["lens cortex", "ANATOMY", 21, 32], ["cataractous", "OBSERVATION", 44, 55], ["eye", "ANATOMY", 64, 67], ["mature", "OBSERVATION_MODIFIER", 79, 85], ["cataract", "OBSERVATION", 86, 94], ["lens", "OBSERVATION_MODIFIER", 116, 120], ["no sign of", "UNCERTAINTY", 167, 177], ["inflammation", "OBSERVATION", 178, 190], ["eye", "ANATOMY", 198, 201], ["reduced", "OBSERVATION_MODIFIER", 226, 233], ["eyes", "ANATOMY", 252, 256], ["cloudy lens", "OBSERVATION", 331, 342], ["no evidence of", "UNCERTAINTY", 377, 391], ["ocular", "ANATOMY", 392, 398], ["inflammation", "OBSERVATION", 399, 411], ["globe", "ANATOMY", 486, 491], ["retina", "ANATOMY", 496, 502], ["normal", "OBSERVATION", 506, 512], ["retina", "ANATOMY", 582, 588], ["detached", "OBSERVATION", 592, 600]]], ["A 10-MHz probe should be used.", [["A 10-MHz probe", "TREATMENT", 0, 14]]], ["Detached retinas are seen as faint lines bulging into the vitreous between the optic disc and ora serrata. \u2022 Electroretinography can be done to determine whether the retina has normal rod and cone function.Classical signs\u2022 Rare finding in older cat with diabetes mellitus. \u2022 Cloudy lens with immature to mature cataract.PathogenesisDiabetic cataract forms because the lens is bathed in a solution that is very high in glucose.", [["retinas", "ANATOMY", 9, 16], ["faint lines", "ANATOMY", 29, 40], ["vitreous", "ANATOMY", 58, 66], ["optic disc", "ANATOMY", 79, 89], ["retina", "ANATOMY", 166, 172], ["rod", "ANATOMY", 184, 187], ["lens", "ANATOMY", 368, 372], ["diabetes mellitus", "DISEASE", 254, 271], ["cataract", "DISEASE", 311, 319], ["cataract", "DISEASE", 341, 349], ["glucose", "CHEMICAL", 418, 425], ["glucose", "CHEMICAL", 418, 425], ["retinas", "MULTI-TISSUE_STRUCTURE", 9, 16], ["vitreous", "TISSUE", 58, 66], ["optic disc", "MULTI-TISSUE_STRUCTURE", 79, 89], ["ora serrata", "ORGANISM", 94, 105], ["retina", "MULTI-TISSUE_STRUCTURE", 166, 172], ["cat", "ORGANISM", 245, 248], ["glucose", "SIMPLE_CHEMICAL", 418, 425], ["ora serrata", "SPECIES", 94, 105], ["Detached retinas", "PROBLEM", 0, 16], ["faint lines bulging into the vitreous", "PROBLEM", 29, 66], ["Electroretinography", "TEST", 109, 128], ["Classical signs", "TEST", 206, 221], ["diabetes mellitus", "PROBLEM", 254, 271], ["Cloudy lens", "PROBLEM", 275, 286], ["immature to mature cataract", "PROBLEM", 292, 319], ["PathogenesisDiabetic cataract forms", "PROBLEM", 320, 355], ["very high in glucose", "PROBLEM", 405, 425], ["retinas", "OBSERVATION", 9, 16], ["faint", "OBSERVATION_MODIFIER", 29, 34], ["lines bulging", "OBSERVATION", 35, 48], ["vitreous", "ANATOMY_MODIFIER", 58, 66], ["optic disc", "ANATOMY", 79, 89], ["ora serrata", "ANATOMY", 94, 105], ["retina", "ANATOMY", 166, 172], ["normal rod", "OBSERVATION", 177, 187], ["diabetes mellitus", "OBSERVATION", 254, 271], ["lens", "ANATOMY", 282, 286], ["immature", "OBSERVATION_MODIFIER", 292, 300], ["mature", "OBSERVATION_MODIFIER", 304, 310], ["cataract", "OBSERVATION", 311, 319], ["cataract", "OBSERVATION", 341, 349], ["lens", "ANATOMY", 368, 372], ["very", "OBSERVATION_MODIFIER", 405, 409], ["high", "OBSERVATION", 410, 414]]], ["The lens cells cannot metabolize the excess glucose by normal anaerobic glycolysis, and therefore uses aerobic glycolysis using the sorbitol pathway and the enzyme aldose reductase as the catalyst.", [["lens cells", "ANATOMY", 4, 14], ["glucose", "CHEMICAL", 44, 51], ["sorbitol", "CHEMICAL", 132, 140], ["glucose", "CHEMICAL", 44, 51], ["sorbitol", "CHEMICAL", 132, 140], ["aldose", "CHEMICAL", 164, 170], ["lens cells", "CELL", 4, 14], ["glucose", "SIMPLE_CHEMICAL", 44, 51], ["sorbitol", "SIMPLE_CHEMICAL", 132, 140], ["aldose reductase", "GENE_OR_GENE_PRODUCT", 164, 180], ["lens cells", "CELL_TYPE", 4, 14], ["enzyme aldose reductase", "PROTEIN", 157, 180], ["the excess glucose", "PROBLEM", 33, 51], ["aerobic glycolysis", "TREATMENT", 103, 121], ["the sorbitol pathway", "TREATMENT", 128, 148], ["the enzyme aldose reductase", "TREATMENT", 153, 180], ["the catalyst", "TREATMENT", 184, 196], ["lens cells", "OBSERVATION", 4, 14], ["anaerobic glycolysis", "OBSERVATION", 62, 82]]], ["The by-product of this process is sugar alcohol (sorbitol), which kills the cell.", [["cell", "ANATOMY", 76, 80], ["alcohol", "CHEMICAL", 40, 47], ["sorbitol", "CHEMICAL", 49, 57], ["sugar alcohol", "CHEMICAL", 34, 47], ["sorbitol", "CHEMICAL", 49, 57], ["sugar alcohol", "SIMPLE_CHEMICAL", 34, 47], ["sorbitol", "SIMPLE_CHEMICAL", 49, 57], ["cell", "CELL", 76, 80], ["sorbitol)", "TREATMENT", 49, 58]]], ["The sugar alcohol is a large molecule that cannot escape through the cell wall, and results in a more concentrated intracellular fluid than the surrounding fluid.", [["cell wall", "ANATOMY", 69, 78], ["intracellular fluid", "ANATOMY", 115, 134], ["fluid", "ANATOMY", 156, 161], ["alcohol", "CHEMICAL", 10, 17], ["sugar alcohol", "CHEMICAL", 4, 17], ["sugar alcohol", "SIMPLE_CHEMICAL", 4, 17], ["cell wall", "TISSUE", 69, 78], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 128], ["fluid", "ORGANISM_SUBSTANCE", 129, 134], ["fluid", "ORGANISM_SUBSTANCE", 156, 161], ["a large molecule", "PROBLEM", 21, 37], ["a more concentrated intracellular fluid", "PROBLEM", 95, 134], ["sugar alcohol", "OBSERVATION", 4, 17], ["large", "OBSERVATION_MODIFIER", 23, 28], ["molecule", "OBSERVATION", 29, 37], ["cell", "OBSERVATION", 69, 73], ["wall", "ANATOMY_MODIFIER", 74, 78], ["more", "OBSERVATION_MODIFIER", 97, 101], ["concentrated", "OBSERVATION_MODIFIER", 102, 114], ["intracellular", "OBSERVATION_MODIFIER", 115, 128], ["fluid", "OBSERVATION", 129, 134], ["surrounding", "OBSERVATION_MODIFIER", 144, 155], ["fluid", "OBSERVATION", 156, 161]]], ["Water is therefore imbibed into the cell, which causes it to swell and rupture.", [["cell", "ANATOMY", 36, 40], ["rupture", "DISEASE", 71, 78], ["cell", "CELL", 36, 40], ["rupture", "PROBLEM", 71, 78], ["cell", "OBSERVATION", 36, 40], ["swell", "OBSERVATION_MODIFIER", 61, 66], ["rupture", "OBSERVATION", 71, 78]]], ["This in turn causes an immune reaction within the eye called lens-induced uveitis.PathogenesisDiabetic cataracts are rare in cats.", [["eye", "ANATOMY", 50, 53], ["lens", "ANATOMY", 61, 65], ["uveitis", "DISEASE", 74, 81], ["PathogenesisDiabetic cataracts", "DISEASE", 82, 112], ["eye", "ORGAN", 50, 53], ["lens", "TISSUE", 61, 65], ["cats", "ORGANISM", 125, 129], ["cats", "SPECIES", 125, 129], ["an immune reaction", "PROBLEM", 20, 38], ["uveitis", "PROBLEM", 74, 81], ["PathogenesisDiabetic cataracts", "PROBLEM", 82, 112], ["immune reaction", "OBSERVATION", 23, 38], ["eye", "ANATOMY", 50, 53], ["lens", "ANATOMY", 61, 65], ["uveitis", "OBSERVATION", 74, 81], ["cataracts", "OBSERVATION", 103, 112]]], ["This is thought to be due to low levels of the enzyme aldose reductase in old cats, which prevents the lens cells from using the sorbitol pathway to the same degree as other animals.Clinical signsCloudy lens and poor vision in a cat with diabetes mellitus.DiagnosisA tentative diagnosis is based on the signs of a cloudy lens consistent with an immature to mature cataract in a cat with diabetes mellitus.TreatmentCataract surgery can be done successfully by a trained ophthalmologist.PathogenesisHypertension causes vasoconstriction of pre-capillary retinal arterioles.", [["lens cells", "ANATOMY", 103, 113], ["Cloudy lens", "ANATOMY", 196, 207], ["pre-capillary retinal arterioles", "ANATOMY", 537, 569], ["sorbitol", "CHEMICAL", 129, 137], ["diabetes mellitus", "DISEASE", 238, 255], ["cataract", "DISEASE", 364, 372], ["diabetes mellitus", "DISEASE", 387, 404], ["Cataract", "DISEASE", 414, 422], ["Hypertension", "DISEASE", 497, 509], ["aldose", "CHEMICAL", 54, 60], ["sorbitol", "CHEMICAL", 129, 137], ["aldose reductase", "GENE_OR_GENE_PRODUCT", 54, 70], ["cats", "ORGANISM", 78, 82], ["lens cells", "CELL", 103, 113], ["sorbitol", "SIMPLE_CHEMICAL", 129, 137], ["cat", "ORGANISM", 229, 232], ["cat", "ORGANISM", 378, 381], ["retinal arterioles", "MULTI-TISSUE_STRUCTURE", 551, 569], ["enzyme aldose reductase", "PROTEIN", 47, 70], ["lens cells", "CELL_TYPE", 103, 113], ["cats", "SPECIES", 78, 82], ["cat", "SPECIES", 229, 232], ["cat", "SPECIES", 378, 381], ["low levels", "PROBLEM", 29, 39], ["the enzyme aldose reductase", "TREATMENT", 43, 70], ["old cats", "PROBLEM", 74, 82], ["the lens cells", "PROBLEM", 99, 113], ["the sorbitol pathway", "TREATMENT", 125, 145], ["Clinical signs", "TEST", 182, 196], ["Cloudy lens", "PROBLEM", 196, 207], ["poor vision", "PROBLEM", 212, 223], ["diabetes mellitus", "PROBLEM", 238, 255], ["a cloudy lens", "PROBLEM", 312, 325], ["an immature to mature cataract", "PROBLEM", 342, 372], ["diabetes mellitus", "PROBLEM", 387, 404], ["Treatment", "TREATMENT", 405, 414], ["Cataract surgery", "TREATMENT", 414, 430], ["PathogenesisHypertension", "PROBLEM", 485, 509], ["vasoconstriction of pre-capillary retinal arterioles", "PROBLEM", 517, 569], ["thought to be", "UNCERTAINTY", 8, 21], ["aldose reductase", "OBSERVATION", 54, 70], ["lens cells", "OBSERVATION", 103, 113], ["lens", "ANATOMY", 203, 207], ["poor vision", "OBSERVATION", 212, 223], ["cloudy lens", "OBSERVATION", 314, 325], ["consistent with", "UNCERTAINTY", 326, 341], ["immature", "OBSERVATION_MODIFIER", 345, 353], ["mature", "OBSERVATION_MODIFIER", 357, 363], ["cataract", "OBSERVATION", 364, 372], ["Hypertension", "OBSERVATION", 497, 509], ["vasoconstriction", "OBSERVATION", 517, 533], ["pre-capillary", "ANATOMY_MODIFIER", 537, 550], ["retinal arterioles", "ANATOMY", 551, 569]]], ["Hypoxia of the arteriole causes smooth muscle necrosis, which leads to vascular dilatation, and leakage of serum and blood.PathogenesisLeakage from vessels causes serous retinal detachment, and subretinal, intraretinal or preretinal hemorrhage.PathogenesisRetinal blood vessels may rupture, causing hemorrhage into the vitreous.PathogenesisHypertensive retinopathy occurs most commonly secondary to chronic renal disease and hyperthyroidism.Clinical signsClassical signs are acute onset of vision loss in an old cat, which is usually bilateral.", [["arteriole", "ANATOMY", 15, 24], ["smooth muscle", "ANATOMY", 32, 45], ["vascular", "ANATOMY", 71, 79], ["serum", "ANATOMY", 107, 112], ["blood", "ANATOMY", 117, 122], ["vessels", "ANATOMY", 148, 155], ["serous retinal", "ANATOMY", 163, 177], ["subretinal", "ANATOMY", 194, 204], ["intraretinal", "ANATOMY", 206, 218], ["preretinal", "ANATOMY", 222, 232], ["blood vessels", "ANATOMY", 264, 277], ["vitreous", "ANATOMY", 319, 327], ["renal", "ANATOMY", 407, 412], ["Hypoxia", "DISEASE", 0, 7], ["necrosis", "DISEASE", 46, 54], ["retinal detachment", "DISEASE", 170, 188], ["preretinal hemorrhage", "DISEASE", 222, 243], ["hemorrhage", "DISEASE", 299, 309], ["Hypertensive retinopathy", "DISEASE", 340, 364], ["chronic renal disease", "DISEASE", 399, 420], ["hyperthyroidism", "DISEASE", 425, 440], ["vision loss", "DISEASE", 490, 501], ["arteriole", "MULTI-TISSUE_STRUCTURE", 15, 24], ["smooth muscle", "TISSUE", 32, 45], ["vascular", "MULTI-TISSUE_STRUCTURE", 71, 79], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 117, 122], ["vessels", "MULTI-TISSUE_STRUCTURE", 148, 155], ["retinal", "MULTI-TISSUE_STRUCTURE", 170, 177], ["subretinal", "IMMATERIAL_ANATOMICAL_ENTITY", 194, 204], ["intraretinal", "IMMATERIAL_ANATOMICAL_ENTITY", 206, 218], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 264, 277], ["vitreous", "ORGANISM_SUBSTANCE", 319, 327], ["renal", "ORGAN", 407, 412], ["cat", "ORGANISM", 512, 515], ["Hypoxia of the arteriole", "PROBLEM", 0, 24], ["smooth muscle necrosis", "PROBLEM", 32, 54], ["vascular dilatation", "PROBLEM", 71, 90], ["leakage of serum and blood", "PROBLEM", 96, 122], ["PathogenesisLeakage from vessels", "PROBLEM", 123, 155], ["serous retinal detachment", "PROBLEM", 163, 188], ["subretinal, intraretinal or preretinal hemorrhage", "PROBLEM", 194, 243], ["PathogenesisRetinal blood vessels", "PROBLEM", 244, 277], ["rupture", "PROBLEM", 282, 289], ["hemorrhage into the vitreous", "PROBLEM", 299, 327], ["Pathogenesis", "PROBLEM", 328, 340], ["Hypertensive retinopathy", "PROBLEM", 340, 364], ["chronic renal disease", "PROBLEM", 399, 420], ["hyperthyroidism", "PROBLEM", 425, 440], ["Clinical signsClassical signs", "PROBLEM", 441, 470], ["vision loss", "PROBLEM", 490, 501], ["an old cat", "PROBLEM", 505, 515], ["arteriole", "ANATOMY", 15, 24], ["smooth", "OBSERVATION_MODIFIER", 32, 38], ["muscle", "ANATOMY", 39, 45], ["necrosis", "OBSERVATION", 46, 54], ["vascular", "ANATOMY", 71, 79], ["dilatation", "OBSERVATION", 80, 90], ["leakage", "OBSERVATION_MODIFIER", 96, 103], ["vessels", "ANATOMY", 148, 155], ["serous retinal detachment", "OBSERVATION", 163, 188], ["subretinal", "OBSERVATION_MODIFIER", 194, 204], ["intraretinal", "ANATOMY_MODIFIER", 206, 218], ["preretinal", "ANATOMY", 222, 232], ["hemorrhage", "OBSERVATION", 233, 243], ["vessels", "ANATOMY", 270, 277], ["rupture", "OBSERVATION", 282, 289], ["hemorrhage", "OBSERVATION", 299, 309], ["vitreous", "OBSERVATION_MODIFIER", 319, 327], ["Hypertensive", "OBSERVATION_MODIFIER", 340, 352], ["retinopathy", "OBSERVATION", 353, 364], ["chronic", "OBSERVATION_MODIFIER", 399, 406], ["renal", "ANATOMY", 407, 412], ["disease", "OBSERVATION", 413, 420], ["hyperthyroidism", "OBSERVATION", 425, 440], ["acute", "OBSERVATION_MODIFIER", 475, 480], ["vision loss", "OBSERVATION", 490, 501], ["old", "OBSERVATION_MODIFIER", 508, 511], ["cat", "OBSERVATION", 512, 515], ["bilateral", "ANATOMY_MODIFIER", 534, 543]]], ["The cat suddenly starts to bump into things, appears to be lost, and has very cautious movements.Clinical signsThe pupils are usually dilated, and non-responsive or poorly responsive light.Clinical signsAffected eyes appear slightly cloudy, and there may be focal red areas visible through the pupil, as a result of retinal hemorrhage.", [["eyes", "ANATOMY", 212, 216], ["focal red areas", "ANATOMY", 258, 273], ["pupil", "ANATOMY", 294, 299], ["retinal", "ANATOMY", 316, 323], ["retinal hemorrhage", "DISEASE", 316, 334], ["cat", "ORGANISM", 4, 7], ["eyes", "ORGAN", 212, 216], ["pupil", "ORGAN", 294, 299], ["retinal", "MULTI-TISSUE_STRUCTURE", 316, 323], ["Clinical signs", "TEST", 97, 111], ["usually dilated", "PROBLEM", 126, 141], ["slightly cloudy", "PROBLEM", 224, 239], ["focal red areas", "PROBLEM", 258, 273], ["retinal hemorrhage", "PROBLEM", 316, 334], ["pupils", "OBSERVATION", 115, 121], ["usually", "OBSERVATION_MODIFIER", 126, 133], ["dilated", "OBSERVATION", 134, 141], ["non-responsive", "OBSERVATION_MODIFIER", 147, 161], ["slightly", "OBSERVATION_MODIFIER", 224, 232], ["cloudy", "OBSERVATION", 233, 239], ["may be", "UNCERTAINTY", 251, 257], ["focal", "OBSERVATION_MODIFIER", 258, 263], ["pupil", "ANATOMY", 294, 299], ["retinal", "ANATOMY", 316, 323], ["hemorrhage", "OBSERVATION", 324, 334]]], ["The vitreous may appear red.", [["vitreous", "ANATOMY", 4, 12], ["vitreous", "MULTI-TISSUE_STRUCTURE", 4, 12], ["red", "PROBLEM", 24, 27], ["vitreous", "OBSERVATION", 4, 12], ["may appear", "UNCERTAINTY", 13, 23], ["red", "OBSERVATION", 24, 27]]], ["Early cases may show hemorrhage along the larger retinal blood vessels.Clinical signsIt is difficult to visualize the retina on fundoscopic examination, as it appears out of focus.", [["retinal blood vessels", "ANATOMY", 49, 70], ["retina", "ANATOMY", 118, 124], ["hemorrhage", "DISEASE", 21, 31], ["retinal blood vessels", "MULTI-TISSUE_STRUCTURE", 49, 70], ["retina", "MULTI-TISSUE_STRUCTURE", 118, 124], ["hemorrhage", "PROBLEM", 21, 31], ["Clinical signs", "TEST", 71, 85], ["fundoscopic examination", "TEST", 128, 151], ["hemorrhage", "OBSERVATION", 21, 31], ["larger", "ANATOMY_MODIFIER", 42, 48], ["retinal", "ANATOMY_MODIFIER", 49, 56], ["blood vessels", "ANATOMY", 57, 70], ["retina", "ANATOMY", 118, 124]]], ["This is caused by retinal detachment, with the retina ballooning into the vitreous, and appears as a thin veil of pale tissue.Clinical signsThese cats may have cardiomegaly, and left ventricular hypertrophy.Clinical signsThere may be other signs suggestive of hypertension, for example, a bounding cardiac apex beat.Clinical signsSystolic arterial blood pressure is usually greater than 160 mmHg.Clinical signsOther signs suggestive of renal and/or thyroid disease, such as progressive weight loss, polydipsia, polyuria and azotemia may be present.DiagnosisClinicians should suspect this problem in any old cat that has suddenly gone blind.DiagnosisOphthalmoscopy will demonstrate vitreal hemorrhage.DiagnosisThe retina will appear out of focus, and hemorrhage adjacent to the major retinal blood vessels is visible.DiagnosisBlood pressure is most commonly measured in the cat using Doppler technology.", [["retinal", "ANATOMY", 18, 25], ["retina", "ANATOMY", 47, 53], ["vitreous", "ANATOMY", 74, 82], ["pale tissue", "ANATOMY", 114, 125], ["left ventricular", "ANATOMY", 178, 194], ["cardiac", "ANATOMY", 298, 305], ["arterial", "ANATOMY", 339, 347], ["blood", "ANATOMY", 348, 353], ["renal", "ANATOMY", 436, 441], ["thyroid", "ANATOMY", 449, 456], ["vitreal", "ANATOMY", 681, 688], ["retina", "ANATOMY", 713, 719], ["retinal blood vessels", "ANATOMY", 783, 804], ["Blood", "ANATOMY", 825, 830], ["retinal detachment", "DISEASE", 18, 36], ["cardiomegaly", "DISEASE", 160, 172], ["left ventricular hypertrophy", "DISEASE", 178, 206], ["hypertension", "DISEASE", 260, 272], ["renal and/or thyroid disease", "DISEASE", 436, 464], ["weight loss", "DISEASE", 486, 497], ["polydipsia", "DISEASE", 499, 509], ["polyuria", "DISEASE", 511, 519], ["azotemia", "DISEASE", 524, 532], ["vitreal hemorrhage", "DISEASE", 681, 699], ["hemorrhage", "DISEASE", 750, 760], ["retinal", "MULTI-TISSUE_STRUCTURE", 18, 25], ["retina", "MULTI-TISSUE_STRUCTURE", 47, 53], ["vitreous", "ORGANISM_SUBSTANCE", 74, 82], ["pale tissue", "TISSUE", 114, 125], ["cats", "ORGANISM", 146, 150], ["ventricular", "MULTI-TISSUE_STRUCTURE", 183, 194], ["arterial", "MULTI-TISSUE_STRUCTURE", 339, 347], ["blood", "ORGANISM_SUBSTANCE", 348, 353], ["renal", "ORGAN", 436, 441], ["thyroid", "ORGAN", 449, 456], ["cat", "ORGANISM", 607, 610], ["vitreal", "MULTI-TISSUE_STRUCTURE", 681, 688], ["retina", "MULTI-TISSUE_STRUCTURE", 713, 719], ["retinal blood vessels", "MULTI-TISSUE_STRUCTURE", 783, 804], ["Blood", "ORGANISM_SUBSTANCE", 825, 830], ["cat", "ORGANISM", 873, 876], ["cats", "SPECIES", 146, 150], ["retinal detachment", "PROBLEM", 18, 36], ["the retina ballooning", "TREATMENT", 43, 64], ["a thin veil of pale tissue", "PROBLEM", 99, 125], ["Clinical signs", "TEST", 126, 140], ["cardiomegaly", "PROBLEM", 160, 172], ["left ventricular hypertrophy", "PROBLEM", 178, 206], ["Clinical signs", "TEST", 207, 221], ["hypertension", "PROBLEM", 260, 272], ["a bounding cardiac apex beat", "PROBLEM", 287, 315], ["Clinical signsSystolic arterial blood pressure", "TEST", 316, 362], ["Clinical signsOther signs", "TEST", 396, 421], ["renal and/or thyroid disease", "PROBLEM", 436, 464], ["progressive weight loss", "PROBLEM", 474, 497], ["polydipsia", "PROBLEM", 499, 509], ["polyuria", "PROBLEM", 511, 519], ["azotemia", "PROBLEM", 524, 532], ["this problem", "PROBLEM", 583, 595], ["DiagnosisOphthalmoscopy", "TEST", 640, 663], ["vitreal hemorrhage", "PROBLEM", 681, 699], ["hemorrhage", "PROBLEM", 750, 760], ["Blood pressure", "TEST", 825, 839], ["Doppler technology", "TEST", 883, 901], ["retinal", "ANATOMY", 18, 25], ["detachment", "OBSERVATION", 26, 36], ["vitreous", "OBSERVATION", 74, 82], ["pale tissue", "OBSERVATION", 114, 125], ["cardiomegaly", "OBSERVATION", 160, 172], ["left ventricular", "ANATOMY", 178, 194], ["hypertrophy", "OBSERVATION", 195, 206], ["suggestive of", "UNCERTAINTY", 246, 259], ["hypertension", "OBSERVATION", 260, 272], ["cardiac", "ANATOMY", 298, 305], ["apex", "ANATOMY_MODIFIER", 306, 310], ["arterial", "ANATOMY_MODIFIER", 339, 347], ["pressure", "OBSERVATION_MODIFIER", 354, 362], ["suggestive of", "UNCERTAINTY", 422, 435], ["renal", "ANATOMY", 436, 441], ["thyroid", "ANATOMY", 449, 456], ["disease", "OBSERVATION", 457, 464], ["progressive", "OBSERVATION_MODIFIER", 474, 485], ["weight loss", "OBSERVATION", 486, 497], ["polydipsia", "OBSERVATION", 499, 509], ["polyuria", "OBSERVATION", 511, 519], ["azotemia", "OBSERVATION", 524, 532], ["may be", "UNCERTAINTY", 533, 539], ["vitreal", "ANATOMY", 681, 688], ["hemorrhage", "OBSERVATION", 689, 699], ["retina", "ANATOMY", 713, 719], ["focus", "OBSERVATION", 739, 744], ["hemorrhage", "OBSERVATION", 750, 760], ["major", "ANATOMY_MODIFIER", 777, 782], ["retinal", "ANATOMY_MODIFIER", 783, 790], ["blood vessels", "ANATOMY", 791, 804], ["pressure", "OBSERVATION_MODIFIER", 831, 839]]], ["Arterial blood pressure greater than 160 mmHg confirms a diagnosis of hypertensive retinopathy.", [["Arterial", "ANATOMY", 0, 8], ["blood", "ANATOMY", 9, 14], ["hypertensive retinopathy", "DISEASE", 70, 94], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["Arterial blood pressure", "TEST", 0, 23], ["hypertensive retinopathy", "PROBLEM", 70, 94], ["pressure", "OBSERVATION_MODIFIER", 15, 23], ["hypertensive", "OBSERVATION_MODIFIER", 70, 82], ["retinopathy", "OBSERVATION", 83, 94]]], ["Most cats with clinical signs have a blood pressure of greater than 200 mmHg.DiagnosisBUN, creatinine and urine protein:creatinine ratios are useful clinical pathology parameters to check renal function.DiagnosisThyroid function should be checked by measuring plasma thyroxine (T4) concentration.DiagnosisFurther useful procedures include cardiac ultrasound, and in some cases, imaging of the thyroid with radioisotopes.TreatmentAmlodipine (Norvasc, Pfizer) is a calcium channel blocker, which has a greater effect on vascular smooth muscle cells than on cardiac muscle cells.", [["blood", "ANATOMY", 37, 42], ["urine", "ANATOMY", 106, 111], ["renal", "ANATOMY", 188, 193], ["Thyroid", "ANATOMY", 212, 219], ["plasma", "ANATOMY", 260, 266], ["cardiac", "ANATOMY", 339, 346], ["thyroid", "ANATOMY", 393, 400], ["vascular smooth muscle cells", "ANATOMY", 518, 546], ["cardiac muscle cells", "ANATOMY", 555, 575], ["creatinine", "CHEMICAL", 91, 101], ["creatinine", "CHEMICAL", 120, 130], ["thyroxine", "CHEMICAL", 267, 276], ["T4", "CHEMICAL", 278, 280], ["TreatmentAmlodipine", "CHEMICAL", 420, 439], ["Norvasc", "CHEMICAL", 441, 448], ["calcium", "CHEMICAL", 463, 470], ["creatinine", "CHEMICAL", 91, 101], ["creatinine", "CHEMICAL", 120, 130], ["thyroxine (T4)", "CHEMICAL", 267, 281], ["TreatmentAmlodipine", "CHEMICAL", 420, 439], ["Norvasc", "CHEMICAL", 441, 448], ["calcium", "CHEMICAL", 463, 470], ["cats", "ORGANISM", 5, 9], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["creatinine", "SIMPLE_CHEMICAL", 91, 101], ["urine", "ORGANISM_SUBSTANCE", 106, 111], ["creatinine", "SIMPLE_CHEMICAL", 120, 130], ["renal", "ORGAN", 188, 193], ["Thyroid", "ORGAN", 212, 219], ["plasma", "ORGANISM_SUBSTANCE", 260, 266], ["thyroxine", "SIMPLE_CHEMICAL", 267, 276], ["T4", "SIMPLE_CHEMICAL", 278, 280], ["thyroid", "ORGAN", 393, 400], ["TreatmentAmlodipine", "SIMPLE_CHEMICAL", 420, 439], ["Norvasc", "SIMPLE_CHEMICAL", 441, 448], ["Pfizer", "SIMPLE_CHEMICAL", 450, 456], ["calcium", "SIMPLE_CHEMICAL", 463, 470], ["vascular smooth muscle cells", "CELL", 518, 546], ["cardiac muscle cells", "CELL", 555, 575], ["vascular smooth muscle cells", "CELL_TYPE", 518, 546], ["cardiac muscle cells", "CELL_TYPE", 555, 575], ["cats", "SPECIES", 5, 9], ["clinical signs", "TEST", 15, 29], ["a blood pressure", "TEST", 35, 51], ["DiagnosisBUN", "TEST", 77, 89], ["creatinine", "TEST", 91, 101], ["urine protein", "TEST", 106, 119], ["creatinine ratios", "TEST", 120, 137], ["clinical pathology parameters", "TEST", 149, 178], ["Thyroid function", "TEST", 212, 228], ["plasma thyroxine (T4) concentration", "TREATMENT", 260, 295], ["cardiac ultrasound", "TEST", 339, 357], ["imaging", "TEST", 378, 385], ["TreatmentAmlodipine (Norvasc, Pfizer)", "TREATMENT", 420, 457], ["a calcium channel blocker", "TREATMENT", 461, 486], ["renal", "ANATOMY", 188, 193], ["thyroid", "ANATOMY", 393, 400], ["radioisotopes", "OBSERVATION", 406, 419], ["greater", "OBSERVATION_MODIFIER", 500, 507], ["vascular", "ANATOMY", 518, 526], ["smooth muscle cells", "OBSERVATION", 527, 546], ["cardiac muscle", "ANATOMY", 555, 569]]], ["The dose is approximately 0.625 mg/cat/day, i.e. 1/4 of a 2.5 mg tablet (USA) or 1/8 of a 5 mg tablet (Australia).TreatmentThe use of corticosteroids is controversial.TreatmentIf hypertension is associated with hypertrophic cardiomyopathy, then calcium channel blockers such as diltiazem may be used.", [["hypertension", "DISEASE", 179, 191], ["hypertrophic cardiomyopathy", "DISEASE", 211, 238], ["calcium", "CHEMICAL", 245, 252], ["diltiazem", "CHEMICAL", 278, 287], ["corticosteroids", "CHEMICAL", 134, 149], ["calcium", "CHEMICAL", 245, 252], ["diltiazem", "CHEMICAL", 278, 287], ["calcium channel blockers", "SIMPLE_CHEMICAL", 245, 269], ["diltiazem", "SIMPLE_CHEMICAL", 278, 287], ["corticosteroids", "TREATMENT", 134, 149], ["Treatment", "TREATMENT", 167, 176], ["hypertension", "PROBLEM", 179, 191], ["hypertrophic cardiomyopathy", "PROBLEM", 211, 238], ["calcium channel blockers", "TREATMENT", 245, 269], ["diltiazem", "TREATMENT", 278, 287], ["hypertension", "OBSERVATION", 179, 191], ["hypertrophic", "OBSERVATION_MODIFIER", 211, 223], ["cardiomyopathy", "OBSERVATION", 224, 238]]], ["For more detail see main reference on page 162 for details (The Cat With Tachycardia, Bradycardia or an Irregular Rhythm).Treatmentb-blockers such as propranolol (Inderal) can also be used in the management of the cardiac disease at 1/4 of a 10 mg tablet q 8 h.TreatmentHyperthyroidism when present, should be treated using surgery, radioactive iodine (131-I) or anti-thyroid drugs such as carbimazole or methimazole.", [["cardiac", "ANATOMY", 214, 221], ["Tachycardia", "DISEASE", 73, 84], ["propranolol", "CHEMICAL", 150, 161], ["Inderal", "CHEMICAL", 163, 170], ["cardiac disease", "DISEASE", 214, 229], ["Hyperthyroidism", "DISEASE", 270, 285], ["radioactive iodine", "CHEMICAL", 333, 351], ["131-I", "CHEMICAL", 353, 358], ["carbimazole", "CHEMICAL", 390, 401], ["methimazole", "CHEMICAL", 405, 416], ["propranolol", "CHEMICAL", 150, 161], ["radioactive iodine", "CHEMICAL", 333, 351], ["131-I", "CHEMICAL", 353, 358], ["carbimazole", "CHEMICAL", 390, 401], ["methimazole", "CHEMICAL", 405, 416], ["Treatmentb-blockers", "SIMPLE_CHEMICAL", 122, 141], ["propranolol", "SIMPLE_CHEMICAL", 150, 161], ["Inderal", "SIMPLE_CHEMICAL", 163, 170], ["cardiac", "ORGAN", 214, 221], ["radioactive iodine", "SIMPLE_CHEMICAL", 333, 351], ["131-I", "SIMPLE_CHEMICAL", 353, 358], ["anti-thyroid drugs", "SIMPLE_CHEMICAL", 363, 381], ["carbimazole", "SIMPLE_CHEMICAL", 390, 401], ["methimazole", "SIMPLE_CHEMICAL", 405, 416], ["Tachycardia", "PROBLEM", 73, 84], ["Bradycardia", "PROBLEM", 86, 97], ["an Irregular Rhythm)", "PROBLEM", 101, 121], ["Treatmentb-blockers", "TREATMENT", 122, 141], ["propranolol (Inderal)", "TREATMENT", 150, 171], ["the cardiac disease", "PROBLEM", 210, 229], ["Hyperthyroidism", "PROBLEM", 270, 285], ["surgery", "TREATMENT", 324, 331], ["radioactive iodine", "TREATMENT", 333, 351], ["anti-thyroid drugs", "TREATMENT", 363, 381], ["carbimazole", "TREATMENT", 390, 401], ["methimazole", "TREATMENT", 405, 416], ["cardiac", "ANATOMY", 214, 221], ["disease", "OBSERVATION", 222, 229]]], ["For more detail see main reference on page 305 (The Cat With Weight Loss and a Good Appetite).TreatmentCats with renal disease should be placed on appropriate medical and dietary management.", [["renal", "ANATOMY", 113, 118], ["renal disease", "DISEASE", 113, 126], ["renal", "ORGAN", 113, 118], ["Weight Loss", "PROBLEM", 61, 72], ["renal disease", "PROBLEM", 113, 126], ["dietary management", "TREATMENT", 171, 189], ["renal", "ANATOMY", 113, 118], ["disease", "OBSERVATION", 119, 126]]], ["For more details see the main reference on page 337 (The Thin, Inappetent Cat).Classical signs\u2022 Show signs of mild uveitis.Classical signs\u2022 \"Snowbank\" inflammation of the pars plana seen through dilated pupil.", [["pars", "ANATOMY", 171, 175], ["pupil", "ANATOMY", 203, 208], ["uveitis", "DISEASE", 115, 122], ["inflammation", "DISEASE", 151, 163], ["pars", "TISSUE", 171, 175], ["pupil", "MULTI-TISSUE_STRUCTURE", 203, 208], ["Classical signs", "TEST", 79, 94], ["mild uveitis", "PROBLEM", 110, 122], ["Classical signs", "TEST", 123, 138], ["Snowbank\" inflammation of the pars plana", "PROBLEM", 141, 181], ["dilated pupil", "PROBLEM", 195, 208], ["signs of", "UNCERTAINTY", 101, 109], ["mild", "OBSERVATION_MODIFIER", 110, 114], ["uveitis", "OBSERVATION", 115, 122], ["inflammation", "OBSERVATION", 151, 163], ["pars plana", "ANATOMY", 171, 181], ["dilated", "OBSERVATION", 195, 202], ["pupil", "ANATOMY", 203, 208]]], ["Appears as cloudy outer vitreous in this area. \u2022 May be other systemic signs such as loss of weight, inappetence and fever.PathogenesisInfection with the virus usually occurs as a result of a bite from another FIV-positive cat.", [["outer vitreous", "ANATOMY", 18, 32], ["loss of weight", "DISEASE", 85, 99], ["inappetence", "DISEASE", 101, 112], ["fever", "DISEASE", 117, 122], ["PathogenesisInfection", "DISEASE", 123, 144], ["vitreous", "ORGANISM_SUBSTANCE", 24, 32], ["FIV", "ORGANISM", 210, 213], ["cat", "ORGANISM", 223, 226], ["cat", "SPECIES", 223, 226], ["cloudy outer vitreous", "PROBLEM", 11, 32], ["other systemic signs", "PROBLEM", 56, 76], ["loss of weight", "PROBLEM", 85, 99], ["inappetence", "PROBLEM", 101, 112], ["fever", "PROBLEM", 117, 122], ["PathogenesisInfection", "PROBLEM", 123, 144], ["the virus", "PROBLEM", 150, 159], ["cloudy", "OBSERVATION", 11, 17], ["outer", "OBSERVATION_MODIFIER", 18, 23], ["vitreous", "OBSERVATION", 24, 32], ["virus", "OBSERVATION", 154, 159]]], ["Transmission in saliva by grooming is thought possible, but rare.PathogenesisAfter infection a viremic phase occurs, which may be associated with a transient fever, generalized lymphadenopathy and neutropenia.", [["infection", "DISEASE", 83, 92], ["fever", "DISEASE", 158, 163], ["lymphadenopathy", "DISEASE", 177, 192], ["neutropenia", "DISEASE", 197, 208], ["saliva", "ORGANISM_SUBSTANCE", 16, 22], ["PathogenesisAfter infection", "PROBLEM", 65, 92], ["a viremic phase", "PROBLEM", 93, 108], ["a transient fever", "PROBLEM", 146, 163], ["generalized lymphadenopathy", "PROBLEM", 165, 192], ["neutropenia", "PROBLEM", 197, 208], ["thought possible", "UNCERTAINTY", 38, 54], ["infection", "OBSERVATION", 83, 92], ["viremic phase", "OBSERVATION", 95, 108], ["may be associated with", "UNCERTAINTY", 123, 145], ["transient", "OBSERVATION_MODIFIER", 148, 157], ["fever", "OBSERVATION", 158, 163], ["generalized", "OBSERVATION_MODIFIER", 165, 176], ["lymphadenopathy", "OBSERVATION", 177, 192], ["neutropenia", "OBSERVATION", 197, 208]]], ["An asymptomatic carrier state or chronic disease then follows.Clinical signsCats that develop signs of FIV may have evidence of generalized systemic disease such as weight loss, and poor body and coat condition.", [["body", "ANATOMY", 187, 191], ["chronic disease", "DISEASE", 33, 48], ["FIV", "DISEASE", 103, 106], ["systemic disease", "DISEASE", 140, 156], ["weight loss", "DISEASE", 165, 176], ["FIV", "ORGANISM", 103, 106], ["body", "ORGANISM_SUBDIVISION", 187, 191], ["FIV", "SPECIES", 103, 106], ["An asymptomatic carrier state", "PROBLEM", 0, 29], ["chronic disease", "PROBLEM", 33, 48], ["signs of FIV", "PROBLEM", 94, 106], ["generalized systemic disease", "PROBLEM", 128, 156], ["weight loss", "PROBLEM", 165, 176], ["poor body and coat condition", "PROBLEM", 182, 210], ["asymptomatic", "OBSERVATION_MODIFIER", 3, 15], ["carrier state", "OBSERVATION", 16, 29], ["chronic", "OBSERVATION_MODIFIER", 33, 40], ["disease", "OBSERVATION", 41, 48], ["FIV", "OBSERVATION", 103, 106], ["may have evidence of", "UNCERTAINTY", 107, 127], ["generalized", "OBSERVATION_MODIFIER", 128, 139], ["systemic", "OBSERVATION_MODIFIER", 140, 148], ["disease", "OBSERVATION", 149, 156], ["weight loss", "OBSERVATION", 165, 176]]], ["Pyrexia, lymphadenopathy and infections of the oral cavity, respiratory tract, skin and other sites may occur.Clinical signsIn the eye, pars planitis or \"snow bank\" inflammation of the pars plana resulting in vitreous cloudiness is thought to be almost pathognomonic for FIV infection.", [["oral cavity", "ANATOMY", 47, 58], ["respiratory tract", "ANATOMY", 60, 77], ["skin", "ANATOMY", 79, 83], ["sites", "ANATOMY", 94, 99], ["eye", "ANATOMY", 131, 134], ["pars planitis", "ANATOMY", 136, 149], ["pars", "ANATOMY", 185, 189], ["vitreous", "ANATOMY", 209, 217], ["Pyrexia", "DISEASE", 0, 7], ["lymphadenopathy", "DISEASE", 9, 24], ["infections of the oral cavity", "DISEASE", 29, 58], ["inflammation", "DISEASE", 165, 177], ["FIV infection", "DISEASE", 271, 284], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 47, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 60, 77], ["skin", "ORGAN", 79, 83], ["eye", "ORGAN", 131, 134], ["pars", "TISSUE", 185, 189], ["vitreous", "MULTI-TISSUE_STRUCTURE", 209, 217], ["FIV", "ORGANISM", 271, 274], ["FIV", "SPECIES", 271, 274], ["Pyrexia", "PROBLEM", 0, 7], ["lymphadenopathy", "PROBLEM", 9, 24], ["infections of the oral cavity", "PROBLEM", 29, 58], ["respiratory tract", "PROBLEM", 60, 77], ["skin and other sites", "PROBLEM", 79, 99], ["pars planitis", "PROBLEM", 136, 149], ["inflammation of the pars plana", "PROBLEM", 165, 195], ["vitreous cloudiness", "PROBLEM", 209, 228], ["FIV infection", "PROBLEM", 271, 284], ["lymphadenopathy", "OBSERVATION", 9, 24], ["infections", "OBSERVATION", 29, 39], ["oral cavity", "ANATOMY", 47, 58], ["respiratory tract", "ANATOMY", 60, 77], ["skin", "ANATOMY", 79, 83], ["eye", "ANATOMY", 131, 134], ["pars plana", "ANATOMY", 185, 195], ["vitreous cloudiness", "OBSERVATION", 209, 228], ["thought to be", "UNCERTAINTY", 232, 245], ["infection", "OBSERVATION", 275, 284]]], ["Other signs of uveitis can also be seen, such as cloudy aqueous and iris inflammation.DiagnosisA tentative diagnosis is based on the clinical signs of vitreous cloudiness described as \"snow bank\" inflammation, in a FIV-positive cat.TreatmentSupportive treatment is indicated, and depends on the organ system affected.TreatmentThe use of steroid anti-inflammatory drugs for the ocular lesion has to be weighed against the potential immunosuppressive effects.Classical signs\u2022 Rare, primary neoplasia that occurs in older cats (7-15 years). \u2022 History of previous severe trauma to eye. \u2022 Anterior uveitis, keratitis (corneal edema and pigmentation) and glaucoma. \u2022 White to pinkish masses may be visible in the vitreous.Clinical signsIntra-ocular sarcoma is a rare primary neoplasia reported only in cats.Clinical signsIt is occurs in older cats 7-15 years of age, that have had a history of ocular trauma 3-10 years previously.Clinical signsThere may be signs of anterior uveitis with keratitis, with edema and pigmentation of the cornea.", [["iris", "ANATOMY", 68, 72], ["vitreous", "ANATOMY", 151, 159], ["organ system", "ANATOMY", 295, 307], ["ocular lesion", "ANATOMY", 377, 390], ["primary neoplasia", "ANATOMY", 480, 497], ["eye", "ANATOMY", 577, 580], ["corneal", "ANATOMY", 613, 620], ["glaucoma", "ANATOMY", 649, 657], ["pinkish masses", "ANATOMY", 670, 684], ["vitreous", "ANATOMY", 707, 715], ["Intra-ocular sarcoma", "ANATOMY", 730, 750], ["primary neoplasia", "ANATOMY", 761, 778], ["ocular", "ANATOMY", 888, 894], ["edema", "ANATOMY", 998, 1003], ["cornea", "ANATOMY", 1028, 1034], ["uveitis", "DISEASE", 15, 22], ["inflammation", "DISEASE", 73, 85], ["vitreous cloudiness", "DISEASE", 151, 170], ["inflammation", "DISEASE", 196, 208], ["steroid", "CHEMICAL", 337, 344], ["ocular lesion", "DISEASE", 377, 390], ["primary neoplasia", "DISEASE", 480, 497], ["trauma", "DISEASE", 567, 573], ["Anterior uveitis", "DISEASE", 584, 600], ["keratitis", "DISEASE", 602, 611], ["corneal edema", "DISEASE", 613, 626], ["glaucoma", "DISEASE", 649, 657], ["Intra-ocular sarcoma", "DISEASE", 730, 750], ["primary neoplasia", "DISEASE", 761, 778], ["ocular trauma", "DISEASE", 888, 901], ["anterior uveitis", "DISEASE", 960, 976], ["keratitis", "DISEASE", 982, 991], ["edema", "DISEASE", 998, 1003], ["steroid", "CHEMICAL", 337, 344], ["aqueous", "ORGANISM_SUBSTANCE", 56, 63], ["iris", "TISSUE", 68, 72], ["vitreous", "ORGANISM_SUBSTANCE", 151, 159], ["FIV", "ORGANISM", 215, 218], ["cat", "ORGANISM", 228, 231], ["organ", "ORGAN", 295, 300], ["steroid", "SIMPLE_CHEMICAL", 337, 344], ["ocular lesion", "PATHOLOGICAL_FORMATION", 377, 390], ["neoplasia", "CANCER", 488, 497], ["cats", "ORGANISM", 519, 523], ["eye", "ORGAN", 577, 580], ["corneal", "TISSUE", 613, 620], ["pinkish masses", "CANCER", 670, 684], ["vitreous", "ORGANISM_SUBSTANCE", 707, 715], ["Intra-ocular sarcoma", "CANCER", 730, 750], ["neoplasia", "CANCER", 769, 778], ["cats", "ORGANISM", 796, 800], ["cats", "ORGANISM", 837, 841], ["edema", "PATHOLOGICAL_FORMATION", 998, 1003], ["cornea", "ORGAN", 1028, 1034], ["cats", "SPECIES", 519, 523], ["cats", "SPECIES", 796, 800], ["cats", "SPECIES", 837, 841], ["FIV", "SPECIES", 215, 218], ["uveitis", "PROBLEM", 15, 22], ["cloudy aqueous and iris inflammation", "PROBLEM", 49, 85], ["vitreous cloudiness", "PROBLEM", 151, 170], ["snow bank\" inflammation", "PROBLEM", 185, 208], ["TreatmentSupportive treatment", "TREATMENT", 232, 261], ["Treatment", "TREATMENT", 317, 326], ["steroid anti-inflammatory drugs", "TREATMENT", 337, 368], ["the ocular lesion", "PROBLEM", 373, 390], ["Classical signs", "PROBLEM", 457, 472], ["primary neoplasia", "PROBLEM", 480, 497], ["previous severe trauma to eye", "PROBLEM", 551, 580], ["Anterior uveitis", "PROBLEM", 584, 600], ["keratitis", "PROBLEM", 602, 611], ["corneal edema", "PROBLEM", 613, 626], ["pigmentation", "PROBLEM", 631, 643], ["glaucoma", "PROBLEM", 649, 657], ["White to pinkish masses", "PROBLEM", 661, 684], ["Intra-ocular sarcoma", "PROBLEM", 730, 750], ["a rare primary neoplasia", "PROBLEM", 754, 778], ["Clinical signs", "TEST", 801, 815], ["ocular trauma", "PROBLEM", 888, 901], ["Clinical signs", "TEST", 924, 938], ["anterior uveitis", "PROBLEM", 960, 976], ["keratitis", "PROBLEM", 982, 991], ["edema", "PROBLEM", 998, 1003], ["pigmentation of the cornea", "PROBLEM", 1008, 1034], ["uveitis", "OBSERVATION", 15, 22], ["cloudy", "OBSERVATION_MODIFIER", 49, 55], ["aqueous", "OBSERVATION_MODIFIER", 56, 63], ["iris inflammation", "OBSERVATION", 68, 85], ["vitreous cloudiness", "OBSERVATION", 151, 170], ["inflammation", "OBSERVATION", 196, 208], ["ocular", "ANATOMY", 377, 383], ["lesion", "OBSERVATION", 384, 390], ["primary", "OBSERVATION_MODIFIER", 480, 487], ["neoplasia", "OBSERVATION", 488, 497], ["severe", "OBSERVATION_MODIFIER", 560, 566], ["trauma", "OBSERVATION", 567, 573], ["eye", "ANATOMY", 577, 580], ["uveitis", "OBSERVATION", 593, 600], ["keratitis", "OBSERVATION", 602, 611], ["corneal", "ANATOMY", 613, 620], ["edema", "OBSERVATION", 621, 626], ["pigmentation", "OBSERVATION_MODIFIER", 631, 643], ["glaucoma", "OBSERVATION", 649, 657], ["pinkish", "OBSERVATION_MODIFIER", 670, 677], ["masses", "OBSERVATION", 678, 684], ["may be", "UNCERTAINTY", 685, 691], ["visible", "OBSERVATION_MODIFIER", 692, 699], ["vitreous", "OBSERVATION", 707, 715], ["Intra-ocular sarcoma", "OBSERVATION", 730, 750], ["rare", "OBSERVATION_MODIFIER", 756, 760], ["primary", "OBSERVATION_MODIFIER", 761, 768], ["neoplasia", "OBSERVATION", 769, 778], ["ocular", "ANATOMY", 888, 894], ["trauma", "OBSERVATION", 895, 901], ["may be signs of", "UNCERTAINTY", 944, 959], ["anterior", "ANATOMY_MODIFIER", 960, 968], ["uveitis", "OBSERVATION", 969, 976], ["keratitis", "OBSERVATION", 982, 991], ["edema", "OBSERVATION", 998, 1003], ["pigmentation", "OBSERVATION_MODIFIER", 1008, 1020], ["cornea", "ANATOMY", 1028, 1034]]], ["These changes may prevent visualization of the intra-ocular structures.Clinical signsSecondary glaucoma is common at this stage of the disease.", [["intra-ocular structures", "ANATOMY", 47, 70], ["glaucoma", "ANATOMY", 95, 103], ["glaucoma", "DISEASE", 95, 103], ["intra-ocular structures", "MULTI-TISSUE_STRUCTURE", 47, 70], ["Clinical signsSecondary glaucoma", "PROBLEM", 71, 103], ["the disease", "PROBLEM", 131, 142], ["intra-ocular structures", "ANATOMY", 47, 70], ["glaucoma", "OBSERVATION", 95, 103], ["disease", "OBSERVATION", 135, 142]]], ["The eye will show buphthalmos (enlarged globe) with engorged scleral vessels.Clinical signsIf the posterior segment of the eye can be visualized, white to pink masses may be seen in the vitreous.Clinical signsThe condition is thought to occur after lens trauma, which triggers the lens epithelial cells to undergo metaplasia.Clinical signsThe neoplasia rapidly extends through the choroid and infiltrates the optic nerve.", [["eye", "ANATOMY", 4, 7], ["buphthalmos", "ANATOMY", 18, 29], ["globe", "ANATOMY", 40, 45], ["scleral vessels", "ANATOMY", 61, 76], ["posterior segment", "ANATOMY", 98, 115], ["eye", "ANATOMY", 123, 126], ["pink masses", "ANATOMY", 155, 166], ["vitreous", "ANATOMY", 186, 194], ["lens", "ANATOMY", 249, 253], ["lens epithelial cells", "ANATOMY", 281, 302], ["metaplasia", "ANATOMY", 314, 324], ["neoplasia", "ANATOMY", 343, 352], ["choroid", "ANATOMY", 381, 388], ["optic nerve", "ANATOMY", 409, 420], ["buphthalmos", "DISEASE", 18, 29], ["trauma", "DISEASE", 254, 260], ["neoplasia", "DISEASE", 343, 352], ["eye", "ORGAN", 4, 7], ["globe", "ORGAN", 40, 45], ["scleral vessels", "MULTI-TISSUE_STRUCTURE", 61, 76], ["posterior segment", "MULTI-TISSUE_STRUCTURE", 98, 115], ["eye", "ORGAN", 123, 126], ["masses", "CANCER", 160, 166], ["vitreous", "ORGANISM_SUBSTANCE", 186, 194], ["lens epithelial cells", "CELL", 281, 302], ["metaplasia", "CANCER", 314, 324], ["neoplasia", "CANCER", 343, 352], ["choroid", "MULTI-TISSUE_STRUCTURE", 381, 388], ["optic nerve", "MULTI-TISSUE_STRUCTURE", 409, 420], ["lens epithelial cells", "CELL_TYPE", 281, 302], ["buphthalmos (enlarged globe", "PROBLEM", 18, 45], ["engorged scleral vessels", "PROBLEM", 52, 76], ["Clinical signs", "TEST", 77, 91], ["white to pink masses", "PROBLEM", 146, 166], ["Clinical signs", "TEST", 195, 209], ["lens trauma", "PROBLEM", 249, 260], ["the lens epithelial cells", "PROBLEM", 277, 302], ["metaplasia", "PROBLEM", 314, 324], ["Clinical signs", "TEST", 325, 339], ["The neoplasia", "PROBLEM", 339, 352], ["infiltrates the optic nerve", "PROBLEM", 393, 420], ["eye", "ANATOMY", 4, 7], ["buphthalmos", "OBSERVATION", 18, 29], ["enlarged", "OBSERVATION_MODIFIER", 31, 39], ["globe", "ANATOMY", 40, 45], ["engorged", "OBSERVATION", 52, 60], ["scleral vessels", "ANATOMY", 61, 76], ["posterior", "ANATOMY_MODIFIER", 98, 107], ["segment", "ANATOMY_MODIFIER", 108, 115], ["eye", "ANATOMY", 123, 126], ["pink", "OBSERVATION_MODIFIER", 155, 159], ["masses", "OBSERVATION", 160, 166], ["may be seen", "UNCERTAINTY", 167, 178], ["vitreous", "OBSERVATION", 186, 194], ["lens epithelial cells", "OBSERVATION", 281, 302], ["metaplasia", "OBSERVATION", 314, 324], ["neoplasia", "OBSERVATION", 343, 352], ["choroid", "ANATOMY", 381, 388], ["infiltrates", "OBSERVATION", 393, 404], ["optic nerve", "ANATOMY", 409, 420]]], ["Metastasis has been reported.Clinical signsSurvival rate is very low.DiagnosisA tentative diagnosis is based on the signalment, history and signs of an old cat with a prior history of trauma and signs of glaucoma, uveitis and keratitis.DiagnosisA definitive diagnosis is based on histological examination of tissue.Diagnosis\u2022 Fine-needle biopsy can be attempted, but may not yield a diagnostic sample if the tumor contains fibrous and cartilagenous tissue. \u2022 Histopathology of enucleated globes shows changes that may include granulation tissue, fibrosarcoma, osteosarcoma and anaplastic spindle cell sarcoma.DiagnosisAll blind globes with chronic uveitis should be watched for the development of this condition.TreatmentEarly enucleation with histopathology should be done on all globes with a prior history of trauma whenever there are changes in the size and shape of the globe, or changes in the anterior chamber and cornea indicative of intra-ocular disease.TreatmentSeverely traumatized blind eyes in cats should be enucleated to prevent the occurrence of this condition, particularly if there has been lens rupture.TreatmentCheck for metastases to regional lymph nodes and other organs such as lungs and liver prior to surgery.", [["glaucoma", "ANATOMY", 204, 212], ["tissue", "ANATOMY", 308, 314], ["tumor", "ANATOMY", 408, 413], ["fibrous", "ANATOMY", 423, 430], ["cartilagenous tissue", "ANATOMY", 435, 455], ["globes", "ANATOMY", 488, 494], ["granulation tissue", "ANATOMY", 526, 544], ["fibrosarcoma", "ANATOMY", 546, 558], ["osteosarcoma", "ANATOMY", 560, 572], ["anaplastic spindle cell sarcoma", "ANATOMY", 577, 608], ["globe", "ANATOMY", 875, 880], ["anterior chamber", "ANATOMY", 900, 916], ["cornea", "ANATOMY", 921, 927], ["intra-ocular", "ANATOMY", 942, 954], ["eyes", "ANATOMY", 999, 1003], ["lens", "ANATOMY", 1109, 1113], ["metastases", "ANATOMY", 1141, 1151], ["lymph nodes", "ANATOMY", 1164, 1175], ["organs", "ANATOMY", 1186, 1192], ["lungs", "ANATOMY", 1201, 1206], ["liver", "ANATOMY", 1211, 1216], ["Metastasis", "DISEASE", 0, 10], ["trauma", "DISEASE", 184, 190], ["glaucoma", "DISEASE", 204, 212], ["uveitis", "DISEASE", 214, 221], ["keratitis", "DISEASE", 226, 235], ["tumor", "DISEASE", 408, 413], ["fibrosarcoma", "DISEASE", 546, 558], ["osteosarcoma", "DISEASE", 560, 572], ["anaplastic spindle cell sarcoma", "DISEASE", 577, 608], ["uveitis", "DISEASE", 648, 655], ["trauma", "DISEASE", 812, 818], ["intra-ocular disease", "DISEASE", 942, 962], ["lens rupture", "DISEASE", 1109, 1121], ["metastases", "DISEASE", 1141, 1151], ["cat", "ORGANISM", 156, 159], ["tissue", "TISSUE", 308, 314], ["tumor", "CANCER", 408, 413], ["fibrous", "TISSUE", 423, 430], ["cartilagenous tissue", "TISSUE", 435, 455], ["globes", "ORGAN", 488, 494], ["granulation tissue", "TISSUE", 526, 544], ["fibrosarcoma", "CANCER", 546, 558], ["osteosarcoma", "CANCER", 560, 572], ["anaplastic spindle cell sarcoma", "CANCER", 577, 608], ["globes", "ORGAN", 781, 787], ["globe", "ORGAN", 875, 880], ["anterior chamber", "MULTI-TISSUE_STRUCTURE", 900, 916], ["cornea", "ORGAN", 921, 927], ["eyes", "ORGAN", 999, 1003], ["cats", "ORGANISM", 1007, 1011], ["lens", "TISSUE", 1109, 1113], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 1164, 1175], ["organs", "ORGAN", 1186, 1192], ["lungs", "ORGAN", 1201, 1206], ["liver", "ORGAN", 1211, 1216], ["cats", "SPECIES", 1007, 1011], ["Metastasis", "PROBLEM", 0, 10], ["Clinical signsSurvival rate", "TEST", 29, 56], ["very low", "PROBLEM", 60, 68], ["an old cat", "PROBLEM", 149, 159], ["trauma", "PROBLEM", 184, 190], ["glaucoma", "PROBLEM", 204, 212], ["uveitis", "PROBLEM", 214, 221], ["keratitis", "PROBLEM", 226, 235], ["histological examination", "TEST", 280, 304], ["Fine-needle biopsy", "TEST", 326, 344], ["the tumor", "PROBLEM", 404, 413], ["fibrous and cartilagenous tissue", "PROBLEM", 423, 455], ["enucleated globes", "PROBLEM", 477, 494], ["granulation tissue", "PROBLEM", 526, 544], ["fibrosarcoma", "PROBLEM", 546, 558], ["osteosarcoma", "PROBLEM", 560, 572], ["anaplastic spindle cell sarcoma", "PROBLEM", 577, 608], ["All blind globes", "PROBLEM", 618, 634], ["chronic uveitis", "PROBLEM", 640, 655], ["this condition", "PROBLEM", 697, 711], ["TreatmentEarly enucleation", "TREATMENT", 712, 738], ["histopathology", "TEST", 744, 758], ["trauma", "PROBLEM", 812, 818], ["changes in the size and shape of the globe", "PROBLEM", 838, 880], ["changes in the anterior chamber and cornea", "PROBLEM", 885, 927], ["intra-ocular disease", "PROBLEM", 942, 962], ["Severely traumatized blind eyes in cats", "PROBLEM", 972, 1011], ["this condition", "PROBLEM", 1062, 1076], ["lens rupture", "PROBLEM", 1109, 1121], ["metastases to regional lymph nodes", "PROBLEM", 1141, 1175], ["other organs such as lungs and liver", "PROBLEM", 1180, 1216], ["surgery", "TREATMENT", 1226, 1233], ["very", "OBSERVATION_MODIFIER", 60, 64], ["low", "OBSERVATION_MODIFIER", 65, 68], ["trauma", "OBSERVATION", 184, 190], ["glaucoma", "OBSERVATION", 204, 212], ["uveitis", "OBSERVATION", 214, 221], ["keratitis", "OBSERVATION", 226, 235], ["tumor", "OBSERVATION", 408, 413], ["fibrous", "OBSERVATION", 423, 430], ["cartilagenous tissue", "OBSERVATION", 435, 455], ["enucleated globes", "OBSERVATION", 477, 494], ["may include", "UNCERTAINTY", 514, 525], ["granulation tissue", "OBSERVATION", 526, 544], ["fibrosarcoma", "OBSERVATION", 546, 558], ["osteosarcoma", "OBSERVATION", 560, 572], ["anaplastic", "OBSERVATION_MODIFIER", 577, 587], ["spindle cell sarcoma", "OBSERVATION", 588, 608], ["globes", "ANATOMY", 628, 634], ["chronic", "OBSERVATION_MODIFIER", 640, 647], ["uveitis", "OBSERVATION", 648, 655], ["enucleation", "OBSERVATION", 727, 738], ["trauma", "OBSERVATION", 812, 818], ["size", "OBSERVATION_MODIFIER", 853, 857], ["shape", "OBSERVATION_MODIFIER", 862, 867], ["globe", "ANATOMY", 875, 880], ["anterior", "ANATOMY_MODIFIER", 900, 908], ["chamber", "ANATOMY_MODIFIER", 909, 916], ["cornea", "ANATOMY", 921, 927], ["indicative of", "UNCERTAINTY", 928, 941], ["intra-ocular disease", "OBSERVATION", 942, 962], ["Severely", "OBSERVATION_MODIFIER", 972, 980], ["traumatized", "OBSERVATION", 981, 992], ["lens", "ANATOMY", 1109, 1113], ["rupture", "OBSERVATION", 1114, 1121], ["metastases", "OBSERVATION", 1141, 1151], ["regional", "ANATOMY_MODIFIER", 1155, 1163], ["lymph nodes", "OBSERVATION", 1164, 1175], ["lungs", "ANATOMY", 1201, 1206], ["liver", "ANATOMY", 1211, 1216], ["surgery", "OBSERVATION", 1226, 1233]]]], "1a3090ed02d858bd208be9cfdb17d7a497fc35ee": [["IntroductionInfectious bronchitis virus (IBV) is one of the primary causes of respiratory disease in domestic fowl.", [["respiratory", "ANATOMY", 78, 89], ["IntroductionInfectious bronchitis virus", "DISEASE", 0, 39], ["respiratory disease", "DISEASE", 78, 97], ["IntroductionInfectious bronchitis virus", "ORGANISM", 0, 39], ["IBV", "ORGANISM", 41, 44], ["IntroductionInfectious bronchitis virus", "SPECIES", 0, 39], ["IntroductionInfectious bronchitis virus", "SPECIES", 0, 39], ["IBV", "SPECIES", 41, 44], ["fowl", "SPECIES", 110, 114], ["IntroductionInfectious bronchitis virus", "PROBLEM", 0, 39], ["respiratory disease", "PROBLEM", 78, 97], ["bronchitis", "OBSERVATION", 23, 33], ["respiratory disease", "OBSERVATION", 78, 97], ["domestic fowl", "OBSERVATION", 101, 114]]], ["IBVs primarily and initially infect the trachea though they can also infect the kidney and oviduct and other epithelial surfaces.", [["trachea", "ANATOMY", 40, 47], ["kidney", "ANATOMY", 80, 86], ["oviduct", "ANATOMY", 91, 98], ["epithelial surfaces", "ANATOMY", 109, 128], ["IBVs", "GENE_OR_GENE_PRODUCT", 0, 4], ["trachea", "ORGAN", 40, 47], ["kidney", "ORGAN", 80, 86], ["oviduct", "ORGAN", 91, 98], ["epithelial surfaces", "TISSUE", 109, 128], ["IBVs", "TREATMENT", 0, 4], ["infect", "OBSERVATION", 29, 35], ["trachea", "ANATOMY", 40, 47], ["kidney", "ANATOMY", 80, 86], ["oviduct", "ANATOMY_MODIFIER", 91, 98], ["epithelial", "ANATOMY_MODIFIER", 109, 119], ["surfaces", "OBSERVATION_MODIFIER", 120, 128]]], ["Infection with IBV reduces the performance of broilers and in laying birds drops in egg production and egg quality can occur.", [["egg", "ANATOMY", 84, 87], ["egg", "ANATOMY", 103, 106], ["IBV", "ORGANISM", 15, 18], ["broilers", "ORGANISM", 46, 54], ["birds", "ORGANISM", 69, 74], ["egg", "ORGANISM_SUBDIVISION", 84, 87], ["egg", "ORGANISM_SUBDIVISION", 103, 106], ["broilers", "SPECIES", 46, 54], ["IBV", "SPECIES", 15, 18], ["broilers", "SPECIES", 46, 54], ["Infection", "PROBLEM", 0, 9], ["IBV", "PROBLEM", 15, 18], ["broilers", "TREATMENT", 46, 54], ["laying birds drops", "TREATMENT", 62, 80], ["IBV", "OBSERVATION", 15, 18]]], ["Live-attenuated vaccines against infectious bronchitis are generally given to chicks at 1 day of age in the hatch-ery by spray, or later in the field by either drinking water or spray.", [["infectious bronchitis", "DISEASE", 33, 54], ["chicks", "SPECIES", 78, 84], ["Live-attenuated vaccines", "TREATMENT", 0, 24], ["infectious bronchitis", "PROBLEM", 33, 54]]], ["However, as with any live-attenuated vaccine administered via the respiratory tract, which must replicate in order to be effective, vaccination at an early age can damage the epithelial lining of the trachea and depending on the extent of this damage, secondary bacterial infections can occur.", [["respiratory tract", "ANATOMY", 66, 83], ["epithelial lining", "ANATOMY", 175, 192], ["trachea", "ANATOMY", 200, 207], ["bacterial infections", "DISEASE", 262, 282], ["respiratory tract", "ORGANISM_SUBDIVISION", 66, 83], ["epithelial lining", "TISSUE", 175, 192], ["trachea", "ORGAN", 200, 207], ["any live-attenuated vaccine", "TREATMENT", 17, 44], ["the respiratory tract", "PROBLEM", 62, 83], ["vaccination", "TREATMENT", 132, 143], ["this damage", "PROBLEM", 239, 250], ["secondary bacterial infections", "PROBLEM", 252, 282], ["respiratory tract", "ANATOMY", 66, 83], ["epithelial", "ANATOMY_MODIFIER", 175, 185], ["lining", "ANATOMY_MODIFIER", 186, 192], ["trachea", "ANATOMY", 200, 207], ["bacterial", "OBSERVATION_MODIFIER", 262, 271], ["infections", "OBSERVATION", 272, 282]]], ["For this reason it is important to assess post vaccinal reactions when preparing vaccine strains.IntroductionVaccination in ovo against Marek's disease and infectious bursal disease is commonplace in the USA [1] .", [["bursal", "ANATOMY", 167, 173], ["Marek's disease", "DISEASE", 136, 151], ["infectious bursal disease", "DISEASE", 156, 181], ["Marek", "ORGANISM", 136, 141], ["bursal", "ORGAN", 167, 173], ["Marek", "SPECIES", 136, 141], ["post vaccinal reactions", "PROBLEM", 42, 65], ["preparing vaccine strains", "TREATMENT", 71, 96], ["IntroductionVaccination", "TREATMENT", 97, 120], ["Marek's disease", "PROBLEM", 136, 151], ["infectious bursal disease", "PROBLEM", 156, 181], ["infectious", "OBSERVATION_MODIFIER", 156, 166]]], ["In ovo delivery gives the advantage that all vaccinations can be done prior to hatching as long as the vaccines are shown to be compatible and safe.", [["ovo delivery", "TREATMENT", 3, 15], ["all vaccinations", "TREATMENT", 41, 57], ["the vaccines", "TREATMENT", 99, 111]]], ["Whilst considerable work has been done on in ovo delivery of Marek and infectious bursal disease vaccines, little work has been done on delivering IBV vaccines in ovo.", [["bursal", "ANATOMY", 82, 88], ["bursal disease", "DISEASE", 82, 96], ["Marek", "ORGANISM", 61, 66], ["bursal", "ORGAN", 82, 88], ["IBV", "ORGANISM", 147, 150], ["Marek", "SPECIES", 61, 66], ["IBV", "SPECIES", 147, 150], ["ovo", "SPECIES", 163, 166], ["Marek", "TREATMENT", 61, 66], ["infectious bursal disease vaccines", "TREATMENT", 71, 105], ["IBV vaccines", "TREATMENT", 147, 159], ["infectious", "OBSERVATION_MODIFIER", 71, 81]]], ["This is due to the fact that most strains of IBV are embryo lethal, both in the 9-12-day-old embryos that are used for producing IB vaccines, and in 18-day-old embryos.", [["embryo", "ANATOMY", 53, 59], ["embryos", "ANATOMY", 93, 100], ["embryos", "ANATOMY", 160, 167], ["IBV", "ORGANISM", 45, 48], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 53, 59], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 93, 100], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 160, 167], ["IBV", "SPECIES", 45, 48], ["IBV", "PROBLEM", 45, 48], ["embryo lethal", "PROBLEM", 53, 66], ["IB vaccines", "TREATMENT", 129, 140]]], ["One group has shown that in ovo vaccination with IBV can be successfully accomplished, although the strain used had residual pathogenicity even at low titres [2] .", [["IBV", "ORGANISM", 49, 52], ["IBV", "SPECIES", 49, 52], ["ovo vaccination", "TREATMENT", 28, 43], ["IBV", "TREATMENT", 49, 52], ["the strain", "PROBLEM", 96, 106], ["residual pathogenicity", "PROBLEM", 116, 138]]], ["As uniform mass application of IBV vaccines post hatch can be problematic with regard to obtaining even distribution of spray or ensuring all birds receive the correct dosage from drinking water, delivering IBV in ovo, via which a precise dosage can be achieved, could bring significant advantages to the poultry industry.IntroductionThe Beaudette strain is a highly egg-adapted virus of the Massachusetts serotype that does not cause damage to the ciliated epithelium of the trachea in vivo [3, 4] .", [["ciliated epithelium", "ANATOMY", 449, 468], ["trachea", "ANATOMY", 476, 483], ["IBV", "ORGANISM", 31, 34], ["birds", "ORGANISM", 142, 147], ["IBV", "ORGANISM", 207, 210], ["ciliated epithelium", "TISSUE", 449, 468], ["trachea", "ORGAN", 476, 483], ["IBV", "SPECIES", 31, 34], ["IBV", "SPECIES", 207, 210], ["IBV vaccines", "TREATMENT", 31, 43], ["spray", "TREATMENT", 120, 125], ["IBV", "TREATMENT", 207, 210], ["The Beaudette strain", "PROBLEM", 334, 354], ["a highly egg", "PROBLEM", 358, 370], ["uniform", "OBSERVATION_MODIFIER", 3, 10], ["mass", "OBSERVATION", 11, 15], ["ciliated", "ANATOMY_MODIFIER", 449, 457], ["epithelium", "ANATOMY_MODIFIER", 458, 468], ["trachea", "ANATOMY", 476, 483]]], ["Previous work has demonstrated that using a reverse genetics approach, the efficacy of the Beaudette strain can be improved by substituting the Beaudette spike protein with the spike protein from the virulent M41 strain, also of the Massachusetts serotype [4] .", [["M41 strain", "ANATOMY", 209, 219], ["M41 strain", "ORGANISM", 209, 219], ["Beaudette spike protein", "PROTEIN", 144, 167], ["spike protein", "PROTEIN", 177, 190], ["a reverse genetics approach", "TREATMENT", 42, 69], ["the Beaudette strain", "PROBLEM", 87, 107], ["the Beaudette spike protein", "PROBLEM", 140, 167], ["the spike protein", "PROBLEM", 173, 190], ["the virulent M41 strain", "PROBLEM", 196, 219]]], ["Interestingly, although this altered the cell tropism of the virus [5] , the pathogenicity was not altered.", [["cell", "ANATOMY", 41, 45], ["cell", "CELL", 41, 45], ["the virus", "PROBLEM", 57, 66], ["the pathogenicity", "PROBLEM", 73, 90], ["cell tropism", "OBSERVATION", 41, 53], ["not", "UNCERTAINTY", 95, 98], ["altered", "OBSERVATION_MODIFIER", 99, 106]]], ["This strain was able to afford significant protection to vaccinated birds against challenge with a virulent M41 strain.", [["birds", "ORGANISM", 68, 73], ["M41 strain", "ORGANISM", 108, 118], ["M41", "SPECIES", 108, 111], ["a virulent M41 strain", "TREATMENT", 97, 118]]], ["The aim of this work was to determine whether Beaudette strain-based IBVs produced by reverse genetics could be used as in ovo vaccines.", [["Beaudette", "CHEMICAL", 46, 55], ["IBVs", "CHEMICAL", 69, 73], ["Beaudette strain", "ORGANISM", 46, 62], ["IBVs", "ORGANISM", 69, 73], ["ovo", "SPECIES", 123, 126], ["ovo vaccines", "TREATMENT", 123, 135]]], ["Therefore the safety and efficacy of these strains were investigated.Embryonated eggsSpecified Pathogen Free (SPF) White Leghorn chicken embryonated eggs (Lohmann, Germany) were used.", [["eggs", "ANATOMY", 149, 153], ["chicken", "ORGANISM", 129, 136], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 149, 153], ["Leghorn", "SPECIES", 121, 128], ["chicken", "SPECIES", 129, 136], ["White Leghorn chicken", "SPECIES", 115, 136], ["these strains", "PROBLEM", 37, 50], ["Embryonated eggsSpecified Pathogen Free (SPF)", "TREATMENT", 69, 114], ["White Leghorn chicken embryonated eggs (Lohmann, Germany)", "TREATMENT", 115, 172], ["Pathogen", "OBSERVATION_MODIFIER", 95, 103], ["Free", "OBSERVATION_MODIFIER", 104, 108]]], ["All chicks were hatched in a contained environment and transferred to negative pressure isolators for the remainder of the experiments.", [["chicks", "ORGANISM", 4, 10], ["chicks", "SPECIES", 4, 10], ["negative pressure isolators", "TREATMENT", 70, 97]]], ["Chick starter crumbs and water were provided ad libitum during the course of the experiments.Candidate vaccine strainsThe Beau-R and BeauR-M41(S) strains were prepared using reverse genetics as described previously [5, 6] .", [["Chick", "ORGANISM", 0, 5], ["Beau-R", "ORGANISM", 122, 128], ["BeauR-M41(S) strains", "ORGANISM", 133, 153], ["Chick", "SPECIES", 0, 5], ["Chick", "SPECIES", 0, 5], ["Chick starter crumbs", "TREATMENT", 0, 20], ["BeauR-M41(S) strains", "TREATMENT", 133, 153]]], ["Both viruses were grown on primary chick kidney cells.", [["kidney cells", "ANATOMY", 41, 53], ["chick", "ORGANISM", 35, 40], ["kidney cells", "CELL", 41, 53], ["primary chick kidney cells", "CELL_TYPE", 27, 53], ["chick", "SPECIES", 35, 40], ["Both viruses", "PROBLEM", 0, 12], ["primary chick kidney cells", "PROBLEM", 27, 53], ["viruses", "OBSERVATION", 5, 12], ["grown", "OBSERVATION_MODIFIER", 18, 23], ["primary chick kidney cells", "OBSERVATION", 27, 53]]], ["The BeauR-M41(S) was passaged ten times on 9-12-day-old embryonated eggs to give BeauR-M41(S) EP10.", [["eggs", "ANATOMY", 68, 72], ["BeauR-M41(S)", "GENE_OR_GENE_PRODUCT", 4, 16], ["embryonated", "ORGANISM", 56, 67], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 68, 72], ["BeauR", "PROTEIN", 4, 9], ["BeauR", "PROTEIN", 81, 86], ["M41(S) EP10", "PROTEIN", 87, 98], ["embryonated eggs", "TREATMENT", 56, 72]]], ["Two commercial vaccines, Nobilis Ma5, (Intervet, referred to as CV1 in the text) and IB MM (Fort Dodge, referred to as CV2 in the text), both of the Massachusetts serotype were used.", [["Nobilis Ma5", "ORGANISM", 25, 36], ["Two commercial vaccines", "TREATMENT", 0, 23], ["the Massachusetts serotype", "TREATMENT", 145, 171]]], ["An M41 strain adapted to chick kidney cells (M41-CK) was also used [4] .", [["kidney cells", "ANATOMY", 31, 43], ["M41-CK", "ANATOMY", 45, 51], ["chick", "ORGANISM", 25, 30], ["kidney cells", "CELL", 31, 43], ["M41-CK", "CELL", 45, 51], ["chick kidney cells", "CELL_TYPE", 25, 43], ["CK", "PROTEIN", 49, 51], ["chick", "SPECIES", 25, 30], ["An M41 strain", "TREATMENT", 0, 13], ["chick kidney cells", "TEST", 25, 43], ["M41", "TEST", 45, 48], ["CK", "TEST", 49, 51], ["kidney", "ANATOMY", 31, 37]]], ["The titres of the viruses were established in 9-12day-old embryonated eggs, calculated using the method of Reed and Muench [7] and expressed as 50% egg infectious doses (EID 50 ).", [["eggs", "ANATOMY", 70, 74], ["embryonated", "ORGANISM", 58, 69], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 70, 74], ["the viruses", "PROBLEM", 14, 25], ["old embryonated eggs", "PROBLEM", 54, 74]]], ["Viruses were diluted in Marek's disease vaccine diluent (Nobilis Marek diluent, Intervet).IBV challenge strainFor the IBV challenge a non-CK adapted Massachusetts serotype M41 strain was given by the oculonasal route (0.1 ml/bird) at a dose of 10 3.0 EID 50 per bird.VaccinationsFor embryo vaccination, eggs on the 18th day of embryo development were inoculated into the amniotic fluid using a 20 gauge, 2.5 cm long needle.", [["embryo", "ANATOMY", 283, 289], ["eggs", "ANATOMY", 303, 307], ["embryo", "ANATOMY", 327, 333], ["amniotic fluid", "ANATOMY", 371, 385], ["Marek's disease", "DISEASE", 24, 39], ["IBV", "ORGANISM", 90, 93], ["IBV", "ORGANISM", 118, 121], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 283, 289], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 303, 307], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 327, 333], ["amniotic fluid", "ORGANISM_SUBSTANCE", 371, 385], ["Marek", "SPECIES", 65, 70], ["Marek's disease vaccine diluent", "SPECIES", 24, 55], ["IBV", "SPECIES", 90, 93], ["IBV", "SPECIES", 118, 121], ["Viruses", "PROBLEM", 0, 7], ["Marek's disease vaccine", "TREATMENT", 24, 47], ["IBV challenge strain", "TREATMENT", 90, 110], ["the IBV challenge", "TREATMENT", 114, 131], ["Massachusetts serotype M41 strain", "TREATMENT", 149, 182], ["Vaccinations", "TREATMENT", 267, 279], ["embryo vaccination", "TREATMENT", 283, 301], ["eggs", "TREATMENT", 303, 307], ["embryo development", "TREATMENT", 327, 345], ["a 20 gauge, 2.5 cm long needle", "TREATMENT", 392, 422], ["amniotic fluid", "OBSERVATION", 371, 385]]], ["Virus dilution (0.1 ml) was inoculated.", [["Virus", "ORGANISM", 0, 5], ["Virus dilution", "TREATMENT", 0, 14]]], ["Placebos received 0.1 ml of the diluent.", [["Placebos", "CHEMICAL", 0, 8], ["Placebos", "TREATMENT", 0, 8], ["the diluent", "TREATMENT", 28, 39]]], ["Eggs were hatched in separate incubators.", [["Eggs", "ANATOMY", 0, 4], ["Eggs", "ORGANISM_SUBSTANCE", 0, 4], ["Eggs", "TREATMENT", 0, 4]]], ["Hatch was assessed after 21.5 days of incubation.VaccinationsFor day-old vaccination each bird received 0.1 ml of the vaccine dilution via the oculonasal route.Assessment of clinical signs post hatchExamination of general health was done daily during the course of the experiments.", [["incubation", "TREATMENT", 38, 48], ["Vaccinations", "TREATMENT", 49, 61], ["the vaccine dilution", "TREATMENT", 114, 134], ["the oculonasal route", "TREATMENT", 139, 159], ["clinical signs", "TEST", 174, 188]]], ["Nasal discharge was assessed by gently squeezing the nares of the chicks and determining if any fluid was visible.Assessment of ciliostasisAssessment of ciliostasis was done as previously described [8] .", [["Nasal", "ANATOMY", 0, 5], ["nares", "ANATOMY", 53, 58], ["fluid", "ANATOMY", 96, 101], ["Nasal", "ORGAN", 0, 5], ["nares", "ORGANISM_SUBDIVISION", 53, 58], ["chicks", "ORGANISM", 66, 72], ["any fluid", "PROBLEM", 92, 101], ["Assessment of ciliostasisAssessment", "TEST", 114, 149], ["ciliostasis", "TEST", 153, 164], ["nares", "ANATOMY", 53, 58], ["fluid", "OBSERVATION", 96, 101]]], ["Chicks were killed by an intravenous injection of barbiturates and their tracheas removed aseptically.", [["intravenous", "ANATOMY", 25, 36], ["tracheas", "ANATOMY", 73, 81], ["barbiturates", "CHEMICAL", 50, 62], ["Chicks", "ORGANISM", 0, 6], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 36], ["tracheas", "ORGAN", 73, 81], ["Chicks", "SPECIES", 0, 6], ["Chicks", "SPECIES", 0, 6], ["an intravenous injection of barbiturates", "TREATMENT", 22, 62], ["their tracheas", "TREATMENT", 67, 81], ["tracheas", "ANATOMY", 73, 81]]], ["Ten, 1 mm explants of each trachea were observed microscopically and the ciliary activity of each ring was scored according to the percentage of the cilia beating on the luminal surface.", [["explants", "ANATOMY", 10, 18], ["trachea", "ANATOMY", 27, 34], ["ciliary", "ANATOMY", 73, 80], ["ring", "ANATOMY", 98, 102], ["cilia", "ANATOMY", 149, 154], ["luminal surface", "ANATOMY", 170, 185], ["luminal", "CHEMICAL", 170, 177], ["trachea", "ORGAN", 27, 34], ["ciliary", "MULTI-TISSUE_STRUCTURE", 73, 80], ["luminal surface", "CELLULAR_COMPONENT", 170, 185], ["1 mm explants of each trachea", "PROBLEM", 5, 34], ["1 mm", "OBSERVATION_MODIFIER", 5, 9], ["trachea", "ANATOMY", 27, 34], ["ciliary activity", "OBSERVATION", 73, 89], ["ring", "OBSERVATION_MODIFIER", 98, 102], ["cilia", "ANATOMY_MODIFIER", 149, 154], ["luminal", "ANATOMY_MODIFIER", 170, 177], ["surface", "ANATOMY_MODIFIER", 178, 185]]], ["Post challenge ciliostasis assessments were done on days 5 and 7, these days coinciding with the peak replication of IBV in the trachea.SerologySerological responses to IBV were studied using an ELISA.", [["trachea", "ANATOMY", 128, 135], ["IBV", "ORGANISM", 117, 120], ["trachea", "ORGAN", 128, 135], ["IBV", "ORGANISM", 169, 172], ["IBV", "SPECIES", 117, 120], ["IBV", "SPECIES", 169, 172], ["Post challenge ciliostasis assessments", "TEST", 0, 38], ["IBV in the trachea", "TREATMENT", 117, 135], ["IBV", "TREATMENT", 169, 172], ["an ELISA", "TEST", 192, 200], ["peak replication", "OBSERVATION", 97, 113], ["IBV", "OBSERVATION", 117, 120], ["trachea", "ANATOMY", 128, 135]]], ["Briefly ELISA plates were coated with M41 antigen and incubated with serial dilutions of test chicken serum for 1 h.", [["serum", "ANATOMY", 102, 107], ["M41 antigen", "GENE_OR_GENE_PRODUCT", 38, 49], ["chicken", "ORGANISM", 94, 101], ["serum", "ORGANISM_SUBSTANCE", 102, 107], ["M41 antigen", "PROTEIN", 38, 49], ["chicken", "SPECIES", 94, 101], ["chicken", "SPECIES", 94, 101], ["Briefly ELISA plates", "TEST", 0, 20], ["M41 antigen", "TREATMENT", 38, 49], ["serial dilutions", "TEST", 69, 85], ["test chicken serum", "TEST", 89, 107]]], ["After washing a rabbit anti chicken antiserum conjugated to alkaline phosphatase was added for 30 min.", [["rabbit", "ORGANISM", 16, 22], ["chicken", "ORGANISM", 28, 35], ["antiserum", "ORGANISM_SUBSTANCE", 36, 45], ["conjugated to alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 46, 80], ["alkaline phosphatase", "PROTEIN", 60, 80], ["rabbit", "SPECIES", 16, 22], ["chicken", "SPECIES", 28, 35], ["rabbit", "SPECIES", 16, 22], ["chicken", "SPECIES", 28, 35], ["a rabbit anti chicken antiserum", "TREATMENT", 14, 45], ["alkaline phosphatase", "TEST", 60, 80]]], ["After washing a p-nitrophenyl phosphate substrate was added for 30 min.", [["p-nitrophenyl phosphate", "CHEMICAL", 16, 39], ["p-nitrophenyl phosphate", "CHEMICAL", 16, 39], ["p-nitrophenyl phosphate substrate", "SIMPLE_CHEMICAL", 16, 49], ["a p-nitrophenyl phosphate substrate", "TREATMENT", 14, 49]]], ["Titres were calculated in comparison to known negative and positive controls and a positive response was considered to be \u22655.64 log 2 .Statistical analysesA two-tailed T-test was used to compare ciliary activity and serological responses. p-values of less than 0.05 were considered to be significant.", [["ciliary", "ANATOMY", 195, 202], ["ciliary", "MULTI-TISSUE_STRUCTURE", 195, 202], ["Titres", "TEST", 0, 6], ["Statistical analysesA", "TEST", 135, 156], ["ciliary activity", "TEST", 195, 211], ["p-values", "TEST", 239, 247], ["significant", "OBSERVATION_MODIFIER", 288, 299]]], ["Thirty-three SPF eggs were inoculated with high doses of the Beau-R (10 6.0 EID 50 ) or BeauR-M41(S) (10 6.0 EID 50 ) vaccines or three graded doses of the commercial vaccine (CV1; 10 4.0 , 10 2.0 or 10 1.0 EID 50 ).", [["eggs", "ANATOMY", 17, 21], ["BeauR-M41", "CHEMICAL", 88, 97], ["SPF", "ORGANISM", 13, 16], ["eggs", "ORGANISM", 17, 21], ["BeauR-M41", "SIMPLE_CHEMICAL", 88, 97], ["BeauR", "TEST", 88, 93], ["vaccines", "TREATMENT", 118, 126], ["the commercial vaccine", "TREATMENT", 152, 174], ["CV1", "TEST", 176, 179]]], ["A placebo vaccinated group was included.", [["A placebo vaccinated group", "TREATMENT", 0, 26]]], ["The chicks were allowed to hatch in separate hatchers, live chicks counted at 21.5 days of incubation and groups of at least 10 chicks formed when the hatch rate allowed.", [["chicks", "ORGANISM", 4, 10], ["chicks", "SPECIES", 4, 10], ["the hatch rate", "TEST", 147, 161]]], ["At 6 days post hatch the birds in each group were examined for nasal discharge and up to five chicks from each group were euthanized, their tracheas removed and assessed for ciliary activity.", [["nasal", "ANATOMY", 63, 68], ["tracheas", "ANATOMY", 140, 148], ["ciliary", "ANATOMY", 174, 181], ["birds", "ORGANISM", 25, 30], ["nasal", "ORGANISM_SUBDIVISION", 63, 68], ["chicks", "ORGANISM", 94, 100], ["tracheas", "ORGAN", 140, 148], ["ciliary", "MULTI-TISSUE_STRUCTURE", 174, 181], ["chicks", "SPECIES", 94, 100], ["nasal discharge", "PROBLEM", 63, 78], ["tracheas", "ANATOMY", 140, 148]]], ["The remaining chicks were bled and serum collected at 4 weeks then challenged with virulent M41 IBV.", [["serum", "ANATOMY", 35, 40], ["chicks", "ORGANISM", 14, 20], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["M41 IBV", "ORGANISM", 92, 99], ["chicks", "SPECIES", 14, 20], ["M41 IBV", "SPECIES", 92, 99], ["serum", "TEST", 35, 40], ["virulent M41 IBV", "TREATMENT", 83, 99], ["chicks", "OBSERVATION_MODIFIER", 14, 20]]], ["At 5 and 7 days post challenge the remaining birds in each group were euthanized, their tracheas removed and assessed for ciliary activity.Experiment 2One hundred SPF eggs were inoculated with a dose of 10 4.0 EID 50 of the Beau-R, BeauR-M41(S) or BeauR-M41(S) EP10 vaccine candidates or with placebo.", [["tracheas", "ANATOMY", 88, 96], ["ciliary", "ANATOMY", 122, 129], ["eggs", "ANATOMY", 167, 171], ["birds", "ORGANISM", 45, 50], ["tracheas", "ORGAN", 88, 96], ["ciliary", "MULTI-TISSUE_STRUCTURE", 122, 129], ["Beau-R", "SIMPLE_CHEMICAL", 224, 230], ["BeauR-M41", "SIMPLE_CHEMICAL", 232, 241], ["BeauR-M41(S) EP10", "SIMPLE_CHEMICAL", 248, 265], ["SPF eggs", "TREATMENT", 163, 171], ["BeauR", "TEST", 232, 237], ["BeauR", "TEST", 248, 253], ["EP10 vaccine", "TREATMENT", 261, 273], ["placebo", "TREATMENT", 293, 300], ["tracheas", "ANATOMY", 88, 96], ["ciliary activity", "OBSERVATION", 122, 138]]], ["The chicks were allowed to hatch in separate hatchers and live chicks counted at 21.5 days of incubation.", [["chicks", "ORGANISM", 4, 10], ["chicks", "SPECIES", 4, 10]]], ["At 2, 5 and 8 days post hatch five chicks from each group were euthanized, their tracheas removed and assessed for ciliary activity.", [["tracheas", "ANATOMY", 81, 89], ["ciliary", "ANATOMY", 115, 122], ["chicks", "ORGANISM", 35, 41], ["tracheas", "ORGAN", 81, 89], ["ciliary", "MULTI-TISSUE_STRUCTURE", 115, 122], ["chicks", "SPECIES", 35, 41], ["tracheas", "ANATOMY", 81, 89]]], ["A group of 20 one-day-old birds were vaccinated with the 10 4 EID 50 of the CV1 commercial vaccine via the oculonasal route.", [["birds", "ORGANISM", 26, 31], ["CV1", "ORGANISM", 76, 79], ["CV1", "SPECIES", 76, 79], ["the CV1 commercial vaccine", "TREATMENT", 72, 98], ["the oculonasal route", "TREATMENT", 103, 123]]], ["At 5 and 8 days post vaccination five chicks from this group were euthanized, their tracheas removed and assessed for ciliary activity.", [["tracheas", "ANATOMY", 84, 92], ["ciliary", "ANATOMY", 118, 125], ["chicks", "ORGANISM", 38, 44], ["tracheas", "ORGAN", 84, 92], ["ciliary", "MULTI-TISSUE_STRUCTURE", 118, 125], ["chicks", "SPECIES", 38, 44], ["vaccination", "TREATMENT", 21, 32], ["tracheas", "ANATOMY", 84, 92], ["ciliary activity", "OBSERVATION", 118, 134]]], ["The chicks were bled and serum collected at 4 weeks then challenged with virulent M41 IBV at 6 weeks.", [["serum", "ANATOMY", 25, 30], ["chicks", "ORGANISM", 4, 10], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["M41 IBV", "ORGANISM", 82, 89], ["chicks", "SPECIES", 4, 10], ["IBV", "SPECIES", 86, 89], ["serum", "TEST", 25, 30], ["virulent M41 IBV", "TREATMENT", 73, 89]]], ["At 5 and 7 days post challenge 5 birds from each group were euthanized, their tracheas removed and assessed for ciliary activity.Experiment 3Sixty SPF eggs were inoculated with a dose of 10 4.0 EID 50 of the BeauR-M41(S) or BeauR-M41(S) EP10 vaccine candidates.", [["tracheas", "ANATOMY", 78, 86], ["ciliary", "ANATOMY", 112, 119], ["birds", "ORGANISM", 33, 38], ["tracheas", "ORGAN", 78, 86], ["ciliary", "MULTI-TISSUE_STRUCTURE", 112, 119], ["BeauR-M41(S) EP10", "SIMPLE_CHEMICAL", 224, 241], ["Experiment 3Sixty SPF eggs", "TREATMENT", 129, 155], ["BeauR", "TEST", 224, 229], ["tracheas", "ANATOMY", 78, 86], ["ciliary activity", "OBSERVATION", 112, 128]]], ["The chicks were allowed to hatch in separate hatchers and live chicks counted at 21.5 days of incubation.", [["chicks", "ORGANISM", 4, 10], ["chicks", "SPECIES", 4, 10]]], ["At 4 and 8 days post hatch the chicks were examined for nasal discharge.", [["nasal", "ANATOMY", 56, 61], ["chicks", "ORGANISM", 31, 37], ["nasal", "ORGANISM_SUBDIVISION", 56, 61], ["chicks", "SPECIES", 31, 37], ["nasal discharge", "PROBLEM", 56, 71]]], ["The chicks were bled and serum collected at 4 weeks then challenged with virulent M41 IBV.", [["serum", "ANATOMY", 25, 30], ["chicks", "ORGANISM", 4, 10], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["M41 IBV", "ORGANISM", 82, 89], ["chicks", "SPECIES", 4, 10], ["M41 IBV", "SPECIES", 82, 89], ["serum", "TEST", 25, 30], ["virulent M41 IBV", "TREATMENT", 73, 89]]], ["At 5 and 7 days post challenge 5 birds from each group were euthanized, their tracheas removed and assessed for ciliary activity.Experiment 4Fifty SPF eggs were inoculated with the BeauR-M41(S) (10 4.0 EID 50 ), Beau-R (10 4.0 EID 50 ) or two different doses of the CV2 vaccines (10 4.0 or 10 1.0 EID 50 ) or with a placebo.", [["tracheas", "ANATOMY", 78, 86], ["ciliary", "ANATOMY", 112, 119], ["Beau-R", "CHEMICAL", 212, 218], ["birds", "ORGANISM", 33, 38], ["tracheas", "ORGAN", 78, 86], ["ciliary", "MULTI-TISSUE_STRUCTURE", 112, 119], ["BeauR-M41", "SPECIES", 181, 190], ["Beau", "TEST", 212, 216], ["the CV2 vaccines", "TREATMENT", 262, 278], ["a placebo", "TREATMENT", 314, 323], ["tracheas", "ANATOMY", 78, 86], ["ciliary activity", "OBSERVATION", 112, 128]]], ["The eggs were marked, mixed in a single incubator and the hatch assessed by counting the marked eggs remaining.Experiment 5Fifty SPF eggs were inoculated with the M41-CK virus (10 4.0 EID 50 ) or with a placebo.", [["eggs", "ANATOMY", 4, 8], ["eggs", "ANATOMY", 96, 100], ["M41-CK virus", "ORGANISM", 163, 175], ["M41-CK virus", "SPECIES", 163, 175], ["a single incubator", "TREATMENT", 31, 49], ["SPF eggs", "PROBLEM", 129, 137], ["the M41-CK virus", "TEST", 159, 175], ["a placebo", "TREATMENT", 201, 210], ["marked", "OBSERVATION_MODIFIER", 14, 20], ["mixed", "OBSERVATION_MODIFIER", 22, 27], ["marked", "OBSERVATION_MODIFIER", 89, 95], ["eggs", "OBSERVATION", 96, 100]]], ["The eggs were marked, mixed in a single incubator and the hatch assessed by counting the marked eggs remaining.The effect on hatchability of embryo vaccination with IBVTo determine if the candidate vaccines based on the Beaudette strain were safe for embryo vaccination, five experiments were performed in which embryonated eggs were inoculated at day 18 of incubation.", [["eggs", "ANATOMY", 4, 8], ["eggs", "ANATOMY", 96, 100], ["embryo", "ANATOMY", 141, 147], ["embryo", "ANATOMY", 251, 257], ["eggs", "ANATOMY", 324, 328], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 141, 147], ["Beaudette strain", "ORGANISM", 220, 236], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 251, 257], ["eggs", "ORGANISM", 324, 328], ["a single incubator", "TREATMENT", 31, 49], ["embryo vaccination", "TREATMENT", 141, 159], ["IBVTo", "TREATMENT", 165, 170], ["the candidate vaccines", "TREATMENT", 184, 206], ["the Beaudette strain", "TREATMENT", 216, 236], ["embryo vaccination", "TREATMENT", 251, 269], ["embryonated eggs", "TREATMENT", 312, 328], ["marked", "OBSERVATION_MODIFIER", 14, 20], ["mixed", "OBSERVATION_MODIFIER", 22, 27], ["marked", "OBSERVATION_MODIFIER", 89, 95], ["eggs", "OBSERVATION", 96, 100]]], ["In Experiments 4 and 5 all eggs were hatched from the same machine to avoid the influence of individual hatchers.", [["eggs", "ORGANISM", 27, 31]]], ["In Experiments 2 and 4 commercial vaccines were included to determine their effect on the hatchability.The effect on hatchability of embryo vaccination with IBVIn Experiment 1, 33 SPF eggs were inoculated with high doses of Beau-R or BeauR-M41(S) or graded doses of the commercial vaccine (CV1).", [["embryo", "ANATOMY", 133, 139], ["eggs", "ANATOMY", 184, 188], ["Beau-R", "CHEMICAL", 224, 230], ["BeauR-M41", "CHEMICAL", 234, 243], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 133, 139], ["SPF eggs", "ORGANISM", 180, 188], ["Beau-R", "SIMPLE_CHEMICAL", 224, 230], ["BeauR-M41", "SIMPLE_CHEMICAL", 234, 243], ["CV1", "ORGANISM", 290, 293], ["SPF", "SPECIES", 180, 183], ["CV1", "SPECIES", 290, 293], ["4 commercial vaccines", "TREATMENT", 21, 42], ["embryo vaccination", "TREATMENT", 133, 151], ["IBVIn Experiment", "TREATMENT", 157, 173], ["SPF eggs", "TEST", 180, 188], ["the commercial vaccine", "TREATMENT", 266, 288]]], ["As shown in Fig. 1A , Beau-R (73%) and BeauR-M41(S) (82%) gave slightly lower hatch than the placebo vaccinates (85%).", [["Beau-R", "SIMPLE_CHEMICAL", 22, 28], ["BeauR-M41", "SIMPLE_CHEMICAL", 39, 48], ["Beau", "TEST", 22, 26], ["BeauR", "TEST", 39, 44], ["slightly lower hatch", "PROBLEM", 63, 83], ["the placebo vaccinates", "TEST", 89, 111]]], ["The lowest hatch in the candidate vaccines was in the Beau-R group which had four fewer chicks hatch than the placebo group.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 54, 60], ["chicks", "ORGANISM", 88, 94], ["chicks", "SPECIES", 88, 94]]], ["This reduction in hatch may have been due to the pathogenicity of Beau-R but could also been an effect of hatching the different groups in separate hatchers.", [["Beau-R", "GENE_OR_GENE_PRODUCT", 66, 72], ["This reduction", "TREATMENT", 0, 14]]], ["In contrast to the candidate vaccines, the CV1 commercial vaccine gave a very poor hatch in all three groups even though 100 (18% hatch), 10,000 (27% hatch) or 100,000 (30% hatch) fold lower doses than Beau-R and BeauR-M41(S) were inoculated.The effect on hatchability of embryo vaccination with IBVIn Experiment 2, 100 SPF eggs were inoculated with 100fold less BeauR-M41(S) or Beau-R (10 4.0 EID 50 ) than in Experiment 1.", [["embryo", "ANATOMY", 272, 278], ["CV1", "ORGANISM", 43, 46], ["Beau-R", "SIMPLE_CHEMICAL", 202, 208], ["BeauR-M41", "SIMPLE_CHEMICAL", 213, 222], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 272, 278], ["CV1", "SPECIES", 43, 46], ["the candidate vaccines", "TREATMENT", 15, 37], ["the CV1 commercial vaccine", "TREATMENT", 39, 65], ["a very poor hatch", "PROBLEM", 71, 88], ["Beau", "TEST", 202, 206], ["BeauR", "TEST", 213, 218], ["embryo vaccination", "TREATMENT", 272, 290], ["IBVIn Experiment", "TREATMENT", 296, 312], ["Beau", "TEST", 379, 383]]], ["In addition the BeauR-M41(S) EP10 strain was included to determine if egg passage could improve the immunogenicity of this strain without affecting its pathogenicity.", [["egg", "ANATOMY", 70, 73], ["BeauR-M41(S) EP10", "GENE_OR_GENE_PRODUCT", 16, 33], ["egg", "ORGANISM_SUBSTANCE", 70, 73], ["EP10 strain", "PROBLEM", 29, 40], ["egg passage", "PROBLEM", 70, 81], ["this strain", "PROBLEM", 118, 129]]], ["Inoculation with any of the candidate vaccines caused a lower hatch than the placebo (82% hatch) in this experiment with the BeauR-M41(S) (75% hatch) vaccine candidate giving the best result (Fig. 1B) .", [["BeauR-M41", "CHEMICAL", 125, 134], ["the candidate vaccines", "TREATMENT", 24, 46], ["a lower hatch", "PROBLEM", 54, 67], ["the BeauR", "TEST", 121, 130]]], ["Though slightly lower than the placebo vaccinates the difference in hatch with these vaccine candidates may again have been due to the different hatchers used.The effect on hatchability of embryo vaccination with IBVIn the third experiment 60 SPF eggs were inoculated with 10 4.0 EID 50 of BeauR-M41(S) or BeauR-M41(S) EP10.", [["embryo", "ANATOMY", 189, 195], ["eggs", "ANATOMY", 247, 251], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 189, 195], ["SPF", "SPECIES", 243, 246], ["slightly lower", "PROBLEM", 7, 21], ["the placebo vaccinates", "TREATMENT", 27, 49], ["these vaccine candidates", "TREATMENT", 79, 103], ["embryo vaccination", "TREATMENT", 189, 207], ["IBVIn", "TREATMENT", 213, 218], ["BeauR", "TEST", 290, 295], ["BeauR", "TEST", 306, 311], ["slightly", "OBSERVATION_MODIFIER", 7, 15], ["lower", "OBSERVATION_MODIFIER", 16, 21]]], ["Inoculation with BeauR-M41(S) gave a higher hatch (70% hatch) than the placebo (68%) whilst inoculation with BeauR-M41(S) EP10 caused a slightly lower hatch (63%) than the placebo (Fig. 1C) .The effect on hatchability of embryo vaccination with IBVIn the fourth experiment 50 SPF eggs were inoculated with BeauR-M41(S) or Beau-R (10 4.0 EID 50 ).", [["embryo", "ANATOMY", 221, 227], ["eggs", "ANATOMY", 280, 284], ["BeauR-M41", "CHEMICAL", 17, 26], ["BeauR-M41", "CHEMICAL", 109, 118], ["BeauR-M41", "SIMPLE_CHEMICAL", 17, 26], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 221, 227], ["SPF", "SPECIES", 276, 279], ["BeauR-M41", "SPECIES", 306, 315], ["a higher hatch", "TREATMENT", 35, 49], ["BeauR", "TEST", 109, 114], ["a slightly lower hatch", "PROBLEM", 134, 156], ["the placebo (Fig", "TREATMENT", 168, 184], ["embryo vaccination", "TREATMENT", 221, 239], ["IBVIn", "TREATMENT", 245, 250], ["BeauR", "TEST", 306, 311], ["Beau", "TEST", 322, 326]]], ["A second commercial vaccine (CV2) was included at doses of 10 4.0 EID 50 and 10 1.0 EID 50 .", [["CV2", "ORGANISM", 29, 32], ["CV2", "SPECIES", 29, 32], ["A second commercial vaccine (CV2)", "TREATMENT", 0, 33]]], ["To exclude any variability in hatchers all eggs in this experiment were placed in the same hatching unit.", [["any variability in hatchers all eggs", "PROBLEM", 11, 47]]], ["BeauR-M41(S) gave a higher hatch (Fig. 1D, 72% hatch) than the placebo (66%) in this experiment, whilst Beau-R vaccine gave a slightly lower hatch (60%) than the placebo.", [["BeauR-M41", "CHEMICAL", 0, 9], ["Beau-R vaccine", "ORGANISM", 104, 118], ["a higher hatch (Fig. 1D", "TREATMENT", 18, 41], ["the placebo", "TREATMENT", 59, 70], ["Beau-R vaccine", "TREATMENT", 104, 118], ["a slightly lower hatch", "TREATMENT", 124, 146], ["the placebo", "TREATMENT", 158, 169]]], ["The CV2 vaccine gave very low hatchability at both doses (6% at 10 4 EID 50 and 20% at 10 1 EID 50 ).The effect on hatchability of embryo vaccination with IBVIn the fifth experiment 50 SPF eggs were inoculated with M41-CK virus (10 4 EID 50 ), the donor of the M41 spike gene inserted into BeauR-M41(S) [5] , or with placebo.", [["embryo", "ANATOMY", 131, 137], ["eggs", "ANATOMY", 189, 193], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 131, 137], ["M41-CK virus", "ORGANISM", 215, 227], ["M41 spike gene", "DNA", 261, 275], ["SPF", "SPECIES", 185, 188], ["M41-CK virus", "SPECIES", 215, 227], ["The CV2 vaccine", "TREATMENT", 0, 15], ["very low hatchability", "PROBLEM", 21, 42], ["embryo vaccination", "TREATMENT", 131, 149], ["IBVIn", "TREATMENT", 155, 160], ["SPF eggs", "TEST", 185, 193], ["M41-CK virus", "TREATMENT", 215, 227], ["placebo", "TREATMENT", 317, 324]]], ["To exclude any variability in hatchers all eggs in this experiment were placed in the same hatching unit.", [["any variability in hatchers all eggs", "PROBLEM", 11, 47]]], ["M41-CK gave 58% hatch in comparison to 89% hatch in the control group.Clinical observations post hatchAs the birds were held in isolators during each trial it was difficult to examine some of the clinical parameters associated with IBV (tracheal rales, coughing and sneezing).", [["tracheal", "ANATOMY", 237, 245], ["coughing", "DISEASE", 253, 261], ["sneezing", "DISEASE", 266, 274], ["M41-CK", "GENE_OR_GENE_PRODUCT", 0, 6], ["birds", "ORGANISM", 109, 114], ["IBV", "ORGANISM", 232, 235], ["tracheal", "MULTI-TISSUE_STRUCTURE", 237, 245], ["M41", "PROTEIN", 0, 3], ["CK", "PROTEIN", 4, 6], ["IBV", "SPECIES", 232, 235], ["M41", "TEST", 0, 3], ["CK", "TEST", 4, 6], ["IBV (tracheal rales", "PROBLEM", 232, 251], ["coughing", "PROBLEM", 253, 261], ["sneezing", "PROBLEM", 266, 274], ["tracheal", "ANATOMY", 237, 245], ["rales", "OBSERVATION", 246, 251]]], ["In Experiment 1 in ovo inoculation with Beau-R or BeauR-M41(S) did not cause any morbidity during the post hatch observation period.", [["ovo", "ORGANISM", 19, 22], ["Beau-R", "GENE_OR_GENE_PRODUCT", 40, 46], ["BeauR-M41", "SIMPLE_CHEMICAL", 50, 59], ["Beau", "TEST", 40, 44], ["any morbidity", "PROBLEM", 77, 90]]], ["Nasal discharge was not detected in birds vaccinated in ovo with either Beau-R or BeauR-M41(S) ( Fig. 2A) suggesting that these viruses were not pathogenic.", [["Nasal", "ANATOMY", 0, 5], ["Nasal", "ORGAN", 0, 5], ["birds", "ORGANISM", 36, 41], ["Beau-R", "GENE_OR_GENE_PRODUCT", 72, 78], ["BeauR-M41(S)", "ORGANISM", 82, 94], ["Fig. 2A", "ORGANISM", 97, 104], ["ovo", "SPECIES", 56, 59], ["these viruses", "PROBLEM", 122, 135], ["pathogenic", "PROBLEM", 145, 155], ["viruses", "OBSERVATION", 128, 135]]], ["In contrast, 38% to 88% of the hatched CV1 in ovo vaccinates had nasal discharge when examined, the occurrence of nasal discharge not being dose dependent.", [["nasal", "ANATOMY", 65, 70], ["nasal", "ANATOMY", 114, 119], ["CV1", "ORGANISM", 39, 42], ["ovo", "ORGANISM", 46, 49], ["nasal", "ORGAN", 65, 70], ["nasal", "ORGANISM_SUBDIVISION", 114, 119], ["ovo", "SPECIES", 46, 49], ["nasal discharge", "PROBLEM", 65, 80], ["nasal discharge", "PROBLEM", 114, 129], ["nasal", "ANATOMY", 114, 119]]], ["In the third experiment none of the birds vaccinated with BeauR-M41(S) or BeauR-M41(S) EP10 had nasal discharge when tested at 4 and 8 days post hatch (data not shown).Clinical observations post hatchOverall these results suggest that the Beau-R, BeauR-M41(S) and BeauR-M41(S) EP10 vaccine candidates are safe for embryo vaccination and the presence of the spike gene from virulent M41 did not have an effect on hatchability, nor cause clinical signs post hatch.Assessment of ciliary activity post hatchAnalysis of ciliary activity post vaccination can be used as a measure of the safety of an IBV vaccine.", [["nasal", "ANATOMY", 96, 101], ["embryo", "ANATOMY", 314, 320], ["ciliary", "ANATOMY", 476, 483], ["ciliary", "ANATOMY", 515, 522], ["birds", "ORGANISM", 36, 41], ["BeauR-M41", "ORGANISM", 58, 67], ["nasal", "ORGAN", 96, 101], ["Beau-R", "GENE_OR_GENE_PRODUCT", 239, 245], ["BeauR-M41", "ORGANISM", 247, 256], ["BeauR-M41(S) EP10", "GENE_OR_GENE_PRODUCT", 264, 281], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 314, 320], ["ciliary", "MULTI-TISSUE_STRUCTURE", 476, 483], ["ciliary", "MULTI-TISSUE_STRUCTURE", 515, 522], ["IBV", "ORGANISM", 594, 597], ["spike gene", "DNA", 357, 367], ["IBV", "SPECIES", 594, 597], ["BeauR", "TEST", 58, 63], ["BeauR", "TEST", 74, 79], ["nasal discharge", "PROBLEM", 96, 111], ["hatch (data", "TEST", 145, 156], ["the Beau", "TEST", 235, 243], ["BeauR", "TEST", 247, 252], ["BeauR-M41(S) EP10 vaccine candidates", "TREATMENT", 264, 300], ["embryo vaccination", "TREATMENT", 314, 332], ["clinical signs post hatch", "PROBLEM", 436, 461], ["ciliary activity", "PROBLEM", 476, 492], ["ciliary activity post vaccination", "TREATMENT", 515, 548], ["an IBV vaccine", "TREATMENT", 591, 605], ["ciliary activity", "OBSERVATION", 476, 492]]], ["In Experiment 1, three birds from the CV1-vaccinated groups and five in each of Beau-R and BeauR-M41(S) in ovo-vaccinated groups were euthanized 6 days post hatch and their ciliary activity assessed.", [["ciliary", "ANATOMY", 173, 180], ["birds", "ORGANISM", 23, 28], ["CV1", "ORGANISM", 38, 41], ["Beau-R", "ORGANISM", 80, 86], ["BeauR-M41(S)", "ORGANISM", 91, 103], ["ovo", "ORGANISM", 107, 110], ["ciliary", "MULTI-TISSUE_STRUCTURE", 173, 180], ["ovo-vaccinated groups", "TREATMENT", 107, 128], ["ciliary activity", "OBSERVATION", 173, 189]]], ["The results are shown in Fig. 2B .", [["2B", "GENE_OR_GENE_PRODUCT", 30, 32]]], ["CV1 inoculated in ovo, although only assessed in three birds, gave very high ciliostasis scores independent of the dose given.", [["CV1", "ORGANISM", 0, 3], ["ovo", "ORGANISM", 18, 21], ["CV1", "SPECIES", 0, 3], ["ovo", "SPECIES", 18, 21], ["very high ciliostasis scores", "PROBLEM", 67, 95], ["inoculated", "OBSERVATION", 4, 14]]], ["Ciliostasis scores for BeauR-M41(S) and Beau-R vaccinates were not significantly different from each other though both were significantly higher than the placebo vaccinates (BeauR-M41(S), p = 0.00006, Beau-R, p = 0.00004).", [["BeauR-M41", "GENE_OR_GENE_PRODUCT", 23, 32], ["Beau-R", "GENE_OR_GENE_PRODUCT", 40, 46], ["Ciliostasis scores", "TEST", 0, 18], ["BeauR", "TEST", 23, 28], ["Beau-R vaccinates", "TEST", 40, 57], ["the placebo vaccinates", "TEST", 150, 172], ["BeauR", "TEST", 174, 179], ["p", "TEST", 188, 189], ["Beau", "TEST", 201, 205], ["p", "TEST", 209, 210]]], ["These scores are acceptable on the grounds of safety [9] , again suggesting that neither of these viruses were pathogenic and that the inclusion of the M41 spike gene does not increase pathogenicity.Assessment of ciliary activity post hatchIn Experiment 2, a more extensive analysis of the ciliostasis caused by the candidate vaccines was undertaken (Fig. 2C) .", [["ciliary", "ANATOMY", 213, 220], ["ciliostasis", "DISEASE", 290, 301], ["M41", "GENE_OR_GENE_PRODUCT", 152, 155], ["ciliary", "MULTI-TISSUE_STRUCTURE", 213, 220], ["ciliostasis", "CANCER", 290, 301], ["M41 spike gene", "DNA", 152, 166], ["These scores", "TEST", 0, 12], ["these viruses", "PROBLEM", 92, 105], ["increase pathogenicity", "PROBLEM", 176, 198], ["ciliary activity", "PROBLEM", 213, 229], ["the ciliostasis", "PROBLEM", 286, 301], ["the candidate vaccines", "TREATMENT", 312, 334], ["acceptable", "OBSERVATION_MODIFIER", 17, 27], ["viruses", "OBSERVATION", 98, 105], ["not", "UNCERTAINTY", 172, 175], ["increase", "OBSERVATION_MODIFIER", 176, 184], ["pathogenicity", "OBSERVATION", 185, 198], ["ciliary activity", "OBSERVATION", 213, 229]]], ["In this experiment an egg-passaged vaccine candidate, BeauR-M41(S) EP10 was included.", [["BeauR-M41(S) EP10", "DNA", 54, 71], ["an egg", "TEST", 19, 25]]], ["The BeauR- M41(S) EP10 vaccinate caused the highest levels of ciliostasis of the Beaudette based strains, though there was no significant difference between the ciliostasis caused by any of the Beaudette vaccine candidates at any time point (data not shown).", [["ciliostasis", "DISEASE", 161, 172], ["EP10 vaccinate", "TREATMENT", 18, 32], ["the Beaudette based strains", "PROBLEM", 77, 104], ["the ciliostasis", "PROBLEM", 157, 172], ["the Beaudette vaccine", "TREATMENT", 190, 211], ["no", "UNCERTAINTY", 123, 125], ["significant", "OBSERVATION_MODIFIER", 126, 137], ["difference", "OBSERVATION", 138, 148]]], ["Peak ciliostasis of the Beaudette based strains was detected at 5 days post hatch and the ciliostasis levels decreased after this time.", [["Peak ciliostasis", "TEST", 0, 16], ["the Beaudette based strains", "PROBLEM", 20, 47], ["the ciliostasis levels", "TEST", 86, 108], ["strains", "OBSERVATION", 40, 47]]], ["The ciliostasis caused by the commercial CV1 vaccine given at day-old was assessed on days 5 and 8 post vaccination.", [["ciliostasis", "DISEASE", 4, 15], ["CV1 vaccine", "ORGANISM", 41, 52], ["CV1", "SPECIES", 41, 44], ["The ciliostasis", "PROBLEM", 0, 15], ["the commercial CV1 vaccine", "TREATMENT", 26, 52], ["vaccination", "TREATMENT", 104, 115]]], ["The highest ciliostasis was detected on day 8 though this was not significantly different to any of the candidate vaccines given in ovo (p = 0.059).Serological response to vaccinationIn Experiment 1 the serological responses were compared at 4 weeks post hatch (Fig. 3A) .", [["The highest ciliostasis", "TEST", 0, 23], ["the candidate vaccines", "TREATMENT", 100, 122], ["Serological response", "TEST", 148, 168], ["the serological responses", "TEST", 199, 224], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["ciliostasis", "OBSERVATION", 12, 23]]], ["The CV1 vaccine given in ovo at all doses gave the highest antibody responses and all birds seroconverted regardless of dose.", [["CV1", "ORGANISM", 4, 7], ["ovo", "ORGANISM", 25, 28], ["birds", "ORGANISM", 86, 91], ["ovo", "SPECIES", 25, 28], ["The CV1 vaccine", "TREATMENT", 0, 15], ["the highest antibody responses", "TREATMENT", 47, 77], ["all birds", "TREATMENT", 82, 91]]], ["The lowest dose of the CV1 vaccine gave a significantly higher response than BeauR-M41(S) (p = 0.004) and Beau-R (p = 0.0004).", [["CV1", "ORGANISM", 23, 26], ["Beau-R", "GENE_OR_GENE_PRODUCT", 106, 112], ["CV1", "SPECIES", 23, 26], ["the CV1 vaccine", "TREATMENT", 19, 34], ["BeauR", "TEST", 77, 82], ["Beau", "TEST", 106, 110]]], ["Beau-R gave a lower antibody response than BeauR-M41(S) but this was not significant (p = 0.1).", [["Beau-R", "GENE_OR_GENE_PRODUCT", 0, 6], ["a lower antibody response", "PROBLEM", 12, 37]]], ["Sixty percent of the Beau-R vaccinates and 80% of the BeauR-M41(S) vaccinates had seroconverted at 4 weeks post hatch.Serological response to vaccinationIn Experiment 2 BeauR-M41(S) EP10 vaccination in ovo gave the highest antibody response of the Beaudette based strains with all birds in the group seroconverting (Fig. 3B) .", [["EP10", "CHEMICAL", 182, 186], ["Beau-R", "GENE_OR_GENE_PRODUCT", 21, 27], ["BeauR-M41(S) vaccinates", "ORGANISM", 54, 77], ["EP10", "ORGANISM", 182, 186], ["ovo", "ORGANISM", 202, 205], ["ovo", "SPECIES", 202, 205], ["the BeauR", "TEST", 50, 59], ["Serological response", "TEST", 118, 138], ["vaccinationIn", "TEST", 142, 155], ["Experiment", "TEST", 156, 166], ["BeauR", "TEST", 169, 174], ["EP10 vaccination", "TREATMENT", 182, 198], ["the Beaudette based strains", "PROBLEM", 244, 271]]], ["The response to BeauR-M41(S) EP10 was significantly higher than both BeauR-M41(S) vaccine (p = 0.002) and Beau-R (p = 0.002) which gave approximately equal responses with only 40% of birds seroconverting in each of these groups (data not shown).", [["BeauR-M41", "CHEMICAL", 16, 25], ["BeauR-M41(S) EP10", "GENE_OR_GENE_PRODUCT", 16, 33], ["Beau-R", "GENE_OR_GENE_PRODUCT", 106, 112], ["birds", "ORGANISM", 183, 188], ["BeauR", "TEST", 16, 21], ["EP10", "TEST", 29, 33], ["BeauR", "TEST", 69, 74], ["Beau", "TEST", 106, 110], ["birds seroconverting", "TREATMENT", 183, 203]]], ["The CV1 vaccine given at day-old gave the highest antibody response in this experiment with 90% of the birds responding.", [["CV1 vaccine", "ORGANISM", 4, 15], ["birds", "ORGANISM", 103, 108], ["The CV1 vaccine", "TREATMENT", 0, 15]]], ["However this response was not significantly different to that induced by BeauR-M41(S) EP10 (p = 0.88).Serological response to vaccinationIn Experiment 3, BeauR-M41(S) EP10 vaccination in ovo gave the highest antibody response with 90% of birds in the group seroconverting (Fig. 3C) .", [["EP10", "CHEMICAL", 167, 171], ["BeauR-M41(S) EP10", "ORGANISM", 154, 171], ["ovo", "ORGANISM", 187, 190], ["birds", "ORGANISM", 238, 243], ["ovo", "SPECIES", 187, 190], ["BeauR", "TEST", 73, 78], ["EP10", "TEST", 86, 90], ["Serological response", "TEST", 102, 122], ["vaccinationIn Experiment", "TEST", 126, 150], ["BeauR", "TEST", 154, 159], ["EP10 vaccination", "TREATMENT", 167, 183]]], ["The response to BeauR-M41(S) EP10 was significantly higher than vaccination in ovo with BeauR-M41(S) (p = 0.0006) and only 40% of the birds vaccinated with BeauR-M41(S) seroconverted (data not shown).Efficacy of the candidate vaccinesIn Experiment 1 (vaccination dose for the Beaudette-based viruses was 10 6 EID 50 ) birds were challenged 4 weeks post hatch with virulent M41 virus and the ciliary activity tested on days 5 and 7 post challenge (Fig. 4A) .", [["ciliary", "ANATOMY", 391, 398], ["BeauR-M41", "CHEMICAL", 16, 25], ["BeauR-M41", "CHEMICAL", 156, 165], ["BeauR-M41(S) EP10", "GENE_OR_GENE_PRODUCT", 16, 33], ["birds", "ORGANISM", 134, 139], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 156, 165], ["birds", "ORGANISM", 318, 323], ["M41 virus", "ORGANISM", 373, 382], ["ciliary", "MULTI-TISSUE_STRUCTURE", 391, 398], ["BeauR", "PROTEIN", 156, 161], ["ovo", "SPECIES", 79, 82], ["BeauR-M41", "SPECIES", 156, 165], ["M41 virus", "SPECIES", 373, 382], ["BeauR", "TEST", 16, 21], ["EP10", "TEST", 29, 33], ["BeauR", "TEST", 88, 93], ["p", "TEST", 102, 103], ["BeauR", "TEST", 156, 161], ["the candidate vaccinesIn Experiment", "TREATMENT", 212, 247], ["vaccination dose", "TREATMENT", 251, 267], ["the Beaudette-based viruses", "TREATMENT", 272, 299], ["virulent M41 virus", "TREATMENT", 364, 382], ["the ciliary activity", "TEST", 387, 407], ["ciliary activity", "OBSERVATION", 391, 407]]], ["For this purpose birds vaccinated with different doses of the CV1 vaccine were pooled to give a group of 10 birds.", [["birds", "ORGANISM", 17, 22], ["CV1", "ORGANISM", 62, 65], ["birds", "ORGANISM", 108, 113], ["CV1", "SPECIES", 62, 65], ["this purpose birds", "TREATMENT", 4, 22], ["the CV1 vaccine", "TREATMENT", 58, 73]]], ["Based on ciliary activity of 50% or less being indicative of protection [9] all of the CV1 vaccinated birds were protected, 90% of the BeauR-M41(S) in ovo-vaccinated birds were protected and 30% of the Beau-R in ovo-vaccinated birds were protected.", [["ciliary", "ANATOMY", 9, 16], ["ciliary", "MULTI-TISSUE_STRUCTURE", 9, 16], ["CV1", "ORGANISM", 87, 90], ["birds", "ORGANISM", 102, 107], ["BeauR-M41(S)", "ORGANISM", 135, 147], ["ovo-vaccinated", "ORGANISM", 151, 165], ["birds", "ORGANISM", 166, 171], ["Beau-R", "ORGANISM", 202, 208], ["ovo-vaccinated", "ORGANISM", 212, 226], ["birds", "ORGANISM", 227, 232], ["ciliary activity", "TEST", 9, 25], ["the BeauR", "TEST", 131, 140], ["ovo-vaccinated birds", "TREATMENT", 151, 171], ["the Beau", "TEST", 198, 206], ["ovo-vaccinated birds", "TREATMENT", 212, 232]]], ["All non-vaccinated birds had at least 95% ciliostasis.", [["ciliostasis", "DISEASE", 42, 53], ["birds", "ORGANISM", 19, 24]]], ["This result indicates that the expression of the spike protein of virulent M41 increases the protective capacity of the BeauR-M41 (S) vaccine in comparison to Beau-R.Efficacy of the candidate vaccinesIn Experiment 2 (vaccination dose for the Beaudette-based viruses was 10 4 EID 50 ) birds were challenged at 6 weeks post hatch with virulent M41 virus and the ciliary activity tested on days 5 and 7 post challenge (Fig. 4B) .", [["ciliary", "ANATOMY", 360, 367], ["BeauR-M41", "CHEMICAL", 120, 129], ["M41", "GENE_OR_GENE_PRODUCT", 75, 78], ["BeauR-M41 (S)", "ORGANISM", 120, 133], ["Beau-R.", "ORGANISM", 159, 166], ["birds", "ORGANISM", 284, 289], ["M41 virus", "ORGANISM", 342, 351], ["ciliary", "MULTI-TISSUE_STRUCTURE", 360, 367], ["spike protein", "PROTEIN", 49, 62], ["virulent M41", "PROTEIN", 66, 78], ["Beau-R.", "SPECIES", 159, 166], ["M41 virus", "SPECIES", 342, 351], ["the spike protein of virulent M41", "PROBLEM", 45, 78], ["the BeauR-M41 (S) vaccine", "TREATMENT", 116, 141], ["the candidate vaccinesIn Experiment", "TREATMENT", 178, 213], ["vaccination dose", "TREATMENT", 217, 233], ["the Beaudette-based viruses", "TREATMENT", 238, 265], ["virulent M41 virus", "TREATMENT", 333, 351], ["the ciliary activity", "TEST", 356, 376], ["ciliary activity", "OBSERVATION", 360, 376]]], ["All non-vaccinated birds had at least 95% ciliostasis.", [["ciliostasis", "DISEASE", 42, 53], ["birds", "ORGANISM", 19, 24]]], ["BeauR-M41(S) EP10 inoculated in ovo protected 70% of the birds whilst none of the Beau-R in ovo vaccinates were protected and only 10% of the birds vaccinated in ovo with BeauR-M41(S) were protected.", [["EP10", "CHEMICAL", 13, 17], ["BeauR-M41", "CHEMICAL", 171, 180], ["birds", "ORGANISM", 57, 62], ["Beau-R", "ORGANISM", 82, 88], ["ovo", "ORGANISM", 92, 95], ["birds", "ORGANISM", 142, 147], ["ovo", "SPECIES", 32, 35], ["ovo", "SPECIES", 92, 95], ["ovo", "SPECIES", 162, 165], ["the Beau", "TEST", 78, 86], ["ovo vaccinates", "TREATMENT", 92, 106], ["BeauR", "TEST", 171, 176]]], ["The CV1 vaccine administered at day-old provided 90% protection.", [["CV1", "ORGANISM", 4, 7], ["The CV1 vaccine", "TREATMENT", 0, 15]]], ["In comparison to Experiment 1 this result suggested that efficacy may be dose and/or time dependent for the Beau-R and BeauR-M41(S) vaccines with better protection given by a high dose (10 6 EID 50 ) with a 4-week challenge (Fig. 4B ) than a lower dose (10 4 EID50) and a 6-week challenge.Efficacy of the candidate vaccinesIn Experiment 3 birds were challenged at 4 weeks post hatch with virulent M41 virus and the ciliary activity tested on days 5 and 7 post challenge (Fig. 4C) .", [["ciliary", "ANATOMY", 415, 422], ["Beau-R", "SIMPLE_CHEMICAL", 108, 114], ["BeauR-M41", "SIMPLE_CHEMICAL", 119, 128], ["birds", "ORGANISM", 339, 344], ["M41 virus", "ORGANISM", 397, 406], ["ciliary", "MULTI-TISSUE_STRUCTURE", 415, 422], ["M41 virus", "SPECIES", 397, 406], ["the Beau-R and BeauR-M41(S) vaccines", "TREATMENT", 104, 140], ["the candidate vaccinesIn Experiment", "TREATMENT", 301, 336], ["virulent M41 virus", "TREATMENT", 388, 406], ["the ciliary activity", "TEST", 411, 431], ["ciliary activity", "OBSERVATION", 415, 431]]], ["All non-vaccinated birds had at least 95% ciliostasis.", [["ciliostasis", "DISEASE", 42, 53], ["birds", "ORGANISM", 19, 24]]], ["One of the birds in the BeauR-M41(S) EP10 in ovo-vaccinated group had to be euthanized due to a genetic defect.", [["EP10", "CHEMICAL", 37, 41], ["birds", "ORGANISM", 11, 16], ["BeauR-M41(S) EP10", "ORGANISM", 24, 41], ["a genetic defect", "PROBLEM", 94, 110], ["defect", "OBSERVATION", 104, 110]]], ["BeauR-M41(S) EP10 inoculated in ovo protected 89% of the vaccinates whilst only 40% of the BeauR-M41(S) in ovo-vaccinated birds were protected.Efficacy of the candidate vaccinesOverall the results indicated that IBV Beaudette strain expressing the spike gene from the M41 strain was safe for delivery to embryos and had potential as an efficacious vaccine.DiscussionAs the poultry industry is moving towards greater use of in ovo vaccination, the purpose of this study was to determine if IBV vaccines based on the Beaudette strain could be delivered via this route.", [["embryos", "ANATOMY", 304, 311], ["BeauR-M41", "CHEMICAL", 0, 9], ["EP10", "CHEMICAL", 13, 17], ["BeauR-M41", "CHEMICAL", 91, 100], ["BeauR-M41(S)", "ORGANISM", 91, 103], ["ovo", "ORGANISM", 107, 110], ["birds", "ORGANISM", 122, 127], ["IBV Beaudette strain", "ORGANISM", 212, 232], ["M41 strain", "ORGANISM", 268, 278], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 304, 311], ["IBV", "ORGANISM", 489, 492], ["spike gene", "DNA", 248, 258], ["ovo", "SPECIES", 32, 35], ["IBV", "SPECIES", 212, 215], ["IBV", "SPECIES", 489, 492], ["EP10", "TEST", 13, 17], ["the vaccinates", "TEST", 53, 67], ["the BeauR", "TEST", 87, 96], ["ovo-vaccinated birds", "TREATMENT", 107, 127], ["the candidate vaccines", "TREATMENT", 155, 177], ["IBV Beaudette strain", "PROBLEM", 212, 232], ["the spike gene from the M41 strain", "PROBLEM", 244, 278], ["delivery to embryos", "TREATMENT", 292, 311], ["an efficacious vaccine", "TREATMENT", 333, 355], ["ovo vaccination", "TREATMENT", 426, 441], ["this study", "TEST", 458, 468], ["IBV vaccines", "TREATMENT", 489, 501], ["the Beaudette strain", "TREATMENT", 511, 531]]], ["Surprisingly, even at high doses, the Beaudette based strains tested did not significantly affect the ability of the chick to hatch (Fig. 1A-D) or cause clinical signs post hatch ( Fig. 2A and Experiment 3, data not shown) when compared to vaccination with a placebo.", [["1A-D", "CHEMICAL", 138, 142], ["chick", "ORGANISM", 117, 122], ["1A-D", "GENE_OR_GENE_PRODUCT", 138, 142], ["the Beaudette based strains", "PROBLEM", 34, 61], ["clinical signs", "PROBLEM", 153, 167], ["a placebo", "TREATMENT", 257, 266]]], ["This is in contrast to work of Wakenell and Sharma [2] whose IBV in ovo vaccine candidate showed residual pathogenicity at a dose of 500 pfu.", [["IBV", "ORGANISM", 61, 64], ["ovo", "ORGANISM", 68, 71], ["IBV", "SPECIES", 61, 64], ["IBV in ovo vaccine", "TREATMENT", 61, 79], ["residual pathogenicity", "PROBLEM", 97, 119]]], ["As expected the embryo adapted commercial vaccines greatly reduced hatchability ( Fig. 1A and D) and gave clinical signs post hatch ( Fig. 2A) .", [["embryo", "ANATOMY", 16, 22], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 16, 22], ["the embryo", "TREATMENT", 12, 22], ["commercial vaccines", "TREATMENT", 31, 50]]], ["The reason why the recombinant Beaudette strains are safe for in ovo vaccination is unknown though could be associated with the passage history of these particular strains.", [["Beaudette strains", "ORGANISM", 31, 48], ["ovo", "SPECIES", 65, 68], ["the recombinant Beaudette strains", "PROBLEM", 15, 48], ["ovo vaccination", "TREATMENT", 65, 80], ["these particular strains", "PROBLEM", 147, 171]]], ["The parent Beaudette virus has been passaged on embryos more than the commercial vaccines and also passaged on CK cells, the precise passage history being unknown.", [["embryos", "ANATOMY", 48, 55], ["CK cells", "ANATOMY", 111, 119], ["Beaudette virus", "ORGANISM", 11, 26], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 48, 55], ["CK cells", "CELL", 111, 119], ["CK cells", "CELL_TYPE", 111, 119], ["Beaudette virus", "SPECIES", 11, 26], ["The parent Beaudette virus", "PROBLEM", 0, 26], ["the commercial vaccines", "TREATMENT", 66, 89], ["CK cells", "TREATMENT", 111, 119], ["virus", "OBSERVATION", 21, 26]]], ["Subsequently the recombinant viruses have been passaged further on CK cells.", [["CK cells", "ANATOMY", 67, 75], ["CK cells", "CELL", 67, 75], ["CK cells", "CELL_LINE", 67, 75], ["the recombinant viruses", "PROBLEM", 13, 36], ["CK cells", "TEST", 67, 75], ["viruses", "OBSERVATION", 29, 36]]], ["In line with the results of Hodgson et al. [4] , with hatched chicks, we found that that the substitution of the Beaudette spike protein with that of the virulent M41 strain did not increase the pathogenicity of the BeauR-M41(S) strain over Beau-R in 18-day-old embryos or post hatch.", [["embryos", "ANATOMY", 262, 269], ["chicks", "ORGANISM", 62, 68], ["M41 strain", "ORGANISM", 163, 173], ["BeauR-M41(S) strain", "ORGANISM", 216, 235], ["Beau-R", "GENE_OR_GENE_PRODUCT", 241, 247], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 262, 269], ["Beaudette spike protein", "PROTEIN", 113, 136], ["the Beaudette spike protein", "PROBLEM", 109, 136], ["the virulent M41 strain", "PROBLEM", 150, 173], ["strain", "PROBLEM", 229, 235], ["Beau", "TEST", 241, 245]]], ["This result suggests that the ability of M41-CK virus to reduce hatchability (to 58% in comparison to 89% with the placebo in Experiment 5) is not associated with the spike protein but may be associated with differences in other genes.", [["M41-CK virus", "ORGANISM", 41, 53], ["spike protein", "PROTEIN", 167, 180], ["M41", "TEST", 41, 44], ["CK virus", "PROBLEM", 45, 53], ["hatchability", "PROBLEM", 64, 76], ["the spike protein", "PROBLEM", 163, 180], ["not associated with", "UNCERTAINTY", 143, 162]]], ["It is interesting to note that further egg passages of the BeauR-M41(S) strain did not increase pathogenicity based on hatching criteria.DiscussionThe ciliostasis test is used to determine the damage to the trachea following growth of IBV in this tissue.", [["egg", "ANATOMY", 39, 42], ["trachea", "ANATOMY", 207, 214], ["tissue", "ANATOMY", 247, 253], ["BeauR", "GENE_OR_GENE_PRODUCT", 59, 64], ["trachea", "ORGAN", 207, 214], ["IBV", "ORGANISM", 235, 238], ["tissue", "TISSUE", 247, 253], ["IBV", "SPECIES", 235, 238], ["further egg passages", "TEST", 31, 51], ["the BeauR", "TEST", 55, 64], ["strain", "PROBLEM", 72, 78], ["increase pathogenicity", "PROBLEM", 87, 109], ["The ciliostasis test", "TEST", 147, 167], ["the damage to the trachea", "PROBLEM", 189, 214], ["IBV", "PROBLEM", 235, 238], ["increase", "OBSERVATION_MODIFIER", 87, 95], ["pathogenicity", "OBSERVATION", 96, 109], ["trachea", "ANATOMY", 207, 214], ["IBV", "OBSERVATION", 235, 238]]], ["The Beaudette-based vaccine strains caused tracheal ciliostasis following in ovo inoculation but at an acceptable level with respect to vaccine safety [9] .", [["tracheal", "ANATOMY", 43, 51], ["Beaudette", "CHEMICAL", 4, 13], ["tracheal ciliostasis", "DISEASE", 43, 63], ["Beaudette", "SIMPLE_CHEMICAL", 4, 13], ["tracheal", "ORGAN", 43, 51], ["ovo", "SPECIES", 77, 80], ["The Beaudette-based vaccine strains", "TREATMENT", 0, 35], ["tracheal ciliostasis", "PROBLEM", 43, 63], ["ovo inoculation", "TREATMENT", 77, 92], ["tracheal", "ANATOMY", 43, 51], ["ciliostasis", "OBSERVATION", 52, 63]]], ["This indicates that the Beaudette strains were able to replicate in the trachea of the in ovovaccinated chicks.", [["trachea", "ANATOMY", 72, 79], ["trachea", "ORGAN", 72, 79], ["chicks", "ORGANISM", 104, 110], ["chicks", "SPECIES", 104, 110], ["the Beaudette strains", "PROBLEM", 20, 41], ["trachea", "ANATOMY", 72, 79], ["ovovaccinated chicks", "OBSERVATION", 90, 110]]], ["In contrast, virtually no tracheal ciliostasis was caused by the Beaudette strains following inoculation of chicks by the oculonasal route [4] , although Beaudette does cause ciliostasis when inoculated onto tracheal organ cultures.", [["tracheal", "ANATOMY", 26, 34], ["tracheal organ cultures", "ANATOMY", 208, 231], ["ciliostasis", "DISEASE", 35, 46], ["ciliostasis", "DISEASE", 175, 186], ["chicks", "ORGANISM", 108, 114], ["chicks", "SPECIES", 108, 114], ["tracheal ciliostasis", "PROBLEM", 26, 46], ["the Beaudette strains", "PROBLEM", 61, 82], ["ciliostasis", "PROBLEM", 175, 186], ["tracheal organ cultures", "TEST", 208, 231], ["no", "UNCERTAINTY", 23, 25], ["tracheal", "ANATOMY", 26, 34], ["ciliostasis", "OBSERVATION", 35, 46], ["organ", "ANATOMY", 217, 222]]], ["This suggests that delivery of IBV in ovo enables it to grow better in the trachea than post hatch delivery possibly due to the embryos ingesting amniotic fluid containing the viral inoculum, introducing the virus directly to the trachea.", [["trachea", "ANATOMY", 75, 82], ["embryos", "ANATOMY", 128, 135], ["amniotic fluid", "ANATOMY", 146, 160], ["trachea", "ANATOMY", 230, 237], ["IBV", "ORGANISM", 31, 34], ["trachea", "ORGAN", 75, 82], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 128, 135], ["amniotic fluid", "ORGANISM_SUBSTANCE", 146, 160], ["trachea", "ORGAN", 230, 237], ["IBV", "SPECIES", 31, 34], ["ovo", "SPECIES", 38, 41], ["IBV", "PROBLEM", 31, 34], ["hatch delivery", "TREATMENT", 93, 107], ["the embryos", "PROBLEM", 124, 135], ["amniotic fluid", "PROBLEM", 146, 160], ["the viral inoculum", "PROBLEM", 172, 190], ["the virus", "PROBLEM", 204, 213], ["IBV", "OBSERVATION", 31, 34], ["trachea", "ANATOMY", 75, 82], ["amniotic fluid", "OBSERVATION", 146, 160], ["viral inoculum", "OBSERVATION", 176, 190], ["trachea", "ANATOMY", 230, 237]]], ["In contrast the commercial vaccine tested caused very high ciliostasis scores post hatch after delivery in ovo (Fig. 2B) .", [["ovo", "SPECIES", 107, 110], ["the commercial vaccine", "TREATMENT", 12, 34], ["very high ciliostasis scores", "PROBLEM", 49, 77], ["delivery", "TREATMENT", 95, 103]]], ["This is in contrast to the results for the commercial vaccine delivered at day-old by nose and eye-drop appli-cation (Fig. 2C) , again suggesting that delivery of IBV in ovo enables it to grow better in the trachea than delivery at day-old.DiscussionInterestingly the spike protein did not appear to affect the amount of ciliostasis caused by the Beau-R and BeauR-M41(S) strains as these strains showed similar results in two experiments (Fig. 2B 10 6 EID 50 & 2C 10 4 EID 50 ).", [["nose", "ANATOMY", 86, 90], ["trachea", "ANATOMY", 207, 214], ["ciliostasis", "DISEASE", 321, 332], ["nose", "ORGANISM_SUBDIVISION", 86, 90], ["IBV", "ORGANISM", 163, 166], ["trachea", "ORGAN", 207, 214], ["Beau-R", "GENE_OR_GENE_PRODUCT", 347, 353], ["BeauR-M41(S)", "GENE_OR_GENE_PRODUCT", 358, 370], ["spike protein", "PROTEIN", 268, 281], ["IBV", "SPECIES", 163, 166], ["ovo", "SPECIES", 170, 173], ["the commercial vaccine", "TREATMENT", 39, 61], ["IBV", "TREATMENT", 163, 166], ["the spike protein", "PROBLEM", 264, 281], ["ciliostasis", "PROBLEM", 321, 332], ["BeauR", "TEST", 358, 363], ["strains", "PROBLEM", 371, 378], ["these strains", "TEST", 382, 395], ["Fig. 2B", "TREATMENT", 439, 446], ["trachea", "ANATOMY", 207, 214]]], ["In contrast in a single experiment (Fig. 2C, 10 4 EID 50 ) the egg-passaged BeauR-M41(S) EP10 virus gave higher, but not significantly higher, ciliostasis scores.", [["egg", "ORGANISM", 63, 66], ["BeauR-M41(S) EP10 virus", "ORGANISM", 76, 99], ["BeauR-M41(S) EP10 virus", "SPECIES", 76, 99], ["the egg", "TEST", 59, 66], ["virus", "PROBLEM", 94, 99], ["egg", "ANATOMY", 63, 66]]], ["It is difficult to draw conclusions from a single experiment but this result suggests that egg passage may have increased the ability of the BeauR-M41(S) EP10 virus to grow in the trachea.DiscussionAlthough a serological response against IBV has not been correlated with protection against virulent IBV respiratory challenge, it is a useful criterion with which to assess the immunogenicity of the virus strain in the host.", [["egg", "ANATOMY", 91, 94], ["trachea", "ANATOMY", 180, 187], ["egg", "ORGANISM", 91, 94], ["BeauR-M41(S) EP10 virus", "ORGANISM", 141, 164], ["trachea", "ORGAN", 180, 187], ["IBV", "ORGANISM", 238, 241], ["IBV", "ORGANISM", 299, 302], ["BeauR-M41(S) EP10 virus", "SPECIES", 141, 164], ["IBV", "SPECIES", 238, 241], ["IBV", "SPECIES", 299, 302], ["egg passage", "PROBLEM", 91, 102], ["virus", "PROBLEM", 159, 164], ["IBV", "PROBLEM", 238, 241], ["protection", "TREATMENT", 271, 281], ["virulent IBV respiratory challenge", "TREATMENT", 290, 324], ["the virus strain", "PROBLEM", 394, 410], ["trachea", "ANATOMY", 180, 187], ["virus", "OBSERVATION", 398, 403]]], ["No significant differences were seen in the serological responses induced by Beau-R and BeauR-M41(S) in two experiments ( Fig. 3A and B) and it is of interest to note that there was no dose dependency regarding the serological response or rate of seroconversion, a 100-fold more virus giving a similar response and seroconversion rate (Fig. 3A versus B) .", [["BeauR-M41", "CHEMICAL", 88, 97], ["Beau-R", "SIMPLE_CHEMICAL", 77, 83], ["BeauR-M41", "SIMPLE_CHEMICAL", 88, 97], ["B", "CELL", 134, 135], ["B", "CELL", 351, 352], ["Beau", "TEST", 77, 81], ["dose dependency", "PROBLEM", 185, 200], ["the serological response", "PROBLEM", 211, 235], ["seroconversion", "PROBLEM", 247, 261], ["a 100-fold more virus", "PROBLEM", 263, 284], ["seroconversion rate", "TEST", 315, 334], ["significant", "OBSERVATION_MODIFIER", 3, 14], ["differences", "OBSERVATION", 15, 26]]], ["However, eggpassaged BeauR-M41(S) EP10 induced significantly higher responses than BeauR-M41(S) (Fig. 3B and C) .", [["M41(S) EP10", "PROTEIN", 27, 38], ["significantly higher responses", "PROBLEM", 47, 77], ["BeauR", "TEST", 83, 88]]], ["This response was not significantly different to that induced by a commercial vaccine given at day-old (Fig. 3B) indicating a high level of immunogenicity of this virus.", [["a commercial vaccine", "TREATMENT", 65, 85], ["this virus", "PROBLEM", 158, 168], ["significantly different", "OBSERVATION_MODIFIER", 22, 45]]], ["The reasons for the difference in immunogenicity of the egg-passaged virus requires further investigation though one could speculate that as the virus may have replicated more in the trachea, it subsequently induced a better immune response.DiscussionThe efficacy of the Beaudette-derived viruses as potential vaccines was studied using a respiratory challenge with the virulent IBV M41 strain, using tracheal ciliary activity as the criterion of protection.", [["trachea", "ANATOMY", 183, 190], ["tracheal ciliary", "ANATOMY", 401, 417], ["egg", "ORGANISM", 56, 59], ["trachea", "ORGAN", 183, 190], ["IBV", "ORGANISM", 379, 382], ["tracheal ciliary", "MULTI-TISSUE_STRUCTURE", 401, 417], ["IBV M41", "SPECIES", 379, 386], ["the difference", "PROBLEM", 16, 30], ["the egg", "PROBLEM", 52, 59], ["passaged virus", "PROBLEM", 60, 74], ["further investigation", "TEST", 84, 105], ["the virus", "PROBLEM", 141, 150], ["potential vaccines", "TREATMENT", 300, 318], ["a respiratory challenge", "TREATMENT", 337, 360], ["the virulent IBV M41 strain", "TREATMENT", 366, 393], ["tracheal ciliary activity", "TREATMENT", 401, 426], ["trachea", "ANATOMY", 183, 190], ["tracheal ciliary", "ANATOMY", 401, 417]]], ["A high dose (10 6 EID 50 ) of BeauR-M41(S) induced levels of protection comparable to that induced by the commercial vaccine given in ovo (Fig. 4A) , though the commercial vaccine was not safe as determined by the criteria described above.", [["BeauR-M41", "CHEMICAL", 30, 39], ["BeauR-M41", "SIMPLE_CHEMICAL", 30, 39], ["Fig. 4A", "ORGANISM", 139, 146], ["ovo", "SPECIES", 134, 137], ["protection", "TREATMENT", 61, 71], ["the commercial vaccine", "TREATMENT", 102, 124], ["the commercial vaccine", "TREATMENT", 157, 179]]], ["The level of protection (90%) resulting from in ovo vaccination with BeauR-M41(S) was higher than that induced by Beau-R (30%), suggesting a positive effect of the M41 spike protein.", [["BeauR-M41", "CHEMICAL", 69, 78], ["BeauR-M41", "SIMPLE_CHEMICAL", 69, 78], ["Beau-R", "GENE_OR_GENE_PRODUCT", 114, 120], ["M41 spike protein", "GENE_OR_GENE_PRODUCT", 164, 181], ["M41 spike protein", "PROTEIN", 164, 181], ["ovo vaccination", "TREATMENT", 48, 63], ["BeauR", "TEST", 69, 74], ["Beau", "TEST", 114, 118], ["the M41 spike protein", "PROBLEM", 160, 181], ["positive effect", "OBSERVATION", 141, 156]]], ["As these viruses appeared to grow equally well in the trachea ( Fig. 2B and C) it can be speculated that the increase in protection observed with the BeauR-M41(S) was due to the M41 spike protein which is homologous to the spike protein of the challenge virus.", [["trachea", "ANATOMY", 54, 61], ["trachea", "ORGAN", 54, 61], ["BeauR-M41(S)", "GENE_OR_GENE_PRODUCT", 150, 162], ["M41", "GENE_OR_GENE_PRODUCT", 178, 181], ["BeauR", "PROTEIN", 150, 155], ["M41(S)", "PROTEIN", 156, 162], ["M41 spike protein", "PROTEIN", 178, 195], ["spike protein", "PROTEIN", 223, 236], ["the M41 spike protein", "PROBLEM", 174, 195], ["the challenge virus", "TREATMENT", 240, 259], ["viruses", "OBSERVATION", 9, 16], ["trachea", "ANATOMY", 54, 61], ["increase", "OBSERVATION_MODIFIER", 109, 117]]], ["Alternatively, as a cytotoxic T cell response is thought to be important in protection against IB challenge [10] it is possible that the 5% amino acid difference between Beau-R and BeauR-M41(S) spike proteins [4] contain relevant CTL epitopes for protection against M41 challenge.", [["T cell", "ANATOMY", 30, 36], ["amino acid", "CHEMICAL", 140, 150], ["M41", "CHEMICAL", 266, 269], ["amino acid", "CHEMICAL", 140, 150], ["T cell", "CELL", 30, 36], ["amino acid", "AMINO_ACID", 140, 150], ["Beau-R", "GENE_OR_GENE_PRODUCT", 170, 176], ["BeauR-M41(S)", "GENE_OR_GENE_PRODUCT", 181, 193], ["BeauR", "PROTEIN", 181, 186], ["M41(S) spike proteins", "PROTEIN", 187, 208], ["CTL epitopes", "PROTEIN", 230, 242], ["a cytotoxic T cell response", "PROBLEM", 18, 45], ["the 5% amino acid difference", "PROBLEM", 133, 161], ["Beau", "TEST", 170, 174], ["BeauR", "TEST", 181, 186], ["spike proteins", "PROBLEM", 194, 208], ["relevant CTL epitopes", "TREATMENT", 221, 242], ["M41 challenge", "TREATMENT", 266, 279], ["thought to be", "UNCERTAINTY", 49, 62]]], ["The results presented herein are in agreement with the finding that vaccination with BeauR-M41(S) given at 8-days-old gave higher protection against virulent M41 challenge than vaccination with Beau-R [4] .DiscussionWe observed a dose and/or time dependency of the protection afforded by BeauR-M41(S) as at a 100-fold lower dose and challenge at 6 weeks the protection fell from 90% (Fig. 4A) to 10% (Fig. 4B ).", [["BeauR-M41", "CHEMICAL", 85, 94], ["M41", "CHEMICAL", 158, 161], ["BeauR-M41", "CHEMICAL", 288, 297], ["BeauR-M41", "CHEMICAL", 288, 297], ["BeauR-M41", "ORGANISM", 85, 94], ["BeauR-M41", "SIMPLE_CHEMICAL", 288, 297], ["M41", "SPECIES", 158, 161], ["higher protection", "TREATMENT", 123, 140], ["virulent M41 challenge", "TREATMENT", 149, 171]]], ["In contrast, the egg-passaged virus, BeauR-M41(S) EP10, at the lower dose (10 4 EID 50 , Fig. 4B and C) provided 70-89% protection in two experiments suggesting that this vaccine was more adapted to growth in the embryo or was more immunogenic.DiscussionIn summary, vaccine candidates based on the Beaudette strain were safe for delivery, by in ovo vaccination, to embryos as determined by their effects on hatchability, nasal discharge post hatch, and ciliary activity.", [["embryo", "ANATOMY", 213, 219], ["embryos", "ANATOMY", 365, 372], ["nasal", "ANATOMY", 421, 426], ["ciliary", "ANATOMY", 453, 460], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 213, 219], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 365, 372], ["nasal", "ORGANISM_SUBDIVISION", 421, 426], ["ciliary", "MULTI-TISSUE_STRUCTURE", 453, 460], ["the egg", "TEST", 13, 20], ["EP10", "TEST", 50, 54], ["this vaccine", "TREATMENT", 166, 178], ["vaccine candidates", "TREATMENT", 266, 284], ["the Beaudette strain", "TREATMENT", 294, 314], ["delivery", "TREATMENT", 329, 337], ["ovo vaccination", "TREATMENT", 345, 360], ["egg", "ANATOMY", 17, 20], ["ciliary activity", "OBSERVATION", 453, 469]]], ["The expression of the M41 spike protein by BeauR-M41(S) did not alter the pathogenicity of the rIBV on the basis of these criteria.", [["M41", "GENE_OR_GENE_PRODUCT", 22, 25], ["BeauR-M41", "GENE_OR_GENE_PRODUCT", 43, 52], ["rIBV", "CANCER", 95, 99], ["M41 spike protein", "PROTEIN", 22, 39], ["BeauR", "PROTEIN", 43, 48], ["M41(S)", "PROTEIN", 49, 55], ["rIBV", "DNA", 95, 99], ["the M41 spike protein", "TEST", 18, 39], ["BeauR", "TEST", 43, 48], ["pathogenicity", "OBSERVATION", 74, 87]]], ["Expression of the M41 spike protein, rather than the Beaudette spike protein, and further egg passage of the virus expressing the M41 spike protein improved the efficacy of the virus.", [["egg", "ANATOMY", 90, 93], ["M41", "GENE_OR_GENE_PRODUCT", 18, 21], ["M41", "GENE_OR_GENE_PRODUCT", 130, 133], ["M41 spike protein", "PROTEIN", 18, 35], ["Beaudette spike protein", "PROTEIN", 53, 76], ["M41 spike protein", "PROTEIN", 130, 147], ["the M41 spike protein", "PROBLEM", 14, 35], ["the Beaudette spike protein", "PROBLEM", 49, 76], ["further egg passage", "PROBLEM", 82, 101], ["the virus", "PROBLEM", 105, 114], ["the virus", "PROBLEM", 173, 182]]], ["To confirm the potential use of these candidate vaccines in the field, future work will concentrate on the effect of maternally derived antibody on the efficacy of these viruses as vaccine candidates following in ovo vaccination.", [["maternally derived antibody", "PROTEIN", 117, 144], ["ovo", "SPECIES", 213, 216], ["these candidate vaccines", "TREATMENT", 32, 56], ["maternally derived antibody", "PROBLEM", 117, 144], ["these viruses", "TREATMENT", 164, 177], ["vaccine candidates", "TREATMENT", 181, 199], ["ovo vaccination", "TREATMENT", 213, 228], ["viruses", "OBSERVATION", 170, 177]]]], "b341f5b4191324cd3b000ed165fcd2e305405155": [["IntroductionKlebsiella pneumoniae (KPN) is a Gram-negative bacterium and opportunistic pathogen belonging to the family Enterobacteriaceae.", [["IntroductionKlebsiella pneumoniae", "ORGANISM", 0, 33], ["KPN", "GENE_OR_GENE_PRODUCT", 35, 38], ["IntroductionKlebsiella pneumoniae", "SPECIES", 0, 33], ["IntroductionKlebsiella pneumoniae", "SPECIES", 0, 33], ["KPN", "SPECIES", 35, 38], ["IntroductionKlebsiella pneumoniae", "PROBLEM", 0, 33], ["a Gram-negative bacterium", "PROBLEM", 43, 68], ["opportunistic pathogen", "PROBLEM", 73, 95], ["pneumoniae", "OBSERVATION", 23, 33], ["Gram-negative", "OBSERVATION_MODIFIER", 45, 58]]], ["It is a natural colonizer of a multitude of body sites such as the gut, skin, respiratory tract, oropharynx, and the reproductive organs.", [["body sites", "ANATOMY", 44, 54], ["gut", "ANATOMY", 67, 70], ["skin", "ANATOMY", 72, 76], ["respiratory tract", "ANATOMY", 78, 95], ["oropharynx", "ANATOMY", 97, 107], ["reproductive organs", "ANATOMY", 117, 136], ["body sites", "MULTI-TISSUE_STRUCTURE", 44, 54], ["gut", "ORGANISM_SUBDIVISION", 67, 70], ["skin", "ORGAN", 72, 76], ["respiratory tract", "ORGANISM_SUBDIVISION", 78, 95], ["oropharynx", "ORGAN", 97, 107], ["reproductive", "ORGAN", 117, 129], ["organs", "ORGAN", 130, 136], ["the gut, skin, respiratory tract, oropharynx, and the reproductive organs", "PROBLEM", 63, 136], ["natural", "OBSERVATION_MODIFIER", 8, 15], ["colonizer", "OBSERVATION", 16, 25], ["gut", "ANATOMY", 67, 70], ["skin", "ANATOMY", 72, 76], ["respiratory tract", "ANATOMY", 78, 95], ["oropharynx", "ANATOMY", 97, 107]]], ["Especially in immunocompromised patients, such as neonates [1] and the elderly, it is a major cause of difficult to treat drug-resistant urinary tract infections (UTIs), infections of soft tissue and open wounds, pneumonia, and sepsis.", [["urinary tract", "ANATOMY", 137, 150], ["soft tissue", "ANATOMY", 184, 195], ["wounds", "ANATOMY", 205, 211], ["urinary tract infections", "DISEASE", 137, 161], ["UTIs", "DISEASE", 163, 167], ["infections", "DISEASE", 170, 180], ["wounds", "DISEASE", 205, 211], ["pneumonia", "DISEASE", 213, 222], ["sepsis", "DISEASE", 228, 234], ["patients", "ORGANISM", 32, 40], ["urinary tract", "ORGANISM_SUBDIVISION", 137, 150], ["soft tissue", "TISSUE", 184, 195], ["wounds", "PATHOLOGICAL_FORMATION", 205, 211], ["patients", "SPECIES", 32, 40], ["resistant urinary tract infections", "PROBLEM", 127, 161], ["UTIs", "PROBLEM", 163, 167], ["soft tissue", "PROBLEM", 184, 195], ["open wounds", "PROBLEM", 200, 211], ["pneumonia", "PROBLEM", 213, 222], ["sepsis", "PROBLEM", 228, 234], ["immunocompromised", "OBSERVATION", 14, 31], ["urinary tract", "ANATOMY", 137, 150], ["infections", "OBSERVATION", 151, 161], ["UTIs", "OBSERVATION", 163, 167], ["soft tissue", "OBSERVATION_MODIFIER", 184, 195], ["open", "OBSERVATION_MODIFIER", 200, 204], ["wounds", "OBSERVATION", 205, 211], ["pneumonia", "OBSERVATION", 213, 222], ["sepsis", "OBSERVATION", 228, 234]]], ["Naturally, KPN is resistant to penicillin, mediated by the chromosomal SHV-1 penicillase, but is able to greatly expand its antimicrobial resistance (AMR) profile by horizontal gene transfer (HTR).", [["KPN", "CHEMICAL", 11, 14], ["penicillin", "CHEMICAL", 31, 41], ["penicillin", "CHEMICAL", 31, 41], ["KPN", "SIMPLE_CHEMICAL", 11, 14], ["penicillin", "SIMPLE_CHEMICAL", 31, 41], ["chromosomal", "CELLULAR_COMPONENT", 59, 70], ["SHV-1", "GENE_OR_GENE_PRODUCT", 71, 76], ["SHV-1", "SPECIES", 71, 76], ["penicillin", "TREATMENT", 31, 41], ["resistant", "OBSERVATION_MODIFIER", 18, 27], ["antimicrobial resistance", "OBSERVATION", 124, 148]]], ["As such it is part of the \"ESKAPE\" group (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter) of pathogens which is a major driver of the current AMR crisis.", [["Enterococcus faecium", "DISEASE", 42, 62], ["Staphylococcus aureus", "DISEASE", 64, 85], ["AMR", "DISEASE", 225, 228], ["Enterococcus faecium", "ORGANISM", 42, 62], ["Staphylococcus aureus", "ORGANISM", 64, 85], ["Klebsiella pneumoniae", "ORGANISM", 87, 108], ["Acinetobacter baumannii", "ORGANISM", 110, 133], ["Pseudomonas aeruginosa", "ORGANISM", 135, 157], ["Enterobacter)", "ORGANISM", 159, 172], ["Enterococcus faecium", "SPECIES", 42, 62], ["Staphylococcus aureus", "SPECIES", 64, 85], ["Klebsiella pneumoniae", "SPECIES", 87, 108], ["Acinetobacter baumannii", "SPECIES", 110, 133], ["Pseudomonas aeruginosa", "SPECIES", 135, 157], ["Enterococcus faecium", "SPECIES", 42, 62], ["Staphylococcus aureus", "SPECIES", 64, 85], ["Klebsiella pneumoniae", "SPECIES", 87, 108], ["Acinetobacter baumannii", "SPECIES", 110, 133], ["Pseudomonas aeruginosa", "SPECIES", 135, 157], ["Enterococcus faecium", "PROBLEM", 42, 62], ["Staphylococcus aureus", "PROBLEM", 64, 85], ["Klebsiella pneumoniae", "PROBLEM", 87, 108], ["Acinetobacter baumannii", "PROBLEM", 110, 133], ["Pseudomonas aeruginosa", "PROBLEM", 135, 157], ["Enterobacter", "PROBLEM", 159, 171], ["pathogens", "PROBLEM", 176, 185], ["the current AMR crisis", "PROBLEM", 213, 235], ["AMR crisis", "OBSERVATION", 225, 235]]], ["Due to its high rate of HTR, mostly mediated by plasmids, many of the new AMR genes discovered in the last decades have been first isolated from KPN before spreading to other Gram-negative organisms.", [["KPN", "GENE_OR_GENE_PRODUCT", 145, 148], ["Gram", "GENE_OR_GENE_PRODUCT", 175, 179], ["plasmids", "DNA", 48, 56], ["AMR genes", "DNA", 74, 83], ["its high rate of HTR", "PROBLEM", 7, 27], ["plasmids", "TREATMENT", 48, 56], ["the new AMR genes", "PROBLEM", 66, 83], ["KPN", "TREATMENT", 145, 148], ["other Gram", "TEST", 169, 179], ["high", "OBSERVATION_MODIFIER", 11, 15], ["plasmids", "OBSERVATION", 48, 56], ["new", "OBSERVATION_MODIFIER", 70, 73], ["AMR genes", "OBSERVATION", 74, 83], ["negative organisms", "OBSERVATION", 180, 198]]], ["Overall, hundreds of mobile resistance genes are known to be associated with KPN [2] .", [["mobile resistance genes", "DNA", 21, 44], ["mobile resistance genes", "PROBLEM", 21, 44], ["hundreds", "OBSERVATION_MODIFIER", 9, 17], ["mobile resistance", "OBSERVATION", 21, 38]]], ["Based on these facts, both the World Health Organization [3] as well as the European Union [4] consider KPN to be a major threat to public health.IntroductionFirst isolated from KPN carried by a patient of Indian origin in Sweden in 2008 [5] , New Delhi metallo-\u03b2-lactamase-1 (NDM-1) confers resistance to almost all \u03b2-lactam antibiotics including carbapenems.", [["metallo-\u03b2-lactamase-1 (NDM-1", "CHEMICAL", 254, 282], ["\u03b2-lactam", "CHEMICAL", 317, 325], ["carbapenems", "CHEMICAL", 348, 359], ["\u03b2-lactam", "CHEMICAL", 317, 325], ["carbapenems", "CHEMICAL", 348, 359], ["KPN", "CANCER", 178, 181], ["patient", "ORGANISM", 195, 202], ["metallo-\u03b2-lactamase-1", "GENE_OR_GENE_PRODUCT", 254, 275], ["NDM-1", "GENE_OR_GENE_PRODUCT", 277, 282], ["\u03b2-lactam antibiotics", "SIMPLE_CHEMICAL", 317, 337], ["carbapenems", "SIMPLE_CHEMICAL", 348, 359], ["patient", "SPECIES", 195, 202], ["KPN", "TREATMENT", 104, 107], ["New Delhi metallo-\u03b2-lactamase", "TEST", 244, 273], ["all \u03b2-lactam antibiotics", "TREATMENT", 313, 337], ["carbapenems", "TREATMENT", 348, 359]]], ["Infections with NDM-1 expressing bacteria are thus only treatable with antibiotics of last-resort such as colistin.", [["Infections", "DISEASE", 0, 10], ["NDM", "DISEASE", 16, 19], ["colistin", "CHEMICAL", 106, 114], ["colistin", "CHEMICAL", 106, 114], ["NDM-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["colistin", "SIMPLE_CHEMICAL", 106, 114], ["Infections", "PROBLEM", 0, 10], ["NDM", "PROBLEM", 16, 19], ["expressing bacteria", "PROBLEM", 22, 41], ["antibiotics", "TREATMENT", 71, 82], ["colistin", "TREATMENT", 106, 114]]], ["Natural reservoirs of bla NDM-1 have been found worldwide with a focus on the Indian subcontinent [6] .IntroductionTo prevent the spread of bla NDM-1 carrying KPN in healthcare settings, rapid screening methods are needed that accurately identify both the organism and AMR genes with high sensitivity.", [["KPN", "CHEMICAL", 159, 162], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 22, 31], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 140, 149], ["KPN", "GENE_OR_GENE_PRODUCT", 159, 162], ["KPN", "DNA", 159, 162], ["AMR genes", "DNA", 269, 278], ["bla NDM-1", "SPECIES", 22, 31], ["bla NDM-1", "SPECIES", 140, 149], ["Introduction", "TREATMENT", 103, 115], ["rapid screening methods", "TEST", 187, 210], ["high sensitivity", "PROBLEM", 284, 300], ["worldwide", "OBSERVATION_MODIFIER", 48, 57]]], ["Today's gold standard is the quantitative polymerase chain reaction (qPCR) that delivers results within about one hour [7] but is constrained to large laboratories due to the need for technically complex thermocyclers with built-in fluorescence detection equipment.IntroductionA novel isothermal alternative to (q)PCR is recombinase polymerase amplification (RPA) [8] .", [["the quantitative polymerase chain reaction", "PROBLEM", 25, 67], ["technically complex thermocyclers", "PROBLEM", 184, 217], ["IntroductionA novel isothermal alternative to (q)PCR", "TREATMENT", 265, 317]]], ["Here, the DNA double helix is opened enzymatically instead of by heat and annealed primers are extended by a DNA polymerase active at 39-42 \u2022 C. Amplification is complete within 5-15 min and, with the addition of a fluorescent probe [9] , can be turned into a real-time format.", [["DNA", "CELLULAR_COMPONENT", 10, 13], ["DNA", "CELLULAR_COMPONENT", 109, 112], ["DNA polymerase", "PROTEIN", 109, 123], ["the DNA double helix", "TREATMENT", 6, 26], ["heat and annealed primers", "TREATMENT", 65, 90], ["a DNA polymerase", "TEST", 107, 123], ["a fluorescent probe", "TREATMENT", 213, 232]]], ["Due to its availability as a ready to use lyophilized enzyme mix, simple incubation requirements as well as the ability to detect target sequences from crude lysates [10] , RPA is an ideal candidate for the development of small and inexpensive nucleic acid detection equipment for use at the point of care.", [["lysates", "ANATOMY", 158, 165], ["nucleic acid", "CHEMICAL", 244, 256], ["RPA", "GENE_OR_GENE_PRODUCT", 173, 176], ["lyophilized enzyme mix", "TREATMENT", 42, 64], ["simple incubation requirements", "TREATMENT", 66, 96], ["crude lysates", "TEST", 152, 165], ["small and inexpensive nucleic acid detection equipment", "PROBLEM", 222, 276], ["small", "OBSERVATION_MODIFIER", 222, 227]]], ["Up until now, a multitude of RPA based detection assays targeting bacteria [11] [12] [13] [14] , viruses [15] [16] [17] [18] [19] [20] , parasites [21] [22] [23] , and microRNAs [24] have been developed.", [["[11] [12] [13] [14] , viruses [15] [16] [17] [18] [19] [20] , parasites [21] [22] [23", "CHEMICAL", 75, 160], ["RPA", "GENE_OR_GENE_PRODUCT", 29, 32], ["bacteria [11] [12] [13] [14]", "SIMPLE_CHEMICAL", 66, 94], ["[15] [16] [17] [18] [19] [20] , parasites [21] [22] [23]", "SIMPLE_CHEMICAL", 105, 161], ["RPA", "PROTEIN", 29, 32], ["RPA based detection assays", "TEST", 29, 55], ["bacteria", "TEST", 66, 74], ["viruses", "TEST", 97, 104], ["parasites", "TEST", 137, 146], ["microRNAs", "TEST", 168, 177]]], ["With the addition of a second primer pair and a corresponding fluorescent probe, RPA assays are also easily duplexed in a single reaction vessel [12, 13] .IntroductionRPA has been shown to work while in contact with a multitude of polymers commonly used to construct microfluidic systems such as cyclic olefin polymer (COP) [25] , (poly)methyl methacrylate (PMMA) [26] , polydimethylsiloxane (PDMS) [27] , and acrylonitrile butadiene styrene (ABS) [28] .", [["vessel", "ANATOMY", 138, 144], ["IntroductionRPA", "CHEMICAL", 155, 170], ["cyclic olefin polymer", "CHEMICAL", 296, 317], ["COP) [25] , (poly)methyl methacrylate", "CHEMICAL", 319, 356], ["PMMA) [26] , polydimethylsiloxane", "CHEMICAL", 358, 391], ["PDMS) [27]", "CHEMICAL", 393, 403], ["acrylonitrile butadiene styrene", "CHEMICAL", 410, 441], ["cyclic olefin", "CHEMICAL", 296, 309], ["(poly)methyl methacrylate", "CHEMICAL", 331, 356], ["PMMA", "CHEMICAL", 358, 362], ["polydimethylsiloxane", "CHEMICAL", 371, 391], ["PDMS", "CHEMICAL", 393, 397], ["acrylonitrile butadiene styrene", "CHEMICAL", 410, 441], ["ABS", "CHEMICAL", 443, 446], ["RPA", "GENE_OR_GENE_PRODUCT", 81, 84], ["vessel", "MULTI-TISSUE_STRUCTURE", 138, 144], ["cyclic olefin polymer", "SIMPLE_CHEMICAL", 296, 317], ["COP) [25]", "SIMPLE_CHEMICAL", 319, 328], ["(poly)methyl methacrylate", "SIMPLE_CHEMICAL", 331, 356], ["PMMA) [26]", "SIMPLE_CHEMICAL", 358, 368], ["polydimethylsiloxane (PDMS) [27]", "SIMPLE_CHEMICAL", 371, 403], ["acrylonitrile butadiene styrene", "SIMPLE_CHEMICAL", 410, 441], ["ABS) [28]", "SIMPLE_CHEMICAL", 443, 452], ["primer pair", "DNA", 30, 41], ["RPA", "PROTEIN", 81, 84], ["a second primer pair", "TREATMENT", 21, 41], ["a corresponding fluorescent probe", "TREATMENT", 46, 79], ["RPA assays", "TEST", 81, 91], ["a multitude of polymers", "TREATMENT", 216, 239], ["microfluidic systems", "TREATMENT", 267, 287], ["cyclic olefin polymer (COP) [25] , (poly)methyl methacrylate (PMMA)", "TREATMENT", 296, 363], ["polydimethylsiloxane (PDMS)", "TREATMENT", 371, 398], ["acrylonitrile butadiene styrene (ABS)", "TREATMENT", 410, 447]]], ["However, all of the aforementioned polymers were structured using classical microfabrication methods.", [["classical microfabrication methods", "TREATMENT", 66, 100]]], ["Only very limited data is available for the compatibility of common 3D printing materials with RPA.", [["RPA", "GENE_OR_GENE_PRODUCT", 95, 98], ["RPA", "PROTEIN", 95, 98]]], ["Yamanaka et al. [29] performed RPA in open top microwell plates printed from black polylactic acid (PLA) by fused deposition modeling (FDM) which were sealed by either an overlay of mineral oil or adhesive foil.", [["oil", "ANATOMY", 190, 193], ["polylactic acid", "CHEMICAL", 83, 98], ["PLA", "CHEMICAL", 100, 103], ["polylactic acid", "CHEMICAL", 83, 98], ["PLA", "CHEMICAL", 100, 103], ["black polylactic acid", "SIMPLE_CHEMICAL", 77, 98], ["PLA", "SIMPLE_CHEMICAL", 100, 103], ["RPA", "PROTEIN", 31, 34], ["RPA in open top microwell plates", "TREATMENT", 31, 63], ["black polylactic acid (PLA", "TREATMENT", 77, 103], ["fused deposition modeling (FDM)", "PROBLEM", 108, 139], ["adhesive foil", "TREATMENT", 197, 210], ["adhesive foil", "OBSERVATION", 197, 210]]], ["End-point readout of the reactions was then performed by hybridization of the amplicons to probes immobilized on a second polycarbonate chip followed by colorimetric detection.IntroductionWhen expanding to fluorescent real time detection of the RPA reaction, autofluorescence as well as fluorescence drift of the material of the reaction vessel become major parameters.", [["vessel", "ANATOMY", 338, 344], ["polycarbonate", "CHEMICAL", 122, 135], ["RPA", "GENE_OR_GENE_PRODUCT", 245, 248], ["vessel", "MULTI-TISSUE_STRUCTURE", 338, 344], ["RPA", "PROTEIN", 245, 248], ["the amplicons", "TREATMENT", 74, 87], ["a second polycarbonate chip", "TREATMENT", 113, 140], ["colorimetric detection", "TEST", 153, 175], ["the RPA reaction", "PROBLEM", 241, 257], ["autofluorescence", "TEST", 259, 275], ["reaction vessel", "OBSERVATION", 329, 344]]], ["Polymers commonly used for the construction of microfluidic systems have intrinsic autofluorescence that decreases due to bleaching under continuous illumination [30] .", [["Polymers", "TREATMENT", 0, 8], ["intrinsic autofluorescence", "PROBLEM", 73, 99]]], ["A recent study [31] of common materials used for FDM found that only a few brands of deep black ABS and PLA showed somewhat acceptable fluorescence behavior in a limited wavelength range from 300-400 nm, which falls outside of the spectra of the most commonly used fluorescent labels used for nucleic acid detection, such as those based on fluorescein.", [["PLA", "CHEMICAL", 104, 107], ["nucleic acid", "CHEMICAL", 293, 305], ["fluorescein", "CHEMICAL", 340, 351], ["PLA", "CHEMICAL", 104, 107], ["fluorescein", "CHEMICAL", 340, 351], ["PLA", "SIMPLE_CHEMICAL", 104, 107], ["nucleic acid", "SIMPLE_CHEMICAL", 293, 305], ["fluorescein", "SIMPLE_CHEMICAL", 340, 351], ["A recent study", "TEST", 0, 14], ["common materials", "TREATMENT", 23, 39], ["deep black ABS", "TEST", 85, 99], ["PLA", "TEST", 104, 107], ["somewhat acceptable fluorescence behavior", "PROBLEM", 115, 156], ["nucleic acid detection", "TEST", 293, 315], ["fluorescein", "TREATMENT", 340, 351], ["deep", "ANATOMY_MODIFIER", 85, 89]]], ["These findings show that FDM, unless new materials are developed, is unsuitable for the construction of monolithic microfluidic systems as the manufacture of optically clear parts with low autofluorescence and fluorescence drift is not possible.", [["FDM", "PROBLEM", 25, 28], ["monolithic microfluidic systems", "TREATMENT", 104, 135], ["low autofluorescence", "PROBLEM", 185, 205], ["fluorescence drift", "PROBLEM", 210, 228], ["new", "OBSERVATION_MODIFIER", 37, 40], ["low autofluorescence", "OBSERVATION", 185, 205], ["fluorescence drift", "OBSERVATION", 210, 228], ["not possible", "UNCERTAINTY", 232, 244]]], ["Kadimisetty et al. [32] have demonstrated successful real-time detection of loop mediated isothermal amplification (LAMP) assays in semi-monolithic micro reactors printed from clear resin (FLGPCL02, Formlabs, Somerville, MA, USA).", [["loop mediated isothermal amplification", "TREATMENT", 76, 114], ["LAMP) assays", "TEST", 116, 128], ["semi-monolithic micro reactors", "PROBLEM", 132, 162]]], ["However, surface coating with polyethylene glycol (PEG) or poly(vinyl alcohol) (PVA) was necessary to achieve satisfactory assay sensitivity for the detection of genomic DNA targets.IntroductionIn this work we seek to advance the state-of-the-art by investigating whether it is possible to manufacture monolithic microreactors suitable for rtRPA by 3D printing technology based on digital light processing (DLP).", [["surface", "ANATOMY", 9, 16], ["polyethylene glycol", "CHEMICAL", 30, 49], ["PEG", "CHEMICAL", 51, 54], ["poly(vinyl alcohol", "CHEMICAL", 59, 77], ["PVA", "CHEMICAL", 80, 83], ["polyethylene glycol", "CHEMICAL", 30, 49], ["PEG", "CHEMICAL", 51, 54], ["poly(vinyl alcohol)", "CHEMICAL", 59, 78], ["PVA", "CHEMICAL", 80, 83], ["polyethylene glycol", "SIMPLE_CHEMICAL", 30, 49], ["PEG", "SIMPLE_CHEMICAL", 51, 54], ["poly(vinyl alcohol)", "SIMPLE_CHEMICAL", 59, 78], ["PVA", "SIMPLE_CHEMICAL", 80, 83], ["DNA", "CELLULAR_COMPONENT", 170, 173], ["rtRPA", "SIMPLE_CHEMICAL", 340, 345], ["genomic DNA targets", "DNA", 162, 181], ["rtRPA", "PROTEIN", 340, 345], ["surface coating with polyethylene glycol (PEG)", "TREATMENT", 9, 55], ["poly(vinyl alcohol) (PVA)", "TREATMENT", 59, 84], ["genomic DNA targets", "PROBLEM", 162, 181], ["manufacture monolithic microreactors", "TREATMENT", 290, 326], ["rtRPA", "TREATMENT", 340, 345]]], ["Our goal is to find a combination of 3D printing material and a post curing protocol that meets the following criteria:Introduction1.IntroductionOptically clear 2.IntroductionNon-inhibitory to RPA chemistry without the need for surface pre-treatment 3.IntroductionLow autofluorescence 4.IntroductionLow fluorescence driftIntroductionThe basic formulation of a printing resin suitable for DLP based printing contains a monomer, a photoinitiator [33] and a blocking agent that limits penetration depth during curing [34] .", [["surface", "ANATOMY", 228, 235], ["DLP", "CHEMICAL", 388, 391], ["RPA", "GENE_OR_GENE_PRODUCT", 193, 196], ["DLP", "SIMPLE_CHEMICAL", 388, 391], ["RPA", "PROTEIN", 193, 196], ["3D printing material", "TREATMENT", 37, 57], ["a post curing protocol", "TREATMENT", 62, 84], ["RPA chemistry", "TEST", 193, 206], ["surface pre-treatment", "TREATMENT", 228, 249], ["a printing resin", "TREATMENT", 358, 374], ["DLP based printing", "TREATMENT", 388, 406], ["a photoinitiator", "TREATMENT", 427, 443], ["a blocking agent", "TREATMENT", 453, 469]]], ["Any of these three components individually or in combination may be responsible for autofluorescence depending on printing and post curing conditions.", [["autofluorescence", "PROBLEM", 84, 100]]], ["First, we investigate monolithic microreactors printed from three methacrylate-based resins for autofluorescence and autofluorescence drift in dependence on post curing and storage conditions by means of a custom made heater/fluorescence detector.", [["methacrylate", "CHEMICAL", 66, 78], ["monolithic microreactors", "PROBLEM", 22, 46], ["three methacrylate-based resins", "TREATMENT", 60, 91], ["autofluorescence", "PROBLEM", 96, 112], ["autofluorescence drift in dependence", "PROBLEM", 117, 153], ["heater/fluorescence detector", "TREATMENT", 218, 246], ["monolithic microreactors", "OBSERVATION", 22, 46], ["autofluorescence drift", "OBSERVATION", 117, 139]]], ["Finally, we demonstrate highly sensitive detection of both the khe and bla NDM-1 genes by rtRPA.3D Printed Monolithic MicroreactorsTo perform rtRPA, a simple to operate single-use microfluidic device was developed (see Figure 1 ) and manufactured by DLP 3D printing.", [["khe", "GENE_OR_GENE_PRODUCT", 63, 66], ["bla", "GENE_OR_GENE_PRODUCT", 71, 74], ["NDM-1", "GENE_OR_GENE_PRODUCT", 75, 80], ["rtRPA", "GENE_OR_GENE_PRODUCT", 90, 95], ["khe and bla NDM-1 genes", "DNA", 63, 86], ["rtRPA", "DNA", 90, 95], ["rtRPA", "PROTEIN", 142, 147], ["bla NDM-1", "SPECIES", 71, 80], ["3D Printed Monolithic MicroreactorsTo perform rtRPA", "TREATMENT", 96, 147], ["microfluidic device", "TREATMENT", 180, 199]]], ["This approach allows the device to be manufactured in a single piece obviating the need to first manufacture a half shell that is subsequently sealed.", [["the device", "TREATMENT", 21, 31], ["a single piece", "TREATMENT", 54, 68], ["a half shell", "TREATMENT", 109, 121], ["sealed", "OBSERVATION_MODIFIER", 143, 149]]], ["The main component is a buried microreactor (diameter: 3 mm, height: 0.8 mm) connected to two ports for filling/emptying (diameter: 0.8 mm, height: 0.8 mm) by micropipette.", [["height", "TEST", 61, 67], ["filling/emptying", "TEST", 104, 120], ["height", "TEST", 140, 146], ["main", "OBSERVATION_MODIFIER", 4, 8], ["component", "OBSERVATION_MODIFIER", 9, 18], ["buried", "OBSERVATION_MODIFIER", 24, 30], ["microreactor", "OBSERVATION_MODIFIER", 31, 43], ["diameter", "OBSERVATION_MODIFIER", 45, 53], ["3 mm", "OBSERVATION_MODIFIER", 55, 59], ["ports", "OBSERVATION_MODIFIER", 94, 99], ["emptying", "OBSERVATION_MODIFIER", 112, 120], ["diameter", "OBSERVATION_MODIFIER", 122, 130], ["0.8 mm", "OBSERVATION_MODIFIER", 132, 138]]], ["The total volume is about 12 \u00b5L.", [["The total volume", "TEST", 0, 16], ["total", "OBSERVATION_MODIFIER", 4, 9], ["volume", "OBSERVATION_MODIFIER", 10, 16]]], ["The overall dimensions of the device are 38 mm \u00d7 10 mm \u00d7 1.7 mm.", [["the device", "TREATMENT", 26, 36], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["dimensions", "OBSERVATION_MODIFIER", 12, 22], ["device", "ANATOMY_MODIFIER", 30, 36], ["38 mm", "OBSERVATION_MODIFIER", 41, 46]]], ["The thickness of the top lid covering the microreactor is 200 \u00b5m (see cross-section in Figure 2 ).", [["The thickness of the top lid", "TREATMENT", 0, 28], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["top", "OBSERVATION_MODIFIER", 21, 24], ["lid", "OBSERVATION_MODIFIER", 25, 28], ["microreactor", "OBSERVATION_MODIFIER", 42, 54], ["200 \u00b5m", "OBSERVATION_MODIFIER", 58, 64]]], ["Devices were designed by computer aided design (CAD) (SolidWorks, Dassault Syst\u00e8mes, V\u00e9lizy-Villacoublay, France) and subsequently exported to a 3D printing pre-processor/slicer (NetFabb, Autodesk, San Rafael, CA, USA).", [["CAD", "PROBLEM", 48, 51]]], ["Here, support structures were added and slicing was performed at a layer thickness of 100 \u00b5m using settings specific to each of the tested printing materials (see Table 1 ).", [["settings", "TREATMENT", 99, 107]]], ["3D printing was then carried out on a SolFlex SF350 (Way2Production, Vienna, Austria) DLP printer using the PowerVat printing bed.3D Printed Monolithic MicroreactorsAfter printing, remaining liquid printing material was let to drip back into the printing bed for at least 15 min.", [["DLP printer", "TREATMENT", 86, 97], ["the PowerVat printing bed", "TREATMENT", 104, 129], ["3D Printed Monolithic MicroreactorsAfter printing", "TREATMENT", 130, 179], ["remaining liquid printing material", "TREATMENT", 181, 215], ["Monolithic MicroreactorsAfter", "OBSERVATION", 141, 170]]], ["The parts were then removed from the printing platform and sonicated for 15 min in isopropyl alcohol (IPA) to remove remaining liquid material sticking to the surfaces.", [["isopropyl alcohol", "CHEMICAL", 83, 100], ["IPA", "CHEMICAL", 102, 105], ["isopropyl alcohol", "CHEMICAL", 83, 100], ["IPA", "CHEMICAL", 102, 105], ["isopropyl alcohol", "SIMPLE_CHEMICAL", 83, 100], ["IPA", "SIMPLE_CHEMICAL", 102, 105], ["isopropyl alcohol (IPA", "TREATMENT", 83, 105], ["remaining liquid material", "TREATMENT", 117, 142], ["liquid material sticking", "OBSERVATION", 127, 151]]], ["The microreactors were then thoroughly flushed with IPA using a wash bottle.", [["IPA", "CHEMICAL", 52, 55], ["The microreactors", "TREATMENT", 0, 17], ["IPA", "TREATMENT", 52, 55], ["a wash bottle", "TREATMENT", 62, 75]]], ["Subsequently, the devices were carefully dried by compressed air and incubated at 40 \u2022 C for at least one hour to evaporate the remaining IPA.", [["IPA", "CHEMICAL", 138, 141], ["the devices", "TREATMENT", 14, 25], ["air", "OBSERVATION", 61, 64]]], ["Finally, post curing was carried out according to the protocols detailed in the following section.Post CuringPost curing was performed by placing cleaned and air-dried parts into the FormCure (Formlabs, USA) post curing instrument.", [["CuringPost curing", "TREATMENT", 103, 120], ["air-dried parts", "TREATMENT", 158, 173]]], ["The FormCure uses high power LEDs at a center wavelength of 405 nm to illuminate parts placed on a central turntable and maintains a preset curing temperature from ambient temperature up to 80 \u00b0C. After curing, parts were stored protected from light at ambient conditions.", [["high power LEDs", "TREATMENT", 18, 33], ["ambient temperature", "TEST", 164, 183]]], ["Table 2 lists the details of the post curing protocols used in this work.Post CuringTo perform fluorescence measurements, the microreactors were placed in the mTFR instrument (see Figure 3 ) and allowed to equilibrate to 39 \u00b0C. Then, measurements were taken each second for a total duration of 60 s.", [["the post curing protocols", "TREATMENT", 29, 54], ["fluorescence measurements", "TEST", 95, 120], ["the microreactors", "TREATMENT", 122, 139]]], ["For absolute fluorescence measurements, the first value of each time-series was used whereas drift values were calculated by taking the difference between the first and last measurements.Post CuringPost curing was performed by placing cleaned and air-dried parts into the FormCure (Formlabs, USA) post curing instrument.", [["absolute fluorescence measurements", "TEST", 4, 38], ["drift values", "PROBLEM", 93, 105], ["CuringPost curing", "TREATMENT", 192, 209], ["air-dried parts", "TREATMENT", 247, 262]]], ["The FormCure uses high power LEDs at a center wavelength of 405 nm to illuminate parts placed on a central turntable and maintains a preset curing temperature from ambient temperature up to 80 \u00b0C. After curing, parts were stored protected from light at ambient conditions.", [["high power LEDs", "TREATMENT", 18, 33], ["ambient temperature", "TEST", 164, 183]]], ["Table 2 lists the details of the post curing protocols used in this work.Post CuringTo perform fluorescence measurements, the microreactors were placed in the mTFR instrument (see Figure 3 ) and allowed to equilibrate to 39 \u00b0C. Then, measurements were taken each second for a total duration of 60 s.", [["the post curing protocols", "TREATMENT", 29, 54], ["fluorescence measurements", "TEST", 95, 120], ["the microreactors", "TREATMENT", 122, 139]]], ["For absolute fluorescence measurements, the first value of each time-series was used whereas drift values were calculated by taking the difference between the first and last measurements.Post CuringPost curing was performed by placing cleaned and air-dried parts into the FormCure (Formlabs, USA) post curing instrument.", [["absolute fluorescence measurements", "TEST", 4, 38], ["drift values", "PROBLEM", 93, 105], ["CuringPost curing", "TREATMENT", 192, 209], ["air-dried parts", "TREATMENT", 247, 262]]], ["The FormCure uses high power LEDs at a center wavelength of 405 nm to illuminate parts placed on a central turntable and maintains a preset curing temperature from ambient temperature up to 80 \u2022 C. After curing, parts were stored protected from light at ambient conditions.", [["high power LEDs", "TREATMENT", 18, 33], ["ambient temperature", "TEST", 164, 183]]], ["Table 2 lists the details of the post curing protocols used in this work.Post CuringTo perform fluorescence measurements, the microreactors were placed in the mTFR instrument (see Figure 3 ) and allowed to equilibrate to 39 \u2022 C. Then, measurements were taken each second for a total duration of 60 s.", [["the post curing protocols", "TREATMENT", 29, 54], ["fluorescence measurements", "TEST", 95, 120], ["the microreactors", "TREATMENT", 122, 139]]], ["For absolute fluorescence measurements, the first value of each time-series was used whereas drift values were calculated by taking the difference between the first and last measurements.", [["absolute fluorescence measurements", "TEST", 4, 38], ["drift values", "PROBLEM", 93, 105]]], ["Details of the three post curing protocols used for this work.Protocol Illumination (min) TemperatureUncured --Mobile Temperature-Controlled Fluorescence Reader (mTFR) InstrumentA combined fluorescence detector/heater instrument (see Figure 3 ) was developed to perform rtRPA.", [["rtRPA", "PROTEIN", 270, 275], ["curing protocols", "TREATMENT", 26, 42], ["Mobile Temperature", "TEST", 111, 129], ["Fluorescence Reader (mTFR)", "TREATMENT", 141, 167], ["InstrumentA combined fluorescence detector/heater instrument", "TREATMENT", 168, 228]]], ["Heating resistors are used for precise temperature control of the 3D printed microfluidic device while fluorescence is measured by a compact epi-fluorescence detector.", [["Heating resistors", "TREATMENT", 0, 17], ["precise temperature control", "TREATMENT", 31, 58], ["the 3D printed microfluidic device", "TREATMENT", 62, 96]]], ["The overall dimensions of the instrument are 170 mm \u00d7 82 mm \u00d7 200 mm.Mobile Temperature-Controlled Fluorescence Reader (mTFR) InstrumentRPA reaction temperature is maintained by closed-loop proportional-integral-derivative (PID) control.", [["Mobile Temperature", "TEST", 69, 87], ["Fluorescence Reader (mTFR)", "TREATMENT", 99, 125], ["InstrumentRPA reaction temperature", "PROBLEM", 126, 160], ["integral-derivative (PID) control", "TREATMENT", 203, 236], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["dimensions", "OBSERVATION_MODIFIER", 12, 22], ["instrument", "OBSERVATION_MODIFIER", 30, 40], ["170 mm", "OBSERVATION_MODIFIER", 45, 51]]], ["The control loop consists of a CAL 3200 PID temperature controller (CAL Controls, Hertfordshire, UK) that drives four heating resistors as well as a PT-100 temperature sensor.", [["a CAL 3200 PID temperature controller", "TREATMENT", 29, 66], ["four heating resistors", "TREATMENT", 113, 135], ["a PT", "TEST", 147, 151]]], ["The heating resistors are wired in series and are attached to an aluminum plate that is in contact with the microfluidic device during operation.", [["aluminum", "CHEMICAL", 65, 73], ["aluminum", "CHEMICAL", 65, 73], ["The heating resistors", "TREATMENT", 0, 21], ["an aluminum plate", "TREATMENT", 62, 79], ["the microfluidic device during operation", "TREATMENT", 104, 144], ["aluminum plate", "OBSERVATION", 65, 79], ["microfluidic device", "OBSERVATION", 108, 127]]], ["PID parameters were found by the controller's automatic tuning function.", [["PID parameters", "TEST", 0, 14]]], ["Incubation temperature is continuously displayed and easily set by front panel controls.Mobile Temperature-Controlled Fluorescence Reader (mTFR) InstrumentMicromachines 2020, 11, x 5 of 18Mobile Temperature-Controlled Fluorescence Reader (mTFR) InstrumentA combined fluorescence detector/heater instrument (see Figure 3 ) was developed to perform rtRPA.", [["rtRPA", "PROTEIN", 347, 352], ["Incubation temperature", "TEST", 0, 22], ["Fluorescence Reader (mTFR)", "TREATMENT", 118, 144], ["Fluorescence Reader (mTFR)", "TREATMENT", 218, 244], ["InstrumentA combined fluorescence detector/heater instrument", "TREATMENT", 245, 305]]], ["Heating resistors are used for precise temperature control of the 3D printed microfluidic device while fluorescence is measured by a compact epi-fluorescence detector.", [["Heating resistors", "TREATMENT", 0, 17], ["precise temperature control", "TREATMENT", 31, 58], ["the 3D printed microfluidic device", "TREATMENT", 62, 96]]], ["The overall dimensions of the instrument are 170 mm \u00d7 82 mm \u00d7 200 mm.Mobile Temperature-Controlled Fluorescence Reader (mTFR) InstrumentRPA reaction temperature is maintained by closed-loop proportional-integral-derivative (PID) control.", [["Mobile Temperature", "TEST", 69, 87], ["Fluorescence Reader (mTFR)", "TREATMENT", 99, 125], ["InstrumentRPA reaction temperature", "PROBLEM", 126, 160], ["integral-derivative (PID) control", "TREATMENT", 203, 236], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["dimensions", "OBSERVATION_MODIFIER", 12, 22], ["instrument", "OBSERVATION_MODIFIER", 30, 40], ["170 mm", "OBSERVATION_MODIFIER", 45, 51]]], ["The control loop consists of a CAL 3200 PID temperature controller (CAL Controls, Hertfordshire, UK) that drives four heating resistors as well as a PT-100 temperature sensor.", [["a CAL 3200 PID temperature controller", "TREATMENT", 29, 66], ["four heating resistors", "TREATMENT", 113, 135], ["a PT", "TEST", 147, 151]]], ["The heating resistors are wired in series and are attached to an aluminum plate that is in contact with the microfluidic device during operation.", [["aluminum", "CHEMICAL", 65, 73], ["aluminum", "CHEMICAL", 65, 73], ["The heating resistors", "TREATMENT", 0, 21], ["an aluminum plate", "TREATMENT", 62, 79], ["the microfluidic device during operation", "TREATMENT", 104, 144], ["aluminum plate", "OBSERVATION", 65, 79], ["microfluidic device", "OBSERVATION", 108, 127]]], ["PID parameters were found by the controller's automatic tuning function.", [["PID parameters", "TEST", 0, 14]]], ["Incubation temperature is continuously displayed and easily set by front panel controls.", [["Incubation temperature", "TEST", 0, 22]]], ["The sample is located below the excitation/detection window of a highly compact epifluorescence detector (ESElog, Qiagen Lake Constance GmbH, Stockach, Germany).", [["sample", "ANATOMY", 4, 10]]], ["The detector has two excitation (E1: 470 nm, E2: 520 nm) and two detection (D1: 550 nm, D2: 600 nm) channels allowing for the simultaneous measurement of two fluorescent dyes.", [["D1", "PROTEIN", 76, 78], ["D2", "PROTEIN", 88, 90], ["the simultaneous measurement", "TEST", 122, 150], ["two fluorescent dyes", "PROBLEM", 154, 174], ["fluorescent dyes", "OBSERVATION", 158, 174]]], ["The output of the detector is directly sent to a laptop computer via RS232 for display and recording.", [["RS232", "DNA", 69, 74], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["For the detection of rtRPA reactions, the combinations of excitation channel 1 and detection channel 1 (E1D1) and excitation channel 2 with detection channel 2 (E2D2) are used in this work.Klebsiella Pneumoniae Genomic DNAA plasmid-free Klebsiella pneumoniae isolate was grown in LB media overnight at 28 \u00b0C in an orbital shaker at 180 rpm.", [["DNAA", "CHEMICAL", 219, 223], ["excitation channel 1", "GENE_OR_GENE_PRODUCT", 58, 78], ["detection channel 1", "GENE_OR_GENE_PRODUCT", 83, 102], ["excitation channel 2", "GENE_OR_GENE_PRODUCT", 114, 134], ["detection channel 2", "GENE_OR_GENE_PRODUCT", 140, 159], ["Klebsiella Pneumoniae", "ORGANISM", 189, 210], ["DNAA plasmid-free Klebsiella pneumoniae", "ORGANISM", 219, 258], ["rtRPA", "PROTEIN", 21, 26], ["excitation channel 1", "PROTEIN", 58, 78], ["detection channel 1", "PROTEIN", 83, 102], ["E1D1", "PROTEIN", 104, 108], ["excitation channel 2", "PROTEIN", 114, 134], ["detection channel 2", "PROTEIN", 140, 159], ["E2D2", "PROTEIN", 161, 165], ["Klebsiella Pneumoniae", "SPECIES", 189, 210], ["Klebsiella pneumoniae", "SPECIES", 237, 258], ["Klebsiella Pneumoniae", "SPECIES", 189, 210], ["Klebsiella pneumoniae", "SPECIES", 237, 258], ["rtRPA reactions", "PROBLEM", 21, 36], ["excitation channel", "TREATMENT", 58, 76], ["excitation channel", "TREATMENT", 114, 132], ["detection channel 2 (E2D2)", "TREATMENT", 140, 166], ["Klebsiella Pneumoniae", "PROBLEM", 189, 210], ["Genomic DNAA plasmid", "TEST", 211, 231], ["free Klebsiella pneumoniae isolate", "PROBLEM", 232, 266], ["Pneumoniae", "OBSERVATION", 200, 210], ["DNAA plasmid", "OBSERVATION", 219, 231], ["free", "OBSERVATION_MODIFIER", 232, 236], ["Klebsiella pneumoniae", "OBSERVATION", 237, 258], ["orbital shaker", "ANATOMY", 314, 328]]], ["Genomic DNA was isolated using the QIAmp DNA Blood Mini kit (Qiagen, The sample is located below the excitation/detection window of a highly compact epi-fluorescence detector (ESElog, Qiagen Lake Constance GmbH, Stockach, Germany).", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["Genomic DNA", "PROBLEM", 0, 11]]], ["The detector has two excitation (E1: 470 nm, E2: 520 nm) and two detection (D1: 550 nm, D2: 600 nm) channels allowing for the simultaneous measurement of two fluorescent dyes.", [["D1", "PROTEIN", 76, 78], ["D2", "PROTEIN", 88, 90], ["the simultaneous measurement", "TEST", 122, 150], ["two fluorescent dyes", "PROBLEM", 154, 174], ["fluorescent dyes", "OBSERVATION", 158, 174]]], ["The output of the detector is directly sent to a laptop computer via RS232 for display and recording.", [["RS232", "DNA", 69, 74], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["For the detection of rtRPA reactions, the combinations of excitation channel 1 and detection channel 1 (E1D1) and excitation channel 2 with detection channel 2 (E2D2) are used in this work.Klebsiella pneumoniae Genomic DNAA plasmid-free Klebsiella pneumoniae isolate was grown in LB media overnight at 28 \u2022 C in an orbital shaker at 180 rpm.", [["DNAA", "CHEMICAL", 219, 223], ["excitation channel 1", "GENE_OR_GENE_PRODUCT", 58, 78], ["detection channel 1", "GENE_OR_GENE_PRODUCT", 83, 102], ["excitation channel 2", "GENE_OR_GENE_PRODUCT", 114, 134], ["detection channel 2", "GENE_OR_GENE_PRODUCT", 140, 159], ["Klebsiella pneumoniae", "ORGANISM", 189, 210], ["DNAA plasmid-free Klebsiella pneumoniae", "ORGANISM", 219, 258], ["rtRPA", "PROTEIN", 21, 26], ["excitation channel 1", "PROTEIN", 58, 78], ["detection channel 1", "PROTEIN", 83, 102], ["E1D1", "PROTEIN", 104, 108], ["excitation channel 2", "PROTEIN", 114, 134], ["detection channel 2", "PROTEIN", 140, 159], ["E2D2", "PROTEIN", 161, 165], ["Klebsiella pneumoniae", "SPECIES", 189, 210], ["Klebsiella pneumoniae", "SPECIES", 237, 258], ["Klebsiella pneumoniae", "SPECIES", 189, 210], ["Klebsiella pneumoniae", "SPECIES", 237, 258], ["rtRPA reactions", "PROBLEM", 21, 36], ["excitation channel", "TREATMENT", 58, 76], ["excitation channel", "TREATMENT", 114, 132], ["detection channel 2 (E2D2)", "TREATMENT", 140, 166], ["Klebsiella pneumoniae", "PROBLEM", 189, 210], ["Genomic DNAA plasmid", "TEST", 211, 231], ["free Klebsiella pneumoniae isolate", "PROBLEM", 232, 266], ["pneumoniae", "OBSERVATION", 200, 210], ["DNAA plasmid", "OBSERVATION", 219, 231], ["free", "OBSERVATION_MODIFIER", 232, 236], ["Klebsiella pneumoniae", "OBSERVATION", 237, 258], ["orbital shaker", "ANATOMY", 315, 329]]], ["Genomic DNA was isolated using the QIAmp DNA Blood Mini kit (Qiagen, Hilden, Germany) and quantified by PicoGreen assay.", [["DNA", "CELLULAR_COMPONENT", 8, 11], ["Genomic DNA", "PROBLEM", 0, 11]]], ["The DNA was subsequently digested by the restriction enzyme EcoRI at 37 \u2022 C for 15 min followed by enzyme inactivation at 65 \u2022 C for 20 min.", [["DNA", "CELLULAR_COMPONENT", 4, 7], ["EcoRI", "GENE_OR_GENE_PRODUCT", 60, 65], ["restriction enzyme EcoRI", "DNA", 41, 65], ["the restriction enzyme EcoRI", "PROBLEM", 37, 65], ["enzyme inactivation", "TREATMENT", 99, 118]]], ["Finally, a dilution series from 10 6 down to 10 2 genome copies/\u00b5L was prepared.bla NDM-1 Resistance GeneA Klebsiella pneumoniae isolate carrying plasmid-encoded bla NDM-1 was acquired from the National Reference Laboratory for multidrug-resistant gram-negative bacteria for Germany (Ruhr-University Bochum) and kept on LB agar.", [["plasmid", "ANATOMY", 146, 153], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 80, 89], ["GeneA Klebsiella pneumoniae", "ORGANISM", 101, 128], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 162, 171], ["plasmid-encoded bla NDM-1", "DNA", 146, 171], ["Klebsiella pneumoniae", "SPECIES", 107, 128], ["Klebsiella pneumoniae", "SPECIES", 107, 128], ["bla NDM-1", "SPECIES", 162, 171], ["a dilution series", "TEST", 9, 26], ["bla NDM", "TEST", 80, 87], ["Klebsiella pneumoniae", "PROBLEM", 107, 128], ["multidrug-resistant gram-negative bacteria", "PROBLEM", 228, 270], ["Klebsiella pneumoniae", "OBSERVATION", 107, 128], ["negative bacteria", "OBSERVATION", 253, 270]]], ["For liquid culture, bacteria were grown overnight at 28 \u2022 C in an orbital shaker at 180 rpm.", [["liquid culture", "TEST", 4, 18], ["bacteria", "PROBLEM", 20, 28], ["orbital shaker", "ANATOMY", 66, 80]]], ["Plasmids were isolated from liquid culture using the QIAprep Miniprep kit (Qiagen, Hilden, Germany).", [["Plasmids", "TREATMENT", 0, 8], ["liquid culture", "TEST", 28, 42], ["the QIAprep Miniprep kit", "TREATMENT", 49, 73]]], ["The bla NDM-1 gene was then amplified by PCR with forward primer 5 -CCAATATTATGCACCCGGTCGC and reverse primer 5 -ATGCGGGCCG TATGAGTGATT.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 4, 13], ["bla NDM-1 gene", "DNA", 4, 18], ["forward primer 5", "DNA", 50, 66], ["reverse primer 5 -ATGCGGGCCG TATGAGTGATT", "DNA", 95, 135], ["The bla NDM", "TEST", 0, 11], ["forward primer", "TREATMENT", 50, 64], ["reverse primer", "TREATMENT", 95, 109], ["ATGCGGGCCG TATGAGTGATT", "TREATMENT", 113, 135]]], ["The resulting amplicon was ligated into a pCRII vector using a TA cloning kit (Invitrogen, Carlsbad, CA, USA).", [["pCRII", "GENE_OR_GENE_PRODUCT", 42, 47], ["pCRII vector", "DNA", 42, 54], ["The resulting amplicon", "TREATMENT", 0, 22], ["a pCRII vector", "TREATMENT", 40, 54], ["a TA cloning kit", "TREATMENT", 61, 77]]], ["TOP10F' chemically competent cells (Invitrogen, Carlsbad, CA, USA) were transformed with the ligation product and clones carrying the bla NDM-1 insert were selected by blue/white screening.", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 134, 143], ["TOP10F' chemically competent cells", "CELL_LINE", 0, 34], ["bla NDM-1 insert", "DNA", 134, 150], ["bla NDM-1", "SPECIES", 134, 143], ["Invitrogen", "TEST", 36, 46], ["the ligation product", "TREATMENT", 89, 109], ["blue/white screening", "TEST", 168, 188], ["competent cells", "OBSERVATION", 19, 34]]], ["Clones were grown in LB medium overnight at 37 \u2022 C in an orbital shaker at 180 rpm and plasmids were isolated using the QIAprep Miniprep kit.", [["plasmids", "ANATOMY", 87, 95], ["Clones", "CELL", 0, 6], ["Miniprep", "ORGANISM", 128, 136], ["plasmids", "DNA", 87, 95], ["plasmids", "TREATMENT", 87, 95], ["the QIAprep Miniprep kit", "TREATMENT", 116, 140], ["orbital", "ANATOMY", 57, 64]]], ["The correct sequence of the bla NDM-1 insert was confirmed by Sanger sequencing.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 28, 37], ["bla NDM-1 insert", "DNA", 28, 44], ["bla NDM-1", "SPECIES", 28, 37], ["the bla NDM", "TREATMENT", 24, 35]]], ["The final bla NDM-1 standard was then prepared by measuring plasmid concentration using the PicoGreen assay (Thermo Fisher, Waltham, MA, USA) on a NanoDrop 3300 instrument and preparation of a dilution series containing 10 6 down to 10 2 plasmid copies/\u00b5L.Reaction SetupRecombinase polymerase amplification (RPA) was performed using reagents supplied with the TwistAmp exo kit (TwistDx, Cambridge, UK).", [["plasmid", "ANATOMY", 60, 67], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 10, 19], ["UK", "GENE_OR_GENE_PRODUCT", 398, 400], ["a NanoDrop 3300 instrument", "TREATMENT", 145, 171], ["a dilution series", "TREATMENT", 191, 208], ["SetupRecombinase polymerase amplification (RPA)", "TREATMENT", 265, 312]]], ["For each singleplex (duplex) reaction, a rehydration mix consisting of 12.2 \u00b5L (11.6 \u00b5L) PCR-grade water, 29.5 \u00b5L (29.5 \u00b5L) rehydration buffer, 2.1 \u00b5L (1.05 \u00b5L) of each primer, and 0.6 \u00b5L (0.6 \u00b5L) exo probe (10 \u00b5M stocks) was prepared and used to rehydrate a freeze-dried reaction pellet.", [["each singleplex (duplex)", "TREATMENT", 4, 28], ["a rehydration mix", "TREATMENT", 39, 56], ["PCR", "TEST", 89, 92], ["rehydration buffer", "TREATMENT", 124, 142]]], ["Template DNA (1 \u00b5L) was then added to each reaction and 2.5 \u00b5L of a 280 mM magnesium acetate (Mg(OAc) 2 ) solution was pipetted into the lid of each tube.", [["magnesium acetate", "CHEMICAL", 75, 92], ["Mg", "CHEMICAL", 94, 96], ["magnesium acetate", "CHEMICAL", 75, 92], ["Mg(OAc) 2", "CHEMICAL", 94, 103], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["magnesium acetate", "SIMPLE_CHEMICAL", 75, 92], ["Mg(OAc) 2", "SIMPLE_CHEMICAL", 94, 103], ["tube", "TISSUE", 149, 153], ["Template DNA", "TEST", 0, 12], ["a 280 mM magnesium acetate (Mg(OAc)", "TREATMENT", 66, 101], ["tube", "OBSERVATION", 149, 153]]], ["In the case of negative control reactions, the DNA template was replaced by 1 \u00b5L of PCR-grade water.", [["DNA", "CELLULAR_COMPONENT", 47, 50], ["DNA template", "DNA", 47, 59], ["negative control reactions", "PROBLEM", 15, 41], ["the DNA template", "TREATMENT", 43, 59], ["PCR", "TEST", 84, 87]]], ["To initiate the reactions, the tubes were briefly spun to add the Mg(OAc) 2 solution to the reaction mix.", [["Mg", "CHEMICAL", 66, 68], ["OAc", "CHEMICAL", 69, 72], ["Mg(OAc) 2", "CHEMICAL", 66, 75], ["Mg(OAc) 2", "SIMPLE_CHEMICAL", 66, 75], ["the reactions", "TREATMENT", 12, 25], ["the tubes", "TREATMENT", 27, 36], ["the Mg(OAc)", "TREATMENT", 62, 73], ["the reaction mix", "TREATMENT", 88, 104]]], ["The tubes were then vortexed and spun again to collect the reagents at the bottom.", [["tubes", "ANATOMY", 4, 9], ["tubes", "ORGANISM_SUBSTANCE", 4, 9], ["The tubes", "TREATMENT", 0, 9], ["the reagents", "TREATMENT", 55, 67], ["tubes", "OBSERVATION", 4, 9], ["bottom", "ANATOMY_MODIFIER", 75, 81]]], ["The activated reaction mix was quickly distributed to new tubes and the 3D printed microreactor according to the scheme detailed in Figure 4 and immediately placed into an ESEQuant (Qiagen Lake Constance GmbH, Stockach, Germany) isothermal fluorescence reader for the tubes and the mTFR instrument for the 3D printed microreactor.", [["The activated reaction mix", "PROBLEM", 0, 26], ["new tubes", "TREATMENT", 54, 63], ["the 3D printed microreactor", "TREATMENT", 68, 95], ["the tubes", "TREATMENT", 264, 273], ["the mTFR instrument", "TREATMENT", 278, 297], ["the 3D printed microreactor", "TREATMENT", 302, 329], ["reaction mix", "OBSERVATION", 14, 26], ["new", "OBSERVATION_MODIFIER", 54, 57], ["tubes", "OBSERVATION", 58, 63]]], ["Since mixing of the RPA reaction a few minutes after the reaction has been initiated has been shown to improve amplification performance, we divide the control reaction into one that is mixed and one that is not mixed for comparison to the microreactor.", [["RPA", "PROTEIN", 20, 23], ["the RPA reaction", "PROBLEM", 16, 32], ["the reaction", "PROBLEM", 53, 65], ["mixed", "OBSERVATION_MODIFIER", 186, 191]]], ["For reactions that are mixed, tubes are removed from the ESEQuant device at the times indicated in Figure 4 vortexed for a few seconds, spun down in a tabletop centrifuge and immediately placed back into the ESEQuant.", [["tubes", "TISSUE", 30, 35], ["reactions", "PROBLEM", 4, 13], ["tubes", "TREATMENT", 30, 35], ["the ESEQuant device", "TREATMENT", 53, 72], ["a tabletop centrifuge", "TREATMENT", 149, 170], ["mixed", "OBSERVATION_MODIFIER", 23, 28], ["tubes", "OBSERVATION", 30, 35]]], ["For positive control reactions, a rehydration mix (47.5 \u00b5 L) consisting of 29.5 \u00b5 L rehydration buffer, 10 \u00b5 L of a 1/10 dilution of positive control DNA, and 8 \u00b5 L positive control primer/probe mix was used to rehydrate a freeze-dried reagent pellet.", [["DNA", "CELLULAR_COMPONENT", 150, 153], ["positive control reactions", "PROBLEM", 4, 30], ["a rehydration mix", "TREATMENT", 32, 49], ["29.5 \u00b5 L rehydration buffer", "TREATMENT", 75, 102], ["positive control DNA", "TREATMENT", 133, 153], ["8 \u00b5 L positive control primer/probe mix", "TREATMENT", 159, 198], ["a freeze-dried reagent pellet", "TREATMENT", 221, 250]]], ["The rehydrated reaction mix was then used as detailed previously with the exception that no control reaction with mixing was performed.RPA Primers and exo ProbesAfter initial tests with a previously published rtRPA assay [14] targeting khe [35] (AF293352) yielded unsatisfactory results in our hands, we constructed a new assay using the primedRPA [36] primer/probe design software.", [["RPA", "GENE_OR_GENE_PRODUCT", 135, 138], ["khe [35]", "SIMPLE_CHEMICAL", 236, 244], ["AF293352", "SIMPLE_CHEMICAL", 246, 254], ["primedRPA [36] primer", "DNA", 338, 359], ["The rehydrated reaction mix", "TREATMENT", 0, 27], ["control reaction", "PROBLEM", 92, 108], ["RPA Primers", "TEST", 135, 146], ["initial tests", "TEST", 167, 180], ["a previously published rtRPA assay", "TEST", 186, 220], ["targeting khe", "TEST", 226, 239], ["the primedRPA [36] primer/probe design software", "TREATMENT", 334, 381], ["reaction mix", "OBSERVATION", 15, 27]]], ["Both primers, as well as the exo probe, were checked for specificity by BLAST alignment against representative Enterobacteriaceae genomes.", [["exo probe", "DNA", 29, 38], ["Enterobacteriaceae genomes", "DNA", 111, 137], ["the exo probe", "TEST", 25, 38], ["BLAST alignment", "TEST", 72, 87], ["representative Enterobacteriaceae genomes", "PROBLEM", 96, 137], ["Enterobacteriaceae genomes", "OBSERVATION", 111, 137]]], ["A further primer screen was also carried out with additional manually designed primer pairs, however, none gave a better performance than the pair generated by primedRPA (data not shown).", [["primer pairs", "DNA", 79, 91], ["primedRPA", "PROTEIN", 160, 169], ["A further primer screen", "TEST", 0, 23]]], ["The khe exo probe is labeled with FAM and detected in channel E1D1.RPA Primers and exo ProbesThe rtRPA assay targeting blaNDM-1 (NC_023908.1, region 107945\u2026108861) was constructed by manual selection of suitable priming and probe regions according to the manufacturer's suggestions [37] and selectivity was checked by BLAST alignment to representative sequences.", [["FAM", "CHEMICAL", 34, 37], ["FAM", "CHEMICAL", 34, 37], ["FAM", "SIMPLE_CHEMICAL", 34, 37], ["RPA", "GENE_OR_GENE_PRODUCT", 67, 70], ["exo Probes", "GENE_OR_GENE_PRODUCT", 83, 93], ["blaNDM-1", "GENE_OR_GENE_PRODUCT", 119, 127], ["khe exo probe", "DNA", 4, 17], ["channel E1D1", "PROTEIN", 54, 66], ["RPA Primers", "DNA", 67, 78], ["rtRPA", "PROTEIN", 97, 102], ["blaNDM-1", "DNA", 119, 127], ["NC_023908.1", "DNA", 129, 140], ["probe regions", "DNA", 224, 237], ["The khe exo probe", "TREATMENT", 0, 17], ["RPA Primers", "TEST", 67, 78], ["exo Probes", "TEST", 83, 93], ["The rtRPA assay", "TEST", 93, 108], ["blaNDM", "TEST", 119, 125]]], ["A primer screen was then carried out to select the primer pair with the best amplification performance and lowest limit of detection.", [["primer pair", "DNA", 51, 62], ["A primer screen", "TEST", 0, 15]]], ["Assay specificity was then confirmed by a negative panel containing DNA extracts from 27 bacterial and fungal species as well as human DNA.", [["extracts", "ANATOMY", 72, 80], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["extracts", "ORGANISM_SUBSTANCE", 72, 80], ["human", "ORGANISM", 129, 134], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["human DNA", "DNA", 129, 138], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["Assay specificity", "TEST", 0, 17], ["DNA extracts", "TEST", 68, 80], ["27 bacterial and fungal species", "PROBLEM", 86, 117], ["human DNA", "PROBLEM", 129, 138], ["27 bacterial", "OBSERVATION_MODIFIER", 86, 98], ["fungal species", "OBSERVATION", 103, 117]]], ["Further details on the development of For positive control reactions, a rehydration mix (47.5 \u00b5L) consisting of 29.5 \u00b5L rehydration buffer, 10 \u00b5L of a 1/10 dilution of positive control DNA, and 8 \u00b5L positive control primer/probe mix was used to rehydrate a freeze-dried reagent pellet.", [["DNA", "CELLULAR_COMPONENT", 185, 188], ["positive control reactions", "PROBLEM", 42, 68], ["a rehydration mix", "TREATMENT", 70, 87], ["29.5 \u00b5L rehydration buffer", "TREATMENT", 112, 138], ["positive control DNA", "TREATMENT", 168, 188], ["8 \u00b5L positive control primer/probe mix", "TREATMENT", 194, 232], ["a freeze-dried reagent pellet", "TREATMENT", 255, 284]]], ["The rehydrated reaction mix was then used as detailed previously with the exception that no control reaction with mixing was performed.RPA Primers and exo ProbesAfter initial tests with a previously published rtRPA assay [14] targeting khe [35] (AF293352) yielded unsatisfactory results in our hands, we constructed a new assay using the primedRPA [36] primer/probe design software.", [["RPA", "GENE_OR_GENE_PRODUCT", 135, 138], ["khe [35]", "SIMPLE_CHEMICAL", 236, 244], ["AF293352", "SIMPLE_CHEMICAL", 246, 254], ["primedRPA [36] primer", "DNA", 338, 359], ["The rehydrated reaction mix", "TREATMENT", 0, 27], ["control reaction", "PROBLEM", 92, 108], ["RPA Primers", "TEST", 135, 146], ["initial tests", "TEST", 167, 180], ["a previously published rtRPA assay", "TEST", 186, 220], ["targeting khe", "TEST", 226, 239], ["the primedRPA [36] primer/probe design software", "TREATMENT", 334, 381], ["reaction mix", "OBSERVATION", 15, 27]]], ["Both primers, as well as the exo probe, were checked for specificity by BLAST alignment against representative Enterobacteriaceae genomes.", [["exo probe", "DNA", 29, 38], ["Enterobacteriaceae genomes", "DNA", 111, 137], ["the exo probe", "TEST", 25, 38], ["BLAST alignment", "TEST", 72, 87], ["representative Enterobacteriaceae genomes", "PROBLEM", 96, 137], ["Enterobacteriaceae genomes", "OBSERVATION", 111, 137]]], ["A further primer screen was also carried out with additional manually designed primer pairs, however, none gave a better performance than the pair generated by primedRPA (data not shown).", [["primer pairs", "DNA", 79, 91], ["primedRPA", "PROTEIN", 160, 169], ["A further primer screen", "TEST", 0, 23]]], ["The khe exo probe is labeled with FAM and detected in channel E1D1.RPA Primers and exo ProbesThe rtRPA assay targeting bla NDM-1 (NC_023908.1, region 107945 . . .", [["FAM", "CHEMICAL", 34, 37], ["FAM", "CHEMICAL", 34, 37], ["FAM", "SIMPLE_CHEMICAL", 34, 37], ["RPA", "GENE_OR_GENE_PRODUCT", 67, 70], ["exo Probes", "GENE_OR_GENE_PRODUCT", 83, 93], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 119, 128], ["khe exo probe", "DNA", 4, 17], ["channel E1D1", "PROTEIN", 54, 66], ["RPA Primers", "DNA", 67, 78], ["bla NDM-1", "DNA", 119, 128], ["NC_023908.1", "DNA", 130, 141], ["bla NDM-1", "SPECIES", 119, 128], ["The khe exo probe", "TREATMENT", 0, 17], ["RPA Primers", "TEST", 67, 78], ["exo Probes", "TEST", 83, 93], ["The rtRPA assay", "TEST", 93, 108], ["bla NDM", "TEST", 119, 126]]], ["108861) was constructed by manual selection of suitable priming and probe regions according to the manufacturer's suggestions [37] and selectivity was checked by BLAST alignment to representative sequences.", [["108861", "CHEMICAL", 0, 6], ["probe regions", "DNA", 68, 81], ["suitable priming and probe regions", "TREATMENT", 47, 81]]], ["A primer screen was then carried out to select the primer pair with the best amplification performance and lowest limit of detection.", [["primer pair", "DNA", 51, 62], ["A primer screen", "TEST", 0, 15]]], ["Assay specificity was then confirmed by a negative panel containing DNA extracts from 27 bacterial and fungal species as well as human DNA.", [["extracts", "ANATOMY", 72, 80], ["DNA", "CELLULAR_COMPONENT", 68, 71], ["extracts", "ORGANISM_SUBSTANCE", 72, 80], ["human", "ORGANISM", 129, 134], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["human DNA", "DNA", 129, 138], ["human", "SPECIES", 129, 134], ["human", "SPECIES", 129, 134], ["Assay specificity", "TEST", 0, 17], ["DNA extracts", "TEST", 68, 80], ["27 bacterial and fungal species", "PROBLEM", 86, 117], ["human DNA", "PROBLEM", 129, 138], ["27 bacterial", "OBSERVATION_MODIFIER", 86, 98], ["fungal species", "OBSERVATION", 103, 117]]], ["The bla NDM-1 exo probe is labeled with LightCycler Red 610 (LC610) and detected in channel E2D2.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 4, 13], ["LightCycler Red 610", "GENE_OR_GENE_PRODUCT", 40, 59], ["bla NDM-1 exo probe", "DNA", 4, 23], ["LC610", "PROTEIN", 61, 66], ["channel E2D2", "PROTEIN", 84, 96], ["The bla NDM", "TEST", 0, 11], ["LightCycler Red", "TEST", 40, 55]]], ["Table 3 gives an overview of the rtRPA primers and probes used in this work.Fluorescence Data ProcessingFor rtRPA measurements, raw fluorescence data was background corrected by first finding the lowest value of each time-series which was then subtracted from all data points in the same time series.", [["rtRPA primers", "DNA", 33, 46], ["the rtRPA primers", "TREATMENT", 29, 46], ["rtRPA measurements", "TEST", 108, 126], ["raw fluorescence data", "TEST", 128, 149]]], ["All nonzero data points taken before the lowest value were then set to zero to establish a stable baseline.", [["stable", "OBSERVATION_MODIFIER", 91, 97]]], ["This background corrected data was then fitted to either a four-(l4) or five-parameter (l5) logarithmic model using the R language qpcR package [38] .", [["l5", "ANATOMY", 88, 90]]], ["Thresholds were obtained by first calculating the mean and standard deviation (stdev) of each no template control (NTC) reaction from 560 s to 1000 s and then defined as mean + four standard deviations.", [["Thresholds", "TEST", 0, 10], ["template control (NTC) reaction", "PROBLEM", 97, 128], ["four", "OBSERVATION_MODIFIER", 177, 181], ["standard deviations", "OBSERVATION", 182, 201]]], ["In case of multiple NTC reactions, the highest value was chosen.", [["multiple NTC reactions", "PROBLEM", 11, 33], ["the highest value", "TEST", 35, 52], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["NTC", "OBSERVATION", 20, 23]]], ["Figures 5 and 6 show the autofluorescence and fluorescence drift measured for increasing curing durations at room temperature and 60 \u2022 C. It can be observed that both parameters are highly dependent on both the printing material and curing temperature as well as excitation/detection wavelength with higher wavelengths displaying lower variation in fluorescence.Influence of Post Curing on AutofluorescenceMicromachines 2020, 11, x 8 of 18Fluorescence Data ProcessingFor rtRPA measurements, raw fluorescence data was background corrected by first finding the lowest value of each time-series which was then subtracted from all data points in the same time series.", [["Figures", "TEST", 0, 7], ["the autofluorescence", "TEST", 21, 41], ["fluorescence drift", "TEST", 46, 64], ["excitation/detection wavelength", "TREATMENT", 263, 294], ["higher wavelengths", "PROBLEM", 300, 318], ["lower variation in fluorescence", "PROBLEM", 330, 361], ["AutofluorescenceMicromachines", "TEST", 390, 419], ["rtRPA measurements", "TEST", 471, 489], ["raw fluorescence data", "TEST", 491, 512], ["lower variation", "OBSERVATION", 330, 345]]], ["All nonzero data points taken before the lowest value were then set to zero to establish a stable baseline.", [["stable", "OBSERVATION_MODIFIER", 91, 97]]], ["This background corrected data was then fitted to either a four-(l4) or five-parameter (l5) logarithmic model using the R language qpcR package [38] .", [["l5", "ANATOMY", 88, 90]]], ["Thresholds were obtained by first calculating the mean and standard deviation (stdev) of each no template control (NTC) reaction from 560 s to 1000 s and then defined as mean + four standard deviations.", [["Thresholds", "TEST", 0, 10], ["template control (NTC) reaction", "PROBLEM", 97, 128], ["four", "OBSERVATION_MODIFIER", 177, 181], ["standard deviations", "OBSERVATION", 182, 201]]], ["In case of multiple NTC reactions, the highest value was chosen.", [["multiple NTC reactions", "PROBLEM", 11, 33], ["the highest value", "TEST", 35, 52], ["multiple", "OBSERVATION_MODIFIER", 11, 19], ["NTC", "OBSERVATION", 20, 23]]], ["Figures 5 and 6 show the autofluorescence and fluorescence drift measured for increasing curing durations at room temperature and 60 \u00b0C. It can be observed that both parameters are highly dependent on both the printing material and curing temperature as well as excitation/detection wavelength with higher wavelengths displaying lower variation in fluorescence.", [["Figures", "TEST", 0, 7], ["the autofluorescence", "TEST", 21, 41], ["fluorescence drift", "TEST", 46, 64], ["excitation/detection wavelength", "TREATMENT", 262, 293], ["higher wavelengths", "PROBLEM", 299, 317], ["lower variation in fluorescence", "PROBLEM", 329, 360], ["lower variation", "OBSERVATION", 329, 344]]], ["NXSG and SFSG display a significant increase in E1D1 during prolonged curing, whereas E2D2 fluorescence increases only minimally.", [["NXSG", "CHEMICAL", 0, 4], ["NXSG", "SIMPLE_CHEMICAL", 0, 4], ["SFSG", "SIMPLE_CHEMICAL", 9, 13], ["E1D1", "GENE_OR_GENE_PRODUCT", 48, 52], ["E2D2", "SIMPLE_CHEMICAL", 86, 90], ["NXSG", "PROTEIN", 0, 4], ["SFSG", "PROTEIN", 9, 13], ["E1D1", "PROTEIN", 48, 52], ["E2D2", "PROTEIN", 86, 90], ["a significant increase in E1D1", "PROBLEM", 22, 52], ["prolonged curing", "TREATMENT", 60, 76], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["increase", "OBSERVATION_MODIFIER", 36, 44]]], ["In contrast, the background fluorescence and drift for NXOC are almost independent of curing duration in both fluorescence channels.Influence of Post Curing on AutofluorescenceCuring at 60 \u2022 C magnifies the increases in background fluorescence that were observed for curing at room temperature.", [["NXOC", "CHEMICAL", 55, 59], ["NXOC", "SIMPLE_CHEMICAL", 55, 59], ["the background fluorescence", "TEST", 13, 40], ["NXOC", "PROBLEM", 55, 59], ["AutofluorescenceCuring", "TREATMENT", 160, 182], ["background fluorescence", "PROBLEM", 220, 243]]], ["Again, NXSG and SFSG show strong correlation of rising fluorescence levels with extended curing for E1D1.", [["SFSG", "SIMPLE_CHEMICAL", 16, 20], ["E1D1", "GENE_OR_GENE_PRODUCT", 100, 104], ["NXSG", "PROTEIN", 7, 11], ["SFSG", "PROTEIN", 16, 20], ["E1D1", "PROTEIN", 100, 104], ["NXSG", "TEST", 7, 11], ["rising fluorescence levels", "PROBLEM", 48, 74]]], ["Additionally, E2D2 shows a larger increase for NXSG and a slight rise for SFSG in comparison to curing at room temperature.", [["SFSG", "CHEMICAL", 74, 78], ["E2D2", "SIMPLE_CHEMICAL", 14, 18], ["NXSG", "SIMPLE_CHEMICAL", 47, 51], ["SFSG", "SIMPLE_CHEMICAL", 74, 78], ["E2D2", "PROTEIN", 14, 18], ["NXSG", "PROTEIN", 47, 51], ["E2D2", "TEST", 14, 18], ["a larger increase for NXSG", "PROBLEM", 25, 51], ["a slight rise", "PROBLEM", 56, 69], ["SFSG", "PROBLEM", 74, 78], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["slight", "OBSERVATION_MODIFIER", 58, 64], ["rise", "OBSERVATION_MODIFIER", 65, 69]]], ["For NXOC, E1D1 fluorescence for curing at 60 \u2022 C is more variable, but no significant change is observable.", [["NXOC", "SIMPLE_CHEMICAL", 4, 8], ["E1D1", "SIMPLE_CHEMICAL", 10, 14], ["E1D1", "PROTEIN", 10, 14], ["NXOC", "PROBLEM", 4, 8], ["significant change", "PROBLEM", 74, 92], ["more variable", "OBSERVATION_MODIFIER", 52, 65], ["no", "UNCERTAINTY", 71, 73], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["change", "OBSERVATION", 86, 92]]], ["For E2D2, NXOC fluorescence is almost identical to that observed for curing at room temperature.Influence of Post Curing on AutofluorescenceIn conclusion, curing at elevated temperatures should be avoided and curing times should be kept as low as possible if low autofluorescence and fluorescence drift are desired.", [["E2D2", "SIMPLE_CHEMICAL", 4, 8], ["NXOC", "SIMPLE_CHEMICAL", 10, 14], ["E2D2", "DNA", 4, 8], ["E2D2", "TREATMENT", 4, 8], ["NXOC fluorescence", "TREATMENT", 10, 27], ["AutofluorescenceIn conclusion", "TREATMENT", 124, 153], ["elevated temperatures", "PROBLEM", 165, 186], ["low autofluorescence", "PROBLEM", 259, 279], ["fluorescence drift", "PROBLEM", 284, 302]]], ["NXOC is seen as the most suitable printing material in this regard, as it shows very low autofluorescence in both channels that is almost independent of post curing duration.Influence of Post Curing on AutofluorescenceMicromachines 2020, 11, x 9 of 18 NXSG and SFSG display a significant increase in E1D1 during prolonged curing, whereas E2D2 fluorescence increases only minimally.", [["NXOC", "CHEMICAL", 0, 4], ["NXOC", "SIMPLE_CHEMICAL", 0, 4], ["E2D2", "SIMPLE_CHEMICAL", 338, 342], ["SFSG", "PROTEIN", 261, 265], ["E1D1", "PROTEIN", 300, 304], ["E2D2", "PROTEIN", 338, 342], ["very low autofluorescence", "PROBLEM", 80, 105], ["AutofluorescenceMicromachines", "TEST", 202, 231], ["prolonged curing", "TREATMENT", 312, 328], ["very", "OBSERVATION_MODIFIER", 80, 84], ["low autofluorescence", "OBSERVATION", 85, 105], ["both channels", "OBSERVATION_MODIFIER", 109, 122], ["significant", "OBSERVATION_MODIFIER", 276, 287], ["increase", "OBSERVATION_MODIFIER", 288, 296]]], ["In contrast, the background fluorescence and drift for NXOC are almost independent of curing duration in both fluorescence channels.Influence of Post Curing on AutofluorescenceCuring at 60 \u00b0C magnifies the increases in background fluorescence that were observed for curing at room temperature.", [["NXOC", "CHEMICAL", 55, 59], ["NXOC", "SIMPLE_CHEMICAL", 55, 59], ["the background fluorescence", "TEST", 13, 40], ["NXOC", "PROBLEM", 55, 59], ["AutofluorescenceCuring", "TREATMENT", 160, 182], ["background fluorescence", "PROBLEM", 219, 242]]], ["Again, NXSG and SFSG show strong correlation of rising fluorescence levels with extended curing for E1D1.", [["SFSG", "SIMPLE_CHEMICAL", 16, 20], ["E1D1", "GENE_OR_GENE_PRODUCT", 100, 104], ["NXSG", "PROTEIN", 7, 11], ["SFSG", "PROTEIN", 16, 20], ["E1D1", "PROTEIN", 100, 104], ["NXSG", "TEST", 7, 11], ["rising fluorescence levels", "PROBLEM", 48, 74]]], ["Additionally, E2D2 shows a larger increase for NXSG and a slight rise for SFSG in comparison to curing at room temperature.", [["SFSG", "CHEMICAL", 74, 78], ["E2D2", "SIMPLE_CHEMICAL", 14, 18], ["NXSG", "SIMPLE_CHEMICAL", 47, 51], ["SFSG", "SIMPLE_CHEMICAL", 74, 78], ["E2D2", "PROTEIN", 14, 18], ["NXSG", "PROTEIN", 47, 51], ["E2D2", "TEST", 14, 18], ["a larger increase for NXSG", "PROBLEM", 25, 51], ["a slight rise", "PROBLEM", 56, 69], ["SFSG", "PROBLEM", 74, 78], ["larger", "OBSERVATION_MODIFIER", 27, 33], ["increase", "OBSERVATION_MODIFIER", 34, 42], ["slight", "OBSERVATION_MODIFIER", 58, 64], ["rise", "OBSERVATION_MODIFIER", 65, 69]]], ["For NXOC, E1D1 fluorescence for curing at 60 \u00b0C is more variable, but no significant change is observable.", [["NXOC", "SIMPLE_CHEMICAL", 4, 8], ["E1D1", "SIMPLE_CHEMICAL", 10, 14], ["E1D1", "PROTEIN", 10, 14], ["significant change", "PROBLEM", 73, 91], ["more variable", "OBSERVATION_MODIFIER", 51, 64], ["no", "UNCERTAINTY", 70, 72], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["change", "OBSERVATION", 85, 91]]], ["For E2D2, NXOC fluorescence is almost identical to that observed for curing at room temperature.Influence of Post Curing on AutofluorescenceIn conclusion, curing at elevated temperatures should be avoided and curing times should be kept as low as possible if low autofluorescence and fluorescence drift are desired.", [["E2D2", "SIMPLE_CHEMICAL", 4, 8], ["NXOC", "SIMPLE_CHEMICAL", 10, 14], ["E2D2", "DNA", 4, 8], ["E2D2", "TREATMENT", 4, 8], ["NXOC fluorescence", "TREATMENT", 10, 27], ["AutofluorescenceIn conclusion", "TREATMENT", 124, 153], ["elevated temperatures", "PROBLEM", 165, 186], ["low autofluorescence", "PROBLEM", 259, 279], ["fluorescence drift", "PROBLEM", 284, 302]]], ["NXOC is seen as the most suitable printing material in this regard, as it shows very low autofluorescence in both channels that is almost independent of post curing duration.Influence of Aging on AutofluorescenceMicroreactors were let to age at ambient laboratory conditions.", [["NXOC", "CHEMICAL", 0, 4], ["NXOC", "SIMPLE_CHEMICAL", 0, 4], ["very low autofluorescence", "PROBLEM", 80, 105], ["AutofluorescenceMicroreactors", "TREATMENT", 196, 225], ["very", "OBSERVATION_MODIFIER", 80, 84], ["low autofluorescence", "OBSERVATION", 85, 105], ["both channels", "OBSERVATION_MODIFIER", 109, 122]]], ["Fluorescence measurements were taken at the day of printing and post curing, after one and seven days and after 30 days.", [["Fluorescence measurements", "TEST", 0, 25]]], ["The results of these measurements are presented in Figure 7 .", [["these measurements", "TEST", 15, 33]]], ["Both NXSG and SFSG show strong initial E1D1 autofluorescence for post curing performed at room temperature and 60 \u00b0C which decreases (60 \u00b0C) or first increases and then decays (room temperature) with longer storage time.", [["NXSG", "CHEMICAL", 5, 9], ["NXSG", "SIMPLE_CHEMICAL", 5, 9], ["SFSG", "SIMPLE_CHEMICAL", 14, 18], ["NXSG", "PROTEIN", 5, 9], ["SFSG", "PROTEIN", 14, 18], ["E1D1", "PROTEIN", 39, 43], ["strong", "OBSERVATION_MODIFIER", 24, 30]]], ["For uncured microreactors, lower autofluorescence is observed that displays a less pronounced change over time.", [["uncured microreactors", "PROBLEM", 4, 25], ["lower autofluorescence", "PROBLEM", 27, 49], ["lower autofluorescence", "OBSERVATION", 27, 49], ["less pronounced", "OBSERVATION_MODIFIER", 78, 93], ["change", "OBSERVATION_MODIFIER", 94, 100]]], ["For E2D2, only NXSG displays high initial autofluorescence for curing at 60 \u00b0C which decays with longer storage to match that of both the uncured microreactors and those post cured at room temperature.", [["NXSG", "CHEMICAL", 15, 19], ["E2D2", "SIMPLE_CHEMICAL", 4, 8], ["NXSG", "SIMPLE_CHEMICAL", 15, 19], ["E2D2", "PROTEIN", 4, 8], ["NXSG", "PROTEIN", 15, 19], ["high initial autofluorescence", "PROBLEM", 29, 58]]], ["In contrast, NXOC does not show large variations in autofluorescence for any of the tested post curing protocols or storage durations.Influence of Aging on AutofluorescenceMicroreactors were let to age at ambient laboratory conditions.", [["NXOC", "CHEMICAL", 13, 17], ["NXOC", "SIMPLE_CHEMICAL", 13, 17], ["large variations in autofluorescence", "PROBLEM", 32, 68], ["AutofluorescenceMicroreactors", "TREATMENT", 156, 185], ["large", "OBSERVATION_MODIFIER", 32, 37], ["variations", "OBSERVATION", 38, 48]]], ["Fluorescence measurements were taken at the day of printing and post curing, after one and seven days and after 30 days.", [["Fluorescence measurements", "TEST", 0, 25]]], ["The results of these measurements are presented in Figure 7 .", [["these measurements", "TEST", 15, 33]]], ["Both NXSG and SFSG show strong initial E1D1 autofluorescence for post curing performed at room temperature and 60 \u2022 C which decreases (60 \u2022 C) or first increases and then decays (room temperature) with longer storage time.", [["NXSG", "CHEMICAL", 5, 9], ["NXSG", "SIMPLE_CHEMICAL", 5, 9], ["SFSG", "SIMPLE_CHEMICAL", 14, 18], ["NXSG", "PROTEIN", 5, 9], ["SFSG", "PROTEIN", 14, 18], ["E1D1", "PROTEIN", 39, 43], ["strong", "OBSERVATION_MODIFIER", 24, 30]]], ["For uncured microreactors, lower autofluorescence is observed that displays a less pronounced change over time.", [["uncured microreactors", "PROBLEM", 4, 25], ["lower autofluorescence", "PROBLEM", 27, 49], ["lower autofluorescence", "OBSERVATION", 27, 49], ["less pronounced", "OBSERVATION_MODIFIER", 78, 93], ["change", "OBSERVATION_MODIFIER", 94, 100]]], ["For E2D2, only NXSG displays high initial autofluorescence for curing at 60 \u2022 C which decays with longer storage to match that of both the uncured microreactors and those post cured at room temperature.", [["NXSG", "CHEMICAL", 15, 19], ["NXSG", "SIMPLE_CHEMICAL", 15, 19], ["E2D2", "PROTEIN", 4, 8], ["NXSG", "PROTEIN", 15, 19], ["high initial autofluorescence", "PROBLEM", 29, 58]]], ["In contrast, NXOC does not show large variations in autofluorescence for any of the tested post curing protocols or storage durations.Influence of 3D Printing Materials on RPA KineticsPositive control rtRPA reactions were performed in microreactors printed from NXSG, NXOC, and SFSG according to the protocol detailed in Section 2.5.1.", [["NXOC", "CHEMICAL", 13, 17], ["NXOC", "SIMPLE_CHEMICAL", 13, 17], ["NXSG", "SIMPLE_CHEMICAL", 262, 266], ["NXOC", "SIMPLE_CHEMICAL", 268, 272], ["large variations in autofluorescence", "PROBLEM", 32, 68], ["3D Printing Materials", "TREATMENT", 147, 168], ["RPA KineticsPositive control rtRPA reactions", "TREATMENT", 172, 216], ["NXOC", "TREATMENT", 268, 272], ["SFSG", "TREATMENT", 278, 282], ["large", "OBSERVATION_MODIFIER", 32, 37], ["variations", "OBSERVATION", 38, 48]]], ["Figure 8 shows a scatter plot of the time-to-positive (TTP) values versus final fluorescence 17 min (2 min reaction setup + 15 min signal acquisition) after Mg(OAc)2 addition for each tested material and post curing protocol.", [["Mg", "CHEMICAL", 157, 159], ["OAc", "CHEMICAL", 160, 163], ["Mg(OAc)2", "CHEMICAL", 157, 165], ["Figure", "TEST", 0, 6], ["a scatter plot", "TEST", 15, 29], ["final fluorescence", "TEST", 74, 92], ["Mg(OAc)", "TREATMENT", 157, 164], ["each tested material and post curing protocol", "TREATMENT", 179, 224]]], ["Also shown are the data points obtained for reference measurements in microcentrifuge tubes.Influence of 3D Printing Materials on RPA KineticsThe ideal measurement would appear in the top left of the plotting plane with a combination of a low TTP value and high final fluorescence.", [["RPA", "PROTEIN", 130, 133], ["TTP", "PROTEIN", 243, 246], ["reference measurements in microcentrifuge tubes", "TREATMENT", 44, 91], ["The ideal measurement", "TEST", 142, 163], ["a low TTP value", "PROBLEM", 237, 252], ["high final fluorescence", "PROBLEM", 257, 280], ["tubes", "OBSERVATION", 86, 91], ["left", "ANATOMY_MODIFIER", 188, 192], ["low", "OBSERVATION_MODIFIER", 239, 242], ["TTP", "OBSERVATION", 243, 246]]], ["Additionally, data points obtained from 3D printed microreactors should cluster together with data points of the microcentrifuge tube reference measurements.Influence of 3D Printing Materials on RPA KineticsFor both NXSG and SFSG, all data points are located outside and to the lower right of the tube reference cluster indicating measurement results that are of lower performance than the references.", [["tube", "TISSUE", 297, 301], ["RPA", "PROTEIN", 195, 198], ["NXSG", "DNA", 216, 220], ["SFSG", "DNA", 225, 229], ["3D printed microreactors", "TREATMENT", 40, 64], ["the microcentrifuge tube", "TREATMENT", 109, 133], ["RPA Kinetics", "TREATMENT", 195, 207], ["lower", "ANATOMY_MODIFIER", 278, 283], ["right", "ANATOMY_MODIFIER", 284, 289], ["tube", "OBSERVATION", 297, 301]]], ["Independent of the post curing protocol, almost all data points obtained for reactions performed in microreactors printed from NXOC cluster well with the reference measurements.", [["the post curing protocol", "TREATMENT", 15, 39], ["reactions", "PROBLEM", 77, 86]]], ["Of these values, those obtained after post curing for 60 min at room temperature yielded the lowest TTP values in combination with the highest final fluorescence.", [["TTP", "SIMPLE_CHEMICAL", 100, 103], ["TTP", "PROTEIN", 100, 103], ["these values", "TEST", 3, 15], ["room temperature", "TEST", 64, 80], ["the lowest TTP values", "PROBLEM", 89, 110]]], ["However, all three post curing protocols lead to comparable results for microreactors printed from NXOC, indicating that post curing may not even be necessary for this material.Influence of 3D Printing Materials on RPA KineticsPositive control rtRPA reactions were performed in microreactors printed from NXSG, NXOC, and SFSG according to the protocol detailed in Section 2.5.1.", [["NXOC", "CHEMICAL", 99, 103], ["NXOC", "SIMPLE_CHEMICAL", 99, 103], ["NXSG", "SIMPLE_CHEMICAL", 305, 309], ["NXOC", "SIMPLE_CHEMICAL", 311, 315], ["curing protocols", "TREATMENT", 24, 40], ["microreactors", "PROBLEM", 72, 85], ["3D Printing Materials", "TREATMENT", 190, 211], ["RPA KineticsPositive control rtRPA reactions", "TREATMENT", 215, 259], ["NXOC", "TREATMENT", 311, 315], ["SFSG", "TREATMENT", 321, 325]]], ["Figure 8 shows a scatter plot of the time-to-positive (TTP) values versus final fluorescence 17 min (2 min reaction setup + 15 min signal acquisition) after Mg(OAc) 2 addition for each tested material and post curing protocol.", [["Mg", "CHEMICAL", 157, 159], ["OAc", "CHEMICAL", 160, 163], ["Mg(OAc) 2", "CHEMICAL", 157, 166], ["Figure", "TEST", 0, 6], ["a scatter plot", "TEST", 15, 29], ["final fluorescence", "TEST", 74, 92], ["Mg(OAc)", "TREATMENT", 157, 164], ["each tested material and post curing protocol", "TREATMENT", 180, 225]]], ["Also shown are the data points obtained for reference measurements in microcentrifuge tubes.Influence of 3D Printing Materials on RPA KineticsThe ideal measurement would appear in the top left of the plotting plane with a combination of a low TTP value and high final fluorescence.", [["RPA", "PROTEIN", 130, 133], ["TTP", "PROTEIN", 243, 246], ["reference measurements in microcentrifuge tubes", "TREATMENT", 44, 91], ["The ideal measurement", "TEST", 142, 163], ["a low TTP value", "PROBLEM", 237, 252], ["high final fluorescence", "PROBLEM", 257, 280], ["tubes", "OBSERVATION", 86, 91], ["left", "ANATOMY_MODIFIER", 188, 192], ["low", "OBSERVATION_MODIFIER", 239, 242], ["TTP", "OBSERVATION", 243, 246]]], ["Additionally, data points obtained from 3D printed microreactors should cluster together with data points of the microcentrifuge tube reference measurements.", [["3D printed microreactors", "TREATMENT", 40, 64], ["the microcentrifuge tube", "TREATMENT", 109, 133]]], ["Figures 9 and 10 show the detection of both the khe and blaNDM-1 genes in microreactors printed from NXOC as well as reference measurements in microcentrifuge tubes with-and without mixing during amplification.Singleplex AssayFor the khe gene, (FAM, E1D1) all tested dilutions are detected by the assay performed in the microreactor.", [["blaNDM-1", "GENE_OR_GENE_PRODUCT", 56, 64], ["khe", "GENE_OR_GENE_PRODUCT", 234, 237], ["khe and blaNDM-1 genes", "DNA", 48, 70], ["microreactors", "DNA", 74, 87], ["NXOC", "DNA", 101, 105], ["khe gene", "DNA", 234, 242], ["E1D1", "DNA", 250, 254], ["Figures", "TEST", 0, 7], ["the detection", "TEST", 22, 35], ["microcentrifuge tubes", "TREATMENT", 143, 164], ["the assay", "TEST", 293, 302]]], ["Final fluorescence intensities measured for the microreactor are close to those measured for the reference assay with mixing.", [["Final fluorescence intensities", "TEST", 0, 30], ["the microreactor", "TREATMENT", 44, 60]]], ["The reference without mixing displays significantly lower final For both NXSG and SFSG, all data points are located outside and to the lower right of the tube reference cluster indicating measurement results that are of lower performance than the references.", [["tube", "TISSUE", 154, 158], ["NXSG", "DNA", 73, 77], ["lower", "ANATOMY_MODIFIER", 135, 140], ["right", "ANATOMY_MODIFIER", 141, 146], ["tube", "OBSERVATION", 154, 158]]], ["Independent of the post curing protocol, almost all data points obtained for reactions performed in microreactors printed from NXOC cluster well with the reference measurements.", [["the post curing protocol", "TREATMENT", 15, 39], ["reactions", "PROBLEM", 77, 86]]], ["Of these values, those obtained after post curing for 60 min at room temperature yielded the lowest TTP values in combination with the highest final fluorescence.", [["TTP", "SIMPLE_CHEMICAL", 100, 103], ["TTP", "PROTEIN", 100, 103], ["these values", "TEST", 3, 15], ["room temperature", "TEST", 64, 80], ["the lowest TTP values", "PROBLEM", 89, 110]]], ["However, all three post curing protocols lead to comparable results for microreactors printed from NXOC, indicating that post curing may not even be necessary for this material.Singleplex Assay3.4.", [["NXOC", "CHEMICAL", 99, 103], ["NXOC", "SIMPLE_CHEMICAL", 99, 103], ["curing protocols", "TREATMENT", 24, 40], ["microreactors", "PROBLEM", 72, 85]]], ["RPA of the khe and bla NDM-1 Genes 3.4.1.", [["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["bla NDM-1", "GENE_OR_GENE_PRODUCT", 19, 28], ["RPA", "PROTEIN", 0, 3], ["khe and bla NDM-1 Genes 3.4", "DNA", 11, 38], ["RPA", "TEST", 0, 3], ["bla NDM", "TEST", 19, 26]]], ["Singleplex Assay Figures 9 and 10 show the detection of both the khe and bla NDM-1 genes in microreactors printed from NXOC as well as reference measurements in microcentrifuge tubes with-and without mixing during amplification.Singleplex AssayFor the khe gene, (FAM, E1D1) all tested dilutions are detected by the assay performed in the microreactor.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 73, 82], ["khe", "GENE_OR_GENE_PRODUCT", 252, 255], ["khe and bla NDM-1 genes", "DNA", 65, 88], ["microreactors", "DNA", 92, 105], ["NXOC", "DNA", 119, 123], ["khe gene", "DNA", 252, 260], ["E1D1", "DNA", 268, 272], ["Singleplex Assay Figures", "TEST", 0, 24], ["the detection", "TEST", 39, 52], ["microcentrifuge tubes", "TREATMENT", 161, 182], ["the assay", "TEST", 311, 320]]], ["Final fluorescence intensities measured for the microreactor are close to those measured for the reference assay with mixing.", [["Final fluorescence intensities", "TEST", 0, 30], ["the microreactor", "TREATMENT", 44, 60]]], ["The reference without mixing displays significantly lower final fluorescence.", [["significantly lower final fluorescence", "PROBLEM", 38, 76], ["significantly", "OBSERVATION_MODIFIER", 38, 51], ["lower", "OBSERVATION_MODIFIER", 52, 57], ["final fluorescence", "OBSERVATION", 58, 76]]], ["This is an interesting result, as the reagents inside the microreactor are not mixed during amplification, indicating that mixing is of higher advantage if the assay is performed in microcentrifuge tubes.", [["the assay", "TEST", 156, 165], ["microcentrifuge tubes", "TREATMENT", 182, 203]]], ["For microfluidic applications, this finding is of importance as mixing is difficult to perform once the RPA reagents are inside a microreactor.", [["microfluidic applications", "TREATMENT", 4, 29], ["a microreactor", "TREATMENT", 128, 142]]], ["As for khe, all tested dilutions of blaNDM-1 (LC610, E2D2) are detected by the assay performed in the microreactor.", [["blaNDM-1", "GENE_OR_GENE_PRODUCT", 36, 44], ["LC610", "CELL", 46, 51], ["E2D2", "GENE_OR_GENE_PRODUCT", 53, 57], ["blaNDM", "PROTEIN", 36, 42], ["E2D2", "PROTEIN", 53, 57], ["blaNDM", "TEST", 36, 42], ["the assay", "TEST", 75, 84]]], ["In this case however, final fluorescence values measured in the microreactor are lower than those measured for the mixed reference, but higher than the reference without mixing.Singleplex AssayThese results also show that there is an advantage to performing RPA in a microfluidic setup, as almost the same assay performance is achieved without the need for mixing when compared to the results obtained for the mixed microcentrifuge tube assay.", [["RPA", "PROTEIN", 258, 261], ["final fluorescence values", "TEST", 22, 47], ["a microfluidic setup", "TREATMENT", 265, 285], ["the mixed microcentrifuge tube assay", "TREATMENT", 406, 442], ["lower", "OBSERVATION_MODIFIER", 81, 86], ["mixed", "OBSERVATION", 115, 120], ["higher", "OBSERVATION_MODIFIER", 136, 142], ["tube assay", "OBSERVATION", 432, 442]]], ["A likely explanation for the observed improved performance may be found in the flat geometry of the microreactor.", [["likely explanation for", "UNCERTAINTY", 2, 24], ["flat geometry", "OBSERVATION_MODIFIER", 79, 92]]], ["Due to the high viscosity of the RPA reagents, initial amplification occurs in discrete microscopic zones around each target molecule.", [["RPA", "GENE_OR_GENE_PRODUCT", 33, 36], ["the RPA reagents", "TREATMENT", 29, 45], ["initial amplification", "TREATMENT", 47, 68], ["high viscosity", "OBSERVATION_MODIFIER", 11, 25], ["discrete", "OBSERVATION_MODIFIER", 79, 87], ["microscopic", "OBSERVATION_MODIFIER", 88, 99], ["zones", "OBSERVATION_MODIFIER", 100, 105], ["target molecule", "OBSERVATION", 118, 133]]], ["We hypothesize that due to the chamber geometry and optical setup, more of these amplification zones are in the optical focus of the epi-fluorescence detector.", [["these amplification zones", "PROBLEM", 75, 100], ["zones", "OBSERVATION_MODIFIER", 95, 100]]], ["For the tube assay, RPA reagents have a higher distribution in the vertical axis and are less optically accessible to the fluorescence detector.", [["tube", "TISSUE", 8, 12], ["RPA", "PROTEIN", 20, 23], ["the tube assay", "TEST", 4, 18], ["RPA reagents", "TREATMENT", 20, 32], ["the fluorescence detector", "TEST", 118, 143], ["tube assay", "OBSERVATION", 8, 18], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["distribution", "OBSERVATION_MODIFIER", 47, 59], ["vertical axis", "OBSERVATION_MODIFIER", 67, 80]]], ["The ESEquant device used for the reference measurements uses an ESElog epifluorescence detector that observes microcentrifuge tubes from the bottom.", [["The ESEquant device", "TREATMENT", 0, 19], ["an ESElog epifluorescence detector", "TREATMENT", 61, 95], ["microcentrifuge tubes", "TREATMENT", 110, 131], ["microcentrifuge tubes", "OBSERVATION", 110, 131], ["bottom", "ANATOMY_MODIFIER", 141, 147]]], ["As for khe, all tested dilutions of bla NDM-1 (LC610, E2D2) are detected by the assay performed in the microreactor.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 36, 45], ["LC610", "GENE_OR_GENE_PRODUCT", 47, 52], ["E2D2", "GENE_OR_GENE_PRODUCT", 54, 58], ["bla NDM-1", "SPECIES", 36, 45], ["bla NDM", "TEST", 36, 43], ["the assay", "TEST", 76, 85]]], ["In this case however, final fluorescence values measured in the microreactor are lower than those measured for the mixed reference, but higher than the reference without mixing.Singleplex AssayThese results also show that there is an advantage to performing RPA in a microfluidic setup, as almost the same assay performance is achieved without the need for mixing when compared to the results obtained for the mixed microcentrifuge tube assay.", [["RPA", "PROTEIN", 258, 261], ["final fluorescence values", "TEST", 22, 47], ["a microfluidic setup", "TREATMENT", 265, 285], ["the mixed microcentrifuge tube assay", "TREATMENT", 406, 442], ["lower", "OBSERVATION_MODIFIER", 81, 86], ["mixed", "OBSERVATION", 115, 120], ["higher", "OBSERVATION_MODIFIER", 136, 142], ["tube assay", "OBSERVATION", 432, 442]]], ["A likely explanation for the observed improved performance may be found in the flat geometry of the microreactor.", [["likely explanation for", "UNCERTAINTY", 2, 24], ["flat geometry", "OBSERVATION_MODIFIER", 79, 92]]], ["Due to the high viscosity of the RPA reagents, initial amplification occurs in discrete microscopic zones around each target molecule.", [["RPA", "GENE_OR_GENE_PRODUCT", 33, 36], ["the RPA reagents", "TREATMENT", 29, 45], ["initial amplification", "TREATMENT", 47, 68], ["high viscosity", "OBSERVATION_MODIFIER", 11, 25], ["discrete", "OBSERVATION_MODIFIER", 79, 87], ["microscopic", "OBSERVATION_MODIFIER", 88, 99], ["zones", "OBSERVATION_MODIFIER", 100, 105], ["target molecule", "OBSERVATION", 118, 133]]], ["We hypothesize that due to the chamber geometry and optical setup, more of these amplification zones are in the optical focus of the epi-fluorescence detector.", [["these amplification zones", "PROBLEM", 75, 100], ["zones", "OBSERVATION_MODIFIER", 95, 100]]], ["For the tube assay, RPA reagents have a higher distribution in the vertical axis and are less optically accessible to the fluorescence detector.", [["tube", "TISSUE", 8, 12], ["RPA", "PROTEIN", 20, 23], ["the tube assay", "TEST", 4, 18], ["RPA reagents", "TREATMENT", 20, 32], ["the fluorescence detector", "TEST", 118, 143], ["tube assay", "OBSERVATION", 8, 18], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["distribution", "OBSERVATION_MODIFIER", 47, 59], ["vertical axis", "OBSERVATION_MODIFIER", 67, 80]]], ["The ESEquant device used for the reference measurements uses an ESElog epi-fluorescence detector that observes microcentrifuge tubes from the bottom.", [["The ESEquant device", "TREATMENT", 0, 19], ["an ESElog epi-fluorescence detector", "TREATMENT", 61, 96], ["microcentrifuge tubes", "TREATMENT", 111, 132], ["microcentrifuge tubes", "OBSERVATION", 111, 132], ["bottom", "ANATOMY_MODIFIER", 142, 148]]], ["Figures 11 and 12 show the simultaneous detection of khe and blaNDM-1 by duplex rtRPA in the 3D printed microreactor as well as the mixed and non-mixed reference reactions.", [["blaNDM-1", "GENE_OR_GENE_PRODUCT", 61, 69], ["blaNDM", "PROTEIN", 61, 67], ["duplex rtRPA", "DNA", 73, 85], ["Figures", "TEST", 0, 7], ["khe", "TEST", 53, 56], ["blaNDM", "TEST", 61, 67], ["duplex rtRPA", "TEST", 73, 85], ["the 3D printed microreactor", "TREATMENT", 89, 116], ["the mixed and non-mixed reference reactions", "PROBLEM", 128, 171]]], ["As is to be expected because of the halved primer concentrations, the duplex assay shows reduced fluorescence evolution in comparison to the singleplex assays.", [["the halved primer concentrations", "PROBLEM", 32, 64], ["the duplex assay", "TEST", 66, 82], ["reduced fluorescence evolution", "PROBLEM", 89, 119], ["the singleplex assays", "TEST", 137, 158], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["fluorescence evolution", "OBSERVATION", 97, 119]]], ["Again, signal performance of the microreactor is observed to be better than that of the non-mixed control.", [["the non-mixed control", "TREATMENT", 84, 105]]], ["For khe, detection sensitivity is identical to that of the singleplex assay.", [["detection sensitivity", "TEST", 9, 30], ["the singleplex assay", "TEST", 55, 75]]], ["For blaNDM-1, sensitivity is decreased by one order of magnitude to 2.5 \u00d7 10 2 DNA molecules for the microreactor.Duplex AssayIn future work, increased performance may be achieved by further optimization of the multiplex assay, for example, as performed by Kim et al. [12] .", [["blaNDM-1", "GENE_OR_GENE_PRODUCT", 4, 12], ["blaNDM", "TEST", 4, 10], ["sensitivity", "TEST", 14, 25], ["the microreactor", "TREATMENT", 97, 113], ["Duplex", "TEST", 114, 120], ["the multiplex assay", "TEST", 207, 226], ["decreased", "OBSERVATION_MODIFIER", 29, 38]]], ["Figures 11 and 12 show the simultaneous detection of khe and bla NDM-1 by duplex rtRPA in the 3D printed microreactor as well as the mixed and non-mixed reference reactions.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 61, 70], ["duplex rtRPA", "DNA", 74, 86], ["Figures", "TEST", 0, 7], ["khe and bla NDM", "PROBLEM", 53, 68], ["duplex rtRPA", "TEST", 74, 86], ["the 3D printed microreactor", "TREATMENT", 90, 117], ["the mixed and non-mixed reference reactions", "PROBLEM", 129, 172]]], ["As is to be expected because of the halved primer concentrations, the duplex assay shows reduced fluorescence evolution in comparison to the singleplex assays.", [["the halved primer concentrations", "PROBLEM", 32, 64], ["the duplex assay", "TEST", 66, 82], ["reduced fluorescence evolution", "PROBLEM", 89, 119], ["the singleplex assays", "TEST", 137, 158], ["reduced", "OBSERVATION_MODIFIER", 89, 96], ["fluorescence evolution", "OBSERVATION", 97, 119]]], ["Again, signal performance of the microreactor is observed to be better than that of the non-mixed control.", [["the non-mixed control", "TREATMENT", 84, 105]]], ["For khe, detection sensitivity is identical to that of the singleplex assay.", [["detection sensitivity", "TEST", 9, 30], ["the singleplex assay", "TEST", 55, 75]]], ["For bla NDM-1 , sensitivity is decreased by one order of magnitude to 2.5 \u00d7 10 2 DNA molecules for the microreactor.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 4, 13], ["bla NDM", "TEST", 4, 11], ["sensitivity", "TEST", 16, 27], ["the microreactor", "TREATMENT", 99, 115], ["decreased", "OBSERVATION_MODIFIER", 31, 40]]], ["In future work, increased performance may be achieved by further optimization of the multiplex assay, for example, as performed by Kim et al. [12] .", [["the multiplex assay", "TEST", 81, 100]]], ["Figure 13 shows the TTP values measured for all single-and duplex assays plotted against the logarithm of the target DNA copy number.", [["DNA", "CELLULAR_COMPONENT", 117, 120], ["TTP", "PROTEIN", 20, 23], ["Figure", "TEST", 0, 6], ["the TTP values", "TEST", 16, 30], ["duplex assays", "TEST", 59, 72]]], ["For the singleplex assays all values obtained for the two highest target concentrations cluster well together while a higher spread was observed for the lowest concentration.", [["the singleplex assays", "TEST", 4, 25]]], ["Furthermore, it can be observed that the values obtained for the microreactor and non-mixed control cluster together for all investigated target copy numbers.Comparison of Single-and Duplex AssaysMicromachines 2020, 11, x 14 of 18 of mixing is assay dependent with mixing improving assay performance for the singleplex detection of blaNDM-1 at low copy numbers, while the detection of khe is not improved.", [["blaNDM-1", "GENE_OR_GENE_PRODUCT", 332, 340], ["blaNDM", "PROTEIN", 332, 338], ["the values", "TEST", 37, 47], ["the microreactor and non-mixed control cluster", "TREATMENT", 61, 107], ["Single-and Duplex AssaysMicromachines", "TEST", 172, 209], ["the singleplex detection", "TEST", 304, 328], ["blaNDM", "TEST", 332, 338], ["improved", "OBSERVATION_MODIFIER", 396, 404]]], ["For the duplex assay, mixing improves detection performance for both genes.", [["the duplex assay", "TEST", 4, 20]]], ["However, overall performance of the microreactor assay is comparable and may be improved by further optimization of the primer/probe concentrations.Summary and ConclusionsIn this work we expanded the state-of-the-art by demonstrating a DLP 3D printing approach that is suitable for the manufacture of microfluidic devices for real-time RPA.", [["RPA", "PROTEIN", 336, 339], ["the microreactor assay", "TEST", 32, 54], ["the primer/probe concentrations", "TREATMENT", 116, 147], ["a DLP 3D printing approach", "TREATMENT", 234, 260], ["microfluidic devices", "TREATMENT", 301, 321]]], ["First, we investigated three commercially available biocompatible printing materials, normally used for dental applications, for their autofluorescence and fluorescence drift as well as the effect of aging in dependence on different post curing protocols.", [["biocompatible printing materials", "TREATMENT", 52, 84], ["dental applications", "TREATMENT", 104, 123], ["their autofluorescence", "TEST", 129, 151], ["fluorescence drift", "PROBLEM", 156, 174], ["different post curing protocols", "TREATMENT", 223, 254]]], ["We found that devices printed from NXOC that were subjected to either no post curing or post curing at ambient temperature displayed very low For the duplex assay, a higher spread is observed for all measurements.", [["NXOC", "SIMPLE_CHEMICAL", 35, 39], ["devices", "TREATMENT", 14, 21], ["ambient temperature", "TEST", 103, 122], ["the duplex assay", "TEST", 146, 162], ["a higher spread", "PROBLEM", 164, 179], ["higher", "OBSERVATION_MODIFIER", 166, 172], ["spread", "OBSERVATION", 173, 179]]], ["Again, the values obtained for the microreactor and non-mixed control cluster together, and in case of the bla NDM-1 duplex assay are distinct from those obtained for the mixed reference.Summary and ConclusionsThese results indicate that rtRPA reactions in microreactors can deliver similar performance as assays in microcentrifuge tubes.", [["NDM-1", "GENE_OR_GENE_PRODUCT", 111, 116], ["rtRPA", "SIMPLE_CHEMICAL", 238, 243], ["the values", "TEST", 7, 17], ["the microreactor", "TREATMENT", 31, 47], ["the bla NDM", "TEST", 103, 114], ["1 duplex assay", "TEST", 115, 129], ["rtRPA reactions in microreactors", "PROBLEM", 238, 270], ["microcentrifuge tubes", "TREATMENT", 316, 337]]], ["Of high importance is the observation that the advantageous effect of mixing is assay dependent with mixing improving assay performance for the singleplex detection of bla NDM-1 at low copy numbers, while the detection of khe is not improved.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 168, 177], ["bla NDM-1", "SPECIES", 168, 177], ["the singleplex detection", "TEST", 140, 164], ["high", "OBSERVATION_MODIFIER", 3, 7], ["improved", "OBSERVATION_MODIFIER", 233, 241]]], ["For the duplex assay, mixing improves detection performance for both genes.", [["the duplex assay", "TEST", 4, 20]]], ["However, overall performance of the microreactor assay is comparable and may be improved by further optimization of the primer/probe concentrations.Summary and ConclusionsIn this work we expanded the state-of-the-art by demonstrating a DLP 3D printing approach that is suitable for the manufacture of microfluidic devices for real-time RPA.", [["RPA", "PROTEIN", 336, 339], ["the microreactor assay", "TEST", 32, 54], ["the primer/probe concentrations", "TREATMENT", 116, 147], ["a DLP 3D printing approach", "TREATMENT", 234, 260], ["microfluidic devices", "TREATMENT", 301, 321]]], ["First, we investigated three commercially available biocompatible printing materials, normally used for dental applications, for their autofluorescence and fluorescence drift as well as the effect of aging in dependence on different post curing protocols.", [["biocompatible printing materials", "TREATMENT", 52, 84], ["dental applications", "TREATMENT", 104, 123], ["their autofluorescence", "TEST", 129, 151], ["fluorescence drift", "PROBLEM", 156, 174], ["different post curing protocols", "TREATMENT", 223, 254]]], ["We found that devices printed from NXOC that were subjected to either no post curing or post curing at ambient temperature displayed very low autofluorescence and autofluorescence drift that were not strongly influenced by aging.", [["NXOC", "SIMPLE_CHEMICAL", 35, 39], ["devices", "TREATMENT", 14, 21], ["ambient temperature", "TEST", 103, 122], ["very low autofluorescence", "PROBLEM", 133, 158], ["autofluorescence drift", "PROBLEM", 163, 185], ["very", "OBSERVATION_MODIFIER", 133, 137], ["low autofluorescence", "OBSERVATION", 138, 158], ["autofluorescence drift", "OBSERVATION", 163, 185]]], ["In the next step, we investigated the performance of an rtRPA positive control assay when performed inside 3D printed microreactors.", [["rtRPA", "SIMPLE_CHEMICAL", 56, 61], ["an rtRPA positive control assay", "TREATMENT", 53, 84]]], ["Final fluorescence after 17 min incubation and the time to positive (TTP) value were used as evaluation metrics.", [["Final fluorescence", "TEST", 0, 18], ["TTP) value", "TEST", 69, 79], ["evaluation metrics", "TEST", 93, 111]]], ["Again, devices printed from NXOC followed by either no post curing or post curing at ambient temperature showed the best performance.", [["NXOC", "CHEMICAL", 28, 32], ["NXOC", "SIMPLE_CHEMICAL", 28, 32], ["ambient temperature", "TEST", 85, 104]]], ["Based on these results, we demonstrated the amplification of the khe and bla NDM-1 genes inside 3D printed microreactors and compared assay performance to non-mixed and mixed controls both for singleplex as well as a duplex assay.", [["bla NDM-1", "GENE_OR_GENE_PRODUCT", 73, 82], ["khe and bla NDM-1 genes", "DNA", 65, 88], ["the amplification of the khe and bla NDM", "PROBLEM", 40, 80], ["3D printed microreactors", "TREATMENT", 96, 120], ["assay performance", "TEST", 134, 151], ["singleplex", "TREATMENT", 193, 203], ["a duplex assay", "TEST", 215, 229]]], ["For the singleplex assays, we achieved a detection limit (at 100% detection) of 2.5 \u00d7 10 1 DNA copies.", [["DNA", "CELLULAR_COMPONENT", 91, 94], ["the singleplex assays", "TEST", 4, 25]]], ["When both assays were combined into a duplex assay, we achieved a limit of detection of 2.5 \u00d7 10 1 copies of khe and 2.5 \u00d7 10 2 copies of bla NDM-1 .Summary and ConclusionsIn conclusion, our work demonstrates the compatibility of real-time RPA with devices manufactured by DLP based 3D printing.", [["a duplex assay", "TEST", 36, 50], ["detection", "TEST", 75, 84], ["khe", "TEST", 109, 112], ["devices", "TREATMENT", 249, 256], ["DLP based 3D printing", "TREATMENT", 273, 294]]], ["We were able to identify an optically clear 3D printing material that allows for the use of amplification detection by the very popular and inexpensive FAM labeling.", [["FAM", "CHEMICAL", 152, 155], ["FAM", "SIMPLE_CHEMICAL", 152, 155], ["amplification detection", "TEST", 92, 115]]], ["This result was quite unexpected, as the DLP 3D printing process uses resins that contain chemicals (such as UV blockers) that are fluorescent in the same wavelength ranges.", [["the DLP 3D printing process uses resins", "TREATMENT", 37, 76], ["UV blockers", "TREATMENT", 109, 120]]], ["Additionally, we demonstrated that by choosing a longer detection wavelength, even lower autofluorescence could be achieved.", [["lower autofluorescence", "PROBLEM", 83, 105]]], ["However, longer wavelength fluorophores tend to have lower quantum yields necessitating more sensitive detection equipment.Summary and ConclusionsA further unexpected result was that for NXSG and SFSG autofluorescence increased with extended light exposure during post curing.", [["NXSG", "CHEMICAL", 187, 191], ["NXSG", "SIMPLE_CHEMICAL", 187, 191], ["SFSG", "SIMPLE_CHEMICAL", 196, 200], ["longer wavelength fluorophores", "TREATMENT", 9, 39], ["lower quantum yields", "PROBLEM", 53, 73], ["NXSG", "PROBLEM", 187, 191], ["SFSG autofluorescence", "PROBLEM", 196, 217]]], ["This finding contrasts our expectation that longer post curing reduces autofluorescence by bleaching of the responsible fluorophore inside the material.", [["autofluorescence", "PROBLEM", 71, 87]]], ["Additionally, autofluorescence was further increased when post curing was carried out at elevated temperature (60 \u2022 C).", [["autofluorescence", "TEST", 14, 30], ["elevated temperature", "PROBLEM", 89, 109], ["increased", "OBSERVATION_MODIFIER", 43, 52]]], ["These findings show that, counterintuitively, as little post curing as possible should be performed if low autofluorescence is desired.Summary and ConclusionsAs has been shown in other work, RPA reagents are readily compatible with high surface to volume ratio reaction vessels without the need for surface passivation by e.g., BSA or PEG.", [["surface", "ANATOMY", 237, 244], ["vessels", "ANATOMY", 270, 277], ["surface", "ANATOMY", 299, 306], ["BSA", "CHEMICAL", 328, 331], ["PEG", "CHEMICAL", 335, 338], ["PEG", "CHEMICAL", 335, 338], ["RPA reagents", "SIMPLE_CHEMICAL", 191, 203], ["vessels", "MULTI-TISSUE_STRUCTURE", 270, 277], ["BSA", "SIMPLE_CHEMICAL", 328, 331], ["PEG", "SIMPLE_CHEMICAL", 335, 338], ["low autofluorescence", "PROBLEM", 103, 123], ["RPA reagents", "TEST", 191, 203], ["surface passivation", "TREATMENT", 299, 318], ["PEG", "TREATMENT", 335, 338], ["vessels", "ANATOMY", 270, 277], ["PEG", "OBSERVATION", 335, 338]]], ["It is likely that due to the high amounts of PEG and proteins present in the RPA reaction mix, RPA \"self-passivates\" its reaction vessel.Summary and ConclusionsIn future work, with the addition of suitable sample preparation technology, fully monolithic micro total analysis systems (\u00b5TAS) for nucleic acid detection may be manufactured just by 3D printing and pre-loading of (lyophilized) reagents.", [["vessel", "ANATOMY", 130, 136], ["PEG", "CHEMICAL", 45, 48], ["nucleic acid", "CHEMICAL", 294, 306], ["PEG", "CHEMICAL", 45, 48], ["PEG", "SIMPLE_CHEMICAL", 45, 48], ["RPA", "SIMPLE_CHEMICAL", 95, 98], ["vessel", "MULTI-TISSUE_STRUCTURE", 130, 136], ["RPA", "PROTEIN", 77, 80], ["PEG and proteins", "TREATMENT", 45, 61], ["nucleic acid detection", "TEST", 294, 316], ["pre-loading of (lyophilized) reagents", "TREATMENT", 361, 398], ["high", "OBSERVATION_MODIFIER", 29, 33], ["amounts", "OBSERVATION_MODIFIER", 34, 41], ["PEG", "OBSERVATION", 45, 48], ["RPA", "ANATOMY", 77, 80], ["reaction vessel", "OBSERVATION", 121, 136]]], ["Such devices have a multitude of applications in diverse areas such as the medical field, food and water analysis or plant pathogens.", [["Such devices", "TREATMENT", 0, 12], ["applications in diverse areas", "TREATMENT", 33, 62], ["water analysis", "TEST", 99, 113], ["plant pathogens", "PROBLEM", 117, 132], ["diverse", "OBSERVATION_MODIFIER", 49, 56]]], ["Funding: Major funding for this work was provided by the European Regional Development Fund (EFRE, Brandenburg, Germany; project \"Infectcontrolmobil\": \"Entwicklung eines Analyseger\u00e4ts zum schnellen vor-Ort Nachweis von Infektionen\"; project number: 85017408) with minor funding from the German Federal Ministry of Education and Research (BMBF; grant no. 16GW0145, SAGE) and the Ministry of Science, Research and Culture (MWFK; grant no. 06-GeCa:H228-05/002/004, Gesundheitscampus Brandenburg-digilog).", [["Entwicklung eines Analyseger\u00e4ts zum schnellen vor-Ort Nachweis von Infektionen", "SPECIES", 152, 230], ["Culture", "TEST", 412, 419]]], ["The APC was funded by the Baden-W\u00fcrttemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.", [["APC", "GENE_OR_GENE_PRODUCT", 4, 7], ["APC", "CELL_TYPE", 4, 7]]]], "PMC7470769": [["IntroductionGlobal solar photovoltaic (PV) capacity is projected to more than double over the next decade from about 500 GW in 2018 to 1290 GW by 2030 (International Energy Agency (IEA), 2018, Masson et al., 2019).", [["IntroductionGlobal solar photovoltaic (PV) capacity", "TREATMENT", 0, 51]]], ["As a result of its zero marginal cost characteristics, PV output is almost always prioritized in electricity grid dispatches and delivered to the grid.", [["PV output", "TEST", 55, 64], ["PV output", "OBSERVATION", 55, 64]]], ["However, as PV composes increasing shares of grid capacity, it will become increasingly common that some available PV output will be unused for technical or economic reasons.", [["PV", "SPECIES", 12, 14], ["grid capacity", "PROBLEM", 45, 58], ["some available PV output", "PROBLEM", 100, 124]]], ["Unlike fuel-based generators whose unused output represents fuel that can be burned to generate output at a later time, unused PV output represents available electricity that is lost forever (Sterling et al., 2017).", [["unused PV output", "PROBLEM", 120, 136], ["PV output", "OBSERVATION", 127, 136]]], ["The term \u201ccurtailment\u201d has emerged as an industry term of art for the practice of foregoing and thus losing available renewable energy output, including PV.IntroductionMost PV curtailment stems from some system constraint that impedes the grid from absorbing more PV output.1To build some intuition around how system constraints can drive curtailment, Fig. 1depicts an actual PV curtailment event in California in May 2018.", [["PV", "SPECIES", 173, 175], ["PV", "SPECIES", 376, 378], ["some system constraint", "PROBLEM", 199, 221], ["PV", "ANATOMY", 153, 155], ["Most PV", "OBSERVATION_MODIFIER", 168, 175]]], ["As PV came online at 6 am, some flexible generators\u2014mostly imports and natural gas\u2014went offline, conceptually \u201cmaking room\u201d for the PV output.", [["PV", "SPECIES", 3, 5], ["some flexible generators", "TREATMENT", 27, 51], ["the PV output", "TEST", 128, 141]]], ["However, at least some non-variable generation on the grid cannot be significantly ramped up or down, at least in the near term, because the generation provides essential grid reliability services or because of mechanical limitations.", [["non-variable", "OBSERVATION_MODIFIER", 23, 35], ["generation", "OBSERVATION", 36, 46]]], ["After the system had scaled back flexible generation, the sum of variable generation (including other renewables) and the inflexible generation began to exceed load, a phenomenon we will refer to as oversupply.", [["the inflexible generation", "PROBLEM", 118, 143], ["a phenomenon", "PROBLEM", 166, 178]]], ["In order to maintain supply/demand balance, the system curtailed about 12,000 MWh of PV output on this particular day, represented by the red area on the top of the chart.IntroductionOversupply and curtailment are largely driven by two mismatches between PV output (supply) and load (demand).", [["PV", "SPECIES", 85, 87], ["PV output", "TEST", 85, 94], ["IntroductionOversupply", "TREATMENT", 171, 193], ["PV output", "TEST", 255, 264], ["red", "OBSERVATION", 138, 141]]], ["First, there is often a temporal mismatch between when PV output is available (midday) and when that output can be absorbed by the grid.", [["a temporal mismatch", "PROBLEM", 22, 41], ["PV output", "TEST", 55, 64], ["temporal", "OBSERVATION_MODIFIER", 24, 32], ["mismatch", "OBSERVATION", 33, 41]]], ["Temporal mismatch is clearly evident in Fig. 1.", [["Temporal mismatch", "PROBLEM", 0, 17], ["mismatch", "OBSERVATION", 9, 17], ["Fig", "OBSERVATION_MODIFIER", 40, 43]]], ["On that day, the PV output peak occurred in the midday when demand was too low to absorb the output.", [["the PV output", "TEST", 13, 26], ["PV", "ANATOMY", 17, 19], ["output peak", "OBSERVATION", 20, 31]]], ["The temporal mismatch is exacerbated by the fact that behind-the-meter PV systems reduce grid net load throughout the day, leaving less load to absorb available utility-scale PV.", [["The temporal mismatch", "PROBLEM", 0, 21], ["grid net load", "PROBLEM", 89, 102], ["temporal", "OBSERVATION_MODIFIER", 4, 12], ["mismatch", "OBSERVATION", 13, 21]]], ["Second, there may be a geographic mismatch between where PV output is available (sunny, dry areas) and where that output can be absorbed (load centers).", [["a geographic mismatch", "PROBLEM", 21, 42], ["PV output", "TEST", 57, 66], ["may be", "UNCERTAINTY", 14, 20], ["geographic", "OBSERVATION_MODIFIER", 23, 33], ["mismatch", "OBSERVATION", 34, 42], ["PV output", "OBSERVATION", 57, 66]]], ["Land use and land cost considerations may also play a role in PV siting, particularly when fixed feed-in tariffs or other incentives are location agnostic (Krauter, 2018).", [["PV", "SPECIES", 62, 64], ["land cost considerations", "TREATMENT", 13, 37], ["PV siting", "TREATMENT", 62, 71]]], ["Geographic mismatches occur when solar-rich regions are located far from load centers and when there is limited transmission capacity connecting the two regions.IntroductionOversupply risk generally increases as more PV is integrated onto the grid (Denholm et al., 2016, Nelson et al., 2018).", [["PV", "SPECIES", 217, 219], ["Geographic mismatches", "PROBLEM", 0, 21], ["limited transmission capacity", "PROBLEM", 104, 133], ["mismatches", "OBSERVATION", 11, 21], ["two", "ANATOMY_MODIFIER", 149, 152], ["regions", "ANATOMY_MODIFIER", 153, 160]]], ["Each marginal unit of PV output pushes down the midday net load, making it more likely that PV output will exceed the grid\u2019s ability to absorb that output during the solar peak.", [["PV output", "TEST", 22, 31], ["PV output", "PROBLEM", 92, 101], ["the solar peak", "TEST", 162, 176], ["marginal", "OBSERVATION_MODIFIER", 5, 13], ["PV output", "OBSERVATION", 22, 31], ["more likely", "UNCERTAINTY", 75, 86]]], ["As a result, PV curtailment is projected to increase as PV composes greater shares of grid capacity (Denholm et al., 2015).", [["PV", "SPECIES", 13, 15], ["PV curtailment", "TREATMENT", 13, 27]]], ["An illustrative example is California, where PV curtailment doubled from 2018 to 2019 alone (CAISO, 2019a).IntroductionPV curtailment is often framed as a loss given that effectively free and clean electricity goes unused (Bird et al., 2016, Henriot, 2015).", [["PV", "SPECIES", 45, 47], ["IntroductionPV curtailment", "PROBLEM", 107, 133], ["a loss", "PROBLEM", 153, 159], ["California", "OBSERVATION_MODIFIER", 27, 37]]], ["Curtailment may also undermine PV project economics and could hinder future PV deployment (Golden and Paulos, 2015).", [["PV", "SPECIES", 31, 33], ["PV", "SPECIES", 76, 78]]], ["As a result, various grid and market practices discourage curtailment.", [["various grid and market practices", "TREATMENT", 13, 46]]], ["For instance, some grid policies require utilities to compensate generators for curtailed output, and some interconnection policies prohibit systems from interconnecting if those systems will result in curtailment.IntroductionIn this paper, we describe the extent of PV curtailment through a novel synthesis of data from four key PV markets where curtailment is occurring: Chile, China, Germany, and the United States.", [["PV", "SPECIES", 267, 269], ["curtailed output", "PROBLEM", 80, 96], ["PV curtailment", "PROBLEM", 267, 281], ["PV curtailment", "OBSERVATION", 267, 281]]], ["Finally, in Section 4 we explore how evolving grid and technological contexts may force a reexamination of grid and market practices that discourage curtailment.", [["a reexamination", "TEST", 88, 103], ["grid and market practices", "TREATMENT", 107, 132]]], ["Wind power systems have\u2014historically\u2014been curtailed at higher rates than PV systems, primarily because more wind capacity has been deployed.", [["Wind power systems", "TEST", 0, 18]]], ["See Bird et al. (2016) for a review of trends in wind curtailment.Chile ::: PV curtailment in key marketsThe Atacama and Antofagasta regions of northern Chile have some of the strongest solar resources in the world.", [["Atacama and Antofagasta regions", "DNA", 109, 140], ["PV", "SPECIES", 76, 78], ["PV", "ANATOMY", 76, 78]]], ["The region has attracted increasing investment in large-scale PV capacity, with more than 1600 MW online by the end of 2018 (Energ\u00eda Abierta, 2019).", [["region", "ANATOMY_MODIFIER", 4, 10], ["attracted", "OBSERVATION_MODIFIER", 15, 24], ["increasing", "OBSERVATION_MODIFIER", 25, 35], ["investment", "OBSERVATION_MODIFIER", 36, 46], ["large", "OBSERVATION_MODIFIER", 50, 55], ["-scale", "OBSERVATION_MODIFIER", 55, 61], ["PV capacity", "OBSERVATION", 62, 73]]], ["There is currently no transmission capacity linking Antofagasta to the rest of the country, leaving more than 800 MW of PV capacity isolated from the large load centers to the south (CEN, 2017).", [["PV", "SPECIES", 120, 122], ["transmission capacity", "PROBLEM", 22, 43], ["PV capacity", "PROBLEM", 120, 131], ["no", "UNCERTAINTY", 19, 21], ["transmission capacity", "OBSERVATION", 22, 43], ["large", "OBSERVATION_MODIFIER", 150, 155], ["load", "OBSERVATION", 156, 160]]], ["Further, there are currently only three 220 kV transmission lines linking Atacama to the rest of the system (CEN, 2017).", [["220 kV", "OBSERVATION_MODIFIER", 40, 46], ["Atacama", "OBSERVATION_MODIFIER", 74, 81], ["rest", "ANATOMY_MODIFIER", 89, 93], ["system", "ANATOMY", 101, 107]]], ["Limited transmission capacity between the northern regions and Santiago is expected to drive increasing PV curtailment in Chile (CNE, 2018).", [["PV", "SPECIES", 104, 106]]], ["Curtailment of all renewables\u2014including wind\u2014increased from about 2% of potential output in 2016 (Matus et al., 2016) to about 6% of output in 2018 (Valgesta Energ\u00eda, 2019).2", [["potential output", "TEST", 72, 88]]]], "PMC3847877": [["BackgroundPorcine reproductive and respiratory syndrome (PRRS) causes significant economic losses in most pig-producing countries [1].", [["BackgroundPorcine reproductive and respiratory syndrome", "DISEASE", 0, 55], ["PRRS", "DISEASE", 57, 61], ["PRRS", "SPECIES", 57, 61], ["BackgroundPorcine reproductive", "PROBLEM", 0, 30], ["respiratory syndrome", "PROBLEM", 35, 55], ["significant economic losses", "PROBLEM", 70, 97], ["respiratory syndrome", "OBSERVATION", 35, 55], ["significant", "OBSERVATION_MODIFIER", 70, 81], ["economic losses", "OBSERVATION", 82, 97]]], ["The causative agent, the PRRS virus (PRRSV), was identified in the early 1990s [1].", [["PRRS virus", "ORGANISM", 25, 35], ["PRRSV", "ORGANISM", 37, 42], ["PRRS virus", "SPECIES", 25, 35], ["PRRS virus", "SPECIES", 25, 35], ["PRRSV", "SPECIES", 37, 42], ["The causative agent", "TREATMENT", 0, 19], ["the PRRS virus", "PROBLEM", 21, 35]]], ["PRRSV is an enveloped, positive-strand RNA virus with a genome of approximately 15 kb, and it belongs to family Arteriviridae and order Nidovirales[1].", [["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["strand RNA virus", "PROBLEM", 32, 48], ["enveloped", "OBSERVATION_MODIFIER", 12, 21]]], ["A remarkable amount of genetic variation has been observed among the PRRSVs isolates worldwide, particularly in Nsp2 [2-5], ORF5 [2-8] and the nucleocapsid (the ORF 7 product) [3,5,8,9].", [["PRRSVs", "GENE_OR_GENE_PRODUCT", 69, 75], ["Nsp2 [2-5", "GENE_OR_GENE_PRODUCT", 112, 121], ["ORF5", "GENE_OR_GENE_PRODUCT", 124, 128], ["nucleocapsid", "PROTEIN", 143, 155], ["ORF 7 product", "PROTEIN", 161, 174], ["genetic variation", "PROBLEM", 23, 40], ["Nsp2", "TEST", 112, 116], ["ORF5", "TEST", 124, 128], ["the nucleocapsid", "PROBLEM", 139, 155], ["remarkable", "OBSERVATION_MODIFIER", 2, 12], ["amount", "OBSERVATION_MODIFIER", 13, 19], ["genetic variation", "OBSERVATION", 23, 40]]], ["The genetic characteristics of the PRRSV strains clearly indicate the existence of two major genotypes, the European type (EU genotype, type 1) and the North American type (NA genotype, type 2) [1].BackgroundDuring PRRSV infection, clinical disease is detectable in all of ages of pigs but is usually observed in nursery-grown pigs [1].", [["PRRSV infection", "DISEASE", 215, 230], ["PRRSV", "ORGANISM", 35, 40], ["PRRSV", "ORGANISM", 215, 220], ["pigs", "ORGANISM", 281, 285], ["pigs", "ORGANISM", 327, 331], ["PRRSV", "SPECIES", 215, 220], ["pigs", "SPECIES", 281, 285], ["pigs", "SPECIES", 327, 331], ["PRRSV", "SPECIES", 35, 40], ["PRRSV", "SPECIES", 215, 220], ["pigs", "SPECIES", 281, 285], ["the PRRSV strains", "PROBLEM", 31, 48], ["BackgroundDuring PRRSV infection", "PROBLEM", 198, 230], ["clinical disease", "PROBLEM", 232, 248], ["PRRSV", "OBSERVATION_MODIFIER", 215, 220], ["infection", "OBSERVATION", 221, 230]]], ["The clinical presentation of PRRSV can range from asymptomatic to devastating, with symptoms such as listlessness, emaciation, hyperpnea, dyspnea, chemosis, abortion, stillbirth and a reduction in semen quality [1].", [["semen", "ANATOMY", 197, 202], ["PRRSV", "DISEASE", 29, 34], ["listlessness", "DISEASE", 101, 113], ["emaciation", "DISEASE", 115, 125], ["hyperpnea", "DISEASE", 127, 136], ["dyspnea", "DISEASE", 138, 145], ["chemosis", "DISEASE", 147, 155], ["abortion", "DISEASE", 157, 165], ["stillbirth", "DISEASE", 167, 177], ["PRRSV", "ORGANISM", 29, 34], ["semen", "ORGANISM_SUBSTANCE", 197, 202], ["PRRSV", "SPECIES", 29, 34], ["PRRSV", "PROBLEM", 29, 34], ["asymptomatic", "PROBLEM", 50, 62], ["symptoms", "PROBLEM", 84, 92], ["listlessness", "PROBLEM", 101, 113], ["emaciation", "PROBLEM", 115, 125], ["hyperpnea", "PROBLEM", 127, 136], ["dyspnea", "PROBLEM", 138, 145], ["chemosis", "PROBLEM", 147, 155], ["abortion", "PROBLEM", 157, 165], ["stillbirth", "PROBLEM", 167, 177], ["a reduction in semen quality", "PROBLEM", 182, 210], ["chemosis", "OBSERVATION", 147, 155]]], ["However, infection with PRRSV predominantly exists at a subclinical level, participating as a cofactor in porcine respiratory disease complex (PRDC) and porcine circovirus associated disease (PCVAD) [10].", [["respiratory", "ANATOMY", 114, 125], ["infection", "DISEASE", 9, 18], ["porcine respiratory disease", "DISEASE", 106, 133], ["porcine circovirus associated disease", "DISEASE", 153, 190], ["PRRSV", "ORGANISM", 24, 29], ["porcine respiratory disease complex", "GENE_OR_GENE_PRODUCT", 106, 141], ["PRDC", "CANCER", 143, 147], ["porcine circovirus", "ORGANISM", 153, 171], ["porcine", "SPECIES", 106, 113], ["porcine circovirus", "SPECIES", 153, 171], ["PRRSV", "SPECIES", 24, 29], ["porcine respiratory disease complex", "SPECIES", 106, 141], ["porcine circovirus", "SPECIES", 153, 171], ["infection", "PROBLEM", 9, 18], ["PRRSV", "PROBLEM", 24, 29], ["a cofactor in porcine respiratory disease complex", "PROBLEM", 92, 141], ["porcine circovirus associated disease", "PROBLEM", 153, 190], ["infection", "OBSERVATION", 9, 18], ["PRRSV", "OBSERVATION", 24, 29], ["respiratory disease", "OBSERVATION", 114, 133], ["porcine circovirus", "OBSERVATION", 153, 171]]], ["PRRSV can be detected using molecular methods from nasal fluid, salivary, serum and tonsil specimens from naturally infected pigs [11].", [["nasal fluid", "ANATOMY", 51, 62], ["salivary", "ANATOMY", 64, 72], ["serum", "ANATOMY", 74, 79], ["tonsil specimens", "ANATOMY", 84, 100], ["PRRSV", "ORGANISM", 0, 5], ["nasal fluid", "ORGANISM_SUBSTANCE", 51, 62], ["salivary", "ORGANISM_SUBSTANCE", 64, 72], ["serum", "ORGANISM_SUBSTANCE", 74, 79], ["tonsil specimens", "TISSUE", 84, 100], ["pigs", "ORGANISM", 125, 129], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 125, 129], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["molecular methods", "TEST", 28, 45], ["nasal fluid, salivary, serum and tonsil specimens", "TEST", 51, 100], ["nasal", "ANATOMY", 51, 56], ["fluid", "OBSERVATION", 57, 62], ["tonsil", "ANATOMY", 84, 90]]], ["However, because PRRSV is common within the swine population, no quantitative real-time PCR assays have been described using the serum samples of both symptomatic and asymptomatic PRRSV-infected pigs.BackgroundThe diagnosis of PRRSV infection has relied on probe-based real-time PCR [12-21], SYBR Green-based PCR [11,22-24], RT-PCR [1], virus isolation [1], immunohistochemistry [1] and serological methods [1].", [["serum samples", "ANATOMY", 129, 142], ["PRRSV-infected", "DISEASE", 180, 194], ["PRRSV infection", "DISEASE", 227, 242], ["PRRSV", "ORGANISM", 17, 22], ["serum samples", "ORGANISM_SUBSTANCE", 129, 142], ["PRRSV", "ORGANISM", 180, 185], ["pigs", "ORGANISM", 195, 199], ["PRRSV", "ORGANISM", 227, 232], ["swine", "SPECIES", 44, 49], ["PRRSV", "SPECIES", 180, 185], ["pigs", "SPECIES", 195, 199], ["PRRSV", "SPECIES", 227, 232], ["PRRSV", "SPECIES", 17, 22], ["swine", "SPECIES", 44, 49], ["PRRSV", "SPECIES", 180, 185], ["pigs", "SPECIES", 195, 199], ["PRRSV", "SPECIES", 227, 232], ["PRRSV", "PROBLEM", 17, 22], ["quantitative real-time PCR assays", "TEST", 65, 98], ["the serum samples", "TEST", 125, 142], ["asymptomatic PRRSV", "PROBLEM", 167, 185], ["PRRSV infection", "PROBLEM", 227, 242], ["PCR", "TEST", 279, 282], ["SYBR Green-based PCR", "TEST", 292, 312], ["RT-PCR", "TEST", 325, 331], ["virus isolation", "TEST", 337, 352], ["immunohistochemistry", "TEST", 358, 378], ["serological methods", "TEST", 387, 406], ["symptomatic", "OBSERVATION_MODIFIER", 151, 162], ["infected pigs", "OBSERVATION", 186, 199], ["PRRSV infection", "OBSERVATION", 227, 242]]], ["Zip nucleic acids (ZNA) are oligonucleotide-oligocation conjugates with multiple cationic spermine moieties attached to the nucleic acid oligomer [25].", [["Zip nucleic acids", "CHEMICAL", 0, 17], ["ZNA", "CHEMICAL", 19, 22], ["spermine", "CHEMICAL", 90, 98], ["nucleic acid", "CHEMICAL", 124, 136], ["spermine", "CHEMICAL", 90, 98], ["Zip nucleic acids", "SIMPLE_CHEMICAL", 0, 17], ["ZNA", "SIMPLE_CHEMICAL", 19, 22], ["Zip nucleic acids", "PROTEIN", 0, 17], ["ZNA", "PROTEIN", 19, 22], ["Zip nucleic acids (ZNA)", "TREATMENT", 0, 23], ["oligonucleotide-oligocation conjugates", "TREATMENT", 28, 66], ["multiple cationic spermine moieties", "TREATMENT", 72, 107], ["the nucleic acid oligomer", "TREATMENT", 120, 145]]], ["The melting temperature of a hybridized ZNA is easily predictable and increases linearly with the length of the oligocation [25].", [["hybridized ZNA", "DNA", 29, 43], ["The melting temperature", "TEST", 0, 23], ["a hybridized ZNA", "TEST", 27, 43], ["increases", "OBSERVATION_MODIFIER", 70, 79], ["linearly", "OBSERVATION_MODIFIER", 80, 88]]], ["ZNA were shown to enable specific and sensitive reactions when used as a primer for PCR and reverse transcription [26].", [["ZNA", "CHEMICAL", 0, 3], ["ZNA", "SIMPLE_CHEMICAL", 0, 3], ["ZNA", "PROTEIN", 0, 3], ["ZNA", "TREATMENT", 0, 3], ["PCR", "TEST", 84, 87]]], ["The present study describes a sensitive method for detecting type 2 PRRSV using real-time fluorescent quantitative PCR with ZNA probes.ZNA probe-based real-time PCR amplification and the limit of detection ::: ResultsTenfold serial plasmid dilutions (101 to 106 copies/\u03bcl) were tested and used to construct the standard curve by plotting the logarithm of the plasmid copy number against the measured quantification cycles (Cq) values.", [["plasmid", "ANATOMY", 232, 239], ["plasmid", "ANATOMY", 359, 366], ["PRRSV", "ORGANISM", 68, 73], ["ZNA probes", "DNA", 124, 134], ["ZNA probe", "DNA", 135, 144], ["PRRSV", "SPECIES", 68, 73], ["The present study", "TEST", 0, 17], ["type 2 PRRSV", "PROBLEM", 61, 73], ["ZNA probes", "TREATMENT", 124, 134], ["ZNA probe", "TREATMENT", 135, 144], ["Tenfold serial plasmid dilutions", "TEST", 217, 249]]], ["The generated standard curve covered a linear range of six orders of magnitude of the standard plasmid DNA.", [["DNA", "CELLULAR_COMPONENT", 103, 106], ["plasmid DNA", "DNA", 95, 106], ["the standard plasmid DNA", "TREATMENT", 82, 106]]], ["The linear correlation (R2) between the Cq and the logarithm of the plasmid copy number was 0.996 (slope = \u22123.91) (Figure 1).", [["slope", "TEST", 99, 104], ["linear", "OBSERVATION_MODIFIER", 4, 10]]], ["To assess the limit of detection of the assay, 100 to 106 copies/\u03bcl of standard plasmid DNA per reaction were tested in 10 replicates.", [["plasmid", "ANATOMY", 80, 87], ["DNA", "CELLULAR_COMPONENT", 88, 91], ["plasmid DNA", "DNA", 80, 91], ["the assay", "TEST", 36, 45], ["standard plasmid DNA", "TREATMENT", 71, 91]]], ["At more than 100 copies, 100% of the replicates were positive, and at 10 copies, 6 (60%) of the replicates were positive (Table 1).Reproducibility and specificity of the ZNA probe-based real-time PCR ::: ResultsThe coefficient of variation of the mean Cq values in the within-run and between-run for standard plasmid DNA precision experiments ranged from 0.52 to 1.87% and from 0.85 to 1.98%, respectively (Table 2).", [["DNA", "CELLULAR_COMPONENT", 317, 320], ["ZNA probe", "DNA", 170, 179], ["Reproducibility", "TEST", 131, 146], ["the ZNA probe", "TEST", 166, 179], ["the mean Cq values", "TEST", 243, 261], ["standard plasmid DNA precision experiments", "TEST", 300, 342], ["coefficient", "OBSERVATION_MODIFIER", 215, 226], ["variation", "OBSERVATION_MODIFIER", 230, 239]]], ["The CV values in the within-run and between-run for clinical specimens that spanned the whole ranged from 0.43 to 4.70% and from 2.11 to 4.45%, respectively (Table 3).", [["specimens", "ANATOMY", 61, 70], ["The CV values", "TEST", 0, 13], ["clinical specimens", "TEST", 52, 70]]], ["We analyzed other swine viruses to test the specificity of the ZNA probe-based real-time PCR.", [["ZNA probe", "DNA", 63, 72], ["swine", "SPECIES", 18, 23], ["swine viruses", "SPECIES", 18, 31], ["other swine viruses", "PROBLEM", 12, 31], ["the ZNA probe", "TEST", 59, 72]]], ["No specific amplifications were detected for any of these samples (data not shown).Detection of the viral load in serum samples from in the PRRSV naturally infected pigs ::: ResultsThe assay was tested on serum from both healthy and PRDC pigs.", [["samples", "ANATOMY", 58, 65], ["serum samples", "ANATOMY", 114, 127], ["serum", "ANATOMY", 205, 210], ["PRRSV naturally infected", "DISEASE", 140, 164], ["serum samples", "ORGANISM_SUBSTANCE", 114, 127], ["PRRSV", "ORGANISM", 140, 145], ["pigs", "ORGANISM", 165, 169], ["serum", "ORGANISM_SUBSTANCE", 205, 210], ["pigs", "ORGANISM", 238, 242], ["pigs", "SPECIES", 165, 169], ["pigs", "SPECIES", 238, 242], ["PRRSV", "SPECIES", 140, 145], ["pigs", "SPECIES", 165, 169], ["PRDC pigs", "SPECIES", 233, 242], ["specific amplifications", "PROBLEM", 3, 26], ["these samples", "TEST", 52, 65], ["the viral load", "TEST", 96, 110], ["serum samples", "TEST", 114, 127], ["The assay", "TEST", 181, 190], ["serum", "TEST", 205, 210], ["viral load", "OBSERVATION", 100, 110]]], ["As determined by ZNA probe-based real-time PCR, 112 (84.2%) of the 133 PRDC pigs and 79 (17.8%) of the 444 asymptomatic pigs were positive (Table 4).", [["pigs", "ORGANISM", 76, 80], ["pigs", "ORGANISM", 120, 124], ["ZNA probe", "DNA", 17, 26], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 120, 124], ["pigs", "SPECIES", 76, 80], ["pigs", "SPECIES", 120, 124], ["ZNA probe", "TEST", 17, 26], ["PCR", "TEST", 43, 46], ["PRDC pigs", "TEST", 71, 80], ["asymptomatic pigs", "TEST", 107, 124]]], ["Using a chi-square test, the correlation between PRRSV and PRDC was calculated.", [["PRRSV", "ORGANISM", 49, 54], ["PRDC", "CANCER", 59, 63], ["PRRSV", "SPECIES", 49, 54], ["a chi-square test", "TEST", 6, 23], ["PRDC", "TEST", 59, 63]]], ["Among the 577 pigs that were analyzed, a positive result for PRRSV appeared to be highly significantly correlated with the presence of PRDC (P <0.0001).", [["pigs", "ORGANISM", 14, 18], ["PRRSV", "ORGANISM", 61, 66], ["pigs", "SPECIES", 14, 18], ["pigs", "SPECIES", 14, 18], ["PRRSV", "SPECIES", 61, 66], ["PRRSV", "PROBLEM", 61, 66], ["PRDC", "TEST", 135, 139]]], ["In addition, the PRRSV load was significantly higher (P <0.0001) in the PRDC pigs (ranging from 1.69 to 7.05 log10 PRRSV genome/\u03bcl, median 4.21 log10) compared to that in the asymptomatic pigs (ranging from 1.32 to 4.70 log10 PRRSV genome/\u03bcl, median 2.75 log10) (Figure 2) (Table 4).", [["PRRSV", "ORGANISM", 17, 22], ["PRDC", "ORGANISM", 72, 76], ["pigs", "ORGANISM", 77, 81], ["pigs", "ORGANISM", 188, 192], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 188, 192], ["PRRSV", "SPECIES", 17, 22], ["pigs", "SPECIES", 77, 81], ["pigs", "SPECIES", 188, 192], ["the PRRSV load", "TEST", 13, 27], ["the PRDC pigs", "TEST", 68, 81], ["PRRSV load", "OBSERVATION", 17, 27], ["higher", "OBSERVATION_MODIFIER", 46, 52]]], ["These data indicated that the levels of viral load correlated with the severity of the clinical presentation of the PRRSV-infected pigs.DiscussionThe molecular diagnosis of PRRSV infection has relied on probe-based real-time PCR [12-21] and SYBR Green-based PCR [11,22-24].", [["PRRSV-infected", "DISEASE", 116, 130], ["PRRSV infection", "DISEASE", 173, 188], ["PRRSV", "ORGANISM", 116, 121], ["pigs", "ORGANISM", 131, 135], ["PRRSV", "ORGANISM", 173, 178], ["SYBR", "GENE_OR_GENE_PRODUCT", 241, 245], ["pigs", "SPECIES", 131, 135], ["PRRSV", "SPECIES", 116, 121], ["pigs", "SPECIES", 131, 135], ["PRRSV", "SPECIES", 173, 178], ["These data", "TEST", 0, 10], ["viral load", "PROBLEM", 40, 50], ["PRRSV infection", "PROBLEM", 173, 188], ["PCR", "TEST", 225, 228], ["SYBR Green-based PCR", "TEST", 241, 261], ["viral load", "OBSERVATION", 40, 50], ["infected pigs", "OBSERVATION", 122, 135], ["PRRSV infection", "OBSERVATION", 173, 188]]], ["This study first describes a new ZNA probe-based real-time PCR for PRRSV and evaluates this method as a diagnostic tool for PRRSV infection.", [["PRRSV infection", "DISEASE", 124, 139], ["PRRSV", "ORGANISM", 67, 72], ["PRRSV", "ORGANISM", 124, 129], ["ZNA probe", "DNA", 33, 42], ["PRRSV", "SPECIES", 67, 72], ["PRRSV", "SPECIES", 124, 129], ["This study", "TEST", 0, 10], ["a new ZNA probe", "TREATMENT", 27, 42], ["PRRSV", "PROBLEM", 67, 72], ["this method", "TEST", 87, 98], ["a diagnostic tool", "TEST", 102, 119], ["PRRSV infection", "PROBLEM", 124, 139], ["infection", "OBSERVATION", 130, 139]]], ["This assay was sensitive, specific and reliable for the amplification of PRRSV cDNA, with a reproducible limit of detection of approximately 100 copies of target DNA per reaction.", [["PRRSV", "ORGANISM", 73, 78], ["DNA", "CELLULAR_COMPONENT", 162, 165], ["PRRSV cDNA", "DNA", 73, 83], ["PRRSV", "SPECIES", 73, 78], ["This assay", "TEST", 0, 10], ["PRRSV cDNA", "PROBLEM", 73, 83]]], ["Both the intra- and inter-assay CVs for standard plasmid DNA and clinical specimens were satisfactorily low.DiscussionA novel type of modified oligonucleotides known as ZNA was recently developed as a method for the clinical diagnosis of pathogens, such as the hepatitis B virus [27].", [["plasmid", "ANATOMY", 49, 56], ["specimens", "ANATOMY", 74, 83], ["ZNA", "CHEMICAL", 169, 172], ["hepatitis B", "DISEASE", 261, 272], ["DNA", "CELLULAR_COMPONENT", 57, 60], ["ZNA", "SIMPLE_CHEMICAL", 169, 172], ["hepatitis B virus", "ORGANISM", 261, 278], ["plasmid DNA", "DNA", 49, 60], ["ZNA", "PROTEIN", 169, 172], ["hepatitis B virus", "SPECIES", 261, 278], ["hepatitis B virus", "SPECIES", 261, 278], ["standard plasmid DNA", "TREATMENT", 40, 60], ["clinical specimens", "TEST", 65, 83], ["modified oligonucleotides", "TREATMENT", 134, 159], ["ZNA", "TREATMENT", 169, 172], ["pathogens", "PROBLEM", 238, 247], ["the hepatitis B virus", "PROBLEM", 257, 278], ["intra", "ANATOMY_MODIFIER", 9, 14], ["pathogens", "OBSERVATION", 238, 247]]], ["ZNAs are able to discriminate between complementary sequence that are a perfect match and those that are mismatched by a single base pair [25].", [["ZNAs", "GENE_OR_GENE_PRODUCT", 0, 4], ["ZNAs", "PROTEIN", 0, 4], ["ZNAs", "TREATMENT", 0, 4]]], ["ZNAs are particularly efficient at low magnesium concentrations, low primer concentrations and high annealing temperatures [25].", [["magnesium", "CHEMICAL", 39, 48], ["magnesium", "CHEMICAL", 39, 48], ["ZNAs", "SIMPLE_CHEMICAL", 0, 4], ["magnesium", "SIMPLE_CHEMICAL", 39, 48], ["ZNAs", "TREATMENT", 0, 4], ["low magnesium concentrations", "PROBLEM", 35, 63], ["low primer concentrations", "PROBLEM", 65, 90], ["high annealing temperatures", "PROBLEM", 95, 122]]], ["ZNA probes provide broad flexibility with respect to experimental design and represent an effective alternative to minor groove binder-DNA and locked nucleic acid probes [26].DiscussionThe viral load is an indicator of active infection, virus-host interaction and disease progression [28].", [["nucleic acid", "CHEMICAL", 150, 162], ["infection", "DISEASE", 226, 235], ["ZNA", "SIMPLE_CHEMICAL", 0, 3], ["DNA", "CELLULAR_COMPONENT", 135, 138], ["nucleic acid", "SIMPLE_CHEMICAL", 150, 162], ["ZNA probes", "DNA", 0, 10], ["ZNA probes", "TREATMENT", 0, 10], ["broad flexibility", "TREATMENT", 19, 36], ["minor groove binder", "TREATMENT", 115, 134], ["DNA and locked nucleic acid probes", "TREATMENT", 135, 169], ["The viral load", "TEST", 185, 199], ["active infection", "PROBLEM", 219, 235], ["virus", "PROBLEM", 237, 242], ["disease progression", "PROBLEM", 264, 283], ["indicator of", "UNCERTAINTY", 206, 218], ["active", "OBSERVATION_MODIFIER", 219, 225], ["infection", "OBSERVATION", 226, 235]]], ["The asymptomatic pigs are believed to serve as important reservoirs for the transmission of PRRSV to uninfected pigs [29].", [["pigs", "ORGANISM", 17, 21], ["PRRSV", "ORGANISM", 92, 97], ["pigs", "ORGANISM", 112, 116], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 112, 116], ["pigs", "SPECIES", 17, 21], ["PRRSV", "SPECIES", 92, 97], ["The asymptomatic pigs", "TREATMENT", 0, 21], ["PRRSV", "PROBLEM", 92, 97]]], ["Seventeen point eight percent (79/444) of the asymptomatic pigs were positive in this study.", [["pigs", "ORGANISM", 59, 63], ["pigs", "SPECIES", 59, 63], ["pigs", "SPECIES", 59, 63], ["the asymptomatic pigs", "TEST", 42, 63], ["this study", "TEST", 81, 91]]], ["Similar findings (15.02%, 70/466) were reported in a study that employed traditional RT-PCR in China [29].", [["a study", "TEST", 51, 58]]], ["However, this is first study to report the viral load using serum samples in asymptomatic PRRSV-infected pigs using ZNA probe-based real-time PCR.", [["serum samples", "ANATOMY", 60, 73], ["PRRSV-infected", "DISEASE", 90, 104], ["serum samples", "ORGANISM_SUBSTANCE", 60, 73], ["PRRSV", "ORGANISM", 90, 95], ["pigs", "ORGANISM", 105, 109], ["ZNA probe", "DNA", 116, 125], ["pigs", "SPECIES", 105, 109], ["PRRSV", "SPECIES", 90, 95], ["pigs", "SPECIES", 105, 109], ["the viral load", "TEST", 39, 53], ["serum samples", "TEST", 60, 73], ["asymptomatic PRRSV", "PROBLEM", 77, 95], ["infected pigs", "TREATMENT", 96, 109], ["ZNA probe", "TREATMENT", 116, 125]]], ["Four asymptomatic PRRSV-infected pigs were detected at levels as high as 4 log10 viral copies/\u03bcl (Figure 2).", [["PRRSV-infected", "DISEASE", 18, 32], ["PRRSV", "ORGANISM", 18, 23], ["pigs", "ORGANISM", 33, 37], ["pigs", "SPECIES", 33, 37], ["PRRSV", "SPECIES", 18, 23], ["pigs", "SPECIES", 33, 37], ["Four asymptomatic PRRSV", "PROBLEM", 0, 23], ["infected pigs", "PROBLEM", 24, 37], ["viral copies", "TEST", 81, 93], ["asymptomatic", "OBSERVATION_MODIFIER", 5, 17], ["PRRSV", "OBSERVATION", 18, 23], ["infected pigs", "OBSERVATION", 24, 37]]], ["This result may be explained by differences in the susceptibility to PRRSV infection.DiscussionThe present study also reinforces a the previous suggestion that PRRSV is one of the major viral agent for PRDC [30,31].", [["PRRSV infection", "DISEASE", 69, 84], ["PRRSV", "ORGANISM", 69, 74], ["PRRSV", "ORGANISM", 160, 165], ["PRRSV", "SPECIES", 69, 74], ["PRRSV", "SPECIES", 160, 165], ["PRRSV infection", "PROBLEM", 69, 84], ["PRRSV", "PROBLEM", 160, 165], ["may be explained", "UNCERTAINTY", 12, 28], ["infection", "OBSERVATION", 75, 84]]], ["PRRSV viraemia was detected in 84.2% (112/133) of the PRDC pigs, ranging from 1.69 to 7.05 log10 PRRSV genome/\u03bcl (mean 4.28 \u00b1 1.31 log10, median 4.21 log10).", [["PRRSV viraemia", "DISEASE", 0, 14], ["PRRSV", "ORGANISM", 0, 5], ["pigs", "ORGANISM", 59, 63], ["PRRSV", "ORGANISM", 97, 102], ["PRRSV", "SPECIES", 0, 5], ["pigs", "SPECIES", 59, 63], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 97, 102], ["PRRSV viraemia", "TEST", 0, 14], ["the PRDC pigs", "TEST", 50, 63], ["PRRSV genome", "TEST", 97, 109], ["mean", "TEST", 114, 118], ["viraemia", "OBSERVATION", 6, 14]]], ["In contrast to the symptomatic pigs, the viraemia of the asymptomatic pigs ranged from 1.32 to 4.7 log10 PRRSV genome/\u03bcl (mean 2.72 \u00b1 0.67 log10, median 2.75 log10).", [["viraemia", "DISEASE", 41, 49], ["pigs", "ORGANISM", 31, 35], ["pigs", "ORGANISM", 70, 74], ["PRRSV", "ORGANISM", 105, 110], ["pigs", "SPECIES", 31, 35], ["pigs", "SPECIES", 70, 74], ["pigs", "SPECIES", 31, 35], ["PRRSV", "SPECIES", 105, 110], ["the viraemia", "TEST", 37, 49], ["the asymptomatic pigs", "TEST", 53, 74], ["PRRSV genome", "TEST", 105, 117], ["mean", "TEST", 122, 126], ["symptomatic", "OBSERVATION_MODIFIER", 19, 30], ["viraemia", "OBSERVATION", 41, 49]]], ["Moreover, based on the present results, it can be concluded that when pigs are infected with PRRSV, the amount of PRRSV in serum samples is significantly higher in PRDC pigs.", [["serum samples", "ANATOMY", 123, 136], ["pigs", "ORGANISM", 70, 74], ["PRRSV", "ORGANISM", 93, 98], ["PRRSV", "ORGANISM", 114, 119], ["serum samples", "ORGANISM_SUBSTANCE", 123, 136], ["PRDC pigs", "ORGANISM", 164, 173], ["pigs", "SPECIES", 70, 74], ["PRRSV", "SPECIES", 93, 98], ["pigs", "SPECIES", 169, 173], ["pigs", "SPECIES", 70, 74], ["PRRSV", "SPECIES", 93, 98], ["PRRSV", "SPECIES", 114, 119], ["pigs", "SPECIES", 169, 173], ["PRRSV", "PROBLEM", 93, 98], ["PRRSV in serum samples", "TEST", 114, 136], ["amount", "OBSERVATION_MODIFIER", 104, 110], ["PRRSV", "OBSERVATION", 114, 119], ["significantly", "OBSERVATION_MODIFIER", 140, 153], ["higher", "OBSERVATION_MODIFIER", 154, 160]]], ["Similar reports had been made for another major viral agent of PRDC, PCV2 [32-34].", [["PRDC", "DISEASE", 63, 67], ["PRDC", "CANCER", 63, 67], ["PCV2", "ORGANISM", 69, 73], ["PRDC", "TREATMENT", 63, 67], ["PCV2", "TREATMENT", 69, 73]]], ["However, there were no previous studies performed for this disease.", [["previous studies", "TEST", 23, 39], ["this disease", "PROBLEM", 54, 66]]], ["The results obtained in the present study indicated that the PRRSV load in serum might be used to assess the importance of PRRS infection in a symptomatic case of PRDC.ConclusionsZNA probe-based real-time PCR can be a useful tool to diagnose asymptomatic PRRSV-infected pigs.", [["serum", "ANATOMY", 75, 80], ["PRDC", "ANATOMY", 163, 167], ["PRRS infection", "DISEASE", 123, 137], ["PRDC", "DISEASE", 163, 167], ["PRRSV-infected", "DISEASE", 255, 269], ["PRRSV", "ORGANISM", 61, 66], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["PRRS", "ORGANISM", 123, 127], ["PRDC", "CANCER", 163, 167], ["PRRSV", "ORGANISM", 255, 260], ["pigs", "ORGANISM", 270, 274], ["PRRSV", "SPECIES", 255, 260], ["pigs", "SPECIES", 270, 274], ["PRRSV", "SPECIES", 61, 66], ["PRRS", "SPECIES", 123, 127], ["PRRSV", "SPECIES", 255, 260], ["pigs", "SPECIES", 270, 274], ["the present study", "TEST", 24, 41], ["the PRRSV load in serum", "TEST", 57, 80], ["PRRS infection", "PROBLEM", 123, 137], ["PRDC", "PROBLEM", 163, 167], ["ConclusionsZNA probe", "TEST", 168, 188], ["time PCR", "TEST", 200, 208], ["asymptomatic PRRSV", "PROBLEM", 242, 260], ["PRRSV load", "OBSERVATION", 61, 71], ["infection", "OBSERVATION", 128, 137], ["infected", "OBSERVATION", 261, 269]]], ["The presence of high PRRSV loads in a sample of animals (>104.2 PRRSV genomes/\u03bcl of serum) is correlated to the presence of PRDC in pigs.Animal, specimen collection and sample preparation ::: MethodsSerum samples were collected from 577 pigs from middle and southern Taiwan from 2012 to 2013.", [["serum", "ANATOMY", 84, 89], ["specimen", "ANATOMY", 145, 153], ["MethodsSerum samples", "ANATOMY", 192, 212], ["PRRSV", "ORGANISM", 21, 26], ["PRRSV", "ORGANISM", 64, 69], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["PRDC", "GENE_OR_GENE_PRODUCT", 124, 128], ["pigs", "ORGANISM", 132, 136], ["MethodsSerum samples", "CANCER", 192, 212], ["pigs", "ORGANISM", 237, 241], ["pigs", "SPECIES", 132, 136], ["pigs", "SPECIES", 237, 241], ["PRRSV", "SPECIES", 21, 26], ["PRRSV", "SPECIES", 64, 69], ["pigs", "SPECIES", 132, 136], ["pigs", "SPECIES", 237, 241], ["high PRRSV loads", "PROBLEM", 16, 32], ["animals", "TEST", 48, 55], ["PRRSV genomes", "TEST", 64, 77], ["PRDC in pigs", "TREATMENT", 124, 136], ["MethodsSerum samples", "TEST", 192, 212], ["high", "OBSERVATION_MODIFIER", 16, 20], ["PRRSV loads", "OBSERVATION", 21, 32]]], ["These animals included 444 healthy pigs and 133 symptomatic pigs (aged from 5 to 12 weeks old) that showed a clinical history of PRDC, such as listlessness, emaciation, hyperpnea or dyspnea.", [["PRDC", "DISEASE", 129, 133], ["listlessness", "DISEASE", 143, 155], ["emaciation", "DISEASE", 157, 167], ["hyperpnea", "DISEASE", 169, 178], ["dyspnea", "DISEASE", 182, 189], ["pigs", "ORGANISM", 35, 39], ["pigs", "ORGANISM", 60, 64], ["pigs", "SPECIES", 35, 39], ["pigs", "SPECIES", 60, 64], ["pigs", "SPECIES", 60, 64], ["PRDC", "PROBLEM", 129, 133], ["listlessness", "PROBLEM", 143, 155], ["emaciation", "PROBLEM", 157, 167], ["hyperpnea", "PROBLEM", 169, 178], ["dyspnea", "PROBLEM", 182, 189], ["dyspnea", "OBSERVATION", 182, 189]]], ["RNA extraction and reverse transcription were performed according to the procedures outlined in Chomczynski [35] and Lin [36], respectively.", [["RNA extraction", "TREATMENT", 0, 14], ["reverse transcription", "TREATMENT", 19, 40]]], ["This study protocol was approved by the Animal Care and Use Committee of the National Pingtung University of Science and Technology.Primer and probe design ::: MethodsA conserved region of the M gene (the ORF 6 product) was identified in 125 nucleotide sequences from Asian (n = 74), European (n = 41), and American (n = 10) available from GenBank, which were aligned using the CLUSTAL W method and the MegAlign program (DNASTAR, Madison, WI).", [["nucleotide", "CHEMICAL", 242, 252], ["nucleotide", "CHEMICAL", 242, 252], ["M gene", "DNA", 193, 199], ["ORF 6 product", "DNA", 205, 218], ["125 nucleotide sequences", "DNA", 238, 262], ["This study protocol", "TEST", 0, 19], ["nucleotide sequences", "TEST", 242, 262], ["the CLUSTAL W method", "TREATMENT", 374, 394]]], ["A 177-bp region was amplified from the ORF 6 gene of PRRSV using the primer pair PRRSV-M177F &-M177R (Table 5).Construction of the plasmid DNA standard curves ::: MethodsA DNA fragment of the ORF 6 gene was amplified from the PRRSV vaccine (Ingelvac\u00ae PRRS MLV, Boehringer Ingelheim) using conventional PCR.", [["ORF 6", "GENE_OR_GENE_PRODUCT", 39, 44], ["PRRSV", "ORGANISM", 53, 58], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["DNA", "CELLULAR_COMPONENT", 172, 175], ["ORF 6", "GENE_OR_GENE_PRODUCT", 192, 197], ["PRRSV", "ORGANISM", 226, 231], ["177-bp region", "DNA", 2, 15], ["ORF 6 gene", "DNA", 39, 49], ["primer pair PRRSV-M177F &-M177R", "DNA", 69, 100], ["MethodsA DNA fragment", "DNA", 163, 184], ["ORF 6 gene", "DNA", 192, 202], ["PRRS", "SPECIES", 251, 255], ["PRRSV", "SPECIES", 53, 58], ["PRRSV", "SPECIES", 226, 231], ["Ingelvac\u00ae PRRS MLV", "SPECIES", 241, 259], ["A 177-bp region", "TREATMENT", 0, 15], ["the primer pair PRRSV", "TEST", 65, 86], ["MethodsA DNA fragment of the ORF", "TREATMENT", 163, 195], ["the PRRSV vaccine", "TREATMENT", 222, 239], ["Ingelvac\u00ae PRRS MLV", "TREATMENT", 241, 259], ["conventional PCR", "TREATMENT", 289, 305], ["fragment", "OBSERVATION_MODIFIER", 176, 184]]], ["The PCR products were cloned using the T&A cloning kit (Yeastern Biotech Co., Ltd., Taipei, Taiwan) and sequenced.", [["PCR products", "DNA", 4, 16], ["The PCR products", "TREATMENT", 0, 16]]], ["The PRRSV plasmids were purified using a plasmid miniprep purification kit (GMbiolab Co., Ltd., Taichung, Taiwan) and quantified by measuring the OD260 using a spectrophotometer (Hitachi U2900, Dallas, TX, USA).", [["plasmids", "ANATOMY", 10, 18], ["PRRSV", "ORGANISM", 4, 9], ["PRRSV plasmids", "DNA", 4, 18], ["PRRSV", "SPECIES", 4, 9], ["The PRRSV plasmids", "TREATMENT", 0, 18], ["a plasmid miniprep purification", "TREATMENT", 39, 70], ["PRRSV plasmids", "OBSERVATION", 4, 18]]], ["A standard curve was generated using 10-fold dilutions (100-106 copies/\u03bcl) of the standard plasmid DNA.ZNA probe-based real-time PCR to detect PRRSV ::: MethodsThe ZNA probe-based real-time PCR assays were performed using the LightCycler Nano (Roche Diagnostics, Mannheim, Germany).", [["plasmid", "ANATOMY", 91, 98], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["ZNA", "SIMPLE_CHEMICAL", 103, 106], ["PRRSV", "ORGANISM", 143, 148], ["plasmid DNA", "DNA", 91, 102], ["ZNA probe", "DNA", 103, 112], ["ZNA probe", "DNA", 164, 173], ["PRRSV", "SPECIES", 143, 148], ["A standard curve", "TREATMENT", 0, 16], ["10-fold dilutions", "TREATMENT", 37, 54], ["the standard plasmid DNA", "TREATMENT", 78, 102], ["ZNA probe", "TREATMENT", 103, 112], ["PRRSV", "PROBLEM", 143, 148], ["Methods", "TREATMENT", 153, 160], ["The ZNA probe", "TEST", 160, 173], ["PCR assays", "TEST", 190, 200]]], ["Each 10 \u03bcl reaction mixture contained 0.2 \u03bcM concentrations of the forward and reverse primers and 3 \u03bcl of the cDNA.", [["cDNA", "DNA", 111, 115], ["Each 10 \u03bcl reaction mixture", "TREATMENT", 0, 27], ["reverse primers", "TREATMENT", 79, 94], ["the cDNA", "TREATMENT", 107, 115]]], ["The thermocycling conditions consisted of 10 min at 95\u00b0C and 45 cycles of 10 sec at 95\u00b0C, 10 sec at 55\u00b0C and 15 sec at 72\u00b0C. Each run included serial 10-fold dilutions of the standard plasmid DNA as a positive control and to construction the standard curve.", [["plasmid", "ANATOMY", 184, 191], ["DNA", "CELLULAR_COMPONENT", 192, 195], ["plasmid DNA", "DNA", 184, 195], ["The thermocycling conditions", "TREATMENT", 0, 28], ["serial 10-fold dilutions", "TREATMENT", 143, 167], ["the standard plasmid DNA", "TREATMENT", 171, 195], ["a positive control", "TREATMENT", 199, 217]]], ["A negative control that was missing the DNA template was included to detect any cross-contamination.Reproducibility and specificity of ZNA probe-based real-time PCR ::: MethodsThe intra- (within-run) and inter- (between runs) assay reproducibility were evaluated using 10-fold serial dilutions of the standard plasmid DNA (from 101-105 copies per reaction), tested in triplicate on three different days.", [["plasmid", "ANATOMY", 310, 317], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["DNA", "CELLULAR_COMPONENT", 318, 321], ["DNA template", "DNA", 40, 52], ["ZNA probe", "DNA", 135, 144], ["plasmid DNA", "DNA", 310, 321], ["missing the DNA template", "PROBLEM", 28, 52], ["any cross-contamination", "PROBLEM", 76, 99], ["Reproducibility", "TEST", 100, 115], ["ZNA probe", "TREATMENT", 135, 144], ["Methods", "TREATMENT", 169, 176], ["assay reproducibility", "TEST", 226, 247], ["10-fold serial dilutions", "TREATMENT", 269, 293], ["the standard plasmid DNA", "TREATMENT", 297, 321], ["negative", "OBSERVATION", 2, 10], ["intra", "OBSERVATION_MODIFIER", 180, 185]]], ["The reproducibility of the method was also evaluated by repeatedly testing the clinical samples, as previously described [37].", [["reproducibility", "OBSERVATION_MODIFIER", 4, 19]]], ["The specificity of the ZNA probe-based real-time PCR assay was assessed by testing nucleic acid extracts of porcine classical swine fever, porcine circovirus type 2, porcine parvovirus and porcine pseudorabies virus.Statistical analysis ::: MethodsStudent\u2019s t-test was used to compare the viral loads between the various clinical symptom groups.", [["extracts", "ANATOMY", 96, 104], ["nucleic acid", "CHEMICAL", 83, 95], ["swine fever", "DISEASE", 126, 137], ["porcine circovirus type", "DISEASE", 139, 162], ["porcine parvovirus", "DISEASE", 166, 184], ["porcine classical swine fever", "ORGANISM", 108, 137], ["porcine circovirus type 2", "ORGANISM", 139, 164], ["porcine parvovirus", "ORGANISM", 166, 184], ["porcine pseudorabies virus", "ORGANISM", 189, 215], ["ZNA probe", "DNA", 23, 32], ["porcine", "SPECIES", 108, 115], ["swine fever", "SPECIES", 126, 137], ["porcine circovirus", "SPECIES", 139, 157], ["porcine parvovirus", "SPECIES", 166, 184], ["porcine pseudorabies virus", "SPECIES", 189, 215], ["porcine classical swine fever", "SPECIES", 108, 137], ["porcine circovirus type 2", "SPECIES", 139, 164], ["porcine parvovirus", "SPECIES", 166, 184], ["porcine pseudorabies virus", "SPECIES", 189, 215], ["the ZNA probe", "TEST", 19, 32], ["PCR assay", "TEST", 49, 58], ["testing nucleic acid extracts", "TEST", 75, 104], ["porcine classical swine fever", "PROBLEM", 108, 137], ["porcine circovirus type 2", "PROBLEM", 139, 164], ["porcine parvovirus", "PROBLEM", 166, 184], ["porcine pseudorabies virus", "PROBLEM", 189, 215], ["MethodsStudent\u2019s t-test", "TEST", 241, 264], ["the viral loads", "TEST", 285, 300], ["porcine parvovirus", "OBSERVATION", 166, 184], ["pseudorabies virus", "OBSERVATION", 197, 215]]], ["The correlation between PRRSV and PRDC was evaluated using the chi-square test with Yate\u2019s correction.", [["PRRSV", "ORGANISM", 24, 29], ["PRDC", "CANCER", 34, 38], ["PRRSV", "SPECIES", 24, 29], ["the chi-square test", "TEST", 59, 78]]], ["P values <0.01 and <0.001 were considered significant and highly significant, respectively.AbbreviationsPRRS: Porcine reproductive and respiratory syndrome; PRRSV: Porcine reproductive and respiratory syndrome virus; PRDC: Porcine respiratory disease complex; RT-PCR: Reverse transcription polymerase chain reaction; PCVAD: Porcine circovirus associated disease; ZNA: Zip nucleic acids; Cq: Quantification cycles.Competing interestsThe authors declare that they have no competing interests.Authors\u2019 contributionsCNL designed the ZNA probe, analyzed the experiments data and wrote the manuscript.", [["Porcine reproductive and respiratory syndrome", "DISEASE", 110, 155], ["Porcine reproductive and respiratory syndrome", "DISEASE", 164, 209], ["Porcine respiratory disease", "DISEASE", 223, 250], ["Porcine circovirus associated disease", "DISEASE", 324, 361], ["Porcine reproductive", "ORGANISM", 110, 130], ["PRRSV", "ORGANISM", 157, 162], ["Porcine reproductive and respiratory syndrome virus", "ORGANISM", 164, 215], ["Porcine circovirus", "ORGANISM", 324, 342], ["Zip nucleic acids", "SIMPLE_CHEMICAL", 368, 385], ["ZNA probe", "DNA", 529, 538], ["Porcine", "SPECIES", 110, 117], ["PRRSV", "SPECIES", 157, 162], ["Porcine", "SPECIES", 164, 171], ["Porcine", "SPECIES", 223, 230], ["Porcine circovirus", "SPECIES", 324, 342], ["PRRSV: Porcine reproductive and respiratory syndrome virus", "SPECIES", 157, 215], ["Porcine circovirus", "SPECIES", 324, 342], ["P values", "TEST", 0, 8], ["Porcine reproductive", "PROBLEM", 110, 130], ["respiratory syndrome", "PROBLEM", 135, 155], ["PRRSV", "PROBLEM", 157, 162], ["Porcine reproductive", "PROBLEM", 164, 184], ["respiratory syndrome virus", "PROBLEM", 189, 215], ["Porcine respiratory disease complex", "PROBLEM", 223, 258], ["Reverse transcription polymerase chain reaction", "PROBLEM", 268, 315], ["Porcine circovirus associated disease", "PROBLEM", 324, 361], ["Zip nucleic acids", "TREATMENT", 368, 385], ["the ZNA probe", "TREATMENT", 525, 538], ["significant", "OBSERVATION_MODIFIER", 65, 76], ["respiratory syndrome", "OBSERVATION", 135, 155], ["respiratory syndrome", "OBSERVATION", 189, 209], ["respiratory disease", "OBSERVATION", 231, 250], ["Porcine circovirus", "OBSERVATION", 324, 342]]], ["WHL participated sample collection and performed the ZNA probe-based real-time PCR.", [["ZNA probe", "DNA", 53, 62], ["the ZNA probe", "TEST", 49, 62]]], ["LNH contributed to the RNA extraction and reverse transcription.", [["LNH", "CHEMICAL", 0, 3], ["LNH", "PROTEIN", 0, 3], ["the RNA extraction", "TREATMENT", 19, 37], ["reverse transcription", "TREATMENT", 42, 63]]], ["SYW performed serum sample separation and arranged the data for statistical analysis.", [["serum sample", "ANATOMY", 14, 26], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["serum sample separation", "TEST", 14, 37], ["the data", "TEST", 51, 59], ["statistical analysis", "TEST", 64, 84]]], ["MTC managed the study, provided materials and reagents, contributed to the interpretation of the data and co-wrote the manuscript.", [["MTC", "DISEASE", 0, 3], ["the study", "TEST", 12, 21]]]]}